(lp0
(dp1
S'line'
p2
S'In pancreatic cancer patients, no association between GDF-15 levels and weight loss was identified.\n'
p3
sS'genes'
p4
(lp5
(dp6
S'index'
p7
I54
sS'uniprot'
p8
S''
p9
sS'lengthInChars'
p10
I6
sS'name'
p11
VGDF-15
p12
sS'lengthInWords'
p13
I1
sasS'diseases'
p14
(lp15
(dp16
g7
I3
sS'cui'
p17
VC0235974
p18
sg10
I17
sg11
Vpancreatic cancer
p19
sg13
I2
sasa(dp20
g2
S'The aim of the present case-control study was to compare the diagnostic value of ULBP2, MIC-1 and carbohydrate antigen 19-9 (CA19-9) in 359 serum samples, consisting of 152 cases of PC, 20 cases of pre-pancreatic cancer, 91 cases of chronic pancreatitis (CP) and 96 normal controls (NC).\n'
p21
sg4
(lp22
(dp23
g7
I125
sg8
VP14209
p24
sg10
I6
sg11
VCA19-9
p25
sg13
I1
sa(dp26
g7
I88
sg8
g9
sg10
I5
sg11
VMIC-1
p27
sg13
I1
sa(dp28
g7
I81
sg8
g9
sg10
I5
sg11
VULBP2
p29
sg13
I1
sa(dp30
g7
I98
sg8
VP14209
p31
sg10
I25
sg11
Vcarbohydrate antigen 19-9
p32
sg13
I3
sasg14
(lp33
(dp34
g7
I202
sg17
VC0235974
p35
sg10
I17
sg11
Vpancreatic cancer
p36
sg13
I2
sa(dp37
g7
I255
sg17
VC0149521
p38
sg10
I2
sg11
VCP
p39
sg13
I1
sa(dp40
g7
I233
sg17
VC0149521
p41
sg10
I20
sg11
Vchronic pancreatitis
p42
sg13
I2
sasa(dp43
g2
S'Macrophage inhibitory cytokine 1 (MIC-1/GDF15) has been identified as a potential novel biomarker for detection of pancreatic cancer (PCa).\n'
p44
sg4
(lp45
(dp46
g7
I34
sg8
g9
sg10
I5
sg11
VMIC-1
p47
sg13
I1
sa(dp48
g7
I0
sg8
g9
sg10
I32
sg11
VMacrophage inhibitory cytokine 1
p49
sg13
I4
sa(dp50
g7
I40
sg8
g9
sg10
I5
sg11
VGDF15
p51
sg13
I1
sasg14
(lp52
(dp53
g7
I115
sg17
VC0235974
p54
sg10
I17
sg11
Vpancreatic cancer
p55
sg13
I2
sa(dp56
g7
I134
sg17
VC0268398
p57
sg10
I3
sg11
VPCa
p58
sg13
I1
sasa(dp59
g2
S'However, the diagnostic value of serum MIC-1 for pancreatic ductal adenocarcinoma (PDAC), particularly for those at the early stage, and the value for treatment response monitoring have not yet been investigated.\n'
p60
sg4
(lp61
(dp62
g7
I33
sg8
g9
sg10
I11
sg11
Vserum MIC-1
p63
sg13
I2
sasg14
(lp64
(dp65
g7
I83
sg17
VC1335302
p66
sg10
I4
sg11
VPDAC
p67
sg13
I1
sa(dp68
g7
I49
sg17
VC1335302
p69
sg10
I32
sg11
Vpancreatic ductal adenocarcinoma
p70
sg13
I3
sasa(dp71
g2
S'CD30 ligand/TNFSF8, chordin-like 2, FGF-10/KGF-2, growth/differentiation factor 15, I-TAC/CXCL11, OSM, and SCF might represent as predictive biomarkers for gemcitabine and erlotinib response of patients with pancreatic cancer.\n'
p72
sg4
(lp73
(dp74
g7
I43
sg8
VP21781
p75
sg10
I5
sg11
VKGF-2
p76
sg13
I1
sa(dp77
g7
I107
sg8
VP21583
p78
sg10
I3
sg11
VSCF
p79
sg13
I1
sa(dp80
g7
I98
sg8
VP13725
p81
sg10
I3
sg11
VOSM
p82
sg13
I1
sa(dp83
g7
I20
sg8
g9
sg10
I14
sg11
Vchordin-like 2
p84
sg13
I2
sa(dp85
g7
I50
sg8
g9
sg10
I29
sg11
Vgrowth/differentiation factor
p86
sg13
I2
sa(dp87
g7
I0
sg8
VP32971
p88
sg10
I11
sg11
VCD30 ligand
p89
sg13
I2
sa(dp90
g7
I90
sg8
g9
sg10
I6
sg11
VCXCL11
p91
sg13
I1
sa(dp92
g7
I12
sg8
VP32971
p93
sg10
I6
sg11
VTNFSF8
p94
sg13
I1
sasg14
(lp95
(dp96
g7
I208
sg17
VC0235974
p97
sg10
I17
sg11
Vpancreatic cancer
p98
sg13
I2
sasa(dp99
g2
S'Radiologists evaluated following CT findings: maximum tumor diameter, percentage of solid component (%solid), air bronchogram, spiculation, adjacency of bullae or interstitial pneumonia (IP) around the tumor, notch, and pleural indent.\n'
p100
sg4
(lp101
sg14
(lp102
(dp103
g7
I54
sg17
VC0027651
p104
sg10
I5
sg11
Vtumor
p105
sg13
I1
sa(dp106
g7
I54
sg17
VC0027651
p107
sg10
I5
sg11
Vtumor
p108
sg13
I1
sa(dp109
g7
I163
sg17
VC0206061
p110
sg10
I22
sg11
Vinterstitial pneumonia
p111
sg13
I2
sa(dp112
g7
I153
sg17
VC0005758
p113
sg10
I6
sg11
Vbullae
p114
sg13
I1
sa(dp115
g7
I187
sg17
VC0206061
p116
sg10
I2
sg11
VIP
p117
sg13
I1
sasa(dp118
g2
S'The results strongly suggest that electronic self-auscultation at a single location (suprasternal notch) can support diagnosis of pneumonia in patients with COPD.\n'
p119
sg4
(lp120
sg14
(lp121
(dp122
g7
I130
sg17
VC0032285
p123
sg10
I9
sg11
Vpneumonia
p124
sg13
I1
sa(dp125
g7
I157
sg17
VC0024117
p126
sg10
I4
sg11
VCOPD
p127
sg13
I1
sasa(dp128
g2
S'We compared patients who underwent PAO for the treatment of Charcot-Marie-Tooth disease hip dysplasia (CMTHD group) with patients who underwent PAO for treatment of hip dysplasia secondary to DDH in terms of (1) modified Harris Hip scores; (2) radiographic correction of acetabular dysplasia; and (3) the rate of complications.\n'
p129
sg4
(lp130
(dp131
g7
I192
sg8
g9
sg10
I3
sg11
VDDH
p132
sg13
I1
sasg14
(lp133
(dp134
g7
I271
sg17
VC1306065
p135
sg10
I20
sg11
Vacetabular dysplasia
p136
sg13
I2
sa(dp137
g7
I88
sg17
VC1328407
p138
sg10
I13
sg11
Vhip dysplasia
p139
sg13
I2
sa(dp140
g7
I60
sg17
VC0007959
p141
sg10
I27
sg11
VCharcot-Marie-Tooth disease
p142
sg13
I2
sa(dp143
g7
I88
sg17
VC1328407
p144
sg10
I13
sg11
Vhip dysplasia
p145
sg13
I2
sasa(dp146
g2
S'Twenty-seven subjects with Charcot-Marie-Tooth disease who underwent a PAO between January 1991 and December 2010 were matched to 54 subjects with DDH on the basis of sex, age, date of surgery, and body mass index.\n'
p147
sg4
(lp148
(dp149
g7
I147
sg8
g9
sg10
I3
sg11
VDDH
p150
sg13
I1
sasg14
(lp151
(dp152
g7
I27
sg17
VC0007959
p153
sg10
I27
sg11
VCharcot-Marie-Tooth disease
p154
sg13
I2
sasa(dp155
g2
S'The purpose of this study is to evaluate the use of the Dega osteotomy in the treatment of hip pathology resulting from both developmental dysplasia (DDH) and neuromuscular disease (NM).\n'
p156
sg4
(lp157
sg14
(lp158
(dp159
g7
I95
sg17
VC0677042
p160
sg10
I9
sg11
Vpathology
p161
sg13
I1
sa(dp162
g7
I182
sg17
VC0027868
p163
sg10
I2
sg11
VNM
p164
sg13
I1
sa(dp165
g7
I139
sg17
VC0334044
p166
sg10
I9
sg11
Vdysplasia
p167
sg13
I1
sa(dp168
g7
I159
sg17
VC0027868
p169
sg10
I21
sg11
Vneuromuscular disease
p170
sg13
I2
sasa(dp171
g2
S'Neuromuscular dysplasia of the hip (NDH) is a sequel of neuromuscular disease, and generally presents later in childhood than DDH.\n'
p172
sg4
(lp173
sg14
(lp174
(dp175
g7
I56
sg17
VC0027868
p176
sg10
I21
sg11
Vneuromuscular disease
p177
sg13
I2
sa(dp178
g7
I14
sg17
VC0334044
p179
sg10
I9
sg11
Vdysplasia
p180
sg13
I1
sasa(dp181
g2
S'To explore this suggestion we ascertained the presence of neuromuscular disease within a cohort of DDH patients, and asked whether the neuromuscular condition is the initial etiology of the dysplasia or a coincidental finding.\n'
p182
sg4
(lp183
sg14
(lp184
(dp185
g7
I190
sg17
VC0334044
p186
sg10
I9
sg11
Vdysplasia
p187
sg13
I1
sa(dp188
g7
I149
sg17
VC0012634
p189
sg10
I9
sg11
Vcondition
p190
sg13
I1
sa(dp191
g7
I58
sg17
VC0027868
p192
sg10
I21
sg11
Vneuromuscular disease
p193
sg13
I2
sasa(dp194
g2
S'We examined 45 infants with nondevelopmental dysplasia of the hip (non-DDH), including congenital deficiency of the femur (CDF) (20 infants), neuromuscular syndrome (five infants), skeletal dysplasia (15 infants), and infection (five infants), and present the sonographic findings.\n'
p195
sg4
(lp196
sg14
(lp197
(dp198
g7
I87
sg17
VC0333006
p199
sg10
I21
sg11
Vcongenital deficiency
p200
sg13
I2
sa(dp201
g7
I218
sg17
VC0009450
p202
sg10
I9
sg11
Vinfection
p203
sg13
I1
sa(dp204
g7
I156
sg17
VC0039082
p205
sg10
I8
sg11
Vsyndrome
p206
sg13
I1
sa(dp207
g7
I181
sg17
VC0410528
p208
sg10
I18
sg11
Vskeletal dysplasia
p209
sg13
I2
sa(dp210
g7
I45
sg17
VC0334044
p211
sg10
I9
sg11
Vdysplasia
p212
sg13
I1
sasa(dp213
g2
S'In previous studies, we demonstrated that human RHBDD2 is over-expressed in the advanced stages of breast and colorectal cancers, suggesting a favorable role in cell proliferation.\n'
p214
sg4
(lp215
sg14
(lp216
(dp217
g7
I166
sg17
VC0334094
p218
sg10
I13
sg11
Vproliferation
p219
sg13
I1
sa(dp220
g7
I110
sg17
VC1527249
p221
sg10
I18
sg11
Vcolorectal cancers
p222
sg13
I2
sasa(dp223
g2
S'So far little is known about the expression of RHBDD2 in other tissues and other species, and because of similarities between cancer and embryonic cells, this study focused on the evaluation of Rhbdd2 expression in embryonic and adult rat tissues.\n'
p224
sg4
(lp225
(dp226
g7
I47
sg8
g9
sg10
I6
sg11
VRHBDD2
p227
sg13
I1
sa(dp228
g7
I194
sg8
g9
sg10
I6
sg11
VRhbdd2
p229
sg13
I1
sasg14
(lp230
(dp231
g7
I126
sg17
VC0006826
p232
sg10
I6
sg11
Vcancer
p233
sg13
I1
sasa(dp234
g2
S'Quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis showed a significant RHBDD2 mRNA overexpression in advanced breast cancer compared with normal tissue samples (p = 0.012).\n'
p235
sg4
(lp236
(dp237
g7
I100
sg8
g9
sg10
I11
sg11
VRHBDD2 mRNA
p238
sg13
I2
sasg14
(lp239
(dp240
g7
I139
sg17
VC0678222
p241
sg10
I13
sg11
Vbreast cancer
p242
sg13
I2
sasa(dp243
g2
S'Immunohistochemistry analysis showed a significant increase of RHBDD2 protein expression in association with breast cancer samples negative for progesterone receptor (p = 0.015).\n'
p244
sg4
(lp245
(dp246
g7
I63
sg8
g9
sg10
I14
sg11
VRHBDD2 protein
p247
sg13
I2
sa(dp248
g7
I144
sg8
VP06401
p249
sg10
I21
sg11
Vprogesterone receptor
p250
sg13
I2
sasg14
(lp251
(dp252
g7
I109
sg17
VC0678222
p253
sg10
I13
sg11
Vbreast cancer
p254
sg13
I2
sasa(dp255
g2
S'Rhomboid domain containing 2 (RHBDD2) was previously observed overexpressed and amplified in breast cancer samples.\n'
p256
sg4
(lp257
(dp258
g7
I0
sg8
g9
sg10
I28
sg11
VRhomboid domain containing 2
p259
sg13
I4
sa(dp260
g7
I30
sg8
g9
sg10
I6
sg11
VRHBDD2
p261
sg13
I1
sasg14
(lp262
(dp263
g7
I93
sg17
VC0678222
p264
sg10
I13
sg11
Vbreast cancer
p265
sg13
I2
sasa(dp266
g2
S'In order to identify biological pathways modulated by RHBDD2, gene expression profiles of RHBDD2 silenced breast cancer cells were analyzed using whole genome human microarray.\n'
p267
sg4
(lp268
(dp269
g7
I54
sg8
g9
sg10
I6
sg11
VRHBDD2
p270
sg13
I1
sa(dp271
g7
I54
sg8
g9
sg10
I6
sg11
VRHBDD2
p272
sg13
I1
sasg14
(lp273
(dp274
g7
I106
sg17
VC0678222
p275
sg10
I13
sg11
Vbreast cancer
p276
sg13
I2
sasa(dp277
g2
S'We used a lentivirus-based approach for stable silencing of RHBDD2 mRNA in the T47D breast cancer cell line, and we examined the transcriptional consequences on UPR genes as well as the phenotypic effects on migration and proliferation processes.\n'
p278
sg4
(lp279
(dp280
g7
I60
sg8
g9
sg10
I11
sg11
VRHBDD2 mRNA
p281
sg13
I2
sasg14
(lp282
(dp283
g7
I84
sg17
VC0678222
p284
sg10
I13
sg11
Vbreast cancer
p285
sg13
I2
sa(dp286
g7
I222
sg17
VC0334094
p287
sg10
I13
sg11
Vproliferation
p288
sg13
I1
sasa(dp289
g2
S'Based on these studies, we hypothesize that RHBDD2 overexpression in breast cancer could represent an adaptive phenotype to the stressful tumor microenvironment by modulating the ER stress response.\n'
p290
sg4
(lp291
(dp292
g7
I44
sg8
g9
sg10
I6
sg11
VRHBDD2
p293
sg13
I1
sasg14
(lp294
(dp295
g7
I69
sg17
VC0678222
p296
sg10
I13
sg11
Vbreast cancer
p297
sg13
I2
sa(dp298
g7
I138
sg17
VC0027651
p299
sg10
I5
sg11
Vtumor
p300
sg13
I1
sasa(dp301
g2
S'In previous studies, we identified rhomboid domain containing 2 (RHBDD2) gene to be markedly overexpressed in breast cancer patients that developed recurrence of the disease.\n'
p302
sg4
(lp303
(dp304
g7
I65
sg8
g9
sg10
I6
sg11
VRHBDD2
p305
sg13
I1
sa(dp306
g7
I35
sg8
g9
sg10
I28
sg11
Vrhomboid domain containing 2
p307
sg13
I4
sasg14
(lp308
(dp309
g7
I148
sg17
VC1458156
p310
sg10
I10
sg11
Vrecurrence
p311
sg13
I1
sa(dp312
g7
I110
sg17
VC0678222
p313
sg10
I13
sg11
Vbreast cancer
p314
sg13
I2
sasa(dp315
g2
S'In this study, we evaluated for the first time RHBDD2 gene expression in colorectal cancer (CRC).\n'
p316
sg4
(lp317
(dp318
g7
I42
sg8
g9
sg10
I16
sg11
Vtime RHBDD2 gene
p319
sg13
I3
sasg14
(lp320
(dp321
g7
I92
sg17
VC1527249
p322
sg10
I3
sg11
VCRC
p323
sg13
I1
sa(dp324
g7
I73
sg17
VC1527249
p325
sg10
I17
sg11
Vcolorectal cancer
p326
sg13
I2
sasa(dp327
g2
S'Overall, these results showed that RHBDD2 overexpression might play a role in colorectal cancer progression.\n'
p328
sg4
(lp329
(dp330
g7
I35
sg8
g9
sg10
I6
sg11
VRHBDD2
p331
sg13
I1
sasg14
(lp332
(dp333
g7
I89
sg17
VC0178874
p334
sg10
I18
sg11
Vcancer progression
p335
sg13
I2
sasa(dp336
g2
S'In the course of breast cancer global gene expression studies, we identified an uncharacterized gene known as RHBDD2 (Rhomboid domain containing 2) to be markedly over-expressed in primary tumors from patients with recurrent disease.\n'
p337
sg4
(lp338
(dp339
g7
I118
sg8
g9
sg10
I28
sg11
VRhomboid domain containing 2
p340
sg13
I4
sa(dp341
g7
I110
sg8
g9
sg10
I6
sg11
VRHBDD2
p342
sg13
I1
sasg14
(lp343
(dp344
g7
I181
sg17
VC0677930
p345
sg10
I14
sg11
Vprimary tumors
p346
sg13
I2
sa(dp347
g7
I17
sg17
VC0678222
p348
sg10
I13
sg11
Vbreast cancer
p349
sg13
I2
sa(dp350
g7
I215
sg17
VC0277556
p351
sg10
I17
sg11
Vrecurrent disease
p352
sg13
I2
sasa(dp353
g2
S'Western-blot, RT-PCR and cDNA sequencing analyses allowed us to identify two RHBDD2 alternatively spliced mRNA isoforms expressed in breast cancer cell lines.\n'
p354
sg4
(lp355
sg14
(lp356
(dp357
g7
I133
sg17
VC0678222
p358
sg10
I13
sg11
Vbreast cancer
p359
sg13
I2
sasa(dp360
g2
S'Interestingly, siRNA-mediated silencing of RHBDD2 expression results in a decrease of MCF7 breast cancer cells proliferation compared with the corresponding controls (p=0.001).\n'
p361
sg4
(lp362
(dp363
g7
I43
sg8
g9
sg10
I6
sg11
VRHBDD2
p364
sg13
I1
sasg14
(lp365
(dp366
g7
I111
sg17
VC0334094
p367
sg10
I13
sg11
Vproliferation
p368
sg13
I1
sa(dp369
g7
I91
sg17
VC0678222
p370
sg10
I13
sg11
Vbreast cancer
p371
sg13
I2
sasa(dp372
g2
S'In conclusion, our findings suggest that RHBDD2 over-expression behaves as an indicator of poor prognosis and may play a role facilitating breast cancer progression.\n'
p373
sg4
(lp374
(dp375
g7
I41
sg8
g9
sg10
I6
sg11
VRHBDD2
p376
sg13
I1
sasg14
(lp377
(dp378
g7
I146
sg17
VC0178874
p379
sg10
I18
sg11
Vcancer progression
p380
sg13
I2
sasa(dp381
g2
S'These effects could also be exerted via the upregulation of eight specific target genes, the subsequent over-activation of the PKC and PI3 K-Akt pathways, and the eventual abnormal cardiac development and VSD.\n'
p382
sg4
(lp383
(dp384
g7
I141
sg8
g9
sg10
I3
sg11
VAkt
p385
sg13
I1
sa(dp386
g7
I127
sg8
VP17252
p387
sg10
I3
sg11
VPKC
p388
sg13
I1
sa(dp389
g7
I135
sg8
VP19957
p390
sg10
I5
sg11
VPI3 K
p391
sg13
I2
sasg14
(lp392
(dp393
g7
I205
sg17
VC0018818
p394
sg10
I3
sg11
VVSD
p395
sg13
I1
sa(dp396
g7
I127
sg17
VC1868682
p397
sg10
I3
sg11
VPKC
p398
sg13
I1
sasa(dp399
g2
S'Reduced translation of CEBPA mRNA has been associated with increased proliferation of bronchial smooth muscle (BSM) cells of asthma patients.\n'
p400
sg4
(lp401
(dp402
g7
I23
sg8
VP49715
p403
sg10
I10
sg11
VCEBPA mRNA
p404
sg13
I2
sasg14
(lp405
(dp406
g7
I125
sg17
VC0004096
p407
sg10
I6
sg11
Vasthma
p408
sg13
I1
sa(dp409
g7
I69
sg17
VC0334094
p410
sg10
I13
sg11
Vproliferation
p411
sg13
I1
sasa(dp412
g2
S'HDM extract reduced the C/EBPAlfa expression in BSM cells of asthma patients, which coincided with significantly increased levels of calreticulin (CRT) protein, an inhibitor of CEBPA mRNA translation.\n'
p413
sg4
(lp414
(dp415
g7
I133
sg8
VP27797
p416
sg10
I12
sg11
Vcalreticulin
p417
sg13
I1
sa(dp418
g7
I177
sg8
VP49715
p419
sg10
I10
sg11
VCEBPA mRNA
p420
sg13
I2
sa(dp421
g7
I147
sg8
VP27797
p422
sg10
I3
sg11
VCRT
p423
sg13
I1
sasg14
(lp424
(dp425
g7
I61
sg17
VC0004096
p426
sg10
I6
sg11
Vasthma
p427
sg13
I1
sasa(dp428
g2
S'In conclusion, HDM extract reduced CEBPA mRNA translation, specifically in asthmatic BSM cells, and 1) upregulated CRT, 2) activated PAR2, and increased 3) IL-6 expression and 4) the proliferation of asthmatic BSM cells.\n'
p429
sg4
(lp430
(dp431
g7
I35
sg8
VP49715
p432
sg10
I10
sg11
VCEBPA mRNA
p433
sg13
I2
sa(dp434
g7
I156
sg8
VP05231
p435
sg10
I4
sg11
VIL-6
p436
sg13
I1
sa(dp437
g7
I133
sg8
VP55085
p438
sg10
I4
sg11
VPAR2
p439
sg13
I1
sasg14
(lp440
(dp441
g7
I183
sg17
VC0334094
p442
sg10
I13
sg11
Vproliferation
p443
sg13
I1
sa(dp444
g7
I75
sg17
VC0004096
p445
sg10
I9
sg11
Vasthmatic
p446
sg13
I1
sa(dp447
g7
I75
sg17
VC0004096
p448
sg10
I9
sg11
Vasthmatic
p449
sg13
I1
sasa(dp450
g2
S'Airway smooth muscle cells from persons with asthma are deficient in C/EBP-alpha, which may explain the finding that CSs do not inhibit the proliferation of these cells in vitro.\n'
p451
sg4
(lp452
(dp453
g7
I69
sg8
g9
sg10
I11
sg11
VC/EBP-alpha
p454
sg13
I1
sasg14
(lp455
(dp456
g7
I45
sg17
VC0004096
p457
sg10
I6
sg11
Vasthma
p458
sg13
I1
sa(dp459
g7
I117
sg17
VC0265338
p460
sg10
I3
sg11
VCSs
p461
sg13
I1
sa(dp462
g7
I140
sg17
VC0334094
p463
sg10
I13
sg11
Vproliferation
p464
sg13
I1
sasa(dp465
g2
S'CCAAT/enhancer-binding proteins (C/EBPs) control cell proliferation; lack of C/EBPalpha correlates with increased proliferation of bronchial smooth muscle cells (BSMCs) of asthmatic patients.\n'
p466
sg4
(lp467
(dp468
g7
I33
sg8
g9
sg10
I6
sg11
VC/EBPs
p469
sg13
I1
sa(dp470
g7
I0
sg8
VP63244
p471
sg10
I31
sg11
VCCAAT/enhancer-binding proteins
p472
sg13
I2
sasg14
(lp473
(dp474
g7
I54
sg17
VC0334094
p475
sg10
I13
sg11
Vproliferation
p476
sg13
I1
sa(dp477
g7
I54
sg17
VC0334094
p478
sg10
I13
sg11
Vproliferation
p479
sg13
I1
sa(dp480
g7
I172
sg17
VC0004096
p481
sg10
I9
sg11
Vasthmatic
p482
sg13
I1
sasa(dp483
g2
S'Expression and function of C/EBPalpha, beta, delta, and epsilon BSMCs of control subjects (n = 9), asthmatic patients (n = 12), and patients with chronic obstructive pulmonary disease (COPD; n = 10) were determined.\n'
p484
sg4
(lp485
sg14
(lp486
(dp487
g7
I185
sg17
VC0024117
p488
sg10
I4
sg11
VCOPD
p489
sg13
I1
sa(dp490
g7
I146
sg17
VC0024117
p491
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p492
sg13
I4
sa(dp493
g7
I99
sg17
VC0004096
p494
sg10
I9
sg11
Vasthmatic
p495
sg13
I1
sasa(dp496
g2
S'The asthmatic group did not appropriately express C/EBPalpha.\n'
p497
sg4
(lp498
sg14
(lp499
(dp500
g7
I4
sg17
VC0004096
p501
sg10
I9
sg11
Vasthmatic
p502
sg13
I1
sasa(dp503
g2
S'Protein analysis and electrophoretic mobility shift assay confirmed the disease-specific expression pattern of C/EBPalpha in asthmatic patients and C/EBPdelta in patients with COPD.\n'
p504
sg4
(lp505
sg14
(lp506
(dp507
g7
I176
sg17
VC0024117
p508
sg10
I4
sg11
VCOPD
p509
sg13
I1
sa(dp510
g7
I125
sg17
VC0004096
p511
sg10
I9
sg11
Vasthmatic
p512
sg13
I1
sasa(dp513
g2
S'The reason for the differences which have been observed in the in vitro properties of airway smooth muscle derived from asthmatic individuals may result from an inherent "supercontractility", an increased tendency to proliferate due to the absence of an inhibitory transcription factor C/EBP-alpha, the influence of an altered extracellular matrix and/or a decrease in release of factors such as PGE(2) which would under normal circumstances inhibit both proliferation and contraction.\n'
p514
sg4
(lp515
(dp516
g7
I265
sg8
g9
sg10
I32
sg11
Vtranscription factor C/EBP-alpha
p517
sg13
I3
sasg14
(lp518
(dp519
g7
I455
sg17
VC0334094
p520
sg10
I13
sg11
Vproliferation
p521
sg13
I1
sa(dp522
g7
I120
sg17
VC0004096
p523
sg10
I9
sg11
Vasthmatic
p524
sg13
I1
sa(dp525
g7
I473
sg17
VC1140999
p526
sg10
I11
sg11
Vcontraction
p527
sg13
I1
sasa(dp528
g2
S'Hepatocellular carcinoma etiology had no detectable influence on miR-122 expression, whereas miR-152 was increased in HCV+ tissue samples.\n'
p529
sg4
(lp530
(dp531
g7
I93
sg8
g9
sg10
I7
sg11
VmiR-152
p532
sg13
I1
sa(dp533
g7
I65
sg8
g9
sg10
I7
sg11
VmiR-122
p534
sg13
I1
sasg14
(lp535
(dp536
g7
I0
sg17
VC1512411
p537
sg10
I24
sg11
VHepatocellular carcinoma
p538
sg13
I2
sasa(dp539
g2
S'Aberrant expressions of the miR-148/152 family (miR-148a, miR-148b, and miR-152) have been documented in many tumor tissues, including hepatocellular carcinoma (HCC).\n'
p540
sg4
(lp541
(dp542
g7
I28
sg8
g9
sg10
I18
sg11
VmiR-148/152 family
p543
sg13
I2
sa(dp544
g7
I58
sg8
g9
sg10
I8
sg11
VmiR-148b
p545
sg13
I1
sa(dp546
g7
I48
sg8
g9
sg10
I8
sg11
VmiR-148a
p547
sg13
I1
sasg14
(lp548
(dp549
g7
I135
sg17
VC2239176
p550
sg10
I24
sg11
Vhepatocellular carcinoma
p551
sg13
I2
sa(dp552
g7
I110
sg17
VC0027651
p553
sg10
I5
sg11
Vtumor
p554
sg13
I1
sa(dp555
g7
I161
sg17
VC2239176
p556
sg10
I3
sg11
VHCC
p557
sg13
I1
sasa(dp558
g2
S'And high expression of HLA-G further suppressed NK against cancer cells, providing a new concept that miR-152 was involved in HBV-induced hepatocellular carcinoma.\n'
p559
sg4
(lp560
(dp561
g7
I23
sg8
VP30486
p562
sg10
I3
sg11
VHLA
p563
sg13
I1
sasg14
(lp564
(dp565
g7
I59
sg17
VC0006826
p566
sg10
I6
sg11
Vcancer
p567
sg13
I1
sa(dp568
g7
I138
sg17
VC1512411
p569
sg10
I24
sg11
Vhepatocellular carcinoma
p570
sg13
I2
sa(dp571
g7
I126
sg17
VC0019163
p572
sg10
I3
sg11
VHBV
p573
sg13
I1
sasa(dp574
g2
S'Further, FDA-approved arsenic trioxide (ATO) and the ND2-SmoA1 mouse model of Medulloblastoma (MB) were used to extend our analyses of combined MRI and Reverse Phase Protein Microarray (RPMA) data to assess tumor responses to ATO and to uncover the complexity of therapeutic molecular biology.\n'
p575
sg4
(lp576
(dp577
g7
I53
sg8
VP03891
p578
sg10
I9
sg11
VND2-SmoA1
p579
sg13
I1
sasg14
(lp580
(dp581
g7
I95
sg17
VC0025149
p582
sg10
I2
sg11
VMB
p583
sg13
I1
sa(dp584
g7
I78
sg17
VC0025149
p585
sg10
I15
sg11
VMedulloblastoma
p586
sg13
I1
sa(dp587
g7
I207
sg17
VC0027651
p588
sg10
I5
sg11
Vtumor
p589
sg13
I1
sasa(dp590
g2
S'Importantly, while ASC deficiency did not affect normal cerebellar development, ASC knockout mice on the Smoothened (ND2:SmoA1) transgenic model of medulloblastoma exhibited a profound reduction in medulloblastoma incidence and a delayed tumor onset.\n'
p591
sg4
(lp592
(dp593
g7
I117
sg8
VP03891
p594
sg10
I3
sg11
VND2
p595
sg13
I1
sa(dp596
g7
I19
sg8
VP08842
p597
sg10
I3
sg11
VASC
p598
sg13
I1
sasg14
(lp599
(dp600
g7
I148
sg17
VC0025149
p601
sg10
I15
sg11
Vmedulloblastoma
p602
sg13
I1
sa(dp603
g7
I148
sg17
VC0025149
p604
sg10
I15
sg11
Vmedulloblastoma
p605
sg13
I1
sa(dp606
g7
I238
sg17
VC0027651
p607
sg10
I5
sg11
Vtumor
p608
sg13
I1
sasa(dp609
g2
S'We report the use of IRDye 800CW chlorotoxin (CLTX) as a targeted imaging agent for brain tumors in a spontaneous mouse model of medulloblastoma, ND2:SmoA1.\n'
p610
sg4
(lp611
(dp612
g7
I146
sg8
VP03891
p613
sg10
I3
sg11
VND2
p614
sg13
I1
sasg14
(lp615
(dp616
g7
I129
sg17
VC0025149
p617
sg10
I15
sg11
Vmedulloblastoma
p618
sg13
I1
sa(dp619
g7
I84
sg17
VC0006118
p620
sg10
I12
sg11
Vbrain tumors
p621
sg13
I2
sasa(dp622
g2
S'Importantly, genetic deletion of Bax in medulloblastoma-prone ND2:SmoA1 transgenic mice greatly accelerated tumorigenesis.\n'
p623
sg4
(lp624
(dp625
g7
I62
sg8
VP03891
p626
sg10
I3
sg11
VND2
p627
sg13
I1
sasg14
(lp628
(dp629
g7
I108
sg17
VC0007621
p630
sg10
I13
sg11
Vtumorigenesis
p631
sg13
I1
sa(dp632
g7
I40
sg17
VC0025149
p633
sg10
I15
sg11
Vmedulloblastoma
p634
sg13
I1
sasa(dp635
g2
S'Five common variants were associated with pancreatic cancer at nominal statistical significance (P &lt; 0.05) with the strongest finding for mt5460g in the ND2 gene [OR = 3.9; 95% confidence interval (CI), 1.5-10; P = 0.004] which encodes an A331T substitution.\n'
p636
sg4
(lp637
(dp638
g7
I156
sg8
VP03891
p639
sg10
I8
sg11
VND2 gene
p640
sg13
I2
sasg14
(lp641
(dp642
g7
I42
sg17
VC0235974
p643
sg10
I17
sg11
Vpancreatic cancer
p644
sg13
I2
sasa(dp645
g2
S'Our findings indicate a critical role of HspBP1 in differential CHIP/Hsp70 activities in neuronal and glial cells and the greater neuronal vulnerability to misfolded proteins in neurodegenerative diseases.\n'
p646
sg4
(lp647
(dp648
g7
I41
sg8
g9
sg10
I6
sg11
VHspBP1
p649
sg13
I1
sa(dp650
g7
I69
sg8
VP34932
p651
sg10
I5
sg11
VHsp70
p652
sg13
I1
sa(dp653
g7
I64
sg8
g9
sg10
I4
sg11
VCHIP
p654
sg13
I1
sasg14
(lp655
(dp656
g7
I178
sg17
VC0524851
p657
sg10
I26
sg11
Vneurodegenerative diseases
p658
sg13
I2
sasa(dp659
g2
S'In this study the adenoviral mediated over-expression of HSP70 interacting protein (HIP) alone was shown to significantly reduce inclusion formation in both an in vitro model of Spinal Bulbar Muscular Atrophy and a primary neuronal model of polyglutamine disease.\n'
p660
sg4
(lp661
(dp662
g7
I57
sg8
VP50502
p663
sg10
I25
sg11
VHSP70 interacting protein
p664
sg13
I3
sa(dp665
g7
I84
sg8
VP47914
p666
sg10
I3
sg11
VHIP
p667
sg13
I1
sasg14
(lp668
(dp669
g7
I192
sg17
VC0026846
p670
sg10
I16
sg11
VMuscular Atrophy
p671
sg13
I2
sasa(dp672
g2
S'To explore the relationship of telomerase, MYC and JAK2 in chronic myeloproliferative diseases, we investigated hTERT and MYC expression in bone marrow cells of essential thrombocythemia (ET) and polycythemia vera (PV).\n'
p673
sg4
(lp674
(dp675
g7
I112
sg8
g9
sg10
I5
sg11
VhTERT
p676
sg13
I1
sa(dp677
g7
I51
sg8
g9
sg10
I4
sg11
VJAK2
p678
sg13
I1
sa(dp679
g7
I43
sg8
VP12524
p680
sg10
I3
sg11
VMYC
p681
sg13
I1
sa(dp682
g7
I43
sg8
VP12524
p683
sg10
I3
sg11
VMYC
p684
sg13
I1
sasg14
(lp685
(dp686
g7
I161
sg17
VC0040028
p687
sg10
I25
sg11
Vessential thrombocythemia
p688
sg13
I2
sa(dp689
g7
I188
sg17
VC0040028
p690
sg10
I2
sg11
VET
p691
sg13
I1
sa(dp692
g7
I196
sg17
VC0032463
p693
sg10
I17
sg11
Vpolycythemia vera
p694
sg13
I2
sa(dp695
g7
I215
sg17
VC0032463
p696
sg10
I2
sg11
VPV
p697
sg13
I1
sasa(dp698
g2
S'DCAF17 mutations are associated with Woodhouse-Sakati syndrome, a rare disorder characterized by alopecia, hypogonadotropic hypogonadism, sensorineural hearing loss, diabetes mellitus, and extrapyramidal movements.\n'
p699
sg4
(lp700
(dp701
g7
I0
sg8
g9
sg10
I6
sg11
VDCAF17
p702
sg13
I1
sasg14
(lp703
(dp704
g7
I166
sg17
VC0011849
p705
sg10
I17
sg11
Vdiabetes mellitus
p706
sg13
I2
sa(dp707
g7
I107
sg17
VC0022735
p708
sg10
I29
sg11
Vhypogonadotropic hypogonadism
p709
sg13
I2
sa(dp710
g7
I66
sg17
VC0678236
p711
sg10
I13
sg11
Vrare disorder
p712
sg13
I2
sa(dp713
g7
I138
sg17
VC0018784
p714
sg10
I26
sg11
Vsensorineural hearing loss
p715
sg13
I3
sa(dp716
g7
I37
sg17
VC0342286
p717
sg10
I25
sg11
VWoodhouse-Sakati syndrome
p718
sg13
I2
sasa(dp719
g2
S'Woodhouse-Sakati syndrome (WSS) is a rare autosomal recessive disorder characterized by alopecia, hypogonadism, diabetes mellitus, intellectual disability, sensorineural deafness, extrapyramidal signs, and low insulinlike growth factor 1 levels.\n'
p720
sg4
(lp721
(dp722
g7
I206
sg8
VP05019
p723
sg10
I31
sg11
Vlow insulinlike growth factor 1
p724
sg13
I5
sasg14
(lp725
(dp726
g7
I180
sg17
VC0234133
p727
sg10
I20
sg11
Vextrapyramidal signs
p728
sg13
I2
sa(dp729
g7
I98
sg17
VC0020619
p730
sg10
I12
sg11
Vhypogonadism
p731
sg13
I1
sa(dp732
g7
I0
sg17
VC0342286
p733
sg10
I25
sg11
VWoodhouse-Sakati syndrome
p734
sg13
I2
sa(dp735
g7
I27
sg17
VC0406587
p736
sg10
I3
sg11
VWSS
p737
sg13
I1
sa(dp738
g7
I156
sg17
VC0018784
p739
sg10
I22
sg11
Vsensorineural deafness
p740
sg13
I2
sa(dp741
g7
I131
sg17
VC0025362
p742
sg10
I23
sg11
Vintellectual disability
p743
sg13
I2
sa(dp744
g7
I112
sg17
VC0011849
p745
sg10
I17
sg11
Vdiabetes mellitus
p746
sg13
I2
sasa(dp747
g2
S'Woodhouse-Sakati syndrome consists of alopecia, hypogonadism, diabetes mellitus, mild mental retardation, sensorineural deafness and ECG abnormalities.\n'
p748
sg4
(lp749
sg14
(lp750
(dp751
g7
I62
sg17
VC0011849
p752
sg10
I17
sg11
Vdiabetes mellitus
p753
sg13
I2
sa(dp754
g7
I81
sg17
VC0026106
p755
sg10
I23
sg11
Vmild mental retardation
p756
sg13
I3
sa(dp757
g7
I48
sg17
VC0020619
p758
sg10
I12
sg11
Vhypogonadism
p759
sg13
I1
sa(dp760
g7
I106
sg17
VC0018784
p761
sg10
I22
sg11
Vsensorineural deafness
p762
sg13
I2
sa(dp763
g7
I0
sg17
VC0342286
p764
sg10
I25
sg11
VWoodhouse-Sakati syndrome
p765
sg13
I2
sasa(dp766
g2
S'A population of CD80+Gr-1+ myeloid cells was found to be expanded in conventional as well as in bone marrow-transplanted mice with disseminated candidiasis, but its depletion increased the IFN-gamma-mediated antifungal resistance.\n'
p767
sg4
(lp768
(dp769
g7
I16
sg8
VP00390
p770
sg10
I10
sg11
VCD80+Gr-1+
p771
sg13
I1
sa(dp772
g7
I189
sg8
VP01579
p773
sg10
I9
sg11
VIFN-gamma
p774
sg13
I1
sasg14
(lp775
(dp776
g7
I131
sg17
VC0153252
p777
sg10
I24
sg11
Vdisseminated candidiasis
p778
sg13
I2
sasa(dp779
g2
S'The patients with esophageal candidiasis had lower CD4+ cell counts (129/microliter) and CD4:CD8 ratios (0.23) than those with oropharyngeal candidiasis (CD4 179/microliter; CD4:CD8 0.35).\n'
p780
sg4
(lp781
(dp782
g7
I178
sg8
VP01732
p783
sg10
I8
sg11
VCD8 0.35
p784
sg13
I2
sa(dp785
g7
I51
sg8
VP01730
p786
sg10
I3
sg11
VCD4
p787
sg13
I1
sa(dp788
g7
I51
sg8
VP01730
p789
sg10
I4
sg11
VCD4+
p790
sg13
I1
sa(dp791
g7
I51
sg8
VP01730
p792
sg10
I3
sg11
VCD4
p793
sg13
I1
sa(dp794
g7
I93
sg8
VP01732
p795
sg10
I3
sg11
VCD8
p796
sg13
I1
sa(dp797
g7
I51
sg8
VP01730
p798
sg10
I3
sg11
VCD4
p799
sg13
I1
sasg14
(lp800
(dp801
g7
I18
sg17
VC0239295
p802
sg10
I22
sg11
Vesophageal candidiasis
p803
sg13
I2
sa(dp804
g7
I127
sg17
VC0919659
p805
sg10
I25
sg11
Voropharyngeal candidiasis
p806
sg13
I2
sasa(dp807
g2
S'We served patients with cystic fibrosis (CF, n=29), cystic fibrosis related diabetes (CFRD, n=19) and healthy controls (n=18) a standardized breakfast (23 g protein, 25 g fat and 76 g carbohydrates) after an overnight fasting.\n'
p808
sg4
(lp809
sg14
(lp810
(dp811
g7
I41
sg17
VC0010674
p812
sg10
I2
sg11
VCF
p813
sg13
I1
sa(dp814
g7
I24
sg17
VC0010674
p815
sg10
I15
sg11
Vcystic fibrosis
p816
sg13
I2
sa(dp817
g7
I52
sg17
VC2242728
p818
sg10
I32
sg11
Vcystic fibrosis related diabetes
p819
sg13
I4
sa(dp820
g7
I86
sg17
VC2242728
p821
sg10
I4
sg11
VCFRD
p822
sg13
I1
sasa(dp823
g2
S'CNS anomalies included 12 Chiari malformations, 2 Dandy-Walker malformations (DWM), 1 variant of Dandy-Walker syndrome (DWS), 3 iniencephalies, 15 anencephalies, 1 alobar holoprosencephaly, 2 isolated hydrocephalies, 3 hydrocephalies with cerebellar hypoplasia, 1 occipital encephalocele, 1 lumbosacral myelomeningocele accompanied with microcephaly.\n'
p824
sg4
(lp825
sg14
(lp826
(dp827
g7
I50
sg17
VC0010964
p828
sg10
I26
sg11
VDandy-Walker malformations
p829
sg13
I2
sa(dp830
g7
I303
sg17
VC0025312
p831
sg10
I16
sg11
Vmyelomeningocele
p832
sg13
I1
sa(dp833
g7
I239
sg17
VC0266470
p834
sg10
I21
sg11
Vcerebellar hypoplasia
p835
sg13
I2
sa(dp836
g7
I26
sg17
VC0003803
p837
sg10
I20
sg11
VChiari malformations
p838
sg13
I2
sa(dp839
g7
I78
sg17
VC0010964
p840
sg10
I3
sg11
VDWM
p841
sg13
I1
sa(dp842
g7
I264
sg17
VC0014067
p843
sg10
I23
sg11
Voccipital encephalocele
p844
sg13
I2
sa(dp845
g7
I97
sg17
VC0010964
p846
sg10
I21
sg11
VDandy-Walker syndrome
p847
sg13
I2
sa(dp848
g7
I337
sg17
VC0025958
p849
sg10
I12
sg11
Vmicrocephaly
p850
sg13
I1
sa(dp851
g7
I120
sg17
VC0010964
p852
sg10
I3
sg11
VDWS
p853
sg13
I1
sa(dp854
g7
I128
sg17
VC0152234
p855
sg10
I14
sg11
Viniencephalies
p856
sg13
I1
sa(dp857
g7
I164
sg17
VC0431363
p858
sg10
I24
sg11
Valobar holoprosencephaly
p859
sg13
I2
sasa(dp860
g2
S'Acrania, alobar holoprosencephaly, cephaloceles, and spina bifida can confidently be diagnosed at that stage and should actively be looked for in every fetus undergoing first-trimester ultrasound.\n'
p861
sg4
(lp862
sg14
(lp863
(dp864
g7
I9
sg17
VC0431363
p865
sg10
I24
sg11
Valobar holoprosencephaly
p866
sg13
I2
sa(dp867
g7
I53
sg17
VC0080178
p868
sg10
I12
sg11
Vspina bifida
p869
sg13
I2
sa(dp870
g7
I0
sg17
VC0702169
p871
sg10
I7
sg11
VAcrania
p872
sg13
I1
sa(dp873
g7
I35
sg17
VC0014065
p874
sg10
I12
sg11
Vcephaloceles
p875
sg13
I1
sasa(dp876
g2
S'We present a new case with 13q deletion syndrome phenotypically characterized by severe major malformations, some of them still undescribed, consisting of left diaphragmatic hernia, right pulmonary sequestration, hypoplastic left heart syndrome, pancreatic agenesis, polysplenia, and catastrophic central nervous system malformations: semilobar holoprosencephaly, occipital myelomeningocele, partial agenesis of the corpus callosum and agenesis of olfactory bulbs.\n'
p877
sg4
(lp878
sg14
(lp879
(dp880
g7
I257
sg17
VC0332907
p881
sg10
I8
sg11
Vagenesis
p882
sg13
I1
sa(dp883
g7
I213
sg17
VC0152101
p884
sg10
I31
sg11
Vhypoplastic left heart syndrome
p885
sg13
I4
sa(dp886
g7
I188
sg17
VC0006288
p887
sg10
I23
sg11
Vpulmonary sequestration
p888
sg13
I2
sa(dp889
g7
I335
sg17
VC0751617
p890
sg10
I27
sg11
Vsemilobar holoprosencephaly
p891
sg13
I2
sa(dp892
g7
I305
sg17
VC0497552
p893
sg10
I28
sg11
Vnervous system malformations
p894
sg13
I3
sa(dp895
g7
I374
sg17
VC0025312
p896
sg10
I16
sg11
Vmyelomeningocele
p897
sg13
I1
sa(dp898
g7
I392
sg17
VC0431368
p899
sg10
I39
sg11
Vpartial agenesis of the corpus callosum
p900
sg13
I6
sa(dp901
g7
I160
sg17
VC0019284
p902
sg10
I20
sg11
Vdiaphragmatic hernia
p903
sg13
I2
sa(dp904
g7
I94
sg17
VC0000768
p905
sg10
I13
sg11
Vmalformations
p906
sg13
I1
sa(dp907
g7
I267
sg17
VC0266631
p908
sg10
I11
sg11
Vpolysplenia
p909
sg13
I1
sa(dp910
g7
I27
sg17
VC0265451
p911
sg10
I21
sg11
V13q deletion syndrome
p912
sg13
I3
sa(dp913
g7
I257
sg17
VC0332907
p914
sg10
I8
sg11
Vagenesis
p915
sg13
I1
sasa(dp916
g2
S'The early scan detected all cases of acrania, alobar holoprosencephaly, exomphalos, gastroschisis, megacystis and body stalk anomaly, 77% of absent hand or foot, 50% of diaphragmatic hernia, 50% of lethal skeletal dysplasias, 60% of polydactyly, 34% of major cardiac defects, 5% of facial clefts and 14% of open spina bifida, but none of agenesis of the corpus callosum, cerebellar or vermian hypoplasia, echogenic lung lesions, bowel obstruction, most renal defects or talipes.\n'
p917
sg4
(lp918
sg14
(lp919
(dp920
g7
I393
sg17
VC0243069
p921
sg10
I10
sg11
Vhypoplasia
p922
sg13
I1
sa(dp923
g7
I214
sg17
VC0334044
p924
sg10
I10
sg11
Vdysplasias
p925
sg13
I1
sa(dp926
g7
I307
sg17
VC0917813
p927
sg10
I17
sg11
Vopen spina bifida
p928
sg13
I3
sa(dp929
g7
I338
sg17
VC0175754
p930
sg10
I31
sg11
Vagenesis of the corpus callosum
p931
sg13
I5
sa(dp932
g7
I84
sg17
VC0265706
p933
sg10
I13
sg11
Vgastroschisis
p934
sg13
I1
sa(dp935
g7
I37
sg17
VC0702169
p936
sg10
I7
sg11
Vacrania
p937
sg13
I1
sa(dp938
g7
I429
sg17
VC0021843
p939
sg10
I17
sg11
Vbowel obstruction
p940
sg13
I2
sa(dp941
g7
I470
sg17
VC0009081
p942
sg10
I7
sg11
Vtalipes
p943
sg13
I1
sa(dp944
g7
I259
sg17
VC0741916
p945
sg10
I15
sg11
Vcardiac defects
p946
sg13
I2
sa(dp947
g7
I46
sg17
VC0431363
p948
sg10
I24
sg11
Valobar holoprosencephaly
p949
sg13
I2
sa(dp950
g7
I282
sg17
VC0685787
p951
sg10
I13
sg11
Vfacial clefts
p952
sg13
I2
sa(dp953
g7
I169
sg17
VC0019284
p954
sg10
I20
sg11
Vdiaphragmatic hernia
p955
sg13
I2
sa(dp956
g7
I72
sg17
VC1306503
p957
sg10
I10
sg11
Vexomphalos
p958
sg13
I1
sa(dp959
g7
I233
sg17
VC0152427
p960
sg10
I11
sg11
Vpolydactyly
p961
sg13
I1
sa(dp962
g7
I119
sg17
VC0935572
p963
sg10
I5
sg11
Vstalk
p964
sg13
I1
sasa(dp965
g2
S'The case presented is, to our knowledge, the first published report comprising a combination of a semilobar holoprosencephaly associated with a Chiari II malformation and a myelomeningocele diagnosed prenatally and confirmed by postmortem neuropathologic evaluation.\n'
p966
sg4
(lp967
sg14
(lp968
(dp969
g7
I154
sg17
VC0000768
p970
sg10
I12
sg11
Vmalformation
p971
sg13
I1
sa(dp972
g7
I98
sg17
VC0751617
p973
sg10
I27
sg11
Vsemilobar holoprosencephaly
p974
sg13
I2
sa(dp975
g7
I173
sg17
VC0025312
p976
sg10
I16
sg11
Vmyelomeningocele
p977
sg13
I1
sasa(dp978
g2
S'These findings indicate that in the case of pre- and postnatal detection of a myelomeningocele and/or Chiari II malformation, possible additional intracranial malformation, such as a semilobar holoprosencephaly, should also be taken into account and vice versa.\n'
p979
sg4
(lp980
sg14
(lp981
(dp982
g7
I78
sg17
VC0025312
p983
sg10
I16
sg11
Vmyelomeningocele
p984
sg13
I1
sa(dp985
g7
I183
sg17
VC0751617
p986
sg10
I27
sg11
Vsemilobar holoprosencephaly
p987
sg13
I2
sa(dp988
g7
I112
sg17
VC0000768
p989
sg10
I12
sg11
Vmalformation
p990
sg13
I1
sa(dp991
g7
I112
sg17
VC0000768
p992
sg10
I12
sg11
Vmalformation
p993
sg13
I1
sasa(dp994
g2
S'We report on a female still-birth with cebocephaly, alobar holoprosencephaly, cleft palate, lumbar spina bifida, sirenomelia, a single umbilical artery, and a 46,XX karyotype, but without maternal diabetes mellitus.\n'
p995
sg4
(lp996
sg14
(lp997
(dp998
g7
I188
sg17
VC1283034
p999
sg10
I26
sg11
Vmaternal diabetes mellitus
p1000
sg13
I3
sa(dp1001
g7
I99
sg17
VC0080178
p1002
sg10
I12
sg11
Vspina bifida
p1003
sg13
I2
sa(dp1004
g7
I113
sg17
VC0037205
p1005
sg10
I11
sg11
Vsirenomelia
p1006
sg13
I1
sa(dp1007
g7
I78
sg17
VC0008925
p1008
sg10
I12
sg11
Vcleft palate
p1009
sg13
I2
sa(dp1010
g7
I39
sg17
VC0266679
p1011
sg10
I11
sg11
Vcebocephaly
p1012
sg13
I1
sa(dp1013
g7
I52
sg17
VC0431363
p1014
sg10
I24
sg11
Valobar holoprosencephaly
p1015
sg13
I2
sa(dp1016
g7
I128
sg17
VC0266795
p1017
sg10
I23
sg11
Vsingle umbilical artery
p1018
sg13
I3
sasa(dp1019
g2
S'The current study provides novel evidence that TGFBeta upregulates the expression of multiple receptor tyrosine kinases (RTKs), including IGF1R, EGFR, PDGFBetaR, and FGFR1 in human hepatocellular carcinoma (HCC) cells.\n'
p1020
sg4
(lp1021
(dp1022
g7
I47
sg8
VP01137
p1023
sg10
I7
sg11
VTGFBeta
p1024
sg13
I1
sa(dp1025
g7
I166
sg8
VP20930
p1026
sg10
I5
sg11
VFGFR1
p1027
sg13
I1
sa(dp1028
g7
I94
sg8
VP29401
p1029
sg10
I25
sg11
Vreceptor tyrosine kinases
p1030
sg13
I3
sa(dp1031
g7
I121
sg8
VP35968
p1032
sg10
I4
sg11
VRTKs
p1033
sg13
I1
sa(dp1034
g7
I138
sg8
VP08069
p1035
sg10
I5
sg11
VIGF1R
p1036
sg13
I1
sasg14
(lp1037
(dp1038
g7
I207
sg17
VC2239176
p1039
sg10
I3
sg11
VHCC
p1040
sg13
I1
sa(dp1041
g7
I181
sg17
VC2239176
p1042
sg10
I24
sg11
Vhepatocellular carcinoma
p1043
sg13
I2
sasa(dp1044
g2
S'While numerical and functional defects of invariant NKT cells have been demonstrated in rheumatoid arthritis (RA), the detailed characterization of proliferative and secretory responses following CD1d-mediated presentation is lacking; the presence of non-invariant populations has never been assessed in human autoimmunity.\n'
p1045
sg4
(lp1046
(dp1047
g7
I196
sg8
VP15813
p1048
sg10
I4
sg11
VCD1d
p1049
sg13
I1
sasg14
(lp1050
(dp1051
g7
I310
sg17
VC0004368
p1052
sg10
I12
sg11
Vautoimmunity
p1053
sg13
I1
sa(dp1054
g7
I110
sg17
VC0003873
p1055
sg10
I2
sg11
VRA
p1056
sg13
I1
sa(dp1057
g7
I148
sg17
VC0334094
p1058
sg10
I13
sg11
Vproliferative
p1059
sg13
I1
sa(dp1060
g7
I88
sg17
VC0003873
p1061
sg10
I20
sg11
Vrheumatoid arthritis
p1062
sg13
I2
sasa(dp1063
g2
S'In adults, angiopoietin-2 (Ang-2) and its soluble receptor (sTie-2) are associated with diabetes, hypertension, and obesity and could be increased in children with OSA and obesity, particularly those with evidence of cardiometabolic alterations.\n'
p1064
sg4
(lp1065
(dp1066
g7
I27
sg8
VP03950
p1067
sg10
I5
sg11
VAng-2
p1068
sg13
I1
sa(dp1069
g7
I11
sg8
g9
sg10
I14
sg11
Vangiopoietin-2
p1070
sg13
I1
sasg14
(lp1071
(dp1072
g7
I98
sg17
VC0020538
p1073
sg10
I12
sg11
Vhypertension
p1074
sg13
I1
sa(dp1075
g7
I88
sg17
VC0011849
p1076
sg10
I8
sg11
Vdiabetes
p1077
sg13
I1
sa(dp1078
g7
I116
sg17
VC0028754
p1079
sg10
I7
sg11
Vobesity
p1080
sg13
I1
sa(dp1081
g7
I116
sg17
VC0028754
p1082
sg10
I7
sg11
Vobesity
p1083
sg13
I1
sa(dp1084
g7
I164
sg17
VC0520679
p1085
sg10
I3
sg11
VOSA
p1086
sg13
I1
sasa(dp1087
g2
S'Children with obesity and OSA had significantly elevated plasma Ang-2 and sTie-2 levels compared to corresponding controls with and without obesity.\n'
p1088
sg4
(lp1089
(dp1090
g7
I57
sg8
VP03950
p1091
sg10
I12
sg11
Vplasma Ang-2
p1092
sg13
I2
sasg14
(lp1093
(dp1094
g7
I14
sg17
VC0028754
p1095
sg10
I7
sg11
Vobesity
p1096
sg13
I1
sa(dp1097
g7
I14
sg17
VC0028754
p1098
sg10
I7
sg11
Vobesity
p1099
sg13
I1
sa(dp1100
g7
I26
sg17
VC0520679
p1101
sg10
I3
sg11
VOSA
p1102
sg13
I1
sasa(dp1103
g2
S'Ang-2 and sTie-2 plasma levels are increased in pediatric OSA and obesity, particularly when endothelial dysfunction or insulin resistance is detectable, and appear to decrease upon OSA treatment.\n'
p1104
sg4
(lp1105
(dp1106
g7
I120
sg8
VP01308
p1107
sg10
I7
sg11
Vinsulin
p1108
sg13
I1
sa(dp1109
g7
I0
sg8
VP03950
p1110
sg10
I5
sg11
VAng-2
p1111
sg13
I1
sasg14
(lp1112
(dp1113
g7
I58
sg17
VC0520679
p1114
sg10
I3
sg11
VOSA
p1115
sg13
I1
sa(dp1116
g7
I66
sg17
VC0028754
p1117
sg10
I7
sg11
Vobesity
p1118
sg13
I1
sa(dp1119
g7
I58
sg17
VC0520679
p1120
sg10
I3
sg11
VOSA
p1121
sg13
I1
sa(dp1122
g7
I120
sg17
VC0021655
p1123
sg10
I18
sg11
Vinsulin resistance
p1124
sg13
I2
sa(dp1125
g7
I93
sg17
VC0856169
p1126
sg10
I23
sg11
Vendothelial dysfunction
p1127
sg13
I2
sasa(dp1128
g2
S'ANG-2 overexpressing mice show increased sWAT vascularization and are resistant to HFD-induced obesity.\n'
p1129
sg4
(lp1130
(dp1131
g7
I0
sg8
VP03950
p1132
sg10
I5
sg11
VANG-2
p1133
sg13
I1
sasg14
(lp1134
(dp1135
g7
I95
sg17
VC0028754
p1136
sg10
I7
sg11
Vobesity
p1137
sg13
I1
sa(dp1138
g7
I46
sg17
VC0027686
p1139
sg10
I15
sg11
Vvascularization
p1140
sg13
I1
sasa(dp1141
g2
S'We studied the effect of sleeve gastrectomy and the influence of FTO rs9930506 polymorphism on Tie-2, angiopoietin-1 and angiopoietin-2 expression in morbid obesity.\n'
p1142
sg4
(lp1143
(dp1144
g7
I102
sg8
g9
sg10
I14
sg11
Vangiopoietin-1
p1145
sg13
I1
sa(dp1146
g7
I121
sg8
g9
sg10
I14
sg11
Vangiopoietin-2
p1147
sg13
I1
sa(dp1148
g7
I65
sg8
g9
sg10
I13
sg11
VFTO rs9930506
p1149
sg13
I2
sa(dp1150
g7
I95
sg8
g9
sg10
I5
sg11
VTie-2
p1151
sg13
I1
sasg14
(lp1152
(dp1153
g7
I150
sg17
VC0028756
p1154
sg10
I14
sg11
Vmorbid obesity
p1155
sg13
I2
sasa(dp1156
g2
S'Those most at risk report a family history of at least one parent with a pre-existing G-alpha protein defect, including night blindness, pseudohypoparathyroidism or adenoma of the thyroid or pituitary gland.\n'
p1157
sg4
(lp1158
sg14
(lp1159
(dp1160
g7
I165
sg17
VC0151468
p1161
sg10
I22
sg11
Vadenoma of the thyroid
p1162
sg13
I4
sa(dp1163
g7
I137
sg17
VC3494506
p1164
sg10
I24
sg11
Vpseudohypoparathyroidism
p1165
sg13
I1
sa(dp1166
g7
I120
sg17
VC0028077
p1167
sg10
I15
sg11
Vnight blindness
p1168
sg13
I2
sasa(dp1169
g2
S'We have previously shown that the ethanol extract of dried Angelica gigas Nakai (AGN) root exerts anticancer activity against androgen receptor (AR)-negative human DU145 and PC-3 prostate cancer xenografts and primary carcinogenesis in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.\n'
p1170
sg4
(lp1171
(dp1172
g7
I126
sg8
VP10275
p1173
sg10
I17
sg11
Vandrogen receptor
p1174
sg13
I2
sa(dp1175
g7
I145
sg8
VP10275
p1176
sg10
I2
sg11
VAR
p1177
sg13
I1
sasg14
(lp1178
(dp1179
g7
I251
sg17
VC0001418
p1180
sg10
I14
sg11
Vadenocarcinoma
p1181
sg13
I1
sa(dp1182
g7
I218
sg17
VC0596263
p1183
sg10
I14
sg11
Vcarcinogenesis
p1184
sg13
I1
sa(dp1185
g7
I179
sg17
VC0600139
p1186
sg10
I15
sg11
Vprostate cancer
p1187
sg13
I2
sasa(dp1188
g2
S'We showed previously that nuclear localization of the androgen receptor (AR) and expression of the androgen-responsive gene FK506-binding protein 5 (FKBP5) in esophageal adenocarcinoma (EAC) tissues were associated with decreased patient survival, suggesting a role for androgens in this cancer.\n'
p1189
sg4
(lp1190
(dp1191
g7
I73
sg8
VP10275
p1192
sg10
I2
sg11
VAR
p1193
sg13
I1
sa(dp1194
g7
I99
sg8
g9
sg10
I48
sg11
Vandrogen-responsive gene FK506-binding protein 5
p1195
sg13
I5
sa(dp1196
g7
I149
sg8
g9
sg10
I5
sg11
VFKBP5
p1197
sg13
I1
sa(dp1198
g7
I54
sg8
VP10275
p1199
sg10
I17
sg11
Vandrogen receptor
p1200
sg13
I2
sasg14
(lp1201
(dp1202
g7
I159
sg17
VC0279628
p1203
sg10
I25
sg11
Vesophageal adenocarcinoma
p1204
sg13
I2
sa(dp1205
g7
I288
sg17
VC0006826
p1206
sg10
I6
sg11
Vcancer
p1207
sg13
I1
sa(dp1208
g7
I186
sg17
VC1275122
p1209
sg10
I3
sg11
VEAC
p1210
sg13
I1
sasa(dp1211
g2
S'Only 5 samples were ERG-/AR- corresponding to adenocarcinoma GS of 6.\n'
p1212
sg4
(lp1213
(dp1214
g7
I46
sg8
VP15104
p1215
sg10
I17
sg11
Vadenocarcinoma GS
p1216
sg13
I2
sasg14
(lp1217
(dp1218
g7
I46
sg17
VC0001418
p1219
sg10
I14
sg11
Vadenocarcinoma
p1220
sg13
I1
sasa(dp1221
g2
S'AR was expressed by 54% (27/50) of ECA including 60% of low grade endometrioid carcinomas, 70% high grade endometrioid carcinomas, 70% serous carcinomas, 50% carcinosarcomas, and 20% clear cell carcinomas.\n'
p1222
sg4
(lp1223
sg14
(lp1224
(dp1225
g7
I79
sg17
VC0007097
p1226
sg10
I10
sg11
Vcarcinomas
p1227
sg13
I1
sa(dp1228
g7
I66
sg17
VC0206687
p1229
sg10
I23
sg11
Vendometrioid carcinomas
p1230
sg13
I2
sa(dp1231
g7
I79
sg17
VC0007097
p1232
sg10
I10
sg11
Vcarcinomas
p1233
sg13
I1
sa(dp1234
g7
I158
sg17
VC0007140
p1235
sg10
I15
sg11
Vcarcinosarcomas
p1236
sg13
I1
sa(dp1237
g7
I66
sg17
VC0206687
p1238
sg10
I23
sg11
Vendometrioid carcinomas
p1239
sg13
I2
sasa(dp1240
g2
S'High AR expression was chiefly restricted to a subset of serous carcinomas (50%).\n'
p1241
sg4
(lp1242
sg14
(lp1243
(dp1244
g7
I64
sg17
VC0007097
p1245
sg10
I10
sg11
Vcarcinomas
p1246
sg13
I1
sasa(dp1247
g2
S'AR expression occurred most often in concert with ER staining, although 5 high grade cancers (1 serous carcinoma, 4 carcinosarcomas) showed AR expression in the absence of ER.\n'
p1248
sg4
(lp1249
sg14
(lp1250
(dp1251
g7
I85
sg17
VC0006826
p1252
sg10
I7
sg11
Vcancers
p1253
sg13
I1
sa(dp1254
g7
I116
sg17
VC0007140
p1255
sg10
I15
sg11
Vcarcinosarcomas
p1256
sg13
I1
sa(dp1257
g7
I96
sg17
VC0206701
p1258
sg10
I16
sg11
Vserous carcinoma
p1259
sg13
I2
sasa(dp1260
g2
S'In summary, AR positivity is seen in over half of ECA in our study, including the majority of low grade endometrioid carcinomas, high grade endometrioid carcinomas, and serous carcinomas.\n'
p1261
sg4
(lp1262
sg14
(lp1263
(dp1264
g7
I104
sg17
VC0206687
p1265
sg10
I23
sg11
Vendometrioid carcinomas
p1266
sg13
I2
sa(dp1267
g7
I117
sg17
VC0007097
p1268
sg10
I10
sg11
Vcarcinomas
p1269
sg13
I1
sa(dp1270
g7
I104
sg17
VC0206687
p1271
sg10
I23
sg11
Vendometrioid carcinomas
p1272
sg13
I2
sasa(dp1273
g2
S'High level expression is seen in half of serous carcinomas and a subset of serous carcinomas and carcinosarcomas show some degree of AR staining in the absence of ER, suggesting a possible role for androgen inhibition in treatment of these cases.\n'
p1274
sg4
(lp1275
sg14
(lp1276
(dp1277
g7
I48
sg17
VC0007097
p1278
sg10
I10
sg11
Vcarcinomas
p1279
sg13
I1
sa(dp1280
g7
I97
sg17
VC0007140
p1281
sg10
I15
sg11
Vcarcinosarcomas
p1282
sg13
I1
sa(dp1283
g7
I48
sg17
VC0007097
p1284
sg10
I10
sg11
Vcarcinomas
p1285
sg13
I1
sasa(dp1286
g2
S'IL-6 and the MSC markers CD166 and nestin were colocalized in macroscopically normal human cartilage taken from the lateral femoral compartment of knees with medial tibiofemoral osteoarthritis.\n'
p1287
sg4
(lp1288
(dp1289
g7
I35
sg8
VP48681
p1290
sg10
I6
sg11
Vnestin
p1291
sg13
I1
sa(dp1292
g7
I25
sg8
g9
sg10
I5
sg11
VCD166
p1293
sg13
I1
sa(dp1294
g7
I13
sg8
g9
sg10
I3
sg11
VMSC
p1295
sg13
I1
sa(dp1296
g7
I0
sg8
VP05231
p1297
sg10
I4
sg11
VIL-6
p1298
sg13
I1
sasg14
(lp1299
(dp1300
g7
I178
sg17
VC0029408
p1301
sg10
I14
sg11
Vosteoarthritis
p1302
sg13
I1
sasa(dp1303
g2
S'In conclusion, our findings support a model where Sirt3 plays a protective role against oxidative stress in oocytes exposed to maternal diabetes through deacetylating SOD2K68.\n'
p1304
sg4
(lp1305
(dp1306
g7
I50
sg8
g9
sg10
I5
sg11
VSirt3
p1307
sg13
I1
sasg14
(lp1308
(dp1309
g7
I127
sg17
VC0085207
p1310
sg10
I17
sg11
Vmaternal diabetes
p1311
sg13
I2
sa(dp1312
g7
I88
sg17
VC0242606
p1313
sg10
I16
sg11
Voxidative stress
p1314
sg13
I2
sasa(dp1315
g2
S'The aim of our study was to investigate the effects of LPL (rs320), LIPC (rs2070895), SCARB1 (rs5888), LCAT (rs2292318), CETP (rs708272), ADIPOQ (rs1501299), RETN (rs3745367), PON1 (rs662), and MNSOD (rs4880) gene polymorphisms on lipid metabolism and diabetic dyslipidemia.\n'
p1316
sg4
(lp1317
(dp1318
g7
I55
sg8
VP06858
p1319
sg10
I3
sg11
VLPL
p1320
sg13
I1
sa(dp1321
g7
I194
sg8
VP04179
p1322
sg10
I5
sg11
VMNSOD
p1323
sg13
I1
sa(dp1324
g7
I121
sg8
VP11597
p1325
sg10
I4
sg11
VCETP
p1326
sg13
I1
sa(dp1327
g7
I86
sg8
g9
sg10
I6
sg11
VSCARB1
p1328
sg13
I1
sa(dp1329
g7
I158
sg8
g9
sg10
I4
sg11
VRETN
p1330
sg13
I1
sa(dp1331
g7
I68
sg8
VP11150
p1332
sg10
I16
sg11
VLIPC (rs2070895)
p1333
sg13
I2
sa(dp1334
g7
I176
sg8
VP27169
p1335
sg10
I4
sg11
VPON1
p1336
sg13
I1
sasg14
(lp1337
(dp1338
g7
I252
sg17
VC3160761
p1339
sg10
I21
sg11
Vdiabetic dyslipidemia
p1340
sg13
I2
sasa(dp1341
g2
S'Significant associations were observed between LPL (rs320) (p&lt;0.001), LIPC (rs2070895) (p&lt;0.001), SCARB1 (rs5888) (p&lt;0.001), LCAT (rs2292318) (p&lt;0.001), CETP (rs708272) (p&lt;0.001), ADIPOQ (rs1501299) (p=0.01), RETN (rs3745367) (p&lt;0.001), and MNSOD (rs4880) (p&lt;0.001) polymorphisms and diabetic dyslipidemia.\n'
p1342
sg4
(lp1343
(dp1344
g7
I73
sg8
VP11150
p1345
sg10
I4
sg11
VLIPC
p1346
sg13
I1
sa(dp1347
g7
I47
sg8
VP06858
p1348
sg10
I3
sg11
VLPL
p1349
sg13
I1
sa(dp1350
g7
I104
sg8
g9
sg10
I6
sg11
VSCARB1
p1351
sg13
I1
sa(dp1352
g7
I259
sg8
VP04179
p1353
sg10
I5
sg11
VMNSOD
p1354
sg13
I1
sa(dp1355
g7
I165
sg8
VP11597
p1356
sg10
I4
sg11
VCETP
p1357
sg13
I1
sa(dp1358
g7
I224
sg8
g9
sg10
I4
sg11
VRETN
p1359
sg13
I1
sasg14
(lp1360
(dp1361
g7
I305
sg17
VC3160761
p1362
sg10
I21
sg11
Vdiabetic dyslipidemia
p1363
sg13
I2
sasa(dp1364
g2
S'LPL (rs320), LIPC (rs2070895), SCARB1 (rs5888), LCAT (rs2292318), CETP (rs708272), ADIPOQ (rs1501299), RETN (rs3745367), and MNSOD (rs4880) polymorphisms play an important role in basic molecular metabolism in diabetic dyslipidemia.\n'
p1365
sg4
(lp1366
(dp1367
g7
I31
sg8
g9
sg10
I6
sg11
VSCARB1
p1368
sg13
I1
sa(dp1369
g7
I13
sg8
VP11150
p1370
sg10
I16
sg11
VLIPC (rs2070895)
p1371
sg13
I2
sa(dp1372
g7
I103
sg8
g9
sg10
I4
sg11
VRETN
p1373
sg13
I1
sa(dp1374
g7
I0
sg8
VP06858
p1375
sg10
I3
sg11
VLPL
p1376
sg13
I1
sa(dp1377
g7
I66
sg8
VP11597
p1378
sg10
I4
sg11
VCETP
p1379
sg13
I1
sa(dp1380
g7
I125
sg8
VP04179
p1381
sg10
I5
sg11
VMNSOD
p1382
sg13
I1
sasg14
(lp1383
(dp1384
g7
I210
sg17
VC3160761
p1385
sg10
I21
sg11
Vdiabetic dyslipidemia
p1386
sg13
I2
sasa(dp1387
g2
S'We studied if YKL-40 is related to inflammation, fibrosis, and/or lung function in subjects exposed to asbestosis.\n'
p1388
sg4
(lp1389
sg14
(lp1390
(dp1391
g7
I35
sg17
VC0021368
p1392
sg10
I12
sg11
Vinflammation
p1393
sg13
I1
sa(dp1394
g7
I103
sg17
VC0003949
p1395
sg10
I10
sg11
Vasbestosis
p1396
sg13
I1
sa(dp1397
g7
I49
sg17
VC0016059
p1398
sg10
I8
sg11
Vfibrosis
p1399
sg13
I1
sasa(dp1400
g2
S'Plasma YKL-40 levels were significantly higher in subjects with asbestosis (n = 19) than in those with no fibrotic findings in HRCT following asbestos exposure (n = 66) or in unexposed healthy controls.\n'
p1401
sg4
(lp1402
(dp1403
g7
I0
sg8
VP36222
p1404
sg10
I13
sg11
VPlasma YKL-40
p1405
sg13
I2
sasg14
(lp1406
(dp1407
g7
I64
sg17
VC0003949
p1408
sg10
I10
sg11
Vasbestosis
p1409
sg13
I1
sasa(dp1410
g2
S'YKL-40 is a promising marker of cardiovascular disease and liver siderosis in Beta-TM patients.\n'
p1411
sg4
(lp1412
(dp1413
g7
I0
sg8
VP36222
p1414
sg10
I6
sg11
VYKL-40
p1415
sg13
I1
sasg14
(lp1416
(dp1417
g7
I65
sg17
VC0037061
p1418
sg10
I9
sg11
Vsiderosis
p1419
sg13
I1
sa(dp1420
g7
I32
sg17
VC0007222
p1421
sg10
I22
sg11
Vcardiovascular disease
p1422
sg13
I2
sasa(dp1423
g2
S'The aim of the study was to analyse the level of serum YKL-40 and plasma chitotriosidase activity of patients with beta-thalassemia to assess whether their expression correlates with liver disease and degree of liver siderosis.\n'
p1424
sg4
(lp1425
(dp1426
g7
I49
sg8
VP36222
p1427
sg10
I12
sg11
Vserum YKL-40
p1428
sg13
I2
sa(dp1429
g7
I66
sg8
g9
sg10
I22
sg11
Vplasma chitotriosidase
p1430
sg13
I2
sasg14
(lp1431
(dp1432
g7
I115
sg17
VC0005283
p1433
sg10
I16
sg11
Vbeta-thalassemia
p1434
sg13
I1
sa(dp1435
g7
I217
sg17
VC0037061
p1436
sg10
I9
sg11
Vsiderosis
p1437
sg13
I1
sa(dp1438
g7
I183
sg17
VC0023895
p1439
sg10
I13
sg11
Vliver disease
p1440
sg13
I2
sasa(dp1441
g2
S'Our results demonstrated that (1) Invasive ductal carcinoma patients with low expression of Slit2 or Robo1 exhibited worse prognosis and brain-specific metastasis, but not liver, bone or lung.\n'
p1442
sg4
(lp1443
(dp1444
g7
I101
sg8
g9
sg10
I5
sg11
VRobo1
p1445
sg13
I1
sa(dp1446
g7
I92
sg8
g9
sg10
I5
sg11
VSlit2
p1447
sg13
I1
sasg14
(lp1448
(dp1449
g7
I152
sg17
VC0027627
p1450
sg10
I10
sg11
Vmetastasis
p1451
sg13
I1
sa(dp1452
g7
I34
sg17
VC1134719
p1453
sg10
I25
sg11
VInvasive ductal carcinoma
p1454
sg13
I3
sasa(dp1455
g2
S'Ten prognostic and diagnostic epigenetic breast cancer biomarkers (PITX2, RASSF1A, PLAU, LHX3, PITX3, LIMK1, SLITRK1, SLIT2, HS3ST2, and TFF1) were analyzed in tissue samples obtained from two patients with invasive ductal carcinoma of the breast.\n'
p1456
sg4
(lp1457
(dp1458
g7
I102
sg8
VP53667
p1459
sg10
I5
sg11
VLIMK1
p1460
sg13
I1
sa(dp1461
g7
I137
sg8
VP04155
p1462
sg10
I4
sg11
VTFF1
p1463
sg13
I1
sa(dp1464
g7
I125
sg8
g9
sg10
I6
sg11
VHS3ST2
p1465
sg13
I1
sa(dp1466
g7
I83
sg8
VP00749
p1467
sg10
I4
sg11
VPLAU
p1468
sg13
I1
sa(dp1469
g7
I109
sg8
g9
sg10
I7
sg11
VSLITRK1
p1470
sg13
I1
sa(dp1471
g7
I89
sg8
g9
sg10
I4
sg11
VLHX3
p1472
sg13
I1
sa(dp1473
g7
I67
sg8
g9
sg10
I5
sg11
VPITX2
p1474
sg13
I1
sa(dp1475
g7
I118
sg8
g9
sg10
I5
sg11
VSLIT2
p1476
sg13
I1
sa(dp1477
g7
I95
sg8
g9
sg10
I5
sg11
VPITX3
p1478
sg13
I1
sasg14
(lp1479
(dp1480
g7
I41
sg17
VC0678222
p1481
sg10
I13
sg11
Vbreast cancer
p1482
sg13
I2
sa(dp1483
g7
I207
sg17
VC1134719
p1484
sg10
I39
sg11
Vinvasive ductal carcinoma of the breast
p1485
sg13
I6
sasa(dp1486
g2
S'The aim of this study is to determine the correlation between methylation status of multiple cancer genes, p16(INK4A), p14(ARF), Cyclin D2 and Slit2 in invasive ductal carcinoma of the breast and paired serum DNA and clinicopathological parameters.\n'
p1487
sg4
(lp1488
(dp1489
g7
I119
sg8
VP03971
p1490
sg10
I3
sg11
Vp14
p1491
sg13
I1
sa(dp1492
g7
I129
sg8
VP30279
p1493
sg10
I9
sg11
VCyclin D2
p1494
sg13
I2
sa(dp1495
g7
I107
sg8
VP42771
p1496
sg10
I3
sg11
Vp16
p1497
sg13
I1
sa(dp1498
g7
I123
sg8
VP42771
p1499
sg10
I3
sg11
VARF
p1500
sg13
I1
sa(dp1501
g7
I143
sg8
g9
sg10
I5
sg11
VSlit2
p1502
sg13
I1
sa(dp1503
g7
I111
sg8
VP42771
p1504
sg10
I5
sg11
VINK4A
p1505
sg13
I1
sasg14
(lp1506
(dp1507
g7
I123
sg17
VC0264490
p1508
sg10
I3
sg11
VARF
p1509
sg13
I1
sa(dp1510
g7
I152
sg17
VC1134719
p1511
sg10
I39
sg11
Vinvasive ductal carcinoma of the breast
p1512
sg13
I6
sa(dp1513
g7
I84
sg17
VC0346429
p1514
sg10
I15
sg11
Vmultiple cancer
p1515
sg13
I2
sasa(dp1516
g2
S'To examine the role of IRS2 in allergic disease, we evaluated the responses of IRS2-deficient (IRS2(-/-)) mice.\n'
p1517
sg4
(lp1518
(dp1519
g7
I23
sg8
g9
sg10
I4
sg11
VIRS2
p1520
sg13
I1
sa(dp1521
g7
I23
sg8
g9
sg10
I4
sg11
VIRS2
p1522
sg13
I1
sa(dp1523
g7
I23
sg8
g9
sg10
I4
sg11
VIRS2
p1524
sg13
I1
sasg14
(lp1525
sa(dp1526
g2
S'Additional work further confirmed CDK6, RICTOR, and CTSB (cathepsin B) as targets of miR-218 and examined the functional role of one of these targets, CDK6, in medulloblastoma.\n'
p1527
sg4
(lp1528
(dp1529
g7
I34
sg8
g9
sg10
I4
sg11
VCDK6
p1530
sg13
I1
sa(dp1531
g7
I34
sg8
g9
sg10
I4
sg11
VCDK6
p1532
sg13
I1
sa(dp1533
g7
I40
sg8
g9
sg10
I6
sg11
VRICTOR
p1534
sg13
I1
sasg14
(lp1535
(dp1536
g7
I160
sg17
VC0025149
p1537
sg10
I15
sg11
Vmedulloblastoma
p1538
sg13
I1
sasa(dp1539
g2
S'Overexpression of CDK6 is present in approximately one-third of medulloblastomas and is an independent poor prognostic marker for this disease.\n'
p1540
sg4
(lp1541
(dp1542
g7
I18
sg8
g9
sg10
I4
sg11
VCDK6
p1543
sg13
I1
sasg14
(lp1544
(dp1545
g7
I64
sg17
VC0025149
p1546
sg10
I16
sg11
Vmedulloblastomas
p1547
sg13
I1
sasa(dp1548
g2
S'MicroRNA (miR)-124 inhibits expression of CDK6 and prevents proliferation of glioblastoma and medulloblastoma cells in vitro.\n'
p1549
sg4
(lp1550
(dp1551
g7
I42
sg8
g9
sg10
I4
sg11
VCDK6
p1552
sg13
I1
sasg14
(lp1553
(dp1554
g7
I94
sg17
VC0025149
p1555
sg10
I15
sg11
Vmedulloblastoma
p1556
sg13
I1
sa(dp1557
g7
I77
sg17
VC0017636
p1558
sg10
I12
sg11
Vglioblastoma
p1559
sg13
I1
sa(dp1560
g7
I60
sg17
VC0334094
p1561
sg10
I13
sg11
Vproliferation
p1562
sg13
I1
sasa(dp1563
g2
S'We examined the effects of miR-124 overexpression on medulloblastoma cells both in vitro and in vivo and compared cell lines that have low and high CDK6 expression.\n'
p1564
sg4
(lp1565
(dp1566
g7
I148
sg8
g9
sg10
I4
sg11
VCDK6
p1567
sg13
I1
sasg14
(lp1568
(dp1569
g7
I53
sg17
VC0025149
p1570
sg10
I15
sg11
Vmedulloblastoma
p1571
sg13
I1
sasa(dp1572
g2
S'MiR-124 overexpression inhibits the proliferation of medulloblastoma cells, and this effect is mediated mostly through the action of miR-124 upon CDK6.\n'
p1573
sg4
(lp1574
(dp1575
g7
I133
sg8
g9
sg10
I7
sg11
VmiR-124
p1576
sg13
I1
sa(dp1577
g7
I0
sg8
g9
sg10
I3
sg11
VMiR
p1578
sg13
I1
sa(dp1579
g7
I146
sg8
g9
sg10
I4
sg11
VCDK6
p1580
sg13
I1
sasg14
(lp1581
(dp1582
g7
I53
sg17
VC0025149
p1583
sg10
I15
sg11
Vmedulloblastoma
p1584
sg13
I1
sa(dp1585
g7
I36
sg17
VC0334094
p1586
sg10
I13
sg11
Vproliferation
p1587
sg13
I1
sasa(dp1588
g2
S'CDK6 is overexpressed in medulloblastoma patients and is associated with an adverse prognosis.\n'
p1589
sg4
(lp1590
(dp1591
g7
I0
sg8
g9
sg10
I4
sg11
VCDK6
p1592
sg13
I1
sasg14
(lp1593
(dp1594
g7
I25
sg17
VC0025149
p1595
sg10
I15
sg11
Vmedulloblastoma
p1596
sg13
I1
sasa(dp1597
g2
S'To investigate the role of CDK6 in medulloblastoma, we assayed the effect of CDK6 inhibition on proliferation by depleting expression with RNA interference (RNAi) or by inhibiting kinase function with a small molecule inhibitor, PD0332991.\n'
p1598
sg4
(lp1599
(dp1600
g7
I27
sg8
g9
sg10
I4
sg11
VCDK6
p1601
sg13
I1
sa(dp1602
g7
I27
sg8
g9
sg10
I4
sg11
VCDK6
p1603
sg13
I1
sasg14
(lp1604
(dp1605
g7
I35
sg17
VC0025149
p1606
sg10
I15
sg11
Vmedulloblastoma
p1607
sg13
I1
sa(dp1608
g7
I96
sg17
VC0334094
p1609
sg10
I13
sg11
Vproliferation
p1610
sg13
I1
sasa(dp1611
g2
S'Gene expression analysis revealed that CDK6 mRNA expression is higher than normal cerebellum in fifteen out of sixteen medulloblastoma patient samples.\n'
p1612
sg4
(lp1613
(dp1614
g7
I39
sg8
g9
sg10
I9
sg11
VCDK6 mRNA
p1615
sg13
I2
sasg14
(lp1616
(dp1617
g7
I119
sg17
VC0025149
p1618
sg10
I15
sg11
Vmedulloblastoma
p1619
sg13
I1
sasa(dp1620
g2
S'Inhibition of CDK6 by RNAi significantly decreased medulloblastoma cell proliferation and colony forming potential.\n'
p1621
sg4
(lp1622
(dp1623
g7
I14
sg8
g9
sg10
I4
sg11
VCDK6
p1624
sg13
I1
sasg14
(lp1625
(dp1626
g7
I51
sg17
VC0025149
p1627
sg10
I15
sg11
Vmedulloblastoma
p1628
sg13
I1
sa(dp1629
g7
I72
sg17
VC0334094
p1630
sg10
I13
sg11
Vproliferation
p1631
sg13
I1
sasa(dp1632
g2
S'Our findings suggest that targeting CDK6 with small molecule inhibitors may prove beneficial in the treatment of medulloblastoma, especially when combined with radiation.\n'
p1633
sg4
(lp1634
(dp1635
g7
I36
sg8
g9
sg10
I4
sg11
VCDK6
p1636
sg13
I1
sasg14
(lp1637
(dp1638
g7
I113
sg17
VC0025149
p1639
sg10
I15
sg11
Vmedulloblastoma
p1640
sg13
I1
sasa(dp1641
g2
S'In trichoblastic fibroma (three cases), CK1/5/10/14, CK7, CK8/18, CK10/11, CK14, CK17 and CK19 were expressed in the basaloid nests, and CK6 and involucrin were detected in the inner layers of keratinous cysts.\n'
p1642
sg4
(lp1643
(dp1644
g7
I75
sg8
VP02533
p1645
sg10
I4
sg11
VCK14
p1646
sg13
I1
sa(dp1647
g7
I145
sg8
VP07476
p1648
sg10
I10
sg11
Vinvolucrin
p1649
sg13
I1
sa(dp1650
g7
I66
sg8
VP13645
p1651
sg10
I7
sg11
VCK10/11
p1652
sg13
I1
sa(dp1653
g7
I53
sg8
VP08729
p1654
sg10
I3
sg11
VCK7
p1655
sg13
I1
sa(dp1656
g7
I40
sg8
VP48729
p1657
sg10
I11
sg11
VCK1/5/10/14
p1658
sg13
I1
sasg14
(lp1659
(dp1660
g7
I3
sg17
VC1704236
p1661
sg10
I21
sg11
Vtrichoblastic fibroma
p1662
sg13
I2
sa(dp1663
g7
I204
sg17
VC0010709
p1664
sg10
I5
sg11
Vcysts
p1665
sg13
I1
sasa(dp1666
g2
S'Since type 1 diabetes mellitus often begins in childhood, we used juvenile (4- to 5-wk-old) rats to demonstrate that a single bout of IIH (5 U/kg sc) reduced plasma glucose by 24% and peak epinephrine by 59% 1 day later.\n'
p1667
sg4
(lp1668
sg14
(lp1669
(dp1670
g7
I6
sg17
VC0011854
p1671
sg10
I24
sg11
Vtype 1 diabetes mellitus
p1672
sg13
I4
sasa(dp1673
g2
S'Plasma membrane NADH oxidoreductase activity, studied using cytosolic NADH as substrate and assayed with DCIP as acceptor, was significantly increased in IDDM patients, suggesting a response to a deficient mitochondrial energetic activity.\n'
p1674
sg4
(lp1675
(dp1676
g7
I60
sg8
VP0C870
p1677
sg10
I14
sg11
Vcytosolic NADH
p1678
sg13
I2
sa(dp1679
g7
I0
sg8
VP28331
p1680
sg10
I35
sg11
VPlasma membrane NADH oxidoreductase
p1681
sg13
I4
sasg14
(lp1682
(dp1683
g7
I154
sg17
VC0011854
p1684
sg10
I4
sg11
VIDDM
p1685
sg13
I1
sasa(dp1686
g2
S'Non insulin-dependent diabetic (NIDDM) mortality is 1.4 to 3.7 times that of non-diabetics.\n'
p1687
sg4
(lp1688
(dp1689
g7
I4
sg8
VP01308
p1690
sg10
I7
sg11
Vinsulin
p1691
sg13
I1
sasg14
(lp1692
(dp1693
g7
I32
sg17
VC0011860
p1694
sg10
I5
sg11
VNIDDM
p1695
sg13
I1
sasa(dp1696
g2
S'In the COPD and asthma patients, the median urinary cotinine concentration was 167 ng/mL (range, 2-5,348 ng/mL) and 47 ng/mL (range, 5-2,735 ng/mL), respectively (p &lt; 0.0001), whereas the median eCO level was 8 ppm (range, 0-31 ppm) and 5 ppm (range, 2-45 ppm), respectively (p &lt; 0.05).\n'
p1697
sg4
(lp1698
(dp1699
g7
I198
sg8
g9
sg10
I3
sg11
VeCO
p1700
sg13
I1
sasg14
(lp1701
(dp1702
g7
I16
sg17
VC0004096
p1703
sg10
I6
sg11
Vasthma
p1704
sg13
I1
sa(dp1705
g7
I198
sg17
VC2675227
p1706
sg10
I3
sg11
VeCO
p1707
sg13
I1
sa(dp1708
g7
I7
sg17
VC0024117
p1709
sg10
I4
sg11
VCOPD
p1710
sg13
I1
sasa(dp1711
g2
S'In 30 (29%) of the patients with asthma or COPD, the urinary cotinine concentration and the eCO level both belied the patient claims of not being current smokers.\n'
p1712
sg4
(lp1713
(dp1714
g7
I92
sg8
g9
sg10
I3
sg11
VeCO
p1715
sg13
I1
sasg14
(lp1716
(dp1717
g7
I43
sg17
VC0024117
p1718
sg10
I4
sg11
VCOPD
p1719
sg13
I1
sa(dp1720
g7
I33
sg17
VC0004096
p1721
sg10
I6
sg11
Vasthma
p1722
sg13
I1
sa(dp1723
g7
I92
sg17
VC2675227
p1724
sg10
I3
sg11
VeCO
p1725
sg13
I1
sasa(dp1726
g2
S'We aimed to study eCO levels in asthmatics and detect the possible factors influencing them.\n'
p1727
sg4
(lp1728
sg14
(lp1729
(dp1730
g7
I18
sg17
VC2675227
p1731
sg10
I3
sg11
VeCO
p1732
sg13
I1
sa(dp1733
g7
I32
sg17
VC0004096
p1734
sg10
I10
sg11
Vasthmatics
p1735
sg13
I1
sasa(dp1736
g2
S'The differences in eCO levels among various asthmatic phenotypes and the correlations between eCO and other measured parameters (spirometric indices, Asthma Control Test score, exhaled nitric oxide, total IgE, blood eosinophils and marker of oxidative damage of proteins) were analysed.\n'
p1737
sg4
(lp1738
(dp1739
g7
I19
sg8
g9
sg10
I3
sg11
VeCO
p1740
sg13
I1
sa(dp1741
g7
I19
sg8
g9
sg10
I3
sg11
VeCO
p1742
sg13
I1
sa(dp1743
g7
I205
sg8
VP01854
p1744
sg10
I3
sg11
VIgE
p1745
sg13
I1
sasg14
(lp1746
(dp1747
g7
I19
sg17
VC2675227
p1748
sg10
I3
sg11
VeCO
p1749
sg13
I1
sa(dp1750
g7
I44
sg17
VC0004096
p1751
sg10
I9
sg11
Vasthmatic
p1752
sg13
I1
sa(dp1753
g7
I19
sg17
VC2675227
p1754
sg10
I3
sg11
VeCO
p1755
sg13
I1
sa(dp1756
g7
I150
sg17
VC0004096
p1757
sg10
I6
sg11
VAsthma
p1758
sg13
I1
sa(dp1759
g7
I205
sg17
VC0270850
p1760
sg10
I3
sg11
VIgE
p1761
sg13
I1
sasa(dp1762
g2
S'Levels of eCO widely differed according to the selected characteristics of asthma.\n'
p1763
sg4
(lp1764
sg14
(lp1765
(dp1766
g7
I10
sg17
VC2675227
p1767
sg10
I3
sg11
VeCO
p1768
sg13
I1
sa(dp1769
g7
I75
sg17
VC0004096
p1770
sg10
I6
sg11
Vasthma
p1771
sg13
I1
sasa(dp1772
g2
S'Asthmatics showed higher eCO concentrations than controls (1.44 +/- 0.12 ppm vs. 0.91 +/- 0.11 ppm, p &lt; 0.001).\n'
p1773
sg4
(lp1774
(dp1775
g7
I25
sg8
g9
sg10
I3
sg11
VeCO
p1776
sg13
I1
sasg14
(lp1777
(dp1778
g7
I0
sg17
VC0004096
p1779
sg10
I10
sg11
VAsthmatics
p1780
sg13
I1
sa(dp1781
g7
I25
sg17
VC2675227
p1782
sg10
I3
sg11
VeCO
p1783
sg13
I1
sasa(dp1784
g2
S'Acute exacerbation of asthma was accompanied by a significant increase in eCO compared to the clinically controlled stage (2.17 +/- 0.36 ppm vs. 1.33 +/- 0.13 ppm, p &lt; 0.001).\n'
p1785
sg4
(lp1786
sg14
(lp1787
(dp1788
g7
I74
sg17
VC2675227
p1789
sg10
I3
sg11
VeCO
p1790
sg13
I1
sa(dp1791
g7
I22
sg17
VC0004096
p1792
sg10
I6
sg11
Vasthma
p1793
sg13
I1
sasa(dp1794
g2
S'Atopic, non-atopic asthma and asthma associated with allergic rhinitis (AR) showed elevated levels of eCO.\n'
p1795
sg4
(lp1796
(dp1797
g7
I53
sg8
g9
sg10
I22
sg11
Vallergic rhinitis (AR)
p1798
sg13
I3
sa(dp1799
g7
I102
sg8
g9
sg10
I3
sg11
VeCO
p1800
sg13
I1
sasg14
(lp1801
(dp1802
g7
I12
sg17
VC0155877
p1803
sg10
I13
sg11
Vatopic asthma
p1804
sg13
I2
sa(dp1805
g7
I53
sg17
VC2607914
p1806
sg10
I17
sg11
Vallergic rhinitis
p1807
sg13
I2
sa(dp1808
g7
I19
sg17
VC0004096
p1809
sg10
I6
sg11
Vasthma
p1810
sg13
I1
sa(dp1811
g7
I102
sg17
VC2675227
p1812
sg10
I3
sg11
VeCO
p1813
sg13
I1
sa(dp1814
g7
I72
sg17
VC2607914
p1815
sg10
I2
sg11
VAR
p1816
sg13
I1
sa(dp1817
g7
I0
sg17
VC0392707
p1818
sg10
I6
sg11
VAtopic
p1819
sg13
I1
sasa(dp1820
g2
S'The levels of eCO negatively correlated with the marker of protein oxidation in asthmatics, especially in atopic form and during acute exacerbation.\n'
p1821
sg4
(lp1822
(dp1823
g7
I14
sg8
g9
sg10
I3
sg11
VeCO
p1824
sg13
I1
sasg14
(lp1825
(dp1826
g7
I14
sg17
VC2675227
p1827
sg10
I3
sg11
VeCO
p1828
sg13
I1
sa(dp1829
g7
I80
sg17
VC0004096
p1830
sg10
I10
sg11
Vasthmatics
p1831
sg13
I1
sa(dp1832
g7
I106
sg17
VC0392707
p1833
sg10
I6
sg11
Vatopic
p1834
sg13
I1
sasa(dp1835
g2
S'In a population of asthmatic children, eCO levels could be considered as a marker of both allergic inflammation and oxidative stress in the airways.\n'
p1836
sg4
(lp1837
(dp1838
g7
I39
sg8
g9
sg10
I3
sg11
VeCO
p1839
sg13
I1
sasg14
(lp1840
(dp1841
g7
I90
sg17
VC0021375
p1842
sg10
I21
sg11
Vallergic inflammation
p1843
sg13
I2
sa(dp1844
g7
I116
sg17
VC0242606
p1845
sg10
I16
sg11
Voxidative stress
p1846
sg13
I2
sa(dp1847
g7
I39
sg17
VC2675227
p1848
sg10
I3
sg11
VeCO
p1849
sg13
I1
sa(dp1850
g7
I19
sg17
VC0004096
p1851
sg10
I9
sg11
Vasthmatic
p1852
sg13
I1
sasa(dp1853
g2
S'Concomitant AR and asthma control were the most important factors affecting the levels of eCO in asthmatic children.\n'
p1854
sg4
(lp1855
(dp1856
g7
I90
sg8
g9
sg10
I3
sg11
VeCO
p1857
sg13
I1
sasg14
(lp1858
(dp1859
g7
I97
sg17
VC0004096
p1860
sg10
I9
sg11
Vasthmatic
p1861
sg13
I1
sa(dp1862
g7
I90
sg17
VC2675227
p1863
sg10
I3
sg11
VeCO
p1864
sg13
I1
sa(dp1865
g7
I19
sg17
VC0004096
p1866
sg10
I6
sg11
Vasthma
p1867
sg13
I1
sasa(dp1868
g2
S'eCO values have been evaluated as potential indicators of inflammation in asthma, stable COPD and exacerbations, cystic fibrosis, lung cancer, or during surgery or critical care.\n'
p1869
sg4
(lp1870
(dp1871
g7
I0
sg8
g9
sg10
I3
sg11
VeCO
p1872
sg13
I1
sasg14
(lp1873
(dp1874
g7
I0
sg17
VC2675227
p1875
sg10
I3
sg11
VeCO
p1876
sg13
I1
sa(dp1877
g7
I58
sg17
VC0021368
p1878
sg10
I12
sg11
Vinflammation
p1879
sg13
I1
sa(dp1880
g7
I113
sg17
VC0010674
p1881
sg10
I15
sg11
Vcystic fibrosis
p1882
sg13
I2
sa(dp1883
g7
I74
sg17
VC0004096
p1884
sg10
I6
sg11
Vasthma
p1885
sg13
I1
sa(dp1886
g7
I130
sg17
VC0684249
p1887
sg10
I11
sg11
Vlung cancer
p1888
sg13
I2
sa(dp1889
g7
I89
sg17
VC0024117
p1890
sg10
I4
sg11
VCOPD
p1891
sg13
I1
sasa(dp1892
g2
S'Twenty-four non-smokers (10 male, 14 female, mean age 17.6 years) and 24 smokers (mean of 3.5 pack-years; 15 male, 9 female, mean age 17.8 years) were compared in terms of lung function, bronchial hyperreactivity (BHR), levels of exhaled carbon monoxide (eCO), exhaled nitric oxide (eNO), and blood counts.\n'
p1893
sg4
(lp1894
sg14
(lp1895
(dp1896
g7
I214
sg17
VC0085129
p1897
sg10
I3
sg11
VBHR
p1898
sg13
I1
sa(dp1899
g7
I255
sg17
VC2675227
p1900
sg10
I3
sg11
VeCO
p1901
sg13
I1
sa(dp1902
g7
I187
sg17
VC0085129
p1903
sg10
I25
sg11
Vbronchial hyperreactivity
p1904
sg13
I2
sa(dp1905
g7
I230
sg17
VC2675227
p1906
sg10
I23
sg11
Vexhaled carbon monoxide
p1907
sg13
I3
sasa(dp1908
g2
S'The concentration of exhaled carbon monoxide (eCO) in young children with stable asthma and during acute asthma attack is not known.\n'
p1909
sg4
(lp1910
sg14
(lp1911
(dp1912
g7
I46
sg17
VC2675227
p1913
sg10
I3
sg11
VeCO
p1914
sg13
I1
sa(dp1915
g7
I21
sg17
VC2675227
p1916
sg10
I23
sg11
Vexhaled carbon monoxide
p1917
sg13
I3
sa(dp1918
g7
I105
sg17
VC0347950
p1919
sg10
I13
sg11
Vasthma attack
p1920
sg13
I2
sa(dp1921
g7
I81
sg17
VC0004096
p1922
sg10
I6
sg11
Vasthma
p1923
sg13
I1
sasa(dp1924
g2
S'In preschool-age children, eCO levels of those with asthma attacks (mean +/- SE, 2.7 +/- 0.3 p.p.m., n= 43) were significantly higher than those of subjects with asymptomatic asthma (0.5 +/- 0.1 p.p.m., P &lt; 0.05), URI (0.8 +/- 0.1 p.p.m., P &lt; 0.05) and healthy children (0.4 +/- 0.1 p.p.m., P &lt; 0.05).\n'
p1925
sg4
(lp1926
(dp1927
g7
I27
sg8
g9
sg10
I3
sg11
VeCO
p1928
sg13
I1
sasg14
(lp1929
(dp1930
g7
I52
sg17
VC0004096
p1931
sg10
I6
sg11
Vasthma
p1932
sg13
I1
sa(dp1933
g7
I27
sg17
VC2675227
p1934
sg10
I3
sg11
VeCO
p1935
sg13
I1
sa(dp1936
g7
I52
sg17
VC0347950
p1937
sg10
I14
sg11
Vasthma attacks
p1938
sg13
I2
sasa(dp1939
g2
S'A multivariate linear regression model showed that eCO was higher in children with asthma attacks independent of age and gender.\n'
p1940
sg4
(lp1941
(dp1942
g7
I51
sg8
g9
sg10
I3
sg11
VeCO
p1943
sg13
I1
sasg14
(lp1944
(dp1945
g7
I51
sg17
VC2675227
p1946
sg10
I3
sg11
VeCO
p1947
sg13
I1
sa(dp1948
g7
I83
sg17
VC0347950
p1949
sg10
I14
sg11
Vasthma attacks
p1950
sg13
I2
sasa(dp1951
g2
S'In 33 asthmatic children followed before and after treatment, eCO levels during asthma attacks significantly decreased after inhalation therapy with a combination of salbutamol and sodium cromoglycate (before therapy, 2.9 +/- 0.4 p.p.m.\n'
p1952
sg4
(lp1953
(dp1954
g7
I62
sg8
g9
sg10
I3
sg11
VeCO
p1955
sg13
I1
sasg14
(lp1956
(dp1957
g7
I80
sg17
VC0347950
p1958
sg10
I14
sg11
Vasthma attacks
p1959
sg13
I2
sa(dp1960
g7
I62
sg17
VC2675227
p1961
sg10
I3
sg11
VeCO
p1962
sg13
I1
sa(dp1963
g7
I6
sg17
VC0004096
p1964
sg10
I9
sg11
Vasthmatic
p1965
sg13
I1
sasa(dp1966
g2
S'The measurement of eCO using a novel collecting system is useful in the recognition of asthma in preschool children.\n'
p1967
sg4
(lp1968
(dp1969
g7
I19
sg8
g9
sg10
I3
sg11
VeCO
p1970
sg13
I1
sasg14
(lp1971
(dp1972
g7
I87
sg17
VC0004096
p1973
sg10
I6
sg11
Vasthma
p1974
sg13
I1
sa(dp1975
g7
I19
sg17
VC2675227
p1976
sg10
I3
sg11
VeCO
p1977
sg13
I1
sasa(dp1978
g2
S'Elevations in E-CO have been observed in critically ill or post-surgical patients and those with various pulmonary diseases associated with inflammation, including chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis and infections.\n'
p1979
sg4
(lp1980
sg14
(lp1981
(dp1982
g7
I238
sg17
VC0021311
p1983
sg10
I10
sg11
Vinfections
p1984
sg13
I1
sa(dp1985
g7
I164
sg17
VC0024117
p1986
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p1987
sg13
I4
sa(dp1988
g7
I210
sg17
VC0004096
p1989
sg10
I6
sg11
Vasthma
p1990
sg13
I1
sa(dp1991
g7
I203
sg17
VC0024117
p1992
sg10
I4
sg11
VCOPD
p1993
sg13
I1
sa(dp1994
g7
I140
sg17
VC0021368
p1995
sg10
I12
sg11
Vinflammation
p1996
sg13
I1
sa(dp1997
g7
I105
sg17
VC0024115
p1998
sg10
I18
sg11
Vpulmonary diseases
p1999
sg13
I2
sa(dp2000
g7
I218
sg17
VC0010674
p2001
sg10
I15
sg11
Vcystic fibrosis
p2002
sg13
I2
sa(dp2003
g7
I41
sg17
VC0010340
p2004
sg10
I14
sg11
Vcritically ill
p2005
sg13
I2
sasa(dp2006
g2
S'The purpose of this meta-analysis is to determine whether eCO is elevated in asthmatics, is regulated by steroid treatment and reflects disease severity and control.\n'
p2007
sg4
(lp2008
(dp2009
g7
I58
sg8
g9
sg10
I3
sg11
VeCO
p2010
sg13
I1
sasg14
(lp2011
(dp2012
g7
I58
sg17
VC2675227
p2013
sg10
I3
sg11
VeCO
p2014
sg13
I1
sa(dp2015
g7
I77
sg17
VC0004096
p2016
sg10
I10
sg11
Vasthmatics
p2017
sg13
I1
sasa(dp2018
g2
S'Observational studies comparing eCO in non-smoking asthmatics and healthy subjects or asthmatics before and after steroid treatment were included.\n'
p2019
sg4
(lp2020
sg14
(lp2021
(dp2022
g7
I32
sg17
VC2675227
p2023
sg10
I3
sg11
VeCO
p2024
sg13
I1
sa(dp2025
g7
I51
sg17
VC0004096
p2026
sg10
I10
sg11
Vasthmatics
p2027
sg13
I1
sa(dp2028
g7
I51
sg17
VC0004096
p2029
sg10
I10
sg11
Vasthmatics
p2030
sg13
I1
sasa(dp2031
g2
S'The eCO level was significantly higher in asthmatics as compared to healthy subjects and in intermittent asthma as compared to persistent asthma.\n'
p2032
sg4
(lp2033
(dp2034
g7
I4
sg8
g9
sg10
I3
sg11
VeCO
p2035
sg13
I1
sasg14
(lp2036
(dp2037
g7
I42
sg17
VC0004096
p2038
sg10
I10
sg11
Vasthmatics
p2039
sg13
I1
sa(dp2040
g7
I92
sg17
VC1740754
p2041
sg10
I19
sg11
Vintermittent asthma
p2042
sg13
I2
sa(dp2043
g7
I4
sg17
VC2675227
p2044
sg10
I3
sg11
VeCO
p2045
sg13
I1
sa(dp2046
g7
I127
sg17
VC3266628
p2047
sg10
I17
sg11
Vpersistent asthma
p2048
sg13
I2
sasa(dp2049
g2
S'However, eCO could not distinguish between steroid-treated asthmatics and steroid-free patients nor separate controlled and partly-controlled asthma from uncontrolled asthma in cross-sectional studies.\n'
p2050
sg4
(lp2051
(dp2052
g7
I9
sg8
g9
sg10
I3
sg11
VeCO
p2053
sg13
I1
sasg14
(lp2054
(dp2055
g7
I59
sg17
VC0004096
p2056
sg10
I6
sg11
Vasthma
p2057
sg13
I1
sa(dp2058
g7
I9
sg17
VC2675227
p2059
sg10
I3
sg11
VeCO
p2060
sg13
I1
sa(dp2061
g7
I59
sg17
VC0004096
p2062
sg10
I10
sg11
Vasthmatics
p2063
sg13
I1
sa(dp2064
g7
I59
sg17
VC0004096
p2065
sg10
I6
sg11
Vasthma
p2066
sg13
I1
sasa(dp2067
g2
S'eCO is elevated in asthmatics but levels only partially reflect disease severity and control.\n'
p2068
sg4
(lp2069
(dp2070
g7
I0
sg8
g9
sg10
I3
sg11
VeCO
p2071
sg13
I1
sasg14
(lp2072
(dp2073
g7
I19
sg17
VC0004096
p2074
sg10
I10
sg11
Vasthmatics
p2075
sg13
I1
sa(dp2076
g7
I0
sg17
VC2675227
p2077
sg10
I3
sg11
VeCO
p2078
sg13
I1
sasa(dp2079
g2
S'eCO might be a potentially useful non-invasive biomarker of airway inflammation and oxidative stress in nonsmoking asthmatics.\n'
p2080
sg4
(lp2081
(dp2082
g7
I0
sg8
g9
sg10
I3
sg11
VeCO
p2083
sg13
I1
sasg14
(lp2084
(dp2085
g7
I67
sg17
VC0021368
p2086
sg10
I12
sg11
Vinflammation
p2087
sg13
I1
sa(dp2088
g7
I0
sg17
VC2675227
p2089
sg10
I3
sg11
VeCO
p2090
sg13
I1
sa(dp2091
g7
I115
sg17
VC0004096
p2092
sg10
I10
sg11
Vasthmatics
p2093
sg13
I1
sa(dp2094
g7
I84
sg17
VC0242606
p2095
sg10
I16
sg11
Voxidative stress
p2096
sg13
I2
sasa(dp2097
g2
S'However, recent studies revealed that genetic inhibition of SphK2 did not significantly impact the severity or progression of inflammatory arthritis, while pharmacologic inhibition of SphK2 led to significantly more severe arthritis.\n'
p2098
sg4
(lp2099
(dp2100
g7
I60
sg8
g9
sg10
I5
sg11
VSphK2
p2101
sg13
I1
sa(dp2102
g7
I60
sg8
g9
sg10
I5
sg11
VSphK2
p2103
sg13
I1
sasg14
(lp2104
(dp2105
g7
I139
sg17
VC0003864
p2106
sg10
I9
sg11
Varthritis
p2107
sg13
I1
sa(dp2108
g7
I126
sg17
VC0003864
p2109
sg10
I22
sg11
Vinflammatory arthritis
p2110
sg13
I2
sasa(dp2111
g2
S'Therefore, SphK2 plays a controversial role in arthritis.\n'
p2112
sg4
(lp2113
(dp2114
g7
I11
sg8
g9
sg10
I5
sg11
VSphK2
p2115
sg13
I1
sasg14
(lp2116
(dp2117
g7
I47
sg17
VC0003864
p2118
sg10
I9
sg11
Varthritis
p2119
sg13
I1
sasa(dp2120
g2
S'A specific SphK2 inhibitor inhibited inflammatory arthritis in one model, while siRNA knockdown of SphK2 worsened arthritis in another.\n'
p2121
sg4
(lp2122
(dp2123
g7
I11
sg8
g9
sg10
I5
sg11
VSphK2
p2124
sg13
I1
sa(dp2125
g7
I11
sg8
g9
sg10
I5
sg11
VSphK2
p2126
sg13
I1
sasg14
(lp2127
(dp2128
g7
I37
sg17
VC0003864
p2129
sg10
I22
sg11
Vinflammatory arthritis
p2130
sg13
I2
sa(dp2131
g7
I50
sg17
VC0003864
p2132
sg10
I9
sg11
Varthritis
p2133
sg13
I1
sasa(dp2134
g2
S'To investigate the role of SphK2 in TNF-Alfa-induced arthritis, we developed SphK2 deficient hTNF-Alfa overexpressing mice and separately treated hTNF-Alfa mice with ABC294640, a SphK2-specific inhibitor.\n'
p2135
sg4
(lp2136
(dp2137
g7
I27
sg8
g9
sg10
I5
sg11
VSphK2
p2138
sg13
I1
sa(dp2139
g7
I27
sg8
g9
sg10
I5
sg11
VSphK2
p2140
sg13
I1
sa(dp2141
g7
I27
sg8
g9
sg10
I5
sg11
VSphK2
p2142
sg13
I1
sa(dp2143
g7
I36
sg8
VP01375
p2144
sg10
I3
sg11
VTNF
p2145
sg13
I1
sasg14
(lp2146
(dp2147
g7
I53
sg17
VC0003864
p2148
sg10
I9
sg11
Varthritis
p2149
sg13
I1
sasa(dp2150
g2
S'Our data show that genetic inhibition of SphK2 did not significantly impact the severity or progression of inflammatory arthritis, while pharmacologic inhibition of SphK2 led to significantly more severe arthritis.\n'
p2151
sg4
(lp2152
(dp2153
g7
I41
sg8
g9
sg10
I5
sg11
VSphK2
p2154
sg13
I1
sa(dp2155
g7
I41
sg8
g9
sg10
I5
sg11
VSphK2
p2156
sg13
I1
sasg14
(lp2157
(dp2158
g7
I107
sg17
VC0003864
p2159
sg10
I22
sg11
Vinflammatory arthritis
p2160
sg13
I2
sa(dp2161
g7
I120
sg17
VC0003864
p2162
sg10
I9
sg11
Varthritis
p2163
sg13
I1
sasa(dp2164
g2
S'In this study, we examined the role of SphK1 and SphK2 in a murine collagen-induced arthritis model by down-regulating each isoenzyme via specific small interfering RNA (siRNA).\n'
p2165
sg4
(lp2166
(dp2167
g7
I39
sg8
g9
sg10
I5
sg11
VSphK1
p2168
sg13
I1
sa(dp2169
g7
I49
sg8
g9
sg10
I5
sg11
VSphK2
p2170
sg13
I1
sasg14
(lp2171
(dp2172
g7
I84
sg17
VC0003864
p2173
sg10
I9
sg11
Varthritis
p2174
sg13
I1
sasa(dp2175
g2
S'Together, these results demonstrate the distinct immunomodulatory roles of SphK1 and SphK2 in the development of inflammatory arthritis by regulating the release of proinflammatory cytokines and T cell responses.\n'
p2176
sg4
(lp2177
(dp2178
g7
I75
sg8
g9
sg10
I5
sg11
VSphK1
p2179
sg13
I1
sa(dp2180
g7
I85
sg8
g9
sg10
I5
sg11
VSphK2
p2181
sg13
I1
sasg14
(lp2182
(dp2183
g7
I113
sg17
VC0003864
p2184
sg10
I22
sg11
Vinflammatory arthritis
p2185
sg13
I2
sasa(dp2186
g2
S'Prefrontal Brodmann Areas (BA) BA46, BA47, and BA9 in autism and age-matched controls were analyzed by blinded researchers.\n'
p2187
sg4
(lp2188
sg14
(lp2189
(dp2190
g7
I54
sg17
VC0004352
p2191
sg10
I6
sg11
Vautism
p2192
sg13
I1
sasa(dp2193
g2
S'We show that the number of parvalbumin+ interneurons in these 3 cortical areas-BA46, BA47, and BA9-is significantly reduced in autism compared with controls.\n'
p2194
sg4
(lp2195
(dp2196
g7
I27
sg8
VP20472
p2197
sg10
I12
sg11
Vparvalbumin+
p2198
sg13
I1
sasg14
(lp2199
(dp2200
g7
I127
sg17
VC0004352
p2201
sg10
I6
sg11
Vautism
p2202
sg13
I1
sasa(dp2203
g2
S'These fetal structures generate regions with abnormal activity in autism, including the dorsolateral prefrontal cortex (BA46), the pars opercularis of the inferior frontal cortex and the fusiform gyrus.\n'
p2204
sg4
(lp2205
sg14
(lp2206
(dp2207
g7
I66
sg17
VC0004352
p2208
sg10
I6
sg11
Vautism
p2209
sg13
I1
sasa(dp2210
g2
S'At the site of disease in leprosy, we found that S100A12 was more strongly expressed in skin lesions from tuberculoid leprosy (T-lep), the self-limiting form of the disease, compared to lepromatous leprosy (L-lep), the progressive form of the disease.\n'
p2211
sg4
(lp2212
(dp2213
g7
I49
sg8
VP80511
p2214
sg10
I7
sg11
VS100A12
p2215
sg13
I1
sasg14
(lp2216
(dp2217
g7
I26
sg17
VC0023343
p2218
sg10
I7
sg11
Vleprosy
p2219
sg13
I1
sa(dp2220
g7
I127
sg17
VC0023351
p2221
sg10
I5
sg11
VT-lep
p2222
sg13
I1
sa(dp2223
g7
I186
sg17
VC0023348
p2224
sg10
I19
sg11
Vlepromatous leprosy
p2225
sg13
I2
sa(dp2226
g7
I106
sg17
VC0023351
p2227
sg10
I19
sg11
Vtuberculoid leprosy
p2228
sg13
I2
sa(dp2229
g7
I207
sg17
VC0023348
p2230
sg10
I5
sg11
VL-lep
p2231
sg13
I1
sasa(dp2232
g2
S'The aim of this study was to predict right ventricular dysfunction (RVD) using plasma concentration of D-dimer, pro-atrial natriuretic peptide (pro-ANP), brain natriuretic peptide (BNP), endothelin-1 (ET-1) and cardiac troponin I (TNI) in patients with pulmonary embolism (PE).\n'
p2233
sg4
(lp2234
(dp2235
g7
I201
sg8
VP05305
p2236
sg10
I4
sg11
VET-1
p2237
sg13
I1
sa(dp2238
g7
I187
sg8
VP20800
p2239
sg10
I12
sg11
Vendothelin-1
p2240
sg13
I1
sa(dp2241
g7
I231
sg8
VP48788
p2242
sg10
I3
sg11
VTNI
p2243
sg13
I1
sa(dp2244
g7
I103
sg8
VP16066
p2245
sg10
I76
sg11
VD-dimer, pro-atrial natriuretic peptide (pro-ANP), brain natriuretic peptide
p2246
sg13
I8
sa(dp2247
g7
I181
sg8
VP16860
p2248
sg10
I3
sg11
VBNP
p2249
sg13
I1
sa(dp2250
g7
I211
sg8
VP24821
p2251
sg10
I18
sg11
Vcardiac troponin I
p2252
sg13
I3
sasg14
(lp2253
(dp2254
g7
I37
sg17
VC0242707
p2255
sg10
I29
sg11
Vright ventricular dysfunction
p2256
sg13
I3
sa(dp2257
g7
I273
sg17
VC0034065
p2258
sg10
I2
sg11
VPE
p2259
sg13
I1
sa(dp2260
g7
I68
sg17
VC0242707
p2261
sg10
I3
sg11
VRVD
p2262
sg13
I1
sa(dp2263
g7
I253
sg17
VC0034065
p2264
sg10
I18
sg11
Vpulmonary embolism
p2265
sg13
I2
sasa(dp2266
g2
S'Atrial natriuretic petide (ANP), brain natriuretic peptide (BNP) and endothelin-1 (ET-1) may reflect the severity of right ventricular dysfunction (RVD) in patients with pulmonary embolism (PE).\n'
p2267
sg4
(lp2268
(dp2269
g7
I27
sg8
VP16066
p2270
sg10
I3
sg11
VANP
p2271
sg13
I1
sa(dp2272
g7
I83
sg8
VP05305
p2273
sg10
I4
sg11
VET-1
p2274
sg13
I1
sa(dp2275
g7
I69
sg8
VP20800
p2276
sg10
I12
sg11
Vendothelin-1
p2277
sg13
I1
sa(dp2278
g7
I0
sg8
VP16066
p2279
sg10
I25
sg11
VAtrial natriuretic petide
p2280
sg13
I3
sasg14
(lp2281
(dp2282
g7
I190
sg17
VC0034065
p2283
sg10
I2
sg11
VPE
p2284
sg13
I1
sa(dp2285
g7
I148
sg17
VC0242707
p2286
sg10
I3
sg11
VRVD
p2287
sg13
I1
sa(dp2288
g7
I117
sg17
VC0242707
p2289
sg10
I29
sg11
Vright ventricular dysfunction
p2290
sg13
I3
sa(dp2291
g7
I170
sg17
VC0034065
p2292
sg10
I18
sg11
Vpulmonary embolism
p2293
sg13
I2
sasa(dp2294
g2
S'Acute pulmonary embolism (PE) is a life-threatening disease, and several vasoconstrictors, including endothelin-1 (ET-1), play a key role in vasoconstriction and hypoxemia during the development of PE.\n'
p2295
sg4
(lp2296
(dp2297
g7
I101
sg8
VP20800
p2298
sg10
I12
sg11
Vendothelin-1
p2299
sg13
I1
sa(dp2300
g7
I115
sg8
VP05305
p2301
sg10
I4
sg11
VET-1
p2302
sg13
I1
sasg14
(lp2303
(dp2304
g7
I6
sg17
VC0034065
p2305
sg10
I18
sg11
Vpulmonary embolism
p2306
sg13
I2
sa(dp2307
g7
I26
sg17
VC0034065
p2308
sg10
I2
sg11
VPE
p2309
sg13
I1
sa(dp2310
g7
I26
sg17
VC0034065
p2311
sg10
I2
sg11
VPE
p2312
sg13
I1
sa(dp2313
g7
I141
sg17
VC1456863
p2314
sg10
I16
sg11
Vvasoconstriction
p2315
sg13
I1
sasa(dp2316
g2
S'Impaired repression of cone-specific genes by the corepressors atrophin-1 (dentatorubral-pallidoluysian atrophy [DRPLA] gene product) and atrophin-2 (arginine-glutamic acid dipeptide repeat [RERE] protein) appeared to be a molecular mechanism mediating the beneficial effect of the p.R311Q mutation.\n'
p2317
sg4
(lp2318
sg14
(lp2319
(dp2320
g7
I113
sg17
VC0751781
p2321
sg10
I5
sg11
VDRPLA
p2322
sg13
I1
sa(dp2323
g7
I75
sg17
VC0751781
p2324
sg10
I36
sg11
Vdentatorubral-pallidoluysian atrophy
p2325
sg13
I2
sa(dp2326
g7
I0
sg17
VC0684336
p2327
sg10
I8
sg11
VImpaired
p2328
sg13
I1
sasa(dp2329
g2
S'RE repeats encoded (RERE) was identified recently as a protein with high homology to the atrophin-1 protein, which appears to be causal in the hereditary neurodegenerative disorder termed dentatorubral-pallidoluysian atrophy (DRPLA) caused by an abnormal glutamine expansion.\n'
p2330
sg4
(lp2331
(dp2332
g7
I89
sg8
VP54259
p2333
sg10
I18
sg11
Vatrophin-1 protein
p2334
sg13
I2
sasg14
(lp2335
(dp2336
g7
I188
sg17
VC0751781
p2337
sg10
I36
sg11
Vdentatorubral-pallidoluysian atrophy
p2338
sg13
I2
sa(dp2339
g7
I226
sg17
VC0751781
p2340
sg10
I5
sg11
VDRPLA
p2341
sg13
I1
sa(dp2342
g7
I143
sg17
VC3273225
p2343
sg10
I37
sg11
Vhereditary neurodegenerative disorder
p2344
sg13
I3
sasa(dp2345
g2
S'The gene isolated, designated RERE, has an open reading frame of 1566 amino acids, of which the C-terminal portion has 67% homology to DRPLA, whereas the N-terminal portion is distinctive.\n'
p2346
sg4
(lp2347
(dp2348
g7
I135
sg8
VP54259
p2349
sg10
I5
sg11
VDRPLA
p2350
sg13
I1
sa(dp2351
g7
I30
sg8
g9
sg10
I4
sg11
VRERE
p2352
sg13
I1
sasg14
(lp2353
(dp2354
g7
I135
sg17
VC0751781
p2355
sg10
I5
sg11
VDRPLA
p2356
sg13
I1
sasa(dp2357
g2
S'Immunoprecipitation and in vitro binding assays demonstrate that the DRPLA and RERE proteins bind each other, for which one of the RE repeats has a primary role, and extended polyglutamine enhances the binding.\n'
p2358
sg4
(lp2359
(dp2360
g7
I79
sg8
g9
sg10
I13
sg11
VRERE proteins
p2361
sg13
I2
sa(dp2362
g7
I69
sg8
VP54259
p2363
sg10
I5
sg11
VDRPLA
p2364
sg13
I1
sasg14
(lp2365
(dp2366
g7
I69
sg17
VC0751781
p2367
sg10
I5
sg11
VDRPLA
p2368
sg13
I1
sasa(dp2369
g2
S'Moreover, when RERE is overexpressed, the distribution of endogenous DRPLA protein alters from the diffused to the speckled pattern in the nucleus so as to co-localize with RERE.\n'
p2370
sg4
(lp2371
(dp2372
g7
I15
sg8
g9
sg10
I4
sg11
VRERE
p2373
sg13
I1
sa(dp2374
g7
I58
sg8
VP54259
p2375
sg10
I24
sg11
Vendogenous DRPLA protein
p2376
sg13
I3
sasg14
(lp2377
(dp2378
g7
I69
sg17
VC0751781
p2379
sg10
I5
sg11
VDRPLA
p2380
sg13
I1
sasa(dp2381
g2
S'More RERE protein is recruited into nuclear aggregates of the DRPLA protein with extended polyglutamine than into those of pure polyglutamine.\n'
p2382
sg4
(lp2383
(dp2384
g7
I62
sg8
VP54259
p2385
sg10
I13
sg11
VDRPLA protein
p2386
sg13
I2
sasg14
(lp2387
(dp2388
g7
I62
sg17
VC0751781
p2389
sg10
I5
sg11
VDRPLA
p2390
sg13
I1
sasa(dp2391
g2
S'The DNB1/ARPh gene, which was found to be ubiquitously expressed in human adult and fetal tissues, is highly related to the DRPLA gene, in which expansion of a CAG triplet appears to be causal in the dentatorubral and pallidolysian atrophy disease phenotype.\n'
p2392
sg4
(lp2393
(dp2394
g7
I124
sg8
VP54259
p2395
sg10
I10
sg11
VDRPLA gene
p2396
sg13
I2
sa(dp2397
g7
I4
sg8
VP55145
p2398
sg10
I4
sg11
VDNB1
p2399
sg13
I1
sasg14
(lp2400
(dp2401
g7
I124
sg17
VC0751781
p2402
sg10
I5
sg11
VDRPLA
p2403
sg13
I1
sa(dp2404
g7
I232
sg17
VC0333641
p2405
sg10
I7
sg11
Vatrophy
p2406
sg13
I1
sasa(dp2407
g2
S'Therefore, we evaluated the roles of CSNK2A1, SIRT6, and phosphorylated SIRT6 and their relationships in breast carcinoma.\n'
p2408
sg4
(lp2409
(dp2410
g7
I37
sg8
VP19784
p2411
sg10
I7
sg11
VCSNK2A1
p2412
sg13
I1
sasg14
(lp2413
(dp2414
g7
I105
sg17
VC0678222
p2415
sg10
I16
sg11
Vbreast carcinoma
p2416
sg13
I2
sasa(dp2417
g2
S'This study demonstrates that CSNK2A1 and SIRT6 are indicators of poor prognosis for breast carcinomas and that CSNK2A1-mediated phosphorylation of SIRT6 might be involved in the progression of breast carcinoma.\n'
p2418
sg4
(lp2419
(dp2420
g7
I29
sg8
VP19784
p2421
sg10
I7
sg11
VCSNK2A1
p2422
sg13
I1
sa(dp2423
g7
I29
sg8
VP19784
p2424
sg10
I7
sg11
VCSNK2A1
p2425
sg13
I1
sasg14
(lp2426
(dp2427
g7
I84
sg17
VC0678222
p2428
sg10
I16
sg11
Vbreast carcinoma
p2429
sg13
I2
sa(dp2430
g7
I84
sg17
VC0678222
p2431
sg10
I17
sg11
Vbreast carcinomas
p2432
sg13
I2
sasa(dp2433
g2
S'RNA expression levels of CDC2L1, CDC2L2, CCNL1, CCNL2, CSNK2A1, CSNK2A2, and CSNK2B genes in breast cancer subtypes were analyzed.\n'
p2434
sg4
(lp2435
(dp2436
g7
I77
sg8
VP67870
p2437
sg10
I12
sg11
VCSNK2B genes
p2438
sg13
I2
sa(dp2439
g7
I64
sg8
VP19784
p2440
sg10
I7
sg11
VCSNK2A2
p2441
sg13
I1
sa(dp2442
g7
I41
sg8
VP49736
p2443
sg10
I5
sg11
VCCNL1
p2444
sg13
I1
sa(dp2445
g7
I55
sg8
VP19784
p2446
sg10
I7
sg11
VCSNK2A1
p2447
sg13
I1
sasg14
(lp2448
(dp2449
g7
I93
sg17
VC0678222
p2450
sg10
I13
sg11
Vbreast cancer
p2451
sg13
I2
sasa(dp2452
g2
S'Recent evidence suggests the role of Wnt signaling in human breast cancer involves elevated levels of nuclear and/or cytoplasmic beta-catenin using immunohistochemistry, overexpression or downregulation of specific Wnt proteins, overexpression of CKII and sFRP4, downregulation of WIF-1 and sFRP1, as well as amplification of DVL-1.\n'
p2453
sg4
(lp2454
(dp2455
g7
I117
sg8
g9
sg10
I24
sg11
Vcytoplasmic beta-catenin
p2456
sg13
I2
sa(dp2457
g7
I247
sg8
VP68400
p2458
sg10
I4
sg11
VCKII
p2459
sg13
I1
sa(dp2460
g7
I326
sg8
VP54792
p2461
sg10
I5
sg11
VDVL-1
p2462
sg13
I1
sa(dp2463
g7
I291
sg8
g9
sg10
I5
sg11
VsFRP1
p2464
sg13
I1
sa(dp2465
g7
I256
sg8
g9
sg10
I5
sg11
VsFRP4
p2466
sg13
I1
sasg14
(lp2467
(dp2468
g7
I60
sg17
VC0678222
p2469
sg10
I13
sg11
Vbreast cancer
p2470
sg13
I2
sa(dp2471
g7
I309
sg17
VC1705759
p2472
sg10
I13
sg11
Vamplification
p2473
sg13
I1
sasa(dp2474
g2
S'By combining the mutational data in the Catalogue of Somatic Mutations in Cancer (COSMIC) and the spatial information in the Protein Data Bank (PDB), SpacePAC is able to identify novel mutation clusters in many proteins such as FGFR3 and CHRM2.\n'
p2475
sg4
(lp2476
(dp2477
g7
I228
sg8
VP22607
p2478
sg10
I5
sg11
VFGFR3
p2479
sg13
I1
sa(dp2480
g7
I238
sg8
VP08172
p2481
sg10
I5
sg11
VCHRM2
p2482
sg13
I1
sasg14
(lp2483
(dp2484
g7
I53
sg17
VC0544886
p2485
sg10
I17
sg11
VSomatic Mutations
p2486
sg13
I2
sa(dp2487
g7
I125
sg17
VC0029401
p2488
sg10
I17
sg11
VProtein Data Bank
p2489
sg13
I3
sa(dp2490
g7
I179
sg17
VC2985438
p2491
sg10
I14
sg11
Vnovel mutation
p2492
sg13
I2
sa(dp2493
g7
I74
sg17
VC0006826
p2494
sg10
I6
sg11
VCancer
p2495
sg13
I1
sa(dp2496
g7
I144
sg17
VC0029401
p2497
sg10
I3
sg11
VPDB
p2498
sg13
I1
sasa(dp2499
g2
S'Colorectal cancer (HCT 116, LoVo, C 170 HM 2, CaCO-2), fibroblast (46-BR.IGI, CCD-18 Co) and fibrosarcoma (HT1080) cell lines were irradiated at 4 gray (4 Gy) and matrix metalloproteinase gene and protein expression examined over a 96 h period by real time polymerase chain reaction and gelatin zymography.\n'
p2500
sg4
(lp2501
(dp2502
g7
I78
sg8
VP21817
p2503
sg10
I9
sg11
VCCD-18 Co
p2504
sg13
I2
sa(dp2505
g7
I163
sg8
g9
sg10
I29
sg11
Vmatrix metalloproteinase gene
p2506
sg13
I3
sa(dp2507
g7
I73
sg8
VP12018
p2508
sg10
I3
sg11
VIGI
p2509
sg13
I1
sasg14
(lp2510
(dp2511
g7
I0
sg17
VC1527249
p2512
sg10
I17
sg11
VColorectal cancer
p2513
sg13
I2
sa(dp2514
g7
I93
sg17
VC0016057
p2515
sg10
I12
sg11
Vfibrosarcoma
p2516
sg13
I1
sa(dp2517
g7
I78
sg17
VC0008928
p2518
sg10
I3
sg11
VCCD
p2519
sg13
I1
sasa(dp2520
g2
S'In addition, because HBL is a major enterotoxin, we also designed HBL gene-specific polymerase chain reaction (PCR) primers, i.e., Hm1 and Hm2, that generated the same results as those of the hemolysis and BCET-RPLA assays.\n'
p2521
sg4
(lp2522
(dp2523
g7
I66
sg8
VP09382
p2524
sg10
I8
sg11
VHBL gene
p2525
sg13
I2
sa(dp2526
g7
I131
sg8
VP11229
p2527
sg10
I3
sg11
VHm1
p2528
sg13
I1
sa(dp2529
g7
I21
sg8
VP09382
p2530
sg10
I3
sg11
VHBL
p2531
sg13
I1
sa(dp2532
g7
I139
sg8
VP08172
p2533
sg10
I3
sg11
VHm2
p2534
sg13
I1
sasg14
(lp2535
(dp2536
g7
I192
sg17
VC0019054
p2537
sg10
I9
sg11
Vhemolysis
p2538
sg13
I1
sasa(dp2539
g2
S'Primers B16S1/B16S2 and Hm1/Hm2 could be combined into a multiplex PCR system for the simultaneous detection of B. cereus group cells and the possible presence of their HBL enterotoxins.\n'
p2540
sg4
(lp2541
(dp2542
g7
I24
sg8
VP11229
p2543
sg10
I3
sg11
VHm1
p2544
sg13
I1
sa(dp2545
g7
I169
sg8
VP09382
p2546
sg10
I16
sg11
VHBL enterotoxins
p2547
sg13
I2
sa(dp2548
g7
I28
sg8
VP08172
p2549
sg10
I3
sg11
VHm2
p2550
sg13
I1
sasg14
(lp2551
sa(dp2552
g2
S'Positive cancer invasion in the cut end was classified as hm2 or dm2 in 8 patients and em2 in 13.\n'
p2553
sg4
(lp2554
(dp2555
g7
I58
sg8
VP08172
p2556
sg10
I3
sg11
Vhm2
p2557
sg13
I1
sasg14
(lp2558
(dp2559
g7
I16
sg17
VC2699153
p2560
sg10
I8
sg11
Vinvasion
p2561
sg13
I1
sa(dp2562
g7
I65
sg17
VC2931689
p2563
sg10
I3
sg11
Vdm2
p2564
sg13
I1
sa(dp2565
g7
I9
sg17
VC0006826
p2566
sg10
I6
sg11
Vcancer
p2567
sg13
I1
sasa(dp2568
g2
S"Biopsy samples from five acquired immune deficiency syndrome (AIDS)-Kaposi's sarcomas and one non-AIDS-associated Kaposi's sarcoma were assayed by in situ RNA hybridization onto paraformaldehyde-fixed, paraffin-embedded skin sections for the presence of two fibroblast growth factor gene transcripts, FGFB and FGF5.\n"
p2569
sg4
(lp2570
(dp2571
g7
I258
sg8
g9
sg10
I41
sg11
Vfibroblast growth factor gene transcripts
p2572
sg13
I5
sa(dp2573
g7
I310
sg8
VP12034
p2574
sg10
I4
sg11
VFGF5
p2575
sg13
I1
sasg14
(lp2576
(dp2577
g7
I25
sg17
VC0001175
p2578
sg10
I35
sg11
Vacquired immune deficiency syndrome
p2579
sg13
I4
sa(dp2580
g7
I62
sg17
VC0001175
p2581
sg10
I4
sg11
VAIDS
p2582
sg13
I1
sa(dp2583
g7
I77
sg17
VC1261473
p2584
sg10
I8
sg11
Vsarcomas
p2585
sg13
I1
sa(dp2586
g7
I68
sg17
VC0036220
p2587
sg10
I16
sg11
VKaposi's sarcoma
p2588
sg13
I2
sa(dp2589
g7
I62
sg17
VC0001175
p2590
sg10
I4
sg11
VAIDS
p2591
sg13
I1
sasa(dp2592
g2
S"FGF5 gene expression was detected in the characteristic Kaposi's sarcoma spindle-shaped cells in the five samples from human immunodeficiency-positive (HIV+) patients.\n"
p2593
sg4
(lp2594
(dp2595
g7
I0
sg8
VP12034
p2596
sg10
I9
sg11
VFGF5 gene
p2597
sg13
I2
sasg14
(lp2598
(dp2599
g7
I125
sg17
VC0021051
p2600
sg10
I16
sg11
Vimmunodeficiency
p2601
sg13
I1
sa(dp2602
g7
I56
sg17
VC0036220
p2603
sg10
I16
sg11
VKaposi's sarcoma
p2604
sg13
I2
sasa(dp2605
g2
S"Furthermore, they demonstrate a contrasting expression pattern of FGF5 and FGFB genes, both involved in the growth factor pathogenic cascade leading to Kaposi's sarcoma.\n"
p2606
sg4
(lp2607
(dp2608
g7
I75
sg8
VP01893
p2609
sg10
I10
sg11
VFGFB genes
p2610
sg13
I2
sa(dp2611
g7
I66
sg8
VP12034
p2612
sg10
I4
sg11
VFGF5
p2613
sg13
I1
sasg14
(lp2614
(dp2615
g7
I152
sg17
VC0036220
p2616
sg10
I16
sg11
VKaposi's sarcoma
p2617
sg13
I2
sasa(dp2618
g2
S"Objective To explore the efficacy of ganoderma lucidum preparation(Ling Zhi) in treating APP/PS-1 transgenic mouse models of Alzheimer's disease(AD).Methods APP/PS-1 transgenic mice of 4 months were randomly divided into model group,ganoderma lucidum treatment groups,including high [2250 mg/(kg*d)] and middle [750 mg/(kg*d)] dose groups,i.e.LZ-H and LZ-M groups,and the positive control group(treated with donepezil hydrochloride [2 mg/(kg*d)]).In addition,C57BL/6J wild mice were selected as normal group.The animals were administered for 4 months.Histopathological examinations including hematoxylin-eosin(HE) staining,immunohistochemistry,special staining,and electron microscopy were applied,and then the pathological morphology and structures in different groups were compared.\n"
p2619
sg4
(lp2620
(dp2621
g7
I89
sg8
g9
sg10
I3
sg11
VAPP
p2622
sg13
I1
sa(dp2623
g7
I93
sg8
VP48651
p2624
sg10
I4
sg11
VPS-1
p2625
sg13
I1
sasg14
(lp2626
(dp2627
g7
I125
sg17
VC1521724
p2628
sg10
I19
sg11
VAlzheimer's disease
p2629
sg13
I2
sasa(dp2630
g2
S'For the hydrogel prepared using the comonomer mixture with 5.0 wt % SBMA, the amount of adsorbed Lyz is 0.91 myg/cm2, which corresponds to only 56.8% of the amount adsorbed on EASY DAY(R) SCLs.\n'
p2631
sg4
(lp2632
sg14
(lp2633
(dp2634
g7
I68
sg17
VC1839259
p2635
sg10
I4
sg11
VSBMA
p2636
sg13
I1
sa(dp2637
g7
I113
sg17
VC0555206
p2638
sg10
I3
sg11
Vcm2
p2639
sg13
I1
sasa(dp2640
g2
S"Objective To evaluate the efficacy of Ganoderma lucidum preparation on the behaviors,biochemistry,and autoimmunity parameters of mouse models of APP/PS-1 double transgenic Alzheimer's disease(AD).Methods A total of 44 4-month-old APP/PS-1 double transgenic AD mice were randomly divided into AD model group,Aricept group,Ganoderma lucidum middle-dose(LZ-M)group,and Ganoderma lucidum high-dose(LZ-H)group,with 11 mice in each group.In addition,10 4-month-old C57BL/6 mice were used as the control group.Water maze test was conducted to observe the behavior changes,and the protein expressions in brain tissues were detected by Western blot analysis.The autoimmune indicators were detected by indirect immunofluorescence method.Results In the navigation experiment,the time of finding the platform was gradually shortened since the 2nd day in the control,LZ-H,and LZ-M groups,and the time of searching the platform in the AD model group gradually increased.On the 5th day,the time of finding platform was significantly shorter in control group (t=5.607,P=0.000) and LZ-H group(t=2.750,P=0.010)than AD model group.In the space exploration experiment,the number of crossing the target platform(t=2.452,P=0.025)and the residence time in the target quadrant(t=2.530,P=0.020)in AD model group mice was significantly smaller/shorter than those in control group;in addition,the number of crossing the target platform in the AD model group was significantly smaller than that in LZ-H group(t=2.317,P=0.030)and LZ-M group(t=2.443,P=0.030),while the residence time in target quadrant decreased significantly(t=2.770,P=0.020)compared with LZ-H group;the number of crossing through the target platform quadrant(t=2.493,P=0.022)and residence time in the target quadrant(t=2.683,P=0.015)in LZ-H group were significantly higher than in Aricept group.Western blot analysis showed that the expression of ApoA1 in the brain tissues of mice in LZ-H and LZ-M groups were significantly higher than those in AD model group(P&lt;0.01,P&lt;0.05);ABeta-40 expression in LZ-H group was significantly lower than that in AD model group(P&lt;0.05);the expressions of Syt1,ApoE,and ABCA1 in brain tissues of mice in LZ-H group were significantly higher than those in model group(P&lt;0.01,P&lt;0.05).The plasma IgG level in Aricept group(t=30.945,P=0.000),LZ-M group(t=25.639,P=0.000)and LZ-H group(t=4.689,P=0.001)were significantly higher than that in the control group.Conclusion Ganoderma lucidum preparation can improve behavior disorders of AD model mice,promote the expressions of ApoA1,ApoE and Syt1,inhibit the expression of ABeta-40 protein,and improve the autoimmune function.\n"
p2641
sg4
(lp2642
(dp2643
g7
I2137
sg8
VP21579
p2644
sg10
I4
sg11
VSyt1
p2645
sg13
I1
sa(dp2646
g7
I1886
sg8
VP02647
p2647
sg10
I5
sg11
VApoA1
p2648
sg13
I1
sa(dp2649
g7
I1065
sg8
VP00390
p2650
sg10
I10
sg11
VLZ-H group
p2651
sg13
I2
sa(dp2652
g7
I2142
sg8
VP02649
p2653
sg10
I4
sg11
VApoE
p2654
sg13
I1
sa(dp2655
g7
I145
sg8
VP48651
p2656
sg10
I8
sg11
VAPP/PS-1
p2657
sg13
I1
sa(dp2658
g7
I2142
sg8
VP02649
p2659
sg10
I4
sg11
VApoE
p2660
sg13
I1
sa(dp2661
g7
I2603
sg8
g9
sg10
I16
sg11
VABeta-40 protein
p2662
sg13
I2
sa(dp2663
g7
I1886
sg8
VP02647
p2664
sg10
I5
sg11
VApoA1
p2665
sg13
I1
sa(dp2666
g7
I2021
sg8
g9
sg10
I8
sg11
VABeta-40
p2667
sg13
I1
sa(dp2668
g7
I1065
sg8
VP00390
p2669
sg10
I10
sg11
VLZ-H group
p2670
sg13
I2
sa(dp2671
g7
I145
sg8
g9
sg10
I3
sg11
VAPP
p2672
sg13
I1
sa(dp2673
g7
I1065
sg8
VP00390
p2674
sg10
I10
sg11
VLZ-H group
p2675
sg13
I2
sa(dp2676
g7
I149
sg8
VP48651
p2677
sg10
I4
sg11
VPS-1
p2678
sg13
I1
sa(dp2679
g7
I2137
sg8
VP21579
p2680
sg10
I4
sg11
VSyt1
p2681
sg13
I1
sasg14
(lp2682
(dp2683
g7
I102
sg17
VC0004368
p2684
sg10
I12
sg11
Vautoimmunity
p2685
sg13
I1
sa(dp2686
g7
I172
sg17
VC1521724
p2687
sg10
I19
sg11
VAlzheimer's disease
p2688
sg13
I2
sa(dp2689
g7
I2494
sg17
VC0004930
p2690
sg10
I18
sg11
Vbehavior disorders
p2691
sg13
I2
sa(dp2692
g7
I653
sg17
VC0443146
p2693
sg10
I10
sg11
Vautoimmune
p2694
sg13
I1
sa(dp2695
g7
I653
sg17
VC0443146
p2696
sg10
I10
sg11
Vautoimmune
p2697
sg13
I1
sasa(dp2698
g2
S'Somatic v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation, present in approximately 10% of metastatic colorectal cancer (mCRC) cases, is associated with poor prognosis.\n'
p2699
sg4
(lp2700
(dp2701
g7
I55
sg8
VP15056
p2702
sg10
I4
sg11
VBRAF
p2703
sg13
I1
sa(dp2704
g7
I0
sg8
VP04049
p2705
sg10
I53
sg11
VSomatic v-Raf murine sarcoma viral oncogene homolog B
p2706
sg13
I8
sasg14
(lp2707
(dp2708
g7
I21
sg17
VC1261473
p2709
sg10
I7
sg11
Vsarcoma
p2710
sg13
I1
sa(dp2711
g7
I133
sg17
VC0948380
p2712
sg10
I4
sg11
VmCRC
p2713
sg13
I1
sa(dp2714
g7
I103
sg17
VC0948380
p2715
sg10
I28
sg11
Vmetastatic colorectal cancer
p2716
sg13
I3
sasa(dp2717
g2
S'All colorectal cancer patients tested for BRAF mutation, from October 2010 to November 2014 were identified.\n'
p2718
sg4
(lp2719
(dp2720
g7
I42
sg8
VP15056
p2721
sg10
I4
sg11
VBRAF
p2722
sg13
I1
sasg14
(lp2723
(dp2724
g7
I4
sg17
VC1527249
p2725
sg10
I17
sg11
Vcolorectal cancer
p2726
sg13
I2
sasa(dp2727
g2
S'The prognostic role of the V600E mutation of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) in metastatic colorectal cancer (mCRC) is well established, but the therapeutic regimen targeting this disease is lacking.\n'
p2728
sg4
(lp2729
(dp2730
g7
I45
sg8
VP15056
p2731
sg10
I92
sg11
Vv-raf murine sarcoma viral oncogene homolog B1 (BRAF) in metastatic colorectal cancer (mCRC)
p2732
sg13
I13
sasg14
(lp2733
(dp2734
g7
I132
sg17
VC0948380
p2735
sg10
I4
sg11
VmCRC
p2736
sg13
I1
sa(dp2737
g7
I102
sg17
VC0948380
p2738
sg10
I28
sg11
Vmetastatic colorectal cancer
p2739
sg13
I3
sa(dp2740
g7
I58
sg17
VC1261473
p2741
sg10
I7
sg11
Vsarcoma
p2742
sg13
I1
sasa(dp2743
g2
S'The aim of our study was to evaluate the incidence of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving first line oxaliplatin based chemotherapy with or without bevacizumab and to evaluate their prognostic and predictive significance.\n'
p2744
sg4
(lp2745
(dp2746
g7
I66
sg8
VP15056
p2747
sg10
I4
sg11
VBRAF
p2748
sg13
I1
sa(dp2749
g7
I60
sg8
VP01111
p2750
sg10
I4
sg11
VNRAS
p2751
sg13
I1
sa(dp2752
g7
I75
sg8
VP42336
p2753
sg10
I6
sg11
VPIK3CA
p2754
sg13
I1
sa(dp2755
g7
I54
sg8
VP01116
p2756
sg10
I4
sg11
VKRAS
p2757
sg13
I1
sasg14
(lp2758
(dp2759
g7
I95
sg17
VC0948380
p2760
sg10
I28
sg11
Vmetastatic colorectal cancer
p2761
sg13
I3
sasa(dp2762
g2
S'Activating BRAF (V-raf murine sarcoma viral oncogene homolog B) mutations occur in approximately 5% to 10% of patients with metastatic colorectal cancer, mostly V600E mutation, and it is associated with distinct clinical and pathological features.\n'
p2763
sg4
(lp2764
(dp2765
g7
I11
sg8
VP15056
p2766
sg10
I4
sg11
VBRAF
p2767
sg13
I1
sa(dp2768
g7
I17
sg8
VP04049
p2769
sg10
I45
sg11
VV-raf murine sarcoma viral oncogene homolog B
p2770
sg13
I7
sasg14
(lp2771
(dp2772
g7
I30
sg17
VC1261473
p2773
sg10
I7
sg11
Vsarcoma
p2774
sg13
I1
sa(dp2775
g7
I124
sg17
VC0948380
p2776
sg10
I28
sg11
Vmetastatic colorectal cancer
p2777
sg13
I3
sasa(dp2778
g2
S'This review aims to provide data about new strategies to target to BRAF gene mutation in metastatic colorectal cancer.\n'
p2779
sg4
(lp2780
(dp2781
g7
I67
sg8
VP15056
p2782
sg10
I9
sg11
VBRAF gene
p2783
sg13
I2
sasg14
(lp2784
(dp2785
g7
I89
sg17
VC0948380
p2786
sg10
I28
sg11
Vmetastatic colorectal cancer
p2787
sg13
I3
sa(dp2788
g7
I67
sg17
VC1511021
p2789
sg10
I18
sg11
VBRAF gene mutation
p2790
sg13
I3
sasa(dp2791
g2
S'The variables of age, incidence of autoimmune hepatitis, model of end-stage liver disease (MELD) score, values for total bilirubin and prothrombin time-international ratio (PT-INR), and Japan Hepatic Encephalopathy Prediction Model (JHEPM) probability at registration were significantly higher in ALF patients than in ALI patients.\n'
p2792
sg4
(lp2793
(dp2794
g7
I135
sg8
VP00734
p2795
sg10
I11
sg11
Vprothrombin
p2796
sg13
I1
sasg14
(lp2797
(dp2798
g7
I35
sg17
VC0241910
p2799
sg10
I20
sg11
Vautoimmune hepatitis
p2800
sg13
I2
sa(dp2801
g7
I76
sg17
VC0023895
p2802
sg10
I13
sg11
Vliver disease
p2803
sg13
I2
sa(dp2804
g7
I192
sg17
VC0019151
p2805
sg10
I22
sg11
VHepatic Encephalopathy
p2806
sg13
I2
sasa(dp2807
g2
S'On the other hand, the multivariate Cox proportional hazard model showed that positivity for serum anti-PD-1 antibody, probable diagnosis based on the revised scoring system proposed by the International Autoimmune Hepatitis Group, and prothrombin activity of less than 60% were associated with the later normalization of serum transaminase levels.\n'
p2808
sg4
(lp2809
(dp2810
g7
I93
sg8
VP18621
p2811
sg10
I24
sg11
Vserum anti-PD-1 antibody
p2812
sg13
I3
sa(dp2813
g7
I322
sg8
g9
sg10
I18
sg11
Vserum transaminase
p2814
sg13
I2
sa(dp2815
g7
I236
sg8
VP00734
p2816
sg10
I11
sg11
Vprothrombin
p2817
sg13
I1
sasg14
(lp2818
(dp2819
g7
I204
sg17
VC0241910
p2820
sg10
I20
sg11
VAutoimmune Hepatitis
p2821
sg13
I2
sasa(dp2822
g2
S'Myeloma cell maturity was classified via immunophenotyping: myeloma cells showing mature plasma cell 1 (MPC-1)-positive and CD49e-positive cells were considered mature type; MPC-1-positive and CD49e-negative cells were considered intermediate type; and MPC-1-negative cells were considered immature type.\n'
p2823
sg4
(lp2824
(dp2825
g7
I124
sg8
VP08648
p2826
sg10
I5
sg11
VCD49e
p2827
sg13
I1
sa(dp2828
g7
I124
sg8
VP08648
p2829
sg10
I5
sg11
VCD49e
p2830
sg13
I1
sasg14
(lp2831
(dp2832
g7
I60
sg17
VC0026764
p2833
sg10
I7
sg11
Vmyeloma
p2834
sg13
I1
sa(dp2835
g7
I0
sg17
VC0026764
p2836
sg10
I7
sg11
VMyeloma
p2837
sg13
I1
sasa(dp2838
g2
S'The findings of this study demonstrate the clinical importance of myeloma cell classification according to immunophenotyping using MPC-1 and CD49e antibodies to determine patient prognosis in this era of novel therapeutic agents.\n'
p2839
sg4
(lp2840
(dp2841
g7
I131
sg8
VP28062
p2842
sg10
I5
sg11
VMPC-1
p2843
sg13
I1
sa(dp2844
g7
I141
sg8
VP08648
p2845
sg10
I16
sg11
VCD49e antibodies
p2846
sg13
I2
sasg14
(lp2847
(dp2848
g7
I66
sg17
VC0026764
p2849
sg10
I7
sg11
Vmyeloma
p2850
sg13
I1
sasa(dp2851
g2
S'On the basis of biopsies of the masses in the pharynx and finger, he was diagnosed with extramedullary plasmablastic plasmacytoma, with somewhat immature CD45(+), MPC-1(-), and CD49e(-).\n'
p2852
sg4
(lp2853
(dp2854
g7
I177
sg8
VP08648
p2855
sg10
I5
sg11
VCD49e
p2856
sg13
I1
sa(dp2857
g7
I154
sg8
VP08575
p2858
sg10
I7
sg11
VCD45(+)
p2859
sg13
I1
sa(dp2860
g7
I163
sg8
VP28062
p2861
sg10
I5
sg11
VMPC-1
p2862
sg13
I1
sasg14
(lp2863
(dp2864
g7
I117
sg17
VC0032131
p2865
sg10
I12
sg11
Vplasmacytoma
p2866
sg13
I1
sasa(dp2867
g2
S'Changes to CD45 negativity and MPC-1 partial positivity were seen, while CD49e negativity persisted, suggesting that the plasmablastic plasmacytoma had reverted to a more immature state.\n'
p2868
sg4
(lp2869
(dp2870
g7
I31
sg8
VP28062
p2871
sg10
I5
sg11
VMPC-1
p2872
sg13
I1
sa(dp2873
g7
I73
sg8
VP08648
p2874
sg10
I5
sg11
VCD49e
p2875
sg13
I1
sa(dp2876
g7
I11
sg8
VP08575
p2877
sg10
I15
sg11
VCD45 negativity
p2878
sg13
I2
sasg14
(lp2879
(dp2880
g7
I135
sg17
VC0032131
p2881
sg10
I12
sg11
Vplasmacytoma
p2882
sg13
I1
sasa(dp2883
g2
S'He had the following poor prognostic factors: 1) multiple extramedullary plasmacytomas, 2) massive myelomatous effusion, 3) increasing immature myeloma cells with plasmablastic morphology, and 4) predominance of MPC1-CD49e-CD45+ phenotype immature myeloma cells.\n'
p2884
sg4
(lp2885
(dp2886
g7
I212
sg8
VP28062
p2887
sg10
I4
sg11
VMPC1
p2888
sg13
I1
sa(dp2889
g7
I223
sg8
VP08575
p2890
sg10
I5
sg11
VCD45+
p2891
sg13
I1
sa(dp2892
g7
I217
sg8
VP08648
p2893
sg10
I5
sg11
VCD49e
p2894
sg13
I1
sasg14
(lp2895
(dp2896
g7
I99
sg17
VC0026764
p2897
sg10
I7
sg11
Vmyeloma
p2898
sg13
I1
sa(dp2899
g7
I111
sg17
VC0013687
p2900
sg10
I8
sg11
Veffusion
p2901
sg13
I1
sa(dp2902
g7
I99
sg17
VC0026764
p2903
sg10
I7
sg11
Vmyeloma
p2904
sg13
I1
sa(dp2905
g7
I73
sg17
VC0032131
p2906
sg10
I13
sg11
Vplasmacytomas
p2907
sg13
I1
sasa(dp2908
g2
S'CD32 was significantly expressed on primary myeloma cells, but immature, MPC-1- myeloma cells expressed CD32 more weakly than mature, MPC-1+ cells.\n'
p2909
sg4
(lp2910
(dp2911
g7
I0
sg8
VP12318
p2912
sg10
I4
sg11
VCD32
p2913
sg13
I1
sa(dp2914
g7
I73
sg8
VP28062
p2915
sg10
I5
sg11
VMPC-1
p2916
sg13
I1
sa(dp2917
g7
I0
sg8
VP12318
p2918
sg10
I4
sg11
VCD32
p2919
sg13
I1
sasg14
(lp2920
(dp2921
g7
I44
sg17
VC0026764
p2922
sg10
I7
sg11
Vmyeloma
p2923
sg13
I1
sa(dp2924
g7
I44
sg17
VC0026764
p2925
sg10
I7
sg11
Vmyeloma
p2926
sg13
I1
sasa(dp2927
g2
S'Treatment with anti-CD32 antibody decreased the viability of normal plasma cells (CD38++ CD19+) more than that of myeloma cells (CD38++ CD19-); CD32-mediated growth suppression was greater in mature MPC-1+ cells than in immature MPC-1- cells.\n'
p2928
sg4
(lp2929
(dp2930
g7
I15
sg8
VP12318
p2931
sg10
I18
sg11
Vanti-CD32 antibody
p2932
sg13
I2
sa(dp2933
g7
I82
sg8
VP28907
p2934
sg10
I12
sg11
VCD38++ CD19+
p2935
sg13
I2
sa(dp2936
g7
I20
sg8
VP12318
p2937
sg10
I4
sg11
VCD32
p2938
sg13
I1
sasg14
(lp2939
(dp2940
g7
I158
sg17
VC0151686
p2941
sg10
I18
sg11
Vgrowth suppression
p2942
sg13
I2
sa(dp2943
g7
I114
sg17
VC0026764
p2944
sg10
I7
sg11
Vmyeloma
p2945
sg13
I1
sasa(dp2946
g2
S'To date, at least 5 subpopulations of plasma cells have been identified in the bone marrow of multiple myeloma (MM) patients with regard to the expression of MPC-1, CD49e (VLA-5), and CD45: MPC-1(-)CD49e(-)CD45(+) proliferative immature cells, MPC-1(-)CD49e(-)CD45(-) immature myeloma cells, MPC-1(+)CD49e(-)CD45(-) and MPC-1(+)CD49e(-)CD45(+) intermediate myeloma cells, and MPC-1(+)CD49e(+)CD45(+) mature myeloma cells.\n'
p2947
sg4
(lp2948
(dp2949
g7
I376
sg8
VP28062
p2950
sg10
I23
sg11
VMPC-1(+)CD49e(+)CD45(+)
p2951
sg13
I1
sa(dp2952
g7
I184
sg8
VP08575
p2953
sg10
I26
sg11
VCD45: MPC-1(-)CD49e(-)CD45
p2954
sg13
I2
sa(dp2955
g7
I158
sg8
VP28062
p2956
sg10
I5
sg11
VMPC-1
p2957
sg13
I1
sa(dp2958
g7
I260
sg8
VP08575
p2959
sg10
I7
sg11
VCD45(-)
p2960
sg13
I1
sa(dp2961
g7
I190
sg8
VP28062
p2962
sg10
I16
sg11
VMPC-1(-)CD49e(-)
p2963
sg13
I1
sa(dp2964
g7
I292
sg8
VP28062
p2965
sg10
I23
sg11
VMPC-1(+)CD49e(-)CD45(-)
p2966
sg13
I1
sa(dp2967
g7
I172
sg8
VP08648
p2968
sg10
I5
sg11
VVLA-5
p2969
sg13
I1
sa(dp2970
g7
I165
sg8
VP08648
p2971
sg10
I5
sg11
VCD49e
p2972
sg13
I1
sa(dp2973
g7
I320
sg8
VP28062
p2974
sg10
I23
sg11
VMPC-1(+)CD49e(-)CD45(+)
p2975
sg13
I1
sasg14
(lp2976
(dp2977
g7
I103
sg17
VC0026764
p2978
sg10
I7
sg11
Vmyeloma
p2979
sg13
I1
sa(dp2980
g7
I94
sg17
VC0026764
p2981
sg10
I16
sg11
Vmultiple myeloma
p2982
sg13
I2
sa(dp2983
g7
I214
sg17
VC0334094
p2984
sg10
I13
sg11
Vproliferative
p2985
sg13
I1
sa(dp2986
g7
I112
sg17
VC0026764
p2987
sg10
I2
sg11
VMM
p2988
sg13
I1
sa(dp2989
g7
I103
sg17
VC0026764
p2990
sg10
I7
sg11
Vmyeloma
p2991
sg13
I1
sa(dp2992
g7
I103
sg17
VC0026764
p2993
sg10
I7
sg11
Vmyeloma
p2994
sg13
I1
sasa(dp2995
g2
S'In 31 cases of progressive MM disease, MPC-1(-) immature and MPC-1(-)CD45(+) proliferative immature myeloma cells were significantly increased up to &gt;25% and &gt;10%, respectively, of the plasma cell fractions (CD38(++) cells), whereas there were no increases in MPC-1(-) or MPC-1(-)CD45(+) proliferative immature myeloma cells in 15 cases of stable disease.\n'
p2996
sg4
(lp2997
(dp2998
g7
I61
sg8
VP28062
p2999
sg10
I15
sg11
VMPC-1(-)CD45(+)
p3000
sg13
I1
sa(dp3001
g7
I214
sg8
VP28907
p3002
sg10
I4
sg11
VCD38
p3003
sg13
I1
sa(dp3004
g7
I61
sg8
VP28062
p3005
sg10
I15
sg11
VMPC-1(-)CD45(+)
p3006
sg13
I1
sa(dp3007
g7
I39
sg8
VP28062
p3008
sg10
I8
sg11
VMPC-1(-)
p3009
sg13
I1
sasg14
(lp3010
(dp3011
g7
I77
sg17
VC0334094
p3012
sg10
I13
sg11
Vproliferative
p3013
sg13
I1
sa(dp3014
g7
I77
sg17
VC0334094
p3015
sg10
I13
sg11
Vproliferative
p3016
sg13
I1
sa(dp3017
g7
I100
sg17
VC0026764
p3018
sg10
I7
sg11
Vmyeloma
p3019
sg13
I1
sa(dp3020
g7
I100
sg17
VC0026764
p3021
sg10
I7
sg11
Vmyeloma
p3022
sg13
I1
sasa(dp3023
g2
S'Interestingly, the proportions of MPC-1(-) and MPC-1(-)CD45(+) immature monoclonal plasma cells also increased in the 7 progressive cases of MGUS.\n'
p3024
sg4
(lp3025
(dp3026
g7
I47
sg8
VP28062
p3027
sg10
I15
sg11
VMPC-1(-)CD45(+)
p3028
sg13
I1
sa(dp3029
g7
I34
sg8
VP28062
p3030
sg10
I5
sg11
VMPC-1
p3031
sg13
I1
sasg14
(lp3032
(dp3033
g7
I141
sg17
VC0026470
p3034
sg10
I4
sg11
VMGUS
p3035
sg13
I1
sasa(dp3036
g2
S'Results with flow cytometry using a combination of MPC1, CD49e, and CD45 supported the morphologic findings for the myeloma cells.\n'
p3037
sg4
(lp3038
(dp3039
g7
I51
sg8
VP28062
p3040
sg10
I4
sg11
VMPC1
p3041
sg13
I1
sa(dp3042
g7
I57
sg8
VP08648
p3043
sg10
I5
sg11
VCD49e
p3044
sg13
I1
sa(dp3045
g7
I68
sg8
VP08575
p3046
sg10
I4
sg11
VCD45
p3047
sg13
I1
sasg14
(lp3048
(dp3049
g7
I116
sg17
VC0026764
p3050
sg10
I7
sg11
Vmyeloma
p3051
sg13
I1
sasa(dp3052
g2
S'Interestingly, the region encompassing the SNF1LK locus has been implicated in congenital heart defects often observed in patients with Down syndrome.\n'
p3053
sg4
(lp3054
(dp3055
g7
I43
sg8
VP57059
p3056
sg10
I12
sg11
VSNF1LK locus
p3057
sg13
I2
sasg14
(lp3058
(dp3059
g7
I136
sg17
VC0013080
p3060
sg10
I13
sg11
VDown syndrome
p3061
sg13
I2
sa(dp3062
g7
I79
sg17
VC0018798
p3063
sg10
I24
sg11
Vcongenital heart defects
p3064
sg13
I3
sasa(dp3065
g2
S'On the other hand, a significant increase was demonstrated in CD14-positive cells at 3 weeks after immunization in only arthritis-developed monkeys regardless of sex.\n'
p3066
sg4
(lp3067
(dp3068
g7
I62
sg8
VP08571
p3069
sg10
I4
sg11
VCD14
p3070
sg13
I1
sasg14
(lp3071
(dp3072
g7
I120
sg17
VC0003864
p3073
sg10
I9
sg11
Varthritis
p3074
sg13
I1
sasa(dp3075
g2
S'We previously reported the accumulation of abnormal myeloid cell populations reacting with CD14 (MY4) monoclonal antibody in the iliac and epiphyseal bone marrow of patients with severe rheumatoid arthritis (RA).\n'
p3076
sg4
(lp3077
(dp3078
g7
I91
sg8
VP08571
p3079
sg10
I4
sg11
VCD14
p3080
sg13
I1
sasg14
(lp3081
(dp3082
g7
I208
sg17
VC0003873
p3083
sg10
I2
sg11
VRA
p3084
sg13
I1
sa(dp3085
g7
I186
sg17
VC0003873
p3086
sg10
I20
sg11
Vrheumatoid arthritis
p3087
sg13
I2
sasa(dp3088
g2
S'Prior to treatment, monocyte-macrophage activation in rheumatoid arthritis was signified by an increased expression of HLA-class II antigens and the CD14 antigen, and by an increased production of neopterin and interleukin-1.\n'
p3089
sg4
(lp3090
(dp3091
g7
I149
sg8
VP08571
p3092
sg10
I12
sg11
VCD14 antigen
p3093
sg13
I2
sa(dp3094
g7
I211
sg8
VP60568
p3095
sg10
I13
sg11
Vinterleukin-1
p3096
sg13
I1
sa(dp3097
g7
I119
sg8
VP30486
p3098
sg10
I21
sg11
VHLA-class II antigens
p3099
sg13
I3
sasg14
(lp3100
(dp3101
g7
I54
sg17
VC0003873
p3102
sg10
I20
sg11
Vrheumatoid arthritis
p3103
sg13
I2
sasa(dp3104
g2
S'Monocytes, defined by staining with the Mo-2 and Leu-M3 monoclonal antibodies which both detect the CD14 antigen, were studied in peripheral blood of control subjects and patients with rheumatoid arthritis as well as in rheumatoid synovial fluid of the latter for expression of activation/differentiation markers.\n'
p3105
sg4
(lp3106
(dp3107
g7
I49
sg8
VP30740
p3108
sg10
I28
sg11
VLeu-M3 monoclonal antibodies
p3109
sg13
I3
sa(dp3110
g7
I100
sg8
VP08571
p3111
sg10
I12
sg11
VCD14 antigen
p3112
sg13
I2
sasg14
(lp3113
(dp3114
g7
I185
sg17
VC0003873
p3115
sg10
I20
sg11
Vrheumatoid arthritis
p3116
sg13
I2
sasa(dp3117
g2
S'We review recent findings implicating variants of FCRL3 (gene for FC receptor-like-3 protein), SCGB3A2 (gene for secretory uteroglobin-related protein 1- UGRP1) as well as other unverified possible candidate genes for GD selected through their documented association with type 1 diabetes mellitus: Tenr-IL2-IL21, CAPSL (encoding calcyphosine-like protein), IFIH1(gene for interferon-induced helicase C domain 1), AFF3, CD226 and PTPN2.\n'
p3118
sg4
(lp3119
(dp3120
g7
I413
sg8
VP51826
p3121
sg10
I4
sg11
VAFF3
p3122
sg13
I1
sa(dp3123
g7
I307
sg8
g9
sg10
I4
sg11
VIL21
p3124
sg13
I1
sa(dp3125
g7
I113
sg8
VP11684
p3126
sg10
I46
sg11
Vsecretory uteroglobin-related protein 1- UGRP1
p3127
sg13
I5
sa(dp3128
g7
I50
sg8
g9
sg10
I5
sg11
VFCRL3
p3129
sg13
I1
sa(dp3130
g7
I329
sg8
g9
sg10
I25
sg11
Vcalcyphosine-like protein
p3131
sg13
I2
sa(dp3132
g7
I429
sg8
VP17706
p3133
sg10
I5
sg11
VPTPN2
p3134
sg13
I1
sa(dp3135
g7
I66
sg8
g9
sg10
I26
sg11
VFC receptor-like-3 protein
p3136
sg13
I3
sa(dp3137
g7
I372
sg8
VP01563
p3138
sg10
I38
sg11
Vinterferon-induced helicase C domain 1
p3139
sg13
I5
sa(dp3140
g7
I357
sg8
g9
sg10
I5
sg11
VIFIH1
p3141
sg13
I1
sa(dp3142
g7
I95
sg8
g9
sg10
I7
sg11
VSCGB3A2
p3143
sg13
I1
sa(dp3144
g7
I303
sg8
VP60568
p3145
sg10
I3
sg11
VIL2
p3146
sg13
I1
sa(dp3147
g7
I419
sg8
g9
sg10
I5
sg11
VCD226
p3148
sg13
I1
sa(dp3149
g7
I313
sg8
g9
sg10
I5
sg11
VCAPSL
p3150
sg13
I1
sasg14
(lp3151
(dp3152
g7
I272
sg17
VC0011854
p3153
sg10
I24
sg11
Vtype 1 diabetes mellitus
p3154
sg13
I4
sasa(dp3155
g2
S'Autoantibody-positive diabetic subjects (n = 1,384) and population-based control subjects (n = 2,235) were genotyped at 20 childhood-onset type 1 diabetes loci and FCRL3, GAD2, TCF7L2, and FTO.\n'
p3156
sg4
(lp3157
(dp3158
g7
I171
sg8
g9
sg10
I4
sg11
VGAD2
p3159
sg13
I1
sasg14
(lp3160
(dp3161
g7
I139
sg17
VC0011854
p3162
sg10
I15
sg11
Vtype 1 diabetes
p3163
sg13
I3
sasa(dp3164
g2
S"We analyzed the same four 5' FCRL3 single nucleotide polymorphism markers, together with three additional exonic single nucleotide polymorphisms in the FCRL3 gene, in cohorts of white Caucasians with Graves' disease (n = 625), type 1 diabetes (n = 279), autoimmune Addison's disease (AAD; n = 200), and RA (n = 769).\n"
p3165
sg4
(lp3166
sg14
(lp3167
(dp3168
g7
I227
sg17
VC0011854
p3169
sg10
I15
sg11
Vtype 1 diabetes
p3170
sg13
I3
sa(dp3171
g7
I254
sg17
VC0271737
p3172
sg10
I28
sg11
Vautoimmune Addison's disease
p3173
sg13
I3
sa(dp3174
g7
I200
sg17
VC0018213
p3175
sg10
I15
sg11
VGraves' disease
p3176
sg13
I2
sa(dp3177
g7
I284
sg17
VC0271737
p3178
sg10
I3
sg11
VAAD
p3179
sg13
I1
sasa(dp3180
g2
S'In vivo, in a model of experimental autoimmune encephalomyelitis, we show that an agonist of DR3 suppressed disease, correlating with expansion of CD4+Foxp3+ Tregs, and this protective effect was lost in Galectin-9-/- mice.\n'
p3181
sg4
(lp3182
(dp3183
g7
I147
sg8
VP01730
p3184
sg10
I10
sg11
VCD4+Foxp3+
p3185
sg13
I1
sa(dp3186
g7
I204
sg8
g9
sg10
I10
sg11
VGalectin-9
p3187
sg13
I1
sasg14
(lp3188
(dp3189
g7
I36
sg17
VC0443146
p3190
sg10
I10
sg11
Vautoimmune
p3191
sg13
I1
sa(dp3192
g7
I47
sg17
VC0014070
p3193
sg10
I17
sg11
Vencephalomyelitis
p3194
sg13
I1
sasa(dp3195
g2
S'Galectin-9 concentrations in CSF were higher in SPMS patients than healthy controls and RRMS patients in both cohorts.\n'
p3196
sg4
(lp3197
(dp3198
g7
I0
sg8
g9
sg10
I10
sg11
VGalectin-9
p3199
sg13
I1
sasg14
(lp3200
sa(dp3201
g2
S'Our objective is to identify phenotypically the position of CD43(+) B cells among peripheral B-lineage cell compartments in healthy donors, with reference to B-cell subsets from patients with systemic lupus erythematosus (SLE).\n'
p3202
sg4
(lp3203
(dp3204
g7
I60
sg8
VP16150
p3205
sg10
I4
sg11
VCD43
p3206
sg13
I1
sasg14
(lp3207
(dp3208
g7
I192
sg17
VC0024141
p3209
sg10
I28
sg11
Vsystemic lupus erythematosus
p3210
sg13
I3
sa(dp3211
g7
I222
sg17
VC0024141
p3212
sg10
I3
sg11
VSLE
p3213
sg13
I1
sasa(dp3214
g2
S'Previous studies indicate that CD43 plays a role in regulating the adhesion of lymphocytes, cell mutation and activation, however, little is known about its effect on systemic lupus erythematosus (SLE).\n'
p3215
sg4
(lp3216
(dp3217
g7
I31
sg8
VP16150
p3218
sg10
I4
sg11
VCD43
p3219
sg13
I1
sasg14
(lp3220
(dp3221
g7
I197
sg17
VC0024141
p3222
sg10
I3
sg11
VSLE
p3223
sg13
I1
sa(dp3224
g7
I67
sg17
VC0001511
p3225
sg10
I8
sg11
Vadhesion
p3226
sg13
I1
sa(dp3227
g7
I167
sg17
VC0024141
p3228
sg10
I28
sg11
Vsystemic lupus erythematosus
p3229
sg13
I3
sasa(dp3230
g2
S'Two new cases of primary Ficolin-3 deficiency are reported here: a 50-year old male, suffering from membranous nephropathy and an 11-month old male infant who was operated on to repair congenital heart disease.\n'
p3231
sg4
(lp3232
(dp3233
g7
I25
sg8
g9
sg10
I9
sg11
VFicolin-3
p3234
sg13
I1
sasg14
(lp3235
(dp3236
g7
I185
sg17
VC0152021
p3237
sg10
I24
sg11
Vcongenital heart disease
p3238
sg13
I3
sa(dp3239
g7
I85
sg17
VC0683278
p3240
sg10
I9
sg11
Vsuffering
p3241
sg13
I1
sa(dp3242
g7
I100
sg17
VC0017665
p3243
sg10
I22
sg11
Vmembranous nephropathy
p3244
sg13
I2
sasa(dp3245
g2
S'In order to investigate its potential pathogenicity for turkeys a UK isolate of Mim from a partridge with sinusitis was first passaged through turkey poults and then assessed for pathogenicity in turkey embryo tracheal organ cultures (TOCs) and in one-day-old turkey poults with or without turkey rhinotracheitis virus (TRTV).\n'
p3246
sg4
(lp3247
(dp3248
g7
I80
sg8
g9
sg10
I3
sg11
VMim
p3249
sg13
I1
sasg14
(lp3250
(dp3251
g7
I290
sg17
VC0275744
p3252
sg10
I22
sg11
Vturkey rhinotracheitis
p3253
sg13
I2
sa(dp3254
g7
I106
sg17
VC0037199
p3255
sg10
I9
sg11
Vsinusitis
p3256
sg13
I1
sasa(dp3257
g2
S'Both up- and down-regulation of the Toll-like receptors (TLRs) and antimicrobial peptides (AMPs) of the sinonasal mucosa have already been associated with the pathogenesis of chronic rhinosinusitis with (CRSwNP) or without (CRSsNP) nasal polyps.\n'
p3258
sg4
(lp3259
(dp3260
g7
I36
sg8
g9
sg10
I19
sg11
VToll-like receptors
p3261
sg13
I2
sa(dp3262
g7
I57
sg8
g9
sg10
I4
sg11
VTLRs
p3263
sg13
I1
sasg14
(lp3264
(dp3265
g7
I159
sg17
VC0699748
p3266
sg10
I12
sg11
Vpathogenesis
p3267
sg13
I1
sa(dp3268
g7
I175
sg17
VC0149516
p3269
sg10
I22
sg11
Vchronic rhinosinusitis
p3270
sg13
I2
sa(dp3271
g7
I232
sg17
VC0027430
p3272
sg10
I12
sg11
Vnasal polyps
p3273
sg13
I2
sasa(dp3274
g2
S'It is suggested that elevated plasma nociceptin level found in Wilson disease patients is due to inhibition of nociceptin-inactivating Zn-metallopeptidases (aminopeptidase N (APN) and endopeptidase 24.15) by the toxic copper deposits in liver and/or brain.\n'
p3275
sg4
(lp3276
(dp3277
g7
I175
sg8
g9
sg10
I3
sg11
VAPN
p3278
sg13
I1
sa(dp3279
g7
I111
sg8
g9
sg10
I44
sg11
Vnociceptin-inactivating Zn-metallopeptidases
p3280
sg13
I2
sa(dp3281
g7
I184
sg8
VP52888
p3282
sg10
I19
sg11
Vendopeptidase 24.15
p3283
sg13
I2
sa(dp3284
g7
I157
sg8
VP15144
p3285
sg10
I16
sg11
Vaminopeptidase N
p3286
sg13
I2
sa(dp3287
g7
I30
sg8
g9
sg10
I17
sg11
Vplasma nociceptin
p3288
sg13
I2
sasg14
(lp3289
(dp3290
g7
I63
sg17
VC0019202
p3291
sg10
I14
sg11
VWilson disease
p3292
sg13
I2
sasa(dp3293
g2
S'It is evident from the study that body iron (serum iron, TIBC &amp; transferrin saturation) level significantly increases among acute myocardial infarction patients in Bangladesh.\n'
p3294
sg4
(lp3295
(dp3296
g7
I68
sg8
VP02787
p3297
sg10
I11
sg11
Vtransferrin
p3298
sg13
I1
sasg14
(lp3299
(dp3300
g7
I128
sg17
VC0155626
p3301
sg10
I27
sg11
Vacute myocardial infarction
p3302
sg13
I3
sasa(dp3303
g2
S'We investigated the relation of NTBI, serum iron, transferrin saturation, and serum ferritin with risk of CHD and acute myocardial infarction (AMI).\n'
p3304
sg4
(lp3305
(dp3306
g7
I78
sg8
VP02794
p3307
sg10
I14
sg11
Vserum ferritin
p3308
sg13
I2
sa(dp3309
g7
I50
sg8
VP02787
p3310
sg10
I11
sg11
Vtransferrin
p3311
sg13
I1
sasg14
(lp3312
(dp3313
g7
I114
sg17
VC0155626
p3314
sg10
I27
sg11
Vacute myocardial infarction
p3315
sg13
I3
sa(dp3316
g7
I143
sg17
VC0155626
p3317
sg10
I3
sg11
VAMI
p3318
sg13
I1
sasa(dp3319
g2
S'Studies investigating the contribution of Cytochrome P4502E1 (CYP2E1) polymorphisms to the etiology of urinary cancer draw inconsistent conclusions.\n'
p3320
sg4
(lp3321
(dp3322
g7
I42
sg8
VP05181
p3323
sg10
I18
sg11
VCytochrome P4502E1
p3324
sg13
I2
sa(dp3325
g7
I62
sg8
VP05181
p3326
sg10
I6
sg11
VCYP2E1
p3327
sg13
I1
sasg14
(lp3328
(dp3329
g7
I111
sg17
VC0006826
p3330
sg10
I6
sg11
Vcancer
p3331
sg13
I1
sasa(dp3332
g2
S'Thus, we performed a meta-analysis to evaluate the association between CYP2E1 Rsa I/Pst I and Dra I polymorphisms and urinary cancer susceptibility.\n'
p3333
sg4
(lp3334
(dp3335
g7
I71
sg8
VP05181
p3336
sg10
I12
sg11
VCYP2E1 Rsa I
p3337
sg13
I3
sa(dp3338
g7
I94
sg8
VP40879
p3339
sg10
I53
sg11
VDra I polymorphisms and urinary cancer susceptibility
p3340
sg13
I7
sa(dp3341
g7
I84
sg8
VP50225
p3342
sg10
I5
sg11
VPst I
p3343
sg13
I2
sasg14
(lp3344
(dp3345
g7
I126
sg17
VC0006826
p3346
sg10
I6
sg11
Vcancer
p3347
sg13
I1
sasa(dp3348
g2
S'Meta-analysis based on the eligible case-control studies that assess the association of CYP2E1 Rsa I/Pst I and Dra I polymorphisms with urinary cancer was conducted.\n'
p3349
sg4
(lp3350
(dp3351
g7
I101
sg8
VP50225
p3352
sg10
I5
sg11
VPst I
p3353
sg13
I2
sa(dp3354
g7
I111
sg8
VP40879
p3355
sg10
I5
sg11
VDra I
p3356
sg13
I2
sa(dp3357
g7
I88
sg8
VP05181
p3358
sg10
I12
sg11
VCYP2E1 Rsa I
p3359
sg13
I3
sasg14
(lp3360
(dp3361
g7
I144
sg17
VC0006826
p3362
sg10
I6
sg11
Vcancer
p3363
sg13
I1
sasa(dp3364
g2
S'We found decreased urinary cancer risk among subjects carrying CYP2E1 RsaI/PstI c1c2 + c2c2 genotype and c2 allele (OR = 0.73, 95% CI = 0.68-0.79 and OR = 0.79, 95% CI = 0.74-0.85, respectively), with 3,301 cases and 3,786 controls from 14 studies.\n'
p3365
sg4
(lp3366
(dp3367
g7
I63
sg8
VP05181
p3368
sg10
I11
sg11
VCYP2E1 RsaI
p3369
sg13
I2
sa(dp3370
g7
I75
sg8
VP00995
p3371
sg10
I9
sg11
VPstI c1c2
p3372
sg13
I2
sasg14
(lp3373
(dp3374
g7
I27
sg17
VC0006826
p3375
sg10
I6
sg11
Vcancer
p3376
sg13
I1
sasa(dp3377
g2
S'However, the meta-analysis based on 5 eligible studies showed no significant association between CYP2E1 Dra I polymorphism and urinary cancer susceptibility in either dominant model or the allele model.\n'
p3378
sg4
(lp3379
(dp3380
g7
I97
sg8
VP05181
p3381
sg10
I59
sg11
VCYP2E1 Dra I polymorphism and urinary cancer susceptibility
p3382
sg13
I8
sasg14
(lp3383
(dp3384
g7
I135
sg17
VC0006826
p3385
sg10
I6
sg11
Vcancer
p3386
sg13
I1
sasa(dp3387
g2
S'Our meta-analysis concluded that CYP2E1 Rsa I/Pst I polymorphism correlates with urinary cancers risk in Asian population; while CYP2E1 Dra I polymorphism might be not significantly associated with the urinary cancer risks.\n'
p3388
sg4
(lp3389
(dp3390
g7
I129
sg8
VP05181
p3391
sg10
I12
sg11
VCYP2E1 Dra I
p3392
sg13
I3
sa(dp3393
g7
I46
sg8
VP50225
p3394
sg10
I5
sg11
VPst I
p3395
sg13
I2
sa(dp3396
g7
I33
sg8
VP05181
p3397
sg10
I12
sg11
VCYP2E1 Rsa I
p3398
sg13
I3
sasg14
(lp3399
(dp3400
g7
I89
sg17
VC0006826
p3401
sg10
I6
sg11
Vcancer
p3402
sg13
I1
sa(dp3403
g7
I89
sg17
VC0006826
p3404
sg10
I7
sg11
Vcancers
p3405
sg13
I1
sasa(dp3406
g2
S'In this study, the effects of chiral pesticide metalaxyl on CYP1A1, CYP1A2, CYP2B1, CYP2B2, CYP2E1 and CYP3A were investigated in human hepatoma HepG2, rat hepatic H4IIE, chicken hepatic LMH and grass carp hepatic L8824 cells.\n'
p3407
sg4
(lp3408
(dp3409
g7
I171
sg8
g9
sg10
I19
sg11
Vchicken hepatic LMH
p3410
sg13
I3
sa(dp3411
g7
I68
sg8
VP05177
p3412
sg10
I6
sg11
VCYP1A2
p3413
sg13
I1
sa(dp3414
g7
I92
sg8
VP05181
p3415
sg10
I6
sg11
VCYP2E1
p3416
sg13
I1
sa(dp3417
g7
I60
sg8
VP04798
p3418
sg10
I6
sg11
VCYP1A1
p3419
sg13
I1
sa(dp3420
g7
I103
sg8
VP08684
p3421
sg10
I5
sg11
VCYP3A
p3422
sg13
I1
sasg14
(lp3423
(dp3424
g7
I201
sg17
VC0263385
p3425
sg10
I4
sg11
Vcarp
p3426
sg13
I1
sa(dp3427
g7
I136
sg17
VC0023903
p3428
sg10
I8
sg11
Vhepatoma
p3429
sg13
I1
sasa(dp3430
g2
S'ER+ cancers exhibited lower ADORA1, ADORA2B, and RYR1 and elevated PDE4A, CYP2A6, and CYP2E expressions.\n'
p3431
sg4
(lp3432
(dp3433
g7
I28
sg8
VP30542
p3434
sg10
I6
sg11
VADORA1
p3435
sg13
I1
sa(dp3436
g7
I36
sg8
VP29275
p3437
sg10
I7
sg11
VADORA2B
p3438
sg13
I1
sa(dp3439
g7
I86
sg8
VP05181
p3440
sg10
I5
sg11
VCYP2E
p3441
sg13
I1
sa(dp3442
g7
I49
sg8
VP21817
p3443
sg10
I4
sg11
VRYR1
p3444
sg13
I1
sasg14
(lp3445
(dp3446
g7
I4
sg17
VC0006826
p3447
sg10
I7
sg11
Vcancers
p3448
sg13
I1
sasa(dp3449
g2
S'The mechanisms were investigated by detecting levels of NADPH Oxidase 4 (NOX4),p22phox, cytochrome P4502E1 (CYP2E1),Bax,B-cell lymphoma 2 (Bcl-2),cleaved-caspase 3 and 9 and phosphorylated extracellular regulated protein kinases(ERK),phosphorylated c-Jun N-terminal kinase (JNK), and phosphorylated p38 mitogen-activated protein kinase (MAPK) using real-time polymerase chain reaction (PCR) and Western blotting.\n'
p3450
sg4
(lp3451
(dp3452
g7
I337
sg8
VP53779
p3453
sg10
I4
sg11
VMAPK
p3454
sg13
I1
sa(dp3455
g7
I249
sg8
VP53779
p3456
sg10
I23
sg11
Vc-Jun N-terminal kinase
p3457
sg13
I3
sa(dp3458
g7
I79
sg8
VP13498
p3459
sg10
I7
sg11
Vp22phox
p3460
sg13
I1
sa(dp3461
g7
I299
sg8
g9
sg10
I36
sg11
Vp38 mitogen-activated protein kinase
p3462
sg13
I4
sa(dp3463
g7
I108
sg8
VP05181
p3464
sg10
I6
sg11
VCYP2E1
p3465
sg13
I1
sa(dp3466
g7
I274
sg8
VP53779
p3467
sg10
I3
sg11
VJNK
p3468
sg13
I1
sa(dp3469
g7
I88
sg8
VP05181
p3470
sg10
I18
sg11
Vcytochrome P4502E1
p3471
sg13
I2
sa(dp3472
g7
I154
sg8
VP39880
p3473
sg10
I7
sg11
Vcaspase
p3474
sg13
I1
sa(dp3475
g7
I115
sg8
VP10415
p3476
sg10
I22
sg11
V,Bax,B-cell lymphoma 2
p3477
sg13
I3
sa(dp3478
g7
I56
sg8
g9
sg10
I15
sg11
VNADPH Oxidase 4
p3479
sg13
I3
sa(dp3480
g7
I189
sg8
VP10398
p3481
sg10
I39
sg11
Vextracellular regulated protein kinases
p3482
sg13
I4
sa(dp3483
g7
I73
sg8
g9
sg10
I4
sg11
VNOX4
p3484
sg13
I1
sa(dp3485
g7
I229
sg8
VP29323
p3486
sg10
I3
sg11
VERK
p3487
sg13
I1
sa(dp3488
g7
I139
sg8
VP10415
p3489
sg10
I5
sg11
VBcl-2
p3490
sg13
I1
sasg14
(lp3491
(dp3492
g7
I120
sg17
VC0079731
p3493
sg10
I15
sg11
VB-cell lymphoma
p3494
sg13
I2
sasa(dp3495
g2
S'This study aimed to determine the serum levels of angiopoietin-like 4 (ANGPTL4) in patients with renal cell carcinoma (RCC) and explore its potential as a biomarker.\n'
p3496
sg4
(lp3497
(dp3498
g7
I50
sg8
g9
sg10
I19
sg11
Vangiopoietin-like 4
p3499
sg13
I2
sa(dp3500
g7
I71
sg8
g9
sg10
I7
sg11
VANGPTL4
p3501
sg13
I1
sasg14
(lp3502
(dp3503
g7
I119
sg17
VC0007134
p3504
sg10
I3
sg11
VRCC
p3505
sg13
I1
sa(dp3506
g7
I97
sg17
VC0007134
p3507
sg10
I20
sg11
Vrenal cell carcinoma
p3508
sg13
I3
sasa(dp3509
g2
S'We have previously shown that angiopoietin-like 4 (angptl4) mRNA, a hypoxia-inducible gene, is highly expressed in clear cell renal-cell carcinoma (ccRCC), the most common subtype of RCC for which no specific marker is available.\n'
p3510
sg4
(lp3511
(dp3512
g7
I51
sg8
g9
sg10
I7
sg11
Vangptl4
p3513
sg13
I1
sa(dp3514
g7
I30
sg8
g9
sg10
I19
sg11
Vangiopoietin-like 4
p3515
sg13
I2
sasg14
(lp3516
(dp3517
g7
I68
sg17
VC0242184
p3518
sg10
I7
sg11
Vhypoxia
p3519
sg13
I1
sa(dp3520
g7
I137
sg17
VC0007097
p3521
sg10
I9
sg11
Vcarcinoma
p3522
sg13
I1
sa(dp3523
g7
I150
sg17
VC0007134
p3524
sg10
I3
sg11
VRCC
p3525
sg13
I1
sasa(dp3526
g2
S'We observed particularly high levels of ANGPTL4 mRNA in tumor cells of conventional renal cell carcinoma.\n'
p3527
sg4
(lp3528
(dp3529
g7
I40
sg8
g9
sg10
I12
sg11
VANGPTL4 mRNA
p3530
sg13
I2
sasg14
(lp3531
(dp3532
g7
I56
sg17
VC0027651
p3533
sg10
I5
sg11
Vtumor
p3534
sg13
I1
sa(dp3535
g7
I71
sg17
VC0279702
p3536
sg10
I33
sg11
Vconventional renal cell carcinoma
p3537
sg13
I4
sasa(dp3538
g2
S'Results The smoking subgroup (n=15) of NSIP patients had a significantly lower % diffusing capacity for carbon monoxide/ alveolar ventilation (DLCO/VA) and tended to have higher SP-D values than the nonsmoking subgroup (n=16).\n'
p3539
sg4
(lp3540
sg14
(lp3541
sa(dp3542
g2
S'As compared with major IIPs such as idiopathic pulmonary fibrosis and fibrotic nonspecific interstitial pneumonia, IPPFE significantly showed higher frequency of cases with a unique pattern of serum biomarkers, which is characterized by an elevated level of SP-D with a normal range of KL-6.\n'
p3543
sg4
(lp3544
(dp3545
g7
I258
sg8
VP35247
p3546
sg10
I4
sg11
VSP-D
p3547
sg13
I1
sasg14
(lp3548
(dp3549
g7
I36
sg17
VC3161101
p3550
sg10
I29
sg11
Vidiopathic pulmonary fibrosis
p3551
sg13
I3
sa(dp3552
g7
I79
sg17
VC1290344
p3553
sg10
I34
sg11
Vnonspecific interstitial pneumonia
p3554
sg13
I3
sasa(dp3555
g2
S'However, associations of serum KL-6 and SP-D with radiologic findings in nonspecific interstitial pneumonia (NSIP) remain unclear.\n'
p3556
sg4
(lp3557
(dp3558
g7
I25
sg8
g9
sg10
I10
sg11
Vserum KL-6
p3559
sg13
I2
sa(dp3560
g7
I40
sg8
VP35247
p3561
sg10
I4
sg11
VSP-D
p3562
sg13
I1
sasg14
(lp3563
(dp3564
g7
I109
sg17
VC1290344
p3565
sg10
I4
sg11
VNSIP
p3566
sg13
I1
sa(dp3567
g7
I73
sg17
VC1290344
p3568
sg10
I34
sg11
Vnonspecific interstitial pneumonia
p3569
sg13
I3
sasa(dp3570
g2
S'To determine whether serum levels of KL-6 and SP-D reflect fibrotic and/or inflammatory processes in NSIP, we investigated the correlation between high-resolution computed tomography (HRCT) findings and serum KL-6 and SP-D levels.\n'
p3571
sg4
(lp3572
(dp3573
g7
I46
sg8
VP35247
p3574
sg10
I4
sg11
VSP-D
p3575
sg13
I1
sa(dp3576
g7
I46
sg8
VP35247
p3577
sg10
I4
sg11
VSP-D
p3578
sg13
I1
sasg14
(lp3579
sa(dp3580
g2
S'Serum levels of KL-6 and SP-D were measured in 21 patients with biopsy-confirmed NSIP.\n'
p3581
sg4
(lp3582
(dp3583
g7
I25
sg8
VP35247
p3584
sg10
I4
sg11
VSP-D
p3585
sg13
I1
sasg14
(lp3586
sa(dp3587
g2
S'Serum levels of SP-D in NSIP showed a positive correlation with the area of ground-glass attenuation without traction bronchiectasis and the inflammatory CT pattern, but the levels were inversely correlated with the area of ground-glass attenuation with traction bronchiectasis and the fibrotic CT pattern.\n'
p3588
sg4
(lp3589
(dp3590
g7
I16
sg8
VP35247
p3591
sg10
I4
sg11
VSP-D
p3592
sg13
I1
sasg14
(lp3593
(dp3594
g7
I109
sg17
VC0264361
p3595
sg10
I23
sg11
Vtraction bronchiectasis
p3596
sg13
I2
sa(dp3597
g7
I109
sg17
VC0264361
p3598
sg10
I23
sg11
Vtraction bronchiectasis
p3599
sg13
I2
sasa(dp3600
g2
S'The results indicate that serum levels of KL-6 in NSIP reflect the overall extent of interstitial lesions, which include both inflammatory and fibrotic lesions, while the levels of SP-D mainly reflect the extent of inflammatory lesions.\n'
p3601
sg4
(lp3602
(dp3603
g7
I181
sg8
VP35247
p3604
sg10
I4
sg11
VSP-D
p3605
sg13
I1
sasg14
(lp3606
sa(dp3607
g2
S'Recently, we identified high expression of 2 RHOGAPs, ARHGAP11A and RACGAP1, in the basal-like breast cancer subtype.\n'
p3608
sg4
(lp3609
(dp3610
g7
I68
sg8
g9
sg10
I7
sg11
VRACGAP1
p3611
sg13
I1
sa(dp3612
g7
I54
sg8
g9
sg10
I9
sg11
VARHGAP11A
p3613
sg13
I1
sasg14
(lp3614
(dp3615
g7
I95
sg17
VC0678222
p3616
sg10
I13
sg11
Vbreast cancer
p3617
sg13
I2
sasa(dp3618
g2
S'We have established that, via the suppression of RhoA, ArhGAP11A and RacGAP1 are both critical drivers of BLBC growth, and propose that RhoGAPs can act as oncogenes in cancer.\n'
p3619
sg4
(lp3620
(dp3621
g7
I69
sg8
g9
sg10
I7
sg11
VRacGAP1
p3622
sg13
I1
sa(dp3623
g7
I49
sg8
VP61586
p3624
sg10
I4
sg11
VRhoA
p3625
sg13
I1
sa(dp3626
g7
I55
sg8
g9
sg10
I9
sg11
VArhGAP11A
p3627
sg13
I1
sasg14
(lp3628
(dp3629
g7
I168
sg17
VC0006826
p3630
sg10
I6
sg11
Vcancer
p3631
sg13
I1
sa(dp3632
g7
I34
sg17
VC0221103
p3633
sg10
I11
sg11
Vsuppression
p3634
sg13
I1
sasa(dp3635
g2
S"We found significant methylation differences at a number of experimentally implicated breast cancer-related genes, including attenuated 5' untranslated region (UTR)/first exon methylation at the proinvasive ARHGAP11A gene in variant mimic-transfected cells.\n"
p3636
sg4
(lp3637
(dp3638
g7
I207
sg8
g9
sg10
I14
sg11
VARHGAP11A gene
p3639
sg13
I2
sasg14
(lp3640
(dp3641
g7
I86
sg17
VC0678222
p3642
sg10
I13
sg11
Vbreast cancer
p3643
sg13
I2
sasa(dp3644
g2
S'Follow-up functional analyses revealed both concurrent increased ARHGAP11A mRNA expression and enhanced invasiveness in variant versus WT piR-021285 mimic-transfected breast cancer cell lines.\n'
p3645
sg4
(lp3646
(dp3647
g7
I65
sg8
g9
sg10
I14
sg11
VARHGAP11A mRNA
p3648
sg13
I2
sasg14
(lp3649
(dp3650
g7
I167
sg17
VC0678222
p3651
sg10
I13
sg11
Vbreast cancer
p3652
sg13
I2
sasa(dp3653
g2
S'Expression of ARHGAP11A in cancer cells suppressed RhoA-dependent mechanisms, such as stress fiber formation and focal adhesion, which made the cells more prone to migrate.\n'
p3654
sg4
(lp3655
(dp3656
g7
I14
sg8
g9
sg10
I9
sg11
VARHGAP11A
p3657
sg13
I1
sa(dp3658
g7
I51
sg8
VP61586
p3659
sg10
I4
sg11
VRhoA
p3660
sg13
I1
sasg14
(lp3661
(dp3662
g7
I119
sg17
VC0001511
p3663
sg10
I8
sg11
Vadhesion
p3664
sg13
I1
sa(dp3665
g7
I27
sg17
VC0006826
p3666
sg10
I6
sg11
Vcancer
p3667
sg13
I1
sasa(dp3668
g2
S'RNAi-based inhibition of Arhgap11a reduced the invasion and in vivo expansion of cancers.\n'
p3669
sg4
(lp3670
(dp3671
g7
I25
sg8
g9
sg10
I9
sg11
VArhgap11a
p3672
sg13
I1
sasg14
(lp3673
(dp3674
g7
I81
sg17
VC0006826
p3675
sg10
I7
sg11
Vcancers
p3676
sg13
I1
sa(dp3677
g7
I47
sg17
VC2699153
p3678
sg10
I8
sg11
Vinvasion
p3679
sg13
I1
sasa(dp3680
g2
S'Additionally, analysis of human specimens showed the significant up-regulation of Arhgap11a in colon cancers, which was correlated with clinical invasion status.\n'
p3681
sg4
(lp3682
(dp3683
g7
I82
sg8
g9
sg10
I9
sg11
VArhgap11a
p3684
sg13
I1
sasg14
(lp3685
(dp3686
g7
I95
sg17
VC0007102
p3687
sg10
I13
sg11
Vcolon cancers
p3688
sg13
I2
sa(dp3689
g7
I145
sg17
VC2699153
p3690
sg10
I8
sg11
Vinvasion
p3691
sg13
I1
sasa(dp3692
g2
S'The present study suggests that ARHGAP11A, a cell cycle-dependent RhoGAP, is a critical regulator of cancer cell mobility and is thus a promising therapeutic target in invasive cancers.\n'
p3693
sg4
(lp3694
(dp3695
g7
I66
sg8
g9
sg10
I6
sg11
VRhoGAP
p3696
sg13
I1
sa(dp3697
g7
I32
sg8
g9
sg10
I9
sg11
VARHGAP11A
p3698
sg13
I1
sasg14
(lp3699
(dp3700
g7
I177
sg17
VC0006826
p3701
sg10
I7
sg11
Vcancers
p3702
sg13
I1
sa(dp3703
g7
I101
sg17
VC0006826
p3704
sg10
I6
sg11
Vcancer
p3705
sg13
I1
sasa(dp3706
g2
S'Identified genome-wide significant loci: 1) corroborated genes implicated in other studies (MTNR1B, ZNF259/APOA5, XPA/FOXE1 (TTF-2), DARC, CCR3, ABO); 2) localized novel genes in plausible biological pathways (PCSK2, ARHGAP11A, CHRNA3); and 3) revealed novel genes with unknown function in obesity pathogenesis (MATK, COL4A1).\n'
p3707
sg4
(lp3708
(dp3709
g7
I312
sg8
VP42679
p3710
sg10
I4
sg11
VMATK
p3711
sg13
I1
sa(dp3712
g7
I114
sg8
VP23025
p3713
sg10
I3
sg11
VXPA
p3714
sg13
I1
sa(dp3715
g7
I139
sg8
VP51677
p3716
sg10
I4
sg11
VCCR3
p3717
sg13
I1
sa(dp3718
g7
I118
sg8
g9
sg10
I5
sg11
VFOXE1
p3719
sg13
I1
sa(dp3720
g7
I125
sg8
g9
sg10
I5
sg11
VTTF-2
p3721
sg13
I1
sa(dp3722
g7
I318
sg8
VP02462
p3723
sg10
I6
sg11
VCOL4A1
p3724
sg13
I1
sa(dp3725
g7
I210
sg8
VP16519
p3726
sg10
I5
sg11
VPCSK2
p3727
sg13
I1
sa(dp3728
g7
I217
sg8
g9
sg10
I9
sg11
VARHGAP11A
p3729
sg13
I1
sa(dp3730
g7
I100
sg8
g9
sg10
I6
sg11
VZNF259
p3731
sg13
I1
sa(dp3732
g7
I92
sg8
VP49286
p3733
sg10
I6
sg11
VMTNR1B
p3734
sg13
I1
sa(dp3735
g7
I228
sg8
VP32297
p3736
sg10
I6
sg11
VCHRNA3
p3737
sg13
I1
sa(dp3738
g7
I107
sg8
g9
sg10
I5
sg11
VAPOA5
p3739
sg13
I1
sasg14
(lp3740
(dp3741
g7
I290
sg17
VC0028754
p3742
sg10
I7
sg11
Vobesity
p3743
sg13
I1
sa(dp3744
g7
I298
sg17
VC0699748
p3745
sg10
I12
sg11
Vpathogenesis
p3746
sg13
I1
sasa(dp3747
g2
S'In contrast to GTG banding, array CGH determined the exact number of deleted genes and thus allowed the identification of candidate genes for cleft palate (GREM1, CX36, MEIS2), congenital heart defect (ACTC, GREM1, CX36, MEIS2), and mental retardation (ARHGAP11A, CHRNA7, CHRM5).\n'
p3748
sg4
(lp3749
(dp3750
g7
I169
sg8
g9
sg10
I5
sg11
VMEIS2
p3751
sg13
I1
sa(dp3752
g7
I163
sg8
g9
sg10
I4
sg11
VCX36
p3753
sg13
I1
sa(dp3754
g7
I272
sg8
VP08912
p3755
sg10
I5
sg11
VCHRM5
p3756
sg13
I1
sa(dp3757
g7
I202
sg8
VP68032
p3758
sg10
I4
sg11
VACTC
p3759
sg13
I1
sa(dp3760
g7
I264
sg8
VP36544
p3761
sg10
I6
sg11
VCHRNA7
p3762
sg13
I1
sa(dp3763
g7
I169
sg8
g9
sg10
I5
sg11
VMEIS2
p3764
sg13
I1
sa(dp3765
g7
I156
sg8
g9
sg10
I5
sg11
VGREM1
p3766
sg13
I1
sa(dp3767
g7
I156
sg8
g9
sg10
I5
sg11
VGREM1
p3768
sg13
I1
sa(dp3769
g7
I163
sg8
g9
sg10
I4
sg11
VCX36
p3770
sg13
I1
sa(dp3771
g7
I253
sg8
g9
sg10
I9
sg11
VARHGAP11A
p3772
sg13
I1
sasg14
(lp3773
(dp3774
g7
I233
sg17
VC0025362
p3775
sg10
I18
sg11
Vmental retardation
p3776
sg13
I2
sa(dp3777
g7
I142
sg17
VC0008925
p3778
sg10
I12
sg11
Vcleft palate
p3779
sg13
I2
sa(dp3780
g7
I34
sg17
VC1855900
p3781
sg10
I3
sg11
VCGH
p3782
sg13
I1
sa(dp3783
g7
I177
sg17
VC0018798
p3784
sg10
I23
sg11
Vcongenital heart defect
p3785
sg13
I3
sasa(dp3786
g2
S"The expression levels of four genes identified by microarray screening (PLCB2, HVCN1, CTSS, and DEF8) and one purine/thiopurine related gene (NME6) correlated significantly with the clinical activity of Crohn's disease.\n"
p3787
sg4
(lp3788
(dp3789
g7
I86
sg8
VP25774
p3790
sg10
I4
sg11
VCTSS
p3791
sg13
I1
sa(dp3792
g7
I110
sg8
g9
sg10
I30
sg11
Vpurine/thiopurine related gene
p3793
sg13
I3
sa(dp3794
g7
I79
sg8
g9
sg10
I5
sg11
VHVCN1
p3795
sg13
I1
sa(dp3796
g7
I96
sg8
g9
sg10
I4
sg11
VDEF8
p3797
sg13
I1
sa(dp3798
g7
I142
sg8
g9
sg10
I4
sg11
VNME6
p3799
sg13
I1
sa(dp3800
g7
I72
sg8
g9
sg10
I5
sg11
VPLCB2
p3801
sg13
I1
sasg14
(lp3802
(dp3803
g7
I203
sg17
VC0010346
p3804
sg10
I15
sg11
VCrohn's disease
p3805
sg13
I2
sasa(dp3806
g2
S'ZNF366, involved in estrogen metabolism and progression of breast cancer, is a new biologically plausible candidate for endometriosis.\n'
p3807
sg4
(lp3808
(dp3809
g7
I0
sg8
g9
sg10
I6
sg11
VZNF366
p3810
sg13
I1
sasg14
(lp3811
(dp3812
g7
I59
sg17
VC0678222
p3813
sg10
I13
sg11
Vbreast cancer
p3814
sg13
I2
sa(dp3815
g7
I120
sg17
VC0014175
p3816
sg10
I13
sg11
Vendometriosis
p3817
sg13
I1
sasa(dp3818
g2
S'Recently, we have identified DC-SCRIPT (ZNF366) as a co-suppressor of ERAlfa and as a strong and independent prognostic marker in ESR1 (ERAlfa gene)-positive breast cancer patients.\n'
p3819
sg4
(lp3820
(dp3821
g7
I29
sg8
g9
sg10
I9
sg11
VDC-SCRIPT
p3822
sg13
I1
sa(dp3823
g7
I40
sg8
g9
sg10
I6
sg11
VZNF366
p3824
sg13
I1
sa(dp3825
g7
I130
sg8
VP03372
p3826
sg10
I4
sg11
VESR1
p3827
sg13
I1
sasg14
(lp3828
(dp3829
g7
I158
sg17
VC0678222
p3830
sg10
I13
sg11
Vbreast cancer
p3831
sg13
I2
sasa(dp3832
g2
S'In this study, we further investigated the molecular mechanism on how DC-SCRIPT inhibits breast cancer cell growth.\n'
p3833
sg4
(lp3834
sg14
(lp3835
(dp3836
g7
I96
sg17
VC1516170
p3837
sg10
I18
sg11
Vcancer cell growth
p3838
sg13
I3
sasa(dp3839
g2
S'DC-SCRIPT mRNA levels from 190 primary ESR1-positive breast tumors were related to global gene expression, followed by gene ontology and pathway analysis.\n'
p3840
sg4
(lp3841
(dp3842
g7
I0
sg8
g9
sg10
I14
sg11
VDC-SCRIPT mRNA
p3843
sg13
I2
sasg14
(lp3844
(dp3845
g7
I53
sg17
VC1458155
p3846
sg10
I13
sg11
Vbreast tumors
p3847
sg13
I2
sasa(dp3848
g2
S'The effect of DC-SCRIPT on breast cancer cell growth and cell cycle arrest was investigated using novel DC-SCRIPT-inducible MCF7 breast cancer cell lines.\n'
p3849
sg4
(lp3850
sg14
(lp3851
(dp3852
g7
I27
sg17
VC0678222
p3853
sg10
I13
sg11
Vbreast cancer
p3854
sg13
I2
sa(dp3855
g7
I34
sg17
VC1516170
p3856
sg10
I18
sg11
Vcancer cell growth
p3857
sg13
I3
sasa(dp3858
g2
S'In the primary ESR1-positive breast tumors, DC-SCRIPT expression negatively correlated with several cell cycle gene ontologies and pathways.\n'
p3859
sg4
(lp3860
(dp3861
g7
I15
sg8
VP03372
p3862
sg10
I4
sg11
VESR1
p3863
sg13
I1
sasg14
(lp3864
(dp3865
g7
I29
sg17
VC1458155
p3866
sg10
I13
sg11
Vbreast tumors
p3867
sg13
I2
sasa(dp3868
g2
S'DC-SCRIPT expression strongly reduced breast cancer cell growth in vitro, breast tumor growth in vivo, and induced cell cycle arrest.\n'
p3869
sg4
(lp3870
(dp3871
g7
I0
sg8
g9
sg10
I9
sg11
VDC-SCRIPT
p3872
sg13
I1
sasg14
(lp3873
(dp3874
g7
I45
sg17
VC1516170
p3875
sg10
I18
sg11
Vcancer cell growth
p3876
sg13
I3
sa(dp3877
g7
I81
sg17
VC0598934
p3878
sg10
I12
sg11
Vtumor growth
p3879
sg13
I2
sasa(dp3880
g2
S'Moreover, in 1,132 primary ESR1-positive breast tumors, DC-SCRIPT expression also correlated with CDKN2B expression.\n'
p3881
sg4
(lp3882
(dp3883
g7
I98
sg8
VP42772
p3884
sg10
I6
sg11
VCDKN2B
p3885
sg13
I1
sa(dp3886
g7
I27
sg8
VP03372
p3887
sg10
I4
sg11
VESR1
p3888
sg13
I1
sasg14
(lp3889
(dp3890
g7
I41
sg17
VC1458155
p3891
sg10
I13
sg11
Vbreast tumors
p3892
sg13
I2
sasa(dp3893
g2
S'Collectively, these data show that DC-SCRIPT acts as a novel regulator of CDKN2B and induces cell cycle arrest in ESR1-positive breast cancer cells.\n'
p3894
sg4
(lp3895
(dp3896
g7
I74
sg8
VP42772
p3897
sg10
I6
sg11
VCDKN2B
p3898
sg13
I1
sa(dp3899
g7
I114
sg8
VP03372
p3900
sg10
I4
sg11
VESR1
p3901
sg13
I1
sasg14
(lp3902
(dp3903
g7
I128
sg17
VC0678222
p3904
sg10
I13
sg11
Vbreast cancer
p3905
sg13
I2
sasa(dp3906
g2
S'We recently found that DC-SCRIPT is a prognostic marker in breast cancer and a unique NR coregulator differentially regulating different classes of NRs.\n'
p3907
sg4
(lp3908
sg14
(lp3909
(dp3910
g7
I59
sg17
VC0678222
p3911
sg10
I13
sg11
Vbreast cancer
p3912
sg13
I2
sasa(dp3913
g2
S'In this study we aimed to validate the prognostic value of DC-SCRIPT mRNA expression in a large independent breast cancer cohort.\n'
p3914
sg4
(lp3915
(dp3916
g7
I59
sg8
g9
sg10
I14
sg11
VDC-SCRIPT mRNA
p3917
sg13
I2
sasg14
(lp3918
(dp3919
g7
I108
sg17
VC0678222
p3920
sg10
I13
sg11
Vbreast cancer
p3921
sg13
I2
sasa(dp3922
g2
S'DC-SCRIPT mRNA levels were measured by real-time PCR in 1,505 primary invasive breast cancers and associated with outcome (disease-free survival (DFS), metastasis-free survival (MFS) and overall survival (OS)) using univariate and multivariable Cox regression analysis.\n'
p3923
sg4
(lp3924
(dp3925
g7
I0
sg8
g9
sg10
I14
sg11
VDC-SCRIPT mRNA
p3926
sg13
I2
sasg14
(lp3927
(dp3928
g7
I152
sg17
VC0027627
p3929
sg10
I10
sg11
Vmetastasis
p3930
sg13
I1
sa(dp3931
g7
I79
sg17
VC0006142
p3932
sg10
I14
sg11
Vbreast cancers
p3933
sg13
I2
sa(dp3934
g7
I178
sg17
VC0024796
p3935
sg10
I3
sg11
VMFS
p3936
sg13
I1
sasa(dp3937
g2
S'This study provides a higher level of evidence that DC-SCRIPT is indeed an independent, pure prognostic, factor for primary breast cancer and shows that DC-SCRIPT mRNA expression is most informative for either ESR1-positive and/or ESR2-low pT1 tumors.\n'
p3938
sg4
(lp3939
(dp3940
g7
I153
sg8
g9
sg10
I14
sg11
VDC-SCRIPT mRNA
p3941
sg13
I2
sa(dp3942
g7
I52
sg8
g9
sg10
I9
sg11
VDC-SCRIPT
p3943
sg13
I1
sasg14
(lp3944
(dp3945
g7
I244
sg17
VC0027651
p3946
sg10
I6
sg11
Vtumors
p3947
sg13
I1
sa(dp3948
g7
I124
sg17
VC0678222
p3949
sg10
I13
sg11
Vbreast cancer
p3950
sg13
I2
sasa(dp3951
g2
S'We investigated the role of dendritic cell-specific transcript (DC-SCRIPT) as coregulator of these nuclear receptors and as a prognostic factor in breast cancer.\n'
p3952
sg4
(lp3953
sg14
(lp3954
(dp3955
g7
I147
sg17
VC0678222
p3956
sg10
I13
sg11
Vbreast cancer
p3957
sg13
I2
sasa(dp3958
g2
S'DC-SCRIPT expression in normal and tumor tissue from breast cancer patients was analyzed by polymerase chain reaction and immunohistochemistry.\n'
p3959
sg4
(lp3960
sg14
(lp3961
(dp3962
g7
I35
sg17
VC0027651
p3963
sg10
I5
sg11
Vtumor
p3964
sg13
I1
sa(dp3965
g7
I53
sg17
VC0678222
p3966
sg10
I13
sg11
Vbreast cancer
p3967
sg13
I2
sasa(dp3968
g2
S'The prognostic value of tumor DC-SCRIPT mRNA expression was assessed in three independent cohorts of breast cancer patients: a discovery group (n = 47) and a validation group (n = 97) (neither of which had received systemic adjuvant therapy) and in a tamoxifen-treated validation group (n = 68) by using a DC-SCRIPT to porphobilinogen deaminase transcript ratio cutoff of 0.15 determined in the discovery group.\n'
p3969
sg4
(lp3970
(dp3971
g7
I319
sg8
VP08397
p3972
sg10
I36
sg11
Vporphobilinogen deaminase transcript
p3973
sg13
I3
sa(dp3974
g7
I30
sg8
g9
sg10
I9
sg11
VDC-SCRIPT
p3975
sg13
I1
sasg14
(lp3976
(dp3977
g7
I101
sg17
VC0678222
p3978
sg10
I13
sg11
Vbreast cancer
p3979
sg13
I2
sa(dp3980
g7
I24
sg17
VC0027651
p3981
sg10
I5
sg11
Vtumor
p3982
sg13
I1
sasa(dp3983
g2
S'DC-SCRIPT is a key regulator of nuclear receptor activity that has prognostic value in breast cancer.\n'
p3984
sg4
(lp3985
sg14
(lp3986
(dp3987
g7
I87
sg17
VC0678222
p3988
sg10
I13
sg11
Vbreast cancer
p3989
sg13
I2
sasa(dp3990
g2
S'Both SNP and gene-based analyses showed promising associations with breast cancer risk for 17 genes: OR10J3, FCER1A, NCF4, CNTNAP1, CTNNB1, KLKB1, ITGB2, ALOX12B, KLK2, IRAK3, KLK4, STAT6, NCF2, CCL1, C1QR1, MBP and NOS1.\n'
p3991
sg4
(lp3992
(dp3993
g7
I140
sg8
VP03952
p3994
sg10
I5
sg11
VKLKB1
p3995
sg13
I1
sa(dp3996
g7
I176
sg8
g9
sg10
I4
sg11
VKLK4
p3997
sg13
I1
sa(dp3998
g7
I189
sg8
VP19878
p3999
sg10
I4
sg11
VNCF2
p4000
sg13
I1
sa(dp4001
g7
I195
sg8
VP22362
p4002
sg10
I4
sg11
VCCL1
p4003
sg13
I1
sa(dp4004
g7
I201
sg8
g9
sg10
I5
sg11
VC1QR1
p4005
sg13
I1
sa(dp4006
g7
I182
sg8
VP42226
p4007
sg10
I5
sg11
VSTAT6
p4008
sg13
I1
sa(dp4009
g7
I169
sg8
g9
sg10
I5
sg11
VIRAK3
p4010
sg13
I1
sa(dp4011
g7
I123
sg8
VP78357
p4012
sg10
I7
sg11
VCNTNAP1
p4013
sg13
I1
sa(dp4014
g7
I132
sg8
VP35222
p4015
sg10
I6
sg11
VCTNNB1
p4016
sg13
I1
sa(dp4017
g7
I147
sg8
VP05107
p4018
sg10
I5
sg11
VITGB2
p4019
sg13
I1
sa(dp4020
g7
I109
sg8
VP12319
p4021
sg10
I6
sg11
VFCER1A
p4022
sg13
I1
sa(dp4023
g7
I117
sg8
g9
sg10
I4
sg11
VNCF4
p4024
sg13
I1
sa(dp4025
g7
I208
sg8
VP13727
p4026
sg10
I3
sg11
VMBP
p4027
sg13
I1
sa(dp4028
g7
I101
sg8
g9
sg10
I6
sg11
VOR10J3
p4029
sg13
I1
sa(dp4030
g7
I216
sg8
VP29475
p4031
sg10
I4
sg11
VNOS1
p4032
sg13
I1
sa(dp4033
g7
I154
sg8
g9
sg10
I7
sg11
VALOX12B
p4034
sg13
I1
sa(dp4035
g7
I163
sg8
VP20151
p4036
sg10
I4
sg11
VKLK2
p4037
sg13
I1
sasg14
(lp4038
(dp4039
g7
I68
sg17
VC0678222
p4040
sg10
I13
sg11
Vbreast cancer
p4041
sg13
I2
sasa(dp4042
g2
S'When the data were divided by menopausal status, the optimal models to predict breast cancer, which included NAF hK2 or PSA and age, were 100% sensitive and 41% specific in pre- vs. 93% sensitive and 12% specific in postmenopausal women.\n'
p4043
sg4
(lp4044
(dp4045
g7
I120
sg8
VP55786
p4046
sg10
I3
sg11
VPSA
p4047
sg13
I1
sa(dp4048
g7
I109
sg8
VP20151
p4049
sg10
I7
sg11
VNAF hK2
p4050
sg13
I2
sasg14
(lp4051
(dp4052
g7
I120
sg17
VC1519176
p4053
sg10
I3
sg11
VPSA
p4054
sg13
I1
sa(dp4055
g7
I79
sg17
VC0678222
p4056
sg10
I13
sg11
Vbreast cancer
p4057
sg13
I2
sasa(dp4058
g2
S'Several lines of evidence suggest that members of the kallikrein family are involved in various malignancies such as prostate (PSA, KLK2, KLK15), ovarian (KLK4, KLK5, KLK6, KLK8, KLK10), and breast cancer (KLK10, KLK13, KLK14).\n'
p4059
sg4
(lp4060
(dp4061
g7
I173
sg8
g9
sg10
I4
sg11
VKLK8
p4062
sg13
I1
sa(dp4063
g7
I155
sg8
g9
sg10
I4
sg11
VKLK4
p4064
sg13
I1
sa(dp4065
g7
I179
sg8
g9
sg10
I5
sg11
VKLK10
p4066
sg13
I1
sa(dp4067
g7
I213
sg8
g9
sg10
I5
sg11
VKLK13
p4068
sg13
I1
sa(dp4069
g7
I132
sg8
VP20151
p4070
sg10
I4
sg11
VKLK2
p4071
sg13
I1
sa(dp4072
g7
I54
sg8
VP06870
p4073
sg10
I17
sg11
Vkallikrein family
p4074
sg13
I2
sa(dp4075
g7
I167
sg8
VP06870
p4076
sg10
I4
sg11
VKLK6
p4077
sg13
I1
sa(dp4078
g7
I138
sg8
g9
sg10
I5
sg11
VKLK15
p4079
sg13
I1
sa(dp4080
g7
I220
sg8
g9
sg10
I5
sg11
VKLK14
p4081
sg13
I1
sa(dp4082
g7
I179
sg8
g9
sg10
I5
sg11
VKLK10
p4083
sg13
I1
sa(dp4084
g7
I161
sg8
g9
sg10
I4
sg11
VKLK5
p4085
sg13
I1
sa(dp4086
g7
I117
sg8
VP55786
p4087
sg10
I8
sg11
Vprostate
p4088
sg13
I1
sa(dp4089
g7
I127
sg8
VP55786
p4090
sg10
I3
sg11
VPSA
p4091
sg13
I1
sasg14
(lp4092
(dp4093
g7
I127
sg17
VC1519176
p4094
sg10
I3
sg11
VPSA
p4095
sg13
I1
sa(dp4096
g7
I191
sg17
VC0678222
p4097
sg10
I13
sg11
Vbreast cancer
p4098
sg13
I2
sa(dp4099
g7
I96
sg17
VC0006826
p4100
sg10
I12
sg11
Vmalignancies
p4101
sg13
I1
sa(dp4102
g7
I117
sg17
VC1519176
p4103
sg10
I8
sg11
Vprostate
p4104
sg13
I1
sasa(dp4105
g2
S'We examined previously the steroid hormone regulation of 2 known androgen-regulated kallikreins, KLK3 (encoding PSA) and KLK2 (encoding human kallikrein 2 or hK2) in BT-474, T-47D, ZR75-1, MCF-7, MFM-223 and BT-20 human breast cancer cells and found that they were differentially regulated, with the cells showing variable responses to androgen.\n'
p4106
sg4
(lp4107
(dp4108
g7
I121
sg8
VP20151
p4109
sg10
I4
sg11
VKLK2
p4110
sg13
I1
sa(dp4111
g7
I142
sg8
VP20151
p4112
sg10
I19
sg11
Vkallikrein 2 or hK2
p4113
sg13
I4
sa(dp4114
g7
I65
sg8
VP10398
p4115
sg10
I30
sg11
Vandrogen-regulated kallikreins
p4116
sg13
I2
sa(dp4117
g7
I136
sg8
VP20151
p4118
sg10
I18
sg11
Vhuman kallikrein 2
p4119
sg13
I3
sasg14
(lp4120
(dp4121
g7
I220
sg17
VC0678222
p4122
sg10
I13
sg11
Vbreast cancer
p4123
sg13
I2
sa(dp4124
g7
I112
sg17
VC1519176
p4125
sg10
I3
sg11
VPSA
p4126
sg13
I1
sasa(dp4127
g2
S'Every breast cancer cell line exhibited a distinct expression pattern of the nuclear receptor co-regulators examined raising the possibility that the relative levels of these co-activators/-repressors might differentially modulate androgen receptor transcriptional activity within the promoter/enhancer region of KLK2 and KLK3 of these cells.\n'
p4128
sg4
(lp4129
(dp4130
g7
I231
sg8
VP10275
p4131
sg10
I17
sg11
Vandrogen receptor
p4132
sg13
I2
sa(dp4133
g7
I322
sg8
VP03952
p4134
sg10
I4
sg11
VKLK3
p4135
sg13
I1
sa(dp4136
g7
I313
sg8
VP20151
p4137
sg10
I4
sg11
VKLK2
p4138
sg13
I1
sasg14
(lp4139
(dp4140
g7
I6
sg17
VC0678222
p4141
sg10
I13
sg11
Vbreast cancer
p4142
sg13
I2
sasa(dp4143
g2
S'Like KLK2 and KLK3, the KLK5 gene is regulated by steroid hormones in the BT-474 breast cancer cell line.\n'
p4144
sg4
(lp4145
(dp4146
g7
I5
sg8
VP20151
p4147
sg10
I4
sg11
VKLK2
p4148
sg13
I1
sa(dp4149
g7
I14
sg8
VP03952
p4150
sg10
I4
sg11
VKLK3
p4151
sg13
I1
sa(dp4152
g7
I24
sg8
g9
sg10
I9
sg11
VKLK5 gene
p4153
sg13
I2
sasg14
(lp4154
(dp4155
g7
I81
sg17
VC0678222
p4156
sg10
I13
sg11
Vbreast cancer
p4157
sg13
I2
sasa(dp4158
g2
S'KLK2 and KLK3 have important applications in prostate cancer diagnostics and, more recently, in breast cancer diagnostics.\n'
p4159
sg4
(lp4160
(dp4161
g7
I9
sg8
VP03952
p4162
sg10
I4
sg11
VKLK3
p4163
sg13
I1
sa(dp4164
g7
I0
sg8
VP20151
p4165
sg10
I4
sg11
VKLK2
p4166
sg13
I1
sasg14
(lp4167
(dp4168
g7
I96
sg17
VC0678222
p4169
sg10
I13
sg11
Vbreast cancer
p4170
sg13
I2
sa(dp4171
g7
I45
sg17
VC0600139
p4172
sg10
I15
sg11
Vprostate cancer
p4173
sg13
I2
sasa(dp4174
g2
S"Oligonucleotide 5'-SH-(A)(12)-AGACAAGAGAGG-3' (Oligo 1) modified AuNPs and oligonucleotide 5'-CAACAGAGAACG-(A)(12)-HS-3' (Oligo 2) modified AuNPs could hybridize with oligonulceotide 5'-CGTTCTCTGTTGCCTCTCTTGTCT-3' (Oligo 3), which resulted in the aggregation of Oligo-AuNPs probes, and triggered the increase of their average diameter.\n"
p4175
sg4
(lp4176
sg14
(lp4177
sa(dp4178
g2
S'To observe the effect of Bushen Huoxue Recipe (BHR) on inhibiting vascular calcification (VC) in chronic renal failure (CRF) rats by regulating BMP-2/Runx2/Osterix signal pathway, and to explore its possible mechanism.\n'
p4179
sg4
(lp4180
(dp4181
g7
I144
sg8
VP12643
p4182
sg10
I5
sg11
VBMP-2
p4183
sg13
I1
sa(dp4184
g7
I150
sg8
g9
sg10
I5
sg11
VRunx2
p4185
sg13
I1
sa(dp4186
g7
I156
sg8
g9
sg10
I7
sg11
VOsterix
p4187
sg13
I1
sasg14
(lp4188
(dp4189
g7
I90
sg17
VC0342649
p4190
sg10
I2
sg11
VVC
p4191
sg13
I1
sa(dp4192
g7
I66
sg17
VC0342649
p4193
sg10
I22
sg11
Vvascular calcification
p4194
sg13
I2
sa(dp4195
g7
I97
sg17
VC0022661
p4196
sg10
I21
sg11
Vchronic renal failure
p4197
sg13
I3
sa(dp4198
g7
I120
sg17
VC0022661
p4199
sg10
I3
sg11
VCRF
p4200
sg13
I1
sasa(dp4201
g2
S'Here, we report that inhibition of Src significantly reduced survival of H37Rv as well as multidrug-resistant (MDR) and extremely drug-resistant (XDR) strains of M. tuberculosis in THP-1 macrophages.\n'
p4202
sg4
(lp4203
(dp4204
g7
I35
sg8
VP12931
p4205
sg10
I3
sg11
VSrc
p4206
sg13
I1
sasg14
(lp4207
(dp4208
g7
I165
sg17
VC0041296
p4209
sg10
I12
sg11
Vtuberculosis
p4210
sg13
I1
sasa(dp4211
g2
S'Src inhibition was also effective in controlling M. tuberculosis infection in guinea pigs.\n'
p4212
sg4
(lp4213
(dp4214
g7
I0
sg8
VP12931
p4215
sg10
I3
sg11
VSrc
p4216
sg13
I1
sasg14
(lp4217
(dp4218
g7
I52
sg17
VC0041296
p4219
sg10
I22
sg11
Vtuberculosis infection
p4220
sg13
I2
sasa(dp4221
g2
S'In guinea pigs, reduced M. tuberculosis burden due to Src inhibition also led to a marked decline in the disease pathology.\n'
p4222
sg4
(lp4223
(dp4224
g7
I54
sg8
VP12931
p4225
sg10
I3
sg11
VSrc
p4226
sg13
I1
sasg14
(lp4227
(dp4228
g7
I27
sg17
VC0041296
p4229
sg10
I12
sg11
Vtuberculosis
p4230
sg13
I1
sa(dp4231
g7
I113
sg17
VC0677042
p4232
sg10
I9
sg11
Vpathology
p4233
sg13
I1
sasa(dp4234
g2
S'We propose that Src inhibitors could be developed into effective host-directed anti-TB drugs, which could be indiscriminately used against both drug-sensitive and drug-resistant strains of M. tuberculosis.\n'
p4235
sg4
(lp4236
(dp4237
g7
I16
sg8
VP12931
p4238
sg10
I3
sg11
VSrc
p4239
sg13
I1
sasg14
(lp4240
(dp4241
g7
I192
sg17
VC0041296
p4242
sg10
I12
sg11
Vtuberculosis
p4243
sg13
I1
sasa(dp4244
g2
S'We explored tyrosine kinase Src as a host factor exploited by virulent M. tuberculosis for intracellular survival.\n'
p4245
sg4
(lp4246
(dp4247
g7
I12
sg8
VP29401
p4248
sg10
I19
sg11
Vtyrosine kinase Src
p4249
sg13
I3
sasg14
(lp4250
(dp4251
g7
I74
sg17
VC0041296
p4252
sg10
I12
sg11
Vtuberculosis
p4253
sg13
I1
sasa(dp4254
g2
S'We show that Src inhibition can effectively control tuberculosis in infected guinea pigs.\n'
p4255
sg4
(lp4256
(dp4257
g7
I13
sg8
VP12931
p4258
sg10
I3
sg11
VSrc
p4259
sg13
I1
sasg14
(lp4260
(dp4261
g7
I52
sg17
VC0041296
p4262
sg10
I12
sg11
Vtuberculosis
p4263
sg13
I1
sasa(dp4264
g2
S'In the current study we aimed to find out the impact of cytokine-inducible Src homology 2 domain protein (CISH) gene polymorphisms on the risk of pulmonary tuberculosis (PTB) in a sample of Iranian population.\n'
p4265
sg4
(lp4266
(dp4267
g7
I56
sg8
g9
sg10
I48
sg11
Vcytokine-inducible Src homology 2 domain protein
p4268
sg13
I6
sa(dp4269
g7
I106
sg8
g9
sg10
I4
sg11
VCISH
p4270
sg13
I1
sasg14
(lp4271
(dp4272
g7
I170
sg17
VC0041327
p4273
sg10
I3
sg11
VPTB
p4274
sg13
I1
sa(dp4275
g7
I146
sg17
VC0041327
p4276
sg10
I22
sg11
Vpulmonary tuberculosis
p4277
sg13
I2
sasa(dp4278
g2
S'A recent multi-center case-control study identified several single nucleotide polymorphisms (SNPs) within the cytokine-inducible SRC homology 2 domain (CISH) gene that are associated with susceptibility to tuberculosis (TB) in both African and Asian populations.\n'
p4279
sg4
(lp4280
(dp4281
g7
I152
sg8
g9
sg10
I4
sg11
VCISH
p4282
sg13
I1
sa(dp4283
g7
I110
sg8
g9
sg10
I40
sg11
Vcytokine-inducible SRC homology 2 domain
p4284
sg13
I5
sasg14
(lp4285
(dp4286
g7
I220
sg17
VC0041296
p4287
sg10
I2
sg11
VTB
p4288
sg13
I1
sa(dp4289
g7
I206
sg17
VC0041296
p4290
sg10
I12
sg11
Vtuberculosis
p4291
sg13
I1
sasa(dp4292
g2
S'Among them, the human Cytokine-inducible Src homology 2(SH2) domain protein (CISH) gene has been very recently reported to be involved in T cell activation and differentiation in response to Mycobacterium tuberculosis infection.\n'
p4293
sg4
(lp4294
(dp4295
g7
I41
sg8
VP12931
p4296
sg10
I14
sg11
VSrc homology 2
p4297
sg13
I3
sasg14
(lp4298
(dp4299
g7
I205
sg17
VC0041296
p4300
sg10
I22
sg11
Vtuberculosis infection
p4301
sg13
I2
sasa(dp4302
g2
S'For the first time, we report different genetic anomalies between adult and paediatric BLs, suggesting age-related heterogeneity in Burkitt lymphomagenesis.\n'
p4303
sg4
(lp4304
sg14
(lp4305
(dp4306
g7
I87
sg17
VC0005859
p4307
sg10
I3
sg11
VBLs
p4308
sg13
I1
sa(dp4309
g7
I140
sg17
VC0598766
p4310
sg10
I15
sg11
Vlymphomagenesis
p4311
sg13
I1
sasa(dp4312
g2
S'Although there are conflicting data regarding prognostic implications of isolated MYC aberrancy in these non-BLs, the co-occurrence of MYC rearrangements and either the antiapoptotic gene B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL2) or the transcriptional repressor BCL6 leads to an entity termed double-hit B-cell lymphoma (DHL) (or triple-hit if all 3 abnormalities are observed) with a particularly poor prognosis and no established treatment paradigms.\n'
p4313
sg4
(lp4314
(dp4315
g7
I275
sg8
VP41182
p4316
sg10
I4
sg11
VBCL6
p4317
sg13
I1
sa(dp4318
g7
I236
sg8
VP10415
p4319
sg10
I4
sg11
VBCL2
p4320
sg13
I1
sa(dp4321
g7
I82
sg8
VP12524
p4322
sg10
I3
sg11
VMYC
p4323
sg13
I1
sa(dp4324
g7
I188
sg8
VP10415
p4325
sg10
I46
sg11
VB-cell chronic lymphocytic leukemia/lymphoma 2
p4326
sg13
I5
sasg14
(lp4327
(dp4328
g7
I317
sg17
VC0079731
p4329
sg10
I15
sg11
VB-cell lymphoma
p4330
sg13
I2
sa(dp4331
g7
I188
sg17
VC1868683
p4332
sg10
I35
sg11
VB-cell chronic lymphocytic leukemia
p4333
sg13
I4
sa(dp4334
g7
I109
sg17
VC0005859
p4335
sg10
I3
sg11
VBLs
p4336
sg13
I1
sa(dp4337
g7
I224
sg17
VC0024299
p4338
sg10
I8
sg11
Vlymphoma
p4339
sg13
I1
sasa(dp4340
g2
S'The clinicopathologic findings in Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) may show significant overlap, and MYC abnormalities, found in all BLs, also occur in a subset of DLBCL.\n'
p4341
sg4
(lp4342
(dp4343
g7
I132
sg8
VP12524
p4344
sg10
I3
sg11
VMYC
p4345
sg13
I1
sasg14
(lp4346
(dp4347
g7
I34
sg17
VC0006413
p4348
sg10
I16
sg11
VBurkitt lymphoma
p4349
sg13
I2
sa(dp4350
g7
I91
sg17
VC0079744
p4351
sg10
I5
sg11
VDLBCL
p4352
sg13
I1
sa(dp4353
g7
I91
sg17
VC0079744
p4354
sg10
I5
sg11
VDLBCL
p4355
sg13
I1
sa(dp4356
g7
I60
sg17
VC0079744
p4357
sg10
I29
sg11
Vdiffuse large B-cell lymphoma
p4358
sg13
I4
sa(dp4359
g7
I52
sg17
VC0006413
p4360
sg10
I2
sg11
VBL
p4361
sg13
I1
sa(dp4362
g7
I164
sg17
VC0005859
p4363
sg10
I3
sg11
VBLs
p4364
sg13
I1
sasa(dp4365
g2
S'Double negative cases were absent in the group of BLs but could be found in approximately one third of the remaining cases of mature aggressive B-cell lymphomas.\n'
p4366
sg4
(lp4367
sg14
(lp4368
(dp4369
g7
I133
sg17
VC0001807
p4370
sg10
I10
sg11
Vaggressive
p4371
sg13
I1
sa(dp4372
g7
I50
sg17
VC0005859
p4373
sg10
I3
sg11
VBLs
p4374
sg13
I1
sa(dp4375
g7
I144
sg17
VC0079731
p4376
sg10
I16
sg11
VB-cell lymphomas
p4377
sg13
I2
sasa(dp4378
g2
S'In particular, we determined the expression and production of several angiogenic factors including tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), Leptin, connective tissue growth factor (CTGF), meningioma-associated complimentary DNA (Mac25), basic fibroblast growth factor (bFGF), and Midkine.\n'
p4379
sg4
(lp4380
(dp4381
g7
I70
sg8
VP19883
p4382
sg10
I76
sg11
Vangiogenic factors including tissue inhibitor of matrix metalloproteinases-1
p4383
sg13
I8
sa(dp4384
g7
I254
sg8
VP53370
p4385
sg10
I30
sg11
Vbasic fibroblast growth factor
p4386
sg13
I4
sa(dp4387
g7
I148
sg8
VP01033
p4388
sg10
I6
sg11
VTIMP-1
p4389
sg13
I1
sa(dp4390
g7
I286
sg8
VP53370
p4391
sg10
I4
sg11
VbFGF
p4392
sg13
I1
sa(dp4393
g7
I198
sg8
VP29279
p4394
sg10
I4
sg11
VCTGF
p4395
sg13
I1
sa(dp4396
g7
I165
sg8
VP29279
p4397
sg10
I31
sg11
Vconnective tissue growth factor
p4398
sg13
I4
sa(dp4399
g7
I157
sg8
VP41159
p4400
sg10
I6
sg11
VLeptin
p4401
sg13
I1
sasg14
(lp4402
(dp4403
g7
I205
sg17
VC0025286
p4404
sg10
I10
sg11
Vmeningioma
p4405
sg13
I1
sasa(dp4406
g2
S'Altered expression levels of several genes identified in this study have been previously noted in meningiomas (eg, growth hormone receptor, IGFBP-7, endothelin receptor A, IGF2).\n'
p4407
sg4
(lp4408
(dp4409
g7
I149
sg8
g9
sg10
I21
sg11
Vendothelin receptor A
p4410
sg13
I3
sa(dp4411
g7
I172
sg8
VP01344
p4412
sg10
I4
sg11
VIGF2
p4413
sg13
I1
sa(dp4414
g7
I115
sg8
VP10912
p4415
sg10
I23
sg11
Vgrowth hormone receptor
p4416
sg13
I3
sasg14
(lp4417
(dp4418
g7
I98
sg17
VC0025286
p4419
sg10
I11
sg11
Vmeningiomas
p4420
sg13
I1
sasa(dp4421
g2
S'mac25, a retinoic acid-inducible gene that is expressed at high levels in senescent epithelial cells, was initially cloned as a gene that is differentially expressed in meningioma.\n'
p4422
sg4
(lp4423
(dp4424
g7
I0
sg8
g9
sg10
I5
sg11
Vmac25
p4425
sg13
I1
sasg14
(lp4426
(dp4427
g7
I169
sg17
VC0025286
p4428
sg10
I10
sg11
Vmeningioma
p4429
sg13
I1
sasa(dp4430
g2
S'mac25 had previously been cloned as a discrete gene, preferentially expressed in normal, leptomeningial cells compared with meningioma tumors.\n'
p4431
sg4
(lp4432
(dp4433
g7
I0
sg8
g9
sg10
I5
sg11
Vmac25
p4434
sg13
I1
sasg14
(lp4435
(dp4436
g7
I135
sg17
VC0027651
p4437
sg10
I6
sg11
Vtumors
p4438
sg13
I1
sa(dp4439
g7
I124
sg17
VC0025286
p4440
sg10
I10
sg11
Vmeningioma
p4441
sg13
I1
sasa(dp4442
g2
S'Outcome assessments included the Sheehan Panic Disorder Scale (SPS), Panic Disorder Severity Scale (PDSS), Bandelow Panic and Agoraphobia Scale (PAS), Hamilton Rating Scale for Anxiety (HAM-A), 21-point Clinician Global Improvement Scale (CGI-21), 21-point Patient Global Improvement (PGI-21) and the Sheehan Disability Scale (SDS).\n'
p4443
sg4
(lp4444
sg14
(lp4445
(dp4446
g7
I327
sg17
VC0272170
p4447
sg10
I3
sg11
VSDS
p4448
sg13
I1
sa(dp4449
g7
I186
sg17
VC0030481
p4450
sg10
I3
sg11
VHAM
p4451
sg13
I1
sa(dp4452
g7
I33
sg17
VC0085292
p4453
sg10
I28
sg11
VSheehan Panic Disorder Scale
p4454
sg13
I4
sa(dp4455
g7
I126
sg17
VC0001818
p4456
sg10
I11
sg11
VAgoraphobia
p4457
sg13
I1
sa(dp4458
g7
I63
sg17
VC0085292
p4459
sg10
I3
sg11
VSPS
p4460
sg13
I1
sa(dp4461
g7
I301
sg17
VC0272170
p4462
sg10
I24
sg11
VSheehan Disability Scale
p4463
sg13
I3
sa(dp4464
g7
I41
sg17
VC1868649
p4465
sg10
I14
sg11
VPanic Disorder
p4466
sg13
I2
sasa(dp4467
g2
S'Taken together, the results of the present study concluded that human FAT2 may function as a key molecule that governs not only PCP, but also NF2-Hpo signaling in arachnoid cells; thus, a mutation in this gene may result in spinal meningioma.\n'
p4468
sg4
(lp4469
(dp4470
g7
I146
sg8
VP55789
p4471
sg10
I3
sg11
VHpo
p4472
sg13
I1
sa(dp4473
g7
I70
sg8
g9
sg10
I4
sg11
VFAT2
p4474
sg13
I1
sa(dp4475
g7
I128
sg8
VP42785
p4476
sg10
I3
sg11
VPCP
p4477
sg13
I1
sasg14
(lp4478
(dp4479
g7
I142
sg17
VC0027832
p4480
sg10
I3
sg11
VNF2
p4481
sg13
I1
sa(dp4482
g7
I128
sg17
VC2919094
p4483
sg10
I3
sg11
VPCP
p4484
sg13
I1
sa(dp4485
g7
I224
sg17
VC0347515
p4486
sg10
I17
sg11
Vspinal meningioma
p4487
sg13
I2
sasa(dp4488
g2
S'Eight human STS cell lines were used: fibrosarcoma (HT1080), liposarcoma (SW872, T778, MLS-402), synovial sarcoma (SW982, SYO1, 1273), and malignant fibrous histiocytoma (U2197).\n'
p4489
sg4
(lp4490
sg14
(lp4491
(dp4492
g7
I139
sg17
VC0334463
p4493
sg10
I30
sg11
Vmalignant fibrous histiocytoma
p4494
sg13
I3
sa(dp4495
g7
I87
sg17
VC0796070
p4496
sg10
I3
sg11
VMLS
p4497
sg13
I1
sa(dp4498
g7
I12
sg17
VC0079588
p4499
sg10
I3
sg11
VSTS
p4500
sg13
I1
sa(dp4501
g7
I38
sg17
VC0016057
p4502
sg10
I12
sg11
Vfibrosarcoma
p4503
sg13
I1
sa(dp4504
g7
I61
sg17
VC0023827
p4505
sg10
I11
sg11
Vliposarcoma
p4506
sg13
I1
sa(dp4507
g7
I97
sg17
VC0039101
p4508
sg10
I16
sg11
Vsynovial sarcoma
p4509
sg13
I2
sasa(dp4510
g2
S'VAE diminished the CI in most of the synovial sarcoma (SW982, SYO1) and liposarcoma (SW872, T778) cell lines as well as HT1080.\n'
p4511
sg4
(lp4512
sg14
(lp4513
(dp4514
g7
I72
sg17
VC0023827
p4515
sg10
I11
sg11
Vliposarcoma
p4516
sg13
I1
sa(dp4517
g7
I37
sg17
VC0039101
p4518
sg10
I16
sg11
Vsynovial sarcoma
p4519
sg13
I2
sasa(dp4520
g2
S'A total of eight different human STS cell lines were used in the study: Fibrosarcoma (HT1080), liposarcoma (SW872, T778 and MLS-402), synovial sarcoma (SW982, SYO1 and 1273) and pleomorphic sarcoma (U2197).\n'
p4521
sg4
(lp4522
sg14
(lp4523
(dp4524
g7
I33
sg17
VC0079588
p4525
sg10
I3
sg11
VSTS
p4526
sg13
I1
sa(dp4527
g7
I77
sg17
VC1261473
p4528
sg10
I7
sg11
Vsarcoma
p4529
sg13
I1
sa(dp4530
g7
I72
sg17
VC0016057
p4531
sg10
I12
sg11
VFibrosarcoma
p4532
sg13
I1
sa(dp4533
g7
I124
sg17
VC0796070
p4534
sg10
I3
sg11
VMLS
p4535
sg13
I1
sa(dp4536
g7
I95
sg17
VC0023827
p4537
sg10
I11
sg11
Vliposarcoma
p4538
sg13
I1
sa(dp4539
g7
I134
sg17
VC0039101
p4540
sg10
I16
sg11
Vsynovial sarcoma
p4541
sg13
I2
sasa(dp4542
g2
S'In SYO-1 synovial sarcoma xenografts, administration of small molecule Tcf/Beta-catenin complex inhibitors significantly reduced tumor growth, associated with diminished AXIN2 protein levels.\n'
p4543
sg4
(lp4544
(dp4545
g7
I170
sg8
g9
sg10
I13
sg11
VAXIN2 protein
p4546
sg13
I2
sasg14
(lp4547
(dp4548
g7
I9
sg17
VC0039101
p4549
sg10
I16
sg11
Vsynovial sarcoma
p4550
sg13
I2
sa(dp4551
g7
I129
sg17
VC0598934
p4552
sg10
I12
sg11
Vtumor growth
p4553
sg13
I2
sasa(dp4554
g2
S'These plasmids were transfected in synovial sarcoma SYO-1 cells and we observed the expression of these proteins using a fluorescence microscope.\n'
p4555
sg4
(lp4556
sg14
(lp4557
(dp4558
g7
I35
sg17
VC0039101
p4559
sg10
I16
sg11
Vsynovial sarcoma
p4560
sg13
I2
sasa(dp4561
g2
S'Furthermore, cell proliferation and colony formation of synovial sarcoma SYO-1 and YaFuSS cells were suppressed by exogenous tSSX expression.\n'
p4562
sg4
(lp4563
sg14
(lp4564
(dp4565
g7
I18
sg17
VC0334094
p4566
sg10
I13
sg11
Vproliferation
p4567
sg13
I1
sa(dp4568
g7
I56
sg17
VC0039101
p4569
sg10
I16
sg11
Vsynovial sarcoma
p4570
sg13
I2
sasa(dp4571
g2
S'Psoriasis area and severity index (PASI), serum P-selectin and interleukin (IL)-6 were monitored throughout the treatment.\n'
p4572
sg4
(lp4573
(dp4574
g7
I42
sg8
VP16109
p4575
sg10
I16
sg11
Vserum P-selectin
p4576
sg13
I2
sa(dp4577
g7
I63
sg8
VP60568
p4578
sg10
I18
sg11
Vinterleukin (IL)-6
p4579
sg13
I2
sasg14
(lp4580
(dp4581
g7
I0
sg17
VC0033860
p4582
sg10
I9
sg11
VPsoriasis
p4583
sg13
I1
sasa(dp4584
g2
S'We aimed to study the association of the endothelial activation biomarkers monocyte chemoattractant protein 1 (MCP-1), soluble (s) E-selectin and P-selectin with disease activity and severity in psoriasis patients treated with anti-TNF-Alfa therapy.\n'
p4585
sg4
(lp4586
(dp4587
g7
I41
sg8
VP14222
p4588
sg10
I68
sg11
Vendothelial activation biomarkers monocyte chemoattractant protein 1
p4589
sg13
I7
sa(dp4590
g7
I227
sg8
VP01375
p4591
sg10
I13
sg11
Vanti-TNF-Alfa
p4592
sg13
I1
sa(dp4593
g7
I146
sg8
VP16109
p4594
sg10
I10
sg11
VP-selectin
p4595
sg13
I1
sasg14
(lp4596
(dp4597
g7
I195
sg17
VC0033860
p4598
sg10
I9
sg11
Vpsoriasis
p4599
sg13
I1
sasa(dp4600
g2
S'Plasma soluble P-selectin concentrations, PDMP and platelet aggregation were significantly elevated in patients with psoriasis, as compared to controls.\n'
p4601
sg4
(lp4602
(dp4603
g7
I0
sg8
VP16109
p4604
sg10
I25
sg11
VPlasma soluble P-selectin
p4605
sg13
I3
sasg14
(lp4606
(dp4607
g7
I117
sg17
VC0033860
p4608
sg10
I9
sg11
Vpsoriasis
p4609
sg13
I1
sasa(dp4610
g2
S'Most efficient among them is the newly identified SOXN (neuroblastoma-derived sulfhydryl oxidase), which comprises 12 exons and maps to 9q34.3.\n'
p4611
sg4
(lp4612
sg14
(lp4613
(dp4614
g7
I56
sg17
VC0027819
p4615
sg10
I13
sg11
Vneuroblastoma
p4616
sg13
I1
sasa(dp4617
g2
S'These results identify SOXN as a major player in regulating the sensitization of neuroblastoma cells for IFN-gamma-induced apoptosis.\n'
p4618
sg4
(lp4619
(dp4620
g7
I105
sg8
VP01579
p4621
sg10
I9
sg11
VIFN-gamma
p4622
sg13
I1
sa(dp4623
g7
I23
sg8
g9
sg10
I4
sg11
VSOXN
p4624
sg13
I1
sasg14
(lp4625
(dp4626
g7
I81
sg17
VC0027819
p4627
sg10
I13
sg11
Vneuroblastoma
p4628
sg13
I1
sasa(dp4629
g2
S'The cartilage proteins melanoma inhibitory activity (MIA) and human cartilage gp-39 (HC gp-39) are candidate autoantigens in rheumatoid arthritis (RA).\n'
p4630
sg4
(lp4631
sg14
(lp4632
(dp4633
g7
I125
sg17
VC0003873
p4634
sg10
I20
sg11
Vrheumatoid arthritis
p4635
sg13
I2
sa(dp4636
g7
I23
sg17
VC0025202
p4637
sg10
I8
sg11
Vmelanoma
p4638
sg13
I1
sa(dp4639
g7
I147
sg17
VC0003873
p4640
sg10
I2
sg11
VRA
p4641
sg13
I1
sasa(dp4642
g2
S'The presented results confirm expression of CDRAP by normal and osteoarthritic articular chondrocytes, but indicate that increased expression levels by chondrocytes are not the cause of the increased levels of CDRAP in the synovial fluid of patients with osteoarthritis.\n'
p4643
sg4
(lp4644
(dp4645
g7
I44
sg8
g9
sg10
I5
sg11
VCDRAP
p4646
sg13
I1
sa(dp4647
g7
I44
sg8
g9
sg10
I5
sg11
VCDRAP
p4648
sg13
I1
sasg14
(lp4649
(dp4650
g7
I255
sg17
VC0029408
p4651
sg10
I14
sg11
Vosteoarthritis
p4652
sg13
I1
sasa(dp4653
g2
S'We have measured the concentration of cartilage-derived retinoic-acid-sensitive protein (CD-RAP) in synovial fluid (SF) from the knees of 49 patients with osteoarthritis (OA) and 79 with rheumatoid arthritis (RA) in order to investigate the correlation between the type of joint disease and level of CD-RAP.\n'
p4654
sg4
(lp4655
sg14
(lp4656
(dp4657
g7
I92
sg17
VC0003873
p4658
sg10
I2
sg11
VRA
p4659
sg13
I1
sa(dp4660
g7
I171
sg17
VC0029408
p4661
sg10
I2
sg11
VOA
p4662
sg13
I1
sa(dp4663
g7
I155
sg17
VC0029408
p4664
sg10
I14
sg11
Vosteoarthritis
p4665
sg13
I1
sa(dp4666
g7
I187
sg17
VC0003873
p4667
sg10
I20
sg11
Vrheumatoid arthritis
p4668
sg13
I2
sa(dp4669
g7
I273
sg17
VC0022408
p4670
sg10
I13
sg11
Vjoint disease
p4671
sg13
I2
sasa(dp4672
g2
S'In this study, we demonstrated that osteopontin (OPN) was dramatically reduced by loss of TSC1/TSC2 complex in Tsc2-null mouse embryonic fibroblasts (MEFs), rat uterine leiomyoma-derived Tsc2-deficient cells, genetically modified mouse TSC models, and clinical samples.\n'
p4673
sg4
(lp4674
(dp4675
g7
I111
sg8
VP49815
p4676
sg10
I4
sg11
VTsc2
p4677
sg13
I1
sa(dp4678
g7
I49
sg8
VP10451
p4679
sg10
I3
sg11
VOPN
p4680
sg13
I1
sa(dp4681
g7
I90
sg8
g9
sg10
I4
sg11
VTSC1
p4682
sg13
I1
sa(dp4683
g7
I36
sg8
VP10451
p4684
sg10
I11
sg11
Vosteopontin
p4685
sg13
I1
sa(dp4686
g7
I111
sg8
VP49815
p4687
sg10
I4
sg11
VTsc2
p4688
sg13
I1
sa(dp4689
g7
I95
sg8
VP49815
p4690
sg10
I4
sg11
VTSC2
p4691
sg13
I1
sasg14
(lp4692
(dp4693
g7
I111
sg17
VC1860707
p4694
sg10
I4
sg11
VTsc2
p4695
sg13
I1
sa(dp4696
g7
I161
sg17
VC0042133
p4697
sg10
I17
sg11
Vuterine leiomyoma
p4698
sg13
I2
sa(dp4699
g7
I90
sg17
VC1854465
p4700
sg10
I4
sg11
VTSC1
p4701
sg13
I1
sa(dp4702
g7
I90
sg17
VC0041341
p4703
sg10
I3
sg11
VTSC
p4704
sg13
I1
sa(dp4705
g7
I111
sg17
VC1860707
p4706
sg10
I4
sg11
VTsc2
p4707
sg13
I1
sa(dp4708
g7
I95
sg17
VC1860707
p4709
sg10
I4
sg11
VTSC2
p4710
sg13
I1
sasa(dp4711
g2
S'TSC2-deficient Eker rat uterine leiomyoma ELT3 cells were stably transfected with empty vector or plasmid for the expression of TSC2.\n'
p4712
sg4
(lp4713
(dp4714
g7
I0
sg8
VP49815
p4715
sg10
I4
sg11
VTSC2
p4716
sg13
I1
sa(dp4717
g7
I0
sg8
VP49815
p4718
sg10
I4
sg11
VTSC2
p4719
sg13
I1
sasg14
(lp4720
(dp4721
g7
I0
sg17
VC1860707
p4722
sg10
I4
sg11
VTSC2
p4723
sg13
I1
sa(dp4724
g7
I24
sg17
VC0042133
p4725
sg10
I17
sg11
Vuterine leiomyoma
p4726
sg13
I2
sa(dp4727
g7
I0
sg17
VC1860707
p4728
sg10
I4
sg11
VTSC2
p4729
sg13
I1
sasa(dp4730
g2
S'By analyzing Tsc2-null mouse embryonic fibroblasts (MEFs) and rat uterine leiomyoma-derived Tsc2-null ELT3 cells, we detected evidence for the involvement of cyclooxygenase 2 (COX2) as a downstream target of mTORC1 in the development of TSC tumors.\n'
p4731
sg4
(lp4732
(dp4733
g7
I13
sg8
VP49815
p4734
sg10
I4
sg11
VTsc2
p4735
sg13
I1
sa(dp4736
g7
I13
sg8
VP49815
p4737
sg10
I4
sg11
VTsc2
p4738
sg13
I1
sa(dp4739
g7
I176
sg8
VP35354
p4740
sg10
I4
sg11
VCOX2
p4741
sg13
I1
sa(dp4742
g7
I158
sg8
VP35354
p4743
sg10
I16
sg11
Vcyclooxygenase 2
p4744
sg13
I2
sasg14
(lp4745
(dp4746
g7
I66
sg17
VC0042133
p4747
sg10
I17
sg11
Vuterine leiomyoma
p4748
sg13
I2
sa(dp4749
g7
I237
sg17
VC0041341
p4750
sg10
I3
sg11
VTSC
p4751
sg13
I1
sa(dp4752
g7
I13
sg17
VC1860707
p4753
sg10
I4
sg11
VTsc2
p4754
sg13
I1
sa(dp4755
g7
I13
sg17
VC1860707
p4756
sg10
I4
sg11
VTsc2
p4757
sg13
I1
sa(dp4758
g7
I241
sg17
VC0027651
p4759
sg10
I6
sg11
Vtumors
p4760
sg13
I1
sasa(dp4761
g2
S'TSC2-positive and TSC2-negative mouse embryonic fibroblasts (MEF), 323-TSC2-positive and 323-TSC2-null MEF and Eker rat uterine leiomyoma (ELT3) cells were treated with doxycycline or rapamycin alone, or in combination.\n'
p4762
sg4
(lp4763
(dp4764
g7
I0
sg8
VP49815
p4765
sg10
I4
sg11
VTSC2
p4766
sg13
I1
sa(dp4767
g7
I0
sg8
VP49815
p4768
sg10
I4
sg11
VTSC2
p4769
sg13
I1
sa(dp4770
g7
I0
sg8
VP49815
p4771
sg10
I4
sg11
VTSC2
p4772
sg13
I1
sa(dp4773
g7
I0
sg8
VP49815
p4774
sg10
I4
sg11
VTSC2
p4775
sg13
I1
sasg14
(lp4776
(dp4777
g7
I0
sg17
VC1860707
p4778
sg10
I4
sg11
VTSC2
p4779
sg13
I1
sa(dp4780
g7
I0
sg17
VC1860707
p4781
sg10
I4
sg11
VTSC2
p4782
sg13
I1
sa(dp4783
g7
I0
sg17
VC1860707
p4784
sg10
I4
sg11
VTSC2
p4785
sg13
I1
sa(dp4786
g7
I120
sg17
VC0042133
p4787
sg10
I17
sg11
Vuterine leiomyoma
p4788
sg13
I2
sa(dp4789
g7
I0
sg17
VC1860707
p4790
sg10
I4
sg11
VTSC2
p4791
sg13
I1
sasa(dp4792
g2
S'Importantly, rapamycin treatment did not affect the expression of AdPLA2 and the production of PGE2 by TSC2-deficient mouse embryonic fibroblast (Tsc2-/-MEFs), rat uterine leiomyoma-derived ELT3 cells, and LAM patient-associated renal angiomyolipoma-derived "mesenchymal" cells.\n'
p4793
sg4
(lp4794
(dp4795
g7
I146
sg8
VP49815
p4796
sg10
I11
sg11
VTsc2-/-MEFs
p4797
sg13
I1
sa(dp4798
g7
I103
sg8
VP49815
p4799
sg10
I41
sg11
VTSC2-deficient mouse embryonic fibroblast
p4800
sg13
I4
sasg14
(lp4801
(dp4802
g7
I229
sg17
VC0241961
p4803
sg10
I20
sg11
Vrenal angiomyolipoma
p4804
sg13
I2
sa(dp4805
g7
I206
sg17
VC0751674
p4806
sg10
I3
sg11
VLAM
p4807
sg13
I1
sa(dp4808
g7
I164
sg17
VC0042133
p4809
sg10
I17
sg11
Vuterine leiomyoma
p4810
sg13
I2
sa(dp4811
g7
I103
sg17
VC1860707
p4812
sg10
I4
sg11
VTSC2
p4813
sg13
I1
sa(dp4814
g7
I146
sg17
VC1860707
p4815
sg10
I4
sg11
VTsc2
p4816
sg13
I1
sasa(dp4817
g2
S'Loss of the Tuberous Sclerosis 2 (TSC2) tumor suppressor has been proposed as a mechanism important for the etiology of uterine leiomyomata based on the Eker rat model.\n'
p4818
sg4
(lp4819
(dp4820
g7
I34
sg8
VP49815
p4821
sg10
I4
sg11
VTSC2
p4822
sg13
I1
sa(dp4823
g7
I12
sg8
VP49815
p4824
sg10
I20
sg11
VTuberous Sclerosis 2
p4825
sg13
I3
sasg14
(lp4826
(dp4827
g7
I120
sg17
VC0042133
p4828
sg10
I19
sg11
Vuterine leiomyomata
p4829
sg13
I2
sa(dp4830
g7
I34
sg17
VC1860707
p4831
sg10
I4
sg11
VTSC2
p4832
sg13
I1
sa(dp4833
g7
I12
sg17
VC1860707
p4834
sg10
I20
sg11
VTuberous Sclerosis 2
p4835
sg13
I3
sa(dp4836
g7
I40
sg17
VC0027651
p4837
sg10
I5
sg11
Vtumor
p4838
sg13
I1
sasa(dp4839
g2
S'However, conflicting evidence showing increased TSC2 expression has been reported in human uterine leiomyomata, suggesting that TSC2 might not be involved in the pathogenesis of this disorder.\n'
p4840
sg4
(lp4841
(dp4842
g7
I48
sg8
VP49815
p4843
sg10
I4
sg11
VTSC2
p4844
sg13
I1
sa(dp4845
g7
I48
sg8
VP49815
p4846
sg10
I4
sg11
VTSC2
p4847
sg13
I1
sasg14
(lp4848
(dp4849
g7
I162
sg17
VC0699748
p4850
sg10
I12
sg11
Vpathogenesis
p4851
sg13
I1
sa(dp4852
g7
I91
sg17
VC0042133
p4853
sg10
I19
sg11
Vuterine leiomyomata
p4854
sg13
I2
sa(dp4855
g7
I48
sg17
VC1860707
p4856
sg10
I4
sg11
VTSC2
p4857
sg13
I1
sa(dp4858
g7
I48
sg17
VC1860707
p4859
sg10
I4
sg11
VTSC2
p4860
sg13
I1
sasa(dp4861
g2
S'In cell culture models of TSC2-deficient LAM patient-derived and rat uterine leiomyoma-derived cells, we found that progesterone treatment or progesterone plus estradiol resulted in increased phosphorylation of Protein Kinase B (Akt) and Extracellular signal-regulated kinases1/2 (ERK1/2), induced the proliferation, and enhanced the migration and invasiveness.\n'
p4862
sg4
(lp4863
(dp4864
g7
I211
sg8
VP31749
p4865
sg10
I16
sg11
VProtein Kinase B
p4866
sg13
I3
sa(dp4867
g7
I26
sg8
VP49815
p4868
sg10
I4
sg11
VTSC2
p4869
sg13
I1
sa(dp4870
g7
I238
sg8
VP35555
p4871
sg10
I41
sg11
VExtracellular signal-regulated kinases1/2
p4872
sg13
I3
sa(dp4873
g7
I229
sg8
g9
sg10
I3
sg11
VAkt
p4874
sg13
I1
sa(dp4875
g7
I281
sg8
VP27361
p4876
sg10
I6
sg11
VERK1/2
p4877
sg13
I1
sasg14
(lp4878
(dp4879
g7
I41
sg17
VC0751674
p4880
sg10
I3
sg11
VLAM
p4881
sg13
I1
sa(dp4882
g7
I302
sg17
VC0334094
p4883
sg10
I13
sg11
Vproliferation
p4884
sg13
I1
sa(dp4885
g7
I26
sg17
VC1860707
p4886
sg10
I4
sg11
VTSC2
p4887
sg13
I1
sa(dp4888
g7
I69
sg17
VC0042133
p4889
sg10
I17
sg11
Vuterine leiomyoma
p4890
sg13
I2
sasa(dp4891
g2
S'We report here that expression of AlfaB-crystallin was upregulated in Tsc1-/- or Tsc2-/- mouse embryonic fibroblasts, Eker rat uterine leiomyoma-derived Tsc2-deficient ELT3 cells, mutant Tsc2-associated mouse kidney tumors, and human lung lymphangioleiomyomatosis nodules.\n'
p4892
sg4
(lp4893
(dp4894
g7
I81
sg8
VP49815
p4895
sg10
I4
sg11
VTsc2
p4896
sg13
I1
sa(dp4897
g7
I34
sg8
VP22914
p4898
sg10
I16
sg11
VAlfaB-crystallin
p4899
sg13
I1
sa(dp4900
g7
I81
sg8
VP49815
p4901
sg10
I4
sg11
VTsc2
p4902
sg13
I1
sa(dp4903
g7
I81
sg8
VP49815
p4904
sg10
I4
sg11
VTsc2
p4905
sg13
I1
sa(dp4906
g7
I70
sg8
g9
sg10
I4
sg11
VTsc1
p4907
sg13
I1
sasg14
(lp4908
(dp4909
g7
I81
sg17
VC1860707
p4910
sg10
I4
sg11
VTsc2
p4911
sg13
I1
sa(dp4912
g7
I70
sg17
VC1854465
p4913
sg10
I4
sg11
VTsc1
p4914
sg13
I1
sa(dp4915
g7
I209
sg17
VC0022665
p4916
sg10
I13
sg11
Vkidney tumors
p4917
sg13
I2
sa(dp4918
g7
I81
sg17
VC1860707
p4919
sg10
I4
sg11
VTsc2
p4920
sg13
I1
sa(dp4921
g7
I264
sg17
VC0028259
p4922
sg10
I7
sg11
Vnodules
p4923
sg13
I1
sa(dp4924
g7
I127
sg17
VC0042133
p4925
sg10
I17
sg11
Vuterine leiomyoma
p4926
sg13
I2
sa(dp4927
g7
I81
sg17
VC1860707
p4928
sg10
I4
sg11
VTsc2
p4929
sg13
I1
sa(dp4930
g7
I180
sg17
VC0596988
p4931
sg10
I6
sg11
Vmutant
p4932
sg13
I1
sa(dp4933
g7
I234
sg17
VC0349649
p4934
sg10
I29
sg11
Vlung lymphangioleiomyomatosis
p4935
sg13
I2
sasa(dp4936
g2
S'Female Eker rats harboring an insertional deletion in one copy of the tuberous sclerosis complex 2 (Tsc2) gene develop uterine leiomyoma, but the underlying mechanism of human uterine leiomyoma is not completely understood.\n'
p4937
sg4
(lp4938
(dp4939
g7
I100
sg8
VP49815
p4940
sg10
I4
sg11
VTsc2
p4941
sg13
I1
sa(dp4942
g7
I70
sg8
VP49815
p4943
sg10
I28
sg11
Vtuberous sclerosis complex 2
p4944
sg13
I4
sasg14
(lp4945
(dp4946
g7
I119
sg17
VC0042133
p4947
sg10
I17
sg11
Vuterine leiomyoma
p4948
sg13
I2
sa(dp4949
g7
I100
sg17
VC1860707
p4950
sg10
I4
sg11
VTsc2
p4951
sg13
I1
sa(dp4952
g7
I70
sg17
VC1860707
p4953
sg10
I28
sg11
Vtuberous sclerosis complex 2
p4954
sg13
I4
sa(dp4955
g7
I119
sg17
VC0042133
p4956
sg10
I17
sg11
Vuterine leiomyoma
p4957
sg13
I2
sasa(dp4958
g2
S'To examine whether down-regulation of tuberin, a TSC2 gene product, is present in human uterine leiomyoma, we analyzed leiomyoma and matched myometrium tissues from 22 Chinese patients with Western blotting and real-time polymerase chain reaction analyses, and found that the expression of tuberin was significantly increased in leiomyoma tissues compared with matched myometrium tissues with inhibition of both the mammalian target of rapacmycin pathway and mitogen-activated protein kinase pathways.\n'
p4959
sg4
(lp4960
(dp4961
g7
I38
sg8
VP49815
p4962
sg10
I7
sg11
Vtuberin
p4963
sg13
I1
sa(dp4964
g7
I49
sg8
VP49815
p4965
sg10
I17
sg11
VTSC2 gene product
p4966
sg13
I3
sa(dp4967
g7
I38
sg8
VP49815
p4968
sg10
I7
sg11
Vtuberin
p4969
sg13
I1
sa(dp4970
g7
I459
sg8
VP53779
p4971
sg10
I32
sg11
Vmitogen-activated protein kinase
p4972
sg13
I3
sasg14
(lp4973
(dp4974
g7
I96
sg17
VC0042133
p4975
sg10
I9
sg11
Vleiomyoma
p4976
sg13
I1
sa(dp4977
g7
I88
sg17
VC0042133
p4978
sg10
I17
sg11
Vuterine leiomyoma
p4979
sg13
I2
sa(dp4980
g7
I96
sg17
VC0042133
p4981
sg10
I9
sg11
Vleiomyoma
p4982
sg13
I1
sa(dp4983
g7
I49
sg17
VC1860707
p4984
sg10
I4
sg11
VTSC2
p4985
sg13
I1
sasa(dp4986
g2
S'Cells derived from an Eker rat uterine leiomyoma (ELT3 cells) are Tsc2-null and these have been used in a rodent cell models for LAM.\n'
p4987
sg4
(lp4988
(dp4989
g7
I66
sg8
VP49815
p4990
sg10
I9
sg11
VTsc2-null
p4991
sg13
I1
sasg14
(lp4992
(dp4993
g7
I129
sg17
VC0751674
p4994
sg10
I3
sg11
VLAM
p4995
sg13
I1
sa(dp4996
g7
I31
sg17
VC0042133
p4997
sg10
I17
sg11
Vuterine leiomyoma
p4998
sg13
I2
sa(dp4999
g7
I66
sg17
VC1860707
p5000
sg10
I4
sg11
VTsc2
p5001
sg13
I1
sasa(dp5002
g2
S'In patients with rheumatoid arthritis, furin is reported to be highly expressed in the synovial pannus compared with healthy persons.\n'
p5003
sg4
(lp5004
(dp5005
g7
I39
sg8
VP09958
p5006
sg10
I5
sg11
Vfurin
p5007
sg13
I1
sasg14
(lp5008
(dp5009
g7
I96
sg17
VC0155094
p5010
sg10
I6
sg11
Vpannus
p5011
sg13
I1
sa(dp5012
g7
I17
sg17
VC0003873
p5013
sg10
I20
sg11
Vrheumatoid arthritis
p5014
sg13
I2
sasa(dp5015
g2
S'Inhibition of furin enhances invasive phenotype of synoviocytes from patients with rheumatoid arthritis, implying a protective role of furin.\n'
p5016
sg4
(lp5017
(dp5018
g7
I14
sg8
VP09958
p5019
sg10
I5
sg11
Vfurin
p5020
sg13
I1
sa(dp5021
g7
I14
sg8
VP09958
p5022
sg10
I5
sg11
Vfurin
p5023
sg13
I1
sasg14
(lp5024
(dp5025
g7
I83
sg17
VC0003873
p5026
sg10
I20
sg11
Vrheumatoid arthritis
p5027
sg13
I2
sasa(dp5028
g2
S'Agents targeting upregulation of furin may have therapeutic potential for rheumatoid arthritis.\n'
p5029
sg4
(lp5030
(dp5031
g7
I33
sg8
VP09958
p5032
sg10
I5
sg11
Vfurin
p5033
sg13
I1
sasg14
(lp5034
(dp5035
g7
I74
sg17
VC0003873
p5036
sg10
I20
sg11
Vrheumatoid arthritis
p5037
sg13
I2
sasa(dp5038
g2
S'The effect of furin and its inhibitor Alfa1-PDX was tested in mice with collagen-induced arthritis (CIA).\n'
p5039
sg4
(lp5040
(dp5041
g7
I14
sg8
VP09958
p5042
sg10
I5
sg11
Vfurin
p5043
sg13
I1
sasg14
(lp5044
(dp5045
g7
I89
sg17
VC0003864
p5046
sg10
I9
sg11
Varthritis
p5047
sg13
I1
sasa(dp5048
g2
S'Systemic administration of furin prevented increases in the arthritis score, joint destruction, and bone loss, in contrast to systemic administration of the furin inhibitor Alfa1-PDX, which enhanced these parameters.\n'
p5049
sg4
(lp5050
(dp5051
g7
I27
sg8
VP09958
p5052
sg10
I5
sg11
Vfurin
p5053
sg13
I1
sa(dp5054
g7
I27
sg8
VP09958
p5055
sg10
I5
sg11
Vfurin
p5056
sg13
I1
sasg14
(lp5057
(dp5058
g7
I60
sg17
VC0003864
p5059
sg10
I9
sg11
Varthritis
p5060
sg13
I1
sa(dp5061
g7
I100
sg17
VC0029453
p5062
sg10
I9
sg11
Vbone loss
p5063
sg13
I2
sasa(dp5064
g2
S'They also suggest that Adamts5 induction in joint components other than cartilage, and its post-translational activation by PACE4 and/or furin may be important in the pathophysiology of arthritis.\n'
p5065
sg4
(lp5066
(dp5067
g7
I23
sg8
g9
sg10
I7
sg11
VAdamts5
p5068
sg13
I1
sa(dp5069
g7
I137
sg8
VP09958
p5070
sg10
I5
sg11
Vfurin
p5071
sg13
I1
sasg14
(lp5072
(dp5073
g7
I186
sg17
VC0003864
p5074
sg10
I9
sg11
Varthritis
p5075
sg13
I1
sasa(dp5076
g2
S'When comparing the chorioamniotic membranes from women in spontaneous preterm labor with acute histologic chorioamnionitis to those without this placental lesion, we found that (1) the mRNA of NLR family pyrin domain-containing protein ( NLRP) 1, NLRP3, NLR family CARD domain-containing protein 4 ( NLRC4), and NOD2 were higher; (2) the NLRP3 protein was increased; (3) the mRNA and active form (p10) of CASP-1 were greater; (4) the mRNA and active form of CASP-4 were increased; (5) the mRNA and mature form of IL-1Beta were higher; (6) the mature form of IL-18 was elevated; and (7) ASC/CASP-1 complex formation was increased.\n'
p5077
sg4
(lp5078
(dp5079
g7
I193
sg8
g9
sg10
I52
sg11
VNLR family pyrin domain-containing protein ( NLRP) 1
p5080
sg13
I8
sa(dp5081
g7
I513
sg8
VP01584
p5082
sg10
I8
sg11
VIL-1Beta
p5083
sg13
I1
sa(dp5084
g7
I300
sg8
g9
sg10
I5
sg11
VNLRC4
p5085
sg13
I1
sa(dp5086
g7
I254
sg8
g9
sg10
I43
sg11
VNLR family CARD domain-containing protein 4
p5087
sg13
I6
sa(dp5088
g7
I458
sg8
VP39880
p5089
sg10
I6
sg11
VCASP-4
p5090
sg13
I1
sa(dp5091
g7
I405
sg8
VP39880
p5092
sg10
I6
sg11
VCASP-1
p5093
sg13
I1
sa(dp5094
g7
I312
sg8
VP22301
p5095
sg10
I4
sg11
VNOD2
p5096
sg13
I1
sa(dp5097
g7
I397
sg8
VP60903
p5098
sg10
I3
sg11
Vp10
p5099
sg13
I1
sasg14
(lp5100
(dp5101
g7
I106
sg17
VC0008495
p5102
sg10
I16
sg11
Vchorioamnionitis
p5103
sg13
I1
sa(dp5104
g7
I70
sg17
VC0022876
p5105
sg10
I13
sg11
Vpreterm labor
p5106
sg13
I2
sasa(dp5107
g2
S'When comparing the chorioamniotic membranes from women in spontaneous labor at term with acute histologic chorioamnionitis to those without this placental lesion, we found that (1) the messenger RNA (mRNA) abundance of NLR family pyrin domain containing 3 ( NLRP3), NLR family CARD domain containing 4 ( NLRC4), absent in melanoma 2 ( AIM2), and nucleotide binding oligomerization domain 2 ( NOD2) was higher; (2) the NLRP3 and NLRC4 protein quantities were increased; (3) the mRNA and protein expressions of CASP-1 and its active forms were greater; (4) CASP-4 was increased at the mRNA level only; (5) the mRNA and protein expressions of IL-1Beta and its mature form were higher; and (6) a modest increase in the total protein concentration and abundance of the mature form of IL-18 was observed.\n'
p5108
sg4
(lp5109
(dp5110
g7
I335
sg8
g9
sg10
I4
sg11
VAIM2
p5111
sg13
I1
sa(dp5112
g7
I266
sg8
g9
sg10
I35
sg11
VNLR family CARD domain containing 4
p5113
sg13
I6
sa(dp5114
g7
I640
sg8
VP01584
p5115
sg10
I8
sg11
VIL-1Beta
p5116
sg13
I1
sa(dp5117
g7
I304
sg8
g9
sg10
I5
sg11
VNLRC4
p5118
sg13
I1
sa(dp5119
g7
I509
sg8
VP39880
p5120
sg10
I6
sg11
VCASP-1
p5121
sg13
I1
sa(dp5122
g7
I219
sg8
g9
sg10
I36
sg11
VNLR family pyrin domain containing 3
p5123
sg13
I6
sa(dp5124
g7
I346
sg8
VP63244
p5125
sg10
I43
sg11
Vnucleotide binding oligomerization domain 2
p5126
sg13
I5
sa(dp5127
g7
I428
sg8
g9
sg10
I13
sg11
VNLRC4 protein
p5128
sg13
I2
sa(dp5129
g7
I392
sg8
VP22301
p5130
sg10
I4
sg11
VNOD2
p5131
sg13
I1
sasg14
(lp5132
(dp5133
g7
I106
sg17
VC0008495
p5134
sg10
I16
sg11
Vchorioamnionitis
p5135
sg13
I1
sa(dp5136
g7
I322
sg17
VC0025202
p5137
sg10
I8
sg11
Vmelanoma
p5138
sg13
I1
sasa(dp5139
g2
S'Mutations in NLRP7 (NOD-like-receptor family, pyrin domain containing 7) are responsible for a type of recurrent pregnancy loss known as recurrent hydatidiform mole (HYDM1).\n'
p5140
sg4
(lp5141
(dp5142
g7
I20
sg8
VP54259
p5143
sg10
I24
sg11
VNOD-like-receptor family
p5144
sg13
I2
sa(dp5145
g7
I13
sg8
g9
sg10
I5
sg11
VNLRP7
p5146
sg13
I1
sa(dp5147
g7
I46
sg8
g9
sg10
I25
sg11
Vpyrin domain containing 7
p5148
sg13
I4
sasg14
(lp5149
(dp5150
g7
I20
sg17
VC0751781
p5151
sg10
I3
sg11
VNOD
p5152
sg13
I1
sa(dp5153
g7
I103
sg17
VC2921106
p5154
sg10
I24
sg11
Vrecurrent pregnancy loss
p5155
sg13
I3
sa(dp5156
g7
I147
sg17
VC0020217
p5157
sg10
I17
sg11
Vhydatidiform mole
p5158
sg13
I2
sa(dp5159
g7
I166
sg17
VC3463897
p5160
sg10
I5
sg11
VHYDM1
p5161
sg13
I1
sasa(dp5162
g2
S'NRG1 fusion-positive lung cancers have emerged as potentially actionable events in lung cancer but clinical support is currently limited and no evidence of efficacy of this approach in cancers beyond lung has been shown.\n'
p5163
sg4
(lp5164
sg14
(lp5165
(dp5166
g7
I26
sg17
VC0006826
p5167
sg10
I7
sg11
Vcancers
p5168
sg13
I1
sa(dp5169
g7
I21
sg17
VC0242379
p5170
sg10
I12
sg11
Vlung cancers
p5171
sg13
I2
sa(dp5172
g7
I21
sg17
VC0242379
p5173
sg10
I11
sg11
Vlung cancer
p5174
sg13
I2
sasa(dp5175
g2
S'In patient 1 an SDC4-NRG1 gene fusion was detected, similar gene fusions having been described in lung cancers previously.\n'
p5176
sg4
(lp5177
(dp5178
g7
I60
sg8
VP35637
p5179
sg10
I12
sg11
Vgene fusions
p5180
sg13
I2
sa(dp5181
g7
I16
sg8
VP31431
p5182
sg10
I4
sg11
VSDC4
p5183
sg13
I1
sasg14
(lp5184
(dp5185
g7
I26
sg17
VC1705736
p5186
sg10
I11
sg11
Vgene fusion
p5187
sg13
I2
sa(dp5188
g7
I98
sg17
VC0242379
p5189
sg10
I12
sg11
Vlung cancers
p5190
sg13
I2
sasa(dp5191
g2
S'Unexpected molecular lesions of the NRG1 gene followed by an aberrant ErbB signaling were recently described as a new molecular features of non-small cell lung cancer, but it has been also sporadically reported in other tumors.\n'
p5192
sg4
(lp5193
(dp5194
g7
I70
sg8
g9
sg10
I4
sg11
VErbB
p5195
sg13
I1
sasg14
(lp5196
(dp5197
g7
I220
sg17
VC0027651
p5198
sg10
I6
sg11
Vtumors
p5199
sg13
I1
sa(dp5200
g7
I140
sg17
VC0007131
p5201
sg10
I26
sg11
Vnon-small cell lung cancer
p5202
sg13
I4
sasa(dp5203
g2
S'We highlight the current knowledge about the ErbB network and NRG1 deregulation in lung cancer and their merger into the ErbB/PI3K-AKT axis modulation and current therapeutic strategies.\n'
p5204
sg4
(lp5205
(dp5206
g7
I45
sg8
g9
sg10
I4
sg11
VErbB
p5207
sg13
I1
sa(dp5208
g7
I131
sg8
g9
sg10
I3
sg11
VAKT
p5209
sg13
I1
sa(dp5210
g7
I126
sg8
VP42336
p5211
sg10
I4
sg11
VPI3K
p5212
sg13
I1
sa(dp5213
g7
I45
sg8
g9
sg10
I12
sg11
VErbB network
p5214
sg13
I2
sasg14
(lp5215
(dp5216
g7
I83
sg17
VC0684249
p5217
sg10
I11
sg11
Vlung cancer
p5218
sg13
I2
sasa(dp5219
g2
S'More advances in knowledge of crosstalk between NRG1, ErbB3 and PI3K-AKT pathways may increase and strongly support the therapeutic choice for lung cancer patients.\n'
p5220
sg4
(lp5221
(dp5222
g7
I64
sg8
VP42336
p5223
sg10
I4
sg11
VPI3K
p5224
sg13
I1
sa(dp5225
g7
I54
sg8
VP21860
p5226
sg10
I5
sg11
VErbB3
p5227
sg13
I1
sa(dp5228
g7
I69
sg8
g9
sg10
I3
sg11
VAKT
p5229
sg13
I1
sasg14
(lp5230
(dp5231
g7
I143
sg17
VC0684249
p5232
sg10
I11
sg11
Vlung cancer
p5233
sg13
I2
sasa(dp5234
g2
S'All coding exons of SCN1B, GABRG2, and CACNB4 genes were screened for mutations in 38 SCN1A-mutation-positive SMEI probands.\n'
p5235
sg4
(lp5236
(dp5237
g7
I86
sg8
VP35498
p5238
sg10
I5
sg11
VSCN1A
p5239
sg13
I1
sa(dp5240
g7
I20
sg8
g9
sg10
I5
sg11
VSCN1B
p5241
sg13
I1
sa(dp5242
g7
I39
sg8
g9
sg10
I12
sg11
VCACNB4 genes
p5243
sg13
I2
sa(dp5244
g7
I27
sg8
VP18507
p5245
sg10
I6
sg11
VGABRG2
p5246
sg13
I1
sasg14
(lp5247
(dp5248
g7
I110
sg17
VC0751122
p5249
sg10
I4
sg11
VSMEI
p5250
sg13
I1
sasa(dp5251
g2
S'Following the univariate analysis, high expressions of nuclear Beta-arrestin1 and p300 were classed as poor prognostic factors for both OS (P = .016) and DFS (P = .025).The expression of Beta-arrestin1 in the nucleus is associated with increased malignant tendency of lung adenocarcinoma, and the predictive value of Beta-arrestin1 may be optimized by combining information about the expression of p300 acetyltransferase.\n'
p5252
sg4
(lp5253
(dp5254
g7
I82
sg8
g9
sg10
I4
sg11
Vp300
p5255
sg13
I1
sa(dp5256
g7
I398
sg8
g9
sg10
I22
sg11
Vp300 acetyltransferase
p5257
sg13
I2
sasg14
(lp5258
(dp5259
g7
I268
sg17
VC0152013
p5260
sg10
I19
sg11
Vlung adenocarcinoma
p5261
sg13
I2
sasa(dp5262
g2
S'Furthermore, we demonstrated that the activation of COX-2 expression by hnRNPA2/B1 was mediated through the cooperation with p300, a transcriptional co-activator, in NSCLC cells.\n'
p5263
sg4
(lp5264
(dp5265
g7
I72
sg8
VP22626
p5266
sg10
I7
sg11
VhnRNPA2
p5267
sg13
I1
sa(dp5268
g7
I52
sg8
VP35354
p5269
sg10
I5
sg11
VCOX-2
p5270
sg13
I1
sa(dp5271
g7
I125
sg8
g9
sg10
I4
sg11
Vp300
p5272
sg13
I1
sasg14
(lp5273
(dp5274
g7
I166
sg17
VC0007131
p5275
sg10
I5
sg11
VNSCLC
p5276
sg13
I1
sasa(dp5277
g2
S'PPARGC1A and PPARGC1B) are key agents in the development and pathophysiology of type 2 diabetes mellitus (T2DM).\n'
p5278
sg4
(lp5279
(dp5280
g7
I0
sg8
g9
sg10
I8
sg11
VPPARGC1A
p5281
sg13
I1
sasg14
(lp5282
(dp5283
g7
I106
sg17
VC0011860
p5284
sg10
I4
sg11
VT2DM
p5285
sg13
I1
sa(dp5286
g7
I80
sg17
VC0011860
p5287
sg10
I24
sg11
Vtype 2 diabetes mellitus
p5288
sg13
I4
sasa(dp5289
g2
S'Furthermore, eight of the 17 CpG sites reside in genes (FSTL1, SORCS2, NRF1, DLC1, PPARGC1B, CHN2, NXPH1) that have prior known associations with obesity, diabetes, and the insulin pathway.\n'
p5290
sg4
(lp5291
(dp5292
g7
I63
sg8
g9
sg10
I6
sg11
VSORCS2
p5293
sg13
I1
sa(dp5294
g7
I93
sg8
VP52757
p5295
sg10
I4
sg11
VCHN2
p5296
sg13
I1
sa(dp5297
g7
I71
sg8
g9
sg10
I4
sg11
VNRF1
p5298
sg13
I1
sa(dp5299
g7
I56
sg8
g9
sg10
I5
sg11
VFSTL1
p5300
sg13
I1
sa(dp5301
g7
I77
sg8
VP63167
p5302
sg10
I4
sg11
VDLC1
p5303
sg13
I1
sa(dp5304
g7
I173
sg8
VP01308
p5305
sg10
I7
sg11
Vinsulin
p5306
sg13
I1
sa(dp5307
g7
I99
sg8
VP58417
p5308
sg10
I5
sg11
VNXPH1
p5309
sg13
I1
sasg14
(lp5310
(dp5311
g7
I155
sg17
VC0011849
p5312
sg10
I8
sg11
Vdiabetes
p5313
sg13
I1
sa(dp5314
g7
I146
sg17
VC0028754
p5315
sg10
I7
sg11
Vobesity
p5316
sg13
I1
sasa(dp5317
g2
S'No significant associations were found, although the top significant CpGs in boys were located in the LRPAP1, HAGH, PPARGC1B, KCNQ1 and KCNQ1DN genes, previously associated to birth weight, Type 2 diabetes, obesity or steroid hormone signaling.\n'
p5318
sg4
(lp5319
(dp5320
g7
I136
sg8
g9
sg10
I13
sg11
VKCNQ1DN genes
p5321
sg13
I2
sa(dp5322
g7
I126
sg8
VP51787
p5323
sg10
I5
sg11
VKCNQ1
p5324
sg13
I1
sa(dp5325
g7
I102
sg8
VP30533
p5326
sg10
I6
sg11
VLRPAP1
p5327
sg13
I1
sa(dp5328
g7
I110
sg8
g9
sg10
I4
sg11
VHAGH
p5329
sg13
I1
sasg14
(lp5330
(dp5331
g7
I190
sg17
VC0011860
p5332
sg10
I15
sg11
VType 2 diabetes
p5333
sg13
I3
sa(dp5334
g7
I207
sg17
VC0028754
p5335
sg10
I7
sg11
Vobesity
p5336
sg13
I1
sasa(dp5337
g2
S'We used a two-stage study design to evaluate whether variations in the peroxisome proliferator-activated receptors (PPAR) and the PPAR gamma co-activator 1 (PGC1) gene families (PPARA, PPARG, PPARD, PPARGC1A, and PPARGC1B) are associated with type 2 diabetes (T2D) risk.\n'
p5338
sg4
(lp5339
(dp5340
g7
I163
sg8
VP19883
p5341
sg10
I13
sg11
Vgene families
p5342
sg13
I2
sa(dp5343
g7
I157
sg8
g9
sg10
I4
sg11
VPGC1
p5344
sg13
I1
sa(dp5345
g7
I199
sg8
g9
sg10
I8
sg11
VPPARGC1A
p5346
sg13
I1
sa(dp5347
g7
I116
sg8
g9
sg10
I4
sg11
VPPAR
p5348
sg13
I1
sa(dp5349
g7
I71
sg8
g9
sg10
I43
sg11
Vperoxisome proliferator-activated receptors
p5350
sg13
I3
sa(dp5351
g7
I130
sg8
g9
sg10
I25
sg11
VPPAR gamma co-activator 1
p5352
sg13
I4
sa(dp5353
g7
I185
sg8
g9
sg10
I5
sg11
VPPARG
p5354
sg13
I1
sa(dp5355
g7
I192
sg8
g9
sg10
I5
sg11
VPPARD
p5356
sg13
I1
sa(dp5357
g7
I178
sg8
g9
sg10
I5
sg11
VPPARA
p5358
sg13
I1
sasg14
(lp5359
(dp5360
g7
I260
sg17
VC0011860
p5361
sg10
I3
sg11
VT2D
p5362
sg13
I1
sa(dp5363
g7
I243
sg17
VC0011860
p5364
sg10
I15
sg11
Vtype 2 diabetes
p5365
sg13
I3
sasa(dp5366
g2
S'A recently identified muscular dystrophy gene TOR1AIP1 was detected as a hub gene in dysferlinopathy.\n'
p5367
sg4
(lp5368
(dp5369
g7
I73
sg8
g9
sg10
I8
sg11
Vhub gene
p5370
sg13
I2
sa(dp5371
g7
I22
sg8
VP43034
p5372
sg10
I32
sg11
Vmuscular dystrophy gene TOR1AIP1
p5373
sg13
I4
sasg14
(lp5374
(dp5375
g7
I22
sg17
VC0026850
p5376
sg10
I18
sg11
Vmuscular dystrophy
p5377
sg13
I2
sa(dp5378
g7
I85
sg17
VC2931687
p5379
sg10
I15
sg11
Vdysferlinopathy
p5380
sg13
I1
sasa(dp5381
g2
S'TorsinA-interacting protein 1 (TOR1AIP1) gene is a novel gene that has recently been described to cause limb-girdle muscular dystrophy (LGMD) with mild dilated cardiomyopathy.\n'
p5382
sg4
(lp5383
(dp5384
g7
I0
sg8
VP14222
p5385
sg10
I29
sg11
VTorsinA-interacting protein 1
p5386
sg13
I3
sasg14
(lp5387
(dp5388
g7
I152
sg17
VC0007193
p5389
sg10
I22
sg11
Vdilated cardiomyopathy
p5390
sg13
I2
sa(dp5391
g7
I104
sg17
VC0686353
p5392
sg10
I30
sg11
Vlimb-girdle muscular dystrophy
p5393
sg13
I3
sa(dp5394
g7
I136
sg17
VC0686353
p5395
sg10
I4
sg11
VLGMD
p5396
sg13
I1
sasa(dp5397
g2
S'We report a family with mutations in TOR1AIP1 where the striking clinical feature is severe cardiac failure requiring cardiac transplant in two siblings, in addition to musculoskeletal weakness and muscular dystrophy.\n'
p5398
sg4
(lp5399
sg14
(lp5400
(dp5401
g7
I92
sg17
VC0018801
p5402
sg10
I15
sg11
Vcardiac failure
p5403
sg13
I2
sa(dp5404
g7
I198
sg17
VC0026850
p5405
sg10
I18
sg11
Vmuscular dystrophy
p5406
sg13
I2
sa(dp5407
g7
I185
sg17
VC1883552
p5408
sg10
I8
sg11
Vweakness
p5409
sg13
I1
sasa(dp5410
g2
S'These scientific contributions strengthen the role of LAP1 in DYT1 dystonia and muscular dystrophy.\n'
p5411
sg4
(lp5412
(dp5413
g7
I62
sg8
g9
sg10
I13
sg11
VDYT1 dystonia
p5414
sg13
I2
sa(dp5415
g7
I54
sg8
VP15144
p5416
sg10
I4
sg11
VLAP1
p5417
sg13
I1
sasg14
(lp5418
(dp5419
g7
I62
sg17
VC1851945
p5420
sg10
I4
sg11
VDYT1
p5421
sg13
I1
sa(dp5422
g7
I67
sg17
VC0393593
p5423
sg10
I8
sg11
Vdystonia
p5424
sg13
I1
sa(dp5425
g7
I80
sg17
VC0026850
p5426
sg10
I18
sg11
Vmuscular dystrophy
p5427
sg13
I2
sasa(dp5428
g2
S'Moreover, LAP1 also interacts with torsinA and emerin, proteins involved in DYT1 dystonia and X-linked Emery-Dreifuss muscular dystrophy disorder, respectively.\n'
p5429
sg4
(lp5430
(dp5431
g7
I76
sg8
g9
sg10
I4
sg11
VDYT1
p5432
sg13
I1
sa(dp5433
g7
I47
sg8
VP50402
p5434
sg10
I6
sg11
Vemerin
p5435
sg13
I1
sa(dp5436
g7
I35
sg8
g9
sg10
I7
sg11
VtorsinA
p5437
sg13
I1
sa(dp5438
g7
I10
sg8
VP15144
p5439
sg10
I4
sg11
VLAP1
p5440
sg13
I1
sasg14
(lp5441
(dp5442
g7
I76
sg17
VC1851945
p5443
sg10
I4
sg11
VDYT1
p5444
sg13
I1
sa(dp5445
g7
I94
sg17
VC0751337
p5446
sg10
I42
sg11
VX-linked Emery-Dreifuss muscular dystrophy
p5447
sg13
I4
sa(dp5448
g7
I81
sg17
VC0393593
p5449
sg10
I8
sg11
Vdystonia
p5450
sg13
I1
sasa(dp5451
g2
S'Deletions encompassing TAK1-binding protein 2 (TAB2) associated with isolated and syndromic congenital heart defects.\n'
p5452
sg4
(lp5453
(dp5454
g7
I23
sg8
g9
sg10
I22
sg11
VTAK1-binding protein 2
p5455
sg13
I3
sa(dp5456
g7
I47
sg8
g9
sg10
I4
sg11
VTAB2
p5457
sg13
I1
sasg14
(lp5458
(dp5459
g7
I92
sg17
VC0018798
p5460
sg10
I24
sg11
Vcongenital heart defects
p5461
sg13
I3
sasa(dp5462
g2
S'Haploinsufficiency of TAB2 was recently implicated as a cause for a variety of congenital heart defects.\n'
p5463
sg4
(lp5464
(dp5465
g7
I22
sg8
g9
sg10
I4
sg11
VTAB2
p5466
sg13
I1
sasg14
(lp5467
(dp5468
g7
I79
sg17
VC0018798
p5469
sg10
I24
sg11
Vcongenital heart defects
p5470
sg13
I3
sasa(dp5471
g2
S'This is the smallest reported deletion involving TAB2 that segregates with congenital heart defects.\n'
p5472
sg4
(lp5473
(dp5474
g7
I49
sg8
g9
sg10
I4
sg11
VTAB2
p5475
sg13
I1
sasg14
(lp5476
(dp5477
g7
I75
sg17
VC0018798
p5478
sg10
I24
sg11
Vcongenital heart defects
p5479
sg13
I3
sasa(dp5480
g2
S'Findings from this family support a key role of TAB2 haploinsufficiency in congenital heart defects and expand the phenotypic spectrum of TAB2-microdeletion syndrome.\n'
p5481
sg4
(lp5482
(dp5483
g7
I48
sg8
g9
sg10
I4
sg11
VTAB2
p5484
sg13
I1
sa(dp5485
g7
I48
sg8
g9
sg10
I4
sg11
VTAB2
p5486
sg13
I1
sasg14
(lp5487
(dp5488
g7
I157
sg17
VC0039082
p5489
sg10
I8
sg11
Vsyndrome
p5490
sg13
I1
sa(dp5491
g7
I75
sg17
VC0018798
p5492
sg10
I24
sg11
Vcongenital heart defects
p5493
sg13
I3
sasa(dp5494
g2
S"In addition, the present deletion is the smallest so far recorded in the 6q25 region encompassing eight known genes [vs. 41 of Bisgaard et al., and 23 of Caselli et al.,], including the TAB2 (likely responsible for the girl's congenital heart defect), LATS1 gene, and the UST gene (a regulator of the homeostasis of proteoglycans, which could have played a role in the abnormal dermal and cartilage elasticity).\n"
p5495
sg4
(lp5496
(dp5497
g7
I272
sg8
g9
sg10
I8
sg11
VUST gene
p5498
sg13
I2
sa(dp5499
g7
I252
sg8
g9
sg10
I10
sg11
VLATS1 gene
p5500
sg13
I2
sa(dp5501
g7
I186
sg8
g9
sg10
I4
sg11
VTAB2
p5502
sg13
I1
sasg14
(lp5503
(dp5504
g7
I226
sg17
VC0018798
p5505
sg10
I23
sg11
Vcongenital heart defect
p5506
sg13
I3
sasa(dp5507
g2
S'The isozymes hPAD2 and hPAD4 have been implicated in the development and progression of several autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.\n'
p5508
sg4
(lp5509
sg14
(lp5510
(dp5511
g7
I96
sg17
VC0004364
p5512
sg10
I19
sg11
Vautoimmune diseases
p5513
sg13
I2
sa(dp5514
g7
I127
sg17
VC0003873
p5515
sg10
I20
sg11
Vrheumatoid arthritis
p5516
sg13
I2
sa(dp5517
g7
I152
sg17
VC0026769
p5518
sg10
I18
sg11
Vmultiple sclerosis
p5519
sg13
I2
sasa(dp5520
g2
S'Protein arginine deiminase 2 (PAD2) plays a key role in the onset and progression of multiple sclerosis, rheumatoid arthritis, and breast cancer.\n'
p5521
sg4
(lp5522
(dp5523
g7
I0
sg8
g9
sg10
I28
sg11
VProtein arginine deiminase 2
p5524
sg13
I4
sa(dp5525
g7
I30
sg8
g9
sg10
I4
sg11
VPAD2
p5526
sg13
I1
sasg14
(lp5527
(dp5528
g7
I105
sg17
VC0003873
p5529
sg10
I20
sg11
Vrheumatoid arthritis
p5530
sg13
I2
sa(dp5531
g7
I131
sg17
VC0678222
p5532
sg10
I13
sg11
Vbreast cancer
p5533
sg13
I2
sa(dp5534
g7
I85
sg17
VC0026769
p5535
sg10
I18
sg11
Vmultiple sclerosis
p5536
sg13
I2
sasa(dp5537
g2
S'The enzyme peptidylarginine deiminase 2 (PAD2) has been associated with inflammatory diseases, such as rheumatoid arthritis and neurodegenerative diseases including multiple sclerosis.\n'
p5538
sg4
(lp5539
(dp5540
g7
I11
sg8
g9
sg10
I28
sg11
Vpeptidylarginine deiminase 2
p5541
sg13
I3
sa(dp5542
g7
I41
sg8
g9
sg10
I4
sg11
VPAD2
p5543
sg13
I1
sasg14
(lp5544
(dp5545
g7
I103
sg17
VC0003873
p5546
sg10
I20
sg11
Vrheumatoid arthritis
p5547
sg13
I2
sa(dp5548
g7
I128
sg17
VC0524851
p5549
sg10
I26
sg11
Vneurodegenerative diseases
p5550
sg13
I2
sa(dp5551
g7
I165
sg17
VC0026769
p5552
sg10
I18
sg11
Vmultiple sclerosis
p5553
sg13
I2
sasa(dp5554
g2
S'Peptidylarginine deiminase 2 (PAD2) and peptidylarginine deiminase 4 (PAD4) are two members of PAD family which are over-expressed in the multiple sclerosis (MS) brain.\n'
p5555
sg4
(lp5556
(dp5557
g7
I95
sg8
g9
sg10
I10
sg11
VPAD family
p5558
sg13
I2
sa(dp5559
g7
I70
sg8
g9
sg10
I4
sg11
VPAD4
p5560
sg13
I1
sa(dp5561
g7
I40
sg8
g9
sg10
I28
sg11
Vpeptidylarginine deiminase 4
p5562
sg13
I3
sa(dp5563
g7
I0
sg8
g9
sg10
I28
sg11
VPeptidylarginine deiminase 2
p5564
sg13
I3
sa(dp5565
g7
I30
sg8
g9
sg10
I4
sg11
VPAD2
p5566
sg13
I1
sasg14
(lp5567
(dp5568
g7
I138
sg17
VC0026769
p5569
sg10
I18
sg11
Vmultiple sclerosis
p5570
sg13
I2
sa(dp5571
g7
I158
sg17
VC0026769
p5572
sg10
I2
sg11
VMS
p5573
sg13
I1
sa(dp5574
g7
I30
sg17
VC1704436
p5575
sg10
I3
sg11
VPAD
p5576
sg13
I1
sasa(dp5577
g2
S"Recent studies have revealed that abnormal activation of PADI2, the gene for which is expressed throughout the nervous system, is likely to be related to the pathogenesis of neuropsychiatric diseases with neurodegenerative processes, such as Alzheimer's disease and multiple sclerosis.\n"
p5578
sg4
(lp5579
(dp5580
g7
I57
sg8
g9
sg10
I5
sg11
VPADI2
p5581
sg13
I1
sasg14
(lp5582
(dp5583
g7
I158
sg17
VC0699748
p5584
sg10
I12
sg11
Vpathogenesis
p5585
sg13
I1
sa(dp5586
g7
I266
sg17
VC0026769
p5587
sg10
I18
sg11
Vmultiple sclerosis
p5588
sg13
I2
sa(dp5589
g7
I111
sg17
VC0027769
p5590
sg10
I7
sg11
Vnervous
p5591
sg13
I1
sa(dp5592
g7
I242
sg17
VC1521724
p5593
sg10
I19
sg11
VAlzheimer's disease
p5594
sg13
I2
sasa(dp5595
g2
S'Giant cell tumor of bone (GCTB) is a locally aggressive primary bone tumor that contains numerous osteoclasts formed from marrow-derived precursors through receptor activator of nuclear factor K-B ligand (RANKL), an osteoclast differentiation factor expressed in neoplastic cells of GCTB.\n'
p5596
sg4
(lp5597
(dp5598
g7
I205
sg8
g9
sg10
I5
sg11
VRANKL
p5599
sg13
I1
sa(dp5600
g7
I156
sg8
VP01160
p5601
sg10
I47
sg11
Vreceptor activator of nuclear factor K-B ligand
p5602
sg13
I7
sasg14
(lp5603
(dp5604
g7
I45
sg17
VC0001807
p5605
sg10
I10
sg11
Vaggressive
p5606
sg13
I1
sa(dp5607
g7
I26
sg17
VC0206638
p5608
sg10
I4
sg11
VGCTB
p5609
sg13
I1
sa(dp5610
g7
I0
sg17
VC0206638
p5611
sg10
I24
sg11
VGiant cell tumor of bone
p5612
sg13
I5
sa(dp5613
g7
I64
sg17
VC0005967
p5614
sg10
I10
sg11
Vbone tumor
p5615
sg13
I2
sa(dp5616
g7
I26
sg17
VC0206638
p5617
sg10
I4
sg11
VGCTB
p5618
sg13
I1
sasa(dp5619
g2
S'Clinically, RANKL inhibition improves bone-metastasis free survival in patients with prostate cancer and disease-free survival in patients with breast cancer.\n'
p5620
sg4
(lp5621
(dp5622
g7
I12
sg8
g9
sg10
I5
sg11
VRANKL
p5623
sg13
I1
sasg14
(lp5624
(dp5625
g7
I43
sg17
VC0027627
p5626
sg10
I10
sg11
Vmetastasis
p5627
sg13
I1
sa(dp5628
g7
I144
sg17
VC0678222
p5629
sg10
I13
sg11
Vbreast cancer
p5630
sg13
I2
sa(dp5631
g7
I85
sg17
VC0600139
p5632
sg10
I15
sg11
Vprostate cancer
p5633
sg13
I2
sasa(dp5634
g2
S'VEGF-Flt-1 signaling induces osteoclastogenesis in OSCC through two possible ways: 1) VEGF produced from OSCC cells can directly stimulate the Flt-1 pathway in preosteoclasts to induce migration to future bone resorbing area and differentiation into osteoclasts, and 2) VEGF-Flt-1 signaling upregulates RANKL expression in OSCC cells, which indirectly leads to osteoclast differentiation.\n'
p5635
sg4
(lp5636
(dp5637
g7
I0
sg8
VP17948
p5638
sg10
I10
sg11
VVEGF-Flt-1
p5639
sg13
I1
sa(dp5640
g7
I5
sg8
VP17948
p5641
sg10
I5
sg11
VFlt-1
p5642
sg13
I1
sa(dp5643
g7
I303
sg8
g9
sg10
I5
sg11
VRANKL
p5644
sg13
I1
sa(dp5645
g7
I5
sg8
VP17948
p5646
sg10
I5
sg11
VFlt-1
p5647
sg13
I1
sasg14
(lp5648
sa(dp5649
g2
S'Thus, the transcriptional targets normally activated by RANKL that promote a proliferative response in luminal progenitors can contribute to the susceptibility of mammary epithelial cells to BRCA1-mutated breast cancers as a consequence of DDR-induced NF-kappaB.\n'
p5650
sg4
(lp5651
(dp5652
g7
I191
sg8
VP38398
p5653
sg10
I5
sg11
VBRCA1
p5654
sg13
I1
sa(dp5655
g7
I252
sg8
VP19838
p5656
sg10
I9
sg11
VNF-kappaB
p5657
sg13
I1
sa(dp5658
g7
I56
sg8
g9
sg10
I5
sg11
VRANKL
p5659
sg13
I1
sasg14
(lp5660
(dp5661
g7
I77
sg17
VC0334094
p5662
sg10
I13
sg11
Vproliferative
p5663
sg13
I1
sa(dp5664
g7
I205
sg17
VC0006142
p5665
sg10
I14
sg11
Vbreast cancers
p5666
sg13
I2
sasa(dp5667
g2
S'Our finding provides mechanistic support for a breast cancer chemoprevention trial with a RANKL inhibitor among high-risk premenopausal women with dense breasts.\n'
p5668
sg4
(lp5669
(dp5670
g7
I90
sg8
g9
sg10
I5
sg11
VRANKL
p5671
sg13
I1
sasg14
(lp5672
(dp5673
g7
I47
sg17
VC0678222
p5674
sg10
I13
sg11
Vbreast cancer
p5675
sg13
I2
sasa(dp5676
g2
S'The present study examined the effects of brucine on the OPG/RANKL/RANK signaling pathway for exploring the mechanism of brucine suppression of bone metastasis in breast cancer.\n'
p5677
sg4
(lp5678
(dp5679
g7
I61
sg8
g9
sg10
I5
sg11
VRANKL
p5680
sg13
I1
sa(dp5681
g7
I57
sg8
g9
sg10
I3
sg11
VOPG
p5682
sg13
I1
sasg14
(lp5683
(dp5684
g7
I129
sg17
VC0221103
p5685
sg10
I11
sg11
Vsuppression
p5686
sg13
I1
sa(dp5687
g7
I163
sg17
VC0678222
p5688
sg10
I13
sg11
Vbreast cancer
p5689
sg13
I2
sa(dp5690
g7
I144
sg17
VC0153690
p5691
sg10
I15
sg11
Vbone metastasis
p5692
sg13
I2
sasa(dp5693
g2
S'The goal of our study was to assess the prognostic impact of the necroptosis relative protein RIPK1 genetic polymorphism in ischemia-reperfusion injury and survival after hepatectomy in hepatocellular carcinoma (HCC) patients.\n'
p5694
sg4
(lp5695
(dp5696
g7
I94
sg8
g9
sg10
I5
sg11
VRIPK1
p5697
sg13
I1
sasg14
(lp5698
(dp5699
g7
I212
sg17
VC2239176
p5700
sg10
I3
sg11
VHCC
p5701
sg13
I1
sa(dp5702
g7
I186
sg17
VC2239176
p5703
sg10
I24
sg11
Vhepatocellular carcinoma
p5704
sg13
I2
sa(dp5705
g7
I124
sg17
VC0022116
p5706
sg10
I8
sg11
Vischemia
p5707
sg13
I1
sa(dp5708
g7
I65
sg17
VC2610958
p5709
sg10
I11
sg11
Vnecroptosis
p5710
sg13
I1
sasa(dp5711
g2
S'Here, we discuss our recent data on RIPK1 in liver injury and hepatocellular carcinoma development and put these into relation to previous experimental findings to underpin that it exerts opposing kinase-dependent and kinase independent functions in liver cells.\n'
p5712
sg4
(lp5713
(dp5714
g7
I36
sg8
g9
sg10
I5
sg11
VRIPK1
p5715
sg13
I1
sasg14
(lp5716
(dp5717
g7
I62
sg17
VC1512411
p5718
sg10
I24
sg11
Vhepatocellular carcinoma
p5719
sg13
I2
sasa(dp5720
g2
S'Moreover, loss of both Ripk1 and Traf2 in LPC not only resulted in caspase-8 hyperactivation but also impaired NF-KB activation, promoting the spontaneous development of hepatocellular carcinoma.\n'
p5721
sg4
(lp5722
(dp5723
g7
I23
sg8
g9
sg10
I5
sg11
VRipk1
p5724
sg13
I1
sa(dp5725
g7
I33
sg8
g9
sg10
I5
sg11
VTraf2
p5726
sg13
I1
sa(dp5727
g7
I67
sg8
VP39880
p5728
sg10
I9
sg11
Vcaspase-8
p5729
sg13
I1
sasg14
(lp5730
(dp5731
g7
I170
sg17
VC1512411
p5732
sg10
I24
sg11
Vhepatocellular carcinoma
p5733
sg13
I2
sa(dp5734
g7
I102
sg17
VC0684336
p5735
sg10
I8
sg11
Vimpaired
p5736
sg13
I1
sasa(dp5737
g2
S'The single-stranded DNA cytidine deaminases APOBEC3B, APOBEC3H haplotype I, and APOBEC3A can contribute to cancer through deamination of cytosine to form promutagenic uracil in genomic DNA.\n'
p5738
sg4
(lp5739
(dp5740
g7
I54
sg8
g9
sg10
I20
sg11
VAPOBEC3H haplotype I
p5741
sg13
I3
sa(dp5742
g7
I44
sg8
g9
sg10
I8
sg11
VAPOBEC3B
p5743
sg13
I1
sa(dp5744
g7
I80
sg8
VP31941
p5745
sg10
I8
sg11
VAPOBEC3A
p5746
sg13
I1
sa(dp5747
g7
I4
sg8
VP32320
p5748
sg10
I39
sg11
Vsingle-stranded DNA cytidine deaminases
p5749
sg13
I4
sasg14
(lp5750
(dp5751
g7
I107
sg17
VC0006826
p5752
sg10
I6
sg11
Vcancer
p5753
sg13
I1
sasa(dp5754
g2
S'To study this, we developed a method to purify full length APOBEC3B and characterized it in comparison to APOBEC3A and APOBEC3H on substrates relevant to cancer mutagenesis.\n'
p5755
sg4
(lp5756
(dp5757
g7
I106
sg8
VP31941
p5758
sg10
I8
sg11
VAPOBEC3A
p5759
sg13
I1
sa(dp5760
g7
I119
sg8
g9
sg10
I8
sg11
VAPOBEC3H
p5761
sg13
I1
sasg14
(lp5762
(dp5763
g7
I154
sg17
VC0006826
p5764
sg10
I6
sg11
Vcancer
p5765
sg13
I1
sasa(dp5766
g2
S'A3H-I also associates with clonal TCA/T-biased mutations in lung adenocarcinoma suggesting this enzyme makes broader contributions to cancer mutagenesis.\n'
p5767
sg4
(lp5768
sg14
(lp5769
(dp5770
g7
I134
sg17
VC0006826
p5771
sg10
I6
sg11
Vcancer
p5772
sg13
I1
sa(dp5773
g7
I60
sg17
VC0152013
p5774
sg10
I19
sg11
Vlung adenocarcinoma
p5775
sg13
I2
sasa(dp5776
g2
S"These studies combine to suggest that A3B and A3H-I, together, explain the bulk of 'APOBEC signature' mutations in cancer.\n"
p5777
sg4
(lp5778
(dp5779
g7
I38
sg8
g9
sg10
I3
sg11
VA3B
p5780
sg13
I1
sasg14
(lp5781
(dp5782
g7
I115
sg17
VC0006826
p5783
sg10
I6
sg11
Vcancer
p5784
sg13
I1
sasa(dp5785
g2
S'TCGA data analyses revealed that expression of APOBEC3D and APOBEC3H also correlates with CD3D across multiple cancer types.\n'
p5786
sg4
(lp5787
(dp5788
g7
I90
sg8
VP04234
p5789
sg10
I4
sg11
VCD3D
p5790
sg13
I1
sa(dp5791
g7
I60
sg8
g9
sg10
I8
sg11
VAPOBEC3H
p5792
sg13
I1
sa(dp5793
g7
I47
sg8
g9
sg10
I8
sg11
VAPOBEC3D
p5794
sg13
I1
sasg14
(lp5795
(dp5796
g7
I102
sg17
VC0346429
p5797
sg10
I15
sg11
Vmultiple cancer
p5798
sg13
I2
sasa(dp5799
g2
S'We found that the T allele of rs139293 in exon 2 of APOBEC3H was significantly associated with decreased risk of lung cancer (odds ratio = 0.76, 95% confidence interval: 0.63-0.91).\n'
p5800
sg4
(lp5801
(dp5802
g7
I52
sg8
g9
sg10
I8
sg11
VAPOBEC3H
p5803
sg13
I1
sasg14
(lp5804
(dp5805
g7
I113
sg17
VC0684249
p5806
sg10
I11
sg11
Vlung cancer
p5807
sg13
I2
sasa(dp5808
g2
S'These results indicate that genetic variants in APOBEC3H may contribute to lung cancer susceptibility in Chinese population.\n'
p5809
sg4
(lp5810
(dp5811
g7
I48
sg8
g9
sg10
I8
sg11
VAPOBEC3H
p5812
sg13
I1
sasg14
(lp5813
(dp5814
g7
I75
sg17
VC0684249
p5815
sg10
I11
sg11
Vlung cancer
p5816
sg13
I2
sasa(dp5817
g2
S'A 56-year-old male with cirrhosis presented with acute bleeding from cardiofundal gastroesophageal varices (GOV) and was treated with endoscopic cyanoacrylate glue.\n'
p5818
sg4
(lp5819
sg14
(lp5820
(dp5821
g7
I24
sg17
VC0023890
p5822
sg10
I9
sg11
Vcirrhosis
p5823
sg13
I1
sa(dp5824
g7
I82
sg17
VC2609266
p5825
sg10
I24
sg11
Vgastroesophageal varices
p5826
sg13
I2
sa(dp5827
g7
I108
sg17
VC2609266
p5828
sg10
I3
sg11
VGOV
p5829
sg13
I1
sa(dp5830
g7
I49
sg17
VC0333276
p5831
sg10
I14
sg11
Vacute bleeding
p5832
sg13
I2
sasa(dp5833
g2
S'At that time, he underwent retreatment with balloon-occluded retrograde obliteration (BRTO), with no recurrence at a follow-up of 14 months.Available treatments for bleeding GOV include methods to (a) directly obstruct the varices (endoscopic variceal ligation , sclerotherapy and cyanoacrylate glue, BRTO) or to (b) decrease portal pressure (surgical portacaval shunts; transportal intrahepatic portosystemic shunt).\n'
p5834
sg4
(lp5835
sg14
(lp5836
(dp5837
g7
I101
sg17
VC1458156
p5838
sg10
I10
sg11
Vrecurrence
p5839
sg13
I1
sa(dp5840
g7
I165
sg17
VC0019080
p5841
sg10
I8
sg11
Vbleeding
p5842
sg13
I1
sa(dp5843
g7
I52
sg17
VC0028778
p5844
sg10
I8
sg11
Voccluded
p5845
sg13
I1
sa(dp5846
g7
I223
sg17
VC0042345
p5847
sg10
I7
sg11
Vvarices
p5848
sg13
I1
sasa(dp5849
g2
S'Gastroesophageal varices (GOV) is a common complication in patients with portal hypertension.\n'
p5850
sg4
(lp5851
sg14
(lp5852
(dp5853
g7
I73
sg17
VC0020541
p5854
sg10
I19
sg11
Vportal hypertension
p5855
sg13
I2
sa(dp5856
g7
I0
sg17
VC2609266
p5857
sg10
I24
sg11
VGastroesophageal varices
p5858
sg13
I2
sa(dp5859
g7
I26
sg17
VC2609266
p5860
sg10
I3
sg11
VGOV
p5861
sg13
I1
sa(dp5862
g7
I43
sg17
VC0009566
p5863
sg10
I12
sg11
Vcomplication
p5864
sg13
I1
sasa(dp5865
g2
S'Gastric varices were categorized as GOV-1 (3%), GOV-2 (61%), and isolated gastric varices type 1 (36%) per Sarin classification.\n'
p5866
sg4
(lp5867
sg14
(lp5868
(dp5869
g7
I74
sg17
VC0017145
p5870
sg10
I15
sg11
Vgastric varices
p5871
sg13
I2
sa(dp5872
g7
I0
sg17
VC0017145
p5873
sg10
I15
sg11
VGastric varices
p5874
sg13
I2
sasa(dp5875
g2
S'Of the 9 children with associated gastroeosophageal varices (GOV), the severity of lesions was reduced in 8 of them.\n'
p5876
sg4
(lp5877
sg14
(lp5878
(dp5879
g7
I52
sg17
VC0042345
p5880
sg10
I7
sg11
Vvarices
p5881
sg13
I1
sasa(dp5882
g2
S'Here, we address the contribution of the EP3 receptor in dictating early outcomes after transient cerebral ischemia.\n'
p5883
sg4
(lp5884
(dp5885
g7
I41
sg8
VP43115
p5886
sg10
I12
sg11
VEP3 receptor
p5887
sg13
I2
sasg14
(lp5888
(dp5889
g7
I88
sg17
VC0917805
p5890
sg10
I27
sg11
Vtransient cerebral ischemia
p5891
sg13
I3
sasa(dp5892
g2
S"Following S1, separate scalp recordings in 4 patients in the epilepsy group displayed EP 3 times in the 'over 300 ms' time window.\n"
p5893
sg4
(lp5894
sg14
(lp5895
(dp5896
g7
I61
sg17
VC0014544
p5897
sg10
I8
sg11
Vepilepsy
p5898
sg13
I1
sasa(dp5899
g2
S'Conversely, patients with endometriosis had significantly shortened activated partial thromboplastin time (APTT) when compared to controls (1.08 +/- 0.06 and 1.12 +/- 0.19, respectively; P &lt; .01).\n'
p5900
sg4
(lp5901
(dp5902
g7
I86
sg8
VP13726
p5903
sg10
I14
sg11
Vthromboplastin
p5904
sg13
I1
sasg14
(lp5905
(dp5906
g7
I26
sg17
VC0014175
p5907
sg10
I13
sg11
Vendometriosis
p5908
sg13
I1
sasa(dp5909
g2
S'Activated partial thromboplastin time is shorter in women with endometriosis but still in the normal range.\n'
p5910
sg4
(lp5911
(dp5912
g7
I18
sg8
VP13726
p5913
sg10
I14
sg11
Vthromboplastin
p5914
sg13
I1
sasg14
(lp5915
(dp5916
g7
I63
sg17
VC0014175
p5917
sg10
I13
sg11
Vendometriosis
p5918
sg13
I1
sasa(dp5919
g2
S'Are the levels of total circulating cell-derived microparticles (cMPs) and circulating tissue factor-containing microparticles (cMP-TF) increased in patients with endometriosis?\n'
p5920
sg4
(lp5921
(dp5922
g7
I128
sg8
VP21941
p5923
sg10
I6
sg11
VcMP-TF
p5924
sg13
I1
sasg14
(lp5925
(dp5926
g7
I163
sg17
VC0014175
p5927
sg10
I13
sg11
Vendometriosis
p5928
sg13
I1
sasa(dp5929
g2
S'Increased expression of tissue factor (a transmembrane receptor for Factor VII/VIIa) in eutopic and ectopic endometrium from patients with endometriosis has been described.\n'
p5930
sg4
(lp5931
(dp5932
g7
I68
sg8
VP08709
p5933
sg10
I15
sg11
VFactor VII/VIIa
p5934
sg13
I2
sasg14
(lp5935
(dp5936
g7
I139
sg17
VC0014175
p5937
sg10
I13
sg11
Vendometriosis
p5938
sg13
I1
sasa(dp5939
g2
S'Tissue factor (TF) expression was elevated in endometriosis and TF concentrations were significantly elevated both in the supernatant of cultured primary endometriotic stromal cells and in peritoneal fluid from women with endometriosis.\n'
p5940
sg4
(lp5941
sg14
(lp5942
(dp5943
g7
I46
sg17
VC0014175
p5944
sg10
I13
sg11
Vendometriosis
p5945
sg13
I1
sa(dp5946
g7
I46
sg17
VC0014175
p5947
sg10
I13
sg11
Vendometriosis
p5948
sg13
I1
sasa(dp5949
g2
S'Here, we first determined the value of ALCAM as a marker of recurrence in endometrioid endometrial cancer by conducting a retrospective multicentre study of 174 primary tumours.\n'
p5950
sg4
(lp5951
(dp5952
g7
I39
sg8
g9
sg10
I5
sg11
VALCAM
p5953
sg13
I1
sasg14
(lp5954
(dp5955
g7
I169
sg17
VC0027651
p5956
sg10
I7
sg11
Vtumours
p5957
sg13
I1
sa(dp5958
g7
I60
sg17
VC1458156
p5959
sg10
I10
sg11
Vrecurrence
p5960
sg13
I1
sa(dp5961
g7
I87
sg17
VC0476089
p5962
sg10
I18
sg11
Vendometrial cancer
p5963
sg13
I2
sasa(dp5964
g2
S'Then we demonstrated in vitro a role for ALCAM in cell migration and invasion by using a loss-of-function model in two endometrial cancer cell lines.\n'
p5965
sg4
(lp5966
(dp5967
g7
I41
sg8
g9
sg10
I5
sg11
VALCAM
p5968
sg13
I1
sasg14
(lp5969
(dp5970
g7
I69
sg17
VC2699153
p5971
sg10
I8
sg11
Vinvasion
p5972
sg13
I1
sa(dp5973
g7
I119
sg17
VC0476089
p5974
sg10
I18
sg11
Vendometrial cancer
p5975
sg13
I2
sasa(dp5976
g2
S'In conclusion, our results highlight the potential of ALCAM as a recurrent biomarker in early-stage endometrioid endometrial cancer and point to ALCAM as an important molecule in endometrial cancer dissemination by regulating cell migration, invasion, and metastasis.\n'
p5977
sg4
(lp5978
(dp5979
g7
I54
sg8
g9
sg10
I5
sg11
VALCAM
p5980
sg13
I1
sasg14
(lp5981
(dp5982
g7
I113
sg17
VC0476089
p5983
sg10
I18
sg11
Vendometrial cancer
p5984
sg13
I2
sa(dp5985
g7
I242
sg17
VC2699153
p5986
sg10
I8
sg11
Vinvasion
p5987
sg13
I1
sa(dp5988
g7
I256
sg17
VC0027627
p5989
sg10
I10
sg11
Vmetastasis
p5990
sg13
I1
sa(dp5991
g7
I113
sg17
VC0476089
p5992
sg10
I18
sg11
Vendometrial cancer
p5993
sg13
I2
sasa(dp5994
g2
S'Overexpressing miR-378 in ovarian cancer cells altered expression of genes associated with angiogenesis (ALCAM, EHD1, ELK3, TLN1), apoptosis (RPN2, HIPK3), and cell cycle regulation (SWAP-70, LSM14A, RDX).\n'
p5995
sg4
(lp5996
(dp5997
g7
I148
sg8
g9
sg10
I5
sg11
VHIPK3
p5998
sg13
I1
sa(dp5999
g7
I15
sg8
g9
sg10
I7
sg11
VmiR-378
p6000
sg13
I1
sa(dp6001
g7
I105
sg8
g9
sg10
I5
sg11
VALCAM
p6002
sg13
I1
sa(dp6003
g7
I192
sg8
g9
sg10
I6
sg11
VLSM14A
p6004
sg13
I1
sa(dp6005
g7
I142
sg8
VP04844
p6006
sg10
I4
sg11
VRPN2
p6007
sg13
I1
sa(dp6008
g7
I200
sg8
VP35241
p6009
sg10
I3
sg11
VRDX
p6010
sg13
I1
sa(dp6011
g7
I183
sg8
g9
sg10
I7
sg11
VSWAP-70
p6012
sg13
I1
sa(dp6013
g7
I118
sg8
VP41970
p6014
sg10
I4
sg11
VELK3
p6015
sg13
I1
sa(dp6016
g7
I124
sg8
g9
sg10
I4
sg11
VTLN1
p6017
sg13
I1
sa(dp6018
g7
I112
sg8
g9
sg10
I4
sg11
VEHD1
p6019
sg13
I1
sasg14
(lp6020
(dp6021
g7
I26
sg17
VC1140680
p6022
sg10
I14
sg11
Vovarian cancer
p6023
sg13
I2
sasa(dp6024
g2
S'Activated leukocyte cell adhesion molecule (ALCAM) is expressed at the surface of epithelial ovarian cancer (EOC) cells and is released in a soluble form (sALCAM) by ADAM-17-mediated shedding.\n'
p6025
sg4
(lp6026
(dp6027
g7
I44
sg8
g9
sg10
I5
sg11
VALCAM
p6028
sg13
I1
sa(dp6029
g7
I166
sg8
VP78536
p6030
sg10
I7
sg11
VADAM-17
p6031
sg13
I1
sa(dp6032
g7
I0
sg8
g9
sg10
I42
sg11
VActivated leukocyte cell adhesion molecule
p6033
sg13
I5
sasg14
(lp6034
(dp6035
g7
I109
sg17
VC0677886
p6036
sg10
I3
sg11
VEOC
p6037
sg13
I1
sa(dp6038
g7
I25
sg17
VC0001511
p6039
sg10
I8
sg11
Vadhesion
p6040
sg13
I1
sa(dp6041
g7
I82
sg17
VC0677886
p6042
sg10
I25
sg11
Vepithelial ovarian cancer
p6043
sg13
I3
sasa(dp6044
g2
S'Here, we show that serum sALCAM levels were significantly higher in epithelial ovarian cancer (EOC) (p &lt; 0.005) than in controls.\n'
p6045
sg4
(lp6046
(dp6047
g7
I19
sg8
g9
sg10
I12
sg11
Vserum sALCAM
p6048
sg13
I2
sasg14
(lp6049
(dp6050
g7
I95
sg17
VC0677886
p6051
sg10
I3
sg11
VEOC
p6052
sg13
I1
sa(dp6053
g7
I68
sg17
VC0677886
p6054
sg10
I25
sg11
Vepithelial ovarian cancer
p6055
sg13
I3
sasa(dp6056
g2
S'To date there are no data on the role of ALCAM in cervical cancer available.\n'
p6057
sg4
(lp6058
(dp6059
g7
I41
sg8
g9
sg10
I5
sg11
VALCAM
p6060
sg13
I1
sasg14
(lp6061
(dp6062
g7
I50
sg17
VC0302592
p6063
sg10
I15
sg11
Vcervical cancer
p6064
sg13
I2
sasa(dp6065
g2
S'In this study, ALCAM expression was analysed by immunohistochemistry (IHC) in tissue samples of 233 patients with cervical cancer, among them 178 with complete follow-up information.\n'
p6066
sg4
(lp6067
sg14
(lp6068
(dp6069
g7
I114
sg17
VC0302592
p6070
sg10
I15
sg11
Vcervical cancer
p6071
sg13
I2
sasa(dp6072
g2
S'ALCAM overexpression was detected (immunoreactive score (IRS) 2-12) in 58.4% of the cervical cancer samples.\n'
p6073
sg4
(lp6074
(dp6075
g7
I0
sg8
g9
sg10
I5
sg11
VALCAM
p6076
sg13
I1
sasg14
(lp6077
(dp6078
g7
I84
sg17
VC0302592
p6079
sg10
I15
sg11
Vcervical cancer
p6080
sg13
I2
sasa(dp6081
g2
S'ESs and USTSs were further separated by CD166 staining, wherein increased expression was associated with ES (P &lt; 0.0001).\n'
p6082
sg4
(lp6083
(dp6084
g7
I40
sg8
g9
sg10
I5
sg11
VCD166
p6085
sg13
I1
sasg14
(lp6086
sa(dp6087
g2
S'USP22 is one of the important targets for inhibiting tumor growth, but clear illustration regarding its effects of telomerase, tumor cell immortality and retinoblastoma cell aging or apoptosis via suppressing TERT/P53 signal pathway remains to be elusive.\n'
p6088
sg4
(lp6089
(dp6090
g7
I209
sg8
g9
sg10
I4
sg11
VTERT
p6091
sg13
I1
sa(dp6092
g7
I0
sg8
g9
sg10
I5
sg11
VUSP22
p6093
sg13
I1
sa(dp6094
g7
I214
sg8
VP42771
p6095
sg10
I3
sg11
VP53
p6096
sg13
I1
sasg14
(lp6097
(dp6098
g7
I53
sg17
VC0027651
p6099
sg10
I5
sg11
Vtumor
p6100
sg13
I1
sa(dp6101
g7
I154
sg17
VC0035335
p6102
sg10
I14
sg11
Vretinoblastoma
p6103
sg13
I1
sa(dp6104
g7
I53
sg17
VC0598934
p6105
sg10
I12
sg11
Vtumor growth
p6106
sg13
I2
sasa(dp6107
g2
S'USP22 played an important role in retinoblastoma cell proliferation/aging and apoptosis.\n'
p6108
sg4
(lp6109
(dp6110
g7
I0
sg8
g9
sg10
I5
sg11
VUSP22
p6111
sg13
I1
sasg14
(lp6112
(dp6113
g7
I34
sg17
VC0035335
p6114
sg10
I14
sg11
Vretinoblastoma
p6115
sg13
I1
sa(dp6116
g7
I54
sg17
VC0334094
p6117
sg10
I13
sg11
Vproliferation
p6118
sg13
I1
sasa(dp6119
g2
S'The reduction of USP22 expression facilitated human retinoblastoma cell aging or apoptosis via suppressing TERT/P53 signal pathway.\n'
p6120
sg4
(lp6121
(dp6122
g7
I17
sg8
g9
sg10
I5
sg11
VUSP22
p6123
sg13
I1
sa(dp6124
g7
I112
sg8
VP42771
p6125
sg10
I3
sg11
VP53
p6126
sg13
I1
sa(dp6127
g7
I107
sg8
g9
sg10
I4
sg11
VTERT
p6128
sg13
I1
sasg14
(lp6129
(dp6130
g7
I52
sg17
VC0035335
p6131
sg10
I14
sg11
Vretinoblastoma
p6132
sg13
I1
sasa(dp6133
g2
S'USP22, thus, may work as a target for treating retinoblastoma.\n'
p6134
sg4
(lp6135
(dp6136
g7
I0
sg8
g9
sg10
I5
sg11
VUSP22
p6137
sg13
I1
sasg14
(lp6138
(dp6139
g7
I47
sg17
VC0035335
p6140
sg10
I14
sg11
Vretinoblastoma
p6141
sg13
I1
sasa(dp6142
g2
S'The present study aimed to investigate the correlation of ubiquitin-specific peptidase 22 (USP22) with acquired resistance to cisplatin in lung adenocarcinoma.\n'
p6143
sg4
(lp6144
(dp6145
g7
I58
sg8
VP62979
p6146
sg10
I31
sg11
Vubiquitin-specific peptidase 22
p6147
sg13
I3
sa(dp6148
g7
I91
sg8
g9
sg10
I5
sg11
VUSP22
p6149
sg13
I1
sasg14
(lp6150
(dp6151
g7
I139
sg17
VC0152013
p6152
sg10
I19
sg11
Vlung adenocarcinoma
p6153
sg13
I2
sasa(dp6154
g2
S'USP22 is a potential target in cisplatin-resistant lung adenocarcinoma and should be considered in future therapeutic practice.\n'
p6155
sg4
(lp6156
(dp6157
g7
I0
sg8
g9
sg10
I5
sg11
VUSP22
p6158
sg13
I1
sasg14
(lp6159
(dp6160
g7
I51
sg17
VC0152013
p6161
sg10
I19
sg11
Vlung adenocarcinoma
p6162
sg13
I2
sasa(dp6163
g2
S'Ubiquitin specific peptidase 22 (USP22), a putative cancer stem cell marker, is overexpressed in liver metastases of colorectal cancer (CRC).\n'
p6164
sg4
(lp6165
(dp6166
g7
I0
sg8
g9
sg10
I31
sg11
VUbiquitin specific peptidase 22
p6167
sg13
I4
sa(dp6168
g7
I33
sg8
g9
sg10
I5
sg11
VUSP22
p6169
sg13
I1
sasg14
(lp6170
(dp6171
g7
I52
sg17
VC0006826
p6172
sg10
I6
sg11
Vcancer
p6173
sg13
I1
sa(dp6174
g7
I97
sg17
VC0494165
p6175
sg10
I16
sg11
Vliver metastases
p6176
sg13
I2
sa(dp6177
g7
I136
sg17
VC1527249
p6178
sg10
I3
sg11
VCRC
p6179
sg13
I1
sa(dp6180
g7
I117
sg17
VC1527249
p6181
sg10
I17
sg11
Vcolorectal cancer
p6182
sg13
I2
sasa(dp6183
g2
S'In this study, we explored the functional role of USP22 in modulating c-Myc stability and its physiological relevance in breast cancer progression.\n'
p6184
sg4
(lp6185
(dp6186
g7
I70
sg8
VP12524
p6187
sg10
I5
sg11
Vc-Myc
p6188
sg13
I1
sa(dp6189
g7
I50
sg8
g9
sg10
I5
sg11
VUSP22
p6190
sg13
I1
sasg14
(lp6191
(dp6192
g7
I128
sg17
VC0178874
p6193
sg10
I18
sg11
Vcancer progression
p6194
sg13
I2
sasa(dp6195
g2
S'We found that USP22 promotes deubiquitination of c-Myc in several breast cancer cell lines, resulting in increased levels of c-Myc.\n'
p6196
sg4
(lp6197
(dp6198
g7
I49
sg8
VP12524
p6199
sg10
I5
sg11
Vc-Myc
p6200
sg13
I1
sa(dp6201
g7
I14
sg8
g9
sg10
I5
sg11
VUSP22
p6202
sg13
I1
sa(dp6203
g7
I49
sg8
VP12524
p6204
sg10
I5
sg11
Vc-Myc
p6205
sg13
I1
sasg14
(lp6206
(dp6207
g7
I66
sg17
VC0678222
p6208
sg10
I13
sg11
Vbreast cancer
p6209
sg13
I2
sasa(dp6210
g2
S'Furthermore, overexpression of USP22 stimulates breast cancer cell growth and colony formation, and increases c-Myc tumorigenic activity.\n'
p6211
sg4
(lp6212
(dp6213
g7
I110
sg8
VP12524
p6214
sg10
I5
sg11
Vc-Myc
p6215
sg13
I1
sa(dp6216
g7
I31
sg8
g9
sg10
I5
sg11
VUSP22
p6217
sg13
I1
sasg14
(lp6218
(dp6219
g7
I55
sg17
VC1516170
p6220
sg10
I18
sg11
Vcancer cell growth
p6221
sg13
I3
sasa(dp6222
g2
S'In conclusion, the present study reveals that USP22 in breast cancer cell lines increases c-Myc stability through c-Myc deubiquitination, which is closely correlated with breast cancer progression.\n'
p6223
sg4
(lp6224
(dp6225
g7
I90
sg8
VP12524
p6226
sg10
I5
sg11
Vc-Myc
p6227
sg13
I1
sa(dp6228
g7
I90
sg8
VP12524
p6229
sg10
I5
sg11
Vc-Myc
p6230
sg13
I1
sa(dp6231
g7
I46
sg8
g9
sg10
I5
sg11
VUSP22
p6232
sg13
I1
sasg14
(lp6233
(dp6234
g7
I178
sg17
VC0178874
p6235
sg10
I18
sg11
Vcancer progression
p6236
sg13
I2
sa(dp6237
g7
I55
sg17
VC0678222
p6238
sg10
I13
sg11
Vbreast cancer
p6239
sg13
I2
sasa(dp6240
g2
S'In this study, we investigated the effects of the deubiquitinating enzyme USP22 on the expression of the drug-resistance genes BMI1 and EZH2 in hepatocellular carcinoma (HCC) and on prognosis.\n'
p6241
sg4
(lp6242
(dp6243
g7
I136
sg8
g9
sg10
I4
sg11
VEZH2
p6244
sg13
I1
sa(dp6245
g7
I74
sg8
g9
sg10
I5
sg11
VUSP22
p6246
sg13
I1
sa(dp6247
g7
I127
sg8
VP35226
p6248
sg10
I4
sg11
VBMI1
p6249
sg13
I1
sasg14
(lp6250
(dp6251
g7
I170
sg17
VC2239176
p6252
sg10
I3
sg11
VHCC
p6253
sg13
I1
sa(dp6254
g7
I144
sg17
VC2239176
p6255
sg10
I24
sg11
Vhepatocellular carcinoma
p6256
sg13
I2
sasa(dp6257
g2
S'Ubiquitin-specific protease 22 (USP22) aberrance has been implicated in several malignancies; however, whether USP22 plays a role in anaplastic thyroid carcinoma (ATC) remains unclear.\n'
p6258
sg4
(lp6259
(dp6260
g7
I0
sg8
g9
sg10
I30
sg11
VUbiquitin-specific protease 22
p6261
sg13
I3
sa(dp6262
g7
I32
sg8
g9
sg10
I5
sg11
VUSP22
p6263
sg13
I1
sa(dp6264
g7
I32
sg8
g9
sg10
I5
sg11
VUSP22
p6265
sg13
I1
sasg14
(lp6266
(dp6267
g7
I80
sg17
VC0006826
p6268
sg10
I12
sg11
Vmalignancies
p6269
sg13
I1
sa(dp6270
g7
I163
sg17
VC0238461
p6271
sg10
I3
sg11
VATC
p6272
sg13
I1
sa(dp6273
g7
I133
sg17
VC0238461
p6274
sg10
I28
sg11
Vanaplastic thyroid carcinoma
p6275
sg13
I3
sasa(dp6276
g2
S'Curcumin might have therapeutic potential in breast cancer through regulating breast cancer-related genes, including SERPINE1, PGAP3, MAP3K1, MAPK1, GSTO2, VIM, SPARC, and FGF2.\n'
p6277
sg4
(lp6278
(dp6279
g7
I161
sg8
VP09486
p6280
sg10
I5
sg11
VSPARC
p6281
sg13
I1
sa(dp6282
g7
I142
sg8
VP28482
p6283
sg10
I5
sg11
VMAPK1
p6284
sg13
I1
sa(dp6285
g7
I134
sg8
g9
sg10
I6
sg11
VMAP3K1
p6286
sg13
I1
sa(dp6287
g7
I78
sg8
VP01893
p6288
sg10
I27
sg11
Vbreast cancer-related genes
p6289
sg13
I3
sa(dp6290
g7
I117
sg8
VP05121
p6291
sg10
I8
sg11
VSERPINE1
p6292
sg13
I1
sa(dp6293
g7
I149
sg8
g9
sg10
I5
sg11
VGSTO2
p6294
sg13
I1
sa(dp6295
g7
I127
sg8
g9
sg10
I5
sg11
VPGAP3
p6296
sg13
I1
sa(dp6297
g7
I172
sg8
g9
sg10
I4
sg11
VFGF2
p6298
sg13
I1
sasg14
(lp6299
(dp6300
g7
I45
sg17
VC0678222
p6301
sg10
I13
sg11
Vbreast cancer
p6302
sg13
I2
sa(dp6303
g7
I45
sg17
VC0678222
p6304
sg10
I13
sg11
Vbreast cancer
p6305
sg13
I2
sasa(dp6306
g2
S'Our data showed that the level of CENPE, BAG2, SOD2, GDI2, CORO1C, CFL1, DSTN, CALD1, PHGDH, PDHA1, AKR1B1, TST and TBCA proteins were significantly up-regulated in the fibroblasts co-cultured with ovarian cancer cells, whereas HSPB1, P4HB and VIM were significantly down-regulated.\n'
p6307
sg4
(lp6308
(dp6309
g7
I93
sg8
VP08559
p6310
sg10
I5
sg11
VPDHA1
p6311
sg13
I1
sa(dp6312
g7
I100
sg8
VP15121
p6313
sg10
I6
sg11
VAKR1B1
p6314
sg13
I1
sa(dp6315
g7
I79
sg8
g9
sg10
I5
sg11
VCALD1
p6316
sg13
I1
sa(dp6317
g7
I67
sg8
VP23528
p6318
sg10
I4
sg11
VCFL1
p6319
sg13
I1
sa(dp6320
g7
I59
sg8
g9
sg10
I6
sg11
VCORO1C
p6321
sg13
I1
sa(dp6322
g7
I116
sg8
g9
sg10
I13
sg11
VTBCA proteins
p6323
sg13
I2
sa(dp6324
g7
I73
sg8
VP60981
p6325
sg10
I4
sg11
VDSTN
p6326
sg13
I1
sa(dp6327
g7
I47
sg8
VP04179
p6328
sg10
I4
sg11
VSOD2
p6329
sg13
I1
sa(dp6330
g7
I53
sg8
VP50395
p6331
sg10
I4
sg11
VGDI2
p6332
sg13
I1
sa(dp6333
g7
I235
sg8
VP07237
p6334
sg10
I4
sg11
VP4HB
p6335
sg13
I1
sa(dp6336
g7
I108
sg8
g9
sg10
I3
sg11
VTST
p6337
sg13
I1
sa(dp6338
g7
I41
sg8
g9
sg10
I4
sg11
VBAG2
p6339
sg13
I1
sa(dp6340
g7
I86
sg8
g9
sg10
I5
sg11
VPHGDH
p6341
sg13
I1
sa(dp6342
g7
I34
sg8
g9
sg10
I5
sg11
VCENPE
p6343
sg13
I1
sasg14
(lp6344
(dp6345
g7
I198
sg17
VC1140680
p6346
sg10
I14
sg11
Vovarian cancer
p6347
sg13
I2
sasa(dp6348
g2
S'Previously, using systems biology approach and cancer signaling networks, we identified top-5 highly expressed and connected proteins (HSP90AB1, CSNK2B, TK1, YWHAB and VIM) in the invasive MDA-MB-231 breast cancer cell line.\n'
p6349
sg4
(lp6350
(dp6351
g7
I158
sg8
VP31946
p6352
sg10
I5
sg11
VYWHAB
p6353
sg13
I1
sa(dp6354
g7
I135
sg8
VP08238
p6355
sg10
I8
sg11
VHSP90AB1
p6356
sg13
I1
sa(dp6357
g7
I153
sg8
VP04183
p6358
sg10
I3
sg11
VTK1
p6359
sg13
I1
sa(dp6360
g7
I145
sg8
VP67870
p6361
sg10
I6
sg11
VCSNK2B
p6362
sg13
I1
sasg14
(lp6363
(dp6364
g7
I200
sg17
VC0678222
p6365
sg10
I13
sg11
Vbreast cancer
p6366
sg13
I2
sa(dp6367
g7
I47
sg17
VC0006826
p6368
sg10
I6
sg11
Vcancer
p6369
sg13
I1
sasa(dp6370
g2
S'MiR-208b was also upregulated in DCM patients, but not in heart failure patients due to ischemic heart disease or myocarditis.\n'
p6371
sg4
(lp6372
(dp6373
g7
I0
sg8
g9
sg10
I8
sg11
VMiR-208b
p6374
sg13
I1
sasg14
(lp6375
(dp6376
g7
I58
sg17
VC0018802
p6377
sg10
I13
sg11
Vheart failure
p6378
sg13
I2
sa(dp6379
g7
I114
sg17
VC0027059
p6380
sg10
I11
sg11
Vmyocarditis
p6381
sg13
I1
sa(dp6382
g7
I88
sg17
VC0151744
p6383
sg10
I22
sg11
Vischemic heart disease
p6384
sg13
I3
sasa(dp6385
g2
S'Elevated cAMP levels increased cell size and altered expression levels of cardiac genes and micro-RNAs associated with hypertrophic cardiomyopathy (HCM), including Myh6, Myh7, Myh7b, Tnni3, Anp, Bnp, Gata4, Mef2c, Mef2d, Nfatc1, miR208a, and miR208b.\n'
p6386
sg4
(lp6387
(dp6388
g7
I221
sg8
g9
sg10
I6
sg11
VNfatc1
p6389
sg13
I1
sa(dp6390
g7
I214
sg8
g9
sg10
I5
sg11
VMef2d
p6391
sg13
I1
sa(dp6392
g7
I176
sg8
g9
sg10
I5
sg11
VMyh7b
p6393
sg13
I1
sa(dp6394
g7
I183
sg8
VP19429
p6395
sg10
I5
sg11
VTnni3
p6396
sg13
I1
sa(dp6397
g7
I200
sg8
VP43694
p6398
sg10
I5
sg11
VGata4
p6399
sg13
I1
sa(dp6400
g7
I190
sg8
VP16066
p6401
sg10
I3
sg11
VAnp
p6402
sg13
I1
sa(dp6403
g7
I164
sg8
VP13533
p6404
sg10
I4
sg11
VMyh6
p6405
sg13
I1
sa(dp6406
g7
I195
sg8
VP16860
p6407
sg10
I3
sg11
VBnp
p6408
sg13
I1
sa(dp6409
g7
I207
sg8
g9
sg10
I5
sg11
VMef2c
p6410
sg13
I1
sasg14
(lp6411
(dp6412
g7
I119
sg17
VC0007194
p6413
sg10
I27
sg11
Vhypertrophic cardiomyopathy
p6414
sg13
I2
sa(dp6415
g7
I148
sg17
VC0007194
p6416
sg10
I3
sg11
VHCM
p6417
sg13
I1
sasa(dp6418
g2
S'The aim of this study was to determine whether miR-208, miR-208b, and miR-499 are expressed with MHC mRNA in human dilated cardiomyopathy (DCM), and whether these levels are related to left ventricular (LV) function and to clinical outcomes.\n'
p6419
sg4
(lp6420
(dp6421
g7
I56
sg8
g9
sg10
I8
sg11
VmiR-208b
p6422
sg13
I1
sa(dp6423
g7
I47
sg8
g9
sg10
I7
sg11
VmiR-208
p6424
sg13
I1
sa(dp6425
g7
I70
sg8
g9
sg10
I7
sg11
VmiR-499
p6426
sg13
I1
sa(dp6427
g7
I97
sg8
VP13747
p6428
sg10
I8
sg11
VMHC mRNA
p6429
sg13
I2
sasg14
(lp6430
(dp6431
g7
I139
sg17
VC0007193
p6432
sg10
I3
sg11
VDCM
p6433
sg13
I1
sa(dp6434
g7
I115
sg17
VC0007193
p6435
sg10
I22
sg11
Vdilated cardiomyopathy
p6436
sg13
I2
sasa(dp6437
g2
S'The goal of this study was to examine the long-term effects of maternal postpartum corticosterone (CORT, a model of postpartum depression) and concurrent FLX on hippocampal neurogenesis in male and female offspring.\n'
p6438
sg4
(lp6439
sg14
(lp6440
(dp6441
g7
I116
sg17
VC0221074
p6442
sg10
I21
sg11
Vpostpartum depression
p6443
sg13
I2
sasa(dp6444
g2
S'Using high-resolution magnetic resonance imaging (MRI), the present pilot study examined the relationship between morning serum cortisol, DHEA(S), and HCV in nineteen normal controls and eighteen unmedicated subjects with Major Depressive Disorder (MDD).\n'
p6445
sg4
(lp6446
sg14
(lp6447
(dp6448
g7
I222
sg17
VC1269683
p6449
sg10
I25
sg11
VMajor Depressive Disorder
p6450
sg13
I3
sa(dp6451
g7
I249
sg17
VC1269683
p6452
sg10
I3
sg11
VMDD
p6453
sg13
I1
sasa(dp6454
g2
S'To assess the association of neural development-related genes LIS1and TSNAX with bipolar disorder in a Chinese Han population.\n'
p6455
sg4
(lp6456
(dp6457
g7
I56
sg8
g9
sg10
I19
sg11
Vgenes LIS1and TSNAX
p6458
sg13
I3
sasg14
(lp6459
(dp6460
g7
I81
sg17
VC0005586
p6461
sg10
I16
sg11
Vbipolar disorder
p6462
sg13
I2
sasa(dp6463
g2
S'Our results indicated that LIS1 and TSNAX genes are not associated with susceptibility to bipolar I disorder in Chinese Han population.\n'
p6464
sg4
(lp6465
(dp6466
g7
I27
sg8
VP43034
p6467
sg10
I4
sg11
VLIS1
p6468
sg13
I1
sa(dp6469
g7
I36
sg8
g9
sg10
I11
sg11
VTSNAX genes
p6470
sg13
I2
sasg14
(lp6471
(dp6472
g7
I27
sg17
VC1843916
p6473
sg10
I4
sg11
VLIS1
p6474
sg13
I1
sa(dp6475
g7
I90
sg17
VC0853193
p6476
sg10
I18
sg11
Vbipolar I disorder
p6477
sg13
I3
sasa(dp6478
g2
S'The translin-associated factor X gene (TSNAX)/disrupted-in-schizophrenia-1 gene (DISC1) has been associated with psychiatric disorders, including schizophrenia, MDD and bipolar disorder.\n'
p6479
sg4
(lp6480
(dp6481
g7
I4
sg8
g9
sg10
I33
sg11
Vtranslin-associated factor X gene
p6482
sg13
I4
sa(dp6483
g7
I81
sg8
g9
sg10
I5
sg11
VDISC1
p6484
sg13
I1
sa(dp6485
g7
I39
sg8
g9
sg10
I5
sg11
VTSNAX
p6486
sg13
I1
sa(dp6487
g7
I45
sg8
g9
sg10
I34
sg11
V/disrupted-in-schizophrenia-1 gene
p6488
sg13
I2
sasg14
(lp6489
(dp6490
g7
I59
sg17
VC0036341
p6491
sg10
I13
sg11
Vschizophrenia
p6492
sg13
I1
sa(dp6493
g7
I59
sg17
VC0036341
p6494
sg10
I13
sg11
Vschizophrenia
p6495
sg13
I1
sa(dp6496
g7
I161
sg17
VC1269683
p6497
sg10
I3
sg11
VMDD
p6498
sg13
I1
sa(dp6499
g7
I113
sg17
VC0004936
p6500
sg10
I21
sg11
Vpsychiatric disorders
p6501
sg13
I2
sa(dp6502
g7
I169
sg17
VC0005586
p6503
sg10
I16
sg11
Vbipolar disorder
p6504
sg13
I2
sasa(dp6505
g2
S'Several investigations have reported that the translin-associated factor X gene (TSNAX)/disrupted-in-schizophrenia-1 gene (DISC1) was associated with major psychiatric disorders including schizophrenia, bipolar disorder (BP), and major depressive disorder (MDD).\n'
p6506
sg4
(lp6507
(dp6508
g7
I123
sg8
g9
sg10
I5
sg11
VDISC1
p6509
sg13
I1
sa(dp6510
g7
I87
sg8
g9
sg10
I34
sg11
V/disrupted-in-schizophrenia-1 gene
p6511
sg13
I2
sa(dp6512
g7
I46
sg8
g9
sg10
I33
sg11
Vtranslin-associated factor X gene
p6513
sg13
I4
sa(dp6514
g7
I81
sg8
g9
sg10
I5
sg11
VTSNAX
p6515
sg13
I1
sasg14
(lp6516
(dp6517
g7
I230
sg17
VC1269683
p6518
sg10
I25
sg11
Vmajor depressive disorder
p6519
sg13
I3
sa(dp6520
g7
I101
sg17
VC0036341
p6521
sg10
I13
sg11
Vschizophrenia
p6522
sg13
I1
sa(dp6523
g7
I257
sg17
VC1269683
p6524
sg10
I3
sg11
VMDD
p6525
sg13
I1
sa(dp6526
g7
I156
sg17
VC0004936
p6527
sg10
I21
sg11
Vpsychiatric disorders
p6528
sg13
I2
sa(dp6529
g7
I221
sg17
VC0005586
p6530
sg10
I2
sg11
VBP
p6531
sg13
I1
sa(dp6532
g7
I203
sg17
VC0005586
p6533
sg10
I16
sg11
Vbipolar disorder
p6534
sg13
I2
sa(dp6535
g7
I101
sg17
VC0036341
p6536
sg10
I13
sg11
Vschizophrenia
p6537
sg13
I1
sasa(dp6538
g2
S'The Translin-associated factor X/Disrupted in Schizophrenia 1 (TRAX/DISC) region was first implicated as a susceptibility locus for schizophrenia by analysis of a large Scottish family in which a t(1;11) translocation cosegregates with schizophrenia, bipolar disorder and recurrent major depression.\n'
p6539
sg4
(lp6540
(dp6541
g7
I4
sg8
g9
sg10
I28
sg11
VTranslin-associated factor X
p6542
sg13
I3
sa(dp6543
g7
I46
sg8
VP35462
p6544
sg10
I15
sg11
VSchizophrenia 1
p6545
sg13
I2
sa(dp6546
g7
I63
sg8
g9
sg10
I4
sg11
VTRAX
p6547
sg13
I1
sasg14
(lp6548
(dp6549
g7
I272
sg17
VC0154409
p6550
sg10
I26
sg11
Vrecurrent major depression
p6551
sg13
I3
sa(dp6552
g7
I132
sg17
VC0036341
p6553
sg10
I13
sg11
Vschizophrenia
p6554
sg13
I1
sa(dp6555
g7
I132
sg17
VC0036341
p6556
sg10
I13
sg11
Vschizophrenia
p6557
sg13
I1
sa(dp6558
g7
I204
sg17
VC0040715
p6559
sg10
I13
sg11
Vtranslocation
p6560
sg13
I1
sa(dp6561
g7
I251
sg17
VC0005586
p6562
sg10
I16
sg11
Vbipolar disorder
p6563
sg13
I2
sa(dp6564
g7
I46
sg17
VC0220702
p6565
sg10
I15
sg11
VSchizophrenia 1
p6566
sg13
I2
sasa(dp6567
g2
S'Two further regions, one in TRAX and the second in DISC1, showed weaker evidence for sex-specific associations of individual haplotypes with bipolar disorder in men and women respectively, P&lt;0.01.\n'
p6568
sg4
(lp6569
(dp6570
g7
I51
sg8
g9
sg10
I5
sg11
VDISC1
p6571
sg13
I1
sasg14
(lp6572
(dp6573
g7
I141
sg17
VC0005586
p6574
sg10
I16
sg11
Vbipolar disorder
p6575
sg13
I2
sasa(dp6576
g2
S'Compared with non-CKD controls, mice with CKD had downregulated expression of GSTA4 at the mRNA and protein levels, with concomitant increase in 4-HNE in arteries and veins.\n'
p6577
sg4
(lp6578
(dp6579
g7
I78
sg8
g9
sg10
I5
sg11
VGSTA4
p6580
sg13
I1
sasg14
(lp6581
sa(dp6582
g2
S'The data showed age-related upregulation of downstream signaling molecules such as mitogen activated protein kinases (MAPKs), activator protein-1 (AP-1), NF-KB, and COX-2 in a cell culture cell system.Taken together, the results of this study show that the formation of adducts between 4-HNE and Src activates inflammatory signaling pathways in the aged kidney, contributing to age-related nephropathy.\n'
p6583
sg4
(lp6584
(dp6585
g7
I165
sg8
VP35354
p6586
sg10
I5
sg11
VCOX-2
p6587
sg13
I1
sa(dp6588
g7
I296
sg8
VP12931
p6589
sg10
I3
sg11
VSrc
p6590
sg13
I1
sa(dp6591
g7
I147
sg8
VP01100
p6592
sg10
I4
sg11
VAP-1
p6593
sg13
I1
sa(dp6594
g7
I288
sg8
VP08246
p6595
sg10
I3
sg11
VHNE
p6596
sg13
I1
sa(dp6597
g7
I83
sg8
VP17980
p6598
sg10
I62
sg11
Vmitogen activated protein kinases (MAPKs), activator protein-1
p6599
sg13
I7
sasg14
(lp6600
(dp6601
g7
I390
sg17
VC0022658
p6602
sg10
I11
sg11
Vnephropathy
p6603
sg13
I1
sasa(dp6604
g2
S'Elevated plasma 4-HNE has been associated with renal failure, septic shock and cardiopulmonary bypass surgery.\n'
p6605
sg4
(lp6606
(dp6607
g7
I9
sg8
VP08246
p6608
sg10
I12
sg11
Vplasma 4-HNE
p6609
sg13
I2
sasg14
(lp6610
(dp6611
g7
I62
sg17
VC0036983
p6612
sg10
I12
sg11
Vseptic shock
p6613
sg13
I2
sa(dp6614
g7
I47
sg17
VC0035078
p6615
sg10
I13
sg11
Vrenal failure
p6616
sg13
I2
sasa(dp6617
g2
S'Additionally, the effect of PlGF (inhibition) on IOP was investigated, since aqueous PlGF is known to be upregulated in glaucoma patients.\n'
p6618
sg4
(lp6619
(dp6620
g7
I28
sg8
VP49763
p6621
sg10
I4
sg11
VPlGF
p6622
sg13
I1
sa(dp6623
g7
I28
sg8
VP49763
p6624
sg10
I4
sg11
VPlGF
p6625
sg13
I1
sasg14
(lp6626
(dp6627
g7
I120
sg17
VC0017601
p6628
sg10
I8
sg11
Vglaucoma
p6629
sg13
I1
sasa(dp6630
g2
S'Inhibition of PlGF also might open alternative perspectives as IOP-lowering strategy for glaucoma patients with increased aqueous PlGF levels.\n'
p6631
sg4
(lp6632
(dp6633
g7
I14
sg8
VP49763
p6634
sg10
I4
sg11
VPlGF
p6635
sg13
I1
sa(dp6636
g7
I14
sg8
VP49763
p6637
sg10
I4
sg11
VPlGF
p6638
sg13
I1
sasg14
(lp6639
(dp6640
g7
I89
sg17
VC0017601
p6641
sg10
I8
sg11
Vglaucoma
p6642
sg13
I1
sasa(dp6643
g2
S'To evaluate changes in the concentrations of placental growth factor (PlGF) and vascular endothelial growth factor-A (VEGF-A) in aqueous humor of patients with neovascular glaucoma (NVG) before and after an intravitreal injection of ranibizumab (IVR) and to determine the underlying correlation between the levels.\n'
p6644
sg4
(lp6645
(dp6646
g7
I80
sg8
g9
sg10
I36
sg11
Vvascular endothelial growth factor-A
p6647
sg13
I4
sa(dp6648
g7
I118
sg8
g9
sg10
I6
sg11
VVEGF-A
p6649
sg13
I1
sa(dp6650
g7
I70
sg8
VP49763
p6651
sg10
I4
sg11
VPlGF
p6652
sg13
I1
sa(dp6653
g7
I45
sg8
VP49763
p6654
sg10
I23
sg11
Vplacental growth factor
p6655
sg13
I3
sasg14
(lp6656
(dp6657
g7
I160
sg17
VC0017609
p6658
sg10
I20
sg11
Vneovascular glaucoma
p6659
sg13
I2
sa(dp6660
g7
I129
sg17
VC0595936
p6661
sg10
I13
sg11
Vaqueous humor
p6662
sg13
I2
sa(dp6663
g7
I182
sg17
VC0017609
p6664
sg10
I3
sg11
VNVG
p6665
sg13
I1
sasa(dp6666
g2
S'ELISA experiments showed that PlGF levels were significantly increased in aqueous humour of glaucoma patients and after VEGF treatment, which may indicate an important contribution of this growth factor to wound healing after trabeculectomy.\n'
p6667
sg4
(lp6668
(dp6669
g7
I30
sg8
VP49763
p6670
sg10
I4
sg11
VPlGF
p6671
sg13
I1
sasg14
(lp6672
(dp6673
g7
I92
sg17
VC0017601
p6674
sg10
I8
sg11
Vglaucoma
p6675
sg13
I1
sasa(dp6676
g2
S'Using a mouse model of glaucoma filtration surgery, we were able to show that intracameral injection of a previously characterized anti-PlGF antibody (ThromboGenics NV) significantly improved surgical outcome by increasing bleb survival and bleb area.\n'
p6677
sg4
(lp6678
(dp6679
g7
I131
sg8
VP49763
p6680
sg10
I18
sg11
Vanti-PlGF antibody
p6681
sg13
I2
sasg14
(lp6682
(dp6683
g7
I223
sg17
VC0005758
p6684
sg10
I4
sg11
Vbleb
p6685
sg13
I1
sa(dp6686
g7
I223
sg17
VC0005758
p6687
sg10
I4
sg11
Vbleb
p6688
sg13
I1
sa(dp6689
g7
I23
sg17
VC0017601
p6690
sg10
I8
sg11
Vglaucoma
p6691
sg13
I1
sasa(dp6692
g2
S'The 17-phenyl PGF(2Alfa) analogue bimatoprost (10a) is the most efficacious ocular hypotensive agent currently available for the treatment of glaucoma or ocular hypertension.\n'
p6693
sg4
(lp6694
sg14
(lp6695
(dp6696
g7
I154
sg17
VC0028840
p6697
sg10
I19
sg11
Vocular hypertension
p6698
sg13
I2
sa(dp6699
g7
I142
sg17
VC0017601
p6700
sg10
I8
sg11
Vglaucoma
p6701
sg13
I1
sa(dp6702
g7
I83
sg17
VC0857353
p6703
sg10
I11
sg11
Vhypotensive
p6704
sg13
I1
sasa(dp6705
g2
S'Latanoprost, a synthetic derivative of the natural prostaglandin F(2a) (PGF(2a)), is a powerful antiglaucoma agent with ocular hypotensive and neuroprotective effects.\n'
p6706
sg4
(lp6707
sg14
(lp6708
(dp6709
g7
I127
sg17
VC0857353
p6710
sg10
I11
sg11
Vhypotensive
p6711
sg13
I1
sasa(dp6712
g2
S'Endotoxaemia enhanced early VT occurs in a TLR-4 and ICAM-1 dependent fashion, and is potentiated by neutropenia.\n'
p6713
sg4
(lp6714
(dp6715
g7
I43
sg8
g9
sg10
I5
sg11
VTLR-4
p6716
sg13
I1
sa(dp6717
g7
I53
sg8
VP05362
p6718
sg10
I6
sg11
VICAM-1
p6719
sg13
I1
sasg14
(lp6720
sa(dp6721
g2
S'The aim of this study was to investigate the mannose-binding lectin 2 (MBL-2), interleukin (IL)-4, Toll-like receptor 4 (TLR-4), angiotensin converting enzyme (ACE), chemokine receptor 5 (CCR-5), and IL-1 receptor antagonist (RA) gene polymorphisms (GPs) in acute leukemias (ALs) and to evaluate their roles in febrile neutropenia (FN) resulting from chemotherapy.\n'
p6722
sg4
(lp6723
(dp6724
g7
I45
sg8
VP11226
p6725
sg10
I24
sg11
Vmannose-binding lectin 2
p6726
sg13
I3
sa(dp6727
g7
I71
sg8
VP11226
p6728
sg10
I5
sg11
VMBL-2
p6729
sg13
I1
sa(dp6730
g7
I200
sg8
g9
sg10
I13
sg11
VIL-1 receptor
p6731
sg13
I2
sa(dp6732
g7
I79
sg8
VP60568
p6733
sg10
I18
sg11
Vinterleukin (IL)-4
p6734
sg13
I2
sa(dp6735
g7
I129
sg8
VP12821
p6736
sg10
I29
sg11
Vangiotensin converting enzyme
p6737
sg13
I3
sa(dp6738
g7
I188
sg8
VP61073
p6739
sg10
I5
sg11
VCCR-5
p6740
sg13
I1
sa(dp6741
g7
I121
sg8
g9
sg10
I5
sg11
VTLR-4
p6742
sg13
I1
sa(dp6743
g7
I166
sg8
VP61073
p6744
sg10
I20
sg11
Vchemokine receptor 5
p6745
sg13
I3
sa(dp6746
g7
I99
sg8
g9
sg10
I20
sg11
VToll-like receptor 4
p6747
sg13
I3
sa(dp6748
g7
I160
sg8
VP12821
p6749
sg10
I3
sg11
VACE
p6750
sg13
I1
sasg14
(lp6751
(dp6752
g7
I332
sg17
VC0746883
p6753
sg10
I2
sg11
VFN
p6754
sg13
I1
sa(dp6755
g7
I250
sg17
VC0272302
p6756
sg10
I3
sg11
VGPs
p6757
sg13
I1
sa(dp6758
g7
I230
sg17
VC0272302
p6759
sg10
I18
sg11
Vgene polymorphisms
p6760
sg13
I2
sa(dp6761
g7
I258
sg17
VC0085669
p6762
sg10
I15
sg11
Vacute leukemias
p6763
sg13
I2
sa(dp6764
g7
I275
sg17
VC0002736
p6765
sg10
I3
sg11
VALs
p6766
sg13
I1
sa(dp6767
g7
I311
sg17
VC0746883
p6768
sg10
I19
sg11
Vfebrile neutropenia
p6769
sg13
I2
sasa(dp6770
g2
S'In a multivariate analysis, adjusted for occurrence of graft-versus-host-disease, Cytomegalovirus serostatus and duration of neutropenia, paired presence of the TLR4 1063A&gt;G and IFNG 874T&gt;A single nucleotide polymorphisms showed a trend towards increased susceptibility to invasive aspergillosis (p = 0.04).\n'
p6771
sg4
(lp6772
(dp6773
g7
I181
sg8
VP01579
p6774
sg10
I9
sg11
VIFNG 874T
p6775
sg13
I2
sasg14
(lp6776
(dp6777
g7
I55
sg17
VC0018133
p6778
sg10
I25
sg11
Vgraft-versus-host-disease
p6779
sg13
I1
sa(dp6780
g7
I279
sg17
VC0238013
p6781
sg10
I22
sg11
Vinvasive aspergillosis
p6782
sg13
I2
sasa(dp6783
g2
S'Four SNPs in the TLR4 gene (rs10759931, rs11536889, rs1927911 and rs6478317) were associated with an increased risk of developing chemotherapy-induced neutropenia, each sustaining correction for multiple testing.\n'
p6784
sg4
(lp6785
sg14
(lp6786
(dp6787
g7
I130
sg17
VC1827687
p6788
sg10
I32
sg11
Vchemotherapy-induced neutropenia
p6789
sg13
I2
sasa(dp6790
g2
S'The rs1064395 single nucleotide polymorphism, within the gene encoding neurocan (NCAN), is reported to be associated with schizophrenia in European populations and may influence brain structure in patients with schizophrenia.\n'
p6791
sg4
(lp6792
(dp6793
g7
I81
sg8
g9
sg10
I4
sg11
VNCAN
p6794
sg13
I1
sa(dp6795
g7
I57
sg8
g9
sg10
I22
sg11
Vgene encoding neurocan
p6796
sg13
I3
sasg14
(lp6797
(dp6798
g7
I122
sg17
VC0036341
p6799
sg10
I13
sg11
Vschizophrenia
p6800
sg13
I1
sa(dp6801
g7
I122
sg17
VC0036341
p6802
sg10
I13
sg11
Vschizophrenia
p6803
sg13
I1
sasa(dp6804
g2
S'In this study, we aimed to explore whether NCAN rs1064395 confers some risk for schizophrenia and cognitive dysfunction in Han Chinese.\n'
p6805
sg4
(lp6806
(dp6807
g7
I43
sg8
g9
sg10
I14
sg11
VNCAN rs1064395
p6808
sg13
I2
sasg14
(lp6809
(dp6810
g7
I80
sg17
VC0036341
p6811
sg10
I13
sg11
Vschizophrenia
p6812
sg13
I1
sa(dp6813
g7
I98
sg17
VC0338656
p6814
sg10
I21
sg11
Vcognitive dysfunction
p6815
sg13
I2
sasa(dp6816
g2
S'The A allele of the single nucleotide polymorphism (SNP) rs1064395 in the NCAN gene has recently been identified as a susceptibility factor for bipolar disorder and schizophrenia.\n'
p6817
sg4
(lp6818
(dp6819
g7
I74
sg8
g9
sg10
I9
sg11
VNCAN gene
p6820
sg13
I2
sasg14
(lp6821
(dp6822
g7
I144
sg17
VC0005586
p6823
sg10
I16
sg11
Vbipolar disorder
p6824
sg13
I2
sa(dp6825
g7
I165
sg17
VC0036341
p6826
sg10
I13
sg11
Vschizophrenia
p6827
sg13
I1
sasa(dp6828
g2
S'Recently, it was shown that some CSPGs members like aggrecan, versican, and neurocan were strongly involved in brain disorders like bipolar disorder (BD), schizophrenia, and ADHD.\n'
p6829
sg4
(lp6830
(dp6831
g7
I52
sg8
VP16112
p6832
sg10
I8
sg11
Vaggrecan
p6833
sg13
I1
sa(dp6834
g7
I174
sg8
g9
sg10
I4
sg11
VADHD
p6835
sg13
I1
sasg14
(lp6836
(dp6837
g7
I174
sg17
VC1263846
p6838
sg10
I4
sg11
VADHD
p6839
sg13
I1
sa(dp6840
g7
I111
sg17
VC0006111
p6841
sg10
I15
sg11
Vbrain disorders
p6842
sg13
I2
sa(dp6843
g7
I132
sg17
VC0005586
p6844
sg10
I16
sg11
Vbipolar disorder
p6845
sg13
I2
sa(dp6846
g7
I150
sg17
VC0005586
p6847
sg10
I2
sg11
VBD
p6848
sg13
I1
sa(dp6849
g7
I155
sg17
VC0036341
p6850
sg10
I13
sg11
Vschizophrenia
p6851
sg13
I1
sasa(dp6852
g2
S'Recent studies have provided strong evidence that variation in the gene neurocan (NCAN, rs1064395) is a common risk factor for bipolar disorder (BD) and schizophrenia.\n'
p6853
sg4
(lp6854
(dp6855
g7
I82
sg8
g9
sg10
I4
sg11
VNCAN
p6856
sg13
I1
sa(dp6857
g7
I72
sg8
g9
sg10
I8
sg11
Vneurocan
p6858
sg13
I1
sasg14
(lp6859
(dp6860
g7
I145
sg17
VC0005586
p6861
sg10
I2
sg11
VBD
p6862
sg13
I1
sa(dp6863
g7
I153
sg17
VC0036341
p6864
sg10
I13
sg11
Vschizophrenia
p6865
sg13
I1
sa(dp6866
g7
I127
sg17
VC0005586
p6867
sg10
I16
sg11
Vbipolar disorder
p6868
sg13
I2
sasa(dp6869
g2
S'In this work, authors investigated the association between previously confirmed bipolar disorder genetic risk factor- neurocan with schizophrenia in a population sample of Bosnia and Herzegovina.\n'
p6870
sg4
(lp6871
sg14
(lp6872
(dp6873
g7
I132
sg17
VC0036341
p6874
sg10
I13
sg11
Vschizophrenia
p6875
sg13
I1
sa(dp6876
g7
I80
sg17
VC0005586
p6877
sg10
I16
sg11
Vbipolar disorder
p6878
sg13
I2
sasa(dp6879
g2
S'A case-control analysis of common genetic polymorphism within neurocan gene and schizophrenia status in a consecutively sampled patient cohort have been done using Fisher-exact test with odds-ratio calculation.\n'
p6880
sg4
(lp6881
sg14
(lp6882
(dp6883
g7
I80
sg17
VC0036341
p6884
sg10
I13
sg11
Vschizophrenia
p6885
sg13
I1
sasa(dp6886
g2
S'Our data suggest that genetic variation in NCAN is a common risk factor for BD and schizophrenia.\n'
p6887
sg4
(lp6888
(dp6889
g7
I43
sg8
g9
sg10
I4
sg11
VNCAN
p6890
sg13
I1
sasg14
(lp6891
(dp6892
g7
I83
sg17
VC0036341
p6893
sg10
I13
sg11
Vschizophrenia
p6894
sg13
I1
sasa(dp6895
g2
S'In contrast, studies have associated primary biliary cirrhosis and primary sclerosing cholangitis with genes encoding major histocompatibility complex proteins and identified loci associated with microbial sensing and immune regulatory pathways outside this region, such as genes encoding IL12, STAT4, IRF5, IL2 and its receptor (IL2R), CD28, and CD80.\n'
p6896
sg4
(lp6897
(dp6898
g7
I308
sg8
VP01589
p6899
sg10
I20
sg11
VIL2 and its receptor
p6900
sg13
I4
sa(dp6901
g7
I330
sg8
VP01589
p6902
sg10
I4
sg11
VIL2R
p6903
sg13
I1
sa(dp6904
g7
I302
sg8
g9
sg10
I4
sg11
VIRF5
p6905
sg13
I1
sa(dp6906
g7
I118
sg8
VP18464
p6907
sg10
I41
sg11
Vmajor histocompatibility complex proteins
p6908
sg13
I4
sa(dp6909
g7
I347
sg8
VP33681
p6910
sg10
I4
sg11
VCD80
p6911
sg13
I1
sa(dp6912
g7
I295
sg8
g9
sg10
I5
sg11
VSTAT4
p6913
sg13
I1
sa(dp6914
g7
I337
sg8
VP33681
p6915
sg10
I4
sg11
VCD28
p6916
sg13
I1
sasg14
(lp6917
(dp6918
g7
I37
sg17
VC0008312
p6919
sg10
I25
sg11
Vprimary biliary cirrhosis
p6920
sg13
I3
sa(dp6921
g7
I67
sg17
VC0566602
p6922
sg10
I30
sg11
Vprimary sclerosing cholangitis
p6923
sg13
I3
sasa(dp6924
g2
S'In this condition, 8CR inhibited edema and myonecrosis induced by the sPLA2 activity of Crotalus durissus terrificus in a dose-dependent manner by decreasing interleukin-1Beta (IL-1Beta), tumor necrosis factor Alfa (TNF-Alfa), prostaglandin E2 (PGE2), and lipid peroxidation.\n'
p6925
sg4
(lp6926
(dp6927
g7
I216
sg8
VP01375
p6928
sg10
I8
sg11
VTNF-Alfa
p6929
sg13
I1
sa(dp6930
g7
I177
sg8
VP01584
p6931
sg10
I8
sg11
VIL-1Beta
p6932
sg13
I1
sa(dp6933
g7
I158
sg8
VP01584
p6934
sg10
I17
sg11
Vinterleukin-1Beta
p6935
sg13
I1
sa(dp6936
g7
I188
sg8
VP01375
p6937
sg10
I26
sg11
Vtumor necrosis factor Alfa
p6938
sg13
I4
sa(dp6939
g7
I70
sg8
VP14555
p6940
sg10
I5
sg11
VsPLA2
p6941
sg13
I1
sasg14
(lp6942
(dp6943
g7
I8
sg17
VC0012634
p6944
sg10
I9
sg11
Vcondition
p6945
sg13
I1
sa(dp6946
g7
I43
sg17
VC0235957
p6947
sg10
I11
sg11
Vmyonecrosis
p6948
sg13
I1
sa(dp6949
g7
I33
sg17
VC0013604
p6950
sg10
I5
sg11
Vedema
p6951
sg13
I1
sa(dp6952
g7
I188
sg17
VC0333516
p6953
sg10
I14
sg11
Vtumor necrosis
p6954
sg13
I2
sasa(dp6955
g2
S'In addition, it was shown that Crotalus durissus terrificus sPLA2 increases cell oxidative stress during edema and myonecrosis, and the antioxidant properties of the polyphenolic compound may be significant in mitigating the pharmacological effect induced by sPLA2 and other snake venom toxins.\n'
p6956
sg4
(lp6957
(dp6958
g7
I60
sg8
VP14555
p6959
sg10
I5
sg11
VsPLA2
p6960
sg13
I1
sasg14
(lp6961
(dp6962
g7
I115
sg17
VC0235957
p6963
sg10
I11
sg11
Vmyonecrosis
p6964
sg13
I1
sa(dp6965
g7
I105
sg17
VC0013604
p6966
sg10
I5
sg11
Vedema
p6967
sg13
I1
sa(dp6968
g7
I81
sg17
VC0242606
p6969
sg10
I16
sg11
Voxidative stress
p6970
sg13
I2
sasa(dp6971
g2
S"Therefore, it's necessary to express CssPLA2 in water-soluble form and determine whether the enzymatic activity of CssPLA2 or cell signalling pathways is involved in liver fibrosis caused by clonorchiasis.\n"
p6972
sg4
(lp6973
sg14
(lp6974
(dp6975
g7
I191
sg17
VC0009021
p6976
sg10
I13
sg11
Vclonorchiasis
p6977
sg13
I1
sa(dp6978
g7
I166
sg17
VC0239946
p6979
sg10
I14
sg11
Vliver fibrosis
p6980
sg13
I2
sasa(dp6981
g2
S'We sought to investigate if mast cell activation and increases in secretory sPLA2s are associated with an increase in PAF and occurrence of dengue haemorrhagic fever (DHF).\n'
p6982
sg4
(lp6983
(dp6984
g7
I66
sg8
g9
sg10
I16
sg11
Vsecretory sPLA2s
p6985
sg13
I2
sasg14
(lp6986
(dp6987
g7
I167
sg17
VC0019100
p6988
sg10
I3
sg11
VDHF
p6989
sg13
I1
sa(dp6990
g7
I140
sg17
VC0019100
p6991
sg10
I25
sg11
Vdengue haemorrhagic fever
p6992
sg13
I3
sa(dp6993
g7
I118
sg17
VC0235480
p6994
sg10
I3
sg11
VPAF
p6995
sg13
I1
sasa(dp6996
g2
S'The changes in the levels of mast cell tryptase, PAF and the activity of sPLA2 were determined throughout the course of illness in 13 adult patients with DHF, and 30 patients with dengue fever (DF).\n'
p6997
sg4
(lp6998
(dp6999
g7
I49
sg8
g9
sg10
I3
sg11
VPAF
p7000
sg13
I1
sa(dp7001
g7
I73
sg8
VP14555
p7002
sg10
I5
sg11
VsPLA2
p7003
sg13
I1
sa(dp7004
g7
I29
sg8
VP15157
p7005
sg10
I18
sg11
Vmast cell tryptase
p7006
sg13
I3
sasg14
(lp7007
(dp7008
g7
I49
sg17
VC0235480
p7009
sg10
I3
sg11
VPAF
p7010
sg13
I1
sa(dp7011
g7
I180
sg17
VC0011311
p7012
sg10
I12
sg11
Vdengue fever
p7013
sg13
I2
sa(dp7014
g7
I110
sg17
VC0242656
p7015
sg10
I17
sg11
Vcourse of illness
p7016
sg13
I3
sa(dp7017
g7
I194
sg17
VC0011311
p7018
sg10
I2
sg11
VDF
p7019
sg13
I1
sasa(dp7020
g2
S'The difference in serum levels of PLA2G2A was analyzed among chronic hepatitis B (CHB), LC, and HCC patients.\n'
p7021
sg4
(lp7022
(dp7023
g7
I34
sg8
VP14555
p7024
sg10
I7
sg11
VPLA2G2A
p7025
sg13
I1
sasg14
(lp7026
(dp7027
g7
I82
sg17
VC0151517
p7028
sg10
I3
sg11
VCHB
p7029
sg13
I1
sa(dp7030
g7
I61
sg17
VC0524909
p7031
sg10
I19
sg11
Vchronic hepatitis B
p7032
sg13
I3
sa(dp7033
g7
I96
sg17
VC2239176
p7034
sg10
I3
sg11
VHCC
p7035
sg13
I1
sasa(dp7036
g2
S'We have previously shown that secreted phospholipases A2 (sPLA2s) from animal venoms inhibit the in vitro development of Plasmodium falciparum, the agent of malaria.\n'
p7037
sg4
(lp7038
(dp7039
g7
I58
sg8
g9
sg10
I6
sg11
VsPLA2s
p7040
sg13
I1
sa(dp7041
g7
I39
sg8
VP04054
p7042
sg10
I17
sg11
Vphospholipases A2
p7043
sg13
I2
sasg14
(lp7044
(dp7045
g7
I157
sg17
VC0024530
p7046
sg10
I7
sg11
Vmalaria
p7047
sg13
I1
sasa(dp7048
g2
S'In addition, the inflammatory-type human group IIA (hGIIA) sPLA2 circulates at high levels in the serum of malaria patients.\n'
p7049
sg4
(lp7050
(dp7051
g7
I59
sg8
VP14555
p7052
sg10
I5
sg11
VsPLA2
p7053
sg13
I1
sasg14
(lp7054
(dp7055
g7
I107
sg17
VC0024530
p7056
sg10
I7
sg11
Vmalaria
p7057
sg13
I1
sasa(dp7058
g2
S'Together, our findings indicate that 4 human sPLA2s are active against P. falciparum in vitro and pave the way to future investigations on their in vivo contribution in malaria pathophysiology.\n'
p7059
sg4
(lp7060
sg14
(lp7061
(dp7062
g7
I169
sg17
VC0024530
p7063
sg10
I7
sg11
Vmalaria
p7064
sg13
I1
sasa(dp7065
g2
S"Two subtypes of phospholipases A2 (PLA2s) with the ability to induce myonecrosis, 'Asp49' and 'Lys49' myotoxins, often coexist in viperid snake venoms.\n"
p7066
sg4
(lp7067
(dp7068
g7
I16
sg8
VP04054
p7069
sg10
I17
sg11
Vphospholipases A2
p7070
sg13
I2
sa(dp7071
g7
I35
sg8
VP04054
p7072
sg10
I5
sg11
VPLA2s
p7073
sg13
I1
sasg14
(lp7074
(dp7075
g7
I69
sg17
VC0235957
p7076
sg10
I11
sg11
Vmyonecrosis
p7077
sg13
I1
sasa(dp7078
g2
S'In order to assess the contribution of the IL-18 to susceptibility to Chronic Chagas Disease, we investigated the association between a single nucleotide polymorphism (SNP) located in the IL-18 gene with the risk of developing Chagas cardiomyopathy.\n'
p7079
sg4
(lp7080
sg14
(lp7081
(dp7082
g7
I227
sg17
VC0007930
p7083
sg10
I21
sg11
VChagas cardiomyopathy
p7084
sg13
I2
sa(dp7085
g7
I78
sg17
VC0041234
p7086
sg10
I14
sg11
VChagas Disease
p7087
sg13
I2
sasa(dp7088
g2
S'We analyzed the rs2043055 marker in the IL18 gene in a cohort of Chagas disease cardiomyopathy patients (n=849) and asymptomatic subjects (n=202).\n'
p7089
sg4
(lp7090
(dp7091
g7
I40
sg8
g9
sg10
I9
sg11
VIL18 gene
p7092
sg13
I2
sasg14
(lp7093
(dp7094
g7
I80
sg17
VC0878544
p7095
sg10
I14
sg11
Vcardiomyopathy
p7096
sg13
I1
sa(dp7097
g7
I65
sg17
VC0041234
p7098
sg10
I14
sg11
VChagas disease
p7099
sg13
I2
sasa(dp7100
g2
S'To describe a peculiar flecked-retina phenotype in a young female affected by early-onset retinal dystrophy due to a heterozygous mutation in the cone-rod transcription factor CRX gene.\n'
p7101
sg4
(lp7102
(dp7103
g7
I176
sg8
g9
sg10
I8
sg11
VCRX gene
p7104
sg13
I2
sasg14
(lp7105
(dp7106
g7
I90
sg17
VC0854723
p7107
sg10
I17
sg11
Vretinal dystrophy
p7108
sg13
I2
sasa(dp7109
g2
S'We identified a novel early-onset retinal dystrophy-related heterozygous CRX mutation associated with early and severe rod and cone dysfunction and regressive flecked-retina appearance on ophthalmoscopy.\n'
p7110
sg4
(lp7111
(dp7112
g7
I73
sg8
g9
sg10
I12
sg11
VCRX mutation
p7113
sg13
I2
sasg14
(lp7114
(dp7115
g7
I34
sg17
VC0854723
p7116
sg10
I17
sg11
Vretinal dystrophy
p7117
sg13
I2
sasa(dp7118
g2
S'We found that retinal disease-related genes were efficiently detected in CRX-transduced cells, most of which are crucial to photoreceptor functions.\n'
p7119
sg4
(lp7120
sg14
(lp7121
(dp7122
g7
I14
sg17
VC0035309
p7123
sg10
I15
sg11
Vretinal disease
p7124
sg13
I2
sasa(dp7125
g2
S'Moreover, by modification of the culture conditions including additional transduction of RAX1 and NEUROD1, we found a greater variety of retinal disease-related genes than that observed in CRX-transduced PBMCs.\n'
p7126
sg4
(lp7127
(dp7128
g7
I98
sg8
g9
sg10
I7
sg11
VNEUROD1
p7129
sg13
I1
sasg14
(lp7130
(dp7131
g7
I137
sg17
VC0035309
p7132
sg10
I15
sg11
Vretinal disease
p7133
sg13
I2
sasa(dp7134
g2
S'These data suggest that CRX acts as a master control gene for reprogramming PBMCs into photoreceptor-like cells and that our induced photoreceptor-like cells might contribute to individualized drug screening and disease modeling of inherited retinal degeneration.\n'
p7135
sg4
(lp7136
(dp7137
g7
I24
sg8
g9
sg10
I3
sg11
VCRX
p7138
sg13
I1
sasg14
(lp7139
(dp7140
g7
I242
sg17
VC0035304
p7141
sg10
I20
sg11
Vretinal degeneration
p7142
sg13
I2
sasa(dp7143
g2
S'These results indicated that rs11134527 in pri-miR-218-2 and rs531564 in pri-miR-124-1 could be associated with CIN and cervical cancer in the Chinese Han population.\n'
p7144
sg4
(lp7145
(dp7146
g7
I73
sg8
VP13489
p7147
sg10
I13
sg11
Vpri-miR-124-1
p7148
sg13
I1
sa(dp7149
g7
I43
sg8
VP13489
p7150
sg10
I13
sg11
Vpri-miR-218-2
p7151
sg13
I1
sasg14
(lp7152
(dp7153
g7
I120
sg17
VC0302592
p7154
sg10
I15
sg11
Vcervical cancer
p7155
sg13
I2
sa(dp7156
g7
I112
sg17
VC0206708
p7157
sg10
I3
sg11
VCIN
p7158
sg13
I1
sasa(dp7159
g2
S'Finally, anisomycin was the highest correlation with DEGs.MiR-124a might be involved in the pathogenesis of hypertension via targeting Ebf3 and Rgs7 bp, which possibly represent a novel and effective strategy for treatment of hypertension.\n'
p7160
sg4
(lp7161
(dp7162
g7
I135
sg8
g9
sg10
I4
sg11
VEbf3
p7163
sg13
I1
sa(dp7164
g7
I53
sg8
g9
sg10
I13
sg11
VDEGs.MiR-124a
p7165
sg13
I1
sa(dp7166
g7
I144
sg8
VP49802
p7167
sg10
I4
sg11
VRgs7
p7168
sg13
I1
sasg14
(lp7169
(dp7170
g7
I92
sg17
VC0699748
p7171
sg10
I12
sg11
Vpathogenesis
p7172
sg13
I1
sa(dp7173
g7
I108
sg17
VC0020538
p7174
sg10
I12
sg11
Vhypertension
p7175
sg13
I1
sa(dp7176
g7
I108
sg17
VC0020538
p7177
sg10
I12
sg11
Vhypertension
p7178
sg13
I1
sasa(dp7179
g2
S'The serum miR-124 expression levels in 114 osteosarcoma patients, 40 periostitis patients and 50 normal controls were detected using real-time quantitative polymerase chain reaction (RT-qPCR).\n'
p7180
sg4
(lp7181
(dp7182
g7
I10
sg8
g9
sg10
I7
sg11
VmiR-124
p7183
sg13
I1
sasg14
(lp7184
(dp7185
g7
I43
sg17
VC0029463
p7186
sg10
I12
sg11
Vosteosarcoma
p7187
sg13
I1
sa(dp7188
g7
I69
sg17
VC0031111
p7189
sg10
I11
sg11
Vperiostitis
p7190
sg13
I1
sasa(dp7191
g2
S'The level of serum miR-124 was remarkably decreased in osteosarcoma patients when compared to periostitis patients and healthy controls (both p&lt; 0.05).\n'
p7192
sg4
(lp7193
(dp7194
g7
I13
sg8
g9
sg10
I13
sg11
Vserum miR-124
p7195
sg13
I2
sasg14
(lp7196
(dp7197
g7
I94
sg17
VC0031111
p7198
sg10
I11
sg11
Vperiostitis
p7199
sg13
I1
sa(dp7200
g7
I55
sg17
VC0029463
p7201
sg10
I12
sg11
Vosteosarcoma
p7202
sg13
I1
sasa(dp7203
g2
S'Moreover, the Kaplan-Meier method with log-rank test showed that osteosarcoma patients with lower serum miR-124 levels had unfavorable 5 year overall survival and disease free survival rates.\n'
p7204
sg4
(lp7205
sg14
(lp7206
(dp7207
g7
I65
sg17
VC0029463
p7208
sg10
I12
sg11
Vosteosarcoma
p7209
sg13
I1
sasa(dp7210
g2
S'It was also demonstrated that miR-124-3p expression was positively associated with mTOR signaling and this relationship was dependent on the tuberous sclerosis proteins 1/2 complex.\n'
p7211
sg4
(lp7212
(dp7213
g7
I30
sg8
g9
sg10
I10
sg11
VmiR-124-3p
p7214
sg13
I1
sa(dp7215
g7
I83
sg8
VP42345
p7216
sg10
I4
sg11
VmTOR
p7217
sg13
I1
sasg14
(lp7218
(dp7219
g7
I141
sg17
VC0041341
p7220
sg10
I18
sg11
Vtuberous sclerosis
p7221
sg13
I2
sasa(dp7222
g2
S'Among these microRNAs, miR-142-3p/5p and miR-146a expression was found to be significantly increased in MPA-treated lupus CD4(+)T cells compared to untreated controls.\n'
p7223
sg4
(lp7224
(dp7225
g7
I23
sg8
g9
sg10
I13
sg11
VmiR-142-3p/5p
p7226
sg13
I1
sa(dp7227
g7
I41
sg8
g9
sg10
I8
sg11
VmiR-146a
p7228
sg13
I1
sasg14
(lp7229
(dp7230
g7
I116
sg17
VC0024131
p7231
sg10
I5
sg11
Vlupus
p7232
sg13
I1
sasa(dp7233
g2
S'To examine the role of microRNA-142-3p/5p (miR-142-3p/5p) in the development of autoimmunity in patients with systemic lupus erythematosus (SLE).\n'
p7234
sg4
(lp7235
(dp7236
g7
I43
sg8
g9
sg10
I13
sg11
VmiR-142-3p/5p
p7237
sg13
I1
sa(dp7238
g7
I23
sg8
g9
sg10
I18
sg11
VmicroRNA-142-3p/5p
p7239
sg13
I1
sasg14
(lp7240
(dp7241
g7
I110
sg17
VC0024141
p7242
sg10
I28
sg11
Vsystemic lupus erythematosus
p7243
sg13
I3
sa(dp7244
g7
I140
sg17
VC0024141
p7245
sg10
I3
sg11
VSLE
p7246
sg13
I1
sa(dp7247
g7
I80
sg17
VC0004368
p7248
sg10
I12
sg11
Vautoimmunity
p7249
sg13
I1
sasa(dp7250
g2
S'To establish the cytologic and immunocytochemical features of lymphangioleiomyomatosis (LAM) cell clusters (LCCs) and to clarify its diagnostic significance for LAM.\n'
p7251
sg4
(lp7252
sg14
(lp7253
(dp7254
g7
I108
sg17
VC1854664
p7255
sg10
I4
sg11
VLCCs
p7256
sg13
I1
sa(dp7257
g7
I62
sg17
VC0751674
p7258
sg10
I24
sg11
Vlymphangioleiomyomatosis
p7259
sg13
I1
sa(dp7260
g7
I88
sg17
VC0751674
p7261
sg10
I3
sg11
VLAM
p7262
sg13
I1
sa(dp7263
g7
I88
sg17
VC0751674
p7264
sg10
I3
sg11
VLAM
p7265
sg13
I1
sasa(dp7266
g2
S'This study aimed to evaluate fibrosis and elastin destruction in childhood interstitial lung disease (chILD) patients.\n'
p7267
sg4
(lp7268
(dp7269
g7
I42
sg8
VP49918
p7270
sg10
I7
sg11
Velastin
p7271
sg13
I1
sasg14
(lp7272
(dp7273
g7
I75
sg17
VC0206062
p7274
sg10
I25
sg11
Vinterstitial lung disease
p7275
sg13
I3
sa(dp7276
g7
I29
sg17
VC0016059
p7277
sg10
I8
sg11
Vfibrosis
p7278
sg13
I1
sasa(dp7279
g2
S'Inhibitors of the cGMP-degrading phosphodiesterase (PDE) 5 have achieved blockbuster status in the treatment of penile erectile dysfunction (PED).\n'
p7280
sg4
(lp7281
(dp7282
g7
I52
sg8
VP49419
p7283
sg10
I3
sg11
VPDE
p7284
sg13
I1
sa(dp7285
g7
I18
sg8
VP22413
p7286
sg10
I32
sg11
VcGMP-degrading phosphodiesterase
p7287
sg13
I2
sasg14
(lp7288
(dp7289
g7
I52
sg17
VC1849508
p7290
sg10
I3
sg11
VPDE
p7291
sg13
I1
sa(dp7292
g7
I33
sg17
VC1849508
p7293
sg10
I17
sg11
Vphosphodiesterase
p7294
sg13
I1
sa(dp7295
g7
I119
sg17
VC0242350
p7296
sg10
I20
sg11
Verectile dysfunction
p7297
sg13
I2
sasa(dp7298
g2
S'To compare the effectiveness of the phosphodiesterase type 5 inhibitor (PDE-5i) tadalafil alone and in combination with a biologically active dietary supplement (BADS) NeyroDoz, containing the precursors of serotonin in patients with erectile dysfunction (ED) associated with secondary premature ejaculation (SPE).\n'
p7299
sg4
(lp7300
(dp7301
g7
I36
sg8
VP22413
p7302
sg10
I34
sg11
Vphosphodiesterase type 5 inhibitor
p7303
sg13
I4
sa(dp7304
g7
I72
sg8
VP49419
p7305
sg10
I6
sg11
VPDE-5i
p7306
sg13
I1
sasg14
(lp7307
(dp7308
g7
I72
sg17
VC1849508
p7309
sg10
I3
sg11
VPDE
p7310
sg13
I1
sa(dp7311
g7
I286
sg17
VC0033038
p7312
sg10
I21
sg11
Vpremature ejaculation
p7313
sg13
I2
sa(dp7314
g7
I256
sg17
VC0242350
p7315
sg10
I2
sg11
VED
p7316
sg13
I1
sa(dp7317
g7
I234
sg17
VC0242350
p7318
sg10
I20
sg11
Verectile dysfunction
p7319
sg13
I2
sasa(dp7320
g2
S'Of these enzymes, PDE5 has attracted a special attention over the years after its recognition as being the target enzyme in treating erectile dysfunction.\n'
p7321
sg4
(lp7322
(dp7323
g7
I18
sg8
g9
sg10
I4
sg11
VPDE5
p7324
sg13
I1
sasg14
(lp7325
(dp7326
g7
I133
sg17
VC0242350
p7327
sg10
I20
sg11
Verectile dysfunction
p7328
sg13
I2
sasa(dp7329
g2
S'Phosphodiesterase (PDE) 5 inhibitor induced muscle relaxation in corporal smooth muscle cells and was used to treat erectile dysfunction by inhibiting cGMP degradation.\n'
p7330
sg4
(lp7331
(dp7332
g7
I0
sg8
VP22413
p7333
sg10
I25
sg11
VPhosphodiesterase (PDE) 5
p7334
sg13
I3
sasg14
(lp7335
(dp7336
g7
I0
sg17
VC1849508
p7337
sg10
I17
sg11
VPhosphodiesterase
p7338
sg13
I1
sa(dp7339
g7
I19
sg17
VC1849508
p7340
sg10
I3
sg11
VPDE
p7341
sg13
I1
sa(dp7342
g7
I44
sg17
VC0700323
p7343
sg10
I17
sg11
Vmuscle relaxation
p7344
sg13
I2
sa(dp7345
g7
I116
sg17
VC0242350
p7346
sg10
I20
sg11
Verectile dysfunction
p7347
sg13
I2
sasa(dp7348
g2
S'Cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase (PDE) inhibitors are hypothesized to improve cognition in schizophrenia and Alzheimer disease by increasing cGMP levels in certain brain regions.\n'
p7349
sg4
(lp7350
(dp7351
g7
I66
sg8
VP49419
p7352
sg10
I3
sg11
VPDE
p7353
sg13
I1
sa(dp7354
g7
I0
sg8
VP22413
p7355
sg10
I64
sg11
VCyclic guanosine monophosphate (cGMP)-specific phosphodiesterase
p7356
sg13
I5
sasg14
(lp7357
(dp7358
g7
I47
sg17
VC1849508
p7359
sg10
I17
sg11
Vphosphodiesterase
p7360
sg13
I1
sa(dp7361
g7
I141
sg17
VC0002395
p7362
sg10
I17
sg11
VAlzheimer disease
p7363
sg13
I2
sa(dp7364
g7
I123
sg17
VC0036341
p7365
sg10
I13
sg11
Vschizophrenia
p7366
sg13
I1
sa(dp7367
g7
I66
sg17
VC1849508
p7368
sg10
I3
sg11
VPDE
p7369
sg13
I1
sasa(dp7370
g2
S"To find out whether increased spinal nociception represents a premotor feature, experimental pain sensitivity was assessed in idiopathic REM-sleep behavior disorder (IRBD) patients with or without signs of a neurodegenerative disorder compared to early Parkinson's disease (ePD) patients and healthy controls (HC).\n"
p7371
sg4
(lp7372
sg14
(lp7373
(dp7374
g7
I247
sg17
VC1849508
p7375
sg10
I25
sg11
Vearly Parkinson's disease
p7376
sg13
I3
sa(dp7377
g7
I208
sg17
VC0524851
p7378
sg10
I26
sg11
Vneurodegenerative disorder
p7379
sg13
I2
sa(dp7380
g7
I147
sg17
VC0004930
p7381
sg10
I17
sg11
Vbehavior disorder
p7382
sg13
I2
sa(dp7383
g7
I274
sg17
VC1849508
p7384
sg10
I3
sg11
VePD
p7385
sg13
I1
sasa(dp7386
g2
S"Phosphodiesterase (PDE) inhibitors are currently under evaluation as agents that may facilitate the improvement of cognitive impairment associated with Alzheimer's disease.\n"
p7387
sg4
(lp7388
(dp7389
g7
I0
sg8
VP22413
p7390
sg10
I23
sg11
VPhosphodiesterase (PDE)
p7391
sg13
I2
sasg14
(lp7392
(dp7393
g7
I0
sg17
VC1849508
p7394
sg10
I17
sg11
VPhosphodiesterase
p7395
sg13
I1
sa(dp7396
g7
I152
sg17
VC1521724
p7397
sg10
I19
sg11
VAlzheimer's disease
p7398
sg13
I2
sa(dp7399
g7
I19
sg17
VC1849508
p7400
sg10
I3
sg11
VPDE
p7401
sg13
I1
sa(dp7402
g7
I115
sg17
VC0338656
p7403
sg10
I20
sg11
Vcognitive impairment
p7404
sg13
I2
sasa(dp7405
g2
S'Notably, much experimental and clinical evidence show that PXR senses xenobiotics and triggers the detoxification response to prevent diseases such as diabetes, obesity, intestinal inflammatory diseases and liver fibrosis.\n'
p7406
sg4
(lp7407
sg14
(lp7408
(dp7409
g7
I161
sg17
VC0028754
p7410
sg10
I7
sg11
Vobesity
p7411
sg13
I1
sa(dp7412
g7
I151
sg17
VC0011849
p7413
sg10
I8
sg11
Vdiabetes
p7414
sg13
I1
sa(dp7415
g7
I99
sg17
VC1622680
p7416
sg10
I23
sg11
Vdetoxification response
p7417
sg13
I2
sa(dp7418
g7
I207
sg17
VC0239946
p7419
sg10
I14
sg11
Vliver fibrosis
p7420
sg13
I2
sasa(dp7421
g2
S'Rescued Tg(INV-Cst6)Cst6ichq/ichq mice survive the neonatal phase, but display severe eye pathology and alopecia after 4 mo.\n'
p7422
sg4
(lp7423
(dp7424
g7
I11
sg8
g9
sg10
I8
sg11
VINV-Cst6
p7425
sg13
I1
sasg14
(lp7426
(dp7427
g7
I90
sg17
VC0677042
p7428
sg10
I9
sg11
Vpathology
p7429
sg13
I1
sasa(dp7430
g2
S'Intriguingly, both Cst6(-/-)Ctsl(-/-) and Cst6(-/-)Ctsl(+/-) mice were viable, but the absence of cystatin M/E caused scarring alopecia in adult animals.\n'
p7431
sg4
(lp7432
(dp7433
g7
I19
sg8
VP04080
p7434
sg10
I4
sg11
VCst6
p7435
sg13
I1
sa(dp7436
g7
I19
sg8
VP04080
p7437
sg10
I4
sg11
VCst6
p7438
sg13
I1
sa(dp7439
g7
I98
sg8
g9
sg10
I12
sg11
Vcystatin M/E
p7440
sg13
I2
sasg14
(lp7441
(dp7442
g7
I118
sg17
VC2936846
p7443
sg10
I17
sg11
Vscarring alopecia
p7444
sg13
I2
sasa(dp7445
g2
S'Transcription factor 4 (TCF-4) was recently identified as a candidate gene for the cause of type 2 diabetes, although the mechanisms have not been fully elucidated.\n'
p7446
sg4
(lp7447
(dp7448
g7
I0
sg8
VP15884
p7449
sg10
I22
sg11
VTranscription factor 4
p7450
sg13
I3
sa(dp7451
g7
I24
sg8
VP15884
p7452
sg10
I5
sg11
VTCF-4
p7453
sg13
I1
sasg14
(lp7454
(dp7455
g7
I92
sg17
VC0011860
p7456
sg10
I15
sg11
Vtype 2 diabetes
p7457
sg13
I3
sasa(dp7458
g2
S'Collectively, these observations demonstrate a disease-promoting role of E2-2 dependent pDCs in the pancreas during autoimmune diabetes in the NOD mouse.\n'
p7459
sg4
(lp7460
(dp7461
g7
I73
sg8
VP15884
p7462
sg10
I4
sg11
VE2-2
p7463
sg13
I1
sasg14
(lp7464
(dp7465
g7
I143
sg17
VC0751781
p7466
sg10
I3
sg11
VNOD
p7467
sg13
I1
sa(dp7468
g7
I116
sg17
VC0205734
p7469
sg10
I19
sg11
Vautoimmune diabetes
p7470
sg13
I2
sasa(dp7471
g2
S'Fecal incontinence and constipation still remain the major complications after procedures for anorectal malformations (ARMs).\n'
p7472
sg4
(lp7473
sg14
(lp7474
(dp7475
g7
I23
sg17
VC0009806
p7476
sg10
I12
sg11
Vconstipation
p7477
sg13
I1
sa(dp7478
g7
I94
sg17
VC2974527
p7479
sg10
I23
sg11
Vanorectal malformations
p7480
sg13
I2
sa(dp7481
g7
I119
sg17
VC0206655
p7482
sg10
I4
sg11
VARMs
p7483
sg13
I1
sa(dp7484
g7
I0
sg17
VC0015732
p7485
sg10
I18
sg11
VFecal incontinence
p7486
sg13
I2
sasa(dp7487
g2
S'Numerous patients with anorectal malformations (ARMs) continue to experience fecal incontinence and constipation following surgical procedures.\n'
p7488
sg4
(lp7489
sg14
(lp7490
(dp7491
g7
I100
sg17
VC0009806
p7492
sg10
I12
sg11
Vconstipation
p7493
sg13
I1
sa(dp7494
g7
I48
sg17
VC0206655
p7495
sg10
I4
sg11
VARMs
p7496
sg13
I1
sa(dp7497
g7
I77
sg17
VC0015732
p7498
sg10
I18
sg11
Vfecal incontinence
p7499
sg13
I2
sa(dp7500
g7
I23
sg17
VC2974527
p7501
sg10
I23
sg11
Vanorectal malformations
p7502
sg13
I2
sasa(dp7503
g2
S"Over the last two decades, advances in laparoscopic surgery and minimally invasive techniques have transformed the operative management of neonatal colorectal surgery for conditions such as anorectal malformations (ARMs) and Hirschsprung's disease.\n"
p7504
sg4
(lp7505
sg14
(lp7506
(dp7507
g7
I215
sg17
VC0206655
p7508
sg10
I4
sg11
VARMs
p7509
sg13
I1
sa(dp7510
g7
I190
sg17
VC2974527
p7511
sg10
I23
sg11
Vanorectal malformations
p7512
sg13
I2
sa(dp7513
g7
I225
sg17
VC0019569
p7514
sg10
I22
sg11
VHirschsprung's disease
p7515
sg13
I2
sasa(dp7516
g2
S"This review describes these advances and outlines the main minimally invasive techniques currently used for management of ARMs and Hirschsprung's disease.\n"
p7517
sg4
(lp7518
sg14
(lp7519
(dp7520
g7
I122
sg17
VC0206655
p7521
sg10
I4
sg11
VARMs
p7522
sg13
I1
sa(dp7523
g7
I131
sg17
VC0019569
p7524
sg10
I22
sg11
VHirschsprung's disease
p7525
sg13
I2
sasa(dp7526
g2
S'Further analysis of the PRKAG3 signaling pathway may provide insights into muscle physiology as well as the pathogenesis of noninsulin-dependent diabetes mellitus in humans, a metabolic disorder associated with impaired glycogen synthesis.\n'
p7527
sg4
(lp7528
(dp7529
g7
I24
sg8
g9
sg10
I6
sg11
VPRKAG3
p7530
sg13
I1
sasg14
(lp7531
(dp7532
g7
I211
sg17
VC0684336
p7533
sg10
I8
sg11
Vimpaired
p7534
sg13
I1
sa(dp7535
g7
I124
sg17
VC0011860
p7536
sg10
I38
sg11
Vnoninsulin-dependent diabetes mellitus
p7537
sg13
I3
sa(dp7538
g7
I176
sg17
VC0025517
p7539
sg10
I18
sg11
Vmetabolic disorder
p7540
sg13
I2
sa(dp7541
g7
I108
sg17
VC0699748
p7542
sg10
I12
sg11
Vpathogenesis
p7543
sg13
I1
sasa(dp7544
g2
S"In primates, a PGBD3 element inserted into the Cockayne syndrome group B (CSB) gene over 43 Mya serves as an alternative 3' terminal exon, enabling the CSB gene to generate both full length CSB and a conserved CSB-PGBD3 fusion protein that joins an N-terminal CSB domain to the C-terminal transposase domain.\n"
p7545
sg4
(lp7546
(dp7547
g7
I152
sg8
VP35548
p7548
sg10
I8
sg11
VCSB gene
p7549
sg13
I2
sa(dp7550
g7
I278
sg8
g9
sg10
I29
sg11
VC-terminal transposase domain
p7551
sg13
I3
sa(dp7552
g7
I74
sg8
VP35548
p7553
sg10
I3
sg11
VCSB
p7554
sg13
I1
sa(dp7555
g7
I15
sg8
g9
sg10
I13
sg11
VPGBD3 element
p7556
sg13
I2
sa(dp7557
g7
I15
sg8
g9
sg10
I5
sg11
VPGBD3
p7558
sg13
I1
sa(dp7559
g7
I47
sg8
VP35548
p7560
sg10
I25
sg11
VCockayne syndrome group B
p7561
sg13
I4
sa(dp7562
g7
I74
sg8
VP35548
p7563
sg10
I3
sg11
VCSB
p7564
sg13
I1
sasg14
(lp7565
(dp7566
g7
I74
sg17
VC1858160
p7567
sg10
I3
sg11
VCSB
p7568
sg13
I1
sa(dp7569
g7
I74
sg17
VC1858160
p7570
sg10
I3
sg11
VCSB
p7571
sg13
I1
sa(dp7572
g7
I74
sg17
VC1858160
p7573
sg10
I3
sg11
VCSB
p7574
sg13
I1
sa(dp7575
g7
I47
sg17
VC1858160
p7576
sg10
I25
sg11
VCockayne syndrome group B
p7577
sg13
I4
sa(dp7578
g7
I74
sg17
VC1858160
p7579
sg10
I3
sg11
VCSB
p7580
sg13
I1
sa(dp7581
g7
I74
sg17
VC1858160
p7582
sg10
I3
sg11
VCSB
p7583
sg13
I1
sasa(dp7584
g2
S'The CSB-PGBD3 fusion protein arose more than 43 million years ago when a 2.5-kb piggyBac 3 (PGBD3) transposon inserted into intron 5 of the Cockayne syndrome Group B (CSB) gene in the common ancestor of all higher primates.\n'
p7585
sg4
(lp7586
(dp7587
g7
I4
sg8
VP35548
p7588
sg10
I3
sg11
VCSB
p7589
sg13
I1
sa(dp7590
g7
I8
sg8
g9
sg10
I5
sg11
VPGBD3
p7591
sg13
I1
sa(dp7592
g7
I8
sg8
g9
sg10
I5
sg11
VPGBD3
p7593
sg13
I1
sa(dp7594
g7
I4
sg8
VP35548
p7595
sg10
I3
sg11
VCSB
p7596
sg13
I1
sa(dp7597
g7
I140
sg8
VP35548
p7598
sg10
I25
sg11
VCockayne syndrome Group B
p7599
sg13
I4
sasg14
(lp7600
(dp7601
g7
I4
sg17
VC1858160
p7602
sg10
I3
sg11
VCSB
p7603
sg13
I1
sa(dp7604
g7
I140
sg17
VC1858160
p7605
sg10
I25
sg11
VCockayne syndrome Group B
p7606
sg13
I4
sa(dp7607
g7
I4
sg17
VC1858160
p7608
sg10
I3
sg11
VCSB
p7609
sg13
I1
sasa(dp7610
g2
S'Our data suggest that the CSB-PGBD3 fusion protein is important in both health and disease, and could play a role in Cockayne syndrome.\n'
p7611
sg4
(lp7612
(dp7613
g7
I30
sg8
g9
sg10
I5
sg11
VPGBD3
p7614
sg13
I1
sa(dp7615
g7
I26
sg8
VP35548
p7616
sg10
I3
sg11
VCSB
p7617
sg13
I1
sasg14
(lp7618
(dp7619
g7
I117
sg17
VC0009207
p7620
sg10
I17
sg11
VCockayne syndrome
p7621
sg13
I2
sa(dp7622
g7
I26
sg17
VC1858160
p7623
sg10
I3
sg11
VCSB
p7624
sg13
I1
sasa(dp7625
g2
S'In this study, we searched for cerebral MBs in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a unique type of small-vessel disease caused by mutations in the Notch3 gene.\n'
p7626
sg4
(lp7627
(dp7628
g7
I214
sg8
g9
sg10
I11
sg11
VNotch3 gene
p7629
sg13
I2
sasg14
(lp7630
(dp7631
g7
I47
sg17
VC0751587
p7632
sg10
I90
sg11
Vcerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
p7633
sg13
I9
sa(dp7634
g7
I139
sg17
VC0751587
p7635
sg10
I7
sg11
VCADASIL
p7636
sg13
I1
sa(dp7637
g7
I40
sg17
VC0221060
p7638
sg10
I3
sg11
VMBs
p7639
sg13
I1
sasa(dp7640
g2
S'Our purposes were (1) to determine the frequency, extent, and pattern of MBs in CADASIL; (2) to analyze the relationship between MBs and T2-hyperintense lesions; and (3) to evaluate the histopathology of brain tissue affected by MBs.\n'
p7641
sg4
(lp7642
(dp7643
g7
I73
sg8
g9
sg10
I3
sg11
VMBs
p7644
sg13
I1
sasg14
(lp7645
(dp7646
g7
I73
sg17
VC0221060
p7647
sg10
I3
sg11
VMBs
p7648
sg13
I1
sa(dp7649
g7
I73
sg17
VC0221060
p7650
sg10
I3
sg11
VMBs
p7651
sg13
I1
sa(dp7652
g7
I73
sg17
VC0221060
p7653
sg10
I3
sg11
VMBs
p7654
sg13
I1
sa(dp7655
g7
I80
sg17
VC0751587
p7656
sg10
I7
sg11
VCADASIL
p7657
sg13
I1
sasa(dp7658
g2
S'Focal areas of signal loss on gradient-echo images suggesting past MBs were found in 11 CADASIL individuals (69%) and no control subjects (P&lt;0.001).\n'
p7659
sg4
(lp7660
(dp7661
g7
I67
sg8
g9
sg10
I3
sg11
VMBs
p7662
sg13
I1
sasg14
(lp7663
(dp7664
g7
I67
sg17
VC0221060
p7665
sg10
I3
sg11
VMBs
p7666
sg13
I1
sa(dp7667
g7
I88
sg17
VC0751587
p7668
sg10
I7
sg11
VCADASIL
p7669
sg13
I1
sasa(dp7670
g2
S'The average number of MBs was 5.9+/-7.3 (range, 0 to 22) in individual CADASIL patients.\n'
p7671
sg4
(lp7672
sg14
(lp7673
(dp7674
g7
I22
sg17
VC0221060
p7675
sg10
I3
sg11
VMBs
p7676
sg13
I1
sa(dp7677
g7
I71
sg17
VC0751587
p7678
sg10
I7
sg11
VCADASIL
p7679
sg13
I1
sasa(dp7680
g2
S'This study shows a high frequency and multiplicity of MBs in individuals with CADASIL.\n'
p7681
sg4
(lp7682
sg14
(lp7683
(dp7684
g7
I78
sg17
VC0751587
p7685
sg10
I7
sg11
VCADASIL
p7686
sg13
I1
sa(dp7687
g7
I54
sg17
VC0221060
p7688
sg10
I3
sg11
VMBs
p7689
sg13
I1
sasa(dp7690
g2
S'At stimulation, the tubulovesicles fuse with the apical canaliculi and the HK-ATPase is incorporated into the apical membrane where it actively pumps H ions in exchange for K. Acute infection with Helicobacter pylori results in hypochlorhydria, whereas chronic infection can cause either hypo- or hyperchlorhydria, depending on the distribution of the infection and the degree of corpus gastritis.\n'
p7691
sg4
(lp7692
(dp7693
g7
I75
sg8
VP38606
p7694
sg10
I9
sg11
VHK-ATPase
p7695
sg13
I1
sasg14
(lp7696
(dp7697
g7
I176
sg17
VC0275518
p7698
sg10
I15
sg11
VAcute infection
p7699
sg13
I2
sa(dp7700
g7
I297
sg17
VC0151713
p7701
sg10
I16
sg11
Vhyperchlorhydria
p7702
sg13
I1
sa(dp7703
g7
I253
sg17
VC0151317
p7704
sg10
I17
sg11
Vchronic infection
p7705
sg13
I2
sa(dp7706
g7
I182
sg17
VC0009450
p7707
sg10
I9
sg11
Vinfection
p7708
sg13
I1
sa(dp7709
g7
I387
sg17
VC0017152
p7710
sg10
I9
sg11
Vgastritis
p7711
sg13
I1
sa(dp7712
g7
I228
sg17
VC0079581
p7713
sg10
I15
sg11
Vhypochlorhydria
p7714
sg13
I1
sasa(dp7715
g2
S'The results directly confirm that the gastric H+/K(+)-ATPase is the causative autoantigen in the genesis of autoimmune gastritis.\n'
p7716
sg4
(lp7717
(dp7718
g7
I38
sg8
VP38606
p7719
sg10
I22
sg11
Vgastric H+/K(+)-ATPase
p7720
sg13
I2
sasg14
(lp7721
(dp7722
g7
I108
sg17
VC0017154
p7723
sg10
I20
sg11
Vautoimmune gastritis
p7724
sg13
I2
sasa(dp7725
g2
S'We conclude that the beta subunit of the gastric H/K ATPase is a major T cell target in autoimmune gastritis and that thymic expression of a single autoantigen can abrogate an autoimmune response to multiple autoantigens.\n'
p7726
sg4
(lp7727
(dp7728
g7
I41
sg8
VP38606
p7729
sg10
I18
sg11
Vgastric H/K ATPase
p7730
sg13
I3
sasg14
(lp7731
(dp7732
g7
I176
sg17
VC0004366
p7733
sg10
I19
sg11
Vautoimmune response
p7734
sg13
I2
sa(dp7735
g7
I88
sg17
VC0017154
p7736
sg10
I20
sg11
Vautoimmune gastritis
p7737
sg13
I2
sasa(dp7738
g2
S'8 cases of pneumophathia osteoplastica (ppo) of branching type observed at patients having no vascular deformities and one case of a focal ppo at a patient with mitral stenosis are reported.\n'
p7739
sg4
(lp7740
(dp7741
g7
I40
sg8
VP50336
p7742
sg10
I3
sg11
Vppo
p7743
sg13
I1
sasg14
(lp7744
(dp7745
g7
I161
sg17
VC0026269
p7746
sg10
I15
sg11
Vmitral stenosis
p7747
sg13
I2
sa(dp7748
g7
I103
sg17
VC0000768
p7749
sg10
I11
sg11
Vdeformities
p7750
sg13
I1
sasa(dp7751
g2
S'Silencing CDKN3 expression could inhibit the ability of cell proliferation and migration, and overexpression of CDKN3 could restore the effects induced by YY1 overexpression in pancreatic cancer cells.\n'
p7752
sg4
(lp7753
(dp7754
g7
I155
sg8
VP25490
p7755
sg10
I3
sg11
VYY1
p7756
sg13
I1
sasg14
(lp7757
(dp7758
g7
I177
sg17
VC0235974
p7759
sg10
I17
sg11
Vpancreatic cancer
p7760
sg13
I2
sa(dp7761
g7
I61
sg17
VC0334094
p7762
sg10
I13
sg11
Vproliferation
p7763
sg13
I1
sasa(dp7764
g2
S'The expression levels of YY1 and CDKN3 were negatively correlated in pancreatic cancer tissues and PDAC patients with higher levels of CDKN3 have poor prognosis.\n'
p7765
sg4
(lp7766
(dp7767
g7
I25
sg8
VP25490
p7768
sg10
I3
sg11
VYY1
p7769
sg13
I1
sasg14
(lp7770
(dp7771
g7
I69
sg17
VC0235974
p7772
sg10
I17
sg11
Vpancreatic cancer
p7773
sg13
I2
sasa(dp7774
g2
S'Vitro and vivo study show that CDKN3 can form a complex with MdM2-P53, thus leading to inhibiting the expression of P21, which is the target gene of P53, and finally facilitates the cell cycle to promote the proliferation of pancreatic cancer cells.\n'
p7775
sg4
(lp7776
(dp7777
g7
I66
sg8
VP42771
p7778
sg10
I3
sg11
VP53
p7779
sg13
I1
sa(dp7780
g7
I116
sg8
VP42857
p7781
sg10
I3
sg11
VP21
p7782
sg13
I1
sa(dp7783
g7
I61
sg8
VP42771
p7784
sg10
I8
sg11
VMdM2-P53
p7785
sg13
I1
sasg14
(lp7786
(dp7787
g7
I225
sg17
VC0235974
p7788
sg10
I17
sg11
Vpancreatic cancer
p7789
sg13
I2
sa(dp7790
g7
I208
sg17
VC0334094
p7791
sg10
I13
sg11
Vproliferation
p7792
sg13
I1
sasa(dp7793
g2
S'Hence, YY1 can directly regulate the expression of CDKN3 and participate in the cycle of pancreatic cancer cells, which can inhibit the progression of pancreatic cancer.\n'
p7794
sg4
(lp7795
(dp7796
g7
I7
sg8
VP25490
p7797
sg10
I3
sg11
VYY1
p7798
sg13
I1
sasg14
(lp7799
(dp7800
g7
I89
sg17
VC0235974
p7801
sg10
I17
sg11
Vpancreatic cancer
p7802
sg13
I2
sa(dp7803
g7
I89
sg17
VC0235974
p7804
sg10
I17
sg11
Vpancreatic cancer
p7805
sg13
I2
sasa(dp7806
g2
S'These results reveal that YY1-CDKN3-MDM2/P53-P21 axis is involved in pancreatic tumorigenesis, which may develop new methods for human pancreatic cancer therapy.\n'
p7807
sg4
(lp7808
(dp7809
g7
I26
sg8
VP25490
p7810
sg10
I3
sg11
VYY1
p7811
sg13
I1
sa(dp7812
g7
I45
sg8
VP42857
p7813
sg10
I3
sg11
VP21
p7814
sg13
I1
sa(dp7815
g7
I41
sg8
VP42771
p7816
sg10
I3
sg11
VP53
p7817
sg13
I1
sasg14
(lp7818
(dp7819
g7
I80
sg17
VC0007621
p7820
sg10
I13
sg11
Vtumorigenesis
p7821
sg13
I1
sa(dp7822
g7
I135
sg17
VC0235974
p7823
sg10
I17
sg11
Vpancreatic cancer
p7824
sg13
I2
sasa(dp7825
g2
S'CDKN3 is often overexpressed in human cancer, and this overexpression correlates with reduced survival in several types of cancer.\n'
p7826
sg4
(lp7827
sg14
(lp7828
(dp7829
g7
I38
sg17
VC0006826
p7830
sg10
I6
sg11
Vcancer
p7831
sg13
I1
sa(dp7832
g7
I38
sg17
VC0006826
p7833
sg10
I6
sg11
Vcancer
p7834
sg13
I1
sasa(dp7835
g2
S'The mechanism of CDKN3 overexpression and the role of CDKN3 transcript variants in human cancer are not entirely clear.\n'
p7836
sg4
(lp7837
(dp7838
g7
I54
sg8
VP26640
p7839
sg10
I25
sg11
VCDKN3 transcript variants
p7840
sg13
I3
sasg14
(lp7841
(dp7842
g7
I89
sg17
VC0006826
p7843
sg10
I6
sg11
Vcancer
p7844
sg13
I1
sasa(dp7845
g2
S'Besides the full-length CDKN3 encoding transcript and a major transcript that skips exon 2 express in normal and cancer cells, minor aberrant transcript variants have been reported.\n'
p7846
sg4
(lp7847
sg14
(lp7848
(dp7849
g7
I113
sg17
VC0006826
p7850
sg10
I6
sg11
Vcancer
p7851
sg13
I1
sasa(dp7852
g2
S'Aberrant CDKN3 transcripts were postulated to encode dominant-negative inhibitors of CDKN3 as an explanation for overexpression of the perceived tumor suppressor gene in human cancer.\n'
p7853
sg4
(lp7854
sg14
(lp7855
(dp7856
g7
I145
sg17
VC0027651
p7857
sg10
I5
sg11
Vtumor
p7858
sg13
I1
sa(dp7859
g7
I176
sg17
VC0006826
p7860
sg10
I6
sg11
Vcancer
p7861
sg13
I1
sasa(dp7862
g2
S'However, while CDKN3 is often overexpressed in human cancer, aberrant CDKN3 transcripts occur infrequently and at lower levels.\n'
p7863
sg4
(lp7864
sg14
(lp7865
(dp7866
g7
I53
sg17
VC0006826
p7867
sg10
I6
sg11
Vcancer
p7868
sg13
I1
sasa(dp7869
g2
S'CDKN3 mutations and copy number alternation are rare in human cancer, implying that neither loss of CDKN3 activity nor constitutive gain of CDKN3 expression offer an advantage to tumorigenesis.\n'
p7870
sg4
(lp7871
sg14
(lp7872
(dp7873
g7
I179
sg17
VC0007621
p7874
sg10
I13
sg11
Vtumorigenesis
p7875
sg13
I1
sa(dp7876
g7
I62
sg17
VC0006826
p7877
sg10
I6
sg11
Vcancer
p7878
sg13
I1
sa(dp7879
g7
I32
sg17
VC0919661
p7880
sg10
I11
sg11
Valternation
p7881
sg13
I1
sasa(dp7882
g2
S'Given that rapidly growing tumors have more mitotic cells, the high level of mitotic CDKN3 expression is the most plausible mechanism of frequent CDKN3 overexpression in human cancer.\n'
p7883
sg4
(lp7884
sg14
(lp7885
(dp7886
g7
I27
sg17
VC0027651
p7887
sg10
I6
sg11
Vtumors
p7888
sg13
I1
sa(dp7889
g7
I176
sg17
VC0006826
p7890
sg10
I6
sg11
Vcancer
p7891
sg13
I1
sasa(dp7892
g2
S'This finding clarifies the mechanism of CDKN3 overexpression in human cancer and questions the view of CDKN3 as a tumor suppressor.\n'
p7893
sg4
(lp7894
sg14
(lp7895
(dp7896
g7
I70
sg17
VC0006826
p7897
sg10
I6
sg11
Vcancer
p7898
sg13
I1
sa(dp7899
g7
I114
sg17
VC0027651
p7900
sg10
I5
sg11
Vtumor
p7901
sg13
I1
sasa(dp7902
g2
S'Abnormal expression of CDKN3 has been found in numerous types of cancer.\n'
p7903
sg4
(lp7904
sg14
(lp7905
(dp7906
g7
I65
sg17
VC0006826
p7907
sg10
I6
sg11
Vcancer
p7908
sg13
I1
sasa(dp7909
g2
S'Since it is unclear whether CDKN3 participates in the development of human gastric cancer, this study assessed the association between CDKN3 expression and cell biological function and demonstrated the clinical significance and prognosis of CDKN3 in human gastric cancer.\n'
p7910
sg4
(lp7911
sg14
(lp7912
(dp7913
g7
I75
sg17
VC0024623
p7914
sg10
I14
sg11
Vgastric cancer
p7915
sg13
I2
sa(dp7916
g7
I75
sg17
VC0024623
p7917
sg10
I14
sg11
Vgastric cancer
p7918
sg13
I2
sasa(dp7919
g2
S'In this study, we found that CDKN3 showed a high expression in 35 paired human gastric cancer tissues and was correlated with poor patient survival, AJCC clinical staging, and recurrence.\n'
p7920
sg4
(lp7921
sg14
(lp7922
(dp7923
g7
I79
sg17
VC0024623
p7924
sg10
I14
sg11
Vgastric cancer
p7925
sg13
I2
sa(dp7926
g7
I176
sg17
VC1458156
p7927
sg10
I10
sg11
Vrecurrence
p7928
sg13
I1
sasa(dp7929
g2
S'Silencing of CDKN3 in human gastric cancer cells can significantly reduce proliferation, migration, invasion, and adhesion abilities.\n'
p7930
sg4
(lp7931
sg14
(lp7932
(dp7933
g7
I100
sg17
VC2699153
p7934
sg10
I8
sg11
Vinvasion
p7935
sg13
I1
sa(dp7936
g7
I28
sg17
VC0024623
p7937
sg10
I14
sg11
Vgastric cancer
p7938
sg13
I2
sa(dp7939
g7
I74
sg17
VC0334094
p7940
sg10
I13
sg11
Vproliferation
p7941
sg13
I1
sa(dp7942
g7
I114
sg17
VC0001511
p7943
sg10
I8
sg11
Vadhesion
p7944
sg13
I1
sasa(dp7945
g2
S'Also, silencing of CDKN3 in human gastric cancer cells can induce G0-G1 cell cycle arrest and apoptosis.\n'
p7946
sg4
(lp7947
sg14
(lp7948
(dp7949
g7
I34
sg17
VC0024623
p7950
sg10
I14
sg11
Vgastric cancer
p7951
sg13
I2
sasa(dp7952
g2
S'Detection of cell cycle marker expression showed that CDKN3 knockdown promotes cell cycle arrest by decreasing the expression of CDK2, CDC25A, CCNB1, and CCNB2 in human gastric cancer cells.\n'
p7953
sg4
(lp7954
(dp7955
g7
I129
sg8
VP24941
p7956
sg10
I4
sg11
VCDK2
p7957
sg13
I1
sa(dp7958
g7
I154
sg8
g9
sg10
I5
sg11
VCCNB2
p7959
sg13
I1
sa(dp7960
g7
I143
sg8
VP14635
p7961
sg10
I5
sg11
VCCNB1
p7962
sg13
I1
sa(dp7963
g7
I135
sg8
VP30304
p7964
sg10
I6
sg11
VCDC25A
p7965
sg13
I1
sasg14
(lp7966
(dp7967
g7
I169
sg17
VC0024623
p7968
sg10
I14
sg11
Vgastric cancer
p7969
sg13
I2
sasa(dp7970
g2
S'The results of this study will help elucidate the oncogene function of CDKN3 in human gastric cancer.\n'
p7971
sg4
(lp7972
sg14
(lp7973
(dp7974
g7
I86
sg17
VC0024623
p7975
sg10
I14
sg11
Vgastric cancer
p7976
sg13
I2
sasa(dp7977
g2
S'However, whether CDKN3 is a potential therapeutic target for breast cancer remains to be elucidated.\n'
p7978
sg4
(lp7979
sg14
(lp7980
(dp7981
g7
I61
sg17
VC0678222
p7982
sg10
I13
sg11
Vbreast cancer
p7983
sg13
I2
sasa(dp7984
g2
S'The present in vitro study aimed to investigate the potential roles of CDKN3 in breast cancer.\n'
p7985
sg4
(lp7986
sg14
(lp7987
(dp7988
g7
I80
sg17
VC0678222
p7989
sg10
I13
sg11
Vbreast cancer
p7990
sg13
I2
sasa(dp7991
g2
S'Breast cancer cell lines were used to detect CDKN3 expression, and CDKN3 expression was silenced to investigate its role in cell apoptosis, cell cycle arrest and migration.\n'
p7992
sg4
(lp7993
sg14
(lp7994
(dp7995
g7
I0
sg17
VC0678222
p7996
sg10
I13
sg11
VBreast cancer
p7997
sg13
I2
sasa(dp7998
g2
S'These results suggest that CDKN3 acts as an oncogene during breast cancer progression.\n'
p7999
sg4
(lp8000
sg14
(lp8001
(dp8002
g7
I67
sg17
VC0178874
p8003
sg10
I18
sg11
Vcancer progression
p8004
sg13
I2
sasa(dp8005
g2
S'CDKN3 may therefore be considered a potential target for the treatment of breast cancer.\n'
p8006
sg4
(lp8007
sg14
(lp8008
(dp8009
g7
I74
sg17
VC0678222
p8010
sg10
I13
sg11
Vbreast cancer
p8011
sg13
I2
sasa(dp8012
g2
S'Paradoxically, CDKN3 is often overexpressed in human cancer.\n'
p8013
sg4
(lp8014
sg14
(lp8015
(dp8016
g7
I53
sg17
VC0006826
p8017
sg10
I6
sg11
Vcancer
p8018
sg13
I1
sasa(dp8019
g2
S'We analysed CDKN3 expression and its association with patient survival in three cohorts of lung adenocarcinoma.\n'
p8020
sg4
(lp8021
sg14
(lp8022
(dp8023
g7
I91
sg17
VC0152013
p8024
sg10
I19
sg11
Vlung adenocarcinoma
p8025
sg13
I2
sasa(dp8026
g2
S"We also examined CDKN3 mutations in the Cancer Genome Atlas (TCGA) and the Moffitt Cancer Center's Total Cancer Care (TCC) projects.\n"
p8027
sg4
(lp8028
sg14
(lp8029
(dp8030
g7
I40
sg17
VC0006826
p8031
sg10
I6
sg11
VCancer
p8032
sg13
I1
sa(dp8033
g7
I118
sg17
VC1861305
p8034
sg10
I3
sg11
VTCC
p8035
sg13
I1
sa(dp8036
g7
I40
sg17
VC0006826
p8037
sg10
I6
sg11
VCancer
p8038
sg13
I1
sa(dp8039
g7
I99
sg17
VC1861305
p8040
sg10
I17
sg11
VTotal Cancer Care
p8041
sg13
I3
sasa(dp8042
g2
S'CDKN3 transcripts were further analysed in a panel of cell lines and lung adenocarcinoma tissues.\n'
p8043
sg4
(lp8044
sg14
(lp8045
(dp8046
g7
I69
sg17
VC0152013
p8047
sg10
I19
sg11
Vlung adenocarcinoma
p8048
sg13
I2
sasa(dp8049
g2
S'CDKN3 is overexpressed in non small cell lung cancer.\n'
p8050
sg4
(lp8051
sg14
(lp8052
(dp8053
g7
I26
sg17
VC0007131
p8054
sg10
I26
sg11
Vnon small cell lung cancer
p8055
sg13
I5
sasa(dp8056
g2
S'High CDKN3 expression is associated with poor overall survival in lung adenocarcinoma.\n'
p8057
sg4
(lp8058
sg14
(lp8059
(dp8060
g7
I66
sg17
VC0152013
p8061
sg10
I19
sg11
Vlung adenocarcinoma
p8062
sg13
I2
sasa(dp8063
g2
S'CDKN3 overexpression is prognostic of poor overall survival in lung adenocarcinoma.\n'
p8064
sg4
(lp8065
sg14
(lp8066
(dp8067
g7
I63
sg17
VC0152013
p8068
sg10
I19
sg11
Vlung adenocarcinoma
p8069
sg13
I2
sasa(dp8070
g2
S'CDKN3 overexpression in lung adenocarcinoma is not attributed to alternative splicing or mutation but is likely due to increased mitotic activity, arguing against CDKN3 as a tumour suppressor.\n'
p8071
sg4
(lp8072
sg14
(lp8073
(dp8074
g7
I174
sg17
VC0027651
p8075
sg10
I6
sg11
Vtumour
p8076
sg13
I1
sa(dp8077
g7
I24
sg17
VC0152013
p8078
sg10
I19
sg11
Vlung adenocarcinoma
p8079
sg13
I2
sasa(dp8080
g2
S'The cyclin-dependent kinase inhibitor 3 (CDKN3) gene, involved in mitosis, is upregulated in cervical cancer (CC).\n'
p8081
sg4
(lp8082
(dp8083
g7
I4
sg8
VP38936
p8084
sg10
I35
sg11
Vcyclin-dependent kinase inhibitor 3
p8085
sg13
I4
sa(dp8086
g7
I41
sg8
VP38936
p8087
sg10
I5
sg11
VCDKN3
p8088
sg13
I1
sasg14
(lp8089
(dp8090
g7
I93
sg17
VC0302592
p8091
sg10
I15
sg11
Vcervical cancer
p8092
sg13
I2
sasa(dp8093
g2
S'The aim of this study is to investigate the possible mechanisms of silence of CDKN3 exerting the suppressive role on epithelial ovarian cancer (EOC).\n'
p8094
sg4
(lp8095
sg14
(lp8096
(dp8097
g7
I144
sg17
VC0677886
p8098
sg10
I3
sg11
VEOC
p8099
sg13
I1
sa(dp8100
g7
I67
sg17
VC0858952
p8101
sg10
I7
sg11
Vsilence
p8102
sg13
I1
sa(dp8103
g7
I117
sg17
VC0677886
p8104
sg10
I25
sg11
Vepithelial ovarian cancer
p8105
sg13
I3
sasa(dp8106
g2
S'Functional studies showed that silence of CDKN3 inhibited cancer cell proliferation by promoting cell cycle progression in G1 phase, decreased cell invasion and promoted EOC cells apoptosis.\n'
p8107
sg4
(lp8108
sg14
(lp8109
(dp8110
g7
I31
sg17
VC0858952
p8111
sg10
I7
sg11
Vsilence
p8112
sg13
I1
sa(dp8113
g7
I58
sg17
VC0006826
p8114
sg10
I6
sg11
Vcancer
p8115
sg13
I1
sa(dp8116
g7
I143
sg17
VC2699153
p8117
sg10
I13
sg11
Vcell invasion
p8118
sg13
I2
sa(dp8119
g7
I70
sg17
VC0334094
p8120
sg10
I13
sg11
Vproliferation
p8121
sg13
I1
sasa(dp8122
g2
S'These findings indicated that CDKN3 might serve as a useful potential target for treatment of ovarian cancer.\n'
p8123
sg4
(lp8124
sg14
(lp8125
(dp8126
g7
I94
sg17
VC1140680
p8127
sg10
I14
sg11
Vovarian cancer
p8128
sg13
I2
sasa(dp8129
g2
S'We first discovered the pro-tumor effect of a controversial cell cycle regulator, cylin-dependent kinase inhibitor 3 (CDKN3), which is highly expressed in colorectal cancer, and the possible related signaling pathways, by bioinformatics tools.\n'
p8130
sg4
(lp8131
(dp8132
g7
I82
sg8
VP19525
p8133
sg10
I34
sg11
Vcylin-dependent kinase inhibitor 3
p8134
sg13
I4
sa(dp8135
g7
I118
sg8
VP19525
p8136
sg10
I5
sg11
VCDKN3
p8137
sg13
I1
sasg14
(lp8138
(dp8139
g7
I28
sg17
VC0027651
p8140
sg10
I5
sg11
Vtumor
p8141
sg13
I1
sa(dp8142
g7
I155
sg17
VC1527249
p8143
sg10
I17
sg11
Vcolorectal cancer
p8144
sg13
I2
sasa(dp8145
g2
S'We found that CDKN3 had remarkable effects in suppressing colorectal cancer cell proliferation and migration, inducing cell cycle arrest and apoptosis in a colorectal cancer cell line, SW480 cells.\n'
p8146
sg4
(lp8147
sg14
(lp8148
(dp8149
g7
I58
sg17
VC1527249
p8150
sg10
I17
sg11
Vcolorectal cancer
p8151
sg13
I2
sa(dp8152
g7
I58
sg17
VC1527249
p8153
sg10
I17
sg11
Vcolorectal cancer
p8154
sg13
I2
sa(dp8155
g7
I81
sg17
VC0334094
p8156
sg10
I13
sg11
Vproliferation
p8157
sg13
I1
sasa(dp8158
g2
S'Our study, for the first time, provided consistent evidence showing overexpression of cell cycle regulator CDKN3, in colorectal cancer.\n'
p8159
sg4
(lp8160
sg14
(lp8161
(dp8162
g7
I117
sg17
VC1527249
p8163
sg10
I17
sg11
Vcolorectal cancer
p8164
sg13
I2
sasa(dp8165
g2
S'The in vitro studies in SW480 cells revealed a unique role of CDKN3 in regulating cellular behavior of colorectal cancer cells, and implied the possibility of targeting CDKN3 as a novel treatment for colorectal cancer.\n'
p8166
sg4
(lp8167
sg14
(lp8168
(dp8169
g7
I103
sg17
VC1527249
p8170
sg10
I17
sg11
Vcolorectal cancer
p8171
sg13
I2
sa(dp8172
g7
I103
sg17
VC1527249
p8173
sg10
I17
sg11
Vcolorectal cancer
p8174
sg13
I2
sasa(dp8175
g2
S'Using in situ hybridization, the expression of key clock genes, including period circadian protein homolog (Per) 1 and 2, cryptochrome 1 (Cry1), circadian locomoter output cycles protein kaput (Clock), brain and muscle ARNT-like protein 1 (Bmal1) and casein kinase 1Epsilon (CK1Epsilon) were retrospectively examined in 51 cases of colorectal carcinoma and 10 cases of adenoma.\n'
p8176
sg4
(lp8177
(dp8178
g7
I219
sg8
VP14222
p8179
sg10
I19
sg11
VARNT-like protein 1
p8180
sg13
I3
sa(dp8181
g7
I275
sg8
VP48729
p8182
sg10
I10
sg11
VCK1Epsilon
p8183
sg13
I1
sa(dp8184
g7
I138
sg8
g9
sg10
I4
sg11
VCry1
p8185
sg13
I1
sa(dp8186
g7
I122
sg8
g9
sg10
I14
sg11
Vcryptochrome 1
p8187
sg13
I2
sa(dp8188
g7
I81
sg8
g9
sg10
I39
sg11
Vcircadian protein homolog (Per) 1 and 2
p8189
sg13
I7
sa(dp8190
g7
I251
sg8
VP48729
p8191
sg10
I22
sg11
Vcasein kinase 1Epsilon
p8192
sg13
I3
sasg14
(lp8193
(dp8194
g7
I369
sg17
VC0001430
p8195
sg10
I7
sg11
Vadenoma
p8196
sg13
I1
sa(dp8197
g7
I332
sg17
VC0009402
p8198
sg10
I20
sg11
Vcolorectal carcinoma
p8199
sg13
I2
sasa(dp8200
g2
S'The present study demonstrated that the protein expression levels of human circadian locomoter output cycles protein kaput (hCLOCK) is significantly increased, while miR-124 is attenuated in high-grade human CRC tissues and in the more invasive colorectal cancer cell lines SW620 and LOVO.\n'
p8201
sg4
(lp8202
(dp8203
g7
I166
sg8
g9
sg10
I7
sg11
VmiR-124
p8204
sg13
I1
sa(dp8205
g7
I124
sg8
g9
sg10
I6
sg11
VhCLOCK
p8206
sg13
I1
sa(dp8207
g7
I69
sg8
g9
sg10
I53
sg11
Vhuman circadian locomoter output cycles protein kaput
p8208
sg13
I7
sasg14
(lp8209
(dp8210
g7
I208
sg17
VC1527249
p8211
sg10
I3
sg11
VCRC
p8212
sg13
I1
sa(dp8213
g7
I245
sg17
VC1527249
p8214
sg10
I17
sg11
Vcolorectal cancer
p8215
sg13
I2
sasa(dp8216
g2
S'The CLOCK gene may be designated as a novel candidate for targeted gene therapy in drug-resistant ovarian cancer.\n'
p8217
sg4
(lp8218
(dp8219
g7
I4
sg8
g9
sg10
I10
sg11
VCLOCK gene
p8220
sg13
I2
sasg14
(lp8221
(dp8222
g7
I98
sg17
VC1140680
p8223
sg10
I14
sg11
Vovarian cancer
p8224
sg13
I2
sasa(dp8225
g2
S"Study distribution by tumor was as follows: breast cancer (n=15), prostate cancer (n=3), pancreatic cancer (n=2), non-Hodgkin's lymphoma (n=2), glioma (n=1), chronic lymphocytic leukemia (n=1), colorectal cancer (n=1), non-small cell lung cancer (n=1) and ovarian cancer (n=1).We identified 10 single nucleotide polymorphisms (SNPs) significantly associated with cancer risk: NPAS2 rs10165970 (mixed and breast cancer shiftworkers), rs895520 (mixed), rs17024869 (breast) and rs7581886 (breast); CLOCK rs3749474 (breast) and rs11943456 (breast); RORA rs7164773 (breast and breast cancer postmenopausal), rs10519097 (breast); RORB rs7867494 (breast cancer postmenopausal), PER3 rs1012477 (breast cancer subgroups) and assessed the level of quality evidence to be intermediate.\n"
p8226
sg4
(lp8227
(dp8228
g7
I495
sg8
g9
sg10
I15
sg11
VCLOCK rs3749474
p8229
sg13
I2
sa(dp8230
g7
I376
sg8
g9
sg10
I16
sg11
VNPAS2 rs10165970
p8231
sg13
I2
sa(dp8232
g7
I671
sg8
VP56645
p8233
sg10
I4
sg11
VPER3
p8234
sg13
I1
sa(dp8235
g7
I624
sg8
g9
sg10
I14
sg11
VRORB rs7867494
p8236
sg13
I2
sasg14
(lp8237
(dp8238
g7
I219
sg17
VC0007131
p8239
sg10
I26
sg11
Vnon-small cell lung cancer
p8240
sg13
I4
sa(dp8241
g7
I144
sg17
VC0017638
p8242
sg10
I6
sg11
Vglioma
p8243
sg13
I1
sa(dp8244
g7
I22
sg17
VC0027651
p8245
sg10
I5
sg11
Vtumor
p8246
sg13
I1
sa(dp8247
g7
I44
sg17
VC0678222
p8248
sg10
I13
sg11
Vbreast cancer
p8249
sg13
I2
sa(dp8250
g7
I44
sg17
VC0678222
p8251
sg10
I13
sg11
Vbreast cancer
p8252
sg13
I2
sa(dp8253
g7
I44
sg17
VC0678222
p8254
sg10
I13
sg11
Vbreast cancer
p8255
sg13
I2
sa(dp8256
g7
I51
sg17
VC0006826
p8257
sg10
I6
sg11
Vcancer
p8258
sg13
I1
sa(dp8259
g7
I89
sg17
VC0235974
p8260
sg10
I17
sg11
Vpancreatic cancer
p8261
sg13
I2
sa(dp8262
g7
I256
sg17
VC1140680
p8263
sg10
I14
sg11
Vovarian cancer
p8264
sg13
I2
sa(dp8265
g7
I44
sg17
VC0678222
p8266
sg10
I13
sg11
Vbreast cancer
p8267
sg13
I2
sa(dp8268
g7
I44
sg17
VC0678222
p8269
sg10
I13
sg11
Vbreast cancer
p8270
sg13
I2
sa(dp8271
g7
I158
sg17
VC0023434
p8272
sg10
I28
sg11
Vchronic lymphocytic leukemia
p8273
sg13
I3
sa(dp8274
g7
I114
sg17
VC0024305
p8275
sg10
I22
sg11
Vnon-Hodgkin's lymphoma
p8276
sg13
I2
sa(dp8277
g7
I66
sg17
VC0600139
p8278
sg10
I15
sg11
Vprostate cancer
p8279
sg13
I2
sa(dp8280
g7
I194
sg17
VC1527249
p8281
sg10
I17
sg11
Vcolorectal cancer
p8282
sg13
I2
sasa(dp8283
g2
S'We summarize fifteen epidemiological studies, including five studies on shift work that have indicated BMAL1, BMAL2, CLOCK, NPAS2, CRY1, CRY2, PER1, PER3 and TIMELESS as a candidate breast cancer risk variants.\n'
p8284
sg4
(lp8285
(dp8286
g7
I149
sg8
VP56645
p8287
sg10
I4
sg11
VPER3
p8288
sg13
I1
sa(dp8289
g7
I131
sg8
g9
sg10
I4
sg11
VCRY1
p8290
sg13
I1
sa(dp8291
g7
I124
sg8
g9
sg10
I5
sg11
VNPAS2
p8292
sg13
I1
sa(dp8293
g7
I158
sg8
VP60174
p8294
sg10
I8
sg11
VTIMELESS
p8295
sg13
I1
sa(dp8296
g7
I143
sg8
g9
sg10
I4
sg11
VPER1
p8297
sg13
I1
sa(dp8298
g7
I117
sg8
g9
sg10
I5
sg11
VCLOCK
p8299
sg13
I1
sa(dp8300
g7
I137
sg8
g9
sg10
I4
sg11
VCRY2
p8301
sg13
I1
sasg14
(lp8302
(dp8303
g7
I182
sg17
VC0678222
p8304
sg10
I13
sg11
Vbreast cancer
p8305
sg13
I2
sasa(dp8306
g2
S'This study sought to determine TANK (rs1921310, rs3820998) gene polymorphism in patients suffering from chronic periodontitis and peri-implantitis among an Iranian population.\n'
p8307
sg4
(lp8308
(dp8309
g7
I31
sg8
g9
sg10
I4
sg11
VTANK
p8310
sg13
I1
sasg14
(lp8311
(dp8312
g7
I89
sg17
VC0683278
p8313
sg10
I9
sg11
Vsuffering
p8314
sg13
I1
sa(dp8315
g7
I104
sg17
VC0266929
p8316
sg10
I21
sg11
Vchronic periodontitis
p8317
sg13
I2
sa(dp8318
g7
I130
sg17
VC2936258
p8319
sg10
I16
sg11
Vperi-implantitis
p8320
sg13
I1
sasa(dp8321
g2
S'The tumor necrosis factor receptor-associated factor family member-associated nuclear factor-KB (NF-KB) activator (TANK) takes part in the tumor necrosis factor-Alfa (TNF-Alfa)-mediated NF-KB signaling pathway and the interferon (IFN)-induction pathways that have relevance to HBV-related liver disease.\n'
p8322
sg4
(lp8323
(dp8324
g7
I4
sg8
VP01375
p8325
sg10
I91
sg11
Vtumor necrosis factor receptor-associated factor family member-associated nuclear factor-KB
p8326
sg13
I9
sa(dp8327
g7
I218
sg8
VP01563
p8328
sg10
I10
sg11
Vinterferon
p8329
sg13
I1
sa(dp8330
g7
I115
sg8
g9
sg10
I4
sg11
VTANK
p8331
sg13
I1
sa(dp8332
g7
I139
sg8
VP01375
p8333
sg10
I26
sg11
Vtumor necrosis factor-Alfa
p8334
sg13
I3
sa(dp8335
g7
I167
sg8
VP01375
p8336
sg10
I8
sg11
VTNF-Alfa
p8337
sg13
I1
sa(dp8338
g7
I230
sg8
VP01562
p8339
sg10
I3
sg11
VIFN
p8340
sg13
I1
sasg14
(lp8341
(dp8342
g7
I4
sg17
VC0333516
p8343
sg10
I14
sg11
Vtumor necrosis
p8344
sg13
I2
sa(dp8345
g7
I289
sg17
VC0023895
p8346
sg10
I13
sg11
Vliver disease
p8347
sg13
I2
sa(dp8348
g7
I4
sg17
VC0333516
p8349
sg10
I14
sg11
Vtumor necrosis
p8350
sg13
I2
sa(dp8351
g7
I277
sg17
VC0019163
p8352
sg10
I3
sg11
VHBV
p8353
sg13
I1
sasa(dp8354
g2
S'These results indicate that treatment with TUDCA may be helpful to counteract obesity-induced hyperinsulinemia through increasing insulin clearance, likely through enhanced liver IDE expression in a mechanism dependent on S1PR2-Insulin pathway activation.\n'
p8355
sg4
(lp8356
(dp8357
g7
I228
sg8
VP01308
p8358
sg10
I7
sg11
VInsulin
p8359
sg13
I1
sa(dp8360
g7
I99
sg8
VP01308
p8361
sg10
I7
sg11
Vinsulin
p8362
sg13
I1
sa(dp8363
g7
I179
sg8
VP14735
p8364
sg10
I3
sg11
VIDE
p8365
sg13
I1
sa(dp8366
g7
I222
sg8
g9
sg10
I5
sg11
VS1PR2
p8367
sg13
I1
sasg14
(lp8368
(dp8369
g7
I78
sg17
VC0028754
p8370
sg10
I7
sg11
Vobesity
p8371
sg13
I1
sa(dp8372
g7
I119
sg17
VC0020459
p8373
sg10
I18
sg11
Vincreasing insulin
p8374
sg13
I2
sa(dp8375
g7
I94
sg17
VC0020459
p8376
sg10
I16
sg11
Vhyperinsulinemia
p8377
sg13
I1
sasa(dp8378
g2
S'Insulin-degrading enzyme (IDE) is a ubiquitous zinc peptidase of the inverzincin family, which has been initially discovered as the enzyme responsible for insulin catabolism; therefore, its involvement in the onset of diabetes has been largely investigated.\n'
p8379
sg4
(lp8380
(dp8381
g7
I0
sg8
VP14735
p8382
sg10
I24
sg11
VInsulin-degrading enzyme
p8383
sg13
I2
sa(dp8384
g7
I47
sg8
g9
sg10
I14
sg11
Vzinc peptidase
p8385
sg13
I2
sa(dp8386
g7
I26
sg8
VP14735
p8387
sg10
I3
sg11
VIDE
p8388
sg13
I1
sa(dp8389
g7
I155
sg8
VP01308
p8390
sg10
I7
sg11
Vinsulin
p8391
sg13
I1
sasg14
(lp8392
(dp8393
g7
I218
sg17
VC0011849
p8394
sg10
I8
sg11
Vdiabetes
p8395
sg13
I1
sasa(dp8396
g2
S'Impairment of the insulin-degrading enzyme (IDE) is associated with obesity and type 2 diabetes mellitus (T2DM).\n'
p8397
sg4
(lp8398
(dp8399
g7
I18
sg8
VP14735
p8400
sg10
I24
sg11
Vinsulin-degrading enzyme
p8401
sg13
I2
sa(dp8402
g7
I44
sg8
VP14735
p8403
sg10
I3
sg11
VIDE
p8404
sg13
I1
sasg14
(lp8405
(dp8406
g7
I106
sg17
VC0011860
p8407
sg10
I4
sg11
VT2DM
p8408
sg13
I1
sa(dp8409
g7
I80
sg17
VC0011860
p8410
sg10
I24
sg11
Vtype 2 diabetes mellitus
p8411
sg13
I4
sa(dp8412
g7
I0
sg17
VC0684336
p8413
sg10
I10
sg11
VImpairment
p8414
sg13
I1
sa(dp8415
g7
I68
sg17
VC0028754
p8416
sg10
I7
sg11
Vobesity
p8417
sg13
I1
sasa(dp8418
g2
S'Several mechanisms have been reported underlying the association of the two disorders, diabetes and dementia, one among which is the insulin-degrading enzyme (IDE) which is known to degrade insulin as well beta-amyloid peptides.\n'
p8419
sg4
(lp8420
(dp8421
g7
I159
sg8
VP14735
p8422
sg10
I3
sg11
VIDE
p8423
sg13
I1
sa(dp8424
g7
I133
sg8
VP14735
p8425
sg10
I24
sg11
Vinsulin-degrading enzyme
p8426
sg13
I2
sa(dp8427
g7
I133
sg8
VP01308
p8428
sg10
I7
sg11
Vinsulin
p8429
sg13
I1
sasg14
(lp8430
(dp8431
g7
I100
sg17
VC0497327
p8432
sg10
I8
sg11
Vdementia
p8433
sg13
I1
sa(dp8434
g7
I211
sg17
VC0011560
p8435
sg10
I7
sg11
Vamyloid
p8436
sg13
I1
sa(dp8437
g7
I87
sg17
VC0011849
p8438
sg10
I8
sg11
Vdiabetes
p8439
sg13
I1
sasa(dp8440
g2
S'We concluded that vitamin D3 ameliorated insulin resistance and hyperinsulinemia in diabetic rat model received HFW through reduction of IDE and activation of insulin receptor phosphorylation.\n'
p8441
sg4
(lp8442
(dp8443
g7
I41
sg8
VP01308
p8444
sg10
I7
sg11
Vinsulin
p8445
sg13
I1
sa(dp8446
g7
I159
sg8
VP01308
p8447
sg10
I16
sg11
Vinsulin receptor
p8448
sg13
I2
sasg14
(lp8449
(dp8450
g7
I64
sg17
VC0020459
p8451
sg10
I16
sg11
Vhyperinsulinemia
p8452
sg13
I1
sa(dp8453
g7
I41
sg17
VC0021655
p8454
sg10
I18
sg11
Vinsulin resistance
p8455
sg13
I2
sasa(dp8456
g2
S'Independently, the same approach identified a second homozygous truncating GZF1 variant in another multiplex consanguineous family affected by severe myopia, retinal detachment, and milder skeletal involvement.\n'
p8457
sg4
(lp8458
(dp8459
g7
I64
sg8
g9
sg10
I23
sg11
Vtruncating GZF1 variant
p8460
sg13
I3
sasg14
(lp8461
(dp8462
g7
I158
sg17
VC0035305
p8463
sg10
I18
sg11
Vretinal detachment
p8464
sg13
I2
sa(dp8465
g7
I143
sg17
VC0271183
p8466
sg10
I13
sg11
Vsevere myopia
p8467
sg13
I2
sasa(dp8468
g2
S'Subgroup analyses found that the IL4RA I50V polymorphism was significantly associated with asthma risk in Asians (OR = 1.72, 95% CI 1.31-2.25, P&lt;0.0001), pediatric asthma risk (OR = 1.50, 95% CI 1.13-1.99, P = 0.005), and atopic asthma risk (OR = 1.88, 95% CI 1.27-2.79, P = 0.002).\n'
p8469
sg4
(lp8470
sg14
(lp8471
(dp8472
g7
I225
sg17
VC0155877
p8473
sg10
I13
sg11
Vatopic asthma
p8474
sg13
I2
sa(dp8475
g7
I91
sg17
VC0004096
p8476
sg10
I6
sg11
Vasthma
p8477
sg13
I1
sa(dp8478
g7
I91
sg17
VC0004096
p8479
sg10
I6
sg11
Vasthma
p8480
sg13
I1
sasa(dp8481
g2
S'To verify the association of transforming growth factor-beta1(TGF-beta1) (C-509T and T869C), CD14 (C-159T), IL-4 (C-590T), IL-4R (ILe50Val) and ADAM33 (S_2) gene polymorphisms with asthma severity in a sample of patients with mild, moderate and severe persistent atopic asthma.\n'
p8482
sg4
(lp8483
(dp8484
g7
I108
sg8
VP05112
p8485
sg10
I4
sg11
VIL-4
p8486
sg13
I1
sa(dp8487
g7
I29
sg8
VP01137
p8488
sg10
I32
sg11
Vtransforming growth factor-beta1
p8489
sg13
I3
sa(dp8490
g7
I144
sg8
g9
sg10
I6
sg11
VADAM33
p8491
sg13
I1
sa(dp8492
g7
I62
sg8
VP01137
p8493
sg10
I9
sg11
VTGF-beta1
p8494
sg13
I1
sa(dp8495
g7
I93
sg8
VP08571
p8496
sg10
I4
sg11
VCD14
p8497
sg13
I1
sasg14
(lp8498
(dp8499
g7
I263
sg17
VC0155877
p8500
sg10
I13
sg11
Vatopic asthma
p8501
sg13
I2
sa(dp8502
g7
I181
sg17
VC0004096
p8503
sg10
I6
sg11
Vasthma
p8504
sg13
I1
sasa(dp8505
g2
S'To investigate the correlation between Chlamydia pneumonia (Cpn) infection and chronic obstructive pulmonary disease (COPD).\n'
p8506
sg4
(lp8507
sg14
(lp8508
(dp8509
g7
I79
sg17
VC0024117
p8510
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p8511
sg13
I4
sa(dp8512
g7
I118
sg17
VC0024117
p8513
sg10
I4
sg11
VCOPD
p8514
sg13
I1
sa(dp8515
g7
I49
sg17
VC0032285
p8516
sg10
I9
sg11
Vpneumonia
p8517
sg13
I1
sa(dp8518
g7
I65
sg17
VC0009450
p8519
sg10
I9
sg11
Vinfection
p8520
sg13
I1
sasa(dp8521
g2
S'Chlamydia pneumoniae (Cpn) infection may play a role in the pathogenesis of chronic obstructive pulmonary disease (COPD).\n'
p8522
sg4
(lp8523
(dp8524
g7
I0
sg8
VP15169
p8525
sg10
I20
sg11
VChlamydia pneumoniae
p8526
sg13
I2
sa(dp8527
g7
I22
sg8
VP15169
p8528
sg10
I3
sg11
VCpn
p8529
sg13
I1
sasg14
(lp8530
(dp8531
g7
I27
sg17
VC0009450
p8532
sg10
I9
sg11
Vinfection
p8533
sg13
I1
sa(dp8534
g7
I115
sg17
VC0024117
p8535
sg10
I4
sg11
VCOPD
p8536
sg13
I1
sa(dp8537
g7
I76
sg17
VC0024117
p8538
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p8539
sg13
I4
sa(dp8540
g7
I60
sg17
VC0699748
p8541
sg10
I12
sg11
Vpathogenesis
p8542
sg13
I1
sasa(dp8543
g2
S'To determine the possible association between Chlamydiae pneumoniae (Cpn) infection and chronic obstructive pulmonary disease (COPD).\n'
p8544
sg4
(lp8545
(dp8546
g7
I46
sg8
VP15169
p8547
sg10
I21
sg11
VChlamydiae pneumoniae
p8548
sg13
I2
sa(dp8549
g7
I69
sg8
VP15169
p8550
sg10
I3
sg11
VCpn
p8551
sg13
I1
sasg14
(lp8552
(dp8553
g7
I127
sg17
VC0024117
p8554
sg10
I4
sg11
VCOPD
p8555
sg13
I1
sa(dp8556
g7
I88
sg17
VC0024117
p8557
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p8558
sg13
I4
sa(dp8559
g7
I74
sg17
VC0009450
p8560
sg10
I9
sg11
Vinfection
p8561
sg13
I1
sasa(dp8562
g2
S'The objective of the study was to investigate the possible association of Chlamydia pneumoniae (Cpn) in acute exacerbations of chronic obstructive pulmonary disease (COPD) patients.\n'
p8563
sg4
(lp8564
(dp8565
g7
I96
sg8
VP15169
p8566
sg10
I3
sg11
VCpn
p8567
sg13
I1
sa(dp8568
g7
I74
sg8
VP15169
p8569
sg10
I20
sg11
VChlamydia pneumoniae
p8570
sg13
I2
sasg14
(lp8571
(dp8572
g7
I127
sg17
VC0024117
p8573
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p8574
sg13
I4
sa(dp8575
g7
I166
sg17
VC0024117
p8576
sg10
I4
sg11
VCOPD
p8577
sg13
I1
sasa(dp8578
g2
S'Reading this article will familiarize the reader with (1) the unique chlamydial intracellular life cycle and the propensity for human chlamydial infections to become persistent and to result in immunopathologic (inflammatory) damage in target organs and (2) current evidence linking Chlamydia pneumoniae (Cpn) infection to obstructive lung diseases (asthma and chronic obstructive pulmonary disease, COPD).\n'
p8579
sg4
(lp8580
(dp8581
g7
I305
sg8
VP15169
p8582
sg10
I3
sg11
VCpn
p8583
sg13
I1
sa(dp8584
g7
I283
sg8
VP15169
p8585
sg10
I20
sg11
VChlamydia pneumoniae
p8586
sg13
I2
sasg14
(lp8587
(dp8588
g7
I400
sg17
VC0024117
p8589
sg10
I4
sg11
VCOPD
p8590
sg13
I1
sa(dp8591
g7
I145
sg17
VC0009450
p8592
sg10
I9
sg11
Vinfection
p8593
sg13
I1
sa(dp8594
g7
I323
sg17
VC0600260
p8595
sg10
I25
sg11
Vobstructive lung diseases
p8596
sg13
I3
sa(dp8597
g7
I134
sg17
VC0008149
p8598
sg10
I21
sg11
Vchlamydial infections
p8599
sg13
I2
sa(dp8600
g7
I361
sg17
VC0024117
p8601
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p8602
sg13
I4
sa(dp8603
g7
I350
sg17
VC0004096
p8604
sg10
I6
sg11
Vasthma
p8605
sg13
I1
sasa(dp8606
g2
S'Although the full clinical significance of these Cpn-obstructive lung disease associations remains to be established, reports of asthma improvement after treatment of Cpn infection deserve further investigation.\n'
p8607
sg4
(lp8608
sg14
(lp8609
(dp8610
g7
I53
sg17
VC0600260
p8611
sg10
I24
sg11
Vobstructive lung disease
p8612
sg13
I3
sa(dp8613
g7
I129
sg17
VC0004096
p8614
sg10
I6
sg11
Vasthma
p8615
sg13
I1
sa(dp8616
g7
I171
sg17
VC0009450
p8617
sg10
I9
sg11
Vinfection
p8618
sg13
I1
sasa(dp8619
g2
S'Taken together, we conclude that EGFR TKIs enhance the sensitivity of NSCLC cells to vATPase inhibitors by decreasing Hif-1Alfa/Bnip3 expression.\n'
p8620
sg4
(lp8621
(dp8622
g7
I128
sg8
g9
sg10
I5
sg11
VBnip3
p8623
sg13
I1
sasg14
(lp8624
(dp8625
g7
I70
sg17
VC0007131
p8626
sg10
I5
sg11
VNSCLC
p8627
sg13
I1
sasa(dp8628
g2
S'We found a significant upregulation of BNIP3 in human lung cancer datasets, and we identified a direct association between BNIP3 expression and survival rate of lung cancer patients.\n'
p8629
sg4
(lp8630
(dp8631
g7
I39
sg8
g9
sg10
I5
sg11
VBNIP3
p8632
sg13
I1
sa(dp8633
g7
I39
sg8
g9
sg10
I5
sg11
VBNIP3
p8634
sg13
I1
sasg14
(lp8635
(dp8636
g7
I54
sg17
VC0684249
p8637
sg10
I11
sg11
Vlung cancer
p8638
sg13
I2
sa(dp8639
g7
I54
sg17
VC0684249
p8640
sg10
I11
sg11
Vlung cancer
p8641
sg13
I2
sasa(dp8642
g2
S'In this study we used 115 NSCLC tissues to examine the immunohistochemical expression of four distinct molecules - the major regulator of autophagy Beclin 1, the anti-apoptotic and anti-autophagic protein Bcl-2, the pro-apoptotic and pro-autophagic protein BNIP3, and a marker of hypoxia and glucolysis, the glucose transporter Glut 1.\n'
p8643
sg4
(lp8644
(dp8645
g7
I138
sg8
g9
sg10
I18
sg11
Vautophagy Beclin 1
p8646
sg13
I3
sa(dp8647
g7
I181
sg8
VP10415
p8648
sg10
I29
sg11
Vanti-autophagic protein Bcl-2
p8649
sg13
I3
sa(dp8650
g7
I234
sg8
g9
sg10
I28
sg11
Vpro-autophagic protein BNIP3
p8651
sg13
I3
sasg14
(lp8652
(dp8653
g7
I280
sg17
VC0242184
p8654
sg10
I7
sg11
Vhypoxia
p8655
sg13
I1
sa(dp8656
g7
I26
sg17
VC0007131
p8657
sg10
I5
sg11
VNSCLC
p8658
sg13
I1
sasa(dp8659
g2
S'In conclusion, the accelerated autophagic status in NSCLC is unrelated to Beclin 1 and BNIP3 expression, but does show significant association with Bcl-2 reactivity.\n'
p8660
sg4
(lp8661
(dp8662
g7
I74
sg8
g9
sg10
I8
sg11
VBeclin 1
p8663
sg13
I2
sa(dp8664
g7
I87
sg8
g9
sg10
I5
sg11
VBNIP3
p8665
sg13
I1
sa(dp8666
g7
I148
sg8
VP10415
p8667
sg10
I5
sg11
VBcl-2
p8668
sg13
I1
sasg14
(lp8669
(dp8670
g7
I52
sg17
VC0007131
p8671
sg10
I5
sg11
VNSCLC
p8672
sg13
I1
sasa(dp8673
g2
S'This study was designed to determine the pattern and correlation between expression of the HIF-1Alfa transcriptional targets TGM2 and BNIP3 in laryngeal cancer, and investigate the association of BNIP3 and TGM2 with clinical outcome in laryngeal squamous cell carcinoma (SCC) patients receiving postoperative radiotherapy.\n'
p8674
sg4
(lp8675
(dp8676
g7
I134
sg8
g9
sg10
I5
sg11
VBNIP3
p8677
sg13
I1
sa(dp8678
g7
I125
sg8
VP21980
p8679
sg10
I4
sg11
VTGM2
p8680
sg13
I1
sa(dp8681
g7
I125
sg8
VP21980
p8682
sg10
I4
sg11
VTGM2
p8683
sg13
I1
sa(dp8684
g7
I134
sg8
g9
sg10
I5
sg11
VBNIP3
p8685
sg13
I1
sasg14
(lp8686
(dp8687
g7
I236
sg17
VC0280324
p8688
sg10
I33
sg11
Vlaryngeal squamous cell carcinoma
p8689
sg13
I4
sa(dp8690
g7
I143
sg17
VC0595989
p8691
sg10
I16
sg11
Vlaryngeal cancer
p8692
sg13
I2
sasa(dp8693
g2
S'Considering tumors with telomere shortening, expression for BNIP3, DAPK1, NDRG1, EGFR, and CDKN2A was significantly higher in NSCLC than in CRC, whereas TP53 was overexpressed in CRC with respect to NSCLC.\n'
p8694
sg4
(lp8695
(dp8696
g7
I140
sg8
VP31749
p8697
sg10
I17
sg11
VCRC, whereas TP53
p8698
sg13
I3
sa(dp8699
g7
I91
sg8
VP42771
p8700
sg10
I6
sg11
VCDKN2A
p8701
sg13
I1
sa(dp8702
g7
I67
sg8
VP53355
p8703
sg10
I5
sg11
VDAPK1
p8704
sg13
I1
sa(dp8705
g7
I140
sg8
VP31749
p8706
sg10
I3
sg11
VCRC
p8707
sg13
I1
sa(dp8708
g7
I74
sg8
g9
sg10
I5
sg11
VNDRG1
p8709
sg13
I1
sa(dp8710
g7
I60
sg8
g9
sg10
I5
sg11
VBNIP3
p8711
sg13
I1
sasg14
(lp8712
(dp8713
g7
I24
sg17
VC1515263
p8714
sg10
I19
sg11
Vtelomere shortening
p8715
sg13
I2
sa(dp8716
g7
I140
sg17
VC1527249
p8717
sg10
I3
sg11
VCRC
p8718
sg13
I1
sa(dp8719
g7
I12
sg17
VC0027651
p8720
sg10
I6
sg11
Vtumors
p8721
sg13
I1
sa(dp8722
g7
I126
sg17
VC0007131
p8723
sg10
I5
sg11
VNSCLC
p8724
sg13
I1
sa(dp8725
g7
I140
sg17
VC1527249
p8726
sg10
I3
sg11
VCRC
p8727
sg13
I1
sa(dp8728
g7
I126
sg17
VC0007131
p8729
sg10
I5
sg11
VNSCLC
p8730
sg13
I1
sasa(dp8731
g2
S'KIAA0513 was previously identified as upregulated in the dorsolateral prefrontal cortex of subjects with schizophrenia by microarray analysis.\n'
p8732
sg4
(lp8733
sg14
(lp8734
(dp8735
g7
I105
sg17
VC0036341
p8736
sg10
I13
sg11
Vschizophrenia
p8737
sg13
I1
sasa(dp8738
g2
S'Genome-wide association studies have resulted in the identification of the FTO gene as an important genetic determinant of diabetes mellitus.\n'
p8739
sg4
(lp8740
(dp8741
g7
I75
sg8
g9
sg10
I8
sg11
VFTO gene
p8742
sg13
I2
sasg14
(lp8743
(dp8744
g7
I123
sg17
VC0011849
p8745
sg10
I17
sg11
Vdiabetes mellitus
p8746
sg13
I2
sasa(dp8747
g2
S'Furthermore, miR-130b-DEX significantly reduced expression of PPAR-Gamma downstream factor perilipin 1 as well as adipogenesis genes fatty acid synthase, acetyl coenzyme A carboxylase, 11Beta hydroxysteroid dehydrogenase type 1 and fat mass and obesity-associated gene, whereas expression as well as enzyme activity of adipose triglyceride lipase and hormone-sensitive lipase were greatly increased.\n'
p8748
sg4
(lp8749
(dp8750
g7
I340
sg8
VP04118
p8751
sg10
I6
sg11
Vlipase
p8752
sg13
I1
sa(dp8753
g7
I154
sg8
g9
sg10
I29
sg11
Vacetyl coenzyme A carboxylase
p8754
sg13
I4
sa(dp8755
g7
I185
sg8
VP49366
p8756
sg10
I42
sg11
V11Beta hydroxysteroid dehydrogenase type 1
p8757
sg13
I5
sa(dp8758
g7
I319
sg8
VP04118
p8759
sg10
I27
sg11
Vadipose triglyceride lipase
p8760
sg13
I3
sa(dp8761
g7
I133
sg8
VP48023
p8762
sg10
I19
sg11
Vfatty acid synthase
p8763
sg13
I3
sa(dp8764
g7
I13
sg8
g9
sg10
I8
sg11
VmiR-130b
p8765
sg13
I1
sa(dp8766
g7
I91
sg8
g9
sg10
I11
sg11
Vperilipin 1
p8767
sg13
I2
sa(dp8768
g7
I62
sg8
g9
sg10
I10
sg11
VPPAR-Gamma
p8769
sg13
I1
sasg14
(lp8770
(dp8771
g7
I245
sg17
VC0028754
p8772
sg10
I7
sg11
Vobesity
p8773
sg13
I1
sasa(dp8774
g2
S'Higher fasting glucose levels may amplify obesity-risk in FTO carriers and lead to an exaggerated weight gain over time.\n'
p8775
sg4
(lp8776
sg14
(lp8777
(dp8778
g7
I42
sg17
VC0028754
p8779
sg10
I7
sg11
Vobesity
p8780
sg13
I1
sasa(dp8781
g2
S'Type 2 diabetes-associated genes TCF7L2 and FTO; and a miRNA, miR21 were further investigated in another B12-supplementation cohort.\n'
p8782
sg4
(lp8783
(dp8784
g7
I44
sg8
g9
sg10
I3
sg11
VFTO
p8785
sg13
I1
sasg14
(lp8786
(dp8787
g7
I0
sg17
VC0011860
p8788
sg10
I15
sg11
VType 2 diabetes
p8789
sg13
I3
sasa(dp8790
g2
S'Recent studies show that FTO single nucleotide polymorphisms (SNPs) are associated with obesity and type 2 diabetes mellitus (T2DM).\n'
p8791
sg4
(lp8792
sg14
(lp8793
(dp8794
g7
I88
sg17
VC0028754
p8795
sg10
I7
sg11
Vobesity
p8796
sg13
I1
sa(dp8797
g7
I126
sg17
VC0011860
p8798
sg10
I4
sg11
VT2DM
p8799
sg13
I1
sa(dp8800
g7
I100
sg17
VC0011860
p8801
sg10
I24
sg11
Vtype 2 diabetes mellitus
p8802
sg13
I4
sasa(dp8803
g2
S'The FTO gene is associated with type-2 diabetes (T2D) and increased fat mass.\n'
p8804
sg4
(lp8805
(dp8806
g7
I4
sg8
g9
sg10
I8
sg11
VFTO gene
p8807
sg13
I2
sasg14
(lp8808
(dp8809
g7
I32
sg17
VC0011860
p8810
sg10
I15
sg11
Vtype-2 diabetes
p8811
sg13
I2
sa(dp8812
g7
I49
sg17
VC0011860
p8813
sg10
I3
sg11
VT2D
p8814
sg13
I1
sasa(dp8815
g2
S'A significant association was found between the perilipin rs1052700 polymorphism and T2D, and between the FTO rs3751812 polymorphism and obesity (P = 0.03 and 0.003, respectively); however, no significant relationship was found between rs3751812 and T2D.\n'
p8816
sg4
(lp8817
(dp8818
g7
I48
sg8
g9
sg10
I19
sg11
Vperilipin rs1052700
p8819
sg13
I2
sasg14
(lp8820
(dp8821
g7
I85
sg17
VC0011860
p8822
sg10
I3
sg11
VT2D
p8823
sg13
I1
sa(dp8824
g7
I85
sg17
VC0011860
p8825
sg10
I3
sg11
VT2D
p8826
sg13
I1
sa(dp8827
g7
I137
sg17
VC0028754
p8828
sg10
I7
sg11
Vobesity
p8829
sg13
I1
sasa(dp8830
g2
S'The FTO rs3751812 polymorphism is a major genetic determinant of obesity, but not T2D.\n'
p8831
sg4
(lp8832
sg14
(lp8833
(dp8834
g7
I65
sg17
VC0028754
p8835
sg10
I7
sg11
Vobesity
p8836
sg13
I1
sa(dp8837
g7
I82
sg17
VC0011860
p8838
sg10
I3
sg11
VT2D
p8839
sg13
I1
sasa(dp8840
g2
S'Recent studies have implicated the FTO gene in child and adult obesity.\n'
p8841
sg4
(lp8842
(dp8843
g7
I35
sg8
g9
sg10
I8
sg11
VFTO gene
p8844
sg13
I2
sasg14
(lp8845
(dp8846
g7
I63
sg17
VC0028754
p8847
sg10
I7
sg11
Vobesity
p8848
sg13
I1
sasa(dp8849
g2
S'Variants (rs1558902, rs1121980, rs9939609, and rs9941349) in the fat mass and obesity-associated (FTO) gene exhibited strong but ethnicity-independent association with obesity.\n'
p8850
sg4
(lp8851
sg14
(lp8852
(dp8853
g7
I78
sg17
VC0028754
p8854
sg10
I7
sg11
Vobesity
p8855
sg13
I1
sa(dp8856
g7
I78
sg17
VC0028754
p8857
sg10
I7
sg11
Vobesity
p8858
sg13
I1
sasa(dp8859
g2
S'We showed that: (1) there was a significant association between the biased usage of IGHV4-34 (binds to the carbohydrate I/i antigens) and inactivating mutation of TNFAIP3 [encoding a global negative regulator of the canonical nuclear factor-KB (NF-KB) pathway] in ocular adnexal MALT lymphoma; (2) IGHV1-69 was significantly overrepresented (54%) in MALT lymphoma of the salivary gland, but was not associated with mutation in any of the 17 genes investigated; and (3) MALT lymphoma lacked mutations that are frequently seen in other B-cell lymphomas characterized by constitutive NF-KB activities, including mutations in CD79B, CARD11, MYD88, TNFRSF11A, and TRAF3.\n'
p8860
sg4
(lp8861
(dp8862
g7
I637
sg8
g9
sg10
I5
sg11
VMYD88
p8863
sg13
I1
sa(dp8864
g7
I644
sg8
g9
sg10
I9
sg11
VTNFRSF11A
p8865
sg13
I1
sa(dp8866
g7
I226
sg8
VP01160
p8867
sg10
I17
sg11
Vnuclear factor-KB
p8868
sg13
I2
sa(dp8869
g7
I629
sg8
g9
sg10
I6
sg11
VCARD11
p8870
sg13
I1
sa(dp8871
g7
I245
sg8
VP01160
p8872
sg10
I5
sg11
VNF-KB
p8873
sg13
I1
sa(dp8874
g7
I659
sg8
g9
sg10
I5
sg11
VTRAF3
p8875
sg13
I1
sa(dp8876
g7
I245
sg8
VP01160
p8877
sg10
I5
sg11
VNF-KB
p8878
sg13
I1
sa(dp8879
g7
I107
sg8
g9
sg10
I25
sg11
Vcarbohydrate I/i antigens
p8880
sg13
I3
sa(dp8881
g7
I163
sg8
VP21580
p8882
sg10
I7
sg11
VTNFAIP3
p8883
sg13
I1
sa(dp8884
g7
I622
sg8
VP40259
p8885
sg10
I5
sg11
VCD79B
p8886
sg13
I1
sasg14
(lp8887
(dp8888
g7
I279
sg17
VC0242647
p8889
sg10
I13
sg11
VMALT lymphoma
p8890
sg13
I2
sa(dp8891
g7
I534
sg17
VC0079731
p8892
sg10
I16
sg11
VB-cell lymphomas
p8893
sg13
I2
sa(dp8894
g7
I264
sg17
VC1335103
p8895
sg10
I28
sg11
Vocular adnexal MALT lymphoma
p8896
sg13
I4
sa(dp8897
g7
I279
sg17
VC0242647
p8898
sg10
I13
sg11
VMALT lymphoma
p8899
sg13
I2
sasa(dp8900
g2
S'Therefore, we aim to assess the correlation of endothelin-1 concentrations with the development and severity of knee osteoarthritis (OA).\n'
p8901
sg4
(lp8902
(dp8903
g7
I47
sg8
VP20800
p8904
sg10
I12
sg11
Vendothelin-1
p8905
sg13
I1
sasg14
(lp8906
(dp8907
g7
I112
sg17
VC0409959
p8908
sg10
I19
sg11
Vknee osteoarthritis
p8909
sg13
I2
sasa(dp8910
g2
S'Together, the results here demonstrate that the febrile response in zymosan-induced arthritis in rats depends on the centrally acting pyrogenic cytokines TNF-Alfa, IL-1Beta, and IL-6, but does not depend on either CRF or ET-1.\n'
p8911
sg4
(lp8912
(dp8913
g7
I221
sg8
VP05305
p8914
sg10
I4
sg11
VET-1
p8915
sg13
I1
sa(dp8916
g7
I178
sg8
VP05231
p8917
sg10
I4
sg11
VIL-6
p8918
sg13
I1
sa(dp8919
g7
I164
sg8
VP01584
p8920
sg10
I8
sg11
VIL-1Beta
p8921
sg13
I1
sa(dp8922
g7
I214
sg8
VP06850
p8923
sg10
I3
sg11
VCRF
p8924
sg13
I1
sa(dp8925
g7
I144
sg8
VP01375
p8926
sg10
I18
sg11
Vcytokines TNF-Alfa
p8927
sg13
I2
sasg14
(lp8928
(dp8929
g7
I84
sg17
VC0003864
p8930
sg10
I9
sg11
Varthritis
p8931
sg13
I1
sa(dp8932
g7
I214
sg17
VC0022661
p8933
sg10
I3
sg11
VCRF
p8934
sg13
I1
sasa(dp8935
g2
S'Antibodies to AQP4 and AQP1 are detected in neuromyelitis optica and are believed to play a pathogenic role.\n'
p8936
sg4
(lp8937
(dp8938
g7
I14
sg8
VP55087
p8939
sg10
I4
sg11
VAQP4
p8940
sg13
I1
sa(dp8941
g7
I23
sg8
VP29972
p8942
sg10
I4
sg11
VAQP1
p8943
sg13
I1
sasg14
(lp8944
(dp8945
g7
I44
sg17
VC0027873
p8946
sg10
I20
sg11
Vneuromyelitis optica
p8947
sg13
I2
sasa(dp8948
g2
S"Among thirteen different mammalian AQPs, AQP1 and AQP4 have been mainly studied in the CNS and evidence has been presented that they play important roles in the pathogenesis of CNS injury, edema and multiple diseases such as multiple sclerosis, neuromyelitis optica spectrum disorders, amyotrophic lateral sclerosis, glioblastoma multiforme, Alzheimer's disease and Parkinson's disease.\n"
p8949
sg4
(lp8950
(dp8951
g7
I50
sg8
VP55087
p8952
sg10
I4
sg11
VAQP4
p8953
sg13
I1
sa(dp8954
g7
I41
sg8
VP29972
p8955
sg10
I4
sg11
VAQP1
p8956
sg13
I1
sasg14
(lp8957
(dp8958
g7
I161
sg17
VC0699748
p8959
sg10
I12
sg11
Vpathogenesis
p8960
sg13
I1
sa(dp8961
g7
I366
sg17
VC0030567
p8962
sg10
I19
sg11
VParkinson's disease
p8963
sg13
I2
sa(dp8964
g7
I317
sg17
VC1621958
p8965
sg10
I23
sg11
Vglioblastoma multiforme
p8966
sg13
I2
sa(dp8967
g7
I286
sg17
VC0002736
p8968
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p8969
sg13
I3
sa(dp8970
g7
I245
sg17
VC0027873
p8971
sg10
I20
sg11
Vneuromyelitis optica
p8972
sg13
I2
sa(dp8973
g7
I342
sg17
VC1521724
p8974
sg10
I19
sg11
VAlzheimer's disease
p8975
sg13
I2
sa(dp8976
g7
I225
sg17
VC0026769
p8977
sg10
I18
sg11
Vmultiple sclerosis
p8978
sg13
I2
sa(dp8979
g7
I189
sg17
VC0013604
p8980
sg10
I5
sg11
Vedema
p8981
sg13
I1
sasa(dp8982
g2
S'ICOSL knockout (ICOSL-KO) mice and wild-type C57BL/6J mice were used as experimental Schistosomiasis model infected with Schistosoma japonicum.\n'
p8983
sg4
(lp8984
sg14
(lp8985
(dp8986
g7
I85
sg17
VC0036323
p8987
sg10
I15
sg11
VSchistosomiasis
p8988
sg13
I1
sasa(dp8989
g2
S'The ICOS-ICOSL signaling has a regulatory effect on CD154-CD40 signaling pathway, and may play an important role in the hepatic egg granuloma formation of Schistosomiasis.\n'
p8990
sg4
(lp8991
(dp8992
g7
I52
sg8
VP29965
p8993
sg10
I5
sg11
VCD154
p8994
sg13
I1
sa(dp8995
g7
I58
sg8
VP25942
p8996
sg10
I4
sg11
VCD40
p8997
sg13
I1
sa(dp8998
g7
I4
sg8
VP16410
p8999
sg10
I10
sg11
VICOS-ICOSL
p9000
sg13
I1
sasg14
(lp9001
(dp9002
g7
I132
sg17
VC0018188
p9003
sg10
I9
sg11
Vgranuloma
p9004
sg13
I1
sa(dp9005
g7
I155
sg17
VC0036323
p9006
sg10
I15
sg11
VSchistosomiasis
p9007
sg13
I1
sasa(dp9008
g2
S'Using models of schistosomiasis in ICOSL KO and the C57BL/6 WT mice, we studied the role of the ICOSL/ICOS interaction in the mediation of the Th17 response in host granulomatous inflammation, particularly in liver fibrosis during S. japonicum infection, and investigated the immune responses and pathology of ICOSL KO mice in these models.\n'
p9009
sg4
(lp9010
(dp9011
g7
I35
sg8
g9
sg10
I8
sg11
VICOSL KO
p9012
sg13
I2
sa(dp9013
g7
I35
sg8
VP16410
p9014
sg10
I4
sg11
VICOS
p9015
sg13
I1
sa(dp9016
g7
I35
sg8
g9
sg10
I8
sg11
VICOSL KO
p9017
sg13
I2
sa(dp9018
g7
I35
sg8
g9
sg10
I5
sg11
VICOSL
p9019
sg13
I1
sasg14
(lp9020
(dp9021
g7
I16
sg17
VC0036323
p9022
sg10
I15
sg11
Vschistosomiasis
p9023
sg13
I1
sa(dp9024
g7
I209
sg17
VC0239946
p9025
sg10
I14
sg11
Vliver fibrosis
p9026
sg13
I2
sa(dp9027
g7
I244
sg17
VC0009450
p9028
sg10
I9
sg11
Vinfection
p9029
sg13
I1
sa(dp9030
g7
I165
sg17
VC0553697
p9031
sg10
I26
sg11
Vgranulomatous inflammation
p9032
sg13
I2
sa(dp9033
g7
I297
sg17
VC0677042
p9034
sg10
I9
sg11
Vpathology
p9035
sg13
I1
sasa(dp9036
g2
S'Importantly, there was a clearly positive correlation between the presence of IL-17-producing cells and ICOS expression in ICOSL KO mice, and additional results indicated that Th17 was involved in the pathological tissue remodeling in liver fibrosis induced by schistosomiasis.\n'
p9037
sg4
(lp9038
(dp9039
g7
I123
sg8
g9
sg10
I8
sg11
VICOSL KO
p9040
sg13
I2
sasg14
(lp9041
(dp9042
g7
I235
sg17
VC0239946
p9043
sg10
I14
sg11
Vliver fibrosis
p9044
sg13
I2
sa(dp9045
g7
I261
sg17
VC0036323
p9046
sg10
I15
sg11
Vschistosomiasis
p9047
sg13
I1
sasa(dp9048
g2
S'LncRNA ZEB1 Antisense 1 (ZEB1-AS1) has been suggested to be an oncogenic role in human hepatocellular carcinoma, osteosarcoma, glioma and esophageal carcinoma progression.\n'
p9049
sg4
(lp9050
(dp9051
g7
I7
sg8
VP37275
p9052
sg10
I4
sg11
VZEB1
p9053
sg13
I1
sa(dp9054
g7
I30
sg8
g9
sg10
I3
sg11
VAS1
p9055
sg13
I1
sa(dp9056
g7
I0
sg8
VP37275
p9057
sg10
I23
sg11
VLncRNA ZEB1 Antisense 1
p9058
sg13
I4
sasg14
(lp9059
(dp9060
g7
I87
sg17
VC1512411
p9061
sg10
I24
sg11
Vhepatocellular carcinoma
p9062
sg13
I2
sa(dp9063
g7
I138
sg17
VC0152018
p9064
sg10
I20
sg11
Vesophageal carcinoma
p9065
sg13
I2
sa(dp9066
g7
I30
sg17
VC1846534
p9067
sg10
I3
sg11
VAS1
p9068
sg13
I1
sa(dp9069
g7
I113
sg17
VC0029463
p9070
sg10
I12
sg11
Vosteosarcoma
p9071
sg13
I1
sa(dp9072
g7
I127
sg17
VC0017638
p9073
sg10
I6
sg11
Vglioma
p9074
sg13
I1
sasa(dp9075
g2
S'ZEB1-AS1 acts as an oncogene in hepatocellular carcinoma, accelerating tumor growth and promoting metastasis.\n'
p9076
sg4
(lp9077
(dp9078
g7
I0
sg8
VP37275
p9079
sg10
I4
sg11
VZEB1
p9080
sg13
I1
sa(dp9081
g7
I5
sg8
g9
sg10
I3
sg11
VAS1
p9082
sg13
I1
sasg14
(lp9083
(dp9084
g7
I32
sg17
VC1512411
p9085
sg10
I24
sg11
Vhepatocellular carcinoma
p9086
sg13
I2
sa(dp9087
g7
I98
sg17
VC0027627
p9088
sg10
I10
sg11
Vmetastasis
p9089
sg13
I1
sa(dp9090
g7
I5
sg17
VC1846534
p9091
sg10
I3
sg11
VAS1
p9092
sg13
I1
sa(dp9093
g7
I71
sg17
VC0598934
p9094
sg10
I12
sg11
Vtumor growth
p9095
sg13
I2
sasa(dp9096
g2
S'LncRNA ZEB1-AS1 has been identified as a tumor oncogene in hepatocellular carcinoma.\n'
p9097
sg4
(lp9098
(dp9099
g7
I12
sg8
g9
sg10
I3
sg11
VAS1
p9100
sg13
I1
sa(dp9101
g7
I7
sg8
VP37275
p9102
sg10
I4
sg11
VZEB1
p9103
sg13
I1
sasg14
(lp9104
(dp9105
g7
I12
sg17
VC1846534
p9106
sg10
I3
sg11
VAS1
p9107
sg13
I1
sa(dp9108
g7
I59
sg17
VC1512411
p9109
sg10
I24
sg11
Vhepatocellular carcinoma
p9110
sg13
I2
sa(dp9111
g7
I41
sg17
VC0027651
p9112
sg10
I5
sg11
Vtumor
p9113
sg13
I1
sasa(dp9114
g2
S"We analyzed the outcome of allo-SCT in a population of FLT3-positive AML patients according to molecular MRD at the pretransplantation workup, assessed by the quantitative expression evaluation of the panleukemic marker Wilms' tumor (WT1) gene.\n"
p9115
sg4
(lp9116
(dp9117
g7
I55
sg8
VP36888
p9118
sg10
I4
sg11
VFLT3
p9119
sg13
I1
sasg14
(lp9120
(dp9121
g7
I220
sg17
VC0027708
p9122
sg10
I12
sg11
VWilms' tumor
p9123
sg13
I2
sa(dp9124
g7
I32
sg17
VC1848934
p9125
sg10
I3
sg11
VSCT
p9126
sg13
I1
sa(dp9127
g7
I105
sg17
VC1840451
p9128
sg10
I3
sg11
VMRD
p9129
sg13
I1
sa(dp9130
g7
I234
sg17
VC0027708
p9131
sg10
I3
sg11
VWT1
p9132
sg13
I1
sa(dp9133
g7
I69
sg17
VC0023467
p9134
sg10
I3
sg11
VAML
p9135
sg13
I1
sasa(dp9136
g2
S'To determine the chemokine receptor expression profile in gastric mucosa-associated lymphoid tissue (MALT) lymphoma, we performed an expression analysis of 19 chemokine receptors at mRNA levels by using real-time RT-PCR, as well as of five chemokine receptors--CCR8, CCR9, CXCR4, CXCR6 and CXCR7--by immunohistochemistry on human tissue samples of Helicobacter pylori-associated gastritis, gastric MALT lymphoma and gastric extranodal diffuse large B-cell lymphoma originating from MALT lymphoma (transformed MALT lymphoma).\n'
p9137
sg4
(lp9138
(dp9139
g7
I261
sg8
VP51685
p9140
sg10
I4
sg11
VCCR8
p9141
sg13
I1
sa(dp9142
g7
I267
sg8
VP51686
p9143
sg10
I4
sg11
VCCR9
p9144
sg13
I1
sa(dp9145
g7
I273
sg8
VP61073
p9146
sg10
I5
sg11
VCXCR4
p9147
sg13
I1
sa(dp9148
g7
I290
sg8
VP25106
p9149
sg10
I5
sg11
VCXCR7
p9150
sg13
I1
sa(dp9151
g7
I280
sg8
g9
sg10
I5
sg11
VCXCR6
p9152
sg13
I1
sasg14
(lp9153
(dp9154
g7
I398
sg17
VC0242647
p9155
sg10
I13
sg11
VMALT lymphoma
p9156
sg13
I2
sa(dp9157
g7
I107
sg17
VC0024299
p9158
sg10
I8
sg11
Vlymphoma
p9159
sg13
I1
sa(dp9160
g7
I435
sg17
VC0079744
p9161
sg10
I29
sg11
Vdiffuse large B-cell lymphoma
p9162
sg13
I4
sa(dp9163
g7
I398
sg17
VC0242647
p9164
sg10
I13
sg11
VMALT lymphoma
p9165
sg13
I2
sa(dp9166
g7
I390
sg17
VC1333782
p9167
sg10
I21
sg11
Vgastric MALT lymphoma
p9168
sg13
I3
sa(dp9169
g7
I348
sg17
VC0343378
p9170
sg10
I40
sg11
VHelicobacter pylori-associated gastritis
p9171
sg13
I3
sasa(dp9172
g2
S'The transformation of gastric MALT lymphomas to gastric extranodal diffuse large B-cell lymphoma was accompanied by upregulation of CCR1, CCR5, CCR7, CCR8, CCR9, CXCR3, CXCR6, CXCR7 and XCR1.\n'
p9173
sg4
(lp9174
(dp9175
g7
I162
sg8
VP49682
p9176
sg10
I5
sg11
VCXCR3
p9177
sg13
I1
sa(dp9178
g7
I169
sg8
g9
sg10
I5
sg11
VCXCR6
p9179
sg13
I1
sa(dp9180
g7
I138
sg8
VP32302
p9181
sg10
I4
sg11
VCCR5
p9182
sg13
I1
sa(dp9183
g7
I132
sg8
VP32246
p9184
sg10
I4
sg11
VCCR1
p9185
sg13
I1
sa(dp9186
g7
I176
sg8
VP25106
p9187
sg10
I5
sg11
VCXCR7
p9188
sg13
I1
sa(dp9189
g7
I156
sg8
VP51686
p9190
sg10
I4
sg11
VCCR9
p9191
sg13
I1
sa(dp9192
g7
I150
sg8
VP51685
p9193
sg10
I4
sg11
VCCR8
p9194
sg13
I1
sa(dp9195
g7
I186
sg8
VP46094
p9196
sg10
I4
sg11
VXCR1
p9197
sg13
I1
sa(dp9198
g7
I144
sg8
VP32248
p9199
sg10
I4
sg11
VCCR7
p9200
sg13
I1
sasg14
(lp9201
(dp9202
g7
I67
sg17
VC0079744
p9203
sg10
I29
sg11
Vdiffuse large B-cell lymphoma
p9204
sg13
I4
sa(dp9205
g7
I4
sg17
VC1510411
p9206
sg10
I14
sg11
Vtransformation
p9207
sg13
I1
sa(dp9208
g7
I30
sg17
VC0242647
p9209
sg10
I14
sg11
VMALT lymphomas
p9210
sg13
I2
sasa(dp9211
g2
S'Feline leukemia virus (FeLV) p27 or gp70 antigen was detected in 21 lymphomas (54%).\n'
p9212
sg4
(lp9213
(dp9214
g7
I29
sg8
VP40305
p9215
sg10
I3
sg11
Vp27
p9216
sg13
I1
sa(dp9217
g7
I36
sg8
g9
sg10
I12
sg11
Vgp70 antigen
p9218
sg13
I2
sasg14
(lp9219
(dp9220
g7
I68
sg17
VC0024299
p9221
sg10
I9
sg11
Vlymphomas
p9222
sg13
I1
sa(dp9223
g7
I0
sg17
VC0085164
p9224
sg10
I15
sg11
VFeline leukemia
p9225
sg13
I2
sasa(dp9226
g2
S'Vaccines to large B cell lymphoma were made by the covalent attachment of an epitope from the gp70 glycoprotein (SSWDFITV) to the N-termini of the conformationally biased, response-selective C5a agonists EP54 (YSFKPMPLaR) and EP67 (YSFKDMP(MeL)aR).\n'
p9227
sg4
(lp9228
(dp9229
g7
I94
sg8
g9
sg10
I17
sg11
Vgp70 glycoprotein
p9230
sg13
I2
sa(dp9231
g7
I191
sg8
VP21730
p9232
sg10
I3
sg11
VC5a
p9233
sg13
I1
sa(dp9234
g7
I240
sg8
VP61006
p9235
sg10
I3
sg11
VMeL
p9236
sg13
I1
sasg14
(lp9237
(dp9238
g7
I18
sg17
VC0079731
p9239
sg10
I15
sg11
VB cell lymphoma
p9240
sg13
I3
sa(dp9241
g7
I240
sg17
VC3149631
p9242
sg10
I3
sg11
VMeL
p9243
sg13
I1
sasa(dp9244
g2
S'Syngeneic Balb/c mice were immunized with these EP54/EP67-containing vaccines and challenged with a lethal dose of the highly liver metastatic and gp70-expressing lymphoma cell line RAW117-H10 to evaluate the ability of these vaccines to induce protective immune outcomes.\n'
p9245
sg4
(lp9246
(dp9247
g7
I147
sg8
g9
sg10
I4
sg11
Vgp70
p9248
sg13
I1
sasg14
(lp9249
(dp9250
g7
I163
sg17
VC0024299
p9251
sg10
I8
sg11
Vlymphoma
p9252
sg13
I1
sasa(dp9253
g2
S'CD8(+) T lymphocytes activated in response to Vaccines 2 and 3 express cytotoxic specificity for gp70-expressing RAW117-H10 lymphoma cells, but not antigen-irrelevant MDA-MB231A human breast cancer cells.\n'
p9254
sg4
(lp9255
(dp9256
g7
I0
sg8
VP01732
p9257
sg10
I3
sg11
VCD8
p9258
sg13
I1
sa(dp9259
g7
I97
sg8
g9
sg10
I4
sg11
Vgp70
p9260
sg13
I1
sasg14
(lp9261
(dp9262
g7
I124
sg17
VC0024299
p9263
sg10
I8
sg11
Vlymphoma
p9264
sg13
I1
sa(dp9265
g7
I184
sg17
VC0678222
p9266
sg10
I13
sg11
Vbreast cancer
p9267
sg13
I2
sasa(dp9268
g2
S'Our strategy relies on the fact that feline leukemia virus subgroup B (FeLV-B) and amphotropic murine leukemia virus (A-MLV) have closely related gp70 surface envelope glycoproteins and use related Na(+)-dependent phosphate symporters, Pit1 and Pit2, respectively, as their receptors.\n'
p9269
sg4
(lp9270
(dp9271
g7
I245
sg8
g9
sg10
I4
sg11
VPit2
p9272
sg13
I1
sa(dp9273
g7
I236
sg8
VP28069
p9274
sg10
I4
sg11
VPit1
p9275
sg13
I1
sa(dp9276
g7
I146
sg8
g9
sg10
I35
sg11
Vgp70 surface envelope glycoproteins
p9277
sg13
I4
sa(dp9278
g7
I198
sg8
VP19525
p9279
sg10
I36
sg11
VNa(+)-dependent phosphate symporters
p9280
sg13
I3
sasg14
(lp9281
(dp9282
g7
I37
sg17
VC0085164
p9283
sg10
I15
sg11
Vfeline leukemia
p9284
sg13
I2
sa(dp9285
g7
I44
sg17
VC0023418
p9286
sg10
I8
sg11
Vleukemia
p9287
sg13
I1
sasa(dp9288
g2
S'Numerous studies have investigated the utility of serum intestinal fatty-acid binding protein (I-FABP) in differentiating acute intestinal ischemia from acute abdomen.\n'
p9289
sg4
(lp9290
(dp9291
g7
I56
sg8
VP12104
p9292
sg10
I37
sg11
Vintestinal fatty-acid binding protein
p9293
sg13
I4
sa(dp9294
g7
I95
sg8
VP12104
p9295
sg10
I6
sg11
VI-FABP
p9296
sg13
I1
sasg14
(lp9297
(dp9298
g7
I122
sg17
VC0001363
p9299
sg10
I25
sg11
Vacute intestinal ischemia
p9300
sg13
I3
sa(dp9301
g7
I153
sg17
VC0000727
p9302
sg10
I13
sg11
Vacute abdomen
p9303
sg13
I2
sasa(dp9304
g2
S'The aim of this meta-analysis is to determine the overall accuracy of serum I-FABP in the diagnosis of acute intestinal ischemia.\n'
p9305
sg4
(lp9306
(dp9307
g7
I70
sg8
VP12104
p9308
sg10
I12
sg11
Vserum I-FABP
p9309
sg13
I2
sasg14
(lp9310
(dp9311
g7
I103
sg17
VC0001363
p9312
sg10
I25
sg11
Vacute intestinal ischemia
p9313
sg13
I3
sasa(dp9314
g2
S'The meta-analysis carried out in this report suggests that the I-FABP may be a useful diagnostic tool to confirm acute intestinal ischemia in acute abdomen, but better-designed trials are still required to confirm our findings.\n'
p9315
sg4
(lp9316
(dp9317
g7
I63
sg8
VP12104
p9318
sg10
I6
sg11
VI-FABP
p9319
sg13
I1
sasg14
(lp9320
(dp9321
g7
I142
sg17
VC0000727
p9322
sg10
I13
sg11
Vacute abdomen
p9323
sg13
I2
sa(dp9324
g7
I113
sg17
VC0001363
p9325
sg10
I25
sg11
Vacute intestinal ischemia
p9326
sg13
I3
sasa(dp9327
g2
S"The aim of the present study was to evaluate whether I-FABP can predict active disease or remission in Crohn's disease (CD) and ulcerative colitis (UC) in a real-life IBD cohort.\n"
p9328
sg4
(lp9329
sg14
(lp9330
(dp9331
g7
I120
sg17
VC0010346
p9332
sg10
I2
sg11
VCD
p9333
sg13
I1
sa(dp9334
g7
I167
sg17
VC0021390
p9335
sg10
I3
sg11
VIBD
p9336
sg13
I1
sa(dp9337
g7
I90
sg17
VC0687702
p9338
sg10
I9
sg11
Vremission
p9339
sg13
I1
sa(dp9340
g7
I148
sg17
VC0009324
p9341
sg10
I2
sg11
VUC
p9342
sg13
I1
sa(dp9343
g7
I103
sg17
VC0010346
p9344
sg10
I15
sg11
VCrohn's disease
p9345
sg13
I2
sa(dp9346
g7
I128
sg17
VC0009324
p9347
sg10
I18
sg11
Vulcerative colitis
p9348
sg13
I2
sasa(dp9349
g2
S'In our study, we found the expression of EWSAT1 was upregulated in ovarian cancer cell lines and samples.\n'
p9350
sg4
(lp9351
sg14
(lp9352
(dp9353
g7
I67
sg17
VC1140680
p9354
sg10
I14
sg11
Vovarian cancer
p9355
sg13
I2
sasa(dp9356
g2
S'Ecoptic expression of EWSAT1 suppressed miR-330-5p expression in ovarian cancer cell.\n'
p9357
sg4
(lp9358
(dp9359
g7
I40
sg8
g9
sg10
I10
sg11
VmiR-330-5p
p9360
sg13
I1
sasg14
(lp9361
(dp9362
g7
I65
sg17
VC1140680
p9363
sg10
I14
sg11
Vovarian cancer
p9364
sg13
I2
sasa(dp9365
g2
S'Moreover, the expression of miR-330-5p was negatively related with the expression of EWSAT1 in ovarian cancer samples.\n'
p9366
sg4
(lp9367
(dp9368
g7
I28
sg8
g9
sg10
I10
sg11
VmiR-330-5p
p9369
sg13
I1
sasg14
(lp9370
(dp9371
g7
I95
sg17
VC1140680
p9372
sg10
I14
sg11
Vovarian cancer
p9373
sg13
I2
sasa(dp9374
g2
S'Ecoptic expression of miR-330-5p suppressed Pdia3 expression and overexpression of EWSAT1 promoted Pdia3 expression in ovarian cancer cell.\n'
p9375
sg4
(lp9376
(dp9377
g7
I22
sg8
g9
sg10
I10
sg11
VmiR-330-5p
p9378
sg13
I1
sa(dp9379
g7
I44
sg8
VP30101
p9380
sg10
I5
sg11
VPdia3
p9381
sg13
I1
sa(dp9382
g7
I44
sg8
VP30101
p9383
sg10
I5
sg11
VPdia3
p9384
sg13
I1
sasg14
(lp9385
(dp9386
g7
I119
sg17
VC1140680
p9387
sg10
I14
sg11
Vovarian cancer
p9388
sg13
I2
sasa(dp9389
g2
S'Overexpression of EWSAT1 increased ovarian cancer cell proliferation, colony formation and invasion through targeting miR-330-5p.\n'
p9390
sg4
(lp9391
(dp9392
g7
I118
sg8
g9
sg10
I10
sg11
VmiR-330-5p
p9393
sg13
I1
sasg14
(lp9394
(dp9395
g7
I55
sg17
VC0334094
p9396
sg10
I13
sg11
Vproliferation
p9397
sg13
I1
sa(dp9398
g7
I91
sg17
VC2699153
p9399
sg10
I8
sg11
Vinvasion
p9400
sg13
I1
sa(dp9401
g7
I35
sg17
VC1140680
p9402
sg10
I14
sg11
Vovarian cancer
p9403
sg13
I2
sasa(dp9404
g2
S'These data suggested that EWSAT1 might act as an oncogene in the development of ovarian cancer partly through inhibiting miR-330-5p expression.\n'
p9405
sg4
(lp9406
(dp9407
g7
I121
sg8
g9
sg10
I10
sg11
VmiR-330-5p
p9408
sg13
I1
sasg14
(lp9409
(dp9410
g7
I80
sg17
VC1140680
p9411
sg10
I14
sg11
Vovarian cancer
p9412
sg13
I2
sasa(dp9413
g2
S'Recently, lncRNA Ewing sarcoma-associated transcript 1 (EWSAT1) was functionally identified in Ewing sarcoma, a highly aggressive primary pediatric bone tumor.\n'
p9414
sg4
(lp9415
(dp9416
g7
I10
sg8
VP11308
p9417
sg10
I44
sg11
VlncRNA Ewing sarcoma-associated transcript 1
p9418
sg13
I5
sasg14
(lp9419
(dp9420
g7
I148
sg17
VC0005967
p9421
sg10
I10
sg11
Vbone tumor
p9422
sg13
I2
sa(dp9423
g7
I17
sg17
VC0553580
p9424
sg10
I13
sg11
VEwing sarcoma
p9425
sg13
I2
sa(dp9426
g7
I119
sg17
VC0001807
p9427
sg10
I10
sg11
Vaggressive
p9428
sg13
I1
sa(dp9429
g7
I17
sg17
VC0553580
p9430
sg10
I13
sg11
VEwing sarcoma
p9431
sg13
I2
sasa(dp9432
g2
S'Long non-coding RNA (lncRNA) Ewing sarcoma associated transcript 1 (EWSAT1) has been identified as an oncogene, and its dysregulation is closed corrected with tumor progression in Ewing sarcoma.\n'
p9433
sg4
(lp9434
sg14
(lp9435
(dp9436
g7
I29
sg17
VC0553580
p9437
sg10
I13
sg11
VEwing sarcoma
p9438
sg13
I2
sa(dp9439
g7
I159
sg17
VC0178874
p9440
sg10
I17
sg11
Vtumor progression
p9441
sg13
I2
sa(dp9442
g7
I29
sg17
VC0553580
p9443
sg10
I13
sg11
VEwing sarcoma
p9444
sg13
I2
sasa(dp9445
g2
S'Recently, high-through put analysis reveals that EWSAT1 is also highly expressed in human nasopharyngeal carcinoma (NPC).\n'
p9446
sg4
(lp9447
sg14
(lp9448
(dp9449
g7
I90
sg17
VC2931822
p9450
sg10
I24
sg11
Vnasopharyngeal carcinoma
p9451
sg13
I2
sa(dp9452
g7
I116
sg17
VC2931822
p9453
sg10
I3
sg11
VNPC
p9454
sg13
I1
sasa(dp9455
g2
S'We determined that long noncoding RNA-277 (Ewing sarcoma-associated transcript 1 [EWSAT1]) is upregulated by EWS-FLI1 in pMPCs.\n'
p9456
sg4
(lp9457
(dp9458
g7
I82
sg8
g9
sg10
I3
sg11
VEWS
p9459
sg13
I1
sa(dp9460
g7
I113
sg8
g9
sg10
I4
sg11
VFLI1
p9461
sg13
I1
sasg14
(lp9462
(dp9463
g7
I43
sg17
VC0553580
p9464
sg10
I13
sg11
VEwing sarcoma
p9465
sg13
I2
sasa(dp9466
g2
S'Inhibition of EWSAT1 expression diminished the ability of Ewing sarcoma cell lines to proliferate and form colonies in soft agar, whereas EWSAT1 inhibition had no effect on other cell types tested.\n'
p9467
sg4
(lp9468
sg14
(lp9469
(dp9470
g7
I58
sg17
VC0553580
p9471
sg10
I13
sg11
VEwing sarcoma
p9472
sg13
I2
sasa(dp9473
g2
S'Analysis of RNAseq data from primary human Ewing sarcoma further supported a role for EWSAT1 in mediating gene repression.\n'
p9474
sg4
(lp9475
sg14
(lp9476
(dp9477
g7
I43
sg17
VC0553580
p9478
sg10
I13
sg11
VEwing sarcoma
p9479
sg13
I2
sasa(dp9480
g2
S'Together, our data reveal that EWSAT1 is a downstream target of EWS-FLI1 that facilitates the development of Ewing sarcoma via the repression of target genes.\n'
p9481
sg4
(lp9482
(dp9483
g7
I31
sg8
g9
sg10
I3
sg11
VEWS
p9484
sg13
I1
sa(dp9485
g7
I68
sg8
g9
sg10
I4
sg11
VFLI1
p9486
sg13
I1
sasg14
(lp9487
(dp9488
g7
I109
sg17
VC0553580
p9489
sg10
I13
sg11
VEwing sarcoma
p9490
sg13
I2
sasa(dp9491
g2
S'Results: The data show that the expression of MZF-1/Elk-1 is correlated with that of PKCAlfa in hepatocellular carcinoma (HCC), but not in bladder and lung cancers.\n'
p9492
sg4
(lp9493
(dp9494
g7
I52
sg8
VP54762
p9495
sg10
I5
sg11
VElk-1
p9496
sg13
I1
sa(dp9497
g7
I46
sg8
VP28698
p9498
sg10
I5
sg11
VMZF-1
p9499
sg13
I1
sasg14
(lp9500
(dp9501
g7
I122
sg17
VC2239176
p9502
sg10
I3
sg11
VHCC
p9503
sg13
I1
sa(dp9504
g7
I151
sg17
VC0242379
p9505
sg10
I12
sg11
Vlung cancers
p9506
sg13
I2
sa(dp9507
g7
I96
sg17
VC2239176
p9508
sg10
I24
sg11
Vhepatocellular carcinoma
p9509
sg13
I2
sasa(dp9510
g2
S'Here, using PEI-Mn0.5Zn0.5Fe2O4 nanoparticles (PEI-MZF-NPs) as magnetic media for MFH (magnetic fluid hyperthermia) and gene transfer vector for gene-therapy, a combined therapy, pHRE-Egr1-HSV-TK/(131)I-antiAFPMcAb-GCV/MFH, for hepatoma is developed.\n'
p9511
sg4
(lp9512
(dp9513
g7
I179
sg8
VP29401
p9514
sg10
I16
sg11
VpHRE-Egr1-HSV-TK
p9515
sg13
I1
sa(dp9516
g7
I12
sg8
g9
sg10
I33
sg11
VPEI-Mn0.5Zn0.5Fe2O4 nanoparticles
p9517
sg13
I2
sa(dp9518
g7
I47
sg8
VP28698
p9519
sg10
I11
sg11
VPEI-MZF-NPs
p9520
sg13
I1
sasg14
(lp9521
(dp9522
g7
I228
sg17
VC0023903
p9523
sg10
I8
sg11
Vhepatoma
p9524
sg13
I1
sa(dp9525
g7
I55
sg17
VC0027341
p9526
sg10
I3
sg11
VNPs
p9527
sg13
I1
sasa(dp9528
g2
S'To explore a new combination of thermal treatment and gene therapy for hepatoma, a heat-inducible herpes simplex virus thymidine kinase/ganciclovir (HSV-TK/GCV) gene therapy system was developed in which thermal energy generated by Mn0.5Zn0.5Fe2O4 nanoparticles (MZF-NPs) under an alternating magnetic field was used to activate gene expression.\n'
p9529
sg4
(lp9530
(dp9531
g7
I232
sg8
g9
sg10
I29
sg11
VMn0.5Zn0.5Fe2O4 nanoparticles
p9532
sg13
I2
sa(dp9533
g7
I156
sg8
VP23434
p9534
sg10
I3
sg11
VGCV
p9535
sg13
I1
sa(dp9536
g7
I153
sg8
VP29401
p9537
sg10
I2
sg11
VTK
p9538
sg13
I1
sa(dp9539
g7
I263
sg8
VP28698
p9540
sg10
I7
sg11
VMZF-NPs
p9541
sg13
I1
sasg14
(lp9542
(dp9543
g7
I71
sg17
VC0023903
p9544
sg10
I8
sg11
Vhepatoma
p9545
sg13
I1
sa(dp9546
g7
I98
sg17
VC0019348
p9547
sg10
I14
sg11
Vherpes simplex
p9548
sg13
I2
sa(dp9549
g7
I267
sg17
VC0027341
p9550
sg10
I3
sg11
VNPs
p9551
sg13
I1
sasa(dp9552
g2
S'Magnet-induced heating was then applied to cells to assess the antihepatoma effects of the polyethylenimine (PEI)-MZF-NPs/pHsp 70-HSV-TK/GCV complex, in vitro and in vivo.\n'
p9553
sg4
(lp9554
(dp9555
g7
I137
sg8
VP23434
p9556
sg10
I3
sg11
VGCV
p9557
sg13
I1
sa(dp9558
g7
I118
sg8
VP0C0P6
p9559
sg10
I3
sg11
VNPs
p9560
sg13
I1
sa(dp9561
g7
I114
sg8
VP28698
p9562
sg10
I3
sg11
VMZF
p9563
sg13
I1
sa(dp9564
g7
I134
sg8
VP29401
p9565
sg10
I2
sg11
VTK
p9566
sg13
I1
sasg14
(lp9567
(dp9568
g7
I118
sg17
VC0027341
p9569
sg10
I3
sg11
VNPs
p9570
sg13
I1
sasa(dp9571
g2
S'In this study, the molecular mechanism of protein kinase C alpha (PKCAlfa) gene regulation in hepatocellular carcinoma (HCC) involving Ets-like protein-1 (Elk-1) and myeloid zinc finger-1 (MZF-1) was investigated.\n'
p9572
sg4
(lp9573
(dp9574
g7
I166
sg8
VP28698
p9575
sg10
I21
sg11
Vmyeloid zinc finger-1
p9576
sg13
I3
sa(dp9577
g7
I155
sg8
VP54762
p9578
sg10
I5
sg11
VElk-1
p9579
sg13
I1
sa(dp9580
g7
I135
sg8
VP17980
p9581
sg10
I18
sg11
VEts-like protein-1
p9582
sg13
I2
sa(dp9583
g7
I42
sg8
VP17252
p9584
sg10
I22
sg11
Vprotein kinase C alpha
p9585
sg13
I4
sa(dp9586
g7
I189
sg8
VP28698
p9587
sg10
I5
sg11
VMZF-1
p9588
sg13
I1
sasg14
(lp9589
(dp9590
g7
I120
sg17
VC2239176
p9591
sg10
I3
sg11
VHCC
p9592
sg13
I1
sa(dp9593
g7
I94
sg17
VC2239176
p9594
sg10
I24
sg11
Vhepatocellular carcinoma
p9595
sg13
I2
sasa(dp9596
g2
S'Besides, PEI-MZF-NPs were used as magnetic media for thermotherapy to treat hepatoma by magnet-induced heating, combined with radiation-gene therapy.\n'
p9597
sg4
(lp9598
(dp9599
g7
I9
sg8
VP28698
p9600
sg10
I11
sg11
VPEI-MZF-NPs
p9601
sg13
I1
sasg14
(lp9602
(dp9603
g7
I17
sg17
VC0027341
p9604
sg10
I3
sg11
VNPs
p9605
sg13
I1
sa(dp9606
g7
I76
sg17
VC0023903
p9607
sg10
I8
sg11
Vhepatoma
p9608
sg13
I1
sasa(dp9609
g2
S'In a recent study on hepatocellular carcinoma (HCC), we have shown that the transcription factors Myeloid Zinc Finger-1 (MZF-1) and Ets-like-protein 1 (Elk-1) are significantly related to protein kinase C alpha (PKCAlfa) expression.\n'
p9610
sg4
(lp9611
(dp9612
g7
I121
sg8
VP28698
p9613
sg10
I5
sg11
VMZF-1
p9614
sg13
I1
sa(dp9615
g7
I132
sg8
VP14222
p9616
sg10
I18
sg11
VEts-like-protein 1
p9617
sg13
I2
sa(dp9618
g7
I188
sg8
VP17252
p9619
sg10
I22
sg11
Vprotein kinase C alpha
p9620
sg13
I4
sa(dp9621
g7
I98
sg8
VP28698
p9622
sg10
I21
sg11
VMyeloid Zinc Finger-1
p9623
sg13
I3
sa(dp9624
g7
I152
sg8
VP54762
p9625
sg10
I5
sg11
VElk-1
p9626
sg13
I1
sasg14
(lp9627
(dp9628
g7
I21
sg17
VC2239176
p9629
sg10
I24
sg11
Vhepatocellular carcinoma
p9630
sg13
I2
sa(dp9631
g7
I47
sg17
VC2239176
p9632
sg10
I3
sg11
VHCC
p9633
sg13
I1
sasa(dp9634
g2
S'Recently, our research into hepatocellular carcinoma (HCC) has shown that the transcription factors Myeloid Zinc Finger-1 (MZF-1) and Ets-like-protein 1 are related to protein kinase C alpha (PKCAlfa) expression.\n'
p9635
sg4
(lp9636
(dp9637
g7
I100
sg8
VP28698
p9638
sg10
I21
sg11
VMyeloid Zinc Finger-1
p9639
sg13
I3
sa(dp9640
g7
I123
sg8
VP28698
p9641
sg10
I5
sg11
VMZF-1
p9642
sg13
I1
sa(dp9643
g7
I168
sg8
VP17252
p9644
sg10
I22
sg11
Vprotein kinase C alpha
p9645
sg13
I4
sa(dp9646
g7
I134
sg8
VP14222
p9647
sg10
I18
sg11
VEts-like-protein 1
p9648
sg13
I2
sasg14
(lp9649
(dp9650
g7
I54
sg17
VC2239176
p9651
sg10
I3
sg11
VHCC
p9652
sg13
I1
sa(dp9653
g7
I28
sg17
VC2239176
p9654
sg10
I24
sg11
Vhepatocellular carcinoma
p9655
sg13
I2
sasa(dp9656
g2
S'Using immunocytochemistry, we investigated the distribution of chromogranin A, chromogranin B, secretoneurin, and, for comparison, dynorphin in hippocampal specimens removed at routine surgery from patients with drug-resistant mesial temporal lobe epilepsy and in autopsy tissues from nonneurologically deceased subjects.\n'
p9657
sg4
(lp9658
(dp9659
g7
I79
sg8
VP08311
p9660
sg10
I14
sg11
Vchromogranin B
p9661
sg13
I2
sa(dp9662
g7
I131
sg8
VP01213
p9663
sg10
I9
sg11
Vdynorphin
p9664
sg13
I1
sa(dp9665
g7
I95
sg8
VP13521
p9666
sg10
I13
sg11
Vsecretoneurin
p9667
sg13
I1
sa(dp9668
g7
I63
sg8
VP10645
p9669
sg10
I14
sg11
Vchromogranin A
p9670
sg13
I2
sasg14
(lp9671
(dp9672
g7
I234
sg17
VC0014556
p9673
sg10
I22
sg11
Vtemporal lobe epilepsy
p9674
sg13
I3
sasa(dp9675
g2
S'The most intriguing change seen in human temporal lobe epilepsy specimens and in the kainic acid model of the rat was the prominent staining of the inner molecular layer, indicating storage of chromogranins A and B and secretoneurin in terminals of reorganized mossy fibers, from which they may be released upon nerve stimulation.\n'
p9676
sg4
(lp9677
(dp9678
g7
I193
sg8
VP08311
p9679
sg10
I39
sg11
Vchromogranins A and B and secretoneurin
p9680
sg13
I6
sasg14
(lp9681
(dp9682
g7
I41
sg17
VC0014556
p9683
sg10
I22
sg11
Vtemporal lobe epilepsy
p9684
sg13
I3
sasa(dp9685
g2
S'Transition of control prediabetic ZDF rats to diabetes was associated with reduced plasma insulin levels, reduced islet insulin content and GSIS, reduced stearoyl-CoA desaturase 2 (SCD 2) expression, and increased islet TAG, diacylglyceride (DAG) and ceramides species containing saturated FA.\n'
p9686
sg4
(lp9687
(dp9688
g7
I114
sg8
VP01308
p9689
sg10
I13
sg11
Vislet insulin
p9690
sg13
I2
sa(dp9691
g7
I154
sg8
g9
sg10
I25
sg11
Vstearoyl-CoA desaturase 2
p9692
sg13
I3
sa(dp9693
g7
I83
sg8
VP01308
p9694
sg10
I14
sg11
Vplasma insulin
p9695
sg13
I2
sa(dp9696
g7
I181
sg8
g9
sg10
I5
sg11
VSCD 2
p9697
sg13
I2
sasg14
(lp9698
(dp9699
g7
I46
sg17
VC0011849
p9700
sg10
I8
sg11
Vdiabetes
p9701
sg13
I1
sa(dp9702
g7
I0
sg17
VC0599156
p9703
sg10
I10
sg11
VTransition
p9704
sg13
I1
sa(dp9705
g7
I163
sg17
VC2678439
p9706
sg10
I3
sg11
VCoA
p9707
sg13
I1
sa(dp9708
g7
I220
sg17
VC0037293
p9709
sg10
I3
sg11
VTAG
p9710
sg13
I1
sa(dp9711
g7
I181
sg17
VC0002895
p9712
sg10
I3
sg11
VSCD
p9713
sg13
I1
sasa(dp9714
g2
S'In this research, we have found that lycorine significantly induces the apoptotic and autophagic capacities of hepatocellular carcinoma (HCC) cells in vitro and in vivo Treatment with specific autophagy inhibitor (3-methyladenine/Bafilomycin A1) or knockdown of LC-3B/Atg5 by siRNA drastically enhances the apoptotic cell death effect by facilitating the switch from autophagy to apoptosis.\n'
p9715
sg4
(lp9716
(dp9717
g7
I268
sg8
g9
sg10
I4
sg11
VAtg5
p9718
sg13
I1
sasg14
(lp9719
(dp9720
g7
I137
sg17
VC2239176
p9721
sg10
I3
sg11
VHCC
p9722
sg13
I1
sa(dp9723
g7
I111
sg17
VC2239176
p9724
sg10
I24
sg11
Vhepatocellular carcinoma
p9725
sg13
I2
sasa(dp9726
g2
S'The differential expression of 10 miRNAs were validated by RT-qPCR (let-7a, let-7d, let-7f and miR-16 were downregulated while miR-29b, miR-142-3p, miR-144, miR-203, and miR-223 were upregulated in OSCC; the expression of miR-1275 was variable in tumours, with high levels associated to regional lymph node invasion; additionally, miR-223 exhibited an association with advanced tumour stage/size).\n'
p9727
sg4
(lp9728
(dp9729
g7
I136
sg8
g9
sg10
I10
sg11
VmiR-142-3p
p9730
sg13
I1
sa(dp9731
g7
I157
sg8
g9
sg10
I7
sg11
VmiR-203
p9732
sg13
I1
sa(dp9733
g7
I127
sg8
g9
sg10
I7
sg11
VmiR-29b
p9734
sg13
I1
sa(dp9735
g7
I148
sg8
g9
sg10
I7
sg11
VmiR-144
p9736
sg13
I1
sa(dp9737
g7
I95
sg8
g9
sg10
I6
sg11
VmiR-16
p9738
sg13
I1
sasg14
(lp9739
(dp9740
g7
I247
sg17
VC0027651
p9741
sg10
I6
sg11
Vtumour
p9742
sg13
I1
sa(dp9743
g7
I247
sg17
VC0027651
p9744
sg10
I7
sg11
Vtumours
p9745
sg13
I1
sa(dp9746
g7
I307
sg17
VC2699153
p9747
sg10
I8
sg11
Vinvasion
p9748
sg13
I1
sasa(dp9749
g2
S'To the best of our knowledge, this is the first report to show the association of miR-1275 with nodal invasion and the upregulation of miR-144 in OSCC.\n'
p9750
sg4
(lp9751
(dp9752
g7
I82
sg8
g9
sg10
I8
sg11
VmiR-1275
p9753
sg13
I1
sasg14
(lp9754
(dp9755
g7
I102
sg17
VC2699153
p9756
sg10
I8
sg11
Vinvasion
p9757
sg13
I1
sasa(dp9758
g2
S"In the subgroup of non-vomiting drinkers with Wernicke's encephalopathy (WE), the slope of the linear regression of AETK on ETK was 1.21, so that apoTK decreased as ETK decreased.\n"
p9759
sg4
(lp9760
(dp9761
g7
I117
sg8
VP51813
p9762
sg10
I3
sg11
VETK
p9763
sg13
I1
sa(dp9764
g7
I117
sg8
VP51813
p9765
sg10
I3
sg11
VETK
p9766
sg13
I1
sasg14
(lp9767
(dp9768
g7
I46
sg17
VC0043121
p9769
sg10
I25
sg11
VWernicke's encephalopathy
p9770
sg13
I2
sa(dp9771
g7
I23
sg17
VC0042963
p9772
sg10
I8
sg11
Vvomiting
p9773
sg13
I1
sa(dp9774
g7
I73
sg17
VC0043121
p9775
sg10
I2
sg11
VWE
p9776
sg13
I1
sasa(dp9777
g2
S'In pancreatic ductal adenocarcinoma, the CCL2-CCR2 chemokine axis is used to recruit tumour-associated macrophages for construction of an immunosuppressive tumour microenvironment.\n'
p9778
sg4
(lp9779
(dp9780
g7
I41
sg8
VP13500
p9781
sg10
I4
sg11
VCCL2
p9782
sg13
I1
sa(dp9783
g7
I46
sg8
VP41597
p9784
sg10
I4
sg11
VCCR2
p9785
sg13
I1
sasg14
(lp9786
(dp9787
g7
I3
sg17
VC1335302
p9788
sg10
I32
sg11
Vpancreatic ductal adenocarcinoma
p9789
sg13
I3
sa(dp9790
g7
I85
sg17
VC0027651
p9791
sg10
I6
sg11
Vtumour
p9792
sg13
I1
sa(dp9793
g7
I85
sg17
VC0027651
p9794
sg10
I6
sg11
Vtumour
p9795
sg13
I1
sasa(dp9796
g2
S'This pathway has prognostic implications in pancreatic cancer, and blockade of CCR2 restores anti-tumour immunity in preclinical models.\n'
p9797
sg4
(lp9798
(dp9799
g7
I79
sg8
VP41597
p9800
sg10
I4
sg11
VCCR2
p9801
sg13
I1
sasg14
(lp9802
(dp9803
g7
I44
sg17
VC0235974
p9804
sg10
I17
sg11
Vpancreatic cancer
p9805
sg13
I2
sa(dp9806
g7
I98
sg17
VC0027651
p9807
sg10
I6
sg11
Vtumour
p9808
sg13
I1
sasa(dp9809
g2
S'To determine the role of the CCL2/CCR2 axis and inflammatory monocytes (CCR2(+)/CD14(+)) as immunotherapeutic targets in the treatment of pancreatic cancer.\n'
p9810
sg4
(lp9811
(dp9812
g7
I29
sg8
VP13500
p9813
sg10
I4
sg11
VCCL2
p9814
sg13
I1
sa(dp9815
g7
I34
sg8
VP41597
p9816
sg10
I4
sg11
VCCR2
p9817
sg13
I1
sa(dp9818
g7
I34
sg8
VP41597
p9819
sg10
I4
sg11
VCCR2
p9820
sg13
I1
sa(dp9821
g7
I80
sg8
VP08571
p9822
sg10
I4
sg11
VCD14
p9823
sg13
I1
sasg14
(lp9824
(dp9825
g7
I138
sg17
VC0235974
p9826
sg10
I17
sg11
Vpancreatic cancer
p9827
sg13
I2
sasa(dp9828
g2
S'A novel CCR2 inhibitor (PF-04136309) was tested in an orthotopic model of murine pancreatic cancer.\n'
p9829
sg4
(lp9830
(dp9831
g7
I8
sg8
VP41597
p9832
sg10
I4
sg11
VCCR2
p9833
sg13
I1
sasg14
(lp9834
(dp9835
g7
I81
sg17
VC0235974
p9836
sg10
I17
sg11
Vpancreatic cancer
p9837
sg13
I2
sasa(dp9838
g2
S'Human pancreatic cancer produces CCL2, and immunosuppressive CCR2(+) macrophages infiltrate these tumors.\n'
p9839
sg4
(lp9840
(dp9841
g7
I33
sg8
VP13500
p9842
sg10
I4
sg11
VCCL2
p9843
sg13
I1
sasg14
(lp9844
(dp9845
g7
I6
sg17
VC0235974
p9846
sg10
I17
sg11
Vpancreatic cancer
p9847
sg13
I2
sa(dp9848
g7
I98
sg17
VC0027651
p9849
sg10
I6
sg11
Vtumors
p9850
sg13
I1
sa(dp9851
g7
I81
sg17
VC0332448
p9852
sg10
I10
sg11
Vinfiltrate
p9853
sg13
I1
sasa(dp9854
g2
S'Inflammatory monocyte recruitment is critical to pancreatic cancer progression, and targeting CCR2 may be an effective immunotherapeutic strategy in this disease.\n'
p9855
sg4
(lp9856
(dp9857
g7
I94
sg8
VP41597
p9858
sg10
I4
sg11
VCCR2
p9859
sg13
I1
sasg14
(lp9860
(dp9861
g7
I22
sg17
VC0271510
p9862
sg10
I11
sg11
Vrecruitment
p9863
sg13
I1
sa(dp9864
g7
I60
sg17
VC0178874
p9865
sg10
I18
sg11
Vcancer progression
p9866
sg13
I2
sasa(dp9867
g2
S'Weaver syndrome (WS) is a rare congenital overgrowth disorder caused by heterozygous mutations in EZH2 (enhancer of zeste homolog 2) or EED (embryonic ectoderm development).\n'
p9868
sg4
(lp9869
sg14
(lp9870
(dp9871
g7
I17
sg17
VC0265210
p9872
sg10
I2
sg11
VWS
p9873
sg13
I1
sa(dp9874
g7
I0
sg17
VC0265210
p9875
sg10
I15
sg11
VWeaver syndrome
p9876
sg13
I2
sa(dp9877
g7
I31
sg17
VC0332887
p9878
sg10
I21
sg11
Vcongenital overgrowth
p9879
sg13
I2
sasa(dp9880
g2
S"We evaluated the associations of six nonsynonymous SNPs in the MMP3, MMP8, and MMP9 genes with skin cancer risk in a nested case-control study of Caucasians within the Nurses' Health Study among 218 melanoma cases, 285 squamous cell carcinoma (SCC) cases, 300 basal cell carcinoma (BCC) cases, and 870 normal controls.\n"
p9881
sg4
(lp9882
(dp9883
g7
I79
sg8
VP14780
p9884
sg10
I10
sg11
VMMP9 genes
p9885
sg13
I2
sa(dp9886
g7
I63
sg8
VP08254
p9887
sg10
I4
sg11
VMMP3
p9888
sg13
I1
sa(dp9889
g7
I69
sg8
VP22894
p9890
sg10
I4
sg11
VMMP8
p9891
sg13
I1
sasg14
(lp9892
(dp9893
g7
I199
sg17
VC0025202
p9894
sg10
I8
sg11
Vmelanoma
p9895
sg13
I1
sa(dp9896
g7
I244
sg17
VC0007137
p9897
sg10
I3
sg11
VSCC
p9898
sg13
I1
sa(dp9899
g7
I95
sg17
VC0007114
p9900
sg10
I11
sg11
Vskin cancer
p9901
sg13
I2
sa(dp9902
g7
I219
sg17
VC0007137
p9903
sg10
I23
sg11
Vsquamous cell carcinoma
p9904
sg13
I3
sa(dp9905
g7
I282
sg17
VC0007117
p9906
sg10
I3
sg11
VBCC
p9907
sg13
I1
sa(dp9908
g7
I260
sg17
VC0007117
p9909
sg10
I20
sg11
Vbasal cell carcinoma
p9910
sg13
I3
sasa(dp9911
g2
S'Ninety-four cases of squamous cell carcinoma and 108 cases of basal cell carcinoma using tissue array in order to determine correlations between the expression of Ki-67, p53, EGFR, CD44v6, MMP-1 and MMP-3, invasiveness and histologic differentiation.\n'
p9912
sg4
(lp9913
(dp9914
g7
I199
sg8
VP08254
p9915
sg10
I5
sg11
VMMP-3
p9916
sg13
I1
sa(dp9917
g7
I189
sg8
VP03956
p9918
sg10
I5
sg11
VMMP-1
p9919
sg13
I1
sa(dp9920
g7
I170
sg8
VP42771
p9921
sg10
I3
sg11
Vp53
p9922
sg13
I1
sa(dp9923
g7
I163
sg8
VP46013
p9924
sg10
I5
sg11
VKi-67
p9925
sg13
I1
sasg14
(lp9926
(dp9927
g7
I21
sg17
VC0007137
p9928
sg10
I23
sg11
Vsquamous cell carcinoma
p9929
sg13
I3
sa(dp9930
g7
I62
sg17
VC0007117
p9931
sg10
I20
sg11
Vbasal cell carcinoma
p9932
sg13
I3
sasa(dp9933
g2
S'A novel zinc oxide-binding peptide (ZBP), FPYPGGDA, with high affinity to ZNP (K a  = 2.26 x 106 M-1) was isolated from a random peptide library and fused with a bacterial antigen, ScaA of Orientia tsutsugamushi, the causative agent of scrub typhus.\n'
p9934
sg4
(lp9935
(dp9936
g7
I36
sg8
g9
sg10
I3
sg11
VZBP
p9937
sg13
I1
sa(dp9938
g7
I8
sg8
VP10070
p9939
sg10
I26
sg11
Vzinc oxide-binding peptide
p9940
sg13
I3
sa(dp9941
g7
I162
sg8
g9
sg10
I17
sg11
Vbacterial antigen
p9942
sg13
I2
sasg14
(lp9943
(dp9944
g7
I198
sg17
VC0036472
p9945
sg10
I13
sg11
Vtsutsugamushi
p9946
sg13
I1
sa(dp9947
g7
I236
sg17
VC0036472
p9948
sg10
I12
sg11
Vscrub typhus
p9949
sg13
I2
sasa(dp9950
g2
S'The results show that the main latex allergen, a glycine-rich protein molecule, can cause cutaneous, inhalant and systemic hypersensitivity reactions.\n'
p9951
sg4
(lp9952
(dp9953
g7
I49
sg8
g9
sg10
I29
sg11
Vglycine-rich protein molecule
p9954
sg13
I3
sasg14
(lp9955
(dp9956
g7
I123
sg17
VC0020517
p9957
sg10
I26
sg11
Vhypersensitivity reactions
p9958
sg13
I2
sasa(dp9959
g2
S'One hundred and one consecutive patients of Han nationality with rheumatic heart disease undergoing valve surgery were enrolled and randomly assigned to an experimental group (n=50, based on CYP2C9 and VKORC1 genotypes, pharmacogenetic-based "predicted warfarin dose" for 3 days and then was adjusted to INR until stable warfarin maintenance dose) or a control group (n=51, 2.5mg/d for 3 days and then was adjusted to INR until stable warfarin maintenance dose).\n'
p9960
sg4
(lp9961
(dp9962
g7
I191
sg8
VP11712
p9963
sg10
I6
sg11
VCYP2C9
p9964
sg13
I1
sa(dp9965
g7
I202
sg8
g9
sg10
I6
sg11
VVKORC1
p9966
sg13
I1
sasg14
(lp9967
(dp9968
g7
I65
sg17
VC0035439
p9969
sg10
I23
sg11
Vrheumatic heart disease
p9970
sg13
I3
sasa(dp9971
g2
S'RNF216) have recently been identified in patients suffering from Gordon Holmes syndrome (GHS), characterized by cognitive decline, dementia, and movement disorders.\n'
p9972
sg4
(lp9973
(dp9974
g7
I0
sg8
g9
sg10
I6
sg11
VRNF216
p9975
sg13
I1
sasg14
(lp9976
(dp9977
g7
I131
sg17
VC0497327
p9978
sg10
I8
sg11
Vdementia
p9979
sg13
I1
sa(dp9980
g7
I89
sg17
VC1859305
p9981
sg10
I3
sg11
VGHS
p9982
sg13
I1
sa(dp9983
g7
I50
sg17
VC0683278
p9984
sg10
I9
sg11
Vsuffering
p9985
sg13
I1
sa(dp9986
g7
I145
sg17
VC0026650
p9987
sg10
I18
sg11
Vmovement disorders
p9988
sg13
I2
sa(dp9989
g7
I65
sg17
VC1859305
p9990
sg10
I22
sg11
VGordon Holmes syndrome
p9991
sg13
I3
sa(dp9992
g7
I112
sg17
VC0338656
p9993
sg10
I17
sg11
Vcognitive decline
p9994
sg13
I2
sasa(dp9995
g2
S'Our current findings of Arc misregulation by TRIAD3A variants suggest that loss-of-function mutations in TRIAD3A may contribute to dementia observed in patients with GHS driven by dysfunctional UPS components, leading to cognitive impairments through the synaptic protein Arc.\n'
p9996
sg4
(lp9997
(dp9998
g7
I24
sg8
g9
sg10
I3
sg11
VArc
p9999
sg13
I1
sa(dp10000
g7
I255
sg8
g9
sg10
I20
sg11
Vsynaptic protein Arc
p10001
sg13
I3
sa(dp10002
g7
I45
sg8
g9
sg10
I16
sg11
VTRIAD3A variants
p10003
sg13
I2
sa(dp10004
g7
I45
sg8
g9
sg10
I7
sg11
VTRIAD3A
p10005
sg13
I1
sasg14
(lp10006
(dp10007
g7
I24
sg17
VC0001857
p10008
sg10
I3
sg11
VArc
p10009
sg13
I1
sa(dp10010
g7
I221
sg17
VC0338656
p10011
sg10
I21
sg11
Vcognitive impairments
p10012
sg13
I2
sa(dp10013
g7
I24
sg17
VC0001857
p10014
sg10
I3
sg11
VArc
p10015
sg13
I1
sa(dp10016
g7
I131
sg17
VC0497327
p10017
sg10
I8
sg11
Vdementia
p10018
sg13
I1
sasa(dp10019
g2
S'Gordon Holmes syndrome (GHS) is a distinct phenotype of autosomal recessive cerebellar ataxia, characterized by ataxia, dementia, reproductive defects and hypogonadism; it has been recently found to be associated with RNF216 mutation.\n'
p10020
sg4
(lp10021
(dp10022
g7
I218
sg8
g9
sg10
I15
sg11
VRNF216 mutation
p10023
sg13
I2
sasg14
(lp10024
(dp10025
g7
I87
sg17
VC0004134
p10026
sg10
I6
sg11
Vataxia
p10027
sg13
I1
sa(dp10028
g7
I120
sg17
VC0497327
p10029
sg10
I8
sg11
Vdementia
p10030
sg13
I1
sa(dp10031
g7
I155
sg17
VC0020619
p10032
sg10
I12
sg11
Vhypogonadism
p10033
sg13
I1
sa(dp10034
g7
I0
sg17
VC1859305
p10035
sg10
I22
sg11
VGordon Holmes syndrome
p10036
sg13
I3
sa(dp10037
g7
I76
sg17
VC0007758
p10038
sg10
I17
sg11
Vcerebellar ataxia
p10039
sg13
I2
sa(dp10040
g7
I24
sg17
VC1859305
p10041
sg10
I3
sg11
VGHS
p10042
sg13
I1
sasa(dp10043
g2
S'The syndrome of hypogonadotropic hypogonadism, ataxia, and dementia can be caused by inactivating mutations in RNF216 or by the combination of mutations in RNF216 and OTUD4.\n'
p10044
sg4
(lp10045
(dp10046
g7
I111
sg8
g9
sg10
I6
sg11
VRNF216
p10047
sg13
I1
sa(dp10048
g7
I167
sg8
g9
sg10
I5
sg11
VOTUD4
p10049
sg13
I1
sa(dp10050
g7
I111
sg8
g9
sg10
I6
sg11
VRNF216
p10051
sg13
I1
sasg14
(lp10052
(dp10053
g7
I16
sg17
VC0022735
p10054
sg10
I29
sg11
Vhypogonadotropic hypogonadism
p10055
sg13
I2
sa(dp10056
g7
I59
sg17
VC0497327
p10057
sg10
I8
sg11
Vdementia
p10058
sg13
I1
sa(dp10059
g7
I47
sg17
VC0004134
p10060
sg10
I6
sg11
Vataxia
p10061
sg13
I1
sa(dp10062
g7
I4
sg17
VC0039082
p10063
sg10
I8
sg11
Vsyndrome
p10064
sg13
I1
sasa(dp10065
g2
S'to investigate the molecular mechanisms and morphological substrate of reduced uterine leiomyoma in patients receiving the selective progesterone receptor modulator (SPRM) ulipristal acetate for 3 months, by estimating the immunohistochemical expression of the markers steroid receptor coactivator 1 (SRC-1), nuclear receptor corepressor 1 (NCoR-1), ER, PgR, Ki-67, p16, TGF-Beta, and VEGF in tumor tissue.\n'
p10066
sg4
(lp10067
(dp10068
g7
I371
sg8
VP18075
p10069
sg10
I8
sg11
VTGF-Beta
p10070
sg13
I1
sa(dp10071
g7
I354
sg8
VP06401
p10072
sg10
I3
sg11
VPgR
p10073
sg13
I1
sa(dp10074
g7
I301
sg8
VP12931
p10075
sg10
I5
sg11
VSRC-1
p10076
sg13
I1
sa(dp10077
g7
I341
sg8
g9
sg10
I6
sg11
VNCoR-1
p10078
sg13
I1
sa(dp10079
g7
I366
sg8
VP42771
p10080
sg10
I3
sg11
Vp16
p10081
sg13
I1
sa(dp10082
g7
I309
sg8
g9
sg10
I30
sg11
Vnuclear receptor corepressor 1
p10083
sg13
I4
sa(dp10084
g7
I359
sg8
VP46013
p10085
sg10
I5
sg11
VKi-67
p10086
sg13
I1
sa(dp10087
g7
I269
sg8
g9
sg10
I30
sg11
Vsteroid receptor coactivator 1
p10088
sg13
I4
sa(dp10089
g7
I133
sg8
VP06401
p10090
sg10
I21
sg11
Vprogesterone receptor
p10091
sg13
I2
sasg14
(lp10092
(dp10093
g7
I79
sg17
VC0042133
p10094
sg10
I17
sg11
Vuterine leiomyoma
p10095
sg13
I2
sa(dp10096
g7
I393
sg17
VC0027651
p10097
sg10
I5
sg11
Vtumor
p10098
sg13
I1
sasa(dp10099
g2
S'The morphological substrate of partial leiomyoma reduction was leiomyocyte apoptosis and dystrophy, tumor stroma sclerosis and hyalinosis with diminished Ki-67 expression and elevated p16 in the smooth muscle cells, trophic nodular tissue disorders exhibited by vascular wall sclerosis and lower VEGF and TGF-Beta expression, and leiomyocyte hormonal reception dysregulation that made itself evident through the reduced expression of SRC-1 with the unchanged expression of PR and ER and the maintained level of NCoR-1.\n'
p10100
sg4
(lp10101
(dp10102
g7
I305
sg8
VP18075
p10103
sg10
I8
sg11
VTGF-Beta
p10104
sg13
I1
sa(dp10105
g7
I511
sg8
g9
sg10
I6
sg11
VNCoR-1
p10106
sg13
I1
sa(dp10107
g7
I184
sg8
VP42771
p10108
sg10
I3
sg11
Vp16
p10109
sg13
I1
sa(dp10110
g7
I434
sg8
VP12931
p10111
sg10
I5
sg11
VSRC-1
p10112
sg13
I1
sasg14
(lp10113
(dp10114
g7
I113
sg17
VC0036429
p10115
sg10
I9
sg11
Vsclerosis
p10116
sg13
I1
sa(dp10117
g7
I89
sg17
VC0333606
p10118
sg10
I9
sg11
Vdystrophy
p10119
sg13
I1
sa(dp10120
g7
I100
sg17
VC0027651
p10121
sg10
I5
sg11
Vtumor
p10122
sg13
I1
sa(dp10123
g7
I39
sg17
VC0023267
p10124
sg10
I9
sg11
Vleiomyoma
p10125
sg13
I1
sa(dp10126
g7
I127
sg17
VC0333438
p10127
sg10
I10
sg11
Vhyalinosis
p10128
sg13
I1
sa(dp10129
g7
I113
sg17
VC0036429
p10130
sg10
I9
sg11
Vsclerosis
p10131
sg13
I1
sasa(dp10132
g2
S'Uenb - N3y4NTb MoneKynRpHble MexaHN3Mbl N MopoonorN4ecKNN cybcTpaT peAyKmyNN neNoMNoMbl MaTKN y namyNeHToK, nony4aBwNx ceneKTNBHblN MoAynRTop nporecTepoHoBblx pemyenTopoB ynNnpNcTana amyeTaT B Te4eHNe 3 Mec, Ha ocHoBaHNN omyeHKN NMMyHorNcToxNMN4ecKoN EKcnpeccNN SRC-1, NCoR-1, ER, PGR, Ki-67, p16, TGF-Beta, VEGF B TKaHN onyxonN.\n'
p10133
sg4
(lp10134
(dp10135
g7
I208
sg8
VP12931
p10136
sg10
I59
sg11
VHa ocHoBaHNN omyeHKN NMMyHorNcToxNMN4ecKoN EKcnpeccNN SRC-1
p10137
sg13
I6
sa(dp10138
g7
I269
sg8
g9
sg10
I6
sg11
VNCoR-1
p10139
sg13
I1
sa(dp10140
g7
I293
sg8
VP42771
p10141
sg10
I3
sg11
Vp16
p10142
sg13
I1
sa(dp10143
g7
I281
sg8
VP06401
p10144
sg10
I3
sg11
VPGR
p10145
sg13
I1
sa(dp10146
g7
I0
sg8
g9
sg10
I206
sg11
VUenb - N3y4NTb MoneKynRpHble MexaHN3Mbl N MopoonorN4ecKNN cybcTpaT peAyKmyNN neNoMNoMbl MaTKN y namyNeHToK, nony4aBwNx ceneKTNBHblN MoAynRTop nporecTepoHoBblx pemyenTopoB ynNnpNcTana amyeTaT B Te4eHNe 3 Mec
p10147
sg13
I24
sa(dp10148
g7
I308
sg8
VP49765
p10149
sg10
I20
sg11
VVEGF B TKaHN onyxonN
p10150
sg13
I4
sa(dp10151
g7
I286
sg8
VP46013
p10152
sg10
I5
sg11
VKi-67
p10153
sg13
I1
sa(dp10154
g7
I298
sg8
VP18075
p10155
sg10
I8
sg11
VTGF-Beta
p10156
sg13
I1
sasg14
(lp10157
sa(dp10158
g2
S'We find that AML1-ETO and corepressor NCoR co-occupy the miR-29a/b-1 locus and downregulate its expression in leukemia cells.\n'
p10159
sg4
(lp10160
(dp10161
g7
I57
sg8
g9
sg10
I17
sg11
VmiR-29a/b-1 locus
p10162
sg13
I2
sa(dp10163
g7
I38
sg8
g9
sg10
I4
sg11
VNCoR
p10164
sg13
I1
sasg14
(lp10165
(dp10166
g7
I110
sg17
VC0023418
p10167
sg10
I8
sg11
Vleukemia
p10168
sg13
I1
sasa(dp10169
g2
S'Authors present the history of a patient with extra-adrenal pheochromocytoma who represents in Hungary the first genetically confirmed case of hereditary paraganglioma/pheochromocytoma syndrome due to disease-causing mutation of the SDHD gene.\n'
p10170
sg4
(lp10171
(dp10172
g7
I233
sg8
g9
sg10
I9
sg11
VSDHD gene
p10173
sg13
I2
sasg14
(lp10174
(dp10175
g7
I46
sg17
VC1257877
p10176
sg10
I30
sg11
Vextra-adrenal pheochromocytoma
p10177
sg13
I2
sa(dp10178
g7
I168
sg17
VC0031511
p10179
sg10
I25
sg11
Vpheochromocytoma syndrome
p10180
sg13
I2
sa(dp10181
g7
I143
sg17
VC1333993
p10182
sg10
I24
sg11
Vhereditary paraganglioma
p10183
sg13
I2
sa(dp10184
g7
I201
sg17
VC2985434
p10185
sg10
I24
sg11
Vdisease-causing mutation
p10186
sg13
I2
sasa(dp10187
g2
S'While SDHD has been more frequently associated with the pathogenesis of head and neck paragangliomas, SDHB mutations were mainly associated with malignant and/or extra-adrenal pheochromocytoma/paraganglioma.\n'
p10188
sg4
(lp10189
(dp10190
g7
I102
sg8
VP21912
p10191
sg10
I14
sg11
VSDHB mutations
p10192
sg13
I2
sa(dp10193
g7
I6
sg8
g9
sg10
I4
sg11
VSDHD
p10194
sg13
I1
sasg14
(lp10195
(dp10196
g7
I56
sg17
VC0699748
p10197
sg10
I12
sg11
Vpathogenesis
p10198
sg13
I1
sa(dp10199
g7
I162
sg17
VC1257877
p10200
sg10
I30
sg11
Vextra-adrenal pheochromocytoma
p10201
sg13
I2
sa(dp10202
g7
I86
sg17
VC0030421
p10203
sg10
I13
sg11
Vparaganglioma
p10204
sg13
I1
sa(dp10205
g7
I86
sg17
VC0030421
p10206
sg10
I14
sg11
Vparagangliomas
p10207
sg13
I1
sasa(dp10208
g2
S'SDHB mutation carriers were more likely than SDHD mutation carriers to develop extraadrenal pheochromocytomas and malignant disease, whereas SDHD mutation carriers had a greater propensity to develop head and neck paragangliomas and multiple tumors.\n'
p10209
sg4
(lp10210
(dp10211
g7
I45
sg8
g9
sg10
I4
sg11
VSDHD
p10212
sg13
I1
sa(dp10213
g7
I45
sg8
g9
sg10
I13
sg11
VSDHD mutation
p10214
sg13
I2
sa(dp10215
g7
I0
sg8
VP21912
p10216
sg10
I4
sg11
VSDHB
p10217
sg13
I1
sasg14
(lp10218
(dp10219
g7
I92
sg17
VC0031511
p10220
sg10
I17
sg11
Vpheochromocytomas
p10221
sg13
I1
sa(dp10222
g7
I233
sg17
VC0260037
p10223
sg10
I15
sg11
Vmultiple tumors
p10224
sg13
I2
sa(dp10225
g7
I114
sg17
VC0442867
p10226
sg10
I17
sg11
Vmalignant disease
p10227
sg13
I2
sa(dp10228
g7
I214
sg17
VC0030421
p10229
sg10
I14
sg11
Vparagangliomas
p10230
sg13
I1
sasa(dp10231
g2
S'In contrast, SDHD mutation carriers, in addition to head and neck paragangliomas, should be observed for multifocal tumors, infrequent malignancy, and the possibility of extraadrenal pheochromocytoma.\n'
p10232
sg4
(lp10233
(dp10234
g7
I13
sg8
g9
sg10
I4
sg11
VSDHD
p10235
sg13
I1
sasg14
(lp10236
(dp10237
g7
I170
sg17
VC1257877
p10238
sg10
I29
sg11
Vextraadrenal pheochromocytoma
p10239
sg13
I2
sa(dp10240
g7
I116
sg17
VC0027651
p10241
sg10
I6
sg11
Vtumors
p10242
sg13
I1
sa(dp10243
g7
I135
sg17
VC0006826
p10244
sg10
I10
sg11
Vmalignancy
p10245
sg13
I1
sa(dp10246
g7
I66
sg17
VC0030421
p10247
sg10
I14
sg11
Vparagangliomas
p10248
sg13
I1
sasa(dp10249
g2
S'However, in the presence of extra-adrenal pheochromocytoma, it may be more useful to screen for VHL, SDHD and SDHB mutations.\n'
p10250
sg4
(lp10251
(dp10252
g7
I110
sg8
VP21912
p10253
sg10
I4
sg11
VSDHB
p10254
sg13
I1
sa(dp10255
g7
I96
sg8
VP40337
p10256
sg10
I3
sg11
VVHL
p10257
sg13
I1
sa(dp10258
g7
I101
sg8
g9
sg10
I4
sg11
VSDHD
p10259
sg13
I1
sasg14
(lp10260
(dp10261
g7
I28
sg17
VC1257877
p10262
sg10
I30
sg11
Vextra-adrenal pheochromocytoma
p10263
sg13
I2
sa(dp10264
g7
I96
sg17
VC0019562
p10265
sg10
I3
sg11
VVHL
p10266
sg13
I1
sasa(dp10267
g2
S'Here we show, using two different techniques, FISH and quantitative PCR that SHFM3 is caused by a minimal 325 kb duplication containing only two genes (BTRC and POLL).\n'
p10268
sg4
(lp10269
(dp10270
g7
I161
sg8
g9
sg10
I4
sg11
VPOLL
p10271
sg13
I1
sa(dp10272
g7
I152
sg8
g9
sg10
I4
sg11
VBTRC
p10273
sg13
I1
sa(dp10274
g7
I77
sg8
VP57775
p10275
sg10
I5
sg11
VSHFM3
p10276
sg13
I1
sasg14
(lp10277
(dp10278
g7
I77
sg17
VC1838652
p10279
sg10
I5
sg11
VSHFM3
p10280
sg13
I1
sa(dp10281
g7
I113
sg17
VC1705960
p10282
sg10
I11
sg11
Vduplication
p10283
sg13
I1
sasa(dp10284
g2
S'The smaller duplication in the second patient contained the LBX1, BTRC, POLL, and DPCD genes and a disrupted extra copy of the dactylin gene, and was nearly identical to the smallest known duplicated region of SHFM3.\n'
p10285
sg4
(lp10286
(dp10287
g7
I82
sg8
g9
sg10
I10
sg11
VDPCD genes
p10288
sg13
I2
sa(dp10289
g7
I127
sg8
VP57775
p10290
sg10
I13
sg11
Vdactylin gene
p10291
sg13
I2
sa(dp10292
g7
I72
sg8
g9
sg10
I4
sg11
VPOLL
p10293
sg13
I1
sa(dp10294
g7
I210
sg8
VP57775
p10295
sg10
I5
sg11
VSHFM3
p10296
sg13
I1
sa(dp10297
g7
I60
sg8
VP52954
p10298
sg10
I4
sg11
VLBX1
p10299
sg13
I1
sa(dp10300
g7
I66
sg8
g9
sg10
I4
sg11
VBTRC
p10301
sg13
I1
sasg14
(lp10302
(dp10303
g7
I210
sg17
VC1838652
p10304
sg10
I5
sg11
VSHFM3
p10305
sg13
I1
sa(dp10306
g7
I12
sg17
VC1705960
p10307
sg10
I11
sg11
Vduplication
p10308
sg13
I1
sasa(dp10309
g2
S'In the diagnostic work-up of alcoholic cardiomyopathy, the confirmation of alcohol abuse by carbohydrate deficient transferrin (CDT) and increased liver enzymes, and the involvement of the heart by markers of heart failure (e.g., NT-proBNP) and of necrosis (e.g., troponins or CKMb) is mandatory.\n'
p10310
sg4
(lp10311
(dp10312
g7
I92
sg8
g9
sg10
I34
sg11
Vcarbohydrate deficient transferrin
p10313
sg13
I3
sa(dp10314
g7
I128
sg8
g9
sg10
I3
sg11
VCDT
p10315
sg13
I1
sasg14
(lp10316
(dp10317
g7
I209
sg17
VC0018802
p10318
sg10
I13
sg11
Vheart failure
p10319
sg13
I2
sa(dp10320
g7
I92
sg17
VC1846385
p10321
sg10
I34
sg11
Vcarbohydrate deficient transferrin
p10322
sg13
I3
sa(dp10323
g7
I75
sg17
VC0085762
p10324
sg10
I13
sg11
Valcohol abuse
p10325
sg13
I2
sa(dp10326
g7
I128
sg17
VC1846385
p10327
sg10
I3
sg11
VCDT
p10328
sg13
I1
sa(dp10329
g7
I29
sg17
VC0007192
p10330
sg10
I24
sg11
Valcoholic cardiomyopathy
p10331
sg13
I2
sasa(dp10332
g2
S'Each 10 myg/m(3) increment in daily mean concentration at lag 2 day was associated with a 0.61% (95% CI: 0.19%, 1.03%) increase in overall respiratory mortality and a 0.67% (95% CI: 0.14%, 1.21%) increase in pneumonia mortality.\n'
p10333
sg4
(lp10334
sg14
(lp10335
(dp10336
g7
I208
sg17
VC0032285
p10337
sg10
I9
sg11
Vpneumonia
p10338
sg13
I1
sasa(dp10339
g2
S'The values of the relative risks for hospitalization for pneumonia and asthma were significant for lag 0 (RR=1.051, 95%CI; 1.016 to 1.088); lag 2 (RR=1.066, 95%CI: 1.023 to 1.113); lag 3 (RR=1.053, 95%CI: 1.015 to 1.092); lag 4 (RR=1.043, 95%CI: 1.004 to 1.088) and lag 5 (RR=1.061, 95%CI: 1.018 to 1.106).\n'
p10340
sg4
(lp10341
(dp10342
g7
I140
sg8
VP16949
p10343
sg10
I5
sg11
Vlag 2
p10344
sg13
I2
sa(dp10345
g7
I266
sg8
VP16949
p10346
sg10
I5
sg11
Vlag 5
p10347
sg13
I2
sa(dp10348
g7
I181
sg8
VP16949
p10349
sg10
I5
sg11
Vlag 3
p10350
sg13
I2
sa(dp10351
g7
I99
sg8
VP16949
p10352
sg10
I5
sg11
Vlag 0
p10353
sg13
I2
sa(dp10354
g7
I222
sg8
VP16949
p10355
sg10
I5
sg11
Vlag 4
p10356
sg13
I2
sasg14
(lp10357
(dp10358
g7
I57
sg17
VC0032285
p10359
sg10
I9
sg11
Vpneumonia
p10360
sg13
I1
sa(dp10361
g7
I71
sg17
VC0004096
p10362
sg10
I6
sg11
Vasthma
p10363
sg13
I1
sasa(dp10364
g2
S'A 10 microg/m increase in bushfire PM10 was associated with a 1.24% (95% confidence interval = 0.22% to 2.27%) increase in all respiratory disease admissions (at lag 0), a 3.80% (1.40% to 6.26%) increase in chronic obstructive pulmonary disease admissions (at lag 2), and a 5.02% (1.77% to 8.37%) increase in adult asthma admissions (at lag 0).\n'
p10365
sg4
(lp10366
(dp10367
g7
I260
sg8
VP16949
p10368
sg10
I5
sg11
Vlag 2
p10369
sg13
I2
sasg14
(lp10370
(dp10371
g7
I315
sg17
VC0004096
p10372
sg10
I6
sg11
Vasthma
p10373
sg13
I1
sa(dp10374
g7
I127
sg17
VC0035242
p10375
sg10
I19
sg11
Vrespiratory disease
p10376
sg13
I2
sa(dp10377
g7
I207
sg17
VC0024117
p10378
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p10379
sg13
I4
sasa(dp10380
g2
S'We confirmed that inhibition of TREM-1 attenuates the severity of colitis at clinically, endoscopically and histologically levels.\n'
p10381
sg4
(lp10382
(dp10383
g7
I32
sg8
g9
sg10
I6
sg11
VTREM-1
p10384
sg13
I1
sasg14
(lp10385
(dp10386
g7
I66
sg17
VC0009319
p10387
sg10
I7
sg11
Vcolitis
p10388
sg13
I1
sasa(dp10389
g2
S'Indeed, TREM-1 receptor and its signaling pathways contribute to the pathology of several non-infectious acute and chronic inflammatory diseases, including atherosclerosis, ischemia reperfusion-induced tissue injury, colitis, fibrosis and cancer.\n'
p10390
sg4
(lp10391
(dp10392
g7
I8
sg8
g9
sg10
I15
sg11
VTREM-1 receptor
p10393
sg13
I2
sasg14
(lp10394
(dp10395
g7
I217
sg17
VC0009319
p10396
sg10
I7
sg11
Vcolitis
p10397
sg13
I1
sa(dp10398
g7
I173
sg17
VC0022116
p10399
sg10
I8
sg11
Vischemia
p10400
sg13
I1
sa(dp10401
g7
I156
sg17
VC0004153
p10402
sg10
I15
sg11
Vatherosclerosis
p10403
sg13
I1
sa(dp10404
g7
I239
sg17
VC0006826
p10405
sg10
I6
sg11
Vcancer
p10406
sg13
I1
sa(dp10407
g7
I226
sg17
VC0016059
p10408
sg10
I8
sg11
Vfibrosis
p10409
sg13
I1
sa(dp10410
g7
I69
sg17
VC0677042
p10411
sg10
I9
sg11
Vpathology
p10412
sg13
I1
sa(dp10413
g7
I94
sg17
VC0009450
p10414
sg10
I10
sg11
Vinfectious
p10415
sg13
I1
sasa(dp10416
g2
S'In CD4(+) T cell- and dextran sodium sulfate-induced models of colitis, Trem1(-/-) mice displayed significantly attenuated disease that was associated with reduced inflammatory infiltrates and diminished expression of pro-inflammatory cytokines.\n'
p10417
sg4
(lp10418
(dp10419
g7
I3
sg8
VP01730
p10420
sg10
I3
sg11
VCD4
p10421
sg13
I1
sa(dp10422
g7
I72
sg8
g9
sg10
I5
sg11
VTrem1
p10423
sg13
I1
sasg14
(lp10424
(dp10425
g7
I63
sg17
VC0009319
p10426
sg10
I7
sg11
Vcolitis
p10427
sg13
I1
sa(dp10428
g7
I177
sg17
VC0332448
p10429
sg10
I11
sg11
Vinfiltrates
p10430
sg13
I1
sasa(dp10431
g2
S'In vivo, the treatment with the TREM-1 antagonist LP17 or control peptide was initiated at the beginning of or after induction of experimental colitis or colitis-associated tumorigenesis.\n'
p10432
sg4
(lp10433
(dp10434
g7
I32
sg8
g9
sg10
I6
sg11
VTREM-1
p10435
sg13
I1
sasg14
(lp10436
(dp10437
g7
I143
sg17
VC0009319
p10438
sg10
I7
sg11
Vcolitis
p10439
sg13
I1
sa(dp10440
g7
I143
sg17
VC0009319
p10441
sg10
I7
sg11
Vcolitis
p10442
sg13
I1
sa(dp10443
g7
I173
sg17
VC0007621
p10444
sg10
I13
sg11
Vtumorigenesis
p10445
sg13
I1
sasa(dp10446
g2
S'In ulcerative colitis, sTREM-1 level was correlated more strongly with the endoscopic activity (r=0.498) than the C-reactive protein level (r=0.386) or erythrocyte sedimentation rate (r=0.272), although not superior to the partial Mayo score (r=0.611).\n'
p10447
sg4
(lp10448
(dp10449
g7
I114
sg8
VP02741
p10450
sg10
I18
sg11
VC-reactive protein
p10451
sg13
I2
sasg14
(lp10452
(dp10453
g7
I3
sg17
VC0009324
p10454
sg10
I18
sg11
Vulcerative colitis
p10455
sg13
I2
sasa(dp10456
g2
S'In ulcerative colitis, sTREM-1 level was correlated most closely with the endoscopic disease activity among serum biomarkers, but was not superior to the clinical activity index.\n'
p10457
sg4
(lp10458
sg14
(lp10459
(dp10460
g7
I3
sg17
VC0009324
p10461
sg10
I18
sg11
Vulcerative colitis
p10462
sg13
I2
sasa(dp10463
g2
S"Our results suggest that sTREM-1 level may represent a complementary marker for the assessment of endoscopic activity in ulcerative colitis, but not in Crohn's disease.\n"
p10464
sg4
(lp10465
sg14
(lp10466
(dp10467
g7
I152
sg17
VC0010346
p10468
sg10
I15
sg11
VCrohn's disease
p10469
sg13
I2
sa(dp10470
g7
I121
sg17
VC0009324
p10471
sg10
I18
sg11
Vulcerative colitis
p10472
sg13
I2
sasa(dp10473
g2
S"Intestinal biopsies and concurrently collected sera from patients with Crohn's disease (CD) and Ulcerative colitis (UC) enrolled in the Swiss IBD cohort study were analyzed for intestinal TREM-1 mRNA and serum sTREM-1 expression.\n"
p10474
sg4
(lp10475
(dp10476
g7
I204
sg8
g9
sg10
I13
sg11
Vserum sTREM-1
p10477
sg13
I2
sa(dp10478
g7
I188
sg8
g9
sg10
I11
sg11
VTREM-1 mRNA
p10479
sg13
I2
sasg14
(lp10480
(dp10481
g7
I96
sg17
VC0009324
p10482
sg10
I18
sg11
VUlcerative colitis
p10483
sg13
I2
sa(dp10484
g7
I71
sg17
VC0010346
p10485
sg10
I15
sg11
VCrohn's disease
p10486
sg13
I2
sa(dp10487
g7
I142
sg17
VC0021390
p10488
sg10
I3
sg11
VIBD
p10489
sg13
I1
sa(dp10490
g7
I116
sg17
VC0009324
p10491
sg10
I2
sg11
VUC
p10492
sg13
I1
sa(dp10493
g7
I88
sg17
VC0010346
p10494
sg10
I2
sg11
VCD
p10495
sg13
I1
sasa(dp10496
g2
S'Serum sTREM-1 and TREM-1 mRNA expression levels were further determined in sera and colonic tissues collected at various time-points post disease induction in an experimental mouse model of colitis and correlated with disease activity.\n'
p10497
sg4
(lp10498
(dp10499
g7
I18
sg8
g9
sg10
I11
sg11
VTREM-1 mRNA
p10500
sg13
I2
sasg14
(lp10501
(dp10502
g7
I190
sg17
VC0009319
p10503
sg10
I7
sg11
Vcolitis
p10504
sg13
I1
sasa(dp10505
g2
S"Three TREM-1 single nucleotide polymorphisms (SNPs, rs2234237, rs3789205, and rs9471535) were genotyped by Taqman technology on 202 Crohn's disease (CD), 265 ulcerative colitis (UC), 138 with intestinal Behcet's disease (BD), and 234 healthy controls and the relationships between these SNPs and IBD development and phenotypes were evaluated.\n"
p10506
sg4
(lp10507
sg14
(lp10508
(dp10509
g7
I203
sg17
VC0004943
p10510
sg10
I16
sg11
VBehcet's disease
p10511
sg13
I2
sa(dp10512
g7
I149
sg17
VC0010346
p10513
sg10
I2
sg11
VCD
p10514
sg13
I1
sa(dp10515
g7
I221
sg17
VC0004943
p10516
sg10
I2
sg11
VBD
p10517
sg13
I1
sa(dp10518
g7
I132
sg17
VC0010346
p10519
sg10
I15
sg11
VCrohn's disease
p10520
sg13
I2
sa(dp10521
g7
I158
sg17
VC0009324
p10522
sg10
I18
sg11
Vulcerative colitis
p10523
sg13
I2
sa(dp10524
g7
I178
sg17
VC0009324
p10525
sg10
I2
sg11
VUC
p10526
sg13
I1
sa(dp10527
g7
I296
sg17
VC0021390
p10528
sg10
I3
sg11
VIBD
p10529
sg13
I1
sasa(dp10530
g2
S"However, TREM-1 SNPs were not significantly associated with the development of Crohn's disease or ulcerative colitis.\n"
p10531
sg4
(lp10532
(dp10533
g7
I9
sg8
g9
sg10
I11
sg11
VTREM-1 SNPs
p10534
sg13
I2
sasg14
(lp10535
(dp10536
g7
I79
sg17
VC0010346
p10537
sg10
I15
sg11
VCrohn's disease
p10538
sg13
I2
sa(dp10539
g7
I98
sg17
VC0009324
p10540
sg10
I18
sg11
Vulcerative colitis
p10541
sg13
I2
sasa(dp10542
g2
S'Stable expression of miR-124 in diffuse large B cell lymphoma (DLBCL) cell lines diminished PDE4B expression.\n'
p10543
sg4
(lp10544
(dp10545
g7
I92
sg8
g9
sg10
I5
sg11
VPDE4B
p10546
sg13
I1
sa(dp10547
g7
I21
sg8
g9
sg10
I7
sg11
VmiR-124
p10548
sg13
I1
sasg14
(lp10549
(dp10550
g7
I63
sg17
VC0079744
p10551
sg10
I5
sg11
VDLBCL
p10552
sg13
I1
sa(dp10553
g7
I32
sg17
VC0079744
p10554
sg10
I29
sg11
Vdiffuse large B cell lymphoma
p10555
sg13
I5
sasa(dp10556
g2
S'Starting from the GSEA, we found that overexpression of the PDE4B in diffuse large B-cell lymphoma (DLBCL) impinge on the same genes/pathways that are abnormally active in GC-resistant tumors.\n'
p10557
sg4
(lp10558
(dp10559
g7
I60
sg8
g9
sg10
I5
sg11
VPDE4B
p10560
sg13
I1
sasg14
(lp10561
(dp10562
g7
I69
sg17
VC0079744
p10563
sg10
I29
sg11
Vdiffuse large B-cell lymphoma
p10564
sg13
I4
sa(dp10565
g7
I185
sg17
VC0027651
p10566
sg10
I6
sg11
Vtumors
p10567
sg13
I1
sa(dp10568
g7
I100
sg17
VC0079744
p10569
sg10
I5
sg11
VDLBCL
p10570
sg13
I1
sasa(dp10571
g2
S'On the basis of biopsies of the masses in the pharynx and finger, he was diagnosed with extramedullary plasmablastic plasmacytoma, with somewhat immature CD45(+), MPC-1(-), and CD49e(-).\n'
p10572
sg4
(lp10573
(dp10574
g7
I177
sg8
VP08648
p10575
sg10
I5
sg11
VCD49e
p10576
sg13
I1
sa(dp10577
g7
I154
sg8
VP08575
p10578
sg10
I7
sg11
VCD45(+)
p10579
sg13
I1
sa(dp10580
g7
I163
sg8
VP28062
p10581
sg10
I5
sg11
VMPC-1
p10582
sg13
I1
sasg14
(lp10583
(dp10584
g7
I117
sg17
VC0032131
p10585
sg10
I12
sg11
Vplasmacytoma
p10586
sg13
I1
sasa(dp10587
g2
S'Changes to CD45 negativity and MPC-1 partial positivity were seen, while CD49e negativity persisted, suggesting that the plasmablastic plasmacytoma had reverted to a more immature state.\n'
p10588
sg4
(lp10589
(dp10590
g7
I31
sg8
VP28062
p10591
sg10
I5
sg11
VMPC-1
p10592
sg13
I1
sa(dp10593
g7
I73
sg8
VP08648
p10594
sg10
I5
sg11
VCD49e
p10595
sg13
I1
sa(dp10596
g7
I11
sg8
VP08575
p10597
sg10
I15
sg11
VCD45 negativity
p10598
sg13
I2
sasg14
(lp10599
(dp10600
g7
I135
sg17
VC0032131
p10601
sg10
I12
sg11
Vplasmacytoma
p10602
sg13
I1
sasa(dp10603
g2
S'He had the following poor prognostic factors: 1) multiple extramedullary plasmacytomas, 2) massive myelomatous effusion, 3) increasing immature myeloma cells with plasmablastic morphology, and 4) predominance of MPC1-CD49e-CD45+ phenotype immature myeloma cells.\n'
p10604
sg4
(lp10605
(dp10606
g7
I212
sg8
VP28062
p10607
sg10
I4
sg11
VMPC1
p10608
sg13
I1
sa(dp10609
g7
I223
sg8
VP08575
p10610
sg10
I5
sg11
VCD45+
p10611
sg13
I1
sa(dp10612
g7
I217
sg8
VP08648
p10613
sg10
I5
sg11
VCD49e
p10614
sg13
I1
sasg14
(lp10615
(dp10616
g7
I99
sg17
VC0026764
p10617
sg10
I7
sg11
Vmyeloma
p10618
sg13
I1
sa(dp10619
g7
I111
sg17
VC0013687
p10620
sg10
I8
sg11
Veffusion
p10621
sg13
I1
sa(dp10622
g7
I99
sg17
VC0026764
p10623
sg10
I7
sg11
Vmyeloma
p10624
sg13
I1
sa(dp10625
g7
I73
sg17
VC0032131
p10626
sg10
I13
sg11
Vplasmacytomas
p10627
sg13
I1
sasa(dp10628
g2
S'Interestingly, the proportions of MPC-1(-) and MPC-1(-)CD45(+) immature monoclonal plasma cells also increased in the 7 progressive cases of MGUS.\n'
p10629
sg4
(lp10630
(dp10631
g7
I47
sg8
VP28062
p10632
sg10
I15
sg11
VMPC-1(-)CD45(+)
p10633
sg13
I1
sa(dp10634
g7
I34
sg8
VP28062
p10635
sg10
I5
sg11
VMPC-1
p10636
sg13
I1
sasg14
(lp10637
(dp10638
g7
I141
sg17
VC0026470
p10639
sg10
I4
sg11
VMGUS
p10640
sg13
I1
sasa(dp10641
g2
S"The main hereditary LMNSs in adulthood are Kennedy's disease, late-onset spinal muscular atrophy and distal hereditary motor neuropathies.\n"
p10642
sg4
(lp10643
sg14
(lp10644
(dp10645
g7
I125
sg17
VC0442874
p10646
sg10
I12
sg11
Vneuropathies
p10647
sg13
I1
sa(dp10648
g7
I73
sg17
VC0026847
p10649
sg10
I23
sg11
Vspinal muscular atrophy
p10650
sg13
I3
sa(dp10651
g7
I43
sg17
VC1839259
p10652
sg10
I17
sg11
VKennedy's disease
p10653
sg13
I2
sasa(dp10654
g2
S'In contrast, spinal muscular atrophy (SMA) involves the specific degeneration of LMNs, with symmetrical muscle weakness and atrophy.\n'
p10655
sg4
(lp10656
sg14
(lp10657
(dp10658
g7
I38
sg17
VC0026847
p10659
sg10
I3
sg11
VSMA
p10660
sg13
I1
sa(dp10661
g7
I65
sg17
VC0011164
p10662
sg10
I12
sg11
Vdegeneration
p10663
sg13
I1
sa(dp10664
g7
I13
sg17
VC0026847
p10665
sg10
I23
sg11
Vspinal muscular atrophy
p10666
sg13
I3
sa(dp10667
g7
I104
sg17
VC0030552
p10668
sg10
I15
sg11
Vmuscle weakness
p10669
sg13
I2
sa(dp10670
g7
I29
sg17
VC0333641
p10671
sg10
I7
sg11
Vatrophy
p10672
sg13
I1
sasa(dp10673
g2
S'Targeting lower motor neurons (LMNs) for gene delivery could be useful for disorders such as spinal muscular atrophy and amyotrophic lateral sclerosis.\n'
p10674
sg4
(lp10675
sg14
(lp10676
(dp10677
g7
I93
sg17
VC0026847
p10678
sg10
I23
sg11
Vspinal muscular atrophy
p10679
sg13
I3
sa(dp10680
g7
I121
sg17
VC0002736
p10681
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p10682
sg13
I3
sasa(dp10683
g2
S'Our previous study showed that reduction of KCa3.1 channel expression by lyso-globotriaosylceramide (lyso-Gb3) inhibits differentiation into myofibroblasts and collagen synthesis, which might lead to development of ascending thoracic aortic aneurysm secondary to Fabry disease.\n'
p10684
sg4
(lp10685
sg14
(lp10686
(dp10687
g7
I225
sg17
VC0162872
p10688
sg10
I24
sg11
Vthoracic aortic aneurysm
p10689
sg13
I3
sa(dp10690
g7
I263
sg17
VC0002986
p10691
sg10
I13
sg11
VFabry disease
p10692
sg13
I2
sasa(dp10693
g2
S'Moreover, lyso-Gb3 suppressed expression of class II phosphatidylinositol 3-kinase C2Beta (PI3KC2Beta) by PKA activation, which reduces the production of phosphatidylinositol 3-phosphate [PI(3)P], and the reduced membrane surface expression of KCa3.1 channel was recovered by increasing the intracellular levels of PI(3)P. Consequently, our findings that lyso-Gb3 inhibited both KCa3.1 channel synthesis and surface expression by increasing intracellular cAMP, and controlled surface expression through changes in PI3KC2Beta-mediated PI(3)P production, suggest that modulation of PKA and PI3KC2Beta activity to control of KCa3.1 channel expression can be an alternative important target to attenuate ascending thoracic aortic aneurysms in Fabry disease.\n'
p10694
sg4
(lp10695
(dp10696
g7
I244
sg8
g9
sg10
I6
sg11
VKCa3.1
p10697
sg13
I1
sa(dp10698
g7
I44
sg8
g9
sg10
I45
sg11
Vclass II phosphatidylinositol 3-kinase C2Beta
p10699
sg13
I5
sa(dp10700
g7
I244
sg8
g9
sg10
I6
sg11
VKCa3.1
p10701
sg13
I1
sa(dp10702
g7
I244
sg8
g9
sg10
I6
sg11
VKCa3.1
p10703
sg13
I1
sa(dp10704
g7
I106
sg8
VP17612
p10705
sg10
I3
sg11
VPKA
p10706
sg13
I1
sa(dp10707
g7
I154
sg8
VP48426
p10708
sg10
I41
sg11
Vphosphatidylinositol 3-phosphate [PI(3)P]
p10709
sg13
I3
sa(dp10710
g7
I106
sg8
VP17612
p10711
sg10
I3
sg11
VPKA
p10712
sg13
I1
sasg14
(lp10713
(dp10714
g7
I739
sg17
VC0002986
p10715
sg10
I13
sg11
VFabry disease
p10716
sg13
I2
sa(dp10717
g7
I710
sg17
VC0162872
p10718
sg10
I25
sg11
Vthoracic aortic aneurysms
p10719
sg13
I3
sasa(dp10720
g2
S'These findings suggest that the KCa3.1 channel can serve as a new target to attenuate and prevent development of ascending thoracic aortic aneurysm in Fabry disease.\n'
p10721
sg4
(lp10722
(dp10723
g7
I32
sg8
g9
sg10
I14
sg11
VKCa3.1 channel
p10724
sg13
I2
sasg14
(lp10725
(dp10726
g7
I151
sg17
VC0002986
p10727
sg10
I13
sg11
VFabry disease
p10728
sg13
I2
sa(dp10729
g7
I123
sg17
VC0162872
p10730
sg10
I24
sg11
Vthoracic aortic aneurysm
p10731
sg13
I3
sasa(dp10732
g2
S'We sequenced BCAs in patients with autism or related NDDs, revealing disruption of 33 loci in four general categories: (1) genes previously associated with abnormal neurodevelopment (e.g., AUTS2, FOXP1, and CDKL5), (2) single-gene contributors to microdeletion syndromes (MBD5, SATB2, EHMT1, and SNURF-SNRPN), (3) novel risk loci (e.g., CHD8, KIRREL3, and ZNF507), and (4) genes associated with later-onset psychiatric disorders (e.g., TCF4, ZNF804A, PDE10A, GRIN2B, and ANK3).\n'
p10733
sg4
(lp10734
(dp10735
g7
I436
sg8
VP15884
p10736
sg10
I4
sg11
VTCF4
p10737
sg13
I1
sa(dp10738
g7
I459
sg8
g9
sg10
I6
sg11
VGRIN2B
p10739
sg13
I1
sa(dp10740
g7
I189
sg8
g9
sg10
I5
sg11
VAUTS2
p10741
sg13
I1
sa(dp10742
g7
I296
sg8
VP63162
p10743
sg10
I11
sg11
VSNURF-SNRPN
p10744
sg13
I1
sa(dp10745
g7
I196
sg8
g9
sg10
I5
sg11
VFOXP1
p10746
sg13
I1
sa(dp10747
g7
I471
sg8
g9
sg10
I4
sg11
VANK3
p10748
sg13
I1
sa(dp10749
g7
I278
sg8
g9
sg10
I5
sg11
VSATB2
p10750
sg13
I1
sa(dp10751
g7
I356
sg8
g9
sg10
I6
sg11
VZNF507
p10752
sg13
I1
sa(dp10753
g7
I207
sg8
g9
sg10
I5
sg11
VCDKL5
p10754
sg13
I1
sa(dp10755
g7
I285
sg8
g9
sg10
I5
sg11
VEHMT1
p10756
sg13
I1
sa(dp10757
g7
I272
sg8
g9
sg10
I4
sg11
VMBD5
p10758
sg13
I1
sa(dp10759
g7
I343
sg8
g9
sg10
I7
sg11
VKIRREL3
p10760
sg13
I1
sa(dp10761
g7
I442
sg8
g9
sg10
I7
sg11
VZNF804A
p10762
sg13
I1
sa(dp10763
g7
I451
sg8
g9
sg10
I6
sg11
VPDE10A
p10764
sg13
I1
sasg14
(lp10765
(dp10766
g7
I35
sg17
VC0004352
p10767
sg10
I6
sg11
Vautism
p10768
sg13
I1
sa(dp10769
g7
I407
sg17
VC0004936
p10770
sg10
I21
sg11
Vpsychiatric disorders
p10771
sg13
I2
sa(dp10772
g7
I261
sg17
VC0039082
p10773
sg10
I9
sg11
Vsyndromes
p10774
sg13
I1
sasa(dp10775
g2
S'Their protein products listed below immediately suggest cell signalling pathways/processes worthy of further investigation in elucidating the mechanism of CpG 5mer activity: caspase 2, the transcription factors Atf4, Hic, HoxB3 and Rqcd1, the splicing factors Rbmx, Sfrs5 and Sfrs7, the DNA replication factors Mcm5 and Brd4, phosphoinositide-3-kinase, annexin A1, mucosa-associated lymphoid tissue lymphoma translocation 1 and three enzymes involved in protein ubiquitylation, Siah1, Gsa7 and Nin283.\n'
p10776
sg4
(lp10777
(dp10778
g7
I266
sg8
g9
sg10
I5
sg11
VSfrs5
p10779
sg13
I1
sa(dp10780
g7
I211
sg8
VP18848
p10781
sg10
I4
sg11
VAtf4
p10782
sg13
I1
sa(dp10783
g7
I276
sg8
g9
sg10
I5
sg11
VSfrs7
p10784
sg13
I1
sa(dp10785
g7
I232
sg8
g9
sg10
I5
sg11
VRqcd1
p10786
sg13
I1
sa(dp10787
g7
I485
sg8
g9
sg10
I4
sg11
VGsa7
p10788
sg13
I1
sa(dp10789
g7
I217
sg8
VP18136
p10790
sg10
I3
sg11
VHic
p10791
sg13
I1
sa(dp10792
g7
I311
sg8
VP33992
p10793
sg10
I4
sg11
VMcm5
p10794
sg13
I1
sa(dp10795
g7
I222
sg8
VP14651
p10796
sg10
I5
sg11
VHoxB3
p10797
sg13
I1
sa(dp10798
g7
I320
sg8
g9
sg10
I4
sg11
VBrd4
p10799
sg13
I1
sa(dp10800
g7
I494
sg8
g9
sg10
I6
sg11
VNin283
p10801
sg13
I1
sa(dp10802
g7
I353
sg8
VP04083
p10803
sg10
I10
sg11
Vannexin A1
p10804
sg13
I2
sa(dp10805
g7
I260
sg8
VP38159
p10806
sg10
I4
sg11
VRbmx
p10807
sg13
I1
sa(dp10808
g7
I478
sg8
g9
sg10
I5
sg11
VSiah1
p10809
sg13
I1
sa(dp10810
g7
I174
sg8
VP42575
p10811
sg10
I9
sg11
Vcaspase 2
p10812
sg13
I2
sa(dp10813
g7
I326
sg8
VP33981
p10814
sg10
I25
sg11
Vphosphoinositide-3-kinase
p10815
sg13
I1
sasg14
(lp10816
(dp10817
g7
I365
sg17
VC0242647
p10818
sg10
I42
sg11
Vmucosa-associated lymphoid tissue lymphoma
p10819
sg13
I4
sa(dp10820
g7
I408
sg17
VC0040715
p10821
sg10
I13
sg11
Vtranslocation
p10822
sg13
I1
sasa(dp10823
g2
S'Multiple cylindromas can have a syndromic association as seen in Brooke-Spiegler syndrome and familial cylindromatosis.\n'
p10824
sg4
(lp10825
sg14
(lp10826
(dp10827
g7
I9
sg17
VC0010606
p10828
sg10
I11
sg11
Vcylindromas
p10829
sg13
I1
sa(dp10830
g7
I94
sg17
VC1851526
p10831
sg10
I24
sg11
Vfamilial cylindromatosis
p10832
sg13
I2
sa(dp10833
g7
I65
sg17
VC1857941
p10834
sg10
I24
sg11
VBrooke-Spiegler syndrome
p10835
sg13
I2
sasa(dp10836
g2
S'A predisposition to multiple cylindromas is seen in patients with Brooke-Spiegler syndrome, who carry germline mutations in the tumour suppressor gene CYLD.\n'
p10837
sg4
(lp10838
(dp10839
g7
I146
sg8
g9
sg10
I9
sg11
Vgene CYLD
p10840
sg13
I2
sasg14
(lp10841
(dp10842
g7
I29
sg17
VC0010606
p10843
sg10
I11
sg11
Vcylindromas
p10844
sg13
I1
sa(dp10845
g7
I66
sg17
VC1857941
p10846
sg10
I24
sg11
VBrooke-Spiegler syndrome
p10847
sg13
I2
sa(dp10848
g7
I128
sg17
VC0027651
p10849
sg10
I6
sg11
Vtumour
p10850
sg13
I1
sasa(dp10851
g2
S'Previous studies of inherited cylindromas have highlighted the frequent presence of bi-allelic truncating CYLD mutations as a recurrent driver mutation.\n'
p10852
sg4
(lp10853
(dp10854
g7
I106
sg8
g9
sg10
I14
sg11
VCYLD mutations
p10855
sg13
I2
sasg14
(lp10856
(dp10857
g7
I30
sg17
VC0010606
p10858
sg10
I11
sg11
Vcylindromas
p10859
sg13
I1
sasa(dp10860
g2
S'Here, we investigated inherited cylindromas from several families with germline CYLD mutations for the presence of MYB activation.\n'
p10861
sg4
(lp10862
(dp10863
g7
I115
sg8
VP10243
p10864
sg10
I3
sg11
VMYB
p10865
sg13
I1
sa(dp10866
g7
I80
sg8
g9
sg10
I4
sg11
VCYLD
p10867
sg13
I1
sasg14
(lp10868
(dp10869
g7
I32
sg17
VC0010606
p10870
sg10
I11
sg11
Vcylindromas
p10871
sg13
I1
sasa(dp10872
g2
S'Cylindroma is a rare skin tumour that is inherited in several skin-tumour syndromes caused by germline mutations in the tumour suppressor gene, CYLD.\n'
p10873
sg4
(lp10874
(dp10875
g7
I144
sg8
g9
sg10
I4
sg11
VCYLD
p10876
sg13
I1
sasg14
(lp10877
(dp10878
g7
I0
sg17
VC0010606
p10879
sg10
I10
sg11
VCylindroma
p10880
sg13
I1
sa(dp10881
g7
I26
sg17
VC0027651
p10882
sg10
I6
sg11
Vtumour
p10883
sg13
I1
sa(dp10884
g7
I26
sg17
VC0027651
p10885
sg10
I6
sg11
Vtumour
p10886
sg13
I1
sa(dp10887
g7
I74
sg17
VC0039082
p10888
sg10
I9
sg11
Vsyndromes
p10889
sg13
I1
sa(dp10890
g7
I21
sg17
VC0037286
p10891
sg10
I11
sg11
Vskin tumour
p10892
sg13
I2
sasa(dp10893
g2
S'The aims of this study were to perform a whole-exome sequencing analysis of a breast cylindroma and to investigate the role of molecular analyses in the differentiation between breast cylindroma, a benign tumour that displays MYB expression, and CYLD gene mutations, and its main differential diagnosis, the breast solid-basaloid adenoid cystic carcinoma, a malignant tumour that is characterized by the presence of the MYB-NFIB fusion gene and MYB overexpression.\n'
p10894
sg4
(lp10895
(dp10896
g7
I424
sg8
g9
sg10
I16
sg11
VNFIB fusion gene
p10897
sg13
I3
sa(dp10898
g7
I226
sg8
VP10243
p10899
sg10
I3
sg11
VMYB
p10900
sg13
I1
sa(dp10901
g7
I226
sg8
VP10243
p10902
sg10
I3
sg11
VMYB
p10903
sg13
I1
sa(dp10904
g7
I246
sg8
g9
sg10
I9
sg11
VCYLD gene
p10905
sg13
I2
sa(dp10906
g7
I226
sg8
VP10243
p10907
sg10
I3
sg11
VMYB
p10908
sg13
I1
sasg14
(lp10909
(dp10910
g7
I330
sg17
VC0010606
p10911
sg10
I24
sg11
Vadenoid cystic carcinoma
p10912
sg13
I3
sa(dp10913
g7
I358
sg17
VC0006826
p10914
sg10
I16
sg11
Vmalignant tumour
p10915
sg13
I2
sa(dp10916
g7
I85
sg17
VC0010606
p10917
sg10
I10
sg11
Vcylindroma
p10918
sg13
I1
sa(dp10919
g7
I198
sg17
VC0086692
p10920
sg10
I13
sg11
Vbenign tumour
p10921
sg13
I2
sa(dp10922
g7
I85
sg17
VC0010606
p10923
sg10
I10
sg11
Vcylindroma
p10924
sg13
I1
sasa(dp10925
g2
S'The clinical presentation of multiple, rare, skin appendage tumours called cylindromas has been attributed to germline mutations in the tumour suppressor gene CYLD (OMIM 605018).\n'
p10926
sg4
(lp10927
(dp10928
g7
I159
sg8
g9
sg10
I4
sg11
VCYLD
p10929
sg13
I1
sasg14
(lp10930
(dp10931
g7
I75
sg17
VC0010606
p10932
sg10
I11
sg11
Vcylindromas
p10933
sg13
I1
sa(dp10934
g7
I60
sg17
VC0027651
p10935
sg10
I6
sg11
Vtumour
p10936
sg13
I1
sa(dp10937
g7
I60
sg17
VC0027651
p10938
sg10
I7
sg11
Vtumours
p10939
sg13
I1
sasa(dp10940
g2
S'Brooke-Spiegler Syndrome (BSS), familial cylindromatosis (FC) and multiple familial trichoepitheliomas (MFT) (OMIM #605041, #132700, #601606 respectively) differ due to the types of other skin appendage tumour seen together with cylindroma, such as spiradenoma and trichoepithelioma.\n'
p10941
sg4
(lp10942
sg14
(lp10943
(dp10944
g7
I84
sg17
VC0349658
p10945
sg10
I17
sg11
Vtrichoepithelioma
p10946
sg13
I1
sa(dp10947
g7
I84
sg17
VC0349658
p10948
sg10
I18
sg11
Vtrichoepitheliomas
p10949
sg13
I1
sa(dp10950
g7
I41
sg17
VC0010606
p10951
sg10
I10
sg11
Vcylindroma
p10952
sg13
I1
sa(dp10953
g7
I188
sg17
VC0345988
p10954
sg10
I21
sg11
Vskin appendage tumour
p10955
sg13
I3
sa(dp10956
g7
I32
sg17
VC1851526
p10957
sg10
I24
sg11
Vfamilial cylindromatosis
p10958
sg13
I2
sa(dp10959
g7
I58
sg17
VC1851526
p10960
sg10
I2
sg11
VFC
p10961
sg13
I1
sa(dp10962
g7
I249
sg17
VC0334347
p10963
sg10
I11
sg11
Vspiradenoma
p10964
sg13
I1
sa(dp10965
g7
I0
sg17
VC1857941
p10966
sg10
I24
sg11
VBrooke-Spiegler Syndrome
p10967
sg13
I2
sa(dp10968
g7
I26
sg17
VC1857941
p10969
sg10
I3
sg11
VBSS
p10970
sg13
I1
sasa(dp10971
g2
S'Unique tumors included a cutaneous cylindroma invasive of skull convexity occurring in familial cylindromatosis and a ganglioneuroma of the middle ear with massive bilateral skull base extension.\n'
p10972
sg4
(lp10973
sg14
(lp10974
(dp10975
g7
I118
sg17
VC0017075
p10976
sg10
I14
sg11
Vganglioneuroma
p10977
sg13
I1
sa(dp10978
g7
I87
sg17
VC1851526
p10979
sg10
I24
sg11
Vfamilial cylindromatosis
p10980
sg13
I2
sa(dp10981
g7
I35
sg17
VC0010606
p10982
sg10
I10
sg11
Vcylindroma
p10983
sg13
I1
sa(dp10984
g7
I7
sg17
VC0027651
p10985
sg10
I6
sg11
Vtumors
p10986
sg13
I1
sasa(dp10987
g2
S'This review will examine and extrapolate from the recent literature to build support for the use of AXT in mitigating neuropathy in normal aging and neurodegenerative disease.\n'
p10988
sg4
(lp10989
(dp10990
g7
I100
sg8
g9
sg10
I3
sg11
VAXT
p10991
sg13
I1
sasg14
(lp10992
(dp10993
g7
I149
sg17
VC0524851
p10994
sg10
I25
sg11
Vneurodegenerative disease
p10995
sg13
I2
sa(dp10996
g7
I118
sg17
VC0442874
p10997
sg10
I10
sg11
Vneuropathy
p10998
sg13
I1
sasa(dp10999
g2
S'We investigated frequencies of single nucleotide polymorphisms (SNPs) in the candidate genes protein tyrosine phosphatase, non-receptor type 22 (PTPN22), B-cell scaffold protein with ankyrin repeats (BANK1), B lymphocyte kinase (Blk), and Fc gamma receptor class IIB (FCGR2B), which have been found to be associated with other autoimmune diseases, CD1A and CD1E, important for antigen presentation of glycolipids, and transient axonal glycoprotein 1 (TAG-1), which is associated with responsiveness to intravenous immunoglobulin in patients with chronic inflammatory demyelinating polyneuropathy.\n'
p11000
sg4
(lp11001
(dp11002
g7
I348
sg8
VP15813
p11003
sg10
I4
sg11
VCD1A
p11004
sg13
I1
sa(dp11005
g7
I200
sg8
g9
sg10
I5
sg11
VBANK1
p11006
sg13
I1
sa(dp11007
g7
I514
sg8
g9
sg10
I14
sg11
Vimmunoglobulin
p11008
sg13
I1
sa(dp11009
g7
I208
sg8
VP51451
p11010
sg10
I19
sg11
VB lymphocyte kinase
p11011
sg13
I3
sa(dp11012
g7
I87
sg8
VP60484
p11013
sg10
I34
sg11
Vgenes protein tyrosine phosphatase
p11014
sg13
I4
sa(dp11015
g7
I418
sg8
g9
sg10
I31
sg11
Vtransient axonal glycoprotein 1
p11016
sg13
I4
sa(dp11017
g7
I268
sg8
VP31995
p11018
sg10
I6
sg11
VFCGR2B
p11019
sg13
I1
sa(dp11020
g7
I239
sg8
VP12314
p11021
sg10
I27
sg11
VFc gamma receptor class IIB
p11022
sg13
I5
sa(dp11023
g7
I145
sg8
g9
sg10
I6
sg11
VPTPN22
p11024
sg13
I1
sa(dp11025
g7
I183
sg8
VP16157
p11026
sg10
I7
sg11
Vankyrin
p11027
sg13
I1
sa(dp11028
g7
I451
sg8
g9
sg10
I5
sg11
VTAG-1
p11029
sg13
I1
sa(dp11030
g7
I229
sg8
VP51451
p11031
sg10
I3
sg11
VBlk
p11032
sg13
I1
sa(dp11033
g7
I123
sg8
g9
sg10
I20
sg11
Vnon-receptor type 22
p11034
sg13
I3
sasg14
(lp11035
(dp11036
g7
I546
sg17
VC0393819
p11037
sg10
I49
sg11
Vchronic inflammatory demyelinating polyneuropathy
p11038
sg13
I4
sa(dp11039
g7
I451
sg17
VC0037293
p11040
sg10
I3
sg11
VTAG
p11041
sg13
I1
sa(dp11042
g7
I327
sg17
VC0004364
p11043
sg10
I19
sg11
Vautoimmune diseases
p11044
sg13
I2
sasa(dp11045
g2
S'To investigate the clinical features of A-pattern exotropia and to evaluate the efficacy of surgical treatment for the correction of A-pattern exotropia (A-XT).\n'
p11046
sg4
(lp11047
sg14
(lp11048
(dp11049
g7
I50
sg17
VC0015310
p11050
sg10
I9
sg11
Vexotropia
p11051
sg13
I1
sa(dp11052
g7
I50
sg17
VC0015310
p11053
sg10
I9
sg11
Vexotropia
p11054
sg13
I1
sasa(dp11055
g2
S'We identified 10 patients from three CA and from two GMS families with WDR73 mutations including the original family described with CA, mental retardation, optic atrophy, and skin abnormalities (CAMOS).\n'
p11056
sg4
(lp11057
(dp11058
g7
I71
sg8
g9
sg10
I5
sg11
VWDR73
p11059
sg13
I1
sasg14
(lp11060
(dp11061
g7
I136
sg17
VC0025362
p11062
sg10
I18
sg11
Vmental retardation
p11063
sg13
I2
sa(dp11064
g7
I156
sg17
VC0029124
p11065
sg10
I13
sg11
Voptic atrophy
p11066
sg13
I2
sa(dp11067
g7
I175
sg17
VC0037268
p11068
sg10
I18
sg11
Vskin abnormalities
p11069
sg13
I2
sa(dp11070
g7
I195
sg17
VC1847114
p11071
sg10
I5
sg11
VCAMOS
p11072
sg13
I1
sasa(dp11073
g2
S'CAMOS (Cerebellar Ataxia with Mental retardation, Optic atrophy and Skin abnormalities) is a rare autosomal recessive syndrome characterized by a nonprogressive congenital cerebellar ataxia associated with mental retardation, optic atrophy, and skin abnormalities.\n'
p11074
sg4
(lp11075
sg14
(lp11076
(dp11077
g7
I161
sg17
VC0852975
p11078
sg10
I28
sg11
Vcongenital cerebellar ataxia
p11079
sg13
I3
sa(dp11080
g7
I206
sg17
VC0025362
p11081
sg10
I18
sg11
Vmental retardation
p11082
sg13
I2
sa(dp11083
g7
I118
sg17
VC0039082
p11084
sg10
I8
sg11
Vsyndrome
p11085
sg13
I1
sa(dp11086
g7
I0
sg17
VC1847114
p11087
sg10
I5
sg11
VCAMOS
p11088
sg13
I1
sa(dp11089
g7
I30
sg17
VC0025362
p11090
sg10
I18
sg11
VMental retardation
p11091
sg13
I2
sa(dp11092
g7
I226
sg17
VC0029124
p11093
sg10
I13
sg11
Voptic atrophy
p11094
sg13
I2
sa(dp11095
g7
I7
sg17
VC0007758
p11096
sg10
I17
sg11
VCerebellar Ataxia
p11097
sg13
I2
sa(dp11098
g7
I68
sg17
VC0037268
p11099
sg10
I18
sg11
VSkin abnormalities
p11100
sg13
I2
sa(dp11101
g7
I50
sg17
VC0029124
p11102
sg10
I13
sg11
VOptic atrophy
p11103
sg13
I2
sa(dp11104
g7
I245
sg17
VC0037268
p11105
sg10
I18
sg11
Vskin abnormalities
p11106
sg13
I2
sasa(dp11107
g2
S'Eyes with laser-treated threshold ROP had significant myopia at both ages (mean spherical equivalent [MSE] in right eye at both refractions -0.72, -1.21 diopters [D]), astigmatism (MSE -1.62, -1.80 D), and anisometropia (MSE 0.82, 1.02 D; ANOVA p &lt; 0.05), and increased refractive errors across ages (paired t test p &lt; 0.05).\n'
p11108
sg4
(lp11109
sg14
(lp11110
(dp11111
g7
I54
sg17
VC0027092
p11112
sg10
I6
sg11
Vmyopia
p11113
sg13
I1
sa(dp11114
g7
I206
sg17
VC0003081
p11115
sg10
I13
sg11
Vanisometropia
p11116
sg13
I1
sa(dp11117
g7
I168
sg17
VC0004106
p11118
sg10
I11
sg11
Vastigmatism
p11119
sg13
I1
sa(dp11120
g7
I273
sg17
VC0034951
p11121
sg10
I17
sg11
Vrefractive errors
p11122
sg13
I2
sa(dp11123
g7
I34
sg17
VC0035344
p11124
sg10
I3
sg11
VROP
p11125
sg13
I1
sasa(dp11126
g2
S'Monocular deprivation does affect the binding parameters (KD and Bmax) of GluRs, which may be a molecular mechanism of the development of amblyopia.\n'
p11127
sg4
(lp11128
sg14
(lp11129
sa(dp11130
g2
S'Expressions of GluRs and CaBPs (i.e., parvalbumin and calbindin D-28k) were observed to be increased in the retinal ganglion cell layer (GCL) and inner nuclear layer (INL) at 3 days and 1 week after the onset of glaucoma.\n'
p11131
sg4
(lp11132
(dp11133
g7
I38
sg8
VP20472
p11134
sg10
I11
sg11
Vparvalbumin
p11135
sg13
I1
sa(dp11136
g7
I54
sg8
VP05937
p11137
sg10
I15
sg11
Vcalbindin D-28k
p11138
sg13
I2
sasg14
(lp11139
(dp11140
g7
I116
sg17
VC0023521
p11141
sg10
I19
sg11
Vganglion cell layer
p11142
sg13
I3
sa(dp11143
g7
I212
sg17
VC0017601
p11144
sg10
I8
sg11
Vglaucoma
p11145
sg13
I1
sa(dp11146
g7
I137
sg17
VC0023521
p11147
sg10
I3
sg11
VGCL
p11148
sg13
I1
sasa(dp11149
g2
S'The finding that both NMDA and non-NMDA GluRs were involved in glutamate-induced excitotoxicity suggests that isolated pig RGCs provide a good model for glaucoma.\n'
p11150
sg4
(lp11151
sg14
(lp11152
(dp11153
g7
I153
sg17
VC0017601
p11154
sg10
I8
sg11
Vglaucoma
p11155
sg13
I1
sasa(dp11156
g2
S'USP45 associates with ERCC1, a subunit of the DNA repair endonuclease XPF-ERCC1, via a short acidic motif outside of the USP45 catalytic domain.\n'
p11157
sg4
(lp11158
(dp11159
g7
I22
sg8
VP07992
p11160
sg10
I5
sg11
VERCC1
p11161
sg13
I1
sa(dp11162
g7
I46
sg8
g9
sg10
I27
sg11
VDNA repair endonuclease XPF
p11163
sg13
I4
sa(dp11164
g7
I22
sg8
VP07992
p11165
sg10
I5
sg11
VERCC1
p11166
sg13
I1
sa(dp11167
g7
I0
sg8
g9
sg10
I5
sg11
VUSP45
p11168
sg13
I1
sa(dp11169
g7
I121
sg8
g9
sg10
I22
sg11
VUSP45 catalytic domain
p11170
sg13
I3
sasg14
(lp11171
(dp11172
g7
I70
sg17
VC0268140
p11173
sg10
I3
sg11
VXPF
p11174
sg13
I1
sasa(dp11175
g2
S'Finally, USP45 localises to sites of DNA damage in a manner dependent on its deubiquitylase activity, but independent of its ability to bind ERCC1-XPF.\n'
p11176
sg4
(lp11177
(dp11178
g7
I147
sg8
g9
sg10
I3
sg11
VXPF
p11179
sg13
I1
sa(dp11180
g7
I141
sg8
VP07992
p11181
sg10
I5
sg11
VERCC1
p11182
sg13
I1
sa(dp11183
g7
I9
sg8
g9
sg10
I5
sg11
VUSP45
p11184
sg13
I1
sasg14
(lp11185
(dp11186
g7
I37
sg17
VC0012860
p11187
sg10
I10
sg11
VDNA damage
p11188
sg13
I2
sa(dp11189
g7
I147
sg17
VC0268140
p11190
sg10
I3
sg11
VXPF
p11191
sg13
I1
sasa(dp11192
g2
S'Together, these results establish USP45 as a new regulator of XPF-ERCC1 crucial for efficient DNA repair.\n'
p11193
sg4
(lp11194
(dp11195
g7
I34
sg8
g9
sg10
I5
sg11
VUSP45
p11196
sg13
I1
sa(dp11197
g7
I62
sg8
g9
sg10
I9
sg11
VXPF-ERCC1
p11198
sg13
I1
sasg14
(lp11199
(dp11200
g7
I62
sg17
VC0268140
p11201
sg10
I3
sg11
VXPF
p11202
sg13
I1
sasa(dp11203
g2
S'We used a polycistronic lentiviral vector (hSTEMCCA-loxP) encoding OCT4, SOX2, KLF4, and cMYC genes and containing loxP sites, excisible by Cre recombinase, to reprogram patient-specific fetal cells derived from prenatal diagnosis for several genetic disorders, such as myotonic dystrophy type 1 (DM1), Beta-thalassemia (Beta-Thal), lymphedema-distichiasis syndrome (LDS), spinal muscular atrophy (SMA), cystic fibrosis (CF), as well as from wild-type (WT) fetal cells.\n'
p11204
sg4
(lp11205
(dp11206
g7
I297
sg8
g9
sg10
I3
sg11
VDM1
p11207
sg13
I1
sa(dp11208
g7
I140
sg8
g9
sg10
I15
sg11
VCre recombinase
p11209
sg13
I2
sa(dp11210
g7
I79
sg8
g9
sg10
I4
sg11
VKLF4
p11211
sg13
I1
sa(dp11212
g7
I270
sg8
g9
sg10
I25
sg11
Vmyotonic dystrophy type 1
p11213
sg13
I4
sa(dp11214
g7
I89
sg8
VP01893
p11215
sg10
I10
sg11
VcMYC genes
p11216
sg13
I2
sa(dp11217
g7
I73
sg8
VP48431
p11218
sg10
I4
sg11
VSOX2
p11219
sg13
I1
sasg14
(lp11220
(dp11221
g7
I333
sg17
VC0265345
p11222
sg10
I32
sg11
Vlymphedema-distichiasis syndrome
p11223
sg13
I2
sa(dp11224
g7
I421
sg17
VC0010674
p11225
sg10
I2
sg11
VCF
p11226
sg13
I1
sa(dp11227
g7
I270
sg17
VC0027126
p11228
sg10
I18
sg11
Vmyotonic dystrophy
p11229
sg13
I2
sa(dp11230
g7
I404
sg17
VC0010674
p11231
sg10
I15
sg11
Vcystic fibrosis
p11232
sg13
I2
sa(dp11233
g7
I243
sg17
VC0019247
p11234
sg10
I17
sg11
Vgenetic disorders
p11235
sg13
I2
sa(dp11236
g7
I297
sg17
VC2931688
p11237
sg10
I3
sg11
VDM1
p11238
sg13
I1
sa(dp11239
g7
I303
sg17
VC0005283
p11240
sg10
I16
sg11
VBeta-thalassemia
p11241
sg13
I1
sa(dp11242
g7
I398
sg17
VC0026847
p11243
sg10
I3
sg11
VSMA
p11244
sg13
I1
sa(dp11245
g7
I373
sg17
VC0026847
p11246
sg10
I23
sg11
Vspinal muscular atrophy
p11247
sg13
I3
sa(dp11248
g7
I367
sg17
VC0265345
p11249
sg10
I3
sg11
VLDS
p11250
sg13
I1
sa(dp11251
g7
I321
sg17
VC0005283
p11252
sg10
I9
sg11
VBeta-Thal
p11253
sg13
I1
sasa(dp11254
g2
S'Twelve CpG loci (11 genes) showed greater than 10% comparative difference in DNA methylation, including hyper-methylated loci of FAM181A, MRI1, PIWIL1, CHFR, DEFA1, MRPL28, AURKA, and hypo-methylated loci of NALP1L5, MAP8KIP3, ACAT2, and PM20D1 in maternal asthma.\n'
p11255
sg4
(lp11256
(dp11257
g7
I173
sg8
VP17038
p11258
sg10
I5
sg11
VAURKA
p11259
sg13
I1
sa(dp11260
g7
I138
sg8
g9
sg10
I4
sg11
VMRI1
p11261
sg13
I1
sa(dp11262
g7
I129
sg8
g9
sg10
I7
sg11
VFAM181A
p11263
sg13
I1
sa(dp11264
g7
I144
sg8
g9
sg10
I6
sg11
VPIWIL1
p11265
sg13
I1
sa(dp11266
g7
I165
sg8
g9
sg10
I6
sg11
VMRPL28
p11267
sg13
I1
sa(dp11268
g7
I152
sg8
g9
sg10
I4
sg11
VCHFR
p11269
sg13
I1
sa(dp11270
g7
I238
sg8
g9
sg10
I6
sg11
VPM20D1
p11271
sg13
I1
sa(dp11272
g7
I158
sg8
VP59665
p11273
sg10
I5
sg11
VDEFA1
p11274
sg13
I1
sa(dp11275
g7
I227
sg8
g9
sg10
I5
sg11
VACAT2
p11276
sg13
I1
sasg14
(lp11277
(dp11278
g7
I257
sg17
VC0004096
p11279
sg10
I6
sg11
Vasthma
p11280
sg13
I1
sasa(dp11281
g2
S'Systemic expression of DEFA1,1B,3,4,CTSG and ELA2 was significantly higher in the neutrophilic asthma (NA) phenotype.\n'
p11282
sg4
(lp11283
(dp11284
g7
I45
sg8
VP08246
p11285
sg10
I4
sg11
VELA2
p11286
sg13
I1
sa(dp11287
g7
I23
sg8
VP59665
p11288
sg10
I5
sg11
VDEFA1
p11289
sg13
I1
sa(dp11290
g7
I36
sg8
VP08311
p11291
sg10
I4
sg11
VCTSG
p11292
sg13
I1
sasg14
(lp11293
(dp11294
g7
I103
sg17
VC2363774
p11295
sg10
I2
sg11
VNA
p11296
sg13
I1
sa(dp11297
g7
I82
sg17
VC2363774
p11298
sg10
I19
sg11
Vneutrophilic asthma
p11299
sg13
I2
sasa(dp11300
g2
S'The objective of this study was to determine the combined influence of alpha thalassemia, fetal hemoglobin, and the UGT1A1 polymorphism on serum bilirubin levels and cholelithiasis in patients with sickle cell disease.\n'
p11301
sg4
(lp11302
(dp11303
g7
I90
sg8
VP14207
p11304
sg10
I16
sg11
Vfetal hemoglobin
p11305
sg13
I2
sa(dp11306
g7
I116
sg8
VP35504
p11307
sg10
I6
sg11
VUGT1A1
p11308
sg13
I1
sasg14
(lp11309
(dp11310
g7
I198
sg17
VC0002895
p11311
sg10
I19
sg11
Vsickle cell disease
p11312
sg13
I3
sa(dp11313
g7
I166
sg17
VC0008350
p11314
sg10
I14
sg11
Vcholelithiasis
p11315
sg13
I1
sa(dp11316
g7
I71
sg17
VC0002312
p11317
sg10
I17
sg11
Valpha thalassemia
p11318
sg13
I2
sasa(dp11319
g2
S'The present study investigated the role of several genetic factors (UGT1A1 promoter (TA)n repeat polymorphism, alpha-globin status), hematological parameters, clinical severity, and hydroxyurea (HU) therapy on the occurrence of cholelithiasis in SCD.\n'
p11320
sg4
(lp11321
(dp11322
g7
I111
sg8
VP69905
p11323
sg10
I12
sg11
Valpha-globin
p11324
sg13
I1
sasg14
(lp11325
(dp11326
g7
I246
sg17
VC0002895
p11327
sg10
I3
sg11
VSCD
p11328
sg13
I1
sa(dp11329
g7
I228
sg17
VC0008350
p11330
sg10
I14
sg11
Vcholelithiasis
p11331
sg13
I1
sasa(dp11332
g2
S'We confirmed that alpha-thalassemia and low basal reticulocyte (RET) count were independent protective factors for cholelithiasis while 7/7, 8/8 and 7/8 UGT1A1 (TA)n genotypes were independent predisposing factors for this complication.\n'
p11333
sg4
(lp11334
sg14
(lp11335
(dp11336
g7
I18
sg17
VC0002312
p11337
sg10
I17
sg11
Valpha-thalassemia
p11338
sg13
I1
sa(dp11339
g7
I115
sg17
VC0008350
p11340
sg10
I14
sg11
Vcholelithiasis
p11341
sg13
I1
sa(dp11342
g7
I223
sg17
VC0009566
p11343
sg10
I12
sg11
Vcomplication
p11344
sg13
I1
sasa(dp11345
g2
S'We explored the potential relationship between steady state serum bilirubin levels and the incidence of cholelithiasis in the context of UGT1A1 gene A(TA)nTAA promoter polymorphism in Omani sickle cell anemia (SCA) patients, homozygotes for African (Benin and Bantu) and Arab-Indian Beta(S) haplotypes, but sharing the same microgeographical environment and comparable life style factors.\n'
p11346
sg4
(lp11347
(dp11348
g7
I137
sg8
VP35504
p11349
sg10
I13
sg11
VUGT1A1 gene A
p11350
sg13
I3
sasg14
(lp11351
(dp11352
g7
I210
sg17
VC0002895
p11353
sg10
I3
sg11
VSCA
p11354
sg13
I1
sa(dp11355
g7
I190
sg17
VC0002895
p11356
sg10
I18
sg11
Vsickle cell anemia
p11357
sg13
I3
sa(dp11358
g7
I104
sg17
VC0008350
p11359
sg10
I14
sg11
Vcholelithiasis
p11360
sg13
I1
sasa(dp11361
g2
S'Thus, not cholelithiasis but total serum bilirubin was influenced by UGT1A1 polymorphism in this SCA cohort.\n'
p11362
sg4
(lp11363
(dp11364
g7
I69
sg8
VP35504
p11365
sg10
I6
sg11
VUGT1A1
p11366
sg13
I1
sasg14
(lp11367
(dp11368
g7
I10
sg17
VC0008350
p11369
sg10
I14
sg11
Vcholelithiasis
p11370
sg13
I1
sasa(dp11371
g2
S'Altogether our data provide the implication of UGT1A1 and SLCO1A2 in sickle cell anemia-related cholelithiasis.\n'
p11372
sg4
(lp11373
(dp11374
g7
I58
sg8
VP46721
p11375
sg10
I7
sg11
VSLCO1A2
p11376
sg13
I1
sa(dp11377
g7
I47
sg8
VP35504
p11378
sg10
I6
sg11
VUGT1A1
p11379
sg13
I1
sasg14
(lp11380
(dp11381
g7
I69
sg17
VC0002895
p11382
sg10
I18
sg11
Vsickle cell anemia
p11383
sg13
I3
sa(dp11384
g7
I96
sg17
VC0008350
p11385
sg10
I14
sg11
Vcholelithiasis
p11386
sg13
I1
sasa(dp11387
g2
S'Present study was aimed to explore the effect of (TA)n UGT1A1 gene promoter polymorphism on bilirubin metabolism, bilirubinaemia, predisposition to cholelithiasis and subsequent cholecystectomy, in Sickle-Cell Anemia (SCA) and beta-Thalasemia major (bTH) in Kuwaiti subjects compared to other population.\n'
p11388
sg4
(lp11389
(dp11390
g7
I55
sg8
VP35504
p11391
sg10
I20
sg11
VUGT1A1 gene promoter
p11392
sg13
I3
sasg14
(lp11393
(dp11394
g7
I198
sg17
VC0002895
p11395
sg10
I18
sg11
VSickle-Cell Anemia
p11396
sg13
I2
sa(dp11397
g7
I114
sg17
VC0020433
p11398
sg10
I14
sg11
Vbilirubinaemia
p11399
sg13
I1
sa(dp11400
g7
I148
sg17
VC0008350
p11401
sg10
I14
sg11
Vcholelithiasis
p11402
sg13
I1
sa(dp11403
g7
I218
sg17
VC0002895
p11404
sg10
I3
sg11
VSCA
p11405
sg13
I1
sasa(dp11406
g2
S'Our results confirm UGT1A1 (TA)7 allele as one of the factors accounting for the hyperbilirubinemia and cholelithiasis observed in SCA and bTH.\n'
p11407
sg4
(lp11408
(dp11409
g7
I20
sg8
VP35504
p11410
sg10
I6
sg11
VUGT1A1
p11411
sg13
I1
sasg14
(lp11412
(dp11413
g7
I81
sg17
VC0020433
p11414
sg10
I18
sg11
Vhyperbilirubinemia
p11415
sg13
I1
sa(dp11416
g7
I104
sg17
VC0008350
p11417
sg10
I14
sg11
Vcholelithiasis
p11418
sg13
I1
sasa(dp11419
g2
S'We analyzed the polymorphism A(TA)nTAA at the UGT1A1 promoter and the relationships between the various A(TA)nTAA genotypes and alleles and bilirubin levels and occurrence of cholelithiasis.\n'
p11420
sg4
(lp11421
(dp11422
g7
I46
sg8
VP35504
p11423
sg10
I15
sg11
VUGT1A1 promoter
p11424
sg13
I2
sasg14
(lp11425
(dp11426
g7
I175
sg17
VC0008350
p11427
sg10
I14
sg11
Vcholelithiasis
p11428
sg13
I1
sasa(dp11429
g2
S'We analyzed the polymorphism A(TA)&lt;formula&gt;_{n}&lt;/formula&gt; TAA at the UGT1A1 promoter and the relationships between the various A(TA)&lt;formula&gt;_{n}&lt;/formula&gt; TAA genotypes and alleles and bilirubin levels and occurrence of cholelithiasis.\n'
p11430
sg4
(lp11431
(dp11432
g7
I81
sg8
VP35504
p11433
sg10
I15
sg11
VUGT1A1 promoter
p11434
sg13
I2
sasg14
(lp11435
(dp11436
g7
I245
sg17
VC0008350
p11437
sg10
I14
sg11
Vcholelithiasis
p11438
sg13
I1
sa(dp11439
g7
I70
sg17
VC0162872
p11440
sg10
I3
sg11
VTAA
p11441
sg13
I1
sa(dp11442
g7
I70
sg17
VC0162872
p11443
sg10
I3
sg11
VTAA
p11444
sg13
I1
sasa(dp11445
g2
S'The ADP-ribosyltransferase 3 gene (ART3) has been reported to be associated with non-obstructive azoospermia (NOA) in the Japanese population.\n'
p11446
sg4
(lp11447
(dp11448
g7
I35
sg8
g9
sg10
I4
sg11
VART3
p11449
sg13
I1
sa(dp11450
g7
I4
sg8
g9
sg10
I29
sg11
VADP-ribosyltransferase 3 gene
p11451
sg13
I3
sasg14
(lp11452
(dp11453
g7
I97
sg17
VC1321542
p11454
sg10
I11
sg11
Vazoospermia
p11455
sg13
I1
sasa(dp11456
g2
S'A recent Japanese study provided evidence that the rs6836703: G&gt;A single-nucleotide polymorphism (SNP) from the ADP-ribosyltransferase 3 (ART3) gene is significantly associated with non-obstructive azoospermia.\n'
p11457
sg4
(lp11458
(dp11459
g7
I115
sg8
g9
sg10
I24
sg11
VADP-ribosyltransferase 3
p11460
sg13
I2
sa(dp11461
g7
I141
sg8
g9
sg10
I4
sg11
VART3
p11462
sg13
I1
sasg14
(lp11463
(dp11464
g7
I201
sg17
VC1321542
p11465
sg10
I11
sg11
Vazoospermia
p11466
sg13
I1
sasa(dp11467
g2
S'The analysis of genes involved in hereditary spherocytosis, by next-generation sequencing in two patients with clinical diagnosis of the disease, showed the presence of the c.1795+1G&gt;A mutation in the SPTB gene.\n'
p11468
sg4
(lp11469
(dp11470
g7
I204
sg8
g9
sg10
I9
sg11
VSPTB gene
p11471
sg13
I2
sasg14
(lp11472
(dp11473
g7
I34
sg17
VC0037889
p11474
sg10
I24
sg11
Vhereditary spherocytosis
p11475
sg13
I2
sasa(dp11476
g2
S'Hereditary spherocytosis stems from mutations in one of the genes encoding ankyrin-1 (ANKI), alpha spectrin (SPTA1) and beta spectrin (SPTB), the anion exchanger 1 (SLC4A 1), and protein 4.2 (EPB42).\n'
p11477
sg4
(lp11478
(dp11479
g7
I120
sg8
VP11277
p11480
sg10
I13
sg11
Vbeta spectrin
p11481
sg13
I2
sa(dp11482
g7
I93
sg8
VP02549
p11483
sg10
I14
sg11
Valpha spectrin
p11484
sg13
I2
sa(dp11485
g7
I192
sg8
VP16452
p11486
sg10
I5
sg11
VEPB42
p11487
sg13
I1
sa(dp11488
g7
I86
sg8
VP16157
p11489
sg10
I4
sg11
VANKI
p11490
sg13
I1
sa(dp11491
g7
I135
sg8
g9
sg10
I4
sg11
VSPTB
p11492
sg13
I1
sa(dp11493
g7
I109
sg8
VP02549
p11494
sg10
I5
sg11
VSPTA1
p11495
sg13
I1
sa(dp11496
g7
I75
sg8
VP16157
p11497
sg10
I9
sg11
Vankyrin-1
p11498
sg13
I1
sa(dp11499
g7
I179
sg8
VP01031
p11500
sg10
I11
sg11
Vprotein 4.2
p11501
sg13
I2
sa(dp11502
g7
I146
sg8
VP02730
p11503
sg10
I17
sg11
Vanion exchanger 1
p11504
sg13
I3
sasg14
(lp11505
(dp11506
g7
I0
sg17
VC0037889
p11507
sg10
I24
sg11
VHereditary spherocytosis
p11508
sg13
I2
sasa(dp11509
g2
S'We also investigated methylation profiles in peripheral blood mononuclear cells from patients with red cell membrane diseases, such as complete protein 4.2 deficiency due to ELB42 mutations, hereditary spherocytosis with EPB3 mutations, and hereditary elliptocytosis with SPTB mutations.\n'
p11510
sg4
(lp11511
(dp11512
g7
I221
sg8
VP02730
p11513
sg10
I14
sg11
VEPB3 mutations
p11514
sg13
I2
sa(dp11515
g7
I272
sg8
g9
sg10
I4
sg11
VSPTB
p11516
sg13
I1
sa(dp11517
g7
I144
sg8
VP01031
p11518
sg10
I11
sg11
Vprotein 4.2
p11519
sg13
I2
sasg14
(lp11520
(dp11521
g7
I241
sg17
VC0013902
p11522
sg10
I25
sg11
Vhereditary elliptocytosis
p11523
sg13
I2
sa(dp11524
g7
I191
sg17
VC0037889
p11525
sg10
I24
sg11
Vhereditary spherocytosis
p11526
sg13
I2
sasa(dp11527
g2
S'The mutations of most cases of hereditary spherocytosis (HS) are located in the following genes: ANK1, SPTB, SLC4A1, EPB42 and SPTA1, which encode ankyrin, spectrin beta-chain, the anion exchanger 1 (band 3), protein 4.2 and spectrin alpha-chain, respectively.\n'
p11528
sg4
(lp11529
(dp11530
g7
I97
sg8
VP16157
p11531
sg10
I4
sg11
VANK1
p11532
sg13
I1
sa(dp11533
g7
I156
sg8
g9
sg10
I19
sg11
Vspectrin beta-chain
p11534
sg13
I2
sa(dp11535
g7
I109
sg8
VP02730
p11536
sg10
I6
sg11
VSLC4A1
p11537
sg13
I1
sa(dp11538
g7
I209
sg8
VP01031
p11539
sg10
I11
sg11
Vprotein 4.2
p11540
sg13
I2
sa(dp11541
g7
I117
sg8
VP16452
p11542
sg10
I5
sg11
VEPB42
p11543
sg13
I1
sa(dp11544
g7
I225
sg8
VP55899
p11545
sg10
I20
sg11
Vspectrin alpha-chain
p11546
sg13
I2
sa(dp11547
g7
I127
sg8
VP02549
p11548
sg10
I5
sg11
VSPTA1
p11549
sg13
I1
sa(dp11550
g7
I147
sg8
VP16157
p11551
sg10
I7
sg11
Vankyrin
p11552
sg13
I1
sa(dp11553
g7
I103
sg8
g9
sg10
I4
sg11
VSPTB
p11554
sg13
I1
sasg14
(lp11555
(dp11556
g7
I31
sg17
VC0037889
p11557
sg10
I24
sg11
Vhereditary spherocytosis
p11558
sg13
I2
sa(dp11559
g7
I57
sg17
VC0037889
p11560
sg10
I2
sg11
VHS
p11561
sg13
I1
sasa(dp11562
g2
S'Mutations in bone morphogenetic protein 1 (BMP1) in humans or deletion of BMP1 and related protease tolloid like 1 (TLL1) in mice lead to osteogenesis imperfecta (OI).\n'
p11563
sg4
(lp11564
(dp11565
g7
I43
sg8
VP14222
p11566
sg10
I4
sg11
VBMP1
p11567
sg13
I1
sa(dp11568
g7
I100
sg8
g9
sg10
I14
sg11
Vtolloid like 1
p11569
sg13
I3
sa(dp11570
g7
I116
sg8
g9
sg10
I4
sg11
VTLL1
p11571
sg13
I1
sa(dp11572
g7
I74
sg8
VP63123
p11573
sg10
I25
sg11
VBMP1 and related protease
p11574
sg13
I4
sa(dp11575
g7
I13
sg8
VP14222
p11576
sg10
I28
sg11
Vbone morphogenetic protein 1
p11577
sg13
I4
sasg14
(lp11578
(dp11579
g7
I163
sg17
VC0029434
p11580
sg10
I2
sg11
VOI
p11581
sg13
I1
sa(dp11582
g7
I138
sg17
VC0029434
p11583
sg10
I23
sg11
Vosteogenesis imperfecta
p11584
sg13
I2
sasa(dp11585
g2
S'Mutations in the proteinase bone morphogenetic protein-1 (BMP1) were recently identified in patients with osteogenesis imperfecta, which can be associated with type 1 dentinogenesis imperfecta.\n'
p11586
sg4
(lp11587
(dp11588
g7
I17
sg8
VP63123
p11589
sg10
I39
sg11
Vproteinase bone morphogenetic protein-1
p11590
sg13
I4
sasg14
(lp11591
(dp11592
g7
I167
sg17
VC0011436
p11593
sg10
I25
sg11
Vdentinogenesis imperfecta
p11594
sg13
I2
sa(dp11595
g7
I106
sg17
VC0029434
p11596
sg10
I23
sg11
Vosteogenesis imperfecta
p11597
sg13
I2
sasa(dp11598
g2
S'We previously showed these mice to have a skeletal phenotype that includes elements of osteogenesis imperfecta (OI), osteomalacia, and deficient osteocyte maturation, observations validated by the finding of BMP1 mutations in a subset of human patients with OI-like phenotypes.\n'
p11599
sg4
(lp11600
sg14
(lp11601
(dp11602
g7
I112
sg17
VC0029434
p11603
sg10
I2
sg11
VOI
p11604
sg13
I1
sa(dp11605
g7
I87
sg17
VC0029434
p11606
sg10
I23
sg11
Vosteogenesis imperfecta
p11607
sg13
I2
sa(dp11608
g7
I112
sg17
VC0029434
p11609
sg10
I2
sg11
VOI
p11610
sg13
I1
sa(dp11611
g7
I117
sg17
VC0029442
p11612
sg10
I12
sg11
Vosteomalacia
p11613
sg13
I1
sasa(dp11614
g2
S'Autosomal recessive osteogenesis imperfecta (OI) accounts for 10% of all OI cases, and, currently, mutations in 10 genes (CRTAP, LEPRE1, PPIB, SERPINH1, FKBP10, SERPINF1, SP7, BMP1, TMEM38B, and WNT1) are known to be responsible for this form of the disease.\n'
p11615
sg4
(lp11616
(dp11617
g7
I171
sg8
g9
sg10
I3
sg11
VSP7
p11618
sg13
I1
sa(dp11619
g7
I182
sg8
g9
sg10
I7
sg11
VTMEM38B
p11620
sg13
I1
sa(dp11621
g7
I122
sg8
g9
sg10
I5
sg11
VCRTAP
p11622
sg13
I1
sa(dp11623
g7
I137
sg8
VP23284
p11624
sg10
I4
sg11
VPPIB
p11625
sg13
I1
sa(dp11626
g7
I143
sg8
VP50454
p11627
sg10
I8
sg11
VSERPINH1
p11628
sg13
I1
sa(dp11629
g7
I153
sg8
g9
sg10
I6
sg11
VFKBP10
p11630
sg13
I1
sa(dp11631
g7
I161
sg8
VP36955
p11632
sg10
I8
sg11
VSERPINF1
p11633
sg13
I1
sa(dp11634
g7
I195
sg8
VP04628
p11635
sg10
I4
sg11
VWNT1
p11636
sg13
I1
sasg14
(lp11637
(dp11638
g7
I20
sg17
VC0029434
p11639
sg10
I23
sg11
Vosteogenesis imperfecta
p11640
sg13
I2
sa(dp11641
g7
I45
sg17
VC0029434
p11642
sg10
I2
sg11
VOI
p11643
sg13
I1
sa(dp11644
g7
I45
sg17
VC0029434
p11645
sg10
I2
sg11
VOI
p11646
sg13
I1
sasa(dp11647
g2
S'Isolated 3-methylcrotonyl-CoA carboxylase deficiency (3MCCD) is an autosomal recessive disorder of leucine metabolism biochemically characterized by accumulation of 3-methylcrotonylglycine (3MCG), 3-methylcrotonic acid (3MCA) and 3-hydroxyisovaleric acid.\n'
p11648
sg4
(lp11649
(dp11650
g7
I0
sg8
g9
sg10
I41
sg11
VIsolated 3-methylcrotonyl-CoA carboxylase
p11651
sg13
I3
sasg14
(lp11652
(dp11653
g7
I54
sg17
VC0268600
p11654
sg10
I5
sg11
V3MCCD
p11655
sg13
I1
sa(dp11656
g7
I9
sg17
VC0268600
p11657
sg10
I43
sg11
V3-methylcrotonyl-CoA carboxylase deficiency
p11658
sg13
I3
sasa(dp11659
g2
S'Isolated 3-methylcrotonyl-CoA carboxylase (MCC) deficiency is an autosomal recessive disorder of leucine metabolism caused by mutations in MCCC1 or MCCC2 encoding the Alfa and Beta subunit of MCC, respectively.\n'
p11660
sg4
(lp11661
(dp11662
g7
I0
sg8
g9
sg10
I41
sg11
VIsolated 3-methylcrotonyl-CoA carboxylase
p11663
sg13
I3
sa(dp11664
g7
I43
sg8
VP23508
p11665
sg10
I3
sg11
VMCC
p11666
sg13
I1
sa(dp11667
g7
I139
sg8
g9
sg10
I5
sg11
VMCCC1
p11668
sg13
I1
sa(dp11669
g7
I148
sg8
g9
sg10
I5
sg11
VMCCC2
p11670
sg13
I1
sa(dp11671
g7
I43
sg8
VP23508
p11672
sg10
I3
sg11
VMCC
p11673
sg13
I1
sasg14
(lp11674
(dp11675
g7
I43
sg17
VC0007129
p11676
sg10
I3
sg11
VMCC
p11677
sg13
I1
sa(dp11678
g7
I43
sg17
VC0007129
p11679
sg10
I3
sg11
VMCC
p11680
sg13
I1
sa(dp11681
g7
I9
sg17
VC0007129
p11682
sg10
I32
sg11
V3-methylcrotonyl-CoA carboxylase
p11683
sg13
I2
sasa(dp11684
g2
S'We performed mutational analysis in the four main HPE causing genes (SHH, SIX3, TGIF, and ZIC2) and GLI3, a gene associated with polydactyly as well as fluorescent in situ hybridization (FISH) to search for microdeletions in these genes and two candidate HPE genes (DISP1 and FOXA2).\n'
p11685
sg4
(lp11686
(dp11687
g7
I90
sg8
g9
sg10
I4
sg11
VZIC2
p11688
sg13
I1
sa(dp11689
g7
I69
sg8
g9
sg10
I3
sg11
VSHH
p11690
sg13
I1
sa(dp11691
g7
I276
sg8
g9
sg10
I5
sg11
VFOXA2
p11692
sg13
I1
sa(dp11693
g7
I255
sg8
VP01893
p11694
sg10
I9
sg11
VHPE genes
p11695
sg13
I2
sa(dp11696
g7
I100
sg8
VP10071
p11697
sg10
I4
sg11
VGLI3
p11698
sg13
I1
sa(dp11699
g7
I266
sg8
g9
sg10
I5
sg11
VDISP1
p11700
sg13
I1
sa(dp11701
g7
I74
sg8
g9
sg10
I4
sg11
VSIX3
p11702
sg13
I1
sa(dp11703
g7
I80
sg8
VP22301
p11704
sg10
I4
sg11
VTGIF
p11705
sg13
I1
sasg14
(lp11706
(dp11707
g7
I129
sg17
VC0152427
p11708
sg10
I11
sg11
Vpolydactyly
p11709
sg13
I1
sasa(dp11710
g2
S'Although the CCK-1 receptor has been shown to be highly expressed in resected human pancreatic cancer samples, its role is less clear.\n'
p11711
sg4
(lp11712
(dp11713
g7
I13
sg8
VP06307
p11714
sg10
I14
sg11
VCCK-1 receptor
p11715
sg13
I2
sasg14
(lp11716
(dp11717
g7
I84
sg17
VC0235974
p11718
sg10
I17
sg11
Vpancreatic cancer
p11719
sg13
I2
sasa(dp11720
g2
S'The aim of this in vitro study was to investigate the CCK-1 receptor expression and the function of the CCK-CCK-1 receptor pathway in the human pancreatic adenocarcinoma cell line, Mia PaCa-2.\n'
p11721
sg4
(lp11722
(dp11723
g7
I54
sg8
VP06307
p11724
sg10
I14
sg11
VCCK-1 receptor
p11725
sg13
I2
sa(dp11726
g7
I104
sg8
VP06307
p11727
sg10
I18
sg11
VCCK-CCK-1 receptor
p11728
sg13
I2
sa(dp11729
g7
I181
sg8
g9
sg10
I10
sg11
VMia PaCa-2
p11730
sg13
I2
sasg14
(lp11731
(dp11732
g7
I185
sg17
VC1836780
p11733
sg10
I4
sg11
VPaCa
p11734
sg13
I1
sa(dp11735
g7
I144
sg17
VC0281361
p11736
sg10
I25
sg11
Vpancreatic adenocarcinoma
p11737
sg13
I2
sasa(dp11738
g2
S'However, the main source of CCK receptors in the pancreatic tumor samples consisted of CCK2-expressing islets and/or CCK1-expressing nerves rather than neoplastic tissue.\n'
p11739
sg4
(lp11740
(dp11741
g7
I28
sg8
VP06307
p11742
sg10
I13
sg11
VCCK receptors
p11743
sg13
I2
sa(dp11744
g7
I117
sg8
g9
sg10
I4
sg11
VCCK1
p11745
sg13
I1
sasg14
(lp11746
(dp11747
g7
I49
sg17
VC0030297
p11748
sg10
I16
sg11
Vpancreatic tumor
p11749
sg13
I2
sasa(dp11750
g2
S'These data indicate that the presence of CCK receptors in human ductal pancreatic tumor samples is mainly due to CCK2 expression in residual pancreatic islets and CCK1 in pancreatic nerves.\n'
p11751
sg4
(lp11752
(dp11753
g7
I41
sg8
VP06307
p11754
sg10
I13
sg11
VCCK receptors
p11755
sg13
I2
sa(dp11756
g7
I163
sg8
g9
sg10
I4
sg11
VCCK1
p11757
sg13
I1
sasg14
(lp11758
(dp11759
g7
I71
sg17
VC0030297
p11760
sg10
I16
sg11
Vpancreatic tumor
p11761
sg13
I2
sasa(dp11762
g2
S'The aim of this study was to evaluate the association of the polymorphisms in TCN2 (rs1801198) gene and in MTRR (rs1801394) gene with nonsyndromic cleft lip and/or palate (NSCL/P) in a Brazilian population.\n'
p11763
sg4
(lp11764
(dp11765
g7
I78
sg8
VP20062
p11766
sg10
I21
sg11
VTCN2 (rs1801198) gene
p11767
sg13
I3
sasg14
(lp11768
(dp11769
g7
I147
sg17
VC0008924
p11770
sg10
I9
sg11
Vcleft lip
p11771
sg13
I2
sasa(dp11772
g2
S'While the roles of the GluN2A and GluN2B subunit in ischemic stroke have been well developed, the role of the GluN2C subunit in ischemia is not well understood.\n'
p11773
sg4
(lp11774
sg14
(lp11775
(dp11776
g7
I128
sg17
VC0022116
p11777
sg10
I8
sg11
Vischemia
p11778
sg13
I1
sa(dp11779
g7
I52
sg17
VC3272363
p11780
sg10
I15
sg11
Vischemic stroke
p11781
sg13
I2
sasa(dp11782
g2
S'In the Western blotting assay, clonidine treatment led to significant up-regulation of the expression level of NR2B and Phospho-NR2B in the hippocampus of the rats when compared with the cerebral ischemia group.\n'
p11783
sg4
(lp11784
(dp11785
g7
I120
sg8
g9
sg10
I12
sg11
VPhospho-NR2B
p11786
sg13
I1
sa(dp11787
g7
I111
sg8
g9
sg10
I4
sg11
VNR2B
p11788
sg13
I1
sasg14
(lp11789
(dp11790
g7
I187
sg17
VC0917798
p11791
sg10
I17
sg11
Vcerebral ischemia
p11792
sg13
I2
sasa(dp11793
g2
S'In conclusion, clonidine could improve the learning and memory ability of rats with cerebral ischemia, and NR2B, ERK1/2, CREB, NF-KB were involved in this effect.\n'
p11794
sg4
(lp11795
(dp11796
g7
I121
sg8
VP16220
p11797
sg10
I4
sg11
VCREB
p11798
sg13
I1
sa(dp11799
g7
I113
sg8
VP27361
p11800
sg10
I6
sg11
VERK1/2
p11801
sg13
I1
sa(dp11802
g7
I107
sg8
g9
sg10
I4
sg11
VNR2B
p11803
sg13
I1
sasg14
(lp11804
(dp11805
g7
I84
sg17
VC0917798
p11806
sg10
I17
sg11
Vcerebral ischemia
p11807
sg13
I2
sasa(dp11808
g2
S'DWEYS-IgG cross-reactive with DNA and the N-methyl-D-aspartate receptor subunits GluN2A/GluN2B has been associated with neuropsychiatric systemic lupus erythematosus (NPSLE).\n'
p11809
sg4
(lp11810
(dp11811
g7
I42
sg8
g9
sg10
I52
sg11
VN-methyl-D-aspartate receptor subunits GluN2A/GluN2B
p11812
sg13
I4
sasg14
(lp11813
(dp11814
g7
I167
sg17
VC0752335
p11815
sg10
I5
sg11
VNPSLE
p11816
sg13
I1
sa(dp11817
g7
I120
sg17
VC0752335
p11818
sg10
I45
sg11
Vneuropsychiatric systemic lupus erythematosus
p11819
sg13
I4
sasa(dp11820
g2
S'Therefore, NMDAR antagonists, especially NR2B-selective ones, combined with IGF-1 may serve as an alternative therapeutic agent for oxidative stress related neurodegenerative disease.\n'
p11821
sg4
(lp11822
(dp11823
g7
I41
sg8
g9
sg10
I4
sg11
VNR2B
p11824
sg13
I1
sa(dp11825
g7
I76
sg8
VP01343
p11826
sg10
I5
sg11
VIGF-1
p11827
sg13
I1
sasg14
(lp11828
(dp11829
g7
I157
sg17
VC0524851
p11830
sg10
I25
sg11
Vneurodegenerative disease
p11831
sg13
I2
sa(dp11832
g7
I132
sg17
VC0242606
p11833
sg10
I16
sg11
Voxidative stress
p11834
sg13
I2
sasa(dp11835
g2
S'Taken together, our results demonstrated that LBP is neuroprotective against ischemic injury by its dual roles in activation of NR2A and inhibition of NR2B signaling pathways, which suggests that LBP may be a superior therapeutic candidate for targeting glutamate excitotoxicity for the treatment of ischemic stroke.\n'
p11836
sg4
(lp11837
(dp11838
g7
I151
sg8
g9
sg10
I4
sg11
VNR2B
p11839
sg13
I1
sa(dp11840
g7
I128
sg8
g9
sg10
I4
sg11
VNR2A
p11841
sg13
I1
sa(dp11842
g7
I46
sg8
VP18428
p11843
sg10
I3
sg11
VLBP
p11844
sg13
I1
sa(dp11845
g7
I46
sg8
VP18428
p11846
sg10
I3
sg11
VLBP
p11847
sg13
I1
sasg14
(lp11848
(dp11849
g7
I300
sg17
VC3272363
p11850
sg10
I15
sg11
Vischemic stroke
p11851
sg13
I2
sa(dp11852
g7
I46
sg17
VC0024031
p11853
sg10
I3
sg11
VLBP
p11854
sg13
I1
sa(dp11855
g7
I46
sg17
VC0024031
p11856
sg10
I3
sg11
VLBP
p11857
sg13
I1
sasa(dp11858
g2
S'The obesity-induced changes in adipose tissue macrophage numbers are mainly due to increases in the triple-positive CD11b+ F4/80+ CD11c+ adipose tissue macrophage subpopulation.\n'
p11859
sg4
(lp11860
(dp11861
g7
I116
sg8
VP11215
p11862
sg10
I20
sg11
VCD11b+ F4/80+ CD11c+
p11863
sg13
I3
sasg14
(lp11864
(dp11865
g7
I4
sg17
VC0028754
p11866
sg10
I7
sg11
Vobesity
p11867
sg13
I1
sasa(dp11868
g2
S'Contrary to our hypothesis that obesity-mediated white AT inflammation is Nlrp3-dependent, we found that Western diet-induced expression of AT inflammatory markers (i.e., Cd68, Cd11c, Emr1, Itgam, Lgals, Il18, Mcp1, Tnf, Ccr2, Ccl5 mRNAs, and Mac-2 protein) were not accompanied by increased caspase-1 cleavage, a hallmark feature of NLRP3 inflammasome activation.\n'
p11869
sg4
(lp11870
(dp11871
g7
I227
sg8
VP13501
p11872
sg10
I10
sg11
VCcl5 mRNAs
p11873
sg13
I2
sa(dp11874
g7
I292
sg8
VP29466
p11875
sg10
I9
sg11
Vcaspase-1
p11876
sg13
I1
sa(dp11877
g7
I221
sg8
VP41597
p11878
sg10
I4
sg11
VCcr2
p11879
sg13
I1
sa(dp11880
g7
I210
sg8
VP13500
p11881
sg10
I4
sg11
VMcp1
p11882
sg13
I1
sa(dp11883
g7
I190
sg8
VP11215
p11884
sg10
I5
sg11
VItgam
p11885
sg13
I1
sa(dp11886
g7
I243
sg8
VP17931
p11887
sg10
I13
sg11
VMac-2 protein
p11888
sg13
I2
sa(dp11889
g7
I216
sg8
VP01375
p11890
sg10
I3
sg11
VTnf
p11891
sg13
I1
sa(dp11892
g7
I184
sg8
g9
sg10
I4
sg11
VEmr1
p11893
sg13
I1
sa(dp11894
g7
I171
sg8
VP34810
p11895
sg10
I4
sg11
VCd68
p11896
sg13
I1
sa(dp11897
g7
I177
sg8
VP20702
p11898
sg10
I5
sg11
VCd11c
p11899
sg13
I1
sa(dp11900
g7
I204
sg8
g9
sg10
I4
sg11
VIl18
p11901
sg13
I1
sasg14
(lp11902
(dp11903
g7
I32
sg17
VC0028754
p11904
sg10
I7
sg11
Vobesity
p11905
sg13
I1
sa(dp11906
g7
I58
sg17
VC0021368
p11907
sg10
I12
sg11
Vinflammation
p11908
sg13
I1
sasa(dp11909
g2
S'In current practice, an antibody cocktail comprising p63, CK903, and AMACR (PIN-4 cocktail) is frequently utilized to evaluate foci suspicious for prostatic adenocarcinoma.\n'
p11910
sg4
(lp11911
(dp11912
g7
I53
sg8
g9
sg10
I3
sg11
Vp63
p11913
sg13
I1
sasg14
(lp11914
(dp11915
g7
I76
sg17
VC0282612
p11916
sg10
I3
sg11
VPIN
p11917
sg13
I1
sa(dp11918
g7
I147
sg17
VC0007112
p11919
sg10
I24
sg11
Vprostatic adenocarcinoma
p11920
sg13
I2
sasa(dp11921
g2
S'Only 2 NA cases displayed an overall PIN-4 staining pattern compatible with prostate cancer.\n'
p11922
sg4
(lp11923
sg14
(lp11924
(dp11925
g7
I76
sg17
VC0600139
p11926
sg10
I15
sg11
Vprostate cancer
p11927
sg13
I2
sa(dp11928
g7
I37
sg17
VC0282612
p11929
sg10
I3
sg11
VPIN
p11930
sg13
I1
sasa(dp11931
g2
S'Although heterogenous staining patterns were seen within individual cases, use of the PIN-4 cocktail effectively discriminates NA from prostate cancer because of the high frequency of coexpression of AMACR and CK903 within NA.\n'
p11932
sg4
(lp11933
(dp11934
g7
I86
sg8
VP63167
p11935
sg10
I5
sg11
VPIN-4
p11936
sg13
I1
sasg14
(lp11937
(dp11938
g7
I86
sg17
VC0282612
p11939
sg10
I3
sg11
VPIN
p11940
sg13
I1
sa(dp11941
g7
I135
sg17
VC0600139
p11942
sg10
I15
sg11
Vprostate cancer
p11943
sg13
I2
sasa(dp11944
g2
S'Kidney and prostate cancer tumor and benign biopsies were stained with hemotoxylin and eosin and prostate biopsies were subjected to PIN-4 immunohistochemistry.\n'
p11945
sg4
(lp11946
(dp11947
g7
I133
sg8
VP63167
p11948
sg10
I5
sg11
VPIN-4
p11949
sg13
I1
sasg14
(lp11950
(dp11951
g7
I11
sg17
VC0600139
p11952
sg10
I15
sg11
Vprostate cancer
p11953
sg13
I2
sa(dp11954
g7
I133
sg17
VC0282612
p11955
sg10
I3
sg11
VPIN
p11956
sg13
I1
sa(dp11957
g7
I27
sg17
VC0027651
p11958
sg10
I5
sg11
Vtumor
p11959
sg13
I1
sasa(dp11960
g2
S'A subset of biopsy sections was analyzed by IHC, and cancerous and non-cancerous regions could be readily visualized by PIN4 staining.\n'
p11961
sg4
(lp11962
(dp11963
g7
I120
sg8
g9
sg10
I4
sg11
VPIN4
p11964
sg13
I1
sasg14
(lp11965
sa(dp11966
g2
S'Elevated serum levels of Ang-2 and high values for the Ang-2/Ang-1 ratio may potentially be used as predictors of worst-case prognoses for P. vivax malaria, especially in patients with thrombocytopenia.\n'
p11967
sg4
(lp11968
(dp11969
g7
I25
sg8
VP03950
p11970
sg10
I5
sg11
VAng-2
p11971
sg13
I1
sa(dp11972
g7
I25
sg8
VP03950
p11973
sg10
I5
sg11
VAng-2
p11974
sg13
I1
sa(dp11975
g7
I61
sg8
VP03950
p11976
sg10
I5
sg11
VAng-1
p11977
sg13
I1
sasg14
(lp11978
(dp11979
g7
I142
sg17
VC0024537
p11980
sg10
I13
sg11
Vvivax malaria
p11981
sg13
I2
sasa(dp11982
g2
S'Dengue-associated thrombocytopenia and endothelial activation are associated with an imbalance in angiopoietin-2: angiopoietin-1 plasma levels.\n'
p11983
sg4
(lp11984
(dp11985
g7
I114
sg8
g9
sg10
I14
sg11
Vangiopoietin-1
p11986
sg13
I1
sa(dp11987
g7
I98
sg8
g9
sg10
I14
sg11
Vangiopoietin-2
p11988
sg13
I1
sasg14
(lp11989
(dp11990
g7
I85
sg17
VC1397014
p11991
sg10
I9
sg11
Vimbalance
p11992
sg13
I1
sa(dp11993
g7
I0
sg17
VC0011311
p11994
sg10
I6
sg11
VDengue
p11995
sg13
I1
sasa(dp11996
g2
S'It has been previously reported that mutations in retinal G protein coupled receptor (RGR) are associated with retinitis pigmentosa.\n'
p11997
sg4
(lp11998
(dp11999
g7
I86
sg8
VP47804
p12000
sg10
I3
sg11
VRGR
p12001
sg13
I1
sa(dp12002
g7
I50
sg8
VP47804
p12003
sg10
I34
sg11
Vretinal G protein coupled receptor
p12004
sg13
I5
sasg14
(lp12005
(dp12006
g7
I111
sg17
VC0035334
p12007
sg10
I20
sg11
Vretinitis pigmentosa
p12008
sg13
I2
sasa(dp12009
g2
S'The present study aims to systemically analyze the potential role of variants of RGR in retinal diseases.\n'
p12010
sg4
(lp12011
(dp12012
g7
I81
sg8
VP47804
p12013
sg10
I3
sg11
VRGR
p12014
sg13
I1
sasg14
(lp12015
(dp12016
g7
I88
sg17
VC0035309
p12017
sg10
I16
sg11
Vretinal diseases
p12018
sg13
I2
sasa(dp12019
g2
S'These data suggest that the recessive retinal disorder previously reported to be due to homozygous mutation in RGR is, at least in part, due to variants in CDHR1 and that the true consequences of RGR knock-out on human retinal structure and function are yet to be determined.\n'
p12020
sg4
(lp12021
(dp12022
g7
I111
sg8
VP47804
p12023
sg10
I3
sg11
VRGR
p12024
sg13
I1
sa(dp12025
g7
I196
sg8
VP47804
p12026
sg10
I13
sg11
VRGR knock-out
p12027
sg13
I2
sa(dp12028
g7
I156
sg8
g9
sg10
I5
sg11
VCDHR1
p12029
sg13
I1
sasg14
(lp12030
(dp12031
g7
I38
sg17
VC0035309
p12032
sg10
I16
sg11
Vretinal disorder
p12033
sg13
I2
sasa(dp12034
g2
S'Rare mutations in the human RGR gene lead to autosomal recessive retinitis pigmentosa or dominantly inherited peripapillary choroidal atrophy.\n'
p12035
sg4
(lp12036
(dp12037
g7
I22
sg8
VP47804
p12038
sg10
I14
sg11
Vhuman RGR gene
p12039
sg13
I3
sasg14
(lp12040
(dp12041
g7
I134
sg17
VC0333641
p12042
sg10
I7
sg11
Vatrophy
p12043
sg13
I1
sa(dp12044
g7
I45
sg17
VC0339526
p12045
sg10
I40
sg11
Vautosomal recessive retinitis pigmentosa
p12046
sg13
I4
sasa(dp12047
g2
S'In Western blot assays, the RGR-d protein was detected in retinas of a large proportion ( approximately 53%) of individual donors, including patients with age-related macular degeneration (AMD).\n'
p12048
sg4
(lp12049
(dp12050
g7
I28
sg8
VP47804
p12051
sg10
I13
sg11
VRGR-d protein
p12052
sg13
I2
sasg14
(lp12053
(dp12054
g7
I155
sg17
VC0242383
p12055
sg10
I32
sg11
Vage-related macular degeneration
p12056
sg13
I3
sa(dp12057
g7
I189
sg17
VC0242383
p12058
sg10
I3
sg11
VAMD
p12059
sg13
I1
sasa(dp12060
g2
S'Mutations in the human gene encoding RGR are associated with retinitis pigmentosa.\n'
p12061
sg4
(lp12062
(dp12063
g7
I17
sg8
VP47804
p12064
sg10
I23
sg11
Vhuman gene encoding RGR
p12065
sg13
I4
sasg14
(lp12066
(dp12067
g7
I61
sg17
VC0035334
p12068
sg10
I20
sg11
Vretinitis pigmentosa
p12069
sg13
I2
sasa(dp12070
g2
S'The induction of ectopic lymph node structures (ELNs) holds great promise to augment immunotherapy against multiple cancers including metastatic melanoma, in which ELN formation has been associated with a unique immune-related gene expression signature composed of distinct chemokines.\n'
p12071
sg4
(lp12072
(dp12073
g7
I48
sg8
g9
sg10
I3
sg11
VELN
p12074
sg13
I1
sasg14
(lp12075
(dp12076
g7
I134
sg17
VC0278883
p12077
sg10
I19
sg11
Vmetastatic melanoma
p12078
sg13
I2
sa(dp12079
g7
I116
sg17
VC0006826
p12080
sg10
I7
sg11
Vcancers
p12081
sg13
I1
sasa(dp12082
g2
S'In recognition of the clinical significance of AML MRD, the European LeukemiaNet (ELN) recently recommended the establishment of CR-MRDNegative as a separate category of treatment response.\n'
p12083
sg4
(lp12084
sg14
(lp12085
(dp12086
g7
I51
sg17
VC1840451
p12087
sg10
I3
sg11
VMRD
p12088
sg13
I1
sa(dp12089
g7
I47
sg17
VC0023467
p12090
sg10
I3
sg11
VAML
p12091
sg13
I1
sasa(dp12092
g2
S'The distribution according to the European LeukemiaNet (ELN) risk categorization from 2010 was 20% favorable, 31% intermediate-1, 28% intermediate-2, and 21% adverse.\n'
p12093
sg4
(lp12094
sg14
(lp12095
sa(dp12096
g2
S'Patients were stratified using the ELN European Leukemia Net classification.\n'
p12097
sg4
(lp12098
sg14
(lp12099
(dp12100
g7
I48
sg17
VC0023418
p12101
sg10
I8
sg11
VLeukemia
p12102
sg13
I1
sasa(dp12103
g2
S'oH(E)mT-DCN treatment also attenuated the expression of major ECM components, such as collagen I/III, elastin and fibronectin and induced tumor cell apoptosis, leading to extensive viral dispersion within orthotopic pancreatic tumors and pancreatic cancer patient-derived tumor spheroids.\n'
p12104
sg4
(lp12105
(dp12106
g7
I102
sg8
VP49918
p12107
sg10
I7
sg11
Velastin
p12108
sg13
I1
sasg14
(lp12109
(dp12110
g7
I138
sg17
VC0027651
p12111
sg10
I5
sg11
Vtumor
p12112
sg13
I1
sa(dp12113
g7
I138
sg17
VC0027651
p12114
sg10
I5
sg11
Vtumor
p12115
sg13
I1
sa(dp12116
g7
I238
sg17
VC0235974
p12117
sg10
I17
sg11
Vpancreatic cancer
p12118
sg13
I2
sa(dp12119
g7
I216
sg17
VC0030297
p12120
sg10
I17
sg11
Vpancreatic tumors
p12121
sg13
I2
sasa(dp12122
g2
S'In this study, we firstly examined neuroprotective effects of pre- or post-treatment with 15 and 30 mg/kg ATX against ischemic damage in the gerbil hippocampal cornus ammonis 1 (CA1) region subjected to 5 min of transient cerebral ischemia using cresyl violet staining, neuronal nuclei immunohistochemistry and Fluoro-J B histofluorescence staining.\n'
p12123
sg4
(lp12124
sg14
(lp12125
(dp12126
g7
I212
sg17
VC0917805
p12127
sg10
I27
sg11
Vtransient cerebral ischemia
p12128
sg13
I3
sasa(dp12129
g2
S'Dysregulation of cysteinyl cathepsins and their inhibitors, cystatins (stefins), were implied in progression of tumorgenesis; nevertheless, their role in sinonasal inverted papilloma (IP) is still unrecognized.\n'
p12130
sg4
(lp12131
(dp12132
g7
I17
sg8
VP25774
p12133
sg10
I20
sg11
Vcysteinyl cathepsins
p12134
sg13
I2
sasg14
(lp12135
(dp12136
g7
I184
sg17
VC1881254
p12137
sg10
I2
sg11
VIP
p12138
sg13
I1
sa(dp12139
g7
I164
sg17
VC1881254
p12140
sg10
I18
sg11
Vinverted papilloma
p12141
sg13
I2
sasa(dp12142
g2
S'Despite fundamental limitations applying to these models, such as the distinct immune system and the different metabolism regulating liver homeostasis in rodents when compared to humans, multiple approaches, such as surgery (bile duct ligation), chemical-induced (3,5-diethoxycarbonyl-1,4-dihydrocollidine, DDC, Alfa-naphthylisothiocyanate, ANIT), viral infections (Rhesus rotavirustype A, RRV-A), and genetic manipulation (Mdr2, Cftr, Pkd1, Pkd2, Prkcsh, Sec63, Pkhd1) have been developed.\n'
p12143
sg4
(lp12144
(dp12145
g7
I424
sg8
VP21439
p12146
sg10
I4
sg11
VMdr2
p12147
sg13
I1
sa(dp12148
g7
I442
sg8
g9
sg10
I4
sg11
VPkd2
p12149
sg13
I1
sa(dp12150
g7
I463
sg8
VP08F94
p12151
sg10
I5
sg11
VPkhd1
p12152
sg13
I1
sa(dp12153
g7
I436
sg8
VP98161
p12154
sg10
I4
sg11
VPkd1
p12155
sg13
I1
sa(dp12156
g7
I456
sg8
g9
sg10
I5
sg11
VSec63
p12157
sg13
I1
sa(dp12158
g7
I430
sg8
VP13569
p12159
sg10
I4
sg11
VCftr
p12160
sg13
I1
sa(dp12161
g7
I448
sg8
VP14314
p12162
sg10
I6
sg11
VPrkcsh
p12163
sg13
I1
sasg14
(lp12164
(dp12165
g7
I442
sg17
VC2751306
p12166
sg10
I4
sg11
VPkd2
p12167
sg13
I1
sa(dp12168
g7
I463
sg17
VC0085548
p12169
sg10
I5
sg11
VPkhd1
p12170
sg13
I1
sa(dp12171
g7
I348
sg17
VC0042769
p12172
sg10
I16
sg11
Vviral infections
p12173
sg13
I2
sa(dp12174
g7
I436
sg17
VC3149841
p12175
sg10
I4
sg11
VPkd1
p12176
sg13
I1
sasa(dp12177
g2
S'Progressive familial intrahepatic cholestasis type 3 (PFIC3) is an autosomal recessive disorder of cholestasis of hepatocellular origin, typically seen in infancy or childhood caused by a defect in the ABCB4 located on chromosome 7.\n'
p12178
sg4
(lp12179
(dp12180
g7
I54
sg8
VP21439
p12181
sg10
I5
sg11
VPFIC3
p12182
sg13
I1
sa(dp12183
g7
I0
sg8
VP21439
p12184
sg10
I52
sg11
VProgressive familial intrahepatic cholestasis type 3
p12185
sg13
I6
sa(dp12186
g7
I202
sg8
VP21439
p12187
sg10
I5
sg11
VABCB4
p12188
sg13
I1
sasg14
(lp12189
(dp12190
g7
I54
sg17
VC1865643
p12191
sg10
I5
sg11
VPFIC3
p12192
sg13
I1
sa(dp12193
g7
I34
sg17
VC0008370
p12194
sg10
I11
sg11
Vcholestasis
p12195
sg13
I1
sa(dp12196
g7
I0
sg17
VC1865643
p12197
sg10
I52
sg11
VProgressive familial intrahepatic cholestasis type 3
p12198
sg13
I6
sasa(dp12199
g2
S'For example, mutations in ABCA1 cause Tangier disease associated with defective efflux of cholesterol and phosphatidylcholine from the plasma membrane to the lipid acceptor protein apoA1 (apolipoprotein AI), mutations in ABCA3 cause neonatal surfactant deficiency associated with a loss in secretion of the lipid pulmonary surfactants from lungs of newborns, mutations in ABCA4 cause Stargardt macular degeneration, a retinal degenerative disease linked to the reduced clearance of retinoid compounds from photoreceptor cells, mutations in ABCA12 cause harlequin and lamellar ichthyosis, skin diseases associated with defective lipid trafficking in keratinocytes, and mutations in ABCB4 and ABCG5/ABCG8 are responsible for progressive intrafamilial hepatic disease and sitosterolaemia associated with defective phospholipid and sterol transport respectively.\n'
p12200
sg4
(lp12201
(dp12202
g7
I188
sg8
VP02656
p12203
sg10
I17
sg11
Vapolipoprotein AI
p12204
sg13
I2
sa(dp12205
g7
I181
sg8
VP02647
p12206
sg10
I5
sg11
VapoA1
p12207
sg13
I1
sa(dp12208
g7
I372
sg8
VP78363
p12209
sg10
I5
sg11
VABCA4
p12210
sg13
I1
sa(dp12211
g7
I221
sg8
g9
sg10
I5
sg11
VABCA3
p12212
sg13
I1
sa(dp12213
g7
I540
sg8
g9
sg10
I6
sg11
VABCA12
p12214
sg13
I1
sa(dp12215
g7
I681
sg8
VP21439
p12216
sg10
I5
sg11
VABCB4
p12217
sg13
I1
sa(dp12218
g7
I697
sg8
g9
sg10
I5
sg11
VABCG8
p12219
sg13
I1
sa(dp12220
g7
I691
sg8
g9
sg10
I5
sg11
VABCG5
p12221
sg13
I1
sasg14
(lp12222
(dp12223
g7
I38
sg17
VC0039292
p12224
sg10
I15
sg11
VTangier disease
p12225
sg13
I2
sa(dp12226
g7
I588
sg17
VC0037274
p12227
sg10
I13
sg11
Vskin diseases
p12228
sg13
I2
sa(dp12229
g7
I426
sg17
VC1285162
p12230
sg10
I20
sg11
Vdegenerative disease
p12231
sg13
I2
sa(dp12232
g7
I394
sg17
VC0242383
p12233
sg10
I20
sg11
Vmacular degeneration
p12234
sg13
I2
sa(dp12235
g7
I749
sg17
VC0023895
p12236
sg10
I15
sg11
Vhepatic disease
p12237
sg13
I2
sa(dp12238
g7
I567
sg17
VC0020758
p12239
sg10
I19
sg11
Vlamellar ichthyosis
p12240
sg13
I2
sa(dp12241
g7
I769
sg17
VC0342907
p12242
sg10
I15
sg11
Vsitosterolaemia
p12243
sg13
I1
sasa(dp12244
g2
S'Overexpression of the oncofetal insulin-like growth factor 2 mRNA-binding protein 2 (IMP2/IGF2BP2) has been described in different cancer types.\n'
p12245
sg4
(lp12246
(dp12247
g7
I90
sg8
g9
sg10
I7
sg11
VIGF2BP2
p12248
sg13
I1
sa(dp12249
g7
I22
sg8
VP01308
p12250
sg10
I61
sg11
Voncofetal insulin-like growth factor 2 mRNA-binding protein 2
p12251
sg13
I8
sa(dp12252
g7
I85
sg8
g9
sg10
I4
sg11
VIMP2
p12253
sg13
I1
sasg14
(lp12254
(dp12255
g7
I131
sg17
VC0006826
p12256
sg10
I6
sg11
Vcancer
p12257
sg13
I1
sasa(dp12258
g2
S'Furthermore, IMP2 expression in these cells correlated with the generation of reactive oxygen species (ROS) and RAC1 expression in BTC cells, suggesting RAC1-induced ROS generation as a potential mechanism of IMP2-promoted progression of GBC.\n'
p12259
sg4
(lp12260
(dp12261
g7
I13
sg8
g9
sg10
I4
sg11
VIMP2
p12262
sg13
I1
sa(dp12263
g7
I112
sg8
VP63000
p12264
sg10
I4
sg11
VRAC1
p12265
sg13
I1
sa(dp12266
g7
I112
sg8
VP63000
p12267
sg10
I4
sg11
VRAC1
p12268
sg13
I1
sa(dp12269
g7
I13
sg8
g9
sg10
I4
sg11
VIMP2
p12270
sg13
I1
sasg14
(lp12271
sa(dp12272
g2
S'We further analyze two independent breast cancer datasets and find that specific isoforms of IGF2BP2, NECTIN4, ITGB6, and KLHDC9 are significantly associated with AZD6244, lapatinib, erlotinib, and paclitaxel, respectively.\n'
p12273
sg4
(lp12274
(dp12275
g7
I122
sg8
g9
sg10
I6
sg11
VKLHDC9
p12276
sg13
I1
sa(dp12277
g7
I93
sg8
g9
sg10
I7
sg11
VIGF2BP2
p12278
sg13
I1
sa(dp12279
g7
I111
sg8
VP18564
p12280
sg10
I5
sg11
VITGB6
p12281
sg13
I1
sa(dp12282
g7
I102
sg8
g9
sg10
I7
sg11
VNECTIN4
p12283
sg13
I1
sasg14
(lp12284
(dp12285
g7
I35
sg17
VC0678222
p12286
sg10
I13
sg11
Vbreast cancer
p12287
sg13
I2
sasa(dp12288
g2
S"RT-qPCR and Spearman's correlation analysis were then performed to measure IGF2BP2 mRNA expression in clinical glioma tissues and its correlation with miR-188 expression.\n"
p12289
sg4
(lp12290
(dp12291
g7
I75
sg8
g9
sg10
I12
sg11
VIGF2BP2 mRNA
p12292
sg13
I2
sasg14
(lp12293
(dp12294
g7
I111
sg17
VC0017638
p12295
sg10
I6
sg11
Vglioma
p12296
sg13
I1
sasa(dp12297
g2
S'Finally, the biological roles of IGF2BP2 in glioma cells were assessed.\n'
p12298
sg4
(lp12299
(dp12300
g7
I33
sg8
g9
sg10
I7
sg11
VIGF2BP2
p12301
sg13
I1
sasg14
(lp12302
(dp12303
g7
I44
sg17
VC0017638
p12304
sg10
I6
sg11
Vglioma
p12305
sg13
I1
sasa(dp12306
g2
S'The present study identified IGF2BP2 as a direct target of miR-188 in glioma, and IGF2BP2 under-expression served tumour-suppressive roles in glioma growth and metastasis.\n'
p12307
sg4
(lp12308
(dp12309
g7
I29
sg8
g9
sg10
I7
sg11
VIGF2BP2
p12310
sg13
I1
sa(dp12311
g7
I29
sg8
g9
sg10
I7
sg11
VIGF2BP2
p12312
sg13
I1
sa(dp12313
g7
I59
sg8
g9
sg10
I7
sg11
VmiR-188
p12314
sg13
I1
sasg14
(lp12315
(dp12316
g7
I114
sg17
VC0027651
p12317
sg10
I6
sg11
Vtumour
p12318
sg13
I1
sa(dp12319
g7
I70
sg17
VC0017638
p12320
sg10
I6
sg11
Vglioma
p12321
sg13
I1
sa(dp12322
g7
I70
sg17
VC0017638
p12323
sg10
I6
sg11
Vglioma
p12324
sg13
I1
sa(dp12325
g7
I160
sg17
VC0027627
p12326
sg10
I10
sg11
Vmetastasis
p12327
sg13
I1
sasa(dp12328
g2
S'Thus, miR-188 had a similar role in glioma by inhibiting the action of its downstream target, IGF2BP2.\n'
p12329
sg4
(lp12330
(dp12331
g7
I6
sg8
g9
sg10
I7
sg11
VmiR-188
p12332
sg13
I1
sa(dp12333
g7
I94
sg8
g9
sg10
I7
sg11
VIGF2BP2
p12334
sg13
I1
sasg14
(lp12335
(dp12336
g7
I36
sg17
VC0017638
p12337
sg10
I6
sg11
Vglioma
p12338
sg13
I1
sasa(dp12339
g2
S"Background: Serum autoantibodies against tumor-associated antigens (TAAs) are detectable in early-stage gastric cancer patients; however, the time point during cancerogenesis when they appear in circulation is still obscure.Methods: In this study, we developed a recombinant antigen microarray and analyzed the prevalence of autoantibodies against 102 TAAs in 829 gastric cancer patients and 929 healthy controls from Caucasian and Asian populations, as well as 100 patients with chronic atrophic gastritis and 775 individuals staged according to different grades of intestinal metaplasia.Results: Six antigens, including CTAG1B/CTAG2, DDX53, IGF2BP2, TP53, and MAGEA3, were predominantly reacting with sera from gastric cancer patients when compared with healthy controls, and the seroreactivity was associated with intestinal-type gastric cancer, but not with patients' Helicobacter pylori status, grade, age, gender, or stage of gastric cancer.\n"
p12340
sg4
(lp12341
(dp12342
g7
I643
sg8
g9
sg10
I7
sg11
VIGF2BP2
p12343
sg13
I1
sa(dp12344
g7
I636
sg8
g9
sg10
I5
sg11
VDDX53
p12345
sg13
I1
sa(dp12346
g7
I41
sg8
VP51572
p12347
sg10
I25
sg11
Vtumor-associated antigens
p12348
sg13
I2
sa(dp12349
g7
I68
sg8
VP51572
p12350
sg10
I4
sg11
VTAAs
p12351
sg13
I1
sa(dp12352
g7
I629
sg8
g9
sg10
I5
sg11
VCTAG2
p12353
sg13
I1
sa(dp12354
g7
I68
sg8
VP51572
p12355
sg10
I4
sg11
VTAAs
p12356
sg13
I1
sa(dp12357
g7
I622
sg8
VP78358
p12358
sg10
I6
sg11
VCTAG1B
p12359
sg13
I1
sasg14
(lp12360
(dp12361
g7
I104
sg17
VC0024623
p12362
sg10
I14
sg11
Vgastric cancer
p12363
sg13
I2
sa(dp12364
g7
I104
sg17
VC0024623
p12365
sg10
I14
sg11
Vgastric cancer
p12366
sg13
I2
sa(dp12367
g7
I567
sg17
VC0334037
p12368
sg10
I21
sg11
Vintestinal metaplasia
p12369
sg13
I2
sa(dp12370
g7
I41
sg17
VC0027651
p12371
sg10
I5
sg11
Vtumor
p12372
sg13
I1
sa(dp12373
g7
I104
sg17
VC0024623
p12374
sg10
I14
sg11
Vgastric cancer
p12375
sg13
I2
sa(dp12376
g7
I104
sg17
VC0024623
p12377
sg10
I14
sg11
Vgastric cancer
p12378
sg13
I2
sa(dp12379
g7
I104
sg17
VC0024623
p12380
sg10
I14
sg11
Vgastric cancer
p12381
sg13
I2
sa(dp12382
g7
I480
sg17
VC0017154
p12383
sg10
I26
sg11
Vchronic atrophic gastritis
p12384
sg13
I3
sasa(dp12385
g2
S'The gene encoding the Insulin-like Growth Factor 2 mRNA binding protein 2/IMP2 is amplified and overexpressed in many human cancers, accompanied by a poorer prognosis.\n'
p12386
sg4
(lp12387
(dp12388
g7
I74
sg8
g9
sg10
I4
sg11
VIMP2
p12389
sg13
I1
sa(dp12390
g7
I22
sg8
VP01308
p12391
sg10
I51
sg11
VInsulin-like Growth Factor 2 mRNA binding protein 2
p12392
sg13
I8
sasg14
(lp12393
(dp12394
g7
I124
sg17
VC0006826
p12395
sg10
I7
sg11
Vcancers
p12396
sg13
I1
sasa(dp12397
g2
S'Herein we show in a diverse array of human cancer cells that IMP2 overexpression stimulates and IMP2 elimination diminishes proliferation by 50-80%.\n'
p12398
sg4
(lp12399
(dp12400
g7
I61
sg8
g9
sg10
I4
sg11
VIMP2
p12401
sg13
I1
sa(dp12402
g7
I61
sg8
g9
sg10
I4
sg11
VIMP2
p12403
sg13
I1
sasg14
(lp12404
(dp12405
g7
I43
sg17
VC0006826
p12406
sg10
I6
sg11
Vcancer
p12407
sg13
I1
sa(dp12408
g7
I124
sg17
VC0334094
p12409
sg10
I13
sg11
Vproliferation
p12410
sg13
I1
sasa(dp12411
g2
S"IMP2 stabilization of HMGA1 mRNA plus IMP2 stimulated IGF2 production synergistically drive cancer cell proliferation and account for IMP2's tumor promoting action.\n"
p12412
sg4
(lp12413
(dp12414
g7
I0
sg8
g9
sg10
I4
sg11
VIMP2
p12415
sg13
I1
sa(dp12416
g7
I0
sg8
g9
sg10
I4
sg11
VIMP2
p12417
sg13
I1
sa(dp12418
g7
I54
sg8
VP01344
p12419
sg10
I4
sg11
VIGF2
p12420
sg13
I1
sa(dp12421
g7
I22
sg8
VP17096
p12422
sg10
I10
sg11
VHMGA1 mRNA
p12423
sg13
I2
sa(dp12424
g7
I0
sg8
g9
sg10
I4
sg11
VIMP2
p12425
sg13
I1
sasg14
(lp12426
(dp12427
g7
I141
sg17
VC0027651
p12428
sg10
I5
sg11
Vtumor
p12429
sg13
I1
sa(dp12430
g7
I92
sg17
VC0006826
p12431
sg10
I6
sg11
Vcancer
p12432
sg13
I1
sa(dp12433
g7
I104
sg17
VC0334094
p12434
sg10
I13
sg11
Vproliferation
p12435
sg13
I1
sasa(dp12436
g2
S'In conclusion, miR-1193 suppressed proliferation and invasion of human breast cancer cells via translational suppression of IGF2BP2.\n'
p12437
sg4
(lp12438
(dp12439
g7
I124
sg8
g9
sg10
I7
sg11
VIGF2BP2
p12440
sg13
I1
sasg14
(lp12441
(dp12442
g7
I53
sg17
VC2699153
p12443
sg10
I8
sg11
Vinvasion
p12444
sg13
I1
sa(dp12445
g7
I109
sg17
VC0221103
p12446
sg10
I11
sg11
Vsuppression
p12447
sg13
I1
sa(dp12448
g7
I35
sg17
VC0334094
p12449
sg10
I13
sg11
Vproliferation
p12450
sg13
I1
sa(dp12451
g7
I71
sg17
VC0678222
p12452
sg10
I13
sg11
Vbreast cancer
p12453
sg13
I2
sasa(dp12454
g2
S'New genes HTRP5, CAPN6, STPK, 14-3-3PKR, and CALM1 and previously known genes including BTK, DDP, GLA, PLP, COL4A5, COL4A6, PAK3, and DCX are localized; candidate loci for other disorders for which genes have not yet been identified, including DFN-2, POF, megalocornea, and syndromic and nonsyndromic mental retardation, are also mapped in the region.\n'
p12455
sg4
(lp12456
(dp12457
g7
I134
sg8
g9
sg10
I3
sg11
VDCX
p12458
sg13
I1
sa(dp12459
g7
I98
sg8
VP06280
p12460
sg10
I3
sg11
VGLA
p12461
sg13
I1
sa(dp12462
g7
I251
sg8
g9
sg10
I3
sg11
VPOF
p12463
sg13
I1
sa(dp12464
g7
I0
sg8
VP01701
p12465
sg10
I15
sg11
VNew genes HTRP5
p12466
sg13
I3
sa(dp12467
g7
I17
sg8
g9
sg10
I5
sg11
VCAPN6
p12468
sg13
I1
sa(dp12469
g7
I103
sg8
g9
sg10
I3
sg11
VPLP
p12470
sg13
I1
sa(dp12471
g7
I24
sg8
VP53350
p12472
sg10
I4
sg11
VSTPK
p12473
sg13
I1
sa(dp12474
g7
I88
sg8
g9
sg10
I3
sg11
VBTK
p12475
sg13
I1
sa(dp12476
g7
I108
sg8
VP29400
p12477
sg10
I6
sg11
VCOL4A5
p12478
sg13
I1
sa(dp12479
g7
I93
sg8
g9
sg10
I3
sg11
VDDP
p12480
sg13
I1
sasg14
(lp12481
(dp12482
g7
I251
sg17
VC0085215
p12483
sg10
I3
sg11
VPOF
p12484
sg13
I1
sa(dp12485
g7
I93
sg17
VC0796074
p12486
sg10
I3
sg11
VDDP
p12487
sg13
I1
sa(dp12488
g7
I301
sg17
VC0025362
p12489
sg10
I18
sg11
Vmental retardation
p12490
sg13
I2
sa(dp12491
g7
I256
sg17
VC0344530
p12492
sg10
I12
sg11
Vmegalocornea
p12493
sg13
I1
sasa(dp12494
g2
S'To study the expression status of Ras-association domain family 7 (RASSF7) and Ras-association domain family 8 (RASSF8) in nodular thyroid goiter (NTG), medullary thyroid carcinoma (MTC), and papillary thyroid carcinoma (PTC) and establish whether a correlation exists between the presence of RASSF7 and RASSF8 proteins and clinicopathological parameters of the disease.\n'
p12495
sg4
(lp12496
(dp12497
g7
I67
sg8
g9
sg10
I6
sg11
VRASSF7
p12498
sg13
I1
sa(dp12499
g7
I67
sg8
g9
sg10
I6
sg11
VRASSF7
p12500
sg13
I1
sa(dp12501
g7
I304
sg8
g9
sg10
I15
sg11
VRASSF8 proteins
p12502
sg13
I2
sa(dp12503
g7
I79
sg8
VP01116
p12504
sg10
I31
sg11
VRas-association domain family 8
p12505
sg13
I4
sa(dp12506
g7
I112
sg8
g9
sg10
I6
sg11
VRASSF8
p12507
sg13
I1
sa(dp12508
g7
I34
sg8
VP01116
p12509
sg10
I31
sg11
VRas-association domain family 7
p12510
sg13
I4
sasg14
(lp12511
(dp12512
g7
I131
sg17
VC0018021
p12513
sg10
I14
sg11
Vthyroid goiter
p12514
sg13
I2
sa(dp12515
g7
I192
sg17
VC0238463
p12516
sg10
I27
sg11
Vpapillary thyroid carcinoma
p12517
sg13
I3
sa(dp12518
g7
I221
sg17
VC0238463
p12519
sg10
I3
sg11
VPTC
p12520
sg13
I1
sa(dp12521
g7
I182
sg17
VC1833921
p12522
sg10
I3
sg11
VMTC
p12523
sg13
I1
sa(dp12524
g7
I153
sg17
VC0238462
p12525
sg10
I27
sg11
Vmedullary thyroid carcinoma
p12526
sg13
I3
sasa(dp12527
g2
S'Moreover, HO-1 diminished ischemia-induced expression of MyoD involved in satellite cell differentiation in HO-1 KO mice.\n'
p12528
sg4
(lp12529
(dp12530
g7
I57
sg8
VP15172
p12531
sg10
I4
sg11
VMyoD
p12532
sg13
I1
sasg14
(lp12533
(dp12534
g7
I26
sg17
VC0022116
p12535
sg10
I8
sg11
Vischemia
p12536
sg13
I1
sasa(dp12537
g2
S'Coprecipitation of CD36, CD9, and alpha6beta1 was also observed on platelets from a patient with Glanzmann thrombasthenia, indicating that alphaII(b)beta3 is not required for the other proteins to associate.\n'
p12538
sg4
(lp12539
(dp12540
g7
I25
sg8
VP21926
p12541
sg10
I3
sg11
VCD9
p12542
sg13
I1
sasg14
(lp12543
(dp12544
g7
I97
sg17
VC0040015
p12545
sg10
I24
sg11
VGlanzmann thrombasthenia
p12546
sg13
I2
sasa(dp12547
g2
S"To rule out a cross-reactivity of the two polyclonal antibodies with GPIIb/IIIa, we studied PECAM1 and CD9 expression on the platelets from a patient with type I Glanzmann's thrombasthenia whose platelets are devoid of GPIIb/IIIa.\n"
p12548
sg4
(lp12549
(dp12550
g7
I69
sg8
VP08514
p12551
sg10
I10
sg11
VGPIIb/IIIa
p12552
sg13
I1
sa(dp12553
g7
I69
sg8
VP08514
p12554
sg10
I10
sg11
VGPIIb/IIIa
p12555
sg13
I1
sa(dp12556
g7
I103
sg8
VP21926
p12557
sg10
I3
sg11
VCD9
p12558
sg13
I1
sasg14
(lp12559
(dp12560
g7
I162
sg17
VC0040015
p12561
sg10
I26
sg11
VGlanzmann's thrombasthenia
p12562
sg13
I2
sasa(dp12563
g2
S'In contrast to TASK-1, which was not differentially expressed in lung cancer vs. normal lung tissue, we found the Na+-coupled nutrient transporters, SLC5A3, SLC5A6, and SLC38A1, transporters for myo-inositol, biotin and glutamine, respectively, to be significantly overexpressed in lung adenocarcinomas.\n'
p12564
sg4
(lp12565
(dp12566
g7
I15
sg8
g9
sg10
I6
sg11
VTASK-1
p12567
sg13
I1
sa(dp12568
g7
I114
sg8
g9
sg10
I33
sg11
VNa+-coupled nutrient transporters
p12569
sg13
I3
sa(dp12570
g7
I157
sg8
g9
sg10
I6
sg11
VSLC5A6
p12571
sg13
I1
sa(dp12572
g7
I169
sg8
g9
sg10
I7
sg11
VSLC38A1
p12573
sg13
I1
sa(dp12574
g7
I149
sg8
VP53794
p12575
sg10
I6
sg11
VSLC5A3
p12576
sg13
I1
sasg14
(lp12577
(dp12578
g7
I65
sg17
VC0684249
p12579
sg10
I11
sg11
Vlung cancer
p12580
sg13
I2
sa(dp12581
g7
I287
sg17
VC0001418
p12582
sg10
I15
sg11
Vadenocarcinomas
p12583
sg13
I1
sasa(dp12584
g2
S'qPCR analysis showed elevated expression of efflux transporters (P-glycoprotein, multidrug resistant protein 2, breast cancer resistant protein) and influx transporters (folate receptor-Alfa, cationic and neutral amino acid transporter, sodium dependent multivitamin transporter) in a time dependent manner.\n'
p12585
sg4
(lp12586
(dp12587
g7
I237
sg8
VP19525
p12588
sg10
I41
sg11
Vsodium dependent multivitamin transporter
p12589
sg13
I4
sa(dp12590
g7
I44
sg8
g9
sg10
I19
sg11
Vefflux transporters
p12591
sg13
I2
sa(dp12592
g7
I213
sg8
g9
sg10
I22
sg11
Vamino acid transporter
p12593
sg13
I3
sa(dp12594
g7
I65
sg8
VP08183
p12595
sg10
I14
sg11
VP-glycoprotein
p12596
sg13
I1
sasg14
(lp12597
(dp12598
g7
I112
sg17
VC0678222
p12599
sg10
I13
sg11
Vbreast cancer
p12600
sg13
I2
sasa(dp12601
g2
S'Immunoblot analysis further confirmed elevated expression of breast cancer resistant protein and sodium dependent multivitamin transporter.\n'
p12602
sg4
(lp12603
(dp12604
g7
I97
sg8
VP19525
p12605
sg10
I41
sg11
Vsodium dependent multivitamin transporter
p12606
sg13
I4
sasg14
(lp12607
(dp12608
g7
I61
sg17
VC0678222
p12609
sg10
I13
sg11
Vbreast cancer
p12610
sg13
I2
sasa(dp12611
g2
S'All these studies demonstrated for the first time the functional and molecular expression of sodium dependent multivitamin transporter (SMVT), a specific carrier-mediated system for biotin uptake, in human derived breast cancer (T47D) cells.\n'
p12612
sg4
(lp12613
(dp12614
g7
I93
sg8
VP19525
p12615
sg10
I41
sg11
Vsodium dependent multivitamin transporter
p12616
sg13
I4
sa(dp12617
g7
I136
sg8
g9
sg10
I4
sg11
VSMVT
p12618
sg13
I1
sasg14
(lp12619
(dp12620
g7
I214
sg17
VC0678222
p12621
sg10
I13
sg11
Vbreast cancer
p12622
sg13
I2
sasa(dp12623
g2
S'The overall objective of this study was to investigate the differential expression of folate receptor-alpha (FR-Alfa), sodium-dependent multivitamin transporter (SMVT), and amino acid transporter [B ((0, +))] in retinoblastoma (Y-79) and retinal pigment epithelial (ARPE-19) cells.\n'
p12624
sg4
(lp12625
(dp12626
g7
I86
sg8
VP15328
p12627
sg10
I21
sg11
Vfolate receptor-alpha
p12628
sg13
I2
sa(dp12629
g7
I162
sg8
g9
sg10
I4
sg11
VSMVT
p12630
sg13
I1
sa(dp12631
g7
I119
sg8
g9
sg10
I41
sg11
Vsodium-dependent multivitamin transporter
p12632
sg13
I3
sasg14
(lp12633
(dp12634
g7
I212
sg17
VC0035335
p12635
sg10
I14
sg11
Vretinoblastoma
p12636
sg13
I1
sasa(dp12637
g2
S'This work demonstrated for the first time the higher expression and affinity of FR-Alfa, SMVT, and B ((0, +)) mRNA levels in retinoblastoma (Y-79) cells compared with retinal pigment epithelial (ARPE-19) cells.\n'
p12638
sg4
(lp12639
(dp12640
g7
I89
sg8
g9
sg10
I4
sg11
VSMVT
p12641
sg13
I1
sasg14
(lp12642
(dp12643
g7
I125
sg17
VC0035335
p12644
sg10
I14
sg11
Vretinoblastoma
p12645
sg13
I1
sasa(dp12646
g2
S'To synthesize a novel camptothecin-poly(ethylene glycol) conjugate (CPT-PEG) which includes biotin as a moiety to enhance nonspecific and/or targeted uptake via the sodium-dependent multivitamin transporter (SMVT) and to evaluate its anticancer activity and apoptosis induction.\n'
p12647
sg4
(lp12648
(dp12649
g7
I165
sg8
g9
sg10
I41
sg11
Vsodium-dependent multivitamin transporter
p12650
sg13
I3
sa(dp12651
g7
I208
sg8
g9
sg10
I4
sg11
VSMVT
p12652
sg13
I1
sasg14
(lp12653
sa(dp12654
g2
S'This suggests that the targeting approach utilizing transporters such as SMVT may substantially improve the delivery of CPT and its anticancer activity by enhancing cellular permeability and possibly retention of CPT.\n'
p12655
sg4
(lp12656
sg14
(lp12657
sa(dp12658
g2
S'We have cloned the human Na+-dependent multivitamin transporter (SMVT), which transports the water-soluble vitamins pantothenate, biotin, and lipoate, from a placental choriocarcinoma cell line (JAR).\n'
p12659
sg4
(lp12660
(dp12661
g7
I19
sg8
g9
sg10
I44
sg11
Vhuman Na+-dependent multivitamin transporter
p12662
sg13
I4
sa(dp12663
g7
I65
sg8
g9
sg10
I4
sg11
VSMVT
p12664
sg13
I1
sasg14
(lp12665
(dp12666
g7
I158
sg17
VC0855173
p12667
sg10
I25
sg11
Vplacental choriocarcinoma
p12668
sg13
I2
sasa(dp12669
g2
S'While the association between IL-16 plasma levels and tumor progression has been reported for many types of cancer, the mechanism for IL-16 involvement has been partially elucidated for three of the cancer types, cutaneous T cell lymphoma (CTCL), multiple myeloma (MM), and breast cancer.\n'
p12670
sg4
(lp12671
(dp12672
g7
I30
sg8
g9
sg10
I5
sg11
VIL-16
p12673
sg13
I1
sa(dp12674
g7
I30
sg8
g9
sg10
I5
sg11
VIL-16
p12675
sg13
I1
sasg14
(lp12676
(dp12677
g7
I213
sg17
VC0079773
p12678
sg10
I25
sg11
Vcutaneous T cell lymphoma
p12679
sg13
I4
sa(dp12680
g7
I108
sg17
VC0006826
p12681
sg10
I6
sg11
Vcancer
p12682
sg13
I1
sa(dp12683
g7
I108
sg17
VC0006826
p12684
sg10
I6
sg11
Vcancer
p12685
sg13
I1
sa(dp12686
g7
I54
sg17
VC0178874
p12687
sg10
I17
sg11
Vtumor progression
p12688
sg13
I2
sa(dp12689
g7
I240
sg17
VC0079773
p12690
sg10
I4
sg11
VCTCL
p12691
sg13
I1
sa(dp12692
g7
I274
sg17
VC0678222
p12693
sg10
I13
sg11
Vbreast cancer
p12694
sg13
I2
sa(dp12695
g7
I247
sg17
VC0026764
p12696
sg10
I16
sg11
Vmultiple myeloma
p12697
sg13
I2
sasa(dp12698
g2
S'Nuclear translocation of pro-interleukin-16 was not observed in late stages of Sezary syndrome, indicating this loss is not reversible.\n'
p12699
sg4
(lp12700
(dp12701
g7
I25
sg8
g9
sg10
I18
sg11
Vpro-interleukin-16
p12702
sg13
I1
sasg14
(lp12703
(dp12704
g7
I8
sg17
VC0040715
p12705
sg10
I13
sg11
Vtranslocation
p12706
sg13
I1
sa(dp12707
g7
I79
sg17
VC0036920
p12708
sg10
I15
sg11
VSezary syndrome
p12709
sg13
I2
sasa(dp12710
g2
S'We propose that it is feasible to use plasma levels of IL-16 as a potential diagnostic marker of Sezary syndrome and to use loss of intracellular IL-16 as a prognostic indicator of disease severity and stage.\n'
p12711
sg4
(lp12712
(dp12713
g7
I55
sg8
g9
sg10
I5
sg11
VIL-16
p12714
sg13
I1
sa(dp12715
g7
I55
sg8
g9
sg10
I5
sg11
VIL-16
p12716
sg13
I1
sasg14
(lp12717
(dp12718
g7
I97
sg17
VC0036920
p12719
sg10
I15
sg11
VSezary syndrome
p12720
sg13
I2
sasa(dp12721
g2
S'By reverse transcription-polymerase chain reaction, interleukin-16 mRNA was detected in 18 of 18 mycosis fungoides lesions investigated.\n'
p12722
sg4
(lp12723
(dp12724
g7
I52
sg8
g9
sg10
I19
sg11
Vinterleukin-16 mRNA
p12725
sg13
I2
sasg14
(lp12726
(dp12727
g7
I97
sg17
VC0026948
p12728
sg10
I17
sg11
Vmycosis fungoides
p12729
sg13
I2
sasa(dp12730
g2
S'Given the biologic properties of interleukin-16 and the parallel activation of the interleukin-2/CD25 pathway, interleukin-16 might be involved in the recruitment and stimulation of CD4+ lymphocytes in mycosis fungoides lesions and therefore contribute to the perpetuation of the associated cutaneous inflammation.\n'
p12731
sg4
(lp12732
(dp12733
g7
I182
sg8
VP01730
p12734
sg10
I4
sg11
VCD4+
p12735
sg13
I1
sa(dp12736
g7
I83
sg8
VP60568
p12737
sg10
I13
sg11
Vinterleukin-2
p12738
sg13
I1
sa(dp12739
g7
I33
sg8
g9
sg10
I14
sg11
Vinterleukin-16
p12740
sg13
I1
sa(dp12741
g7
I33
sg8
g9
sg10
I14
sg11
Vinterleukin-16
p12742
sg13
I1
sa(dp12743
g7
I97
sg8
VP01589
p12744
sg10
I4
sg11
VCD25
p12745
sg13
I1
sasg14
(lp12746
(dp12747
g7
I202
sg17
VC0026948
p12748
sg10
I17
sg11
Vmycosis fungoides
p12749
sg13
I2
sa(dp12750
g7
I151
sg17
VC0271510
p12751
sg10
I11
sg11
Vrecruitment
p12752
sg13
I1
sa(dp12753
g7
I301
sg17
VC0021368
p12754
sg10
I12
sg11
Vinflammation
p12755
sg13
I1
sasa(dp12756
g2
S'Three additional patients with possible parathyroid adenomas at 11C-choline PET/CT were ultimately found to have thyroid lesions on the basis of tissue diagnosis; however, none of these patients had abnormal calcium or parathyroid hormone levels.\n'
p12757
sg4
(lp12758
(dp12759
g7
I219
sg8
VP01270
p12760
sg10
I19
sg11
Vparathyroid hormone
p12761
sg13
I2
sasg14
(lp12762
(dp12763
g7
I40
sg17
VC0262587
p12764
sg10
I20
sg11
Vparathyroid adenomas
p12765
sg13
I2
sasa(dp12766
g2
S'Patients with primary hyperparathyroidism generally have a single parathyroid adenoma that causes excessive excretion of parathyroid hormone.\n'
p12767
sg4
(lp12768
(dp12769
g7
I121
sg8
VP01270
p12770
sg10
I19
sg11
Vparathyroid hormone
p12771
sg13
I2
sasg14
(lp12772
(dp12773
g7
I66
sg17
VC0262587
p12774
sg10
I19
sg11
Vparathyroid adenoma
p12775
sg13
I2
sa(dp12776
g7
I14
sg17
VC0221002
p12777
sg10
I27
sg11
Vprimary hyperparathyroidism
p12778
sg13
I2
sasa(dp12779
g2
S'Although double adenomas are not yet widely acknowledged, presurgical imaging and nuclear scans can help to localize multiple lesions, and intraoperative parathyroid hormone assays can confirm the diagnosis and cure.\n'
p12780
sg4
(lp12781
(dp12782
g7
I154
sg8
VP01270
p12783
sg10
I19
sg11
Vparathyroid hormone
p12784
sg13
I2
sasg14
(lp12785
(dp12786
g7
I16
sg17
VC0001430
p12787
sg10
I8
sg11
Vadenomas
p12788
sg13
I1
sasa(dp12789
g2
S'Finally, MMGP analysis revealed a positive correlation between the transcript levels of B7-H4 and proliferation-related genes including MKI67, CCNA1, and Myc in several patients with multiple myeloma.\n'
p12790
sg4
(lp12791
(dp12792
g7
I154
sg8
VP12524
p12793
sg10
I3
sg11
VMyc
p12794
sg13
I1
sa(dp12795
g7
I143
sg8
VP78396
p12796
sg10
I5
sg11
VCCNA1
p12797
sg13
I1
sa(dp12798
g7
I88
sg8
g9
sg10
I5
sg11
VB7-H4
p12799
sg13
I1
sa(dp12800
g7
I136
sg8
VP46013
p12801
sg10
I5
sg11
VMKI67
p12802
sg13
I1
sa(dp12803
g7
I98
sg8
VP01893
p12804
sg10
I27
sg11
Vproliferation-related genes
p12805
sg13
I2
sasg14
(lp12806
(dp12807
g7
I98
sg17
VC0334094
p12808
sg10
I13
sg11
Vproliferation
p12809
sg13
I1
sa(dp12810
g7
I183
sg17
VC0026764
p12811
sg10
I16
sg11
Vmultiple myeloma
p12812
sg13
I2
sasa(dp12813
g2
S'The purpose of this study was to evaluate the expression of cyclin A1 mRNA in patients with myelodysplastic syndrome (MDS) and its clinical significance.\n'
p12814
sg4
(lp12815
(dp12816
g7
I60
sg8
VP78396
p12817
sg10
I14
sg11
Vcyclin A1 mRNA
p12818
sg13
I3
sasg14
(lp12819
(dp12820
g7
I92
sg17
VC3463824
p12821
sg10
I24
sg11
Vmyelodysplastic syndrome
p12822
sg13
I2
sa(dp12823
g7
I118
sg17
VC0265219
p12824
sg10
I3
sg11
VMDS
p12825
sg13
I1
sasa(dp12826
g2
S'Cyclin A1 mRNA was detectable in 11 of 11 patients with acute myeloid leukemia, three of three patients with acute biphenotypic leukemia, eight of eight patients with myelodysplastic syndrome, 59 of 69 patients with chronic myelogenous leukemia (CML) at diagnosis, 13 of 15 patients with CML in blastic transformation, 10 of 18 patients with chronic lymphocytic leukemia, two of nine patients with essential thrombocythemia, and only two of 10 patients with acute lymphoblastic leukemia (ALL) with both cyclin A1 RT-PCR positive ALL leukemias being undifferentiated relapses.\n'
p12827
sg4
(lp12828
(dp12829
g7
I0
sg8
VP78396
p12830
sg10
I14
sg11
VCyclin A1 mRNA
p12831
sg13
I3
sa(dp12832
g7
I503
sg8
VP78396
p12833
sg10
I12
sg11
Vcyclin A1 RT
p12834
sg13
I3
sasg14
(lp12835
(dp12836
g7
I488
sg17
VC1961102
p12837
sg10
I3
sg11
VALL
p12838
sg13
I1
sa(dp12839
g7
I246
sg17
VC0023473
p12840
sg10
I3
sg11
VCML
p12841
sg13
I1
sa(dp12842
g7
I109
sg17
VC0023464
p12843
sg10
I27
sg11
Vacute biphenotypic leukemia
p12844
sg13
I3
sa(dp12845
g7
I246
sg17
VC0023473
p12846
sg10
I3
sg11
VCML
p12847
sg13
I1
sa(dp12848
g7
I342
sg17
VC0023434
p12849
sg10
I28
sg11
Vchronic lymphocytic leukemia
p12850
sg13
I3
sa(dp12851
g7
I56
sg17
VC0023467
p12852
sg10
I22
sg11
Vacute myeloid leukemia
p12853
sg13
I3
sa(dp12854
g7
I167
sg17
VC0033027
p12855
sg10
I24
sg11
Vmyelodysplastic syndrome
p12856
sg13
I2
sa(dp12857
g7
I398
sg17
VC0040028
p12858
sg10
I25
sg11
Vessential thrombocythemia
p12859
sg13
I2
sa(dp12860
g7
I303
sg17
VC1510411
p12861
sg10
I14
sg11
Vtransformation
p12862
sg13
I1
sa(dp12863
g7
I216
sg17
VC0023473
p12864
sg10
I28
sg11
Vchronic myelogenous leukemia
p12865
sg13
I3
sa(dp12866
g7
I458
sg17
VC1961102
p12867
sg10
I28
sg11
Vacute lymphoblastic leukemia
p12868
sg13
I3
sa(dp12869
g7
I488
sg17
VC1961102
p12870
sg10
I3
sg11
VALL
p12871
sg13
I1
sa(dp12872
g7
I533
sg17
VC0023418
p12873
sg10
I9
sg11
Vleukemias
p12874
sg13
I1
sasa(dp12875
g2
S'Mice with ANP showed increased apoptosis of pancreatic acinar cells, pancreatic myeloperoxidase activity, serum lactate dehydrogenase activity, amylase, tumor necrosis factor-Alfa (TNF-Alfa), interleukin-6 (IL-6) levels as well as decreased serum IL-10 level, pancreatic expression of heat shock factor 1 (HSF1), sirtuin 1 (SIRT1) and p53, but the ratio of acetylated HSF1 and p53 was markedly increased.\n'
p12876
sg4
(lp12877
(dp12878
g7
I80
sg8
VP05164
p12879
sg10
I15
sg11
Vmyeloperoxidase
p12880
sg13
I1
sa(dp12881
g7
I324
sg8
g9
sg10
I5
sg11
VSIRT1
p12882
sg13
I1
sa(dp12883
g7
I335
sg8
VP42771
p12884
sg10
I3
sg11
Vp53
p12885
sg13
I1
sa(dp12886
g7
I144
sg8
VP04746
p12887
sg10
I7
sg11
Vamylase
p12888
sg13
I1
sa(dp12889
g7
I313
sg8
g9
sg10
I9
sg11
Vsirtuin 1
p12890
sg13
I2
sa(dp12891
g7
I306
sg8
g9
sg10
I4
sg11
VHSF1
p12892
sg13
I1
sa(dp12893
g7
I153
sg8
VP01375
p12894
sg10
I26
sg11
Vtumor necrosis factor-Alfa
p12895
sg13
I3
sa(dp12896
g7
I285
sg8
g9
sg10
I19
sg11
Vheat shock factor 1
p12897
sg13
I4
sa(dp12898
g7
I192
sg8
VP05231
p12899
sg10
I13
sg11
Vinterleukin-6
p12900
sg13
I1
sa(dp12901
g7
I335
sg8
VP42771
p12902
sg10
I3
sg11
Vp53
p12903
sg13
I1
sa(dp12904
g7
I306
sg8
g9
sg10
I4
sg11
VHSF1
p12905
sg13
I1
sa(dp12906
g7
I106
sg8
VP49366
p12907
sg10
I27
sg11
Vserum lactate dehydrogenase
p12908
sg13
I3
sa(dp12909
g7
I241
sg8
g9
sg10
I11
sg11
Vserum IL-10
p12910
sg13
I2
sa(dp12911
g7
I10
sg8
VP16066
p12912
sg10
I3
sg11
VANP
p12913
sg13
I1
sa(dp12914
g7
I181
sg8
VP01375
p12915
sg10
I8
sg11
VTNF-Alfa
p12916
sg13
I1
sa(dp12917
g7
I207
sg8
VP05231
p12918
sg10
I4
sg11
VIL-6
p12919
sg13
I1
sasg14
(lp12920
(dp12921
g7
I153
sg17
VC0333516
p12922
sg10
I14
sg11
Vtumor necrosis
p12923
sg13
I2
sasa(dp12924
g2
S'These data suggest that resveratrol protects against L-arginine-induced ANP, which may be related to the enhancement of SIRT1-mediated deacetylation of p53 and HSF1.\n'
p12925
sg4
(lp12926
(dp12927
g7
I72
sg8
VP16066
p12928
sg10
I3
sg11
VANP
p12929
sg13
I1
sa(dp12930
g7
I160
sg8
g9
sg10
I4
sg11
VHSF1
p12931
sg13
I1
sa(dp12932
g7
I120
sg8
g9
sg10
I5
sg11
VSIRT1
p12933
sg13
I1
sa(dp12934
g7
I152
sg8
VP42771
p12935
sg10
I3
sg11
Vp53
p12936
sg13
I1
sasg14
(lp12937
sa(dp12938
g2
S'The aim of this study was to explore the role of the p38 mitogen-activated protein kinase (p38MAPK)/p53 signaling pathway in injury to the intestinal mucosal barrier during severe acute pancreatitis (SAP).\n'
p12939
sg4
(lp12940
(dp12941
g7
I91
sg8
g9
sg10
I7
sg11
Vp38MAPK
p12942
sg13
I1
sa(dp12943
g7
I53
sg8
g9
sg10
I36
sg11
Vp38 mitogen-activated protein kinase
p12944
sg13
I4
sa(dp12945
g7
I100
sg8
VP42771
p12946
sg10
I3
sg11
Vp53
p12947
sg13
I1
sasg14
(lp12948
(dp12949
g7
I180
sg17
VC0001339
p12950
sg10
I18
sg11
Vacute pancreatitis
p12951
sg13
I2
sasa(dp12952
g2
S'Furthermore, compared with homozygous missense mutations, compound heterozygous mutations appeared to have a more severe effect on phenotype, causing more severe growth retardation in ORC4 and more frequently pulmonary emphysema in CDT1.\n'
p12953
sg4
(lp12954
(dp12955
g7
I232
sg8
g9
sg10
I4
sg11
VCDT1
p12956
sg13
I1
sasg14
(lp12957
(dp12958
g7
I162
sg17
VC0151686
p12959
sg10
I18
sg11
Vgrowth retardation
p12960
sg13
I2
sa(dp12961
g7
I209
sg17
VC0034067
p12962
sg10
I19
sg11
Vpulmonary emphysema
p12963
sg13
I2
sasa(dp12964
g2
S'We recently identified an RBP HNRNPL as a novel prostate cancer dependency via regulation of RNA splicing, suggesting the potential to target RBP or RBP-RNA interaction to treat cancer.\n'
p12965
sg4
(lp12966
(dp12967
g7
I26
sg8
g9
sg10
I3
sg11
VRBP
p12968
sg13
I1
sa(dp12969
g7
I26
sg8
g9
sg10
I10
sg11
VRBP HNRNPL
p12970
sg13
I2
sa(dp12971
g7
I149
sg8
g9
sg10
I7
sg11
VRBP-RNA
p12972
sg13
I1
sasg14
(lp12973
(dp12974
g7
I57
sg17
VC0006826
p12975
sg10
I6
sg11
Vcancer
p12976
sg13
I1
sa(dp12977
g7
I48
sg17
VC0600139
p12978
sg10
I15
sg11
Vprostate cancer
p12979
sg13
I2
sasa(dp12980
g2
S'HNRNPL directly regulates the alternative splicing of a set of RNAs, including those encoding the androgen receptor, the key lineage-specific prostate cancer oncogene.\n'
p12981
sg4
(lp12982
(dp12983
g7
I0
sg8
VP14866
p12984
sg10
I6
sg11
VHNRNPL
p12985
sg13
I1
sa(dp12986
g7
I98
sg8
VP10275
p12987
sg10
I17
sg11
Vandrogen receptor
p12988
sg13
I2
sasg14
(lp12989
(dp12990
g7
I142
sg17
VC0600139
p12991
sg10
I15
sg11
Vprostate cancer
p12992
sg13
I2
sasa(dp12993
g2
S'Collectively, our data reveal HNRNPL and its RNA clients as players in prostate cancer growth and potential therapeutic targets.\n'
p12994
sg4
(lp12995
sg14
(lp12996
(dp12997
g7
I71
sg17
VC0600139
p12998
sg10
I15
sg11
Vprostate cancer
p12999
sg13
I2
sasa(dp13000
g2
S'Heterogeneous nuclear ribonucleoprotein L (hnRNP-L) is a promoter of various kinds of cancers, but its actions in bladder cancer (BC) are unclear.\n'
p13001
sg4
(lp13002
(dp13003
g7
I0
sg8
VP14866
p13004
sg10
I41
sg11
VHeterogeneous nuclear ribonucleoprotein L
p13005
sg13
I4
sa(dp13006
g7
I43
sg8
VP14866
p13007
sg10
I7
sg11
VhnRNP-L
p13008
sg13
I1
sasg14
(lp13009
(dp13010
g7
I86
sg17
VC0006826
p13011
sg10
I7
sg11
Vcancers
p13012
sg13
I1
sa(dp13013
g7
I114
sg17
VC0699885
p13014
sg10
I14
sg11
Vbladder cancer
p13015
sg13
I2
sa(dp13016
g7
I130
sg17
VC0699885
p13017
sg10
I2
sg11
VBC
p13018
sg13
I1
sasa(dp13019
g2
S'In this study, we examined the role of HnRNP-L in prostate cancer (Pca).\n'
p13020
sg4
(lp13021
(dp13022
g7
I39
sg8
VP14866
p13023
sg10
I26
sg11
VHnRNP-L in prostate cancer
p13024
sg13
I4
sa(dp13025
g7
I67
sg8
g9
sg10
I3
sg11
VPca
p13026
sg13
I1
sasg14
(lp13027
(dp13028
g7
I50
sg17
VC0600139
p13029
sg10
I15
sg11
Vprostate cancer
p13030
sg13
I2
sa(dp13031
g7
I67
sg17
VC0268398
p13032
sg10
I3
sg11
VPca
p13033
sg13
I1
sasa(dp13034
g2
S'These results suggest a rationale for dose reduction of doxorubicin and docetaxel in prostate cancer therapy, since the doses needed to achieve 50% cell death may be decreased by approximately 4- to 15-fold or 3- to 8-fold, respectively, after a pre-treatment with ciprofloxacin.\n'
p13035
sg4
(lp13036
sg14
(lp13037
(dp13038
g7
I85
sg17
VC0600139
p13039
sg10
I15
sg11
Vprostate cancer
p13040
sg13
I2
sasa(dp13041
g2
S'This study investigated the presence of CA I and II autoantibodies in patients with iron deficiency anemia (IDA).\n'
p13042
sg4
(lp13043
(dp13044
g7
I40
sg8
VP00915
p13045
sg10
I26
sg11
VCA I and II autoantibodies
p13046
sg13
I5
sasg14
(lp13047
(dp13048
g7
I108
sg17
VC0162316
p13049
sg10
I3
sg11
VIDA
p13050
sg13
I1
sa(dp13051
g7
I84
sg17
VC0162316
p13052
sg10
I22
sg11
Viron deficiency anemia
p13053
sg13
I3
sasa(dp13054
g2
S'Compared with controls, CAIII concentration was lower in iron deficiency anemia (P&lt;0.01), but higher in beta-thalassemia anemia (P&lt;0.001).\n'
p13055
sg4
(lp13056
(dp13057
g7
I24
sg8
VP07451
p13058
sg10
I5
sg11
VCAIII
p13059
sg13
I1
sasg14
(lp13060
(dp13061
g7
I73
sg17
VC0002871
p13062
sg10
I6
sg11
Vanemia
p13063
sg13
I1
sa(dp13064
g7
I107
sg17
VC0005283
p13065
sg10
I16
sg11
Vbeta-thalassemia
p13066
sg13
I1
sa(dp13067
g7
I57
sg17
VC0162316
p13068
sg10
I22
sg11
Viron deficiency anemia
p13069
sg13
I3
sasa(dp13070
g2
S'The levels of erythrocyte carbonic anhydrase isozymes (CA-B and CA-C) were determined by a quantitative immunochemical technique in order to elucidate their clinical significances in patients with iron deficiency anemia.\n'
p13071
sg4
(lp13072
(dp13073
g7
I14
sg8
VP35218
p13074
sg10
I39
sg11
Verythrocyte carbonic anhydrase isozymes
p13075
sg13
I4
sasg14
(lp13076
(dp13077
g7
I197
sg17
VC0162316
p13078
sg10
I22
sg11
Viron deficiency anemia
p13079
sg13
I3
sasa(dp13080
g2
S'1 The levels of erythrocyte CA-B per gram hemoglobin, CA-B per ml erythrocyte and CA-C per gram hemoglobin all increased but CA-C per ml erythrocyte did not increased in iron deficiency anemia.\n'
p13081
sg4
(lp13082
(dp13083
g7
I42
sg8
g9
sg10
I10
sg11
Vhemoglobin
p13084
sg13
I1
sa(dp13085
g7
I37
sg8
g9
sg10
I15
sg11
Vgram hemoglobin
p13086
sg13
I2
sasg14
(lp13087
(dp13088
g7
I170
sg17
VC0162316
p13089
sg10
I22
sg11
Viron deficiency anemia
p13090
sg13
I3
sasa(dp13091
g2
S'The content of CA-B synthesized in lysates was much higher than that of CA-C. 6 In iron deficiency anemia, the increase of erythrocyte CA is speculated to be compensatory mechanism, which brought about the transportation of CO2 and right shifts of O2 dissociation curve.\n'
p13092
sg4
(lp13093
sg14
(lp13094
(dp13095
g7
I83
sg17
VC0162316
p13096
sg10
I22
sg11
Viron deficiency anemia
p13097
sg13
I3
sa(dp13098
g7
I251
sg17
VC0086168
p13099
sg10
I12
sg11
Vdissociation
p13100
sg13
I1
sasa(dp13101
g2
S'Inhibition of inducible T-cell kinase (ITK), a nonreceptor tyrosine kinase, may represent a novel treatment for allergic asthma.\n'
p13102
sg4
(lp13103
(dp13104
g7
I39
sg8
VP19823
p13105
sg10
I3
sg11
VITK
p13106
sg13
I1
sa(dp13107
g7
I14
sg8
VP19823
p13108
sg10
I23
sg11
Vinducible T-cell kinase
p13109
sg13
I3
sasg14
(lp13110
(dp13111
g7
I112
sg17
VC0155877
p13112
sg10
I15
sg11
Vallergic asthma
p13113
sg13
I2
sasa(dp13114
g2
S'Here we show that Itk, a mediator of T cell receptor signalling required for Th2 immune responses and the development of asthma, is a positive regulator of Th9 differentiation.\n'
p13115
sg4
(lp13116
(dp13117
g7
I37
sg8
g9
sg10
I15
sg11
VT cell receptor
p13118
sg13
I3
sa(dp13119
g7
I18
sg8
VP19823
p13120
sg10
I3
sg11
VItk
p13121
sg13
I1
sasg14
(lp13122
(dp13123
g7
I121
sg17
VC0004096
p13124
sg10
I6
sg11
Vasthma
p13125
sg13
I1
sasa(dp13126
g2
S'Compared to wild-type mice, ITK knockout mice are resistant to asthma and exhibit reduced lung inflammation and decreased amounts of TH2-type cytokines in the bronchoalveolar lavage fluid.\n'
p13127
sg4
(lp13128
sg14
(lp13129
(dp13130
g7
I90
sg17
VC0032285
p13131
sg10
I17
sg11
Vlung inflammation
p13132
sg13
I2
sa(dp13133
g7
I63
sg17
VC0004096
p13134
sg10
I6
sg11
Vasthma
p13135
sg13
I1
sasa(dp13136
g2
S'Unexpectedly, inhibition of the kinase activity of ITK during or after antigen rechallenge in an ovalbumin-induced mouse model of asthma failed to reduce airway hyperresponsiveness and inflammation.\n'
p13137
sg4
(lp13138
(dp13139
g7
I51
sg8
VP19823
p13140
sg10
I3
sg11
VITK
p13141
sg13
I1
sasg14
(lp13142
(dp13143
g7
I130
sg17
VC0004096
p13144
sg10
I6
sg11
Vasthma
p13145
sg13
I1
sa(dp13146
g7
I185
sg17
VC0021368
p13147
sg10
I12
sg11
Vinflammation
p13148
sg13
I1
sasa(dp13149
g2
S'Thus, our studies predict that inhibition of the kinase activity of ITK may not be therapeutic in patients with asthma.\n'
p13150
sg4
(lp13151
(dp13152
g7
I68
sg8
VP19823
p13153
sg10
I3
sg11
VITK
p13154
sg13
I1
sasg14
(lp13155
(dp13156
g7
I112
sg17
VC0004096
p13157
sg10
I6
sg11
Vasthma
p13158
sg13
I1
sasa(dp13159
g2
S'FeNO levels were significantly elevated in the asthma compared to the control group (26 +/- 18 versus 11 +/- 4 ppb; p &lt; 0.05), and trended higher than levels in the tetraplegia group (15 +/- 6; p = 0.08).\n'
p13160
sg4
(lp13161
sg14
(lp13162
(dp13163
g7
I47
sg17
VC0004096
p13164
sg10
I6
sg11
Vasthma
p13165
sg13
I1
sa(dp13166
g7
I111
sg17
VC1266144
p13167
sg10
I3
sg11
Vppb
p13168
sg13
I1
sa(dp13169
g7
I168
sg17
VC0034372
p13170
sg10
I11
sg11
Vtetraplegia
p13171
sg13
I1
sasa(dp13172
g2
S'The medicinal chemistry community has directed considerable efforts toward the discovery of selective inhibitors of interleukin-2 inducible T-cell kinase (ITK), given its role in T-cell signaling downstream of the T-cell receptor (TCR) and the implications of this target for inflammatory disorders such as asthma.\n'
p13173
sg4
(lp13174
(dp13175
g7
I130
sg8
VP19823
p13176
sg10
I23
sg11
Vinducible T-cell kinase
p13177
sg13
I3
sa(dp13178
g7
I214
sg8
g9
sg10
I15
sg11
VT-cell receptor
p13179
sg13
I2
sa(dp13180
g7
I116
sg8
VP60568
p13181
sg10
I13
sg11
Vinterleukin-2
p13182
sg13
I1
sa(dp13183
g7
I231
sg8
g9
sg10
I3
sg11
VTCR
p13184
sg13
I1
sa(dp13185
g7
I155
sg8
VP19823
p13186
sg10
I3
sg11
VITK
p13187
sg13
I1
sasg14
(lp13188
(dp13189
g7
I307
sg17
VC0004096
p13190
sg10
I6
sg11
Vasthma
p13191
sg13
I1
sasa(dp13192
g2
S'The caspase-3 apoptotic index was a strong risk factor for subsequent gestational trophoblastic neoplasia development.\n'
p13193
sg4
(lp13194
(dp13195
g7
I4
sg8
VP42574
p13196
sg10
I9
sg11
Vcaspase-3
p13197
sg13
I1
sasg14
(lp13198
(dp13199
g7
I70
sg17
VC1135868
p13200
sg10
I35
sg11
Vgestational trophoblastic neoplasia
p13201
sg13
I3
sasa(dp13202
g2
S'The two genes were CXCL6 (chemokine (C-X-C motif) ligand 6) and BBS5 (Bardet-Biedl syndrome 5).\n'
p13203
sg4
(lp13204
(dp13205
g7
I19
sg8
VP80162
p13206
sg10
I5
sg11
VCXCL6
p13207
sg13
I1
sa(dp13208
g7
I64
sg8
g9
sg10
I4
sg11
VBBS5
p13209
sg13
I1
sa(dp13210
g7
I70
sg8
g9
sg10
I23
sg11
VBardet-Biedl syndrome 5
p13211
sg13
I3
sa(dp13212
g7
I36
sg8
VP80162
p13213
sg10
I22
sg11
V(C-X-C motif) ligand 6
p13214
sg13
I4
sasg14
(lp13215
(dp13216
g7
I70
sg17
VC0752166
p13217
sg10
I21
sg11
VBardet-Biedl syndrome
p13218
sg13
I2
sasa(dp13219
g2
S'Compared with patients with a false-positive penicillin allergy result (confirmed by negative penicillin skin testing result), patients reporting a true penicillin allergy confirmed by positive penicillin skin test results tended to be more frequently men (61.5% versus 44.5%; Delta 17.0%; 95% CI -13.5% to 42%), black (69.2% versus 44.5%; Delta 24.7%; 95% CI -6.9% to 46.8%), and have no family history of drug allergy (7.7% versus 17.5%; Delta9.8%; 95% CI -20.9% to 20.4%), but self-reported other drug allergies more frequently (61.5% versus 38.7%; Delta 22.9%; 95% CI -7.7% to 47.5%).\n'
p13220
sg4
(lp13221
sg14
(lp13222
(dp13223
g7
I407
sg17
VC0013182
p13224
sg10
I12
sg11
Vdrug allergy
p13225
sg13
I2
sa(dp13226
g7
I45
sg17
VC0030824
p13227
sg10
I18
sg11
Vpenicillin allergy
p13228
sg13
I2
sa(dp13229
g7
I45
sg17
VC0030824
p13230
sg10
I18
sg11
Vpenicillin allergy
p13231
sg13
I2
sa(dp13232
g7
I500
sg17
VC0013182
p13233
sg10
I14
sg11
Vdrug allergies
p13234
sg13
I2
sasa(dp13235
g2
S'We identified 12 biomarkers consistently associated with either clinical groups "upstream" towards culture-positive TB on the TB disease spectrum (CD14, FCGR1A, FPR1, MMP9, RAB24, SEC14L1, and TIMP2) or "downstream" towards a decreased likelihood of TB disease (BLR1, CD3E, CD8A, IL7R, and TGFBR2), suggesting a correlation with MTB-related pathology and high relevance to a future POC test for pediatric TB.\n'
p13236
sg4
(lp13237
(dp13238
g7
I147
sg8
VP08571
p13239
sg10
I4
sg11
VCD14
p13240
sg13
I1
sa(dp13241
g7
I173
sg8
g9
sg10
I5
sg11
VRAB24
p13242
sg13
I1
sa(dp13243
g7
I153
sg8
VP12314
p13244
sg10
I6
sg11
VFCGR1A
p13245
sg13
I1
sa(dp13246
g7
I268
sg8
VP07766
p13247
sg10
I4
sg11
VCD3E
p13248
sg13
I1
sa(dp13249
g7
I274
sg8
VP01732
p13250
sg10
I4
sg11
VCD8A
p13251
sg13
I1
sa(dp13252
g7
I262
sg8
VP32302
p13253
sg10
I4
sg11
VBLR1
p13254
sg13
I1
sa(dp13255
g7
I180
sg8
g9
sg10
I7
sg11
VSEC14L1
p13256
sg13
I1
sa(dp13257
g7
I167
sg8
VP14780
p13258
sg10
I4
sg11
VMMP9
p13259
sg13
I1
sa(dp13260
g7
I193
sg8
VP16035
p13261
sg10
I5
sg11
VTIMP2
p13262
sg13
I1
sa(dp13263
g7
I161
sg8
VP21462
p13264
sg10
I4
sg11
VFPR1
p13265
sg13
I1
sa(dp13266
g7
I290
sg8
VP37173
p13267
sg10
I6
sg11
VTGFBR2
p13268
sg13
I1
sasg14
(lp13269
(dp13270
g7
I341
sg17
VC0677042
p13271
sg10
I9
sg11
Vpathology
p13272
sg13
I1
sasa(dp13273
g2
S'However, aberrant expression of class III Beta-tubulin has been observed in passaged RPE cells and RPE cells with dedifferentiated morphology in pathologic epiretinal membranes from idiopathic macular pucker, proliferative vitreoretinopathy (PVR) and proliferative diabetic retinopathy (PDR).\n'
p13274
sg4
(lp13275
(dp13276
g7
I42
sg8
VP68371
p13277
sg10
I12
sg11
VBeta-tubulin
p13278
sg13
I1
sasg14
(lp13279
(dp13280
g7
I251
sg17
VC0154830
p13281
sg10
I34
sg11
Vproliferative diabetic retinopathy
p13282
sg13
I3
sa(dp13283
g7
I209
sg17
VC1860404
p13284
sg10
I31
sg11
Vproliferative vitreoretinopathy
p13285
sg13
I2
sa(dp13286
g7
I242
sg17
VC1860404
p13287
sg10
I3
sg11
VPVR
p13288
sg13
I1
sa(dp13289
g7
I287
sg17
VC0154830
p13290
sg10
I3
sg11
VPDR
p13291
sg13
I1
sa(dp13292
g7
I156
sg17
VC0339543
p13293
sg10
I20
sg11
Vepiretinal membranes
p13294
sg13
I2
sa(dp13295
g7
I193
sg17
VC0154853
p13296
sg10
I14
sg11
Vmacular pucker
p13297
sg13
I2
sasa(dp13298
g2
S'Disorders in the ability ofleukocytes to produce IFN-alpha and IFN-gamma were detected in patients with bronchial asthma and allergic rhinitis.\n'
p13299
sg4
(lp13300
(dp13301
g7
I63
sg8
VP01579
p13302
sg10
I9
sg11
VIFN-gamma
p13303
sg13
I1
sa(dp13304
g7
I49
sg8
VP01562
p13305
sg10
I9
sg11
VIFN-alpha
p13306
sg13
I1
sasg14
(lp13307
(dp13308
g7
I125
sg17
VC2607914
p13309
sg10
I17
sg11
Vallergic rhinitis
p13310
sg13
I2
sa(dp13311
g7
I104
sg17
VC0004096
p13312
sg10
I16
sg11
Vbronchial asthma
p13313
sg13
I2
sasa(dp13314
g2
S"Factors underlying the 'exacerbation-prone' phenotype are incompletely understood but include extrinsic factors: cigarette smoking, medication non-compliance, psychosocial factors, and co-morbidities such as gastroesophageal reflux disease, rhinosinusitis, obesity, and intolerance to non-steroidal anti-inflammatory medications; as well as intrinsic factors such as deficient epithelial cell production of the anti-viral type I interferons (IFN-alpha and IFN-beta).\n"
p13315
sg4
(lp13316
(dp13317
g7
I411
sg8
VP29475
p13318
sg10
I29
sg11
Vanti-viral type I interferons
p13319
sg13
I4
sa(dp13320
g7
I442
sg8
VP01562
p13321
sg10
I9
sg11
VIFN-alpha
p13322
sg13
I1
sa(dp13323
g7
I456
sg8
VP01574
p13324
sg10
I8
sg11
VIFN-beta
p13325
sg13
I1
sasg14
(lp13326
(dp13327
g7
I257
sg17
VC0028754
p13328
sg10
I7
sg11
Vobesity
p13329
sg13
I1
sa(dp13330
g7
I208
sg17
VC0017168
p13331
sg10
I31
sg11
Vgastroesophageal reflux disease
p13332
sg13
I3
sa(dp13333
g7
I241
sg17
VC0948780
p13334
sg10
I14
sg11
Vrhinosinusitis
p13335
sg13
I1
sasa(dp13336
g2
S'These data indicate that therapeutic strategies using SAHPs targeting CD36, but not necessarily mimicking all apolipoprotein A-I functions, may be considered a possible new treatment approach for inflammation-induced ALI and pulmonary edema.\n'
p13337
sg4
(lp13338
(dp13339
g7
I110
sg8
VP02647
p13340
sg10
I18
sg11
Vapolipoprotein A-I
p13341
sg13
I2
sasg14
(lp13342
(dp13343
g7
I196
sg17
VC0021368
p13344
sg10
I12
sg11
Vinflammation
p13345
sg13
I1
sa(dp13346
g7
I225
sg17
VC0034063
p13347
sg10
I15
sg11
Vpulmonary edema
p13348
sg13
I2
sasa(dp13349
g2
S"The enhanced expression of IL-17 that is observed in patients with Crohn's disease could act on intestinal fibroblasts to induce expression of transcription factor NFKBIZ and proinflammatory chemokine CXCL1.\n"
p13350
sg4
(lp13351
(dp13352
g7
I143
sg8
VP35398
p13353
sg10
I63
sg11
Vtranscription factor NFKBIZ and proinflammatory chemokine CXCL1
p13354
sg13
I7
sasg14
(lp13355
(dp13356
g7
I67
sg17
VC0010346
p13357
sg10
I15
sg11
VCrohn's disease
p13358
sg13
I2
sasa(dp13359
g2
S'In the majority of cases, autosomal dominant nonsyndromic hearing loss is postlingual and progressive, with the exception of hearing impairment in families in which the impairment is linked to DFNA3, DFNA8/12, and DFNA24, the novel locus described in this report.\n'
p13360
sg4
(lp13361
(dp13362
g7
I193
sg8
g9
sg10
I5
sg11
VDFNA3
p13363
sg13
I1
sa(dp13364
g7
I200
sg8
g9
sg10
I8
sg11
VDFNA8/12
p13365
sg13
I1
sasg14
(lp13366
(dp13367
g7
I214
sg17
VC1853451
p13368
sg10
I6
sg11
VDFNA24
p13369
sg13
I1
sa(dp13370
g7
I133
sg17
VC0684336
p13371
sg10
I10
sg11
Vimpairment
p13372
sg13
I1
sa(dp13373
g7
I58
sg17
VC0011053
p13374
sg10
I12
sg11
Vhearing loss
p13375
sg13
I2
sa(dp13376
g7
I200
sg17
VC1832187
p13377
sg10
I5
sg11
VDFNA8
p13378
sg13
I1
sa(dp13379
g7
I133
sg17
VC0684336
p13380
sg10
I10
sg11
Vimpairment
p13381
sg13
I1
sasa(dp13382
g2
S'The morphological similarity and resemblance of keratin 1, 10, and 14 profiles, and p63 and Beta-catenin expression between mixed epidermal and inner root sheath hybrid cysts and keratoacanthomas suggests that hybrid cysts progressed to keratoacanthomas, and the cells from infundibular cells to inner root sheath cells of the pilar segment seem to be the origin of rat keratoacanthomas.\n'
p13383
sg4
(lp13384
(dp13385
g7
I48
sg8
VP04264
p13386
sg10
I9
sg11
Vkeratin 1
p13387
sg13
I2
sa(dp13388
g7
I84
sg8
g9
sg10
I3
sg11
Vp63
p13389
sg13
I1
sa(dp13390
g7
I92
sg8
VP35222
p13391
sg10
I12
sg11
VBeta-catenin
p13392
sg13
I1
sasg14
(lp13393
(dp13394
g7
I179
sg17
VC0022572
p13395
sg10
I16
sg11
Vkeratoacanthomas
p13396
sg13
I1
sa(dp13397
g7
I179
sg17
VC0022572
p13398
sg10
I16
sg11
Vkeratoacanthomas
p13399
sg13
I1
sa(dp13400
g7
I169
sg17
VC0010709
p13401
sg10
I5
sg11
Vcysts
p13402
sg13
I1
sa(dp13403
g7
I179
sg17
VC0022572
p13404
sg10
I16
sg11
Vkeratoacanthomas
p13405
sg13
I1
sa(dp13406
g7
I169
sg17
VC0010709
p13407
sg10
I5
sg11
Vcysts
p13408
sg13
I1
sasa(dp13409
g2
S'UCDs include a spectrum of enzyme deficiencies, namely n-acetylglutamate synthase deficiency (NAGS), carbamoyl phosphate synthetase I deficiency (CPS1), ornithine transcarbamylase deficiency (OTC), argininosuccinate lyase deficiency (ASL), citrullinemia type I (ASS1), and argininemia (ARG).\n'
p13410
sg4
(lp13411
(dp13412
g7
I55
sg8
g9
sg10
I26
sg11
Vn-acetylglutamate synthase
p13413
sg13
I2
sa(dp13414
g7
I153
sg8
VP00480
p13415
sg10
I26
sg11
Vornithine transcarbamylase
p13416
sg13
I2
sa(dp13417
g7
I146
sg8
VP31327
p13418
sg10
I4
sg11
VCPS1
p13419
sg13
I1
sa(dp13420
g7
I101
sg8
VP31327
p13421
sg10
I32
sg11
Vcarbamoyl phosphate synthetase I
p13422
sg13
I4
sa(dp13423
g7
I262
sg8
VP00966
p13424
sg10
I4
sg11
VASS1
p13425
sg13
I1
sa(dp13426
g7
I240
sg8
VP00966
p13427
sg10
I20
sg11
Vcitrullinemia type I
p13428
sg13
I3
sa(dp13429
g7
I198
sg8
VP04424
p13430
sg10
I23
sg11
Vargininosuccinate lyase
p13431
sg13
I2
sasg14
(lp13432
(dp13433
g7
I153
sg17
VC0268542
p13434
sg10
I37
sg11
Vornithine transcarbamylase deficiency
p13435
sg13
I3
sa(dp13436
g7
I286
sg17
VC0268548
p13437
sg10
I3
sg11
VARG
p13438
sg13
I1
sa(dp13439
g7
I101
sg17
VC0751753
p13440
sg10
I43
sg11
Vcarbamoyl phosphate synthetase I deficiency
p13441
sg13
I5
sa(dp13442
g7
I240
sg17
VC0175683
p13443
sg10
I13
sg11
Vcitrullinemia
p13444
sg13
I1
sa(dp13445
g7
I55
sg17
VC0268543
p13446
sg10
I37
sg11
Vn-acetylglutamate synthase deficiency
p13447
sg13
I3
sa(dp13448
g7
I234
sg17
VC0268547
p13449
sg10
I3
sg11
VASL
p13450
sg13
I1
sa(dp13451
g7
I273
sg17
VC0268548
p13452
sg10
I11
sg11
Vargininemia
p13453
sg13
I1
sa(dp13454
g7
I94
sg17
VC0268543
p13455
sg10
I4
sg11
VNAGS
p13456
sg13
I1
sa(dp13457
g7
I198
sg17
VC0268547
p13458
sg10
I34
sg11
Vargininosuccinate lyase deficiency
p13459
sg13
I3
sa(dp13460
g7
I192
sg17
VC0268542
p13461
sg10
I3
sg11
VOTC
p13462
sg13
I1
sasa(dp13463
g2
S'Recovery was also associated with maternal obesity, and there was some ethnic variation - in the adjusted analysis indigenous (Orang Asal) Malaysians had lower odds of recovery.\n'
p13464
sg4
(lp13465
sg14
(lp13466
(dp13467
g7
I43
sg17
VC0028754
p13468
sg10
I7
sg11
Vobesity
p13469
sg13
I1
sasa(dp13470
g2
S'Argininosuccinic acid lyase (ASL) deficiency, caused by mutations in the ASL gene (OMIM: 608310) is a urea cycle disorder that has pleiotropic presentations.\n'
p13471
sg4
(lp13472
(dp13473
g7
I73
sg8
VP30566
p13474
sg10
I8
sg11
VASL gene
p13475
sg13
I2
sa(dp13476
g7
I29
sg8
VP30566
p13477
sg10
I3
sg11
VASL
p13478
sg13
I1
sa(dp13479
g7
I0
sg8
g9
sg10
I27
sg11
VArgininosuccinic acid lyase
p13480
sg13
I3
sasg14
(lp13481
(dp13482
g7
I102
sg17
VC0154246
p13483
sg10
I19
sg11
Vurea cycle disorder
p13484
sg13
I3
sasa(dp13485
g2
S'These include N-acetylglutamate synthase deficiency (NAGSD); Carbamyl phosphate synthetase 1 deficiency (CPS1D); Ornithine transcarbamylase deficiency (OTCD); Argininosuccinate synthetase deficiency (ASSD) (Citrullinemia); Argininosuccinate lyase deficiency (ASLD) (Argininosuccinic aciduria); Arginase deficiency (ARGD, Argininemia); Hyperornithinemia, hyperammonemia, homocitrullinuria (HHH) syndrome (or mitochondrial ornithine transporter 1 deficiency [ORNT1D]); and Citrullinemia type II (mitochondrial aspartate/glutamate carrier deficiency [CITRIN]).\n'
p13486
sg4
(lp13487
(dp13488
g7
I407
sg8
g9
sg10
I37
sg11
Vmitochondrial ornithine transporter 1
p13489
sg13
I4
sa(dp13490
g7
I61
sg8
g9
sg10
I31
sg11
VCarbamyl phosphate synthetase 1
p13491
sg13
I4
sa(dp13492
g7
I223
sg8
VP04424
p13493
sg10
I23
sg11
VArgininosuccinate lyase
p13494
sg13
I2
sa(dp13495
g7
I294
sg8
VP05089
p13496
sg10
I8
sg11
VArginase
p13497
sg13
I1
sa(dp13498
g7
I113
sg8
VP00480
p13499
sg10
I26
sg11
VOrnithine transcarbamylase
p13500
sg13
I2
sa(dp13501
g7
I159
sg8
VP00966
p13502
sg10
I28
sg11
VArgininosuccinate synthetase
p13503
sg13
I2
sa(dp13504
g7
I14
sg8
g9
sg10
I26
sg11
VN-acetylglutamate synthase
p13505
sg13
I2
sa(dp13506
g7
I494
sg8
g9
sg10
I61
sg11
Vmitochondrial aspartate/glutamate carrier deficiency [CITRIN]
p13507
sg13
I5
sasg14
(lp13508
(dp13509
g7
I389
sg17
VC0268540
p13510
sg10
I3
sg11
VHHH
p13511
sg13
I1
sa(dp13512
g7
I335
sg17
VC0599035
p13513
sg10
I17
sg11
VHyperornithinemia
p13514
sg13
I1
sa(dp13515
g7
I394
sg17
VC0039082
p13516
sg10
I8
sg11
Vsyndrome
p13517
sg13
I1
sa(dp13518
g7
I159
sg17
VC0175683
p13519
sg10
I39
sg11
VArgininosuccinate synthetase deficiency
p13520
sg13
I3
sa(dp13521
g7
I14
sg17
VC0268543
p13522
sg10
I37
sg11
VN-acetylglutamate synthase deficiency
p13523
sg13
I3
sa(dp13524
g7
I315
sg17
VC0268548
p13525
sg10
I4
sg11
VARGD
p13526
sg13
I1
sa(dp13527
g7
I223
sg17
VC0268547
p13528
sg10
I34
sg11
VArgininosuccinate lyase deficiency
p13529
sg13
I3
sa(dp13530
g7
I207
sg17
VC0175683
p13531
sg10
I13
sg11
VCitrullinemia
p13532
sg13
I1
sa(dp13533
g7
I152
sg17
VC0268542
p13534
sg10
I4
sg11
VOTCD
p13535
sg13
I1
sa(dp13536
g7
I53
sg17
VC0268543
p13537
sg10
I5
sg11
VNAGSD
p13538
sg13
I1
sa(dp13539
g7
I200
sg17
VC0175683
p13540
sg10
I4
sg11
VASSD
p13541
sg13
I1
sa(dp13542
g7
I259
sg17
VC0268547
p13543
sg10
I4
sg11
VASLD
p13544
sg13
I1
sa(dp13545
g7
I207
sg17
VC0175683
p13546
sg10
I13
sg11
VCitrullinemia
p13547
sg13
I1
sa(dp13548
g7
I321
sg17
VC0268548
p13549
sg10
I11
sg11
VArgininemia
p13550
sg13
I1
sa(dp13551
g7
I266
sg17
VC0268547
p13552
sg10
I25
sg11
VArgininosuccinic aciduria
p13553
sg13
I2
sa(dp13554
g7
I354
sg17
VC0220994
p13555
sg10
I14
sg11
Vhyperammonemia
p13556
sg13
I1
sa(dp13557
g7
I113
sg17
VC0268542
p13558
sg10
I37
sg11
VOrnithine transcarbamylase deficiency
p13559
sg13
I3
sa(dp13560
g7
I294
sg17
VC0268548
p13561
sg10
I19
sg11
VArginase deficiency
p13562
sg13
I2
sasa(dp13563
g2
S'Cardiomyopathy [methylmalonic (MMA) and propionic aciduria (PA)], prolonged QTc interval (PA), optic nerve atrophy [MMA, isovaleric aciduria (IVA)], pancytopenia (PA), and macrocephaly [glutaric aciduria type 1 (GA1)] were exclusively found in OAD patients, whereas hepatic involvement was more frequent in UCD patients, in particular in argininosuccinate lyase (ASL) deficiency.\n'
p13564
sg4
(lp13565
(dp13566
g7
I363
sg8
VP30566
p13567
sg10
I3
sg11
VASL
p13568
sg13
I1
sa(dp13569
g7
I338
sg8
VP04424
p13570
sg10
I23
sg11
Vargininosuccinate lyase
p13571
sg13
I2
sasg14
(lp13572
(dp13573
g7
I186
sg17
VC0268595
p13574
sg10
I24
sg11
Vglutaric aciduria type 1
p13575
sg13
I4
sa(dp13576
g7
I60
sg17
VC2717876
p13577
sg10
I2
sg11
VPA
p13578
sg13
I1
sa(dp13579
g7
I149
sg17
VC0030312
p13580
sg10
I12
sg11
Vpancytopenia
p13581
sg13
I1
sa(dp13582
g7
I121
sg17
VC0268575
p13583
sg10
I19
sg11
Visovaleric aciduria
p13584
sg13
I2
sa(dp13585
g7
I31
sg17
VC0276096
p13586
sg10
I3
sg11
VMMA
p13587
sg13
I1
sa(dp13588
g7
I60
sg17
VC2717876
p13589
sg10
I2
sg11
VPA
p13590
sg13
I1
sa(dp13591
g7
I0
sg17
VC0878544
p13592
sg10
I14
sg11
VCardiomyopathy
p13593
sg13
I1
sa(dp13594
g7
I95
sg17
VC0029124
p13595
sg10
I19
sg11
Voptic nerve atrophy
p13596
sg13
I3
sa(dp13597
g7
I40
sg17
VC2717876
p13598
sg10
I18
sg11
Vpropionic aciduria
p13599
sg13
I2
sa(dp13600
g7
I60
sg17
VC2717876
p13601
sg10
I2
sg11
VPA
p13602
sg13
I1
sa(dp13603
g7
I172
sg17
VC0221355
p13604
sg10
I12
sg11
Vmacrocephaly
p13605
sg13
I1
sa(dp13606
g7
I15
sg17
VC0276096
p13607
sg10
I14
sg11
V[methylmalonic
p13608
sg13
I1
sa(dp13609
g7
I31
sg17
VC0276096
p13610
sg10
I3
sg11
VMMA
p13611
sg13
I1
sa(dp13612
g7
I66
sg17
VC1560305
p13613
sg10
I22
sg11
Vprolonged QTc interval
p13614
sg13
I3
sa(dp13615
g7
I142
sg17
VC0268575
p13616
sg10
I3
sg11
VIVA
p13617
sg13
I1
sasa(dp13618
g2
S'Fifteen patients (8 argininosuccinate lyase deficiency, 3 argininosuccinic acid synthetase deficiency, 3 ornithine transcarbamylase deficiency, 1 arginase deficiency) ages 2 months through 5 years enrolled in and completed the study.\n'
p13619
sg4
(lp13620
(dp13621
g7
I58
sg8
g9
sg10
I32
sg11
Vargininosuccinic acid synthetase
p13622
sg13
I3
sa(dp13623
g7
I20
sg8
VP04424
p13624
sg10
I23
sg11
Vargininosuccinate lyase
p13625
sg13
I2
sa(dp13626
g7
I103
sg8
VP00480
p13627
sg10
I51
sg11
V3 ornithine transcarbamylase deficiency, 1 arginase
p13628
sg13
I6
sasg14
(lp13629
(dp13630
g7
I105
sg17
VC0268542
p13631
sg10
I37
sg11
Vornithine transcarbamylase deficiency
p13632
sg13
I3
sa(dp13633
g7
I146
sg17
VC0268548
p13634
sg10
I19
sg11
Varginase deficiency
p13635
sg13
I2
sa(dp13636
g7
I58
sg17
VC0175683
p13637
sg10
I43
sg11
Vargininosuccinic acid synthetase deficiency
p13638
sg13
I4
sa(dp13639
g7
I20
sg17
VC0268547
p13640
sg10
I34
sg11
Vargininosuccinate lyase deficiency
p13641
sg13
I3
sasa(dp13642
g2
S'The 20 genes with at least a 3-fold change, annotated with known phenotypic associations in the current gene databank (phenotype association, fold change) were aspartoacylase (Canavan disease, 9.96), growth hormone receptor (Laron dwarfism, idiopathic short stature, 8.25), lipoprotein lipase (familial chylomicronemia syndrome, lipoprotein lipase deficiency, 8.00), vitamin D (1,25- dihydroxyvitamin D3) receptor (involutional osteoporosis, vitamin D resistant rickets, 7.94), intercellular adhesion molecule 1 human rhinovirus receptor (cerebral malaria susceptibility, 7.16), peroxisomal membrane protein 3 35-kDa (Refsum disease, infantile form, Zellweger syndrome-3, 6.00), Bardet-Biedl syndrome 2 (Bardet-Biedl syndrome, 5.87), ribosomal protein S19 (Diamond Blackfan anemia, 5.85), apolipoprotein C-III (hypertriglyceridemia, 5.44), argininosuccinate lyase (argininosuccinicaciduria, 5.22), myosin VA (Griscelli syndrome-type pigmentary dilution with mental retardation, 4.92), lysozyme (renal amyloidosis, 4.17), SAM domain, SH3 domain and nuclear localisation signals 1 (Cherubism, 4.12 ), von Hippel-Lindau syndrome (hemangioblastoma, cerebellar, somatic, von Hippel-Lindau syndrome, 3.94), early-onset breast cancer 1 (BRCA1, papillary serous carcinoma of the peritoneum, 3.73), UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase (inclusion body myopathy, autosomal recessive, sialuria, 3.53), apolipoprotein A-I (amyloidosis, 3 or more types, hypoalphalipoproteinemia, 3.29), midline 1 Opitz/BBB syndrome (Opitz G syndrome, type I, 3.28), ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide (familial hemiplegic migraine, 3.05).\n'
p13643
sg4
(lp13644
(dp13645
g7
I789
sg8
VP02656
p13646
sg10
I20
sg11
Vapolipoprotein C-III
p13647
sg13
I2
sa(dp13648
g7
I274
sg8
VP06858
p13649
sg10
I18
sg11
Vlipoprotein lipase
p13650
sg13
I2
sa(dp13651
g7
I898
sg8
g9
sg10
I9
sg11
Vmyosin VA
p13652
sg13
I2
sa(dp13653
g7
I274
sg8
VP06858
p13654
sg10
I18
sg11
Vlipoprotein lipase
p13655
sg13
I2
sa(dp13656
g7
I1201
sg8
VP38398
p13657
sg10
I27
sg11
Vearly-onset breast cancer 1
p13658
sg13
I4
sa(dp13659
g7
I865
sg8
VP04424
p13660
sg10
I30
sg11
Vargininosuccinicaciduria, 5.22
p13661
sg13
I2
sa(dp13662
g7
I985
sg8
VP61626
p13663
sg10
I8
sg11
Vlysozyme
p13664
sg13
I1
sa(dp13665
g7
I1417
sg8
VP02647
p13666
sg10
I18
sg11
Vapolipoprotein A-I
p13667
sg13
I2
sa(dp13668
g7
I840
sg8
VP04424
p13669
sg10
I23
sg11
Vargininosuccinate lyase
p13670
sg13
I2
sa(dp13671
g7
I200
sg8
VP10912
p13672
sg10
I23
sg11
Vgrowth hormone receptor
p13673
sg13
I3
sa(dp13674
g7
I478
sg8
VP05362
p13675
sg10
I59
sg11
Vintercellular adhesion molecule 1 human rhinovirus receptor
p13676
sg13
I7
sa(dp13677
g7
I734
sg8
VP39019
p13678
sg10
I21
sg11
Vribosomal protein S19
p13679
sg13
I3
sa(dp13680
g7
I1021
sg8
g9
sg10
I10
sg11
VSAM domain
p13681
sg13
I2
sa(dp13682
g7
I1230
sg8
VP38398
p13683
sg10
I5
sg11
VBRCA1
p13684
sg13
I1
sa(dp13685
g7
I1563
sg8
VP38606
p13686
sg10
I6
sg11
VATPase
p13687
sg13
I1
sa(dp13688
g7
I160
sg8
VP45381
p13689
sg10
I14
sg11
Vaspartoacylase
p13690
sg13
I1
sasg14
(lp13691
(dp13692
g7
I492
sg17
VC0001511
p13693
sg10
I8
sg11
Vadhesion
p13694
sg13
I1
sa(dp13695
g7
I225
sg17
VC0271568
p13696
sg10
I14
sg11
VLaron dwarfism
p13697
sg13
I2
sa(dp13698
g7
I1237
sg17
VC0334359
p13699
sg10
I26
sg11
Vpapillary serous carcinoma
p13700
sg13
I3
sa(dp13701
g7
I995
sg17
VC0268382
p13702
sg10
I17
sg11
Vrenal amyloidosis
p13703
sg13
I2
sa(dp13704
g7
I865
sg17
VC0268547
p13705
sg10
I24
sg11
Vargininosuccinicaciduria
p13706
sg13
I1
sa(dp13707
g7
I303
sg17
VC1274228
p13708
sg10
I24
sg11
Vchylomicronemia syndrome
p13709
sg13
I2
sa(dp13710
g7
I757
sg17
VC1260899
p13711
sg10
I23
sg11
VDiamond Blackfan anemia
p13712
sg13
I3
sa(dp13713
g7
I176
sg17
VC0206307
p13714
sg10
I15
sg11
VCanavan disease
p13715
sg13
I2
sa(dp13716
g7
I442
sg17
VC2363065
p13717
sg10
I27
sg11
Vvitamin D resistant rickets
p13718
sg13
I4
sa(dp13719
g7
I958
sg17
VC0025362
p13720
sg10
I18
sg11
Vmental retardation
p13721
sg13
I2
sa(dp13722
g7
I329
sg17
VC0023817
p13723
sg10
I29
sg11
Vlipoprotein lipase deficiency
p13724
sg13
I3
sa(dp13725
g7
I539
sg17
VC0024534
p13726
sg10
I16
sg11
Vcerebral malaria
p13727
sg13
I2
sa(dp13728
g7
I679
sg17
VC2936863
p13729
sg10
I23
sg11
VBardet-Biedl syndrome 2
p13730
sg13
I3
sa(dp13731
g7
I1099
sg17
VC0019562
p13732
sg10
I26
sg11
Vvon Hippel-Lindau syndrome
p13733
sg13
I3
sa(dp13734
g7
I1080
sg17
VC0008029
p13735
sg10
I9
sg11
VCherubism
p13736
sg13
I1
sa(dp13737
g7
I1400
sg17
VC0342853
p13738
sg10
I8
sg11
Vsialuria
p13739
sg13
I1
sa(dp13740
g7
I241
sg17
VC1740819
p13741
sg10
I24
sg11
Vidiopathic short stature
p13742
sg13
I3
sa(dp13743
g7
I1099
sg17
VC0019562
p13744
sg10
I26
sg11
Vvon Hippel-Lindau syndrome
p13745
sg13
I3
sa(dp13746
g7
I1213
sg17
VC0678222
p13747
sg10
I13
sg11
Vbreast cancer
p13748
sg13
I2
sa(dp13749
g7
I319
sg17
VC0039082
p13750
sg10
I8
sg11
Vsyndrome
p13751
sg13
I1
sa(dp13752
g7
I618
sg17
VC0282527
p13753
sg10
I30
sg11
VRefsum disease, infantile form
p13754
sg13
I4
sa(dp13755
g7
I1127
sg17
VC0206734
p13756
sg10
I16
sg11
Vhemangioblastoma
p13757
sg13
I1
sa(dp13758
g7
I1536
sg17
VC2936904
p13759
sg10
I10
sg11
VG syndrome
p13760
sg13
I2
sa(dp13761
g7
I650
sg17
VC0043459
p13762
sg10
I18
sg11
VZellweger syndrome
p13763
sg13
I2
sa(dp13764
g7
I1021
sg17
VC1563296
p13765
sg10
I3
sg11
VSAM
p13766
sg13
I1
sa(dp13767
g7
I415
sg17
VC0029459
p13768
sg10
I25
sg11
Vinvolutional osteoporosis
p13769
sg13
I2
sa(dp13770
g7
I1354
sg17
VC1833373
p13771
sg10
I44
sg11
Vinclusion body myopathy, autosomal recessive
p13772
sg13
I5
sa(dp13773
g7
I679
sg17
VC0752166
p13774
sg10
I21
sg11
VBardet-Biedl syndrome
p13775
sg13
I2
sa(dp13776
g7
I1617
sg17
VC0338484
p13777
sg10
I28
sg11
Vfamilial hemiplegic migraine
p13778
sg13
I3
sa(dp13779
g7
I1001
sg17
VC0002726
p13780
sg10
I11
sg11
Vamyloidosis
p13781
sg13
I1
sa(dp13782
g7
I1516
sg17
VC2936904
p13783
sg10
I12
sg11
VBBB syndrome
p13784
sg13
I2
sasa(dp13785
g2
S'Thirteen families were investigated, of which two were affected by N-acetylglutamate synthase deficiency, four by carbamoylphosphate synthetase 1 deficiency, one by ornithine transcarbamylase deficiency, three by argininosuccinate synthetase deficiency, two by argininosuccinate lyase deficiency, and one by arginase deficiency.\n'
p13786
sg4
(lp13787
(dp13788
g7
I67
sg8
g9
sg10
I26
sg11
VN-acetylglutamate synthase
p13789
sg13
I2
sa(dp13790
g7
I261
sg8
VP04424
p13791
sg10
I23
sg11
Vargininosuccinate lyase
p13792
sg13
I2
sa(dp13793
g7
I213
sg8
VP00966
p13794
sg10
I28
sg11
Vargininosuccinate synthetase
p13795
sg13
I2
sa(dp13796
g7
I308
sg8
VP05089
p13797
sg10
I8
sg11
Varginase
p13798
sg13
I1
sa(dp13799
g7
I114
sg8
VP31327
p13800
sg10
I31
sg11
Vcarbamoylphosphate synthetase 1
p13801
sg13
I3
sa(dp13802
g7
I165
sg8
VP00480
p13803
sg10
I26
sg11
Vornithine transcarbamylase
p13804
sg13
I2
sasg14
(lp13805
(dp13806
g7
I213
sg17
VC0175683
p13807
sg10
I39
sg11
Vargininosuccinate synthetase deficiency
p13808
sg13
I3
sa(dp13809
g7
I308
sg17
VC0268548
p13810
sg10
I19
sg11
Varginase deficiency
p13811
sg13
I2
sa(dp13812
g7
I165
sg17
VC0268542
p13813
sg10
I37
sg11
Vornithine transcarbamylase deficiency
p13814
sg13
I3
sa(dp13815
g7
I67
sg17
VC0268543
p13816
sg10
I37
sg11
VN-acetylglutamate synthase deficiency
p13817
sg13
I3
sa(dp13818
g7
I261
sg17
VC0268547
p13819
sg10
I34
sg11
Vargininosuccinate lyase deficiency
p13820
sg13
I3
sasa(dp13821
g2
S'In this study, we examined the relationship between the lactic acid concentration and expression of LDHA and GLUT1, which are related to the Warburg effect, in human head and neck squamous cell carcinoma (HNSCC).\n'
p13822
sg4
(lp13823
(dp13824
g7
I100
sg8
VP00338
p13825
sg10
I4
sg11
VLDHA
p13826
sg13
I1
sa(dp13827
g7
I109
sg8
VP11166
p13828
sg10
I5
sg11
VGLUT1
p13829
sg13
I1
sasg14
(lp13830
(dp13831
g7
I141
sg17
VC1520120
p13832
sg10
I14
sg11
VWarburg effect
p13833
sg13
I2
sa(dp13834
g7
I205
sg17
VC1168401
p13835
sg10
I5
sg11
VHNSCC
p13836
sg13
I1
sa(dp13837
g7
I166
sg17
VC1168401
p13838
sg10
I37
sg11
Vhead and neck squamous cell carcinoma
p13839
sg13
I6
sasa(dp13840
g2
S'We found that cetuximab downregulated lactate dehydrogenase A (LDH-A) and inhibited glycolysis in cetuximab-sensitive head and neck squamous cell carcinoma (HNSCC) cells in an HIF-1Alfa downregulation-dependent manner.\n'
p13841
sg4
(lp13842
(dp13843
g7
I38
sg8
VP49366
p13844
sg10
I23
sg11
Vlactate dehydrogenase A
p13845
sg13
I3
sa(dp13846
g7
I63
sg8
VP00338
p13847
sg10
I5
sg11
VLDH-A
p13848
sg13
I1
sasg14
(lp13849
(dp13850
g7
I157
sg17
VC1168401
p13851
sg10
I5
sg11
VHNSCC
p13852
sg13
I1
sa(dp13853
g7
I118
sg17
VC1168401
p13854
sg10
I37
sg11
Vhead and neck squamous cell carcinoma
p13855
sg13
I6
sasa(dp13856
g2
S'An Australian cohort of 252 unrelated familial hypertrophic cardiomyopathy patients were screened for mutations in the Ca(2+) regulatory genes, sorcin (SRI), calstabin (FKBP1B), calsequestrin (CASQ2), phospholamban (PLN), sarcolipin (SLN), calreticulin (CALR3) and calmodulin (CALM).\n'
p13857
sg4
(lp13858
(dp13859
g7
I277
sg8
g9
sg10
I4
sg11
VCALM
p13860
sg13
I1
sa(dp13861
g7
I169
sg8
VP68106
p13862
sg10
I6
sg11
VFKBP1B
p13863
sg13
I1
sa(dp13864
g7
I265
sg8
g9
sg10
I10
sg11
Vcalmodulin
p13865
sg13
I1
sa(dp13866
g7
I240
sg8
VP27797
p13867
sg10
I20
sg11
Vcalreticulin (CALR3)
p13868
sg13
I2
sa(dp13869
g7
I178
sg8
VP31415
p13870
sg10
I13
sg11
Vcalsequestrin
p13871
sg13
I1
sa(dp13872
g7
I222
sg8
g9
sg10
I10
sg11
Vsarcolipin
p13873
sg13
I1
sa(dp13874
g7
I193
sg8
g9
sg10
I5
sg11
VCASQ2
p13875
sg13
I1
sa(dp13876
g7
I234
sg8
g9
sg10
I3
sg11
VSLN
p13877
sg13
I1
sa(dp13878
g7
I144
sg8
VP30626
p13879
sg10
I12
sg11
Vsorcin (SRI)
p13880
sg13
I2
sa(dp13881
g7
I119
sg8
VP01893
p13882
sg10
I23
sg11
VCa(2+) regulatory genes
p13883
sg13
I3
sasg14
(lp13884
(dp13885
g7
I38
sg17
VC0949658
p13886
sg10
I36
sg11
Vfamilial hypertrophic cardiomyopathy
p13887
sg13
I3
sasa(dp13888
g2
S'The validated proteins contain the clinically used hepatocellular carcinoma (HCC) biomarker alpha-fetoprotein (AFP) and the reported biomarker candidates Heat shock protein HSP 90-beta (HSP90), fatty acid-binding protein, epidermal (FABP5) and alcohol dehydrogenase 4 (ADH4), which demonstrated the robustness of the strategy.\n'
p13889
sg4
(lp13890
(dp13891
g7
I269
sg8
VP40394
p13892
sg10
I4
sg11
VADH4
p13893
sg13
I1
sa(dp13894
g7
I111
sg8
VP02771
p13895
sg10
I3
sg11
VAFP
p13896
sg13
I1
sa(dp13897
g7
I194
sg8
VP00505
p13898
sg10
I26
sg11
Vfatty acid-binding protein
p13899
sg13
I3
sa(dp13900
g7
I173
sg8
g9
sg10
I11
sg11
VHSP 90-beta
p13901
sg13
I2
sa(dp13902
g7
I222
sg8
VP08319
p13903
sg10
I45
sg11
Vepidermal (FABP5) and alcohol dehydrogenase 4
p13904
sg13
I6
sa(dp13905
g7
I92
sg8
VP02771
p13906
sg10
I17
sg11
Valpha-fetoprotein
p13907
sg13
I1
sa(dp13908
g7
I186
sg8
VP07900
p13909
sg10
I5
sg11
VHSP90
p13910
sg13
I1
sasg14
(lp13911
(dp13912
g7
I77
sg17
VC2239176
p13913
sg10
I3
sg11
VHCC
p13914
sg13
I1
sa(dp13915
g7
I51
sg17
VC2239176
p13916
sg10
I24
sg11
Vhepatocellular carcinoma
p13917
sg13
I2
sa(dp13918
g7
I173
sg17
VC0034152
p13919
sg10
I3
sg11
VHSP
p13920
sg13
I1
sasa(dp13921
g2
S'In vivo, Hsp90Beta promoted VEGFRs and CD31 expression in human hepatocellular carcinoma tumor xenografts and was associated with increased tumor microvessel density.\n'
p13922
sg4
(lp13923
(dp13924
g7
I28
sg8
VP35968
p13925
sg10
I6
sg11
VVEGFRs
p13926
sg13
I1
sa(dp13927
g7
I39
sg8
VP69905
p13928
sg10
I4
sg11
VCD31
p13929
sg13
I1
sa(dp13930
g7
I9
sg8
VP08238
p13931
sg10
I9
sg11
VHsp90Beta
p13932
sg13
I1
sasg14
(lp13933
(dp13934
g7
I89
sg17
VC0027651
p13935
sg10
I5
sg11
Vtumor
p13936
sg13
I1
sa(dp13937
g7
I64
sg17
VC1512411
p13938
sg10
I24
sg11
Vhepatocellular carcinoma
p13939
sg13
I2
sa(dp13940
g7
I89
sg17
VC0027651
p13941
sg10
I5
sg11
Vtumor
p13942
sg13
I1
sasa(dp13943
g2
S'In this study we report an apparent synergy between TGF-Beta1 and Hsp90Beta in stimulating migratory behaviour of colon cancer cells when signalling occurs via AlfavBeta6 integrin as opposed to the canonical TGF-Beta1 pathway.\n'
p13944
sg4
(lp13945
(dp13946
g7
I52
sg8
VP01137
p13947
sg10
I9
sg11
VTGF-Beta1
p13948
sg13
I1
sa(dp13949
g7
I52
sg8
VP01137
p13950
sg10
I23
sg11
VTGF-Beta1 and Hsp90Beta
p13951
sg13
I3
sasg14
(lp13952
(dp13953
g7
I114
sg17
VC0699790
p13954
sg10
I12
sg11
Vcolon cancer
p13955
sg13
I2
sasa(dp13956
g2
S'Our findings indicate that the C allele of the novel colorectal cancer-associated variant rs2282151 is associated with increased expression levels of HSP90AB1, which is expressed higher in colorectal tumor tissues than in normal tissues.\n'
p13957
sg4
(lp13958
(dp13959
g7
I150
sg8
VP08238
p13960
sg10
I8
sg11
VHSP90AB1
p13961
sg13
I1
sa(dp13962
g7
I53
sg8
VP31749
p13963
sg10
I46
sg11
Vcolorectal cancer-associated variant rs2282151
p13964
sg13
I4
sasg14
(lp13965
(dp13966
g7
I53
sg17
VC1527249
p13967
sg10
I17
sg11
Vcolorectal cancer
p13968
sg13
I2
sa(dp13969
g7
I189
sg17
VC0009404
p13970
sg10
I16
sg11
Vcolorectal tumor
p13971
sg13
I2
sasa(dp13972
g2
S'Bortezomib induced internalization and degradation of c-KIT by binding c-KIT to Cbl, an E3 ubiquitin-protein ligase, and the subsequent release of Apaf-1, which was originally bound to the c-KIT-Hsp90Beta-Apaf-1 complex, induced primary apoptosis in GIST-T1 cells.\n'
p13973
sg4
(lp13974
(dp13975
g7
I54
sg8
VP10721
p13976
sg10
I5
sg11
Vc-KIT
p13977
sg13
I1
sa(dp13978
g7
I189
sg8
VP10721
p13979
sg10
I15
sg11
Vc-KIT-Hsp90Beta
p13980
sg13
I1
sa(dp13981
g7
I91
sg8
VP49427
p13982
sg10
I24
sg11
Vubiquitin-protein ligase
p13983
sg13
I2
sa(dp13984
g7
I80
sg8
VP22681
p13985
sg10
I3
sg11
VCbl
p13986
sg13
I1
sa(dp13987
g7
I54
sg8
VP10721
p13988
sg10
I5
sg11
Vc-KIT
p13989
sg13
I1
sasg14
(lp13990
(dp13991
g7
I250
sg17
VC1847319
p13992
sg10
I4
sg11
VGIST
p13993
sg13
I1
sasa(dp13994
g2
S'Both Annexin A1 and HSP90Beta were GlcNAcylated, and their protein expressions were elevated in colon cancer, compared to normal tissues.\n'
p13995
sg4
(lp13996
(dp13997
g7
I5
sg8
VP04083
p13998
sg10
I10
sg11
VAnnexin A1
p13999
sg13
I2
sa(dp14000
g7
I20
sg8
VP08238
p14001
sg10
I9
sg11
VHSP90Beta
p14002
sg13
I1
sasg14
(lp14003
(dp14004
g7
I96
sg17
VC0699790
p14005
sg10
I12
sg11
Vcolon cancer
p14006
sg13
I2
sasa(dp14007
g2
S'Moreover, specific changes of GlcNAc abundances in Annexin A1 and HSP90Beta suggested that tumor-specific glycan patterns could serve as candidate biomarkers of colon cancer for distinguishing cancer patients from healthy individuals.\n'
p14008
sg4
(lp14009
(dp14010
g7
I66
sg8
VP08238
p14011
sg10
I9
sg11
VHSP90Beta
p14012
sg13
I1
sa(dp14013
g7
I51
sg8
VP04083
p14014
sg10
I10
sg11
VAnnexin A1
p14015
sg13
I2
sasg14
(lp14016
(dp14017
g7
I91
sg17
VC0027651
p14018
sg10
I5
sg11
Vtumor
p14019
sg13
I1
sa(dp14020
g7
I167
sg17
VC0006826
p14021
sg10
I6
sg11
Vcancer
p14022
sg13
I1
sa(dp14023
g7
I161
sg17
VC0699790
p14024
sg10
I12
sg11
Vcolon cancer
p14025
sg13
I2
sasa(dp14026
g2
S'In addition, the knockdown of PEPCK, which is the rate-limiting enzyme for gluconeogenesis, led to a reduction in glucose production in rat hepatoma H4IIEC3 cells.\n'
p14027
sg4
(lp14028
(dp14029
g7
I30
sg8
VP35558
p14030
sg10
I5
sg11
VPEPCK
p14031
sg13
I1
sasg14
(lp14032
(dp14033
g7
I140
sg17
VC0023903
p14034
sg10
I8
sg11
Vhepatoma
p14035
sg13
I1
sasa(dp14036
g2
S'We recently reported expression of the chemokine receptors CXC chemokine receptor 3 (CXCR3) and CC chemokine receptor 4 (CCR4) in adult T-cell leukemia/lymphoma and showed a preferential expression of CCR4 and its association with an unfavorable outcome.\n'
p14037
sg4
(lp14038
(dp14039
g7
I39
sg8
VP55773
p14040
sg10
I44
sg11
Vchemokine receptors CXC chemokine receptor 3
p14041
sg13
I6
sa(dp14042
g7
I96
sg8
g9
sg10
I23
sg11
VCC chemokine receptor 4
p14043
sg13
I4
sa(dp14044
g7
I121
sg8
VP51679
p14045
sg10
I4
sg11
VCCR4
p14046
sg13
I1
sa(dp14047
g7
I85
sg8
VP49682
p14048
sg10
I5
sg11
VCXCR3
p14049
sg13
I1
sa(dp14050
g7
I121
sg8
VP51679
p14051
sg10
I4
sg11
VCCR4
p14052
sg13
I1
sasg14
(lp14053
(dp14054
g7
I130
sg17
VC0023493
p14055
sg10
I30
sg11
Vadult T-cell leukemia/lymphoma
p14056
sg13
I3
sasa(dp14057
g2
S'We present a review of the current knowledge on cellular metabolism in non-cancerous and cancerous thyroid tissues, focusing on the monocarboxylate transporters MCT1 and MCT4, and on a transporter of the outer mitochondrial membrane TOMM20.\n'
p14058
sg4
(lp14059
(dp14060
g7
I132
sg8
VP23946
p14061
sg10
I33
sg11
Vmonocarboxylate transporters MCT1
p14062
sg13
I3
sa(dp14063
g7
I204
sg8
g9
sg10
I35
sg11
Vouter mitochondrial membrane TOMM20
p14064
sg13
I4
sa(dp14065
g7
I170
sg8
g9
sg10
I4
sg11
VMCT4
p14066
sg13
I1
sasg14
(lp14067
sa(dp14068
g2
S'Papillary thyroid cancer and FA thyrocytes had high staining for TOMM20 compared to NCT and nodular goiter (NG) (P &lt; 0.01).\n'
p14069
sg4
(lp14070
(dp14071
g7
I65
sg8
g9
sg10
I6
sg11
VTOMM20
p14072
sg13
I1
sasg14
(lp14073
(dp14074
g7
I0
sg17
VC0238463
p14075
sg10
I24
sg11
VPapillary thyroid cancer
p14076
sg13
I3
sa(dp14077
g7
I108
sg17
VC1318500
p14078
sg10
I2
sg11
VNG
p14079
sg13
I1
sa(dp14080
g7
I92
sg17
VC1318500
p14081
sg10
I14
sg11
Vnodular goiter
p14082
sg13
I2
sasa(dp14083
g2
S'Staining patterns of MCT1 and TOMM20 in 35 human thyroid samples (15 ATC, 12 papillary thyroid cancer [PTC], and eight non-cancerous thyroid) and nine ATC mouse orthotopic xenografts were assessed by visual and Aperio digital scoring.\n'
p14084
sg4
(lp14085
(dp14086
g7
I21
sg8
VP23946
p14087
sg10
I15
sg11
VMCT1 and TOMM20
p14088
sg13
I3
sasg14
(lp14089
(dp14090
g7
I77
sg17
VC0238463
p14091
sg10
I24
sg11
Vpapillary thyroid cancer
p14092
sg13
I3
sa(dp14093
g7
I103
sg17
VC0238463
p14094
sg10
I3
sg11
VPTC
p14095
sg13
I1
sasa(dp14096
g2
S'TOMM20 is also highly expressed in both ATC and PTC compared to non-cancerous thyroid tissue (P&lt;.01 for both).\n'
p14097
sg4
(lp14098
(dp14099
g7
I0
sg8
g9
sg10
I6
sg11
VTOMM20
p14100
sg13
I1
sasg14
(lp14101
(dp14102
g7
I48
sg17
VC0238463
p14103
sg10
I3
sg11
VPTC
p14104
sg13
I1
sasa(dp14105
g2
S'High MCT1 and TOMM20 expression is also found in ATC mouse xenograft tumors compared to non-cancerous thyroid tissue (P&lt;.001).\n'
p14106
sg4
(lp14107
(dp14108
g7
I5
sg8
VP23946
p14109
sg10
I4
sg11
VMCT1
p14110
sg13
I1
sa(dp14111
g7
I14
sg8
g9
sg10
I6
sg11
VTOMM20
p14112
sg13
I1
sasg14
(lp14113
(dp14114
g7
I69
sg17
VC0027651
p14115
sg10
I6
sg11
Vtumors
p14116
sg13
I1
sasa(dp14117
g2
S'ATC has metabolic features that distinguish it from PTC and non-cancerous thyroid tissue, including high expression of MCT1 and TOMM20.\n'
p14118
sg4
(lp14119
(dp14120
g7
I128
sg8
g9
sg10
I6
sg11
VTOMM20
p14121
sg13
I1
sa(dp14122
g7
I119
sg8
VP23946
p14123
sg10
I4
sg11
VMCT1
p14124
sg13
I1
sasg14
(lp14125
(dp14126
g7
I52
sg17
VC0238463
p14127
sg10
I3
sg11
VPTC
p14128
sg13
I1
sasa(dp14129
g2
S'PTC has low expression of MCT1 and non-cancerous thyroid tissue has low expression of both MCT1 and TOMM20.\n'
p14130
sg4
(lp14131
(dp14132
g7
I100
sg8
g9
sg10
I6
sg11
VTOMM20
p14133
sg13
I1
sa(dp14134
g7
I26
sg8
VP23946
p14135
sg10
I4
sg11
VMCT1
p14136
sg13
I1
sa(dp14137
g7
I26
sg8
VP23946
p14138
sg10
I4
sg11
VMCT1
p14139
sg13
I1
sa(dp14140
g7
I0
sg8
g9
sg10
I3
sg11
VPTC
p14141
sg13
I1
sasg14
(lp14142
(dp14143
g7
I0
sg17
VC0238463
p14144
sg10
I3
sg11
VPTC
p14145
sg13
I1
sasa(dp14146
g2
S'AM can induce a metastatic phenotype in prostate cancer cells through its action on TRPV2 calcium channels and is also capable of influencing localised levels of RANKL in the bone to favour tumourigenesis.\n'
p14147
sg4
(lp14148
(dp14149
g7
I84
sg8
g9
sg10
I22
sg11
VTRPV2 calcium channels
p14150
sg13
I3
sa(dp14151
g7
I162
sg8
g9
sg10
I5
sg11
VRANKL
p14152
sg13
I1
sasg14
(lp14153
(dp14154
g7
I40
sg17
VC0600139
p14155
sg10
I15
sg11
Vprostate cancer
p14156
sg13
I2
sasa(dp14157
g2
S'To determine the profiles of soluble cytokine receptors and cytokines, including mostly their ligands, in the vitreous humor of patients with B-cell vitreoretinal lymphoma (VRL) and uveitis.\n'
p14158
sg4
(lp14159
sg14
(lp14160
(dp14161
g7
I163
sg17
VC0024299
p14162
sg10
I8
sg11
Vlymphoma
p14163
sg13
I1
sa(dp14164
g7
I182
sg17
VC0042164
p14165
sg10
I7
sg11
Vuveitis
p14166
sg13
I1
sasa(dp14167
g2
S'In analyses in patients with VRL, elevation of sVEGFR1 and sVEGFR2 levels was more prominent in patients with systemic metastatic retinal lymphoma (SMRL) than in those with primary VRL/primary central nervous system lymphoma (PVRL/PCNSL).\n'
p14168
sg4
(lp14169
sg14
(lp14170
(dp14171
g7
I231
sg17
VC0280803
p14172
sg10
I5
sg11
VPCNSL
p14173
sg13
I1
sa(dp14174
g7
I185
sg17
VC0280803
p14175
sg10
I39
sg11
Vprimary central nervous system lymphoma
p14176
sg13
I5
sa(dp14177
g7
I130
sg17
VC0339556
p14178
sg10
I16
sg11
Vretinal lymphoma
p14179
sg13
I2
sasa(dp14180
g2
S'For example in prostate cancer cells, the TRPV2 activation following lysophospholipid or adrenomedullin stimulation enhances the invasiveness of cancer cells; furthermore, the increased malignancy of castration-resistant prostate cancer cells was associated with enhanced TRPV2 expression, mainly in metastatic prostate cancer cells.\n'
p14181
sg4
(lp14182
(dp14183
g7
I42
sg8
g9
sg10
I5
sg11
VTRPV2
p14184
sg13
I1
sa(dp14185
g7
I42
sg8
g9
sg10
I5
sg11
VTRPV2
p14186
sg13
I1
sa(dp14187
g7
I89
sg8
VP35318
p14188
sg10
I14
sg11
Vadrenomedullin
p14189
sg13
I1
sasg14
(lp14190
(dp14191
g7
I300
sg17
VC0936223
p14192
sg10
I26
sg11
Vmetastatic prostate cancer
p14193
sg13
I3
sa(dp14194
g7
I186
sg17
VC0006826
p14195
sg10
I10
sg11
Vmalignancy
p14196
sg13
I1
sa(dp14197
g7
I15
sg17
VC0600139
p14198
sg10
I15
sg11
Vprostate cancer
p14199
sg13
I2
sa(dp14200
g7
I15
sg17
VC0600139
p14201
sg10
I15
sg11
Vprostate cancer
p14202
sg13
I2
sa(dp14203
g7
I24
sg17
VC0006826
p14204
sg10
I6
sg11
Vcancer
p14205
sg13
I1
sasa(dp14206
g2
S'In this regard, bladder cancer tumors show loss or reduction of a short TRPV2 variant during cancer progression, with increased malignancy and invasiveness.\n'
p14207
sg4
(lp14208
(dp14209
g7
I72
sg8
g9
sg10
I5
sg11
VTRPV2
p14210
sg13
I1
sasg14
(lp14211
(dp14212
g7
I31
sg17
VC0027651
p14213
sg10
I6
sg11
Vtumors
p14214
sg13
I1
sa(dp14215
g7
I128
sg17
VC0006826
p14216
sg10
I10
sg11
Vmalignancy
p14217
sg13
I1
sa(dp14218
g7
I93
sg17
VC0178874
p14219
sg10
I18
sg11
Vcancer progression
p14220
sg13
I2
sa(dp14221
g7
I16
sg17
VC0699885
p14222
sg10
I14
sg11
Vbladder cancer
p14223
sg13
I2
sasa(dp14224
g2
S'TRPV2 and TRPM7 expression levels and TRPV2 activator-induced intracellular Ca(2+) increases were significantly higher, whereas TRPV4 expression and TRPV4 activator-induced intracellular Ca(2+) increases were significantly lower in mouse bladder cancer (MBT-2) cells compared to normal mouse urothelial cells.\n'
p14225
sg4
(lp14226
(dp14227
g7
I0
sg8
g9
sg10
I5
sg11
VTRPV2
p14228
sg13
I1
sa(dp14229
g7
I0
sg8
g9
sg10
I5
sg11
VTRPV2
p14230
sg13
I1
sa(dp14231
g7
I10
sg8
g9
sg10
I5
sg11
VTRPM7
p14232
sg13
I1
sasg14
(lp14233
(dp14234
g7
I238
sg17
VC0699885
p14235
sg10
I14
sg11
Vbladder cancer
p14236
sg13
I2
sasa(dp14237
g2
S'Increases in the expression of TRPV2 mRNA, immunoreactivity, and TRPV2 activator-induced intracellular Ca(2+) were also observed in T24 human bladder cancer cells.\n'
p14238
sg4
(lp14239
(dp14240
g7
I31
sg8
g9
sg10
I10
sg11
VTRPV2 mRNA
p14241
sg13
I2
sa(dp14242
g7
I31
sg8
g9
sg10
I5
sg11
VTRPV2
p14243
sg13
I1
sasg14
(lp14244
(dp14245
g7
I142
sg17
VC0699885
p14246
sg10
I14
sg11
Vbladder cancer
p14247
sg13
I2
sasa(dp14248
g2
S'These results suggested that TRPV2 and TRPM7 were functionally expressed in bladder cancer cells and served as negative regulators of bladder cancer cell proliferation, most likely to prevent excess mechanical stresses.\n'
p14249
sg4
(lp14250
(dp14251
g7
I39
sg8
g9
sg10
I5
sg11
VTRPM7
p14252
sg13
I1
sa(dp14253
g7
I29
sg8
g9
sg10
I5
sg11
VTRPV2
p14254
sg13
I1
sasg14
(lp14255
(dp14256
g7
I76
sg17
VC0699885
p14257
sg10
I14
sg11
Vbladder cancer
p14258
sg13
I2
sa(dp14259
g7
I76
sg17
VC0699885
p14260
sg10
I14
sg11
Vbladder cancer
p14261
sg13
I2
sa(dp14262
g7
I154
sg17
VC0334094
p14263
sg10
I13
sg11
Vproliferation
p14264
sg13
I1
sasa(dp14265
g2
S'On the other hand, in prostate cancer cells, Ca2+-dependent activation of TRPV2 induced by lysophospholipids increases the invasion of tumor cells.\n'
p14266
sg4
(lp14267
(dp14268
g7
I74
sg8
g9
sg10
I5
sg11
VTRPV2
p14269
sg13
I1
sasg14
(lp14270
(dp14271
g7
I123
sg17
VC2699153
p14272
sg10
I8
sg11
Vinvasion
p14273
sg13
I1
sa(dp14274
g7
I22
sg17
VC0600139
p14275
sg10
I15
sg11
Vprostate cancer
p14276
sg13
I2
sa(dp14277
g7
I135
sg17
VC0027651
p14278
sg10
I5
sg11
Vtumor
p14279
sg13
I1
sasa(dp14280
g2
S'In addition, the progression of prostate cancer to the castration-resistant phenotype is characterized by de novo TRPV2 expression, with higher TRPV2 transcript levels in patients with metastatic cancer.\n'
p14281
sg4
(lp14282
(dp14283
g7
I114
sg8
g9
sg10
I5
sg11
VTRPV2
p14284
sg13
I1
sa(dp14285
g7
I144
sg8
g9
sg10
I16
sg11
VTRPV2 transcript
p14286
sg13
I2
sasg14
(lp14287
(dp14288
g7
I17
sg17
VC1739135
p14289
sg10
I30
sg11
Vprogression of prostate cancer
p14290
sg13
I4
sa(dp14291
g7
I185
sg17
VC0027627
p14292
sg10
I17
sg11
Vmetastatic cancer
p14293
sg13
I2
sasa(dp14294
g2
S'The aim of the present study was to investigate the effects of TRPV2 on the proliferation, migration and invasion of 5637 bladder cancer cells in vitro.\n'
p14295
sg4
(lp14296
(dp14297
g7
I63
sg8
g9
sg10
I5
sg11
VTRPV2
p14298
sg13
I1
sasg14
(lp14299
(dp14300
g7
I76
sg17
VC0334094
p14301
sg10
I13
sg11
Vproliferation
p14302
sg13
I1
sa(dp14303
g7
I105
sg17
VC2699153
p14304
sg10
I8
sg11
Vinvasion
p14305
sg13
I1
sa(dp14306
g7
I122
sg17
VC0699885
p14307
sg10
I14
sg11
Vbladder cancer
p14308
sg13
I2
sasa(dp14309
g2
S'Rat TRPV2 cDNA was transfected into 5637 bladder cancer cells and changes in the behavior of the cells were detected.\n'
p14310
sg4
(lp14311
(dp14312
g7
I0
sg8
g9
sg10
I14
sg11
VRat TRPV2 cDNA
p14313
sg13
I3
sasg14
(lp14314
(dp14315
g7
I41
sg17
VC0699885
p14316
sg10
I14
sg11
Vbladder cancer
p14317
sg13
I2
sasa(dp14318
g2
S'It was observed that TRPV2 enhanced bladder cancer cell migration and invasion; however, it did not affect cell proliferation in vitro.\n'
p14319
sg4
(lp14320
(dp14321
g7
I21
sg8
g9
sg10
I5
sg11
VTRPV2
p14322
sg13
I1
sasg14
(lp14323
(dp14324
g7
I112
sg17
VC0334094
p14325
sg10
I13
sg11
Vproliferation
p14326
sg13
I1
sa(dp14327
g7
I36
sg17
VC0699885
p14328
sg10
I14
sg11
Vbladder cancer
p14329
sg13
I2
sa(dp14330
g7
I70
sg17
VC2699153
p14331
sg10
I8
sg11
Vinvasion
p14332
sg13
I1
sasa(dp14333
g2
S'The results of this study suggest that TRPV2 channels are a potential therapeutic target for bladder carcinoma.\n'
p14334
sg4
(lp14335
(dp14336
g7
I39
sg8
g9
sg10
I14
sg11
VTRPV2 channels
p14337
sg13
I2
sasg14
(lp14338
(dp14339
g7
I93
sg17
VC0699885
p14340
sg10
I17
sg11
Vbladder carcinoma
p14341
sg13
I2
sasa(dp14342
g2
S'The Transient Receptor Potential channel TRPV2 is known to promote in prostate cancer cell migration and invasive phenotype and is correlated with the stage and grade of bladder cancer.\n'
p14343
sg4
(lp14344
(dp14345
g7
I41
sg8
g9
sg10
I5
sg11
VTRPV2
p14346
sg13
I1
sasg14
(lp14347
(dp14348
g7
I170
sg17
VC0699885
p14349
sg10
I14
sg11
Vbladder cancer
p14350
sg13
I2
sa(dp14351
g7
I70
sg17
VC0600139
p14352
sg10
I15
sg11
Vprostate cancer
p14353
sg13
I2
sasa(dp14354
g2
S'Initial studies showed that expression profile of some TRP channels, notably TRP melastatin 8 (TRPM8), TRP vanilloid 6 (TRPV6),TRP canonical (TRPC6) and TRPV2, is changing during the development and the progression of prostate cancer towards the hormone-refractory stages.\n'
p14355
sg4
(lp14356
(dp14357
g7
I95
sg8
g9
sg10
I5
sg11
VTRPM8
p14358
sg13
I1
sa(dp14359
g7
I142
sg8
g9
sg10
I5
sg11
VTRPC6
p14360
sg13
I1
sa(dp14361
g7
I55
sg8
VP13686
p14362
sg10
I3
sg11
VTRP
p14363
sg13
I1
sa(dp14364
g7
I120
sg8
g9
sg10
I5
sg11
VTRPV6
p14365
sg13
I1
sa(dp14366
g7
I103
sg8
VP13686
p14367
sg10
I15
sg11
VTRP vanilloid 6
p14368
sg13
I3
sa(dp14369
g7
I153
sg8
g9
sg10
I5
sg11
VTRPV2
p14370
sg13
I1
sa(dp14371
g7
I55
sg8
VP13686
p14372
sg10
I12
sg11
VTRP channels
p14373
sg13
I2
sa(dp14374
g7
I77
sg8
VP13686
p14375
sg10
I16
sg11
VTRP melastatin 8
p14376
sg13
I3
sasg14
(lp14377
(dp14378
g7
I203
sg17
VC1739135
p14379
sg10
I30
sg11
Vprogression of prostate cancer
p14380
sg13
I4
sasa(dp14381
g2
S'The expression of TRPV2 mRNA in bladder cancer cell lines (T24, a poorly differentiated UC cell line and RT4, a well-differentiated UC cell line) was analyzed using reverse transcriptase-polymerase chain reaction.\n'
p14382
sg4
(lp14383
(dp14384
g7
I18
sg8
g9
sg10
I10
sg11
VTRPV2 mRNA
p14385
sg13
I2
sa(dp14386
g7
I165
sg8
VP63136
p14387
sg10
I21
sg11
Vreverse transcriptase
p14388
sg13
I2
sasg14
(lp14389
(dp14390
g7
I32
sg17
VC0699885
p14391
sg10
I14
sg11
Vbladder cancer
p14392
sg13
I2
sasa(dp14393
g2
S'Furthermore, the effects of resveratrol and Shh on human colorectal cancer HCT116 cells were in a dose- and time-dependent manner.\n'
p14394
sg4
(lp14395
(dp14396
g7
I44
sg8
g9
sg10
I3
sg11
VShh
p14397
sg13
I1
sasg14
(lp14398
(dp14399
g7
I57
sg17
VC1527249
p14400
sg10
I17
sg11
Vcolorectal cancer
p14401
sg13
I2
sasa(dp14402
g2
S'Furthermore, knockdown of PFTK1 suppressed the expression of Shh as well as Smo, Ptc, and Gli-1 in colon cancer cells.\n'
p14403
sg4
(lp14404
(dp14405
g7
I76
sg8
g9
sg10
I3
sg11
VSmo
p14406
sg13
I1
sa(dp14407
g7
I61
sg8
g9
sg10
I3
sg11
VShh
p14408
sg13
I1
sa(dp14409
g7
I81
sg8
g9
sg10
I3
sg11
VPtc
p14410
sg13
I1
sa(dp14411
g7
I90
sg8
VP08151
p14412
sg10
I5
sg11
VGli-1
p14413
sg13
I1
sasg14
(lp14414
(dp14415
g7
I99
sg17
VC0699790
p14416
sg10
I12
sg11
Vcolon cancer
p14417
sg13
I2
sa(dp14418
g7
I81
sg17
VC0238463
p14419
sg10
I3
sg11
VPtc
p14420
sg13
I1
sasa(dp14421
g2
S'Taken together, these results suggest that knockdown of PFTK1 inhibited the proliferation and invasion of colon cancer cells as well as the EMT progress by suppressing the Sonic hedgehog signaling pathway.\n'
p14422
sg4
(lp14423
(dp14424
g7
I140
sg8
g9
sg10
I3
sg11
VEMT
p14425
sg13
I1
sa(dp14426
g7
I172
sg8
g9
sg10
I14
sg11
VSonic hedgehog
p14427
sg13
I2
sasg14
(lp14428
(dp14429
g7
I106
sg17
VC0699790
p14430
sg10
I12
sg11
Vcolon cancer
p14431
sg13
I2
sa(dp14432
g7
I76
sg17
VC0334094
p14433
sg10
I13
sg11
Vproliferation
p14434
sg13
I1
sa(dp14435
g7
I94
sg17
VC2699153
p14436
sg10
I8
sg11
Vinvasion
p14437
sg13
I1
sasa(dp14438
g2
S'This case illustrates the potential severity of the renal anomalies in the BOR syndrome and the inadequacy of oligohydramnios and maternal serum alpha-fetoprotein as screening methods for renal agenesis.\n'
p14439
sg4
(lp14440
sg14
(lp14441
(dp14442
g7
I75
sg17
VC0265234
p14443
sg10
I12
sg11
VBOR syndrome
p14444
sg13
I2
sa(dp14445
g7
I52
sg17
VC0266292
p14446
sg10
I15
sg11
Vrenal anomalies
p14447
sg13
I2
sa(dp14448
g7
I188
sg17
VC0542519
p14449
sg10
I14
sg11
Vrenal agenesis
p14450
sg13
I2
sa(dp14451
g7
I110
sg17
VC0079924
p14452
sg10
I15
sg11
Voligohydramnios
p14453
sg13
I1
sasa(dp14454
g2
S'Severe sepsis and antibiotic use were both associated with moderate thrombocytopenia, and proton pump inhibitor use was statistically significant in both univariate and multivariate analysis.\n'
p14455
sg4
(lp14456
sg14
(lp14457
(dp14458
g7
I0
sg17
VC1719672
p14459
sg10
I13
sg11
VSevere sepsis
p14460
sg13
I2
sasa(dp14461
g2
S'Thrombocytopenia is associated with poor prognosis, and the association between moderate thrombocytopenia and proton pump inhibitor use is relatively novel and should be validated in prospective studies.\n'
p14462
sg4
(lp14463
sg14
(lp14464
sa(dp14465
g2
S'We identified 12 biomarkers consistently associated with either clinical groups "upstream" towards culture-positive TB on the TB disease spectrum (CD14, FCGR1A, FPR1, MMP9, RAB24, SEC14L1, and TIMP2) or "downstream" towards a decreased likelihood of TB disease (BLR1, CD3E, CD8A, IL7R, and TGFBR2), suggesting a correlation with MTB-related pathology and high relevance to a future POC test for pediatric TB.\n'
p14466
sg4
(lp14467
(dp14468
g7
I147
sg8
VP08571
p14469
sg10
I4
sg11
VCD14
p14470
sg13
I1
sa(dp14471
g7
I173
sg8
g9
sg10
I5
sg11
VRAB24
p14472
sg13
I1
sa(dp14473
g7
I153
sg8
VP12314
p14474
sg10
I6
sg11
VFCGR1A
p14475
sg13
I1
sa(dp14476
g7
I268
sg8
VP07766
p14477
sg10
I4
sg11
VCD3E
p14478
sg13
I1
sa(dp14479
g7
I274
sg8
VP01732
p14480
sg10
I4
sg11
VCD8A
p14481
sg13
I1
sa(dp14482
g7
I262
sg8
VP32302
p14483
sg10
I4
sg11
VBLR1
p14484
sg13
I1
sa(dp14485
g7
I180
sg8
g9
sg10
I7
sg11
VSEC14L1
p14486
sg13
I1
sa(dp14487
g7
I167
sg8
VP14780
p14488
sg10
I4
sg11
VMMP9
p14489
sg13
I1
sa(dp14490
g7
I193
sg8
VP16035
p14491
sg10
I5
sg11
VTIMP2
p14492
sg13
I1
sa(dp14493
g7
I161
sg8
VP21462
p14494
sg10
I4
sg11
VFPR1
p14495
sg13
I1
sa(dp14496
g7
I290
sg8
VP37173
p14497
sg10
I6
sg11
VTGFBR2
p14498
sg13
I1
sasg14
(lp14499
(dp14500
g7
I341
sg17
VC0677042
p14501
sg10
I9
sg11
Vpathology
p14502
sg13
I1
sasa(dp14503
g2
S'Western blot assay further confirmed that anti-ICAM-T0901317 liposomes inhibited retinoblastoma (Rb) phosphorylation and MCM6 expression.\n'
p14504
sg4
(lp14505
(dp14506
g7
I81
sg8
g9
sg10
I19
sg11
Vretinoblastoma (Rb)
p14507
sg13
I2
sa(dp14508
g7
I121
sg8
g9
sg10
I4
sg11
VMCM6
p14509
sg13
I1
sasg14
(lp14510
(dp14511
g7
I97
sg17
VC0035335
p14512
sg10
I2
sg11
VRb
p14513
sg13
I1
sa(dp14514
g7
I81
sg17
VC0035335
p14515
sg10
I14
sg11
Vretinoblastoma
p14516
sg13
I1
sasa(dp14517
g2
S'Inhibition of MCM6 and MCM7 expression by nTZDpa and rosiglitazone paralleled their effect to inhibit phosphorylation of the retinoblastoma protein and cell proliferation.\n'
p14518
sg4
(lp14519
(dp14520
g7
I125
sg8
g9
sg10
I22
sg11
Vretinoblastoma protein
p14521
sg13
I2
sa(dp14522
g7
I23
sg8
VP33993
p14523
sg10
I4
sg11
VMCM7
p14524
sg13
I1
sa(dp14525
g7
I14
sg8
g9
sg10
I4
sg11
VMCM6
p14526
sg13
I1
sasg14
(lp14527
(dp14528
g7
I125
sg17
VC0035335
p14529
sg10
I14
sg11
Vretinoblastoma
p14530
sg13
I1
sa(dp14531
g7
I157
sg17
VC0334094
p14532
sg10
I13
sg11
Vproliferation
p14533
sg13
I1
sasa(dp14534
g2
S"Snord3A expression was also elevated in scrapie infected mice, but not in PrP(0/0) mice, indicating that while the expression levels of this transcript may reflect diverse prion etiologies, they are not related to the loss of PrP(C)'s function.\n"
p14535
sg4
(lp14536
(dp14537
g7
I74
sg8
g9
sg10
I3
sg11
VPrP
p14538
sg13
I1
sasg14
(lp14539
(dp14540
g7
I40
sg17
VC0036457
p14541
sg10
I7
sg11
Vscrapie
p14542
sg13
I1
sasa(dp14543
g2
S'We hypothesize that in addition to its function as a disease marker, Snord3A may play an important role in the mechanism of prion disease manifestation and progression.\n'
p14544
sg4
(lp14545
sg14
(lp14546
(dp14547
g7
I124
sg17
VC0162534
p14548
sg10
I13
sg11
Vprion disease
p14549
sg13
I2
sasa(dp14550
g2
S'Her son has type 1 diabetes, arthritis, reduced IgG levels and IgA deficiency, but has not inherited the TNFRSF13B/TACI mutation.\n'
p14551
sg4
(lp14552
(dp14553
g7
I63
sg8
VP11912
p14554
sg10
I3
sg11
VIgA
p14555
sg13
I1
sa(dp14556
g7
I105
sg8
g9
sg10
I9
sg11
VTNFRSF13B
p14557
sg13
I1
sa(dp14558
g7
I115
sg8
g9
sg10
I4
sg11
VTACI
p14559
sg13
I1
sasg14
(lp14560
(dp14561
g7
I29
sg17
VC0003864
p14562
sg10
I9
sg11
Varthritis
p14563
sg13
I1
sa(dp14564
g7
I12
sg17
VC0011854
p14565
sg10
I15
sg11
Vtype 1 diabetes
p14566
sg13
I3
sa(dp14567
g7
I63
sg17
VC0162538
p14568
sg10
I14
sg11
VIgA deficiency
p14569
sg13
I2
sasa(dp14570
g2
S'Our results support the hypothesis that increased TACI expression on NOD B cells contributes to the pathogenesis of type 1 diabetes in the NOD mouse.\n'
p14571
sg4
(lp14572
(dp14573
g7
I69
sg8
VP54259
p14574
sg10
I5
sg11
VNOD B
p14575
sg13
I2
sa(dp14576
g7
I50
sg8
g9
sg10
I4
sg11
VTACI
p14577
sg13
I1
sasg14
(lp14578
(dp14579
g7
I116
sg17
VC0011854
p14580
sg10
I15
sg11
Vtype 1 diabetes
p14581
sg13
I3
sa(dp14582
g7
I69
sg17
VC0751781
p14583
sg10
I3
sg11
VNOD
p14584
sg13
I1
sa(dp14585
g7
I69
sg17
VC0751781
p14586
sg10
I3
sg11
VNOD
p14587
sg13
I1
sa(dp14588
g7
I100
sg17
VC0699748
p14589
sg10
I12
sg11
Vpathogenesis
p14590
sg13
I1
sasa(dp14591
g2
S'A family member with a wild type TACI variant had CVID-related phenotype including IgA deficiency and type 1 diabetes.\n'
p14592
sg4
(lp14593
(dp14594
g7
I50
sg8
g9
sg10
I22
sg11
VCVID-related phenotype
p14595
sg13
I2
sa(dp14596
g7
I23
sg8
g9
sg10
I22
sg11
Vwild type TACI variant
p14597
sg13
I4
sa(dp14598
g7
I83
sg8
VP11912
p14599
sg10
I3
sg11
VIgA
p14600
sg13
I1
sasg14
(lp14601
(dp14602
g7
I102
sg17
VC0011854
p14603
sg10
I15
sg11
Vtype 1 diabetes
p14604
sg13
I3
sa(dp14605
g7
I50
sg17
VC0009447
p14606
sg10
I4
sg11
VCVID
p14607
sg13
I1
sa(dp14608
g7
I83
sg17
VC0162538
p14609
sg10
I14
sg11
VIgA deficiency
p14610
sg13
I2
sasa(dp14611
g2
S'We mapped the loci contributing to the increased proportion of TACI(high) expressing splenic B cells and found that the control of TACI expression was strongly linked to chromosome 1, in a region which includes the insulin-dependent diabetes (Idd) 5 loci.\n'
p14612
sg4
(lp14613
(dp14614
g7
I63
sg8
g9
sg10
I4
sg11
VTACI
p14615
sg13
I1
sa(dp14616
g7
I215
sg8
VP01308
p14617
sg10
I7
sg11
Vinsulin
p14618
sg13
I1
sasg14
(lp14619
(dp14620
g7
I215
sg17
VC0011854
p14621
sg10
I26
sg11
Vinsulin-dependent diabetes
p14622
sg13
I2
sa(dp14623
g7
I243
sg17
VC0011854
p14624
sg10
I3
sg11
VIdd
p14625
sg13
I1
sasa(dp14626
g2
S'Our findings corroborate the notion that B cell deviations contribute to type 1 diabetes development, and suggest a temporal regulation of TACI(high) expression, possibly influenced by the ongoing autoimmune process.\n'
p14627
sg4
(lp14628
sg14
(lp14629
(dp14630
g7
I73
sg17
VC0011854
p14631
sg10
I15
sg11
Vtype 1 diabetes
p14632
sg13
I3
sa(dp14633
g7
I197
sg17
VC0443146
p14634
sg10
I18
sg11
Vautoimmune process
p14635
sg13
I2
sasa(dp14636
g2
S'Octamer-binding transcription factor 4 (OCT4) was closely related to pancreatic cancer progression, but its regulation in pancreatic cancer by microRNA (miRNA) is not fully clear.\n'
p14637
sg4
(lp14638
(dp14639
g7
I0
sg8
VP15884
p14640
sg10
I38
sg11
VOctamer-binding transcription factor 4
p14641
sg13
I4
sa(dp14642
g7
I40
sg8
VP15884
p14643
sg10
I4
sg11
VOCT4
p14644
sg13
I1
sasg14
(lp14645
(dp14646
g7
I69
sg17
VC0235974
p14647
sg10
I17
sg11
Vpancreatic cancer
p14648
sg13
I2
sa(dp14649
g7
I80
sg17
VC0178874
p14650
sg10
I18
sg11
Vcancer progression
p14651
sg13
I2
sasa(dp14652
g2
S'This study was designed to investigate the expression of the T-box transcription factor 4 (TBX4), a tumor biomarker that was previously identified by proteomics, in pancreatic ductal adenocarcinoma (PDAC) and evaluate its clinical utility as a potential prognostic biomarkers for PDAC.\n'
p14653
sg4
(lp14654
(dp14655
g7
I91
sg8
VP57082
p14656
sg10
I4
sg11
VTBX4
p14657
sg13
I1
sa(dp14658
g7
I61
sg8
VP15884
p14659
sg10
I28
sg11
VT-box transcription factor 4
p14660
sg13
I4
sasg14
(lp14661
(dp14662
g7
I100
sg17
VC0027651
p14663
sg10
I5
sg11
Vtumor
p14664
sg13
I1
sa(dp14665
g7
I199
sg17
VC1335302
p14666
sg10
I4
sg11
VPDAC
p14667
sg13
I1
sa(dp14668
g7
I199
sg17
VC1335302
p14669
sg10
I4
sg11
VPDAC
p14670
sg13
I1
sa(dp14671
g7
I165
sg17
VC1335302
p14672
sg10
I32
sg11
Vpancreatic ductal adenocarcinoma
p14673
sg13
I3
sasa(dp14674
g2
S'Whereas the pathological functions of LTB4/BLT1 axis in allergy, autoimmunity and cardiovascular disorders are well established; its role in cancer is only beginning to emerge.\n'
p14675
sg4
(lp14676
(dp14677
g7
I43
sg8
g9
sg10
I4
sg11
VBLT1
p14678
sg13
I1
sasg14
(lp14679
(dp14680
g7
I141
sg17
VC0006826
p14681
sg10
I6
sg11
Vcancer
p14682
sg13
I1
sa(dp14683
g7
I56
sg17
VC0020517
p14684
sg10
I7
sg11
Vallergy
p14685
sg13
I1
sa(dp14686
g7
I65
sg17
VC0004368
p14687
sg10
I12
sg11
Vautoimmunity
p14688
sg13
I1
sa(dp14689
g7
I82
sg17
VC0007222
p14690
sg10
I24
sg11
Vcardiovascular disorders
p14691
sg13
I2
sasa(dp14692
g2
S'Bioluminescence tomography (BLT) is a powerful non-invasive molecular imaging tool for in vivo studies of glioma in mice.\n'
p14693
sg4
(lp14694
sg14
(lp14695
(dp14696
g7
I106
sg17
VC0017638
p14697
sg10
I6
sg11
Vglioma
p14698
sg13
I1
sasa(dp14699
g2
S'To the best of our knowledge, this is the first study that achieved such accurate BLT morphological reconstruction of orthotopic glioma without using any segmented tumor structure from any other structural imaging modalities as the prior for reconstruction guidance.\n'
p14700
sg4
(lp14701
sg14
(lp14702
(dp14703
g7
I129
sg17
VC0017638
p14704
sg10
I6
sg11
Vglioma
p14705
sg13
I1
sa(dp14706
g7
I164
sg17
VC0027651
p14707
sg10
I5
sg11
Vtumor
p14708
sg13
I1
sasa(dp14709
g2
S'This enabled BLT more suitable and practical for in vivo imaging of orthotopic glioma mouse models.\n'
p14710
sg4
(lp14711
sg14
(lp14712
(dp14713
g7
I79
sg17
VC0017638
p14714
sg10
I6
sg11
Vglioma
p14715
sg13
I1
sasa(dp14716
g2
S'The major objective of this study is to address this gap in our understanding of how IDO1 expression contributes to the biology of GBM, and whether its level of expression is a determinant of GBM patient outcome.Experimental Design: Patient-resected GBM, The Cancer Genome Atlas, human T-cell:GBM cocultures, as well as nu/nu, NOD-scid, and humanized (NSG-SGM3-BLT) mice-engrafted human GBM form the basis of our investigation.Results:In situ hybridization for IDO1 revealed transcript expression throughout patient-resected GBM, whereas immunohistochemical IDO1 positivity was highly variable.\n'
p14717
sg4
(lp14718
(dp14719
g7
I85
sg8
VP14902
p14720
sg10
I4
sg11
VIDO1
p14721
sg13
I1
sa(dp14722
g7
I85
sg8
VP14902
p14723
sg10
I4
sg11
VIDO1
p14724
sg13
I1
sasg14
(lp14725
(dp14726
g7
I331
sg17
VC0085110
p14727
sg10
I4
sg11
Vscid
p14728
sg13
I1
sa(dp14729
g7
I131
sg17
VC0017636
p14730
sg10
I3
sg11
VGBM
p14731
sg13
I1
sa(dp14732
g7
I259
sg17
VC0006826
p14733
sg10
I6
sg11
VCancer
p14734
sg13
I1
sa(dp14735
g7
I327
sg17
VC0751781
p14736
sg10
I3
sg11
VNOD
p14737
sg13
I1
sa(dp14738
g7
I131
sg17
VC0017636
p14739
sg10
I3
sg11
VGBM
p14740
sg13
I1
sa(dp14741
g7
I131
sg17
VC0017636
p14742
sg10
I3
sg11
VGBM
p14743
sg13
I1
sa(dp14744
g7
I131
sg17
VC0017636
p14745
sg10
I3
sg11
VGBM
p14746
sg13
I1
sa(dp14747
g7
I131
sg17
VC0017636
p14748
sg10
I3
sg11
VGBM
p14749
sg13
I1
sa(dp14750
g7
I131
sg17
VC0017636
p14751
sg10
I3
sg11
VGBM
p14752
sg13
I1
sasa(dp14753
g2
S'Together with CT, BLT can provide precision radiation guidance and robust tumor volume assessment in small animal cancer research.\n'
p14754
sg4
(lp14755
sg14
(lp14756
(dp14757
g7
I114
sg17
VC0006826
p14758
sg10
I6
sg11
Vcancer
p14759
sg13
I1
sa(dp14760
g7
I74
sg17
VC0027651
p14761
sg10
I5
sg11
Vtumor
p14762
sg13
I1
sasa(dp14763
g2
S'Variation of detected bioluminescence signals emitted from molecular cancer cells was depicted on BLT images.\n'
p14764
sg4
(lp14765
sg14
(lp14766
(dp14767
g7
I69
sg17
VC0006826
p14768
sg10
I6
sg11
Vcancer
p14769
sg13
I1
sasa(dp14770
g2
S'Multispectral BLT images elaborated on early detection of cancer cells, characteristics of tumor growth, and metastasis for more accurate determination of internal bioluminescent sources.\n'
p14771
sg4
(lp14772
sg14
(lp14773
(dp14774
g7
I58
sg17
VC0006826
p14775
sg10
I6
sg11
Vcancer
p14776
sg13
I1
sa(dp14777
g7
I91
sg17
VC0598934
p14778
sg10
I12
sg11
Vtumor growth
p14779
sg13
I2
sa(dp14780
g7
I109
sg17
VC0027627
p14781
sg10
I10
sg11
Vmetastasis
p14782
sg13
I1
sasa(dp14783
g2
S'Registration of BLT with CT images guided molecular cancer cells on anatomical coordinates.\n'
p14784
sg4
(lp14785
sg14
(lp14786
(dp14787
g7
I52
sg17
VC0006826
p14788
sg10
I6
sg11
Vcancer
p14789
sg13
I1
sasa(dp14790
g2
S'The BLT imaging was a useful tool to localize cancer cells and to quantify radiation response.\n'
p14791
sg4
(lp14792
sg14
(lp14793
(dp14794
g7
I46
sg17
VC0006826
p14795
sg10
I6
sg11
Vcancer
p14796
sg13
I1
sasa(dp14797
g2
S'Application of BLT led to more accurate definition of tumor volumes including molecular probe-based microscopic cancer cells.\n'
p14798
sg4
(lp14799
sg14
(lp14800
(dp14801
g7
I54
sg17
VC0027651
p14802
sg10
I5
sg11
Vtumor
p14803
sg13
I1
sa(dp14804
g7
I112
sg17
VC0006826
p14805
sg10
I6
sg11
Vcancer
p14806
sg13
I1
sasa(dp14807
g2
S'Thus, in this report, we not only provide a novel strategy to expand super-charged NK cells, but also demonstrate that rapid and sustained expansion of residual T cells within the purified NK cells during expansion with DCs or OCs could be a potential mechanism by which the numbers and function of NK cells decline in cancer patients and in BLT-humanized mice.\n'
p14808
sg4
(lp14809
sg14
(lp14810
(dp14811
g7
I220
sg17
VC0268238
p14812
sg10
I3
sg11
VDCs
p14813
sg13
I1
sa(dp14814
g7
I319
sg17
VC0006826
p14815
sg10
I6
sg11
Vcancer
p14816
sg13
I1
sasa(dp14817
g2
S'Verrucous carcinoma (VC) is a variant of well-differentiated squamous cell carcinoma and in the anal region is regarded as synonymous with giant condyloma (Buschke-Loewenstein tumour) (BLT).\n'
p14818
sg4
(lp14819
sg14
(lp14820
(dp14821
g7
I176
sg17
VC0027651
p14822
sg10
I6
sg11
Vtumour
p14823
sg13
I1
sa(dp14824
g7
I145
sg17
VC0009663
p14825
sg10
I9
sg11
Vcondyloma
p14826
sg13
I1
sa(dp14827
g7
I0
sg17
VC0206706
p14828
sg10
I19
sg11
VVerrucous carcinoma
p14829
sg13
I2
sa(dp14830
g7
I139
sg17
VC0017547
p14831
sg10
I5
sg11
Vgiant
p14832
sg13
I1
sa(dp14833
g7
I21
sg17
VC0206706
p14834
sg10
I2
sg11
VVC
p14835
sg13
I1
sa(dp14836
g7
I61
sg17
VC0007137
p14837
sg10
I23
sg11
Vsquamous cell carcinoma
p14838
sg13
I3
sasa(dp14839
g2
S'To test this idea, we infected migrating neural crest cells of chicken embryos with  replication-competent avian sarcoma virus expressing either FgfR2(C278F), a receptor mutation found in Crouzon syndrome or the ligand Fgf8.\n'
p14840
sg4
(lp14841
(dp14842
g7
I219
sg8
VP55075
p14843
sg10
I4
sg11
VFgf8
p14844
sg13
I1
sasg14
(lp14845
(dp14846
g7
I48
sg17
VC0206138
p14847
sg10
I5
sg11
Vcrest
p14848
sg13
I1
sa(dp14849
g7
I188
sg17
VC0010273
p14850
sg10
I16
sg11
VCrouzon syndrome
p14851
sg13
I2
sa(dp14852
g7
I107
sg17
VC0004426
p14853
sg10
I13
sg11
Vavian sarcoma
p14854
sg13
I2
sasa(dp14855
g2
S'These defects are similar in presentation to several human craniofacial disorders (e.g., craniosynostosis, hemifacial microsomia), and may be related to increased levels of bone metabolism observed in ace(ti282a)/fgf8 heterozygotes.\n'
p14856
sg4
(lp14857
(dp14858
g7
I213
sg8
VP55075
p14859
sg10
I4
sg11
Vfgf8
p14860
sg13
I1
sasg14
(lp14861
(dp14862
g7
I89
sg17
VC0010278
p14863
sg10
I16
sg11
Vcraniosynostosis
p14864
sg13
I1
sa(dp14865
g7
I107
sg17
VC1306710
p14866
sg10
I21
sg11
Vhemifacial microsomia
p14867
sg13
I2
sasa(dp14868
g2
S'Since FGF8 maps to the same chromosomal region as FGFR2, has indeed been shown to be a ligand for FGFR2, and has an expression pattern consistent with limb and craniofacial anomalies, we have screened two kindreds with Pfeiffer syndrome that were previously linked to markers from 10q24-25 and a large number of individuals with craniosynostosis and limb anomalies for mutations in the coding sequence of FGF8.\n'
p14869
sg4
(lp14870
(dp14871
g7
I6
sg8
VP55075
p14872
sg10
I4
sg11
VFGF8
p14873
sg13
I1
sa(dp14874
g7
I6
sg8
VP55075
p14875
sg10
I4
sg11
VFGF8
p14876
sg13
I1
sasg14
(lp14877
(dp14878
g7
I329
sg17
VC0010278
p14879
sg10
I16
sg11
Vcraniosynostosis
p14880
sg13
I1
sa(dp14881
g7
I219
sg17
VC0265303
p14882
sg10
I17
sg11
VPfeiffer syndrome
p14883
sg13
I2
sasa(dp14884
g2
S'The results demonstrated that rhTrx-1 significantly improved neurological functions and reduced cerebral infarction and apoptotic cell death at 24h after MCAO.\n'
p14885
sg4
(lp14886
sg14
(lp14887
(dp14888
g7
I96
sg17
VC0038454
p14889
sg10
I19
sg11
Vcerebral infarction
p14890
sg13
I2
sasa(dp14891
g2
S'Treatment with Trx1 siRNA significantly increased mortality, behavioral deficits, and cerebral infarction volume and exacerbated neuronal cell apoptotic death after MCAO injury.\n'
p14892
sg4
(lp14893
(dp14894
g7
I15
sg8
VP60606
p14895
sg10
I10
sg11
VTrx1 siRNA
p14896
sg13
I2
sasg14
(lp14897
(dp14898
g7
I86
sg17
VC0038454
p14899
sg10
I19
sg11
Vcerebral infarction
p14900
sg13
I2
sasa(dp14901
g2
S'The results showed that intravenously administered rhTrx-1 (10 mg/kg) significantly improved neurological functions and reduced cerebral infarction and apoptotic cell death following cerebral ischemia.\n'
p14902
sg4
(lp14903
sg14
(lp14904
(dp14905
g7
I128
sg17
VC0038454
p14906
sg10
I19
sg11
Vcerebral infarction
p14907
sg13
I2
sa(dp14908
g7
I183
sg17
VC0917798
p14909
sg10
I17
sg11
Vcerebral ischemia
p14910
sg13
I2
sasa(dp14911
g2
S'Furthermore, the suppression on ONOO- formation by either rhTrx-1 or an ONOO- scavenger uric acid reduced cerebral infarct size in mice subjected to cerebral ischemia.\n'
p14912
sg4
(lp14913
sg14
(lp14914
(dp14915
g7
I149
sg17
VC0007785
p14916
sg10
I17
sg11
Vcerebral ischemia
p14917
sg13
I2
sa(dp14918
g7
I17
sg17
VC0221103
p14919
sg10
I11
sg11
Vsuppression
p14920
sg13
I1
sa(dp14921
g7
I106
sg17
VC0007785
p14922
sg10
I16
sg11
Vcerebral infarct
p14923
sg13
I2
sasa(dp14924
g2
S'Proenkephalin (pro-ENK), a stable and reliable surrogate marker for unstable enkephalins, was found to be associated with acute kidney injury and chronic renal failure in previous studies.\n'
p14925
sg4
(lp14926
(dp14927
g7
I0
sg8
VP01210
p14928
sg10
I13
sg11
VProenkephalin
p14929
sg13
I1
sa(dp14930
g7
I15
sg8
VP01210
p14931
sg10
I7
sg11
Vpro-ENK
p14932
sg13
I1
sasg14
(lp14933
(dp14934
g7
I146
sg17
VC0022661
p14935
sg10
I21
sg11
Vchronic renal failure
p14936
sg13
I3
sasa(dp14937
g2
S'PENK and NGAL concentrations were measured and GFR was estimated by using the isotope dilution mass spectrometry traceable-Modification of Diet in Renal Disease (MDRD) Study and three Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations: CKD-EPI(Cr), CDK-EPI(CysC), and CKD-EPI(Cr-CysC).\n'
p14938
sg4
(lp14939
(dp14940
g7
I268
sg8
VP10646
p14941
sg10
I7
sg11
VCDK-EPI
p14942
sg13
I1
sa(dp14943
g7
I0
sg8
VP01210
p14944
sg10
I4
sg11
VPENK
p14945
sg13
I1
sa(dp14946
g7
I184
sg8
VP10646
p14947
sg10
I49
sg11
VChronic Kidney Disease Epidemiology Collaboration
p14948
sg13
I5
sa(dp14949
g7
I9
sg8
VP80188
p14950
sg10
I4
sg11
VNGAL
p14951
sg13
I1
sa(dp14952
g7
I295
sg8
VP22676
p14953
sg10
I7
sg11
VCr-CysC
p14954
sg13
I1
sa(dp14955
g7
I235
sg8
VP10646
p14956
sg10
I7
sg11
VCKD-EPI
p14957
sg13
I1
sasg14
(lp14958
(dp14959
g7
I184
sg17
VC1561643
p14960
sg10
I22
sg11
VChronic Kidney Disease
p14961
sg13
I3
sa(dp14962
g7
I239
sg17
VC0267963
p14963
sg10
I3
sg11
VEPI
p14964
sg13
I1
sa(dp14965
g7
I147
sg17
VC0022658
p14966
sg10
I13
sg11
VRenal Disease
p14967
sg13
I2
sa(dp14968
g7
I239
sg17
VC0267963
p14969
sg10
I3
sg11
VEPI
p14970
sg13
I1
sa(dp14971
g7
I239
sg17
VC0267963
p14972
sg10
I3
sg11
VEPI
p14973
sg13
I1
sa(dp14974
g7
I239
sg17
VC0267963
p14975
sg10
I3
sg11
VEPI
p14976
sg13
I1
sasa(dp14977
g2
S'Proenkephalin cleavage products stored within cells, which included the 5.3-kDa peptide, could be released upon stimulation of cells with BaCl2 (2-fold above basal levels), 8-bromo-cAMP or CRF (7- and 8-fold above basal levels, respectively), and a mixture of BaCl2 and 8-bromo-cAMP (20-fold above basal levels).\n'
p14978
sg4
(lp14979
(dp14980
g7
I0
sg8
VP01210
p14981
sg10
I13
sg11
VProenkephalin
p14982
sg13
I1
sasg14
(lp14983
(dp14984
g7
I189
sg17
VC0022661
p14985
sg10
I3
sg11
VCRF
p14986
sg13
I1
sasa(dp14987
g2
S'Part 1 focuses on anti-metabotropic glutamate receptor 1-, anti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII-associated autoimmune cerebellar ataxia (ACA); part 2 covers anti-protein kinase C gamma-, anti-glutamate receptor delta-2-, anti-Ca/RhoGTPase-activating protein 26- and anti-voltage-gated calcium channel-associated ACA; and part 3 reviews the current knowledge on anti-Tr/delta notch-like epidermal growth factor-related receptor-, anti-Nb/AP3B2-, anti-Yo/cerebellar degeneration-related protein 2- and Purkinje cell antibody 2-associated ACA, discusses differential diagnostic aspects and provides a summary and outlook.\n'
p14988
sg4
(lp14989
(dp14990
g7
I59
sg8
g9
sg10
I126
sg11
Vanti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII
p14991
sg13
I12
sa(dp14992
g7
I527
sg8
g9
sg10
I5
sg11
VAP3B2
p14993
sg13
I1
sa(dp14994
g7
I247
sg8
VP05129
p14995
sg10
I61
sg11
Vanti-protein kinase C gamma-, anti-glutamate receptor delta-2
p14996
sg13
I7
sa(dp14997
g7
I18
sg8
VP42261
p14998
sg10
I38
sg11
Vanti-metabotropic glutamate receptor 1
p14999
sg13
I4
sa(dp15000
g7
I356
sg8
g9
sg10
I49
sg11
Vanti-voltage-gated calcium channel-associated ACA
p15001
sg13
I4
sa(dp15002
g7
I476
sg8
VP01133
p15003
sg10
I40
sg11
Vepidermal growth factor-related receptor
p15004
sg13
I4
sasg14
(lp15005
(dp15006
g7
I227
sg17
VC0007758
p15007
sg10
I3
sg11
VACA
p15008
sg13
I1
sa(dp15009
g7
I227
sg17
VC0007758
p15010
sg10
I3
sg11
VACA
p15011
sg13
I1
sa(dp15012
g7
I227
sg17
VC0007758
p15013
sg10
I3
sg11
VACA
p15014
sg13
I1
sa(dp15015
g7
I197
sg17
VC0007758
p15016
sg10
I28
sg11
Vautoimmune cerebellar ataxia
p15017
sg13
I3
sa(dp15018
g7
I543
sg17
VC0262404
p15019
sg10
I23
sg11
Vcerebellar degeneration
p15020
sg13
I2
sasa(dp15021
g2
S'Part 1 focuses on anti-metabotropic glutamate receptor 1-, anti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII-associated autoimmune cerebellar ataxia (ACA); part 2 covers anti-protein kinase C gamma-, anti-glutamate receptor delta-2-, anti-Ca/RhoGTPase-activating protein 26- and anti-voltage-gated calcium channel-associated ACA; and part 3 reviews the current knowledge on anti-Tr/delta notch-like epidermal growth factor-related receptor-, anti-Nb/AP3B2-, anti-Yo/cerebellar degeneration-related protein 2- and Purkinje cell antibody 2-associated ACA, discusses differential diagnostic aspects, and provides a summary and outlook.\n'
p15022
sg4
(lp15023
(dp15024
g7
I59
sg8
g9
sg10
I126
sg11
Vanti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII
p15025
sg13
I12
sa(dp15026
g7
I527
sg8
g9
sg10
I5
sg11
VAP3B2
p15027
sg13
I1
sa(dp15028
g7
I247
sg8
VP05129
p15029
sg10
I61
sg11
Vanti-protein kinase C gamma-, anti-glutamate receptor delta-2
p15030
sg13
I7
sa(dp15031
g7
I18
sg8
VP42261
p15032
sg10
I38
sg11
Vanti-metabotropic glutamate receptor 1
p15033
sg13
I4
sa(dp15034
g7
I356
sg8
g9
sg10
I49
sg11
Vanti-voltage-gated calcium channel-associated ACA
p15035
sg13
I4
sa(dp15036
g7
I476
sg8
VP01133
p15037
sg10
I40
sg11
Vepidermal growth factor-related receptor
p15038
sg13
I4
sasg14
(lp15039
(dp15040
g7
I227
sg17
VC0007758
p15041
sg10
I3
sg11
VACA
p15042
sg13
I1
sa(dp15043
g7
I227
sg17
VC0007758
p15044
sg10
I3
sg11
VACA
p15045
sg13
I1
sa(dp15046
g7
I227
sg17
VC0007758
p15047
sg10
I3
sg11
VACA
p15048
sg13
I1
sa(dp15049
g7
I197
sg17
VC0007758
p15050
sg10
I28
sg11
Vautoimmune cerebellar ataxia
p15051
sg13
I3
sa(dp15052
g7
I543
sg17
VC0262404
p15053
sg10
I23
sg11
Vcerebellar degeneration
p15054
sg13
I2
sasa(dp15055
g2
S'Part 1 focuses on anti-metabotropic glutamate receptor 1-, anti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII-associated autoimmune cerebellar ataxia (ACA); part 2 covers anti-protein kinase C gamma-, anti-glutamate receptor delta-2-, anti-Ca/RhoGTPase-activating protein 26- and anti-voltage-gated calcium channel-associated ACA; and part 3 reviews the current knowledge on anti-Tr/delta notch-like epidermal growth factor-related receptor-, anti-Nb/AP3B2-, anti-Yo/cerebellar degeneration-related protein 2- and Purkinje cell antibody 2-associated ACA, discusses differential diagnostic aspects and provides a summary and outlook.\n'
p15056
sg4
(lp15057
(dp15058
g7
I59
sg8
g9
sg10
I126
sg11
Vanti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII
p15059
sg13
I12
sa(dp15060
g7
I527
sg8
g9
sg10
I5
sg11
VAP3B2
p15061
sg13
I1
sa(dp15062
g7
I247
sg8
VP05129
p15063
sg10
I61
sg11
Vanti-protein kinase C gamma-, anti-glutamate receptor delta-2
p15064
sg13
I7
sa(dp15065
g7
I18
sg8
VP42261
p15066
sg10
I38
sg11
Vanti-metabotropic glutamate receptor 1
p15067
sg13
I4
sa(dp15068
g7
I356
sg8
g9
sg10
I49
sg11
Vanti-voltage-gated calcium channel-associated ACA
p15069
sg13
I4
sa(dp15070
g7
I476
sg8
VP01133
p15071
sg10
I40
sg11
Vepidermal growth factor-related receptor
p15072
sg13
I4
sasg14
(lp15073
(dp15074
g7
I227
sg17
VC0007758
p15075
sg10
I3
sg11
VACA
p15076
sg13
I1
sa(dp15077
g7
I227
sg17
VC0007758
p15078
sg10
I3
sg11
VACA
p15079
sg13
I1
sa(dp15080
g7
I227
sg17
VC0007758
p15081
sg10
I3
sg11
VACA
p15082
sg13
I1
sa(dp15083
g7
I197
sg17
VC0007758
p15084
sg10
I28
sg11
Vautoimmune cerebellar ataxia
p15085
sg13
I3
sa(dp15086
g7
I543
sg17
VC0262404
p15087
sg10
I23
sg11
Vcerebellar degeneration
p15088
sg13
I2
sasa(dp15089
g2
S"Lastly, a recent study identified delta/notch-like epidermal growth factor-related receptor (DNER) as the target antigen of Tr antibodies, a marker of cerebellar ataxia and Hodgkin's lymphoma.\n"
p15090
sg4
(lp15091
(dp15092
g7
I51
sg8
VP01133
p15093
sg10
I40
sg11
Vepidermal growth factor-related receptor
p15094
sg13
I4
sasg14
(lp15095
(dp15096
g7
I173
sg17
VC0019829
p15097
sg10
I18
sg11
VHodgkin's lymphoma
p15098
sg13
I2
sa(dp15099
g7
I151
sg17
VC0007758
p15100
sg10
I17
sg11
Vcerebellar ataxia
p15101
sg13
I2
sasa(dp15102
g2
S'Real-time quantitative PCR confirmed significantly increased expression of HAS2, CHSY1, and C4ST1 in the combined groups of CLE lesions (n = 8) compared to healthy controls (n = 4).\n'
p15103
sg4
(lp15104
(dp15105
g7
I75
sg8
g9
sg10
I4
sg11
VHAS2
p15106
sg13
I1
sa(dp15107
g7
I81
sg8
g9
sg10
I5
sg11
VCHSY1
p15108
sg13
I1
sa(dp15109
g7
I92
sg8
g9
sg10
I5
sg11
VC4ST1
p15110
sg13
I1
sasg14
(lp15111
(dp15112
g7
I124
sg17
VC2931489
p15113
sg10
I3
sg11
VCLE
p15114
sg13
I1
sasa(dp15115
g2
S'Thus, the increase in HA in CLE presumably results from upregulation of HAS2, whereas CHSY1 and C4ST1 appear to contribute to increased CS.\n'
p15116
sg4
(lp15117
(dp15118
g7
I96
sg8
g9
sg10
I5
sg11
VC4ST1
p15119
sg13
I1
sa(dp15120
g7
I86
sg8
g9
sg10
I5
sg11
VCHSY1
p15121
sg13
I1
sa(dp15122
g7
I72
sg8
g9
sg10
I4
sg11
VHAS2
p15123
sg13
I1
sasg14
(lp15124
(dp15125
g7
I28
sg17
VC2931489
p15126
sg10
I3
sg11
VCLE
p15127
sg13
I1
sasa(dp15128
g2
S'Through Part 4 of Maintenance of Certification for Family Physicians (MC-FP), American Board of Family Medicine (ABFM) diplomates participate in quality improvement (QI) modules for diabetes.\n'
p15129
sg4
(lp15130
sg14
(lp15131
(dp15132
g7
I182
sg17
VC0011849
p15133
sg10
I8
sg11
Vdiabetes
p15134
sg13
I1
sasa(dp15135
g2
S'Family physicians participating in MC-FP implemented improvement projects and showed quality improvements in caring for patients with diabetes.\n'
p15136
sg4
(lp15137
sg14
(lp15138
(dp15139
g7
I134
sg17
VC0011849
p15140
sg10
I8
sg11
Vdiabetes
p15141
sg13
I1
sasa(dp15142
g2
S"Insulin-dependent diabetes mellitus (IDDM) and Graves' disease (GD) are autoimmune endocrinopathies and associated with distinct HLA-DR and -DQ alleles as well as several tumor necrosis factor alpha (TNF-alpha) and beta (TNF-beta) alleles.\n"
p15143
sg4
(lp15144
(dp15145
g7
I129
sg8
VP30486
p15146
sg10
I6
sg11
VHLA-DR
p15147
sg13
I1
sa(dp15148
g7
I171
sg8
VP01375
p15149
sg10
I27
sg11
Vtumor necrosis factor alpha
p15150
sg13
I4
sa(dp15151
g7
I200
sg8
VP01375
p15152
sg10
I9
sg11
VTNF-alpha
p15153
sg13
I1
sa(dp15154
g7
I221
sg8
VP01375
p15155
sg10
I8
sg11
VTNF-beta
p15156
sg13
I1
sa(dp15157
g7
I0
sg8
VP01308
p15158
sg10
I7
sg11
VInsulin
p15159
sg13
I1
sasg14
(lp15160
(dp15161
g7
I64
sg17
VC0018213
p15162
sg10
I2
sg11
VGD
p15163
sg13
I1
sa(dp15164
g7
I72
sg17
VC0443146
p15165
sg10
I10
sg11
Vautoimmune
p15166
sg13
I1
sa(dp15167
g7
I171
sg17
VC0333516
p15168
sg10
I14
sg11
Vtumor necrosis
p15169
sg13
I2
sa(dp15170
g7
I0
sg17
VC0011854
p15171
sg10
I35
sg11
VInsulin-dependent diabetes mellitus
p15172
sg13
I3
sa(dp15173
g7
I47
sg17
VC0018213
p15174
sg10
I15
sg11
VGraves' disease
p15175
sg13
I2
sa(dp15176
g7
I83
sg17
VC0014130
p15177
sg10
I16
sg11
Vendocrinopathies
p15178
sg13
I1
sa(dp15179
g7
I37
sg17
VC0011854
p15180
sg10
I4
sg11
VIDDM
p15181
sg13
I1
sasa(dp15182
g2
S"Studies in Caucasians have suggested that the TNFB gene might be a susceptibility gene for Graves' disease.\n"
p15183
sg4
(lp15184
(dp15185
g7
I46
sg8
VP10515
p15186
sg10
I9
sg11
VTNFB gene
p15187
sg13
I2
sasg14
(lp15188
(dp15189
g7
I91
sg17
VC0018213
p15190
sg10
I15
sg11
VGraves' disease
p15191
sg13
I2
sasa(dp15192
g2
S"To investigate further the role of TNFB in predisposition to Graves' disease, we determined whether the TNFB disease associations in the Chinese were similar to those in Caucasians.\n"
p15193
sg4
(lp15194
(dp15195
g7
I35
sg8
VP10515
p15196
sg10
I4
sg11
VTNFB
p15197
sg13
I1
sasg14
(lp15198
(dp15199
g7
I61
sg17
VC0018213
p15200
sg10
I15
sg11
VGraves' disease
p15201
sg13
I2
sasa(dp15202
g2
S"We conclude that the TNFB associations with Graves' disease in the Hong Kong Chinese differ between the genders and from those described in Caucasians.\n"
p15203
sg4
(lp15204
sg14
(lp15205
(dp15206
g7
I44
sg17
VC0018213
p15207
sg10
I15
sg11
VGraves' disease
p15208
sg13
I2
sasa(dp15209
g2
S"The TNFB gene is not a susceptibility gene for Graves' disease.\n"
p15210
sg4
(lp15211
(dp15212
g7
I4
sg8
VP10515
p15213
sg10
I9
sg11
VTNFB gene
p15214
sg13
I2
sasg14
(lp15215
(dp15216
g7
I47
sg17
VC0018213
p15217
sg10
I15
sg11
VGraves' disease
p15218
sg13
I2
sasa(dp15219
g2
S"We show here a significant association of TNF beta polymorphisms with Graves' disease.\n"
p15220
sg4
(lp15221
(dp15222
g7
I42
sg8
VP01375
p15223
sg10
I8
sg11
VTNF beta
p15224
sg13
I2
sasg14
(lp15225
(dp15226
g7
I70
sg17
VC0018213
p15227
sg10
I15
sg11
VGraves' disease
p15228
sg13
I2
sasa(dp15229
g2
S"Although TNF beta polymorphisms are linked to A1B8DR3, these results suggest that they represent an additional susceptibility marker in Graves' disease.\n"
p15230
sg4
(lp15231
(dp15232
g7
I9
sg8
VP01375
p15233
sg10
I8
sg11
VTNF beta
p15234
sg13
I2
sasg14
(lp15235
(dp15236
g7
I136
sg17
VC0018213
p15237
sg10
I15
sg11
VGraves' disease
p15238
sg13
I2
sasa(dp15239
g2
S'Here, we summarize our findings of targeted SOX9 destruction by SCFFBW7 (Skp1/Cul1/F-box) in medulloblastoma and its potential for therapeutic intervention.\n'
p15240
sg4
(lp15241
(dp15242
g7
I78
sg8
g9
sg10
I4
sg11
VCul1
p15243
sg13
I1
sa(dp15244
g7
I44
sg8
VP48436
p15245
sg10
I16
sg11
VSOX9 destruction
p15246
sg13
I2
sa(dp15247
g7
I73
sg8
VP63208
p15248
sg10
I4
sg11
VSkp1
p15249
sg13
I1
sasg14
(lp15250
(dp15251
g7
I93
sg17
VC0025149
p15252
sg10
I15
sg11
Vmedulloblastoma
p15253
sg13
I1
sasa(dp15254
g2
S'A point mutation in mouse Vps33a (Buff mouse) causes albinism and bleeding (Hermansky-Pudlak syndrome) because of abnormalities in the trafficking of melanosomes and platelets.\n'
p15255
sg4
(lp15256
(dp15257
g7
I26
sg8
g9
sg10
I6
sg11
VVps33a
p15258
sg13
I1
sasg14
(lp15259
(dp15260
g7
I53
sg17
VC0001916
p15261
sg10
I8
sg11
Valbinism
p15262
sg13
I1
sa(dp15263
g7
I66
sg17
VC0019080
p15264
sg10
I8
sg11
Vbleeding
p15265
sg13
I1
sa(dp15266
g7
I76
sg17
VC0079504
p15267
sg10
I25
sg11
VHermansky-Pudlak syndrome
p15268
sg13
I2
sasa(dp15269
g2
S'A mutation in the Vps33a gene causes Hermansky-Pudlak Syndrome (HPS)-like-symptoms in the buff (bf) mouse mutant.\n'
p15270
sg4
(lp15271
(dp15272
g7
I18
sg8
g9
sg10
I11
sg11
VVps33a gene
p15273
sg13
I2
sasg14
(lp15274
(dp15275
g7
I64
sg17
VC0242994
p15276
sg10
I3
sg11
VHPS
p15277
sg13
I1
sa(dp15278
g7
I37
sg17
VC0079504
p15279
sg10
I25
sg11
VHermansky-Pudlak Syndrome
p15280
sg13
I2
sa(dp15281
g7
I106
sg17
VC0596988
p15282
sg10
I6
sg11
Vmutant
p15283
sg13
I1
sasa(dp15284
g2
S'Epicardial LGEs were identified in 10/13 and pericarditis in 6/13 RAH.\n'
p15285
sg4
(lp15286
sg14
(lp15287
(dp15288
g7
I45
sg17
VC0031046
p15289
sg10
I12
sg11
Vpericarditis
p15290
sg13
I1
sasa(dp15291
g2
S'An RA relapse was observed after 7-40 days in 10/13 RAH with myopericarditis.\n'
p15292
sg4
(lp15293
sg14
(lp15294
(dp15295
g7
I6
sg17
VC0277556
p15296
sg10
I7
sg11
Vrelapse
p15297
sg13
I1
sa(dp15298
g7
I61
sg17
VC0854532
p15299
sg10
I15
sg11
Vmyopericarditis
p15300
sg13
I1
sasa(dp15301
g2
S'We found that LGI3 and its receptors, ADAM22 and ADAM23, were significantly downregulated in glioma tissues.\n'
p15302
sg4
(lp15303
(dp15304
g7
I49
sg8
g9
sg10
I6
sg11
VADAM23
p15305
sg13
I1
sa(dp15306
g7
I14
sg8
g9
sg10
I4
sg11
VLGI3
p15307
sg13
I1
sa(dp15308
g7
I38
sg8
g9
sg10
I6
sg11
VADAM22
p15309
sg13
I1
sasg14
(lp15310
(dp15311
g7
I93
sg17
VC0017638
p15312
sg10
I6
sg11
Vglioma
p15313
sg13
I1
sasa(dp15314
g2
S'Analysis of expression microarray data of glioma cohorts demonstrated that low expression levels of LGI3, ADAM22 and ADAM23 were significantly associated with poor prognosis of glioma.\n'
p15315
sg4
(lp15316
(dp15317
g7
I106
sg8
g9
sg10
I6
sg11
VADAM22
p15318
sg13
I1
sa(dp15319
g7
I100
sg8
g9
sg10
I4
sg11
VLGI3
p15320
sg13
I1
sa(dp15321
g7
I117
sg8
g9
sg10
I6
sg11
VADAM23
p15322
sg13
I1
sasg14
(lp15323
(dp15324
g7
I42
sg17
VC0017638
p15325
sg10
I6
sg11
Vglioma
p15326
sg13
I1
sa(dp15327
g7
I42
sg17
VC0017638
p15328
sg10
I6
sg11
Vglioma
p15329
sg13
I1
sasa(dp15330
g2
S'Rather, we observed that, in ADAM23-heterotypic environments, ADAM23-negative cells promote tumor growth and metastasis by enhancing the proliferation and invasion of adjacent A23-positive cells through the production of LGI4 (Leucine-rich Glioma Inactivated 4) and nitric oxide (NO).\n'
p15331
sg4
(lp15332
(dp15333
g7
I227
sg8
VP30740
p15334
sg10
I33
sg11
VLeucine-rich Glioma Inactivated 4
p15335
sg13
I4
sa(dp15336
g7
I221
sg8
g9
sg10
I4
sg11
VLGI4
p15337
sg13
I1
sasg14
(lp15338
(dp15339
g7
I92
sg17
VC0598934
p15340
sg10
I12
sg11
Vtumor growth
p15341
sg13
I2
sa(dp15342
g7
I137
sg17
VC0334094
p15343
sg10
I13
sg11
Vproliferation
p15344
sg13
I1
sa(dp15345
g7
I155
sg17
VC2699153
p15346
sg10
I8
sg11
Vinvasion
p15347
sg13
I1
sa(dp15348
g7
I240
sg17
VC0017638
p15349
sg10
I6
sg11
VGlioma
p15350
sg13
I1
sa(dp15351
g7
I109
sg17
VC0027627
p15352
sg10
I10
sg11
Vmetastasis
p15353
sg13
I1
sasa(dp15354
g2
S'The aim of the present study was to evaluate ADAM28 and Insulin Like Growth Factor Binding Protein-3 (IGFBP-3)) gene expression in colorectal carcinoma tissues with regard to the overweight or obese status of the patients using an oligonucleotide microarray technique.\n'
p15355
sg4
(lp15356
(dp15357
g7
I102
sg8
VP17936
p15358
sg10
I7
sg11
VIGFBP-3
p15359
sg13
I1
sa(dp15360
g7
I45
sg8
g9
sg10
I6
sg11
VADAM28
p15361
sg13
I1
sa(dp15362
g7
I56
sg8
VP01308
p15363
sg10
I44
sg11
VInsulin Like Growth Factor Binding Protein-3
p15364
sg13
I6
sasg14
(lp15365
(dp15366
g7
I193
sg17
VC0028754
p15367
sg10
I5
sg11
Vobese
p15368
sg13
I1
sa(dp15369
g7
I131
sg17
VC0009402
p15370
sg10
I20
sg11
Vcolorectal carcinoma
p15371
sg13
I2
sa(dp15372
g7
I179
sg17
VC0497406
p15373
sg10
I10
sg11
Voverweight
p15374
sg13
I1
sasa(dp15375
g2
S'The expression of cancer stem cell marker cluster of differentiation 271 (CD271) was determined in traditional two-dimensional (2D) and 3D cultures of C918 uveal melanoma cells by fluorescent immunocytochemistry.\n'
p15376
sg4
(lp15377
sg14
(lp15378
(dp15379
g7
I156
sg17
VC0220633
p15380
sg10
I14
sg11
Vuveal melanoma
p15381
sg13
I2
sa(dp15382
g7
I18
sg17
VC0006826
p15383
sg10
I6
sg11
Vcancer
p15384
sg13
I1
sasa(dp15385
g2
S'The missense mutation (c.370G &gt; A) in the TGFBI gene and insert mutation (c.1456-1457ins GAT) in the KRT12 gene were identified in a 23-year-old male patient with concurrent KC and GCD.\n'
p15386
sg4
(lp15387
(dp15388
g7
I77
sg8
g9
sg10
I18
sg11
Vc.1456-1457ins GAT
p15389
sg13
I2
sa(dp15390
g7
I104
sg8
g9
sg10
I10
sg11
VKRT12 gene
p15391
sg13
I2
sasg14
(lp15392
sa(dp15393
g2
S'This study investigated the TGFBI gene mutation types in outpatients clinically diagnosed with granular corneal dystrophy (GCD) prior to phototherapeutic keratectomy (PTK), also calculated the mutation rate of subjects with normal corneas, but positive family history.\n'
p15394
sg4
(lp15395
(dp15396
g7
I167
sg8
g9
sg10
I3
sg11
VPTK
p15397
sg13
I1
sa(dp15398
g7
I137
sg8
g9
sg10
I28
sg11
Vphototherapeutic keratectomy
p15399
sg13
I2
sasg14
(lp15400
(dp15401
g7
I95
sg17
VC0018179
p15402
sg10
I26
sg11
Vgranular corneal dystrophy
p15403
sg13
I3
sa(dp15404
g7
I123
sg17
VC0018179
p15405
sg10
I3
sg11
VGCD
p15406
sg13
I1
sasa(dp15407
g2
S'To describe 2 unrelated families with multiple members demonstrating a less commonly recognized vortex pattern of corneal deposits confirmed to be granular corneal dystrophy type 1 (GCD1) after identification of the p.(Arg555Trp) mutation in the transforming growth factor Beta-induced gene (TGFBI).\n'
p15408
sg4
(lp15409
(dp15410
g7
I246
sg8
VP18075
p15411
sg10
I31
sg11
Vtransforming growth factor Beta
p15412
sg13
I4
sasg14
(lp15413
(dp15414
g7
I182
sg17
VC1641846
p15415
sg10
I4
sg11
VGCD1
p15416
sg13
I1
sa(dp15417
g7
I114
sg17
VC0162281
p15418
sg10
I16
sg11
Vcorneal deposits
p15419
sg13
I2
sa(dp15420
g7
I147
sg17
VC1641846
p15421
sg10
I33
sg11
Vgranular corneal dystrophy type 1
p15422
sg13
I5
sasa(dp15423
g2
S'Screening of TGFBI in both families revealed a heterozygous missense mutation [p.(Arg555Trp)] in exon 12, confirming the diagnosis of GCD1.\n'
p15424
sg4
(lp15425
sg14
(lp15426
(dp15427
g7
I134
sg17
VC1641846
p15428
sg10
I4
sg11
VGCD1
p15429
sg13
I1
sasa(dp15430
g2
S'Although this pattern of dystrophic deposits is not recognized by clinicians as a typical phenotype of GCD1, it is consistent with the production of the majority of the TGFBI protein by the corneal epithelium.\n'
p15431
sg4
(lp15432
sg14
(lp15433
(dp15434
g7
I103
sg17
VC1641846
p15435
sg10
I4
sg11
VGCD1
p15436
sg13
I1
sasa(dp15437
g2
S'In this study, patients with macular corneal dystrophy (MCD; n = 18), granular corneal dystrophy type 1 (GCD1; n = 12), and lattice corneal dystrophy type 1 (LCD1; n = 4), as well as 50 healthy controls, were subjected to clinical and genetic examinations.\n'
p15438
sg4
(lp15439
sg14
(lp15440
(dp15441
g7
I158
sg17
VC1690006
p15442
sg10
I4
sg11
VLCD1
p15443
sg13
I1
sa(dp15444
g7
I70
sg17
VC1641846
p15445
sg10
I33
sg11
Vgranular corneal dystrophy type 1
p15446
sg13
I5
sa(dp15447
g7
I105
sg17
VC1641846
p15448
sg10
I4
sg11
VGCD1
p15449
sg13
I1
sa(dp15450
g7
I29
sg17
VC0024439
p15451
sg10
I25
sg11
Vmacular corneal dystrophy
p15452
sg13
I3
sa(dp15453
g7
I56
sg17
VC1636149
p15454
sg10
I3
sg11
VMCD
p15455
sg13
I1
sa(dp15456
g7
I124
sg17
VC2931650
p15457
sg10
I32
sg11
Vlattice corneal dystrophy type 1
p15458
sg13
I5
sasa(dp15459
g2
S'Variations were analyzed with DNA sequencing in the coding region of CHST6 in patients with MCD and exons 4 and 12 in TGFBI in patients with LCD1 and GCD1.\n'
p15460
sg4
(lp15461
(dp15462
g7
I69
sg8
g9
sg10
I5
sg11
VCHST6
p15463
sg13
I1
sasg14
(lp15464
(dp15465
g7
I141
sg17
VC1690006
p15466
sg10
I4
sg11
VLCD1
p15467
sg13
I1
sa(dp15468
g7
I92
sg17
VC1636149
p15469
sg10
I3
sg11
VMCD
p15470
sg13
I1
sa(dp15471
g7
I150
sg17
VC1641846
p15472
sg10
I4
sg11
VGCD1
p15473
sg13
I1
sasa(dp15474
g2
S'The previously reported R555W mutation in TGFBI was detected in 12 patients with GCD1, and the R124C mutation in TGFBI was detected in four patients with LCD1.\n'
p15475
sg4
(lp15476
sg14
(lp15477
(dp15478
g7
I81
sg17
VC1641846
p15479
sg10
I4
sg11
VGCD1
p15480
sg13
I1
sa(dp15481
g7
I154
sg17
VC1690006
p15482
sg10
I4
sg11
VLCD1
p15483
sg13
I1
sasa(dp15484
g2
S'We detected previously reported, well-known hot spot mutations in TGFBI in the patients with GCD1 and LCD1.\n'
p15485
sg4
(lp15486
sg14
(lp15487
(dp15488
g7
I93
sg17
VC1641846
p15489
sg10
I4
sg11
VGCD1
p15490
sg13
I1
sa(dp15491
g7
I44
sg17
VC0263214
p15492
sg10
I8
sg11
Vhot spot
p15493
sg13
I2
sa(dp15494
g7
I102
sg17
VC1690006
p15495
sg10
I4
sg11
VLCD1
p15496
sg13
I1
sasa(dp15497
g2
S'TGFBeta1-induced expression of transforming growth factor Beta-induced protein (TGFBIp) and extracellular matrix (ECM) genes plays a major role in the development of granular corneal dystrophy type 2 (GCD2: also called Avellino corneal dystrophy).\n'
p15498
sg4
(lp15499
(dp15500
g7
I0
sg8
VP01137
p15501
sg10
I8
sg11
VTGFBeta1
p15502
sg13
I1
sa(dp15503
g7
I31
sg8
VP18075
p15504
sg10
I31
sg11
Vtransforming growth factor Beta
p15505
sg13
I4
sa(dp15506
g7
I92
sg8
g9
sg10
I32
sg11
Vextracellular matrix (ECM) genes
p15507
sg13
I4
sasg14
(lp15508
(dp15509
g7
I219
sg17
VC1275685
p15510
sg10
I26
sg11
VAvellino corneal dystrophy
p15511
sg13
I3
sa(dp15512
g7
I166
sg17
VC1275685
p15513
sg10
I33
sg11
Vgranular corneal dystrophy type 2
p15514
sg13
I5
sasa(dp15515
g2
S'We examined the role of chromatin markers such as histone H3 lysine methylation (H3Kme) in TGFBeta1-induced TGFBIp and ECM gene expression in normal and GCD2-derived human corneal fibroblasts.\n'
p15516
sg4
(lp15517
(dp15518
g7
I91
sg8
VP01137
p15519
sg10
I8
sg11
VTGFBeta1
p15520
sg13
I1
sa(dp15521
g7
I119
sg8
g9
sg10
I8
sg11
VECM gene
p15522
sg13
I2
sa(dp15523
g7
I50
sg8
g9
sg10
I10
sg11
Vhistone H3
p15524
sg13
I2
sasg14
(lp15525
sa(dp15526
g2
S'Transcription and extracellular-secretion levels of TGFBIp were high in normal cells compared with those in GCD2-derived cells and were related to H3K4me3 levels but not to DNA methylation over the TGFBI locus.\n'
p15527
sg4
(lp15528
sg14
(lp15529
sa(dp15530
g2
S'This study expands on our previous research investigating dystrophic stromal aggregates, with the aim of better elucidating the pathomechanism of two conditions arising from the most common TGFBI mutations: granular corneal dystrophy type 1 (GCD1; R555W) and lattice corneal dystrophy type 1 (LCD1; R124C).\n'
p15531
sg4
(lp15532
sg14
(lp15533
(dp15534
g7
I259
sg17
VC2931650
p15535
sg10
I32
sg11
Vlattice corneal dystrophy type 1
p15536
sg13
I5
sa(dp15537
g7
I207
sg17
VC1641846
p15538
sg10
I33
sg11
Vgranular corneal dystrophy type 1
p15539
sg13
I5
sa(dp15540
g7
I293
sg17
VC1690006
p15541
sg10
I4
sg11
VLCD1
p15542
sg13
I1
sa(dp15543
g7
I242
sg17
VC1641846
p15544
sg10
I4
sg11
VGCD1
p15545
sg13
I1
sasa(dp15546
g2
S'Patient corneas with GCD1 and LCD1 were stained with hematoxylin and eosin and Congo red to visualize stromal nonamyloid and amyloid deposits, respectively.\n'
p15547
sg4
(lp15548
sg14
(lp15549
(dp15550
g7
I30
sg17
VC1690006
p15551
sg10
I4
sg11
VLCD1
p15552
sg13
I1
sa(dp15553
g7
I21
sg17
VC1641846
p15554
sg10
I4
sg11
VGCD1
p15555
sg13
I1
sa(dp15556
g7
I125
sg17
VC2936349
p15557
sg10
I16
sg11
Vamyloid deposits
p15558
sg13
I2
sasa(dp15559
g2
S'An increase in the number of residues experiencing cleavage was observed in both GCD1 aggregates and LCD1 deposits.\n'
p15560
sg4
(lp15561
sg14
(lp15562
(dp15563
g7
I81
sg17
VC1641846
p15564
sg10
I4
sg11
VGCD1
p15565
sg13
I1
sa(dp15566
g7
I101
sg17
VC1690006
p15567
sg10
I4
sg11
VLCD1
p15568
sg13
I1
sasa(dp15569
g2
S'The study reveals previously unknown differences between the protein composition of GCD1 and LCD1 aggregates, and confirms the presence of the HtrA1 protease in LCD1-amyloid aggregates.\n'
p15570
sg4
(lp15571
(dp15572
g7
I143
sg8
g9
sg10
I14
sg11
VHtrA1 protease
p15573
sg13
I2
sasg14
(lp15574
(dp15575
g7
I93
sg17
VC1690006
p15576
sg10
I4
sg11
VLCD1
p15577
sg13
I1
sa(dp15578
g7
I93
sg17
VC1690006
p15579
sg10
I4
sg11
VLCD1
p15580
sg13
I1
sa(dp15581
g7
I166
sg17
VC0011560
p15582
sg10
I7
sg11
Vamyloid
p15583
sg13
I1
sa(dp15584
g7
I84
sg17
VC1641846
p15585
sg10
I4
sg11
VGCD1
p15586
sg13
I1
sasa(dp15587
g2
S'GCD is a Category 1, Stromal, TGFBI-associated corneal dystrophy.\n'
p15588
sg4
(lp15589
sg14
(lp15590
(dp15591
g7
I47
sg17
VC0010036
p15592
sg10
I17
sg11
Vcorneal dystrophy
p15593
sg13
I2
sasa(dp15594
g2
S'We show here that the Arg555Trp mutant of the fourth fasciclin 1 (FAS1-4) domain of the protein (TGFBIp/keratoepithelin/Betaig-h3), associated with granular corneal dystrophy type 1, is significantly less susceptible to proteolysis by thermolysin and trypsin than the WT domain.\n'
p15595
sg4
(lp15596
(dp15597
g7
I66
sg8
g9
sg10
I6
sg11
VFAS1-4
p15598
sg13
I1
sa(dp15599
g7
I251
sg8
VP35030
p15600
sg10
I7
sg11
Vtrypsin
p15601
sg13
I1
sa(dp15602
g7
I22
sg8
g9
sg10
I16
sg11
VArg555Trp mutant
p15603
sg13
I2
sasg14
(lp15604
(dp15605
g7
I32
sg17
VC0596988
p15606
sg10
I6
sg11
Vmutant
p15607
sg13
I1
sa(dp15608
g7
I148
sg17
VC0018179
p15609
sg10
I26
sg11
Vgranular corneal dystrophy
p15610
sg13
I3
sasa(dp15611
g2
S'MiR-139-5p has been reported to be overexpressed in many types of cancers, but its role in bladder cancer has not been elucidated yet.\n'
p15612
sg4
(lp15613
(dp15614
g7
I0
sg8
g9
sg10
I10
sg11
VMiR-139-5p
p15615
sg13
I1
sasg14
(lp15616
(dp15617
g7
I91
sg17
VC0699885
p15618
sg10
I14
sg11
Vbladder cancer
p15619
sg13
I2
sa(dp15620
g7
I66
sg17
VC0006826
p15621
sg10
I7
sg11
Vcancers
p15622
sg13
I1
sasa(dp15623
g2
S'Here, we report that miR-139-5p functions as a tumor suppressor in bladder cancer and inhibits the cancer stem cell self-renewal by targeting Bmi1 directly.\n'
p15624
sg4
(lp15625
(dp15626
g7
I21
sg8
g9
sg10
I10
sg11
VmiR-139-5p
p15627
sg13
I1
sa(dp15628
g7
I142
sg8
VP35226
p15629
sg10
I4
sg11
VBmi1
p15630
sg13
I1
sasg14
(lp15631
(dp15632
g7
I47
sg17
VC0027651
p15633
sg10
I5
sg11
Vtumor
p15634
sg13
I1
sa(dp15635
g7
I67
sg17
VC0699885
p15636
sg10
I14
sg11
Vbladder cancer
p15637
sg13
I2
sa(dp15638
g7
I75
sg17
VC0006826
p15639
sg10
I6
sg11
Vcancer
p15640
sg13
I1
sasa(dp15641
g2
S'We found that miR-139-5p expression was significantly downregulated in the bladder cancer specimens compared with that in adjacent normal tissues.\n'
p15642
sg4
(lp15643
(dp15644
g7
I14
sg8
g9
sg10
I10
sg11
VmiR-139-5p
p15645
sg13
I1
sasg14
(lp15646
(dp15647
g7
I75
sg17
VC0699885
p15648
sg10
I14
sg11
Vbladder cancer
p15649
sg13
I2
sasa(dp15650
g2
S'In vitro, restoration of miR-139-5p expression significantly inhibited the proliferation of bladder cancer cells.\n'
p15651
sg4
(lp15652
(dp15653
g7
I25
sg8
g9
sg10
I10
sg11
VmiR-139-5p
p15654
sg13
I1
sasg14
(lp15655
(dp15656
g7
I75
sg17
VC0334094
p15657
sg10
I13
sg11
Vproliferation
p15658
sg13
I1
sa(dp15659
g7
I92
sg17
VC0699885
p15660
sg10
I14
sg11
Vbladder cancer
p15661
sg13
I2
sasa(dp15662
g2
S'Stem cell-related proteins such as c-MYC, NANOG, OCT4, and KLF4 and signaling pathways such as Wnt signaling were suppressed by restoration of miR-139-5p in bladder cancer cells.\n'
p15663
sg4
(lp15664
(dp15665
g7
I143
sg8
g9
sg10
I10
sg11
VmiR-139-5p
p15666
sg13
I1
sa(dp15667
g7
I42
sg8
g9
sg10
I5
sg11
VNANOG
p15668
sg13
I1
sa(dp15669
g7
I35
sg8
VP12524
p15670
sg10
I5
sg11
Vc-MYC
p15671
sg13
I1
sa(dp15672
g7
I59
sg8
g9
sg10
I4
sg11
VKLF4
p15673
sg13
I1
sa(dp15674
g7
I0
sg8
VP02649
p15675
sg10
I26
sg11
VStem cell-related proteins
p15676
sg13
I3
sasg14
(lp15677
(dp15678
g7
I157
sg17
VC0699885
p15679
sg10
I14
sg11
Vbladder cancer
p15680
sg13
I2
sasa(dp15681
g2
S'In addition, miR-139-5p expression also blocked self-renewal of bladder cancer stem cells by inhibiting Bmi1.\n'
p15682
sg4
(lp15683
(dp15684
g7
I104
sg8
VP35226
p15685
sg10
I4
sg11
VBmi1
p15686
sg13
I1
sa(dp15687
g7
I13
sg8
g9
sg10
I10
sg11
VmiR-139-5p
p15688
sg13
I1
sasg14
(lp15689
(dp15690
g7
I64
sg17
VC0699885
p15691
sg10
I14
sg11
Vbladder cancer
p15692
sg13
I2
sasa(dp15693
g2
S'In summary, our study supports that miR-139-5p acts as a tumor suppressor in bladder cancer development and suppresses cancer stem cell property of bladder cancer.\n'
p15694
sg4
(lp15695
(dp15696
g7
I36
sg8
g9
sg10
I10
sg11
VmiR-139-5p
p15697
sg13
I1
sasg14
(lp15698
(dp15699
g7
I77
sg17
VC0699885
p15700
sg10
I14
sg11
Vbladder cancer
p15701
sg13
I2
sa(dp15702
g7
I57
sg17
VC0027651
p15703
sg10
I5
sg11
Vtumor
p15704
sg13
I1
sa(dp15705
g7
I77
sg17
VC0699885
p15706
sg10
I14
sg11
Vbladder cancer
p15707
sg13
I2
sa(dp15708
g7
I85
sg17
VC0006826
p15709
sg10
I6
sg11
Vcancer
p15710
sg13
I1
sasa(dp15711
g2
S'Our study also suggests that miR-139-5p has the potential to be used as a therapeutic molecule for bladder cancer treatment.\n'
p15712
sg4
(lp15713
(dp15714
g7
I29
sg8
g9
sg10
I10
sg11
VmiR-139-5p
p15715
sg13
I1
sasg14
(lp15716
(dp15717
g7
I99
sg17
VC0699885
p15718
sg10
I14
sg11
Vbladder cancer
p15719
sg13
I2
sasa(dp15720
g2
S'We present a case with CblC disease and pulmonary arterial hypertension (PAH) as the main symptom.\n'
p15721
sg4
(lp15722
(dp15723
g7
I23
sg8
g9
sg10
I4
sg11
VCblC
p15724
sg13
I1
sasg14
(lp15725
(dp15726
g7
I40
sg17
VC0152171
p15727
sg10
I31
sg11
Vpulmonary arterial hypertension
p15728
sg13
I3
sa(dp15729
g7
I73
sg17
VC0152171
p15730
sg10
I3
sg11
VPAH
p15731
sg13
I1
sa(dp15732
g7
I90
sg17
VC1457887
p15733
sg10
I7
sg11
Vsymptom
p15734
sg13
I1
sasa(dp15735
g2
S'CblC disease should be considered in the differential diagnosis of pulmonary hypertension.\n'
p15736
sg4
(lp15737
(dp15738
g7
I0
sg8
g9
sg10
I4
sg11
VCblC
p15739
sg13
I1
sasg14
(lp15740
(dp15741
g7
I67
sg17
VC0020542
p15742
sg10
I22
sg11
Vpulmonary hypertension
p15743
sg13
I2
sasa(dp15744
g2
S"Genetic association of rs678849 along with neuroimaging and biomarker phenotypes, parallel with the known involvements of the OPRD1 in drug abuse, provided additional support for targeting these receptors as potential therapeutic targets in both neurodegenerative diseases and neuropsychiactric disorders such as Alzheimer's disease.\n"
p15745
sg4
(lp15746
(dp15747
g7
I126
sg8
VP41143
p15748
sg10
I5
sg11
VOPRD1
p15749
sg13
I1
sasg14
(lp15750
(dp15751
g7
I313
sg17
VC1521724
p15752
sg10
I19
sg11
VAlzheimer's disease
p15753
sg13
I2
sa(dp15754
g7
I246
sg17
VC0524851
p15755
sg10
I26
sg11
Vneurodegenerative diseases
p15756
sg13
I2
sa(dp15757
g7
I135
sg17
VC0013146
p15758
sg10
I10
sg11
Vdrug abuse
p15759
sg13
I2
sasa(dp15760
g2
S'Recently, a robust up-regulation of human natural killer-1 sulfotransferase (HNK-1ST) was found in several subsets of melanoma cells during RA-mediated differentiation.\n'
p15761
sg4
(lp15762
(dp15763
g7
I36
sg8
g9
sg10
I39
sg11
Vhuman natural killer-1 sulfotransferase
p15764
sg13
I4
sa(dp15765
g7
I77
sg8
g9
sg10
I7
sg11
VHNK-1ST
p15766
sg13
I1
sasg14
(lp15767
(dp15768
g7
I118
sg17
VC0025202
p15769
sg10
I8
sg11
Vmelanoma
p15770
sg13
I1
sasa(dp15771
g2
S'Here, we show that HNK-1ST changed the glycosylation state and reduced the ligand binding activity of Alfa-dystroglycan (Alfa-DG) in RA-treated S91 melanoma cells, which contributed to an attenuation of cell migration.\n'
p15772
sg4
(lp15773
(dp15774
g7
I121
sg8
g9
sg10
I7
sg11
VAlfa-DG
p15775
sg13
I1
sa(dp15776
g7
I102
sg8
g9
sg10
I17
sg11
VAlfa-dystroglycan
p15777
sg13
I1
sa(dp15778
g7
I19
sg8
g9
sg10
I7
sg11
VHNK-1ST
p15779
sg13
I1
sasg14
(lp15780
(dp15781
g7
I148
sg17
VC0025202
p15782
sg10
I8
sg11
Vmelanoma
p15783
sg13
I1
sasa(dp15784
g2
S'Ten genes of importance for HNK-1 biosynthesis (B3GAT1, B3GAT2, and CHST10) or for the formation of perineuronal nets (TNR, BCAN, NCAN, HAPLN1, HAPLN2, HAPLN3, and HAPLN4) were investigated for potential involvement in schizophrenia (SCZ) susceptibility, by genotyping 104 tagSNPs in the Scandinavian Collaboration on Psychiatric Etiology sample (849 cases; 1602 control subjects).\n'
p15785
sg4
(lp15786
(dp15787
g7
I144
sg8
g9
sg10
I6
sg11
VHAPLN2
p15788
sg13
I1
sa(dp15789
g7
I28
sg8
g9
sg10
I5
sg11
VHNK-1
p15790
sg13
I1
sa(dp15791
g7
I119
sg8
g9
sg10
I3
sg11
VTNR
p15792
sg13
I1
sa(dp15793
g7
I83
sg8
g9
sg10
I34
sg11
Vthe formation of perineuronal nets
p15794
sg13
I5
sa(dp15795
g7
I130
sg8
g9
sg10
I4
sg11
VNCAN
p15796
sg13
I1
sa(dp15797
g7
I136
sg8
VP10915
p15798
sg10
I6
sg11
VHAPLN1
p15799
sg13
I1
sa(dp15800
g7
I124
sg8
g9
sg10
I4
sg11
VBCAN
p15801
sg13
I1
sa(dp15802
g7
I152
sg8
g9
sg10
I6
sg11
VHAPLN3
p15803
sg13
I1
sa(dp15804
g7
I48
sg8
g9
sg10
I6
sg11
VB3GAT1
p15805
sg13
I1
sa(dp15806
g7
I68
sg8
g9
sg10
I6
sg11
VCHST10
p15807
sg13
I1
sa(dp15808
g7
I56
sg8
g9
sg10
I6
sg11
VB3GAT2
p15809
sg13
I1
sa(dp15810
g7
I164
sg8
g9
sg10
I6
sg11
VHAPLN4
p15811
sg13
I1
sasg14
(lp15812
(dp15813
g7
I234
sg17
VC0036341
p15814
sg10
I3
sg11
VSCZ
p15815
sg13
I1
sa(dp15816
g7
I219
sg17
VC0036341
p15817
sg10
I13
sg11
Vschizophrenia
p15818
sg13
I1
sasa(dp15819
g2
S'We show that CHST10 is also regulated by RARgamma in a significant subset of human melanoma cells, and three-dimensional cell culture migration assays suggest that CHST10 functions as a suppressor of invasiveness, but not proliferation, in these cells.\n'
p15820
sg4
(lp15821
(dp15822
g7
I41
sg8
VP13631
p15823
sg10
I8
sg11
VRARgamma
p15824
sg13
I1
sa(dp15825
g7
I13
sg8
g9
sg10
I6
sg11
VCHST10
p15826
sg13
I1
sa(dp15827
g7
I13
sg8
g9
sg10
I6
sg11
VCHST10
p15828
sg13
I1
sasg14
(lp15829
(dp15830
g7
I83
sg17
VC0025202
p15831
sg10
I8
sg11
Vmelanoma
p15832
sg13
I1
sa(dp15833
g7
I222
sg17
VC0334094
p15834
sg10
I13
sg11
Vproliferation
p15835
sg13
I1
sasa(dp15836
g2
S'Induction of CHST10 by RARgamma-activating retinoids may present a novel therapeutic strategy to inhibit invasiveness in a subset of melanoma patients.\n'
p15837
sg4
(lp15838
(dp15839
g7
I23
sg8
VP13631
p15840
sg10
I8
sg11
VRARgamma
p15841
sg13
I1
sa(dp15842
g7
I13
sg8
g9
sg10
I6
sg11
VCHST10
p15843
sg13
I1
sasg14
(lp15844
(dp15845
g7
I133
sg17
VC0025202
p15846
sg10
I8
sg11
Vmelanoma
p15847
sg13
I1
sasa(dp15848
g2
S'No disease-associated mutations were detected in the candidate genes SEMA4C, CNGA3 or HNK1ST from within the region.\n'
p15849
sg4
(lp15850
(dp15851
g7
I77
sg8
g9
sg10
I5
sg11
VCNGA3
p15852
sg13
I1
sa(dp15853
g7
I86
sg8
g9
sg10
I6
sg11
VHNK1ST
p15854
sg13
I1
sa(dp15855
g7
I69
sg8
g9
sg10
I6
sg11
VSEMA4C
p15856
sg13
I1
sasg14
(lp15857
sa(dp15858
g2
S'Most XLMTM patients develop severe muscle weakness leading to respiratory failure and death, typically within 2 years of age.\n'
p15859
sg4
(lp15860
sg14
(lp15861
(dp15862
g7
I35
sg17
VC0030552
p15863
sg10
I15
sg11
Vmuscle weakness
p15864
sg13
I2
sa(dp15865
g7
I62
sg17
VC1145670
p15866
sg10
I19
sg11
Vrespiratory failure
p15867
sg13
I2
sa(dp15868
g7
I5
sg17
VC0410203
p15869
sg10
I5
sg11
VXLMTM
p15870
sg13
I1
sasa(dp15871
g2
S'Mutations in the MTM1 gene cause X-linked myotubular myopathy (XLMTM), characterized by neonatal hypotonia and respiratory failure, and are responsible for a premature mortality in affected males.\n'
p15872
sg4
(lp15873
(dp15874
g7
I17
sg8
g9
sg10
I9
sg11
VMTM1 gene
p15875
sg13
I2
sasg14
(lp15876
(dp15877
g7
I17
sg17
VC0410203
p15878
sg10
I4
sg11
VMTM1
p15879
sg13
I1
sa(dp15880
g7
I33
sg17
VC0410203
p15881
sg10
I28
sg11
VX-linked myotubular myopathy
p15882
sg13
I3
sa(dp15883
g7
I88
sg17
VC0270971
p15884
sg10
I18
sg11
Vneonatal hypotonia
p15885
sg13
I2
sa(dp15886
g7
I63
sg17
VC0410203
p15887
sg10
I5
sg11
VXLMTM
p15888
sg13
I1
sa(dp15889
g7
I111
sg17
VC1145670
p15890
sg10
I19
sg11
Vrespiratory failure
p15891
sg13
I2
sasa(dp15892
g2
S'X-linked myotubular myopathy (XLMTM) is a congenital neuromuscular disorder defined by severe hypotonia, respiratory failure and histopathologic changes in muscle biopsy.\n'
p15893
sg4
(lp15894
sg14
(lp15895
(dp15896
g7
I0
sg17
VC0410203
p15897
sg10
I28
sg11
VX-linked myotubular myopathy
p15898
sg13
I3
sa(dp15899
g7
I105
sg17
VC1145670
p15900
sg10
I19
sg11
Vrespiratory failure
p15901
sg13
I2
sa(dp15902
g7
I30
sg17
VC0410203
p15903
sg10
I5
sg11
VXLMTM
p15904
sg13
I1
sa(dp15905
g7
I94
sg17
VC0026827
p15906
sg10
I9
sg11
Vhypotonia
p15907
sg13
I1
sa(dp15908
g7
I42
sg17
VC0596371
p15909
sg10
I33
sg11
Vcongenital neuromuscular disorder
p15910
sg13
I3
sasa(dp15911
g2
S'Centronuclear (myotubular) myopathy (CNM) is congenital and produces various degrees of muscular weakness and associated complications such as respiratory failure.\n'
p15912
sg4
(lp15913
sg14
(lp15914
(dp15915
g7
I27
sg17
VC0026848
p15916
sg10
I8
sg11
Vmyopathy
p15917
sg13
I1
sa(dp15918
g7
I143
sg17
VC1145670
p15919
sg10
I19
sg11
Vrespiratory failure
p15920
sg13
I2
sa(dp15921
g7
I88
sg17
VC0151786
p15922
sg10
I17
sg11
Vmuscular weakness
p15923
sg13
I2
sasa(dp15924
g2
S'Patients with XLMTM often have severe perinatal weakness that requires mechanical ventilation to prevent death from respiratory failure.\n'
p15925
sg4
(lp15926
sg14
(lp15927
(dp15928
g7
I48
sg17
VC1883552
p15929
sg10
I8
sg11
Vweakness
p15930
sg13
I1
sa(dp15931
g7
I116
sg17
VC1145670
p15932
sg10
I19
sg11
Vrespiratory failure
p15933
sg13
I2
sa(dp15934
g7
I14
sg17
VC0410203
p15935
sg10
I5
sg11
VXLMTM
p15936
sg13
I1
sasa(dp15937
g2
S'This review addresses hearing loss as it occurs and has been reported in Muenke syndrome as well as six additional FGFR related craniosynostosis syndromes (Apert syndrome, Pfeiffer syndrome, Crouzon syndrome, Beare-Stevenson syndrome, Crouzon syndrome with acanthosis nigricans, and Jackson-Weiss syndrome.\n'
p15938
sg4
(lp15939
sg14
(lp15940
(dp15941
g7
I235
sg17
VC2677099
p15942
sg10
I42
sg11
VCrouzon syndrome with acanthosis nigricans
p15943
sg13
I5
sa(dp15944
g7
I22
sg17
VC0011053
p15945
sg10
I12
sg11
Vhearing loss
p15946
sg13
I2
sa(dp15947
g7
I162
sg17
VC0220658
p15948
sg10
I18
sg11
Vsyndrome, Pfeiffer
p15949
sg13
I2
sa(dp15950
g7
I128
sg17
VC0010278
p15951
sg10
I26
sg11
Vcraniosynostosis syndromes
p15952
sg13
I2
sa(dp15953
g7
I181
sg17
VC2931196
p15954
sg10
I17
sg11
Vsyndrome, Crouzon
p15955
sg13
I2
sa(dp15956
g7
I283
sg17
VC0795998
p15957
sg10
I22
sg11
VJackson-Weiss syndrome
p15958
sg13
I2
sa(dp15959
g7
I209
sg17
VC1852406
p15960
sg10
I24
sg11
VBeare-Stevenson syndrome
p15961
sg13
I2
sa(dp15962
g7
I73
sg17
VC1864436
p15963
sg10
I15
sg11
VMuenke syndrome
p15964
sg13
I2
sa(dp15965
g7
I80
sg17
VC0039082
p15966
sg10
I8
sg11
Vsyndrome
p15967
sg13
I1
sa(dp15968
g7
I181
sg17
VC2931196
p15969
sg10
I17
sg11
Vsyndrome, Crouzon
p15970
sg13
I2
sasa(dp15971
g2
S'Our literature review revealed the following incidences of hearing loss in FGFR craniosynostoses: 61% in Muenke syndrome, 80% in Apert Syndrome, 92% in Pfeiffer syndrome, 74% in Crouzon syndrome, 68% in Jackson Weiss syndrome, 4% in Beare Stevenson syndrome and 14% in Crouzon syndrome with Acanthosis Nigricans.\n'
p15972
sg4
(lp15973
sg14
(lp15974
(dp15975
g7
I112
sg17
VC0039082
p15976
sg10
I8
sg11
Vsyndrome
p15977
sg13
I1
sa(dp15978
g7
I59
sg17
VC0011053
p15979
sg10
I12
sg11
Vhearing loss
p15980
sg13
I2
sa(dp15981
g7
I80
sg17
VC0010278
p15982
sg10
I16
sg11
Vcraniosynostoses
p15983
sg13
I1
sa(dp15984
g7
I203
sg17
VC0795998
p15985
sg10
I22
sg11
VJackson Weiss syndrome
p15986
sg13
I3
sa(dp15987
g7
I269
sg17
VC2677099
p15988
sg10
I42
sg11
VCrouzon syndrome with Acanthosis Nigricans
p15989
sg13
I5
sa(dp15990
g7
I105
sg17
VC1864436
p15991
sg10
I15
sg11
VMuenke syndrome
p15992
sg13
I2
sa(dp15993
g7
I178
sg17
VC0010273
p15994
sg10
I16
sg11
VCrouzon syndrome
p15995
sg13
I2
sa(dp15996
g7
I152
sg17
VC0265303
p15997
sg10
I17
sg11
VPfeiffer syndrome
p15998
sg13
I2
sa(dp15999
g7
I129
sg17
VC0001193
p16000
sg10
I14
sg11
VApert Syndrome
p16001
sg13
I2
sasa(dp16002
g2
S'This study reveals the pleiotropic effects of the FGFR2 Y394C mutation evidenced by cutis gyrata, acanthosis nigricans, and craniosynostosis and provides a useful model for investigating the molecular mechanisms of skin and skull development.\n'
p16003
sg4
(lp16004
sg14
(lp16005
(dp16006
g7
I98
sg17
VC0000889
p16007
sg10
I20
sg11
Vacanthosis nigricans
p16008
sg13
I2
sa(dp16009
g7
I124
sg17
VC0010278
p16010
sg10
I16
sg11
Vcraniosynostosis
p16011
sg13
I1
sasa(dp16012
g2
S'Some cases of congenital skeletal disorders with an FGFR2 mutation show skin phenotypes, including acne, cutis gyrata, and acanthosis nigricans.\n'
p16013
sg4
(lp16014
sg14
(lp16015
(dp16016
g7
I99
sg17
VC0001144
p16017
sg10
I4
sg11
Vacne
p16018
sg13
I1
sa(dp16019
g7
I123
sg17
VC0000889
p16020
sg10
I20
sg11
Vacanthosis nigricans
p16021
sg13
I2
sasa(dp16022
g2
S'Peripheral nerve and spinal cord injuries, along with other painful syndromes such as fibromyalgia, diabetic neuropathy, chemotherapeutic neuropathy, trigeminal neuralgia, complex regional pain syndrome, and/or irritable bowel syndrome, cause several neuroplasticity changes in the nervous system along its entire axis affecting the different neuronal nuclei.\n'
p16023
sg4
(lp16024
sg14
(lp16025
(dp16026
g7
I282
sg17
VC0027769
p16027
sg10
I7
sg11
Vnervous
p16028
sg13
I1
sa(dp16029
g7
I100
sg17
VC0011882
p16030
sg10
I19
sg11
Vdiabetic neuropathy
p16031
sg13
I2
sa(dp16032
g7
I60
sg17
VC0030193
p16033
sg10
I7
sg11
Vpainful
p16034
sg13
I1
sa(dp16035
g7
I86
sg17
VC0016053
p16036
sg10
I12
sg11
Vfibromyalgia
p16037
sg13
I1
sa(dp16038
g7
I172
sg17
VC0458219
p16039
sg10
I30
sg11
Vcomplex regional pain syndrome
p16040
sg13
I4
sa(dp16041
g7
I161
sg17
VC0027796
p16042
sg10
I9
sg11
Vneuralgia
p16043
sg13
I1
sa(dp16044
g7
I211
sg17
VC0022104
p16045
sg10
I24
sg11
Virritable bowel syndrome
p16046
sg13
I3
sa(dp16047
g7
I138
sg17
VC0152177
p16048
sg10
I22
sg11
Vneuropathy, trigeminal
p16049
sg13
I2
sa(dp16050
g7
I68
sg17
VC0039082
p16051
sg10
I9
sg11
Vsyndromes
p16052
sg13
I1
sa(dp16053
g7
I28
sg17
VC0035334
p16054
sg10
I4
sg11
Vcord
p16055
sg13
I1
sasa(dp16056
g2
S"Sortilin-related receptor with LDLR class A repeats (SORLA, SORL1, or LR11) is a genetic risk factor associated with Alzheimer's disease (AD).\n"
p16057
sg4
(lp16058
(dp16059
g7
I0
sg8
g9
sg10
I51
sg11
VSortilin-related receptor with LDLR class A repeats
p16060
sg13
I7
sa(dp16061
g7
I60
sg8
g9
sg10
I5
sg11
VSORL1
p16062
sg13
I1
sa(dp16063
g7
I53
sg8
g9
sg10
I5
sg11
VSORLA
p16064
sg13
I1
sasg14
(lp16065
(dp16066
g7
I138
sg17
VC1521724
p16067
sg10
I2
sg11
VAD
p16068
sg13
I1
sa(dp16069
g7
I117
sg17
VC1521724
p16070
sg10
I19
sg11
VAlzheimer's disease
p16071
sg13
I2
sasa(dp16072
g2
S"A meta-analysis was performed to identify empirical data assessing the effects of a single nucleotide polymorphisms of sortilin-related receptor on Alzheimer's disease based on 14 studies involving 37941 cases and 49727 control studies.\n"
p16073
sg4
(lp16074
(dp16075
g7
I119
sg8
g9
sg10
I25
sg11
Vsortilin-related receptor
p16076
sg13
I2
sasg14
(lp16077
(dp16078
g7
I148
sg17
VC1521724
p16079
sg10
I19
sg11
VAlzheimer's disease
p16080
sg13
I2
sasa(dp16081
g2
S"Given these data, we provide crucial evidence to manifest that a significant relationship exists between SORL1 polymorphisms and the susceptibility of Alzheimer's disease.\n"
p16082
sg4
(lp16083
(dp16084
g7
I105
sg8
g9
sg10
I5
sg11
VSORL1
p16085
sg13
I1
sasg14
(lp16086
(dp16087
g7
I151
sg17
VC1521724
p16088
sg10
I19
sg11
VAlzheimer's disease
p16089
sg13
I2
sasa(dp16090
g2
S'Furthermore, a third SORL1 variant, c.5195G &gt; C, recently identified in a Swedish case control cohort included in the European Early-Onset Dementia (EU EOD) consortium study, was detected in two affected siblings in a third family with familial EOAD.\n'
p16091
sg4
(lp16092
(dp16093
g7
I21
sg8
g9
sg10
I13
sg11
VSORL1 variant
p16094
sg13
I2
sasg14
(lp16095
(dp16096
g7
I142
sg17
VC0497327
p16097
sg10
I8
sg11
VDementia
p16098
sg13
I1
sasa(dp16099
g2
S'Thrombospondin-1 (TSP1) is a ligand for CD47 and TSP1-/- mice are protected from pulmonary hypertension (PH).\n'
p16100
sg4
(lp16101
(dp16102
g7
I18
sg8
VP07996
p16103
sg10
I4
sg11
VTSP1
p16104
sg13
I1
sa(dp16105
g7
I18
sg8
VP07996
p16106
sg10
I4
sg11
VTSP1
p16107
sg13
I1
sa(dp16108
g7
I0
sg8
VP07996
p16109
sg10
I16
sg11
VThrombospondin-1
p16110
sg13
I1
sa(dp16111
g7
I40
sg8
g9
sg10
I4
sg11
VCD47
p16112
sg13
I1
sasg14
(lp16113
(dp16114
g7
I105
sg17
VC0020542
p16115
sg10
I2
sg11
VPH
p16116
sg13
I1
sa(dp16117
g7
I81
sg17
VC0020542
p16118
sg10
I22
sg11
Vpulmonary hypertension
p16119
sg13
I2
sasa(dp16120
g2
S'We further discuss therapeutic strategies for enhancing or inhibiting CD47 signaling and applications of such agents in preclinical models of ischemia and ischemia/reperfusion injuries, organ transplantation, pulmonary hypertension, radioprotection, and cancer.\n'
p16121
sg4
(lp16122
(dp16123
g7
I70
sg8
g9
sg10
I4
sg11
VCD47
p16124
sg13
I1
sasg14
(lp16125
(dp16126
g7
I142
sg17
VC0022116
p16127
sg10
I8
sg11
Vischemia
p16128
sg13
I1
sa(dp16129
g7
I254
sg17
VC0006826
p16130
sg10
I6
sg11
Vcancer
p16131
sg13
I1
sa(dp16132
g7
I209
sg17
VC0020542
p16133
sg10
I22
sg11
Vpulmonary hypertension
p16134
sg13
I2
sa(dp16135
g7
I142
sg17
VC0022116
p16136
sg10
I8
sg11
Vischemia
p16137
sg13
I1
sasa(dp16138
g2
S'In present study, anticancer activity of ethanol extract of Chinese propolis (EECP) at 25, 50, 100, and 200  my g/mL was explored by testing the cytotoxicity in MCF-7 (human breast cancer ER(+)) and MDA-MB-231 (human breast cancer ER(-)) cells.\n'
p16139
sg4
(lp16140
sg14
(lp16141
(dp16142
g7
I145
sg17
VC0596402
p16143
sg10
I12
sg11
Vcytotoxicity
p16144
sg13
I1
sa(dp16145
g7
I174
sg17
VC0678222
p16146
sg10
I13
sg11
Vbreast cancer
p16147
sg13
I2
sa(dp16148
g7
I174
sg17
VC0678222
p16149
sg10
I13
sg11
Vbreast cancer
p16150
sg13
I2
sasa(dp16151
g2
S'We exposed human pancreatic cancer cell line MiaPaCa-2 (CRL-1420) to 34  my g/mL of LE for 24, 48, and 72 hours.\n'
p16152
sg4
(lp16153
sg14
(lp16154
(dp16155
g7
I17
sg17
VC0235974
p16156
sg10
I17
sg11
Vpancreatic cancer
p16157
sg13
I2
sasa(dp16158
g2
S'In addition, variations in JAG1 have been found to be associated with multiple types of cancer including breast cancer and adrenocortical carcinoma.\n'
p16159
sg4
(lp16160
(dp16161
g7
I27
sg8
VP78504
p16162
sg10
I4
sg11
VJAG1
p16163
sg13
I1
sasg14
(lp16164
(dp16165
g7
I105
sg17
VC0678222
p16166
sg10
I13
sg11
Vbreast cancer
p16167
sg13
I2
sa(dp16168
g7
I88
sg17
VC0006826
p16169
sg10
I6
sg11
Vcancer
p16170
sg13
I1
sa(dp16171
g7
I123
sg17
VC0206686
p16172
sg10
I24
sg11
Vadrenocortical carcinoma
p16173
sg13
I2
sasa(dp16174
g2
S'The role of the extract in pancreatic cancer treatment was associated with down-regulation of Notch-4 and Jagged-1 in Notch signaling pathway.\n'
p16175
sg4
(lp16176
sg14
(lp16177
(dp16178
g7
I27
sg17
VC0235974
p16179
sg10
I17
sg11
Vpancreatic cancer
p16180
sg13
I2
sasa(dp16181
g2
S'The patient was a 64-year-old man with situs inversus totalis who had previously undergone sigmoidectomy with regional lymphadenectomy for sigmoid colon cancer at age 62.\n'
p16182
sg4
(lp16183
sg14
(lp16184
(dp16185
g7
I39
sg17
VC0037221
p16186
sg10
I14
sg11
Vsitus inversus
p16187
sg13
I2
sa(dp16188
g7
I139
sg17
VC0751498
p16189
sg10
I20
sg11
Vsigmoid colon cancer
p16190
sg13
I3
sasa(dp16191
g2
S'For the treatment of hepatic metastases from sigmoid colon cancer in a patient with situs inversus totalis, "left" hepatic lobectomy, partial hepatectomy, and radiofrequency ablation therapy were performed.\n'
p16192
sg4
(lp16193
sg14
(lp16194
(dp16195
g7
I21
sg17
VC0494165
p16196
sg10
I18
sg11
Vhepatic metastases
p16197
sg13
I2
sa(dp16198
g7
I45
sg17
VC0751498
p16199
sg10
I20
sg11
Vsigmoid colon cancer
p16200
sg13
I3
sa(dp16201
g7
I84
sg17
VC0037221
p16202
sg10
I14
sg11
Vsitus inversus
p16203
sg13
I2
sasa(dp16204
g2
S'On day 25, pulmonary eosinophilia, airway hyperresponsiveness, mucus hypersecretion, inflammatory cytokines such as IL-4, -5 and -13 in BAL fluid, gene expression of inflammatory mediators such as 5-LOX, E-selectin, VCAM-1, CCL5, TNF-Alfa, AMCase, Ym2, YKL-40, Muc5ac, CCL2 and iNOS in animal lung tissues, and serum IgE were determined.\n'
p16205
sg4
(lp16206
(dp16207
g7
I278
sg8
g9
sg10
I4
sg11
ViNOS
p16208
sg13
I1
sa(dp16209
g7
I269
sg8
VP13500
p16210
sg10
I4
sg11
VCCL2
p16211
sg13
I1
sa(dp16212
g7
I224
sg8
VP13501
p16213
sg10
I4
sg11
VCCL5
p16214
sg13
I1
sa(dp16215
g7
I311
sg8
VP01854
p16216
sg10
I9
sg11
Vserum IgE
p16217
sg13
I2
sa(dp16218
g7
I204
sg8
VP16581
p16219
sg10
I10
sg11
VE-selectin
p16220
sg13
I1
sa(dp16221
g7
I230
sg8
VP01375
p16222
sg10
I8
sg11
VTNF-Alfa
p16223
sg13
I1
sa(dp16224
g7
I197
sg8
VP09917
p16225
sg10
I5
sg11
V5-LOX
p16226
sg13
I1
sa(dp16227
g7
I116
sg8
VP05112
p16228
sg10
I4
sg11
VIL-4
p16229
sg13
I1
sa(dp16230
g7
I216
sg8
VP19320
p16231
sg10
I6
sg11
VVCAM-1
p16232
sg13
I1
sa(dp16233
g7
I253
sg8
VP36222
p16234
sg10
I6
sg11
VYKL-40
p16235
sg13
I1
sasg14
(lp16236
(dp16237
g7
I317
sg17
VC0270850
p16238
sg10
I3
sg11
VIgE
p16239
sg13
I1
sa(dp16240
g7
I11
sg17
VC0034068
p16241
sg10
I22
sg11
Vpulmonary eosinophilia
p16242
sg13
I2
sasa(dp16243
g2
S'Our results show that tropical pulmonary eosinophilia mice exhibited increased levels of IL-4, IL-5, CCL5, and CCL11 in the bronchoalveolar lavage fluid and lung parenchyma along with elevated titers of IgE and IgG subtypes in the serum.\n'
p16244
sg4
(lp16245
(dp16246
g7
I95
sg8
VP05113
p16247
sg10
I4
sg11
VIL-5
p16248
sg13
I1
sa(dp16249
g7
I203
sg8
VP01854
p16250
sg10
I3
sg11
VIgE
p16251
sg13
I1
sa(dp16252
g7
I111
sg8
VP51671
p16253
sg10
I5
sg11
VCCL11
p16254
sg13
I1
sa(dp16255
g7
I89
sg8
VP05112
p16256
sg10
I4
sg11
VIL-4
p16257
sg13
I1
sa(dp16258
g7
I101
sg8
VP13501
p16259
sg10
I4
sg11
VCCL5
p16260
sg13
I1
sasg14
(lp16261
(dp16262
g7
I203
sg17
VC0270850
p16263
sg10
I3
sg11
VIgE
p16264
sg13
I1
sa(dp16265
g7
I22
sg17
VC0014458
p16266
sg10
I31
sg11
Vtropical pulmonary eosinophilia
p16267
sg13
I3
sasa(dp16268
g2
S'A(2B) R deficiency resulted in a dramatic reduction on Th2-type airways responses with decreased pulmonary eosinophilia without augmenting neutrophilia, and decreased lung IL-4, IL-5, and IL-13 production.\n'
p16269
sg4
(lp16270
(dp16271
g7
I188
sg8
VP35225
p16272
sg10
I5
sg11
VIL-13
p16273
sg13
I1
sa(dp16274
g7
I167
sg8
VP05112
p16275
sg10
I9
sg11
Vlung IL-4
p16276
sg13
I2
sa(dp16277
g7
I178
sg8
VP05113
p16278
sg10
I4
sg11
VIL-5
p16279
sg13
I1
sasg14
(lp16280
(dp16281
g7
I97
sg17
VC0034068
p16282
sg10
I22
sg11
Vpulmonary eosinophilia
p16283
sg13
I2
sasa(dp16284
g2
S'Both isoforms caused pulmonary infiltration of lymphocytes and neutrophils, whereas mm IL-33 also caused pulmonary eosinophilia and goblet cell hyperplasia and increased expression of IL-4, IL-5, IL-13, IL-17, MCP-1, and KC.\n'
p16285
sg4
(lp16286
(dp16287
g7
I190
sg8
VP05113
p16288
sg10
I4
sg11
VIL-5
p16289
sg13
I1
sa(dp16290
g7
I184
sg8
VP05112
p16291
sg10
I4
sg11
VIL-4
p16292
sg13
I1
sa(dp16293
g7
I210
sg8
VP41597
p16294
sg10
I5
sg11
VMCP-1
p16295
sg13
I1
sa(dp16296
g7
I196
sg8
VP35225
p16297
sg10
I5
sg11
VIL-13
p16298
sg13
I1
sasg14
(lp16299
(dp16300
g7
I21
sg17
VC0235896
p16301
sg10
I22
sg11
Vpulmonary infiltration
p16302
sg13
I2
sa(dp16303
g7
I144
sg17
VC0020507
p16304
sg10
I11
sg11
Vhyperplasia
p16305
sg13
I1
sa(dp16306
g7
I105
sg17
VC0034068
p16307
sg10
I22
sg11
Vpulmonary eosinophilia
p16308
sg13
I2
sasa(dp16309
g2
S'Germline deficiency of the cell surface receptor chain ST2 abrogated the mm IL-33-induced Th2-associated effects (pulmonary eosinophilia, goblet cell hyperplasia, and increased IL-4 and IL-5), yet the lymphocytic infiltration induced by full-length mouse IL-33 or mm IL-33 was not fully abrogated by the absence of ST2.\n'
p16310
sg4
(lp16311
(dp16312
g7
I177
sg8
VP05112
p16313
sg10
I4
sg11
VIL-4
p16314
sg13
I1
sa(dp16315
g7
I237
sg8
g9
sg10
I23
sg11
Vfull-length mouse IL-33
p16316
sg13
I3
sa(dp16317
g7
I186
sg8
VP05113
p16318
sg10
I4
sg11
VIL-5
p16319
sg13
I1
sasg14
(lp16320
(dp16321
g7
I114
sg17
VC0034068
p16322
sg10
I22
sg11
Vpulmonary eosinophilia
p16323
sg13
I2
sa(dp16324
g7
I201
sg17
VC1262091
p16325
sg10
I24
sg11
Vlymphocytic infiltration
p16326
sg13
I2
sa(dp16327
g7
I150
sg17
VC0020507
p16328
sg10
I11
sg11
Vhyperplasia
p16329
sg13
I1
sasa(dp16330
g2
S'OVA-challenged STAT6-/- mice had neither AHR nor pulmonary eosinophilia, but had increased expression of mRNA for TNF-Alfa, IFN-Gamma and IL-4.\n'
p16331
sg4
(lp16332
(dp16333
g7
I138
sg8
VP05112
p16334
sg10
I4
sg11
VIL-4
p16335
sg13
I1
sa(dp16336
g7
I114
sg8
VP01375
p16337
sg10
I3
sg11
VTNF
p16338
sg13
I1
sa(dp16339
g7
I124
sg8
VP01579
p16340
sg10
I9
sg11
VIFN-Gamma
p16341
sg13
I1
sa(dp16342
g7
I41
sg8
VP35869
p16343
sg10
I3
sg11
VAHR
p16344
sg13
I1
sa(dp16345
g7
I15
sg8
VP42226
p16346
sg10
I5
sg11
VSTAT6
p16347
sg13
I1
sasg14
(lp16348
(dp16349
g7
I49
sg17
VC0034068
p16350
sg10
I22
sg11
Vpulmonary eosinophilia
p16351
sg13
I2
sasa(dp16352
g2
S'GLP-1R agonists are used to treat diabetes and obesity, and a GLP-2R agonist is approved to treat short bowel syndrome.\n'
p16353
sg4
(lp16354
(dp16355
g7
I0
sg8
g9
sg10
I6
sg11
VGLP-1R
p16356
sg13
I1
sa(dp16357
g7
I62
sg8
g9
sg10
I6
sg11
VGLP-2R
p16358
sg13
I1
sasg14
(lp16359
(dp16360
g7
I47
sg17
VC0028754
p16361
sg10
I7
sg11
Vobesity
p16362
sg13
I1
sa(dp16363
g7
I98
sg17
VC0036992
p16364
sg10
I20
sg11
Vshort bowel syndrome
p16365
sg13
I3
sa(dp16366
g7
I34
sg17
VC0011849
p16367
sg10
I8
sg11
Vdiabetes
p16368
sg13
I1
sasa(dp16369
g2
S'RNA-seq analysis and quantitative real-time polymerase chain reaction (qRT-PCR) were performed to evaluate the presence of GLP-1R and GLP-2R in EAT and subcutaneous fat (SAT) obtained from 8 subjects with coronary artery disease and type 2 diabetes mellitus undergoing elective cardiac surgery.\n'
p16370
sg4
(lp16371
(dp16372
g7
I134
sg8
g9
sg10
I6
sg11
VGLP-2R
p16373
sg13
I1
sa(dp16374
g7
I123
sg8
g9
sg10
I6
sg11
VGLP-1R
p16375
sg13
I1
sasg14
(lp16376
(dp16377
g7
I205
sg17
VC1956346
p16378
sg10
I23
sg11
Vcoronary artery disease
p16379
sg13
I3
sa(dp16380
g7
I233
sg17
VC0011860
p16381
sg10
I24
sg11
Vtype 2 diabetes mellitus
p16382
sg13
I4
sasa(dp16383
g2
S'Gastric tissue samples of non-obese patients (NOB, n=10) and obese patients without diabetes (OB, n=31) and with diabetes (OWD, n=12) were used to evaluate GLP2R expression and distribution.\n'
p16384
sg4
(lp16385
(dp16386
g7
I156
sg8
g9
sg10
I5
sg11
VGLP2R
p16387
sg13
I1
sasg14
(lp16388
(dp16389
g7
I30
sg17
VC0028754
p16390
sg10
I5
sg11
Vobese
p16391
sg13
I1
sa(dp16392
g7
I84
sg17
VC0011849
p16393
sg10
I8
sg11
Vdiabetes
p16394
sg13
I1
sa(dp16395
g7
I30
sg17
VC0028754
p16396
sg10
I5
sg11
Vobese
p16397
sg13
I1
sa(dp16398
g7
I84
sg17
VC0011849
p16399
sg10
I8
sg11
Vdiabetes
p16400
sg13
I1
sasa.